Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

A-1 

APPENDIX A 

STUDY PROTOCOL AND AMENDMENTS 






















Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

B-1 

APPENDIX B 

ANALYSES OF BULK TEST SUBSTANCE 

B-1 Interim Sponsor Gasoline MTBE Vapor Condensate Characterization 

(Gas Chromatographic Profile) 

B-2 Gasoline MTBE Vapor Condensate Analysis at LRRI (Gas Chromatographic 

Profile) of Individual 420-Pound Tanks Used During Study 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

B-1 Interim Sponsor Gasoline MTBE Vapor Condensate Characterization 

(Gas Chromatographic Profile) 

B-2
Study Number FY01-013

B-3
Study Number FY01-013

B-4
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

B-2 Gasoline MTBE Vapor Condensate Analysis at LRRI 

(Gas Chromatographic Profile) of Individual 420-Pound Tanks Used During Study 

B-5
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A16**

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 2.2

n-Butane 11.1

Isopentane 31.0

n-Pentane 9.1

trans-2-pentene 2.0

2-methyl-2-butene 2.9

MTBE/2,3-dimethylbutane

MTBE 21.3

2,3-dimethylbutane 0.9

2-methylpentane 4.5

3-methylpentane 2.6

n-Hexane 2.1

Methylcyclopentane 1.1

2,4-dimethylpentane 0.9

Benzene 1.5

2-methylhexane 1.0

2,3-dimethylpentane 1.0

3-methylhexane 1.1

Isooctane 1.2

Toluene 2.5

0 0.0 100.00

Date Used: 5-17-01 thru 6-28-01

** Note: This tank was inadvertently not analyzed prior to use. 

However, hydrocarbon profiles were obtained during use. These 

results are included on the following pages. Animal exposures 

began on May 23, 2001, so chamber hydrocarbon 

characterization began on that date.

A16_051701

Study Number FY01-013

B-6
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

5-23-01

Week 

Starting 

5-28-01

Week 

Starting 

5-23-01

Week 

Starting 

5-28-01

Week 

Starting 

5-23-01

Week 

Starting 

5-28-01

Isobutane 2.2 2.5 2.2 2.2 2.2 2.1 2.3n-butane 11.1 10.2 9.3 10.2 10.5 10.5 10.9Isopentane 31.0 26.9 26.6 30.1 30.2 30.7 31.5n-pentane 9.1 8.7 8.7 8.9 9.0 8.9 9.1trans-2-pentene 2.0 2.9 2.7 2.1 2.2 2.1 2.12-methyl-2-butene 2.9 3.9 3.7 2.9 2.9 2.9 3.1MTBE/2,3-dimethylbutaneMTBE 21.3 20.9 20.7 23.0 22.7 22.8 22.92,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 5.2 4.6 4.4 4.4 4.53-methylpentane 2.6 2.7 3.1 2.4 2.6 2.6 2.6n-hexane 2.1 2.2 2.5 2.1 2.2 2.2 2.0Methylcyclopentane 1.1 2.1 1.5 1.2 1.0 1.2 1.12,4-dimethylpentane 0.9 2.3 0.9 1.1 1.0 0.9 0.9Benzene 1.5 1.7 2.5 1.6 1.5 1.5 1.22-methylhexane 1.0 1.1 1.2 1.0 1.0 1.1 0.92,3-dimethylpentane 1.0 2.4 1.7 1.2 1.2 1.2 1.13-methylhexane 1.1 1.3 2.1 1.3 1.2 1.2 0.9Isooctane 1.2 0.7 1.9 1.3 1.4 1.5 1.2Toluene 2.5 2.0 2.5 1.8 1.7 1.3 0.8

Low (2.0g/m3) Mid (10g/m3) Mid (10g/m3)

May 2001

Study Number FY01-013

B-7
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

6-4-01

Week 

Starting 

6-11-01

Week 

Starting 

6-18-01

Week 

Starting 

6-25-01

Week 

Starting 

6-4-01

Week 

Starting 

6-11-01

Week 

Starting 

6-18-01

Week 

Starting 

6-25-01

Week 

Starting 

6-4-01

Week 

Starting 

6-11-01

Week 

Starting 

6-18-01

Week 

Starting 

6-25-01

Isobutane 2.2 2.6 2.2 2.3 2.2 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1n-butane 11.1 8.8 9.1 9.6 9.8 10.2 10.4 10.5 10.3 10.9 10.7 10.5 10.5Isopentane 31.0 24.9 26.0 26.8 26.2 29.9 30.0 30.2 29.8 31.9 31.1 30.7 30.6n-pentane 9.1 7.7 8.5 7.8 8.6 8.8 8.8 8.9 8.9 9.1 9.1 8.9 8.9trans-2-pentene 2.0 3.8 3.0 3.0 3.0 2.2 2.2 2.1 2.2 2.1 2.2 2.0 2.12-methyl-2-butene 2.9 4.0 4.3 3.7 3.6 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 20.9 21.8 21.0 19.0 22.6 23.4 21.9 22.4 23.0 22.5 22.3 22.32,3-dimethylbutane 0.9 0.9 0.9 0.9 0.8 1.0 1.0 0.9 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.3 4.9 4.3 4.9 4.5 4.4 4.6 4.5 4.4 4.5 4.5 4.43-methylpentane 2.6 2.9 2.9 2.7 2.7 2.5 2.5 2.6 2.7 2.5 2.5 2.6 2.6n-hexane 2.1 2.6 2.3 2.5 3.2 2.1 2.1 2.2 2.1 1.9 2.1 2.2 2.3Methylcyclopentane 1.1 1.8 1.4 1.7 1.7 1.2 1.1 1.2 1.2 1.0 1.1 1.2 1.22,4-dimethylpentane 0.9 2.0 1.5 1.0 0.9 1.0 1.1 1.0 1.0 1.1 1.0 0.9 1.0Benzene 1.5 2.0 2.2 1.8 2.4 2.0 1.8 1.7 2.0 1.1 1.5 1.6 1.72-methylhexane 1.0 2.0 1.0 1.4 1.9 1.0 1.0 1.0 1.1 0.9 1.0 1.0 1.02,3-dimethylpentane 1.0 2.7 2.2 2.2 2.3 1.3 1.2 1.3 1.3 1.0 1.1 1.1 1.13-methylhexane 1.1 1.5 1.8 1.6 1.0 1.1 1.2 1.2 1.1 1.0 1.1 1.2 1.2Isooctane 1.2 1.8 1.9 2.2 1.8 1.4 1.2 1.3 1.4 1.2 1.2 1.3 1.4Toluene 2.5 2.9 2.3 3.6 3.9 2.0 1.6 2.2 2.0 0.6 1.4 2.0 2.0

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

June 2001

Study Number FY01-013

B-8
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A20

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 12081 1.8 2.2

n-Butane 62083 9.3 11.1

Isopentane 200525 29.9 31.0

n-Pentane 59754 8.9 9.1

trans-2-pentene 13883 2.1 2.0

2-methyl-2-butene 19538 2.9 2.9

MTBE/2,3-dimethylbutane 163911

MTBE 157273 23.4 21.3

2,3-dimethylbutane 6638 1.0 0.9

2-methylpentane 31116 4.6 4.5

3-methylpentane 17790 2.7 2.6

n-Hexane 15557 2.3 2.1

Methylcyclopentane 7639 1.1 1.1

2,4-dimethylpentane 6766 1.0 0.9

Benzene 11990 1.8 1.5

2-methylhexane 7347 1.1 1.0

2,3-dimethylpentane 8189 1.2 1.0

3-methylhexane 8232 1.2 1.1

Isooctane 9140 1.4 1.2

Toluene 15135 2.3 2.5

670676 100.0 100.00

Date: 6-28-01

A20_062801.xls

Study Number FY01-013

B-9
Study Number FY01-013

B-10
Study Number FY01-013

B-11
Study Number FY01-013

B-12
Study Number FY01-013

B-13
Study Number FY01-013

B-14
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A23

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 24066 1.9 2.2

n-Butane 124208 9.6 11.1

Isopentane 390755 30.3 31.0

n-Pentane 114755 8.9 9.1

trans-2-pentene 26072 2.0 2.0

2-methyl-2-butene 37329 2.9 2.9

MTBE/2,3-dimethylbutane 316483

MTBE 303665 23.6 21.3

2,3-dimethylbutane 12818 1.0 0.9

2-methylpentane 58671 4.6 4.5

3-methylpentane 33731 2.6 2.6

n-Hexane 27840 2.2 2.1

Methylcyclopentane 14535 1.1 1.1

2,4-dimethylpentane 11639 0.9 0.9

Benzene 21799 1.7 1.5

2-methylhexane 13446 1.0 1.0

2,3-dimethylpentane 14314 1.1 1.0

3-methylhexane 15329 1.2 1.1

Isooctane 16033 1.2 1.2

Toluene 27858 2.2 2.5

1288863 100.0 100.00

Date: 7-9-02

A23_02190.xls

Study Number FY01-013

B-15
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A12

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 45580 1.8 2.2

n-Butane 239088 9.5 11.1

Isopentane 767122 30.6 31.0

n-Pentane 223541 8.9 9.1

trans-2-pentene 50305 2.0 2.0

2-methyl-2-butene 71894 2.9 2.9

MTBE/2,3-dimethylbutane 606223 24.2

MTBE 581671 23.2 21.3

2,3-dimethylbutane 24552 1.0 0.9

2-methylpentane 115101 4.6 4.5

3-methylpentane 65991 2.6 2.6

n-Hexane 53855 2.1 2.1

Methylcyclopentane 29026 1.2 1.1

2,4-dimethylpentane 24922 1.0 0.9

Benzene 42066 1.7 1.5

2-methylhexane 25308 1.0 1.0

2,3-dimethylpentane 27214 1.1 1.0

3-methylhexane 29182 1.2 1.1

Isooctane 31795 1.3 1.2

Toluene 56890 2.3 2.5

2505103 100.0 100.00

Date: 9/12/02

A12_022253.xls

Study Number FY01-013

B-16
Study Number FY01-013

B-17
Study Number FY01-013

B-18
Study Number FY01-013

B-19
Study Number FY01-013

B-20
Study Number FY01-013

B-21
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

C-1 

APPENDIX C 

RESULTS OF PERIODIC SEROLOGICAL EVALUATIONS 
Study Number FY01-013

C-2
Study Number FY01-013

C-3
Study Number FY01-013

C-4
Study Number FY01-013

C-5
Study Number FY01-013

C-6
Study Number FY01-013

C-7
Study Number FY01-013

C-8
Study Number FY01-013

C-9
Study Number FY01-013

C-10
Study Number FY01-013

C-11
Study Number FY01-013

C-12
Study Number FY01-013

C-13
Study Number FY01-013

C-14
Study Number FY01-013

C-15
Study Number FY01-013

C-16
Study Number FY01-013

C-17
Study Number FY01-013

C-18
Study Number FY01-013

C-19
Study Number FY01-013

C-20
Study Number FY01-013

C-21
Study Number FY01-013

C-22
Study Number FY01-013

C-23
Study Number FY01-013

C-24
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

D-1 

APPENDIX D 

RESULTS OF FEED AND WATER ANALYSES 
Study Number FY01-013

D-2
Study Number FY01-013

D-3
Study Number FY01-013

D-4
Study Number FY01-013

D-5
Study Number FY01-013

D-6
Study Number FY01-013

D-7
Study Number FY01-013

D-8
Study Number FY01-013

D-9
Study Number FY01-013

D-10
Study Number FY01-013

D-11
Study Number FY01-013

D-12
Study Number FY01-013

D-13
Study Number FY01-013

D-14
Study Number FY01-013

D-15
Study Number FY01-013

D-16
Study Number FY01-013

D-17
Study Number FY01-013

D-18
Study Number FY01-013

D-19
Study Number FY01-013

D-20
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

E-1 

APPENDIX E 

SUMMARIES OF GMVC ANALYSES IN 

EXPOSURE CHAMBERS AND EXPOSURE ROOM 

E-1 Three Day Stability Assessment and Nominal GMVC Usage 

E-2 Pre-Study Homogeneity Study 

E-3 T90 Determination 

E-4 Absence of Aerosol Confirmation 

E-5 GMVC Daily Exposure Concentrations and Nominal Usage 

E-6 Summary of GMVC Room Air Sampling Results 

E-7 Aerosol Scientist’s Report 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-1 Three Day Stability Assessment and Nominal GMVC Usage 

E-2
Study Number FY01-013

E-3
Study Number FY01-013

E-4
Study Number FY01-013

E-5
Study Number FY01-013

E-6
Study Number FY01-013

E-7
Study Number FY01-013

E-8
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-2 Pre-Study Homogeneity Study 

E-9
Study Number FY01-013

E-10
Study Number FY01-013

E-11
Study Number FY01-013

E-12
Study Number FY01-013

E-13
Study Number FY01-013

E-14
Study Number FY01-013

E-15
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-3 T90 Determination 

E-16
Study Number FY01-013

E-17
Study Number FY01-013

E-18
Study Number FY01-013

E-19
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-4 Absence of Aerosol Confirmation 

E-20
Study Number FY01-013

E-21
Study Number FY01-013

E-22
Study Number FY01-013

E-23
Study Number FY01-013

E-24
Study Number FY01-013

E-25
Study Number FY01-013

E-26
Study Number FY01-013

E-27
Study Number FY01-013

E-28
Study Number FY01-013

E-29
Study Number FY01-013

E-30
Study Number FY01-013

E-31
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-5 GMVC Daily Exposure Concentrations and Nominal Usage 

E-32
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Anticipated)

5/23/2001 1 2.08 0.08 9.73 0.53 19.17 0.57 4909 4700 96

5/24/2001 2 1.93 0.16 9.14 0.49 17.76 1.50 4534 4390 97

5/25/2001 3 2.02 0.07 9.92 0.53 19.50 0.46 5195 4955 95

5/28/2001 4 1.96 0.03 9.80 0.17 18.73 0.11 5086 4985 98

5/29/2001 5 1.98 0.05 10.19 0.62 19.18 0.60 5246 5045 96

5/30/2001 6 2.03 0.11 9.57 0.19 18.84 0.12 5096 4660 91

5/31/2001 7 1.98 0.15 8.74 0.75 18.28 1.73 4860 4505 93

6/1/2001 8 1.97 0.04 9.56 0.27 18.89 0.38 5171 4780 92

6/4/2001 9 2.05 0.08 9.27 0.45 19.12 0.48 5155 4720 92

6/5/2001 10 1.94 0.04 9.34 0.39 19.48 0.21 5171 4865 94

6/6/2001 11 1.93 0.10 9.62 0.11 21.02 0.33 5564 5355 96

6/7/2001 12 1.88 0.06 9.93 0.39 20.65 0.63 5427 5220 96

6/8/2001 13 1.92 0.04 9.76 0.39 20.14 1.25 5310 5055 95

6/11/2001 14 2.00 0.08 9.73 0.24 20.35 0.53 5581 5360 96

6/12/2001 15 1.94 0.03 9.52 0.08 20.16 0.55 5450 5265 97

6/13/2001 16 1.98 0.04 9.46 0.07 19.47 0.85 5330 5110 96

6/14/2001 17 2.01 0.06 10.13 0.52 19.87 0.82 5529 5280 95

6/15/2001 18 1.98 0.06 9.66 0.16 20.29 0.47 5499 5225 95

6/18/2001 19 2.01 0.08 9.60 0.33 19.96 0.93 5450 5145 94

6/19/2001 20 2.00 0.07 9.62 0.11 20.51 0.48 5409 5085 94

6/20/2001 21 2.05 0.05 10.15 0.49 20.48 1.27 5506 5170 94

6/21/2001 22 2.02 0.02 9.70 0.31 21.02 0.62 5484 5105 93

6/22/2001 23 2.08 0.06 10.00 0.19 21.31 0.42 5579 4970 89

6/25/2001 24 2.04 0.06 9.99 0.11 20.44 0.42 5411 5195 96

6/26/2001 25 2.06 0.10 10.27 0.07 20.41 0.36 5498 5280 96

6/27/2001 26 2.08 0.09 10.09 0.20 20.67 0.25 5456 5135 94

6/28/2001 27 2.11 0.06 10.33 0.09 20.67 0.42 5521 5160 93

6/29/2001 28 2.12 0.06 10.21 0.04 20.61 0.15 5511 5120 93

7/2/2001 29 2.10 0.11 10.21 0.58 19.27 0.62 5270 4885 93

7/3/2001 30 1.98 0.09 10.10 0.16 20.60 0.34 5460 5040 92

7/4/2001 ** Holiday Holiday Holiday Holiday

7/5/2001 31 2.04 0.08 9.66 0.48 20.27 0.33 5600 5170 92

7/6/2001 32 2.08 0.06 10.37 0.13 20.53 0.33 6027 5610 93

7/9/2001 33 2.26 0.08 10.09 0.06 21.84 0.17 5778 5395 93

7/10/2001 34 1.94 0.12 10.17 0.10 20.85 0.27 5556 5185 93

7/11/2001 35 2.03 0.08 10.02 0.54 19.67 0.27 5449 5160 95

7/12/2001 36 2.07 0.07 10.11 0.40 20.66 0.95 5438 5165 95

7/13/2001 37 1.99 0.11 10.60 0.14 20.45 0.39 5519 5200 94

7/16/2001 38 1.99 0.09 10.10 0.47 20.25 0.64 5438 5135 94

7/17/2001 39 1.99 0.02 9.56 0.13 19.85 0.19 5268 5040 96

7/18/2001 40 1.96 0.08 10.21 0.22 20.62 0.42 5498 5190 94

7/19/2001 41 1.86 0.13 10.00 0.42 19.75 0.98 5332 5160 97

7/20/2001 42 2.11 0.06 10.14 0.22 20.77 0.51 5614 5390 96

7/23/2001 43 1.98 0.09 10.16 0.27 19.56 0.50 5247 5035 96

7/24/2001 44 1.97 0.03 10.70 0.04 21.49 0.39 5756 5450 95

7/25/2001 45 2.01 0.08 10.39 0.31 20.08 0.45 5406 5350 99

7/26/2001 46 2.01 0.14 10.14 0.16 19.43 0.87 5254 4945 94

7/27/2001 47 2.11 0.08 10.58 0.07 20.32 0.10 5481 5385 98

7/30/2001 48 1.86 0.03 10.43 0.15 20.70 0.30 5662 5675 100

7/31/2001 49 1.98 0.14 9.93 0.09 19.71 0.57 5225 5180 99

8/1/2001 50 1.99 0.07 10.25 0.35 19.67 0.80 5250 5100 97

8/2/2001 51 1.97 0.07 10.00 0.22 19.28 0.40 5416 5235 97

8/3/2001 52 2.01 0.04 9.83 0.25 20.73 0.35 5422 5280 97

8/6/2001 53 2.03 0.03 10.68 0.13 20.36 0.72 5521 5365 97

8/7/2001 54 2.04 0.07 9.67 0.38 20.92 0.27 5226 5095 97

8/8/2001 55 1.96 0.04 9.73 0.41 19.70 0.63 5046 4840 96

8/9/2001 56 1.99 0.10 10.40 0.45 21.03 0.36 5371 5175 96

8/10/2001 57 2.05 0.07 10.47 0.06 20.32 0.32 5473 5275 96

8/13/2001 58 2.01 0.02 10.18 0.15 20.76 0.15 5491 5185 94

8/14/2001 59 2.00 0.09 9.99 0.46 18.71 0.30 5083 4805 95

8/15/2001 60 1.99 0.04 9.56 0.27 20.33 0.23 5291 5075 96

8/16/2001 61 1.96 0.10 10.04 0.44 20.19 0.38 5392 5130 95

8/17/2001 62 1.96 0.03 9.85 0.38 19.37 0.72 5197 4990 96

8/20/2001 63 2.05 0.03 10.02 0.56 19.61 0.46 5184 5085 98

8/21/2001 64 1.94 0.03 9.66 0.13 20.34 0.25 5314 5175 97

8/22/2001 65 1.94 0.06 9.86 0.33 20.01 0.38 5548 5375 97

8/23/2001 66 2.13 0.03 10.45 0.12 19.17 0.12 5513 5285 96

Date

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

Study Number FY01-013

E-33
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

8/24/2001 67 2.09 0.06 10.18 0.03 19.03 0.31 5728 5480 96

8/27/2001 68 2.00 0.02 9.97 0.08 20.26 0.35 5345 5195 97

8/28/2001 69 1.99 0.06 9.54 0.06 19.92 0.31 5159 5020 97

8/29/2001 70 2.11 0.03 9.87 0.15 20.97 0.08 5437 5235 96

8/30/2001 71 1.96 0.03 9.93 0.29 20.26 0.40 5346 5130 96

8/31/2001 72 2.04 0.03 9.73 0.17 19.21 0.34 5118 5005 98

9/3/2001 73 2.08 0.10 9.35 0.16 20.87 0.03 5702 5550 97

9/4/2001 74 2.14 0.05 9.80 0.25 19.45 0.33 5322 5140 97

9/5/2001 75 1.92 0.05 9.47 0.40 19.84 0.40 5381 5210 97

9/6/2001 76 1.99 0.05 9.73 0.21 20.09 0.62 5350 5180 97

9/7/2001 77 1.96 0.04 9.27 0.08 18.98 0.60 5618 5255 94

9/10/2001 78 1.97 0.03 9.64 0.11 19.58 0.20 5452 5195 95

9/11/2001 79 1.99 0.11 9.75 0.14 19.33 0.37 5440 5160 95

9/12/2001 80 1.95 0.06 9.79 0.77 19.29 0.34 5472 5290 97

9/13/2001 81 1.89 0.05 9.98 0.62 19.65 0.27 5563 5375 97

9/14/2001 82 1.88 0.02 9.63 0.26 19.03 0.37 5306 5150 97

9/17/2001 83 2.18 0.03 9.98 0.04 19.81 0.11 5809 5625 97

9/18/2001 84 2.04 0.11 9.25 0.04 18.71 0.30 5444 5330 98

9/19/2001 85 1.94 0.03 10.36 0.27 20.90 0.09 6045 5860 97

9/20/2001 86 2.04 0.05 10.11 0.22 20.03 0.20 5830 5625 96

9/21/2001 87 2.00 0.11 10.03 0.33 20.11 0.25 5927 5700 96

9/24/2001 88 1.91 0.03 9.45 0.16 20.35 0.08 5332 5475 103

9/25/2001 89 2.04 0.13 10.02 0.16 20.44 0.14 5700 5505 97

9/26/2001 90 2.04 0.07 10.04 0.17 20.76 0.35 5775 5610 97

9/27/2001 91 2.03 0.08 10.49 0.50 20.49 0.57 5776 5670 98

9/28/2001 92 2.12 0.06 10.67 0.41 20.76 0.71 6074 5920 97

10/1/2001 93 2.12 0.06 10.69 0.22 21.45 0.05 6015 5945 99

10/2/2001 94 2.16 0.06 10.74 0.04 21.61 0.04 6055 6025 100

10/3/2001 95 2.04 0.02 10.82 0.30 21.09 0.09 5969 5825 98

10/4/2001 96 1.99 0.01 10.56 0.10 21.65 0.19 6114 6025 99

10/5/2001 97 1.99 0.10 10.02 0.22 18.99 0.24 5584 5595 100

10/8/2001 98 2.18 0.03 10.82 0.03 21.36 0.10 6218 5850 94

10/9/2001 99 2.00 0.02 10.68 0.11 20.58 0.60 6015 5700 95

10/10/2001 100 2.06 0.02 9.95 0.18 21.06 0.12 6029 5655 94

10/11/2001 101 1.97 0.06 10.13 0.23 20.08 0.23 5909 5555 94

10/12/2001 102 1.94 0.08 9.58 0.31 19.31 0.47 5595 5315 95

10/15/2001 103 1.99 0.07 10.16 0.17 19.91 0.12 5545 5520 100

10/16/2001 104 2.05 0.01 9.84 0.21 20.12 0.30 5423 5435 100

10/17/2001 105 2.00 0.08 9.95 0.67 20.03 0.80 5402 5130 95

10/18/2001 106 1.96 0.10 10.14 0.53 19.77 0.71 5366 5055 94

10/19/2001 107 1.95 0.07 10.40 0.40 19.98 0.42 5553 5220 94

10/22/2001 108 2.01 0.04 10.35 0.13 19.82 0.32 5500 5220 95

10/23/2001 109 2.05 0.15 9.70 0.64 19.93 0.71 5404 5270 98

10/24/2001 110 2.03 0.09 10.32 0.14 20.94 0.03 5754 5510 96

10/25/2001 111 2.03 0.04 10.63 0.08 21.31 0.22 5805 5520 95

10/26/2001 112 2.08 0.01 10.72 0.01 20.31 0.05 5732 5330 93

10/29/2001 113 1.95 0.02 10.80 0.18 20.71 0.03 5880 5375 91

10/30/2001 114 1.92 0.02 9.99 0.42 20.19 0.41 5610 5155 92

10/31/2001 115 1.99 0.07 9.88 0.51 18.75 0.43 5333 4900 92

11/1/2001 116 1.91 0.12 9.98 0.26 20.51 0.43 5708 5250 92

11/2/2001 117 1.91 0.02 10.44 0.37 20.67 0.02 5731 5400 94

11/5/2001 118 2.01 0.07 10.01 0.60 21.48 0.26 5953 5340 90

11/6/2001 119 2.02 0.06 9.96 0.69 19.38 0.83 5545 4940 89

11/7/2001 120 2.10 0.09 10.39 0.06 20.87 0.11 5908 5290 90

11/8/2001 121 2.05 0.06 10.72 0.22 21.30 0.37 5973 5365 90

11/9/2001 122 2.04 0.09 10.17 0.06 21.25 0.34 6046 5495 91

11/12/2001 123 2.04 0.11 9.89 0.08 20.44 0.20 5642 5595 99

11/13/2001 124 2.12 0.11 9.65 0.38 20.76 0.25 5639 5665 100

11/14/2001 125 1.96 0.09 9.43 0.08 19.34 0.03 5325 5330 100

11/15/2001 126 2.14 0.03 10.05 0.65 21.20 0.34 5813 5725 98

11/16/2001 127 2.13 0.02 10.60 0.33 20.29 0.17 5599 5410 97

11/19/2001 128 1.96 0.13 9.86 0.23 19.44 0.35 5482 5410 99

11/20/2001 129 1.88 0.04 10.86 0.27 18.73 0.78 5397 5595 104

11/21/2001 130 2.05 0.03 10.25 0.37 18.28 0.25 5257 5470 104

11/22/2001 ** Holiday Holiday Holiday Holiday

11/23/2001 131 2.03 0.04 10.54 0.13 20.18 0.60 5766 5875 102

11/26/2001 132 2.13 0.09 10.54 0.62 19.38 0.11 5479 5210 95

Study Number FY01-013

E-34
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

11/27/2001 133 2.11 0.04 10.16 0.39 20.13 0.48 5561 5240 94

11/28/2001 134* N/A* N/A* N/A* N/A* N/A* N/A* N/A* N/A* N/A*

11/29/2001 135 1.89 0.09 10.94 0.10 19.23 0.12 5453 5165 95

11/30/2001 136 2.00 0.08 10.02 0.23 19.55 0.69 5348 5275 99

12/3/2001 137 1.96 0.04 10.65 0.22 21.67 0.36 5849 5310 91

12/4/2001 138 1.95 0.06 10.08 0.36 20.63 0.55 5589 5080 91

12/5/2001 139 1.92 0.06 10.77 0.29 19.95 0.01 5635 5080 90

12/6/2001 140 2.00 0.04 9.73 0.32 21.27 0.10 5711 5215 91

12/7/2001 141 1.98 0.03 10.26 0.07 21.90 0.02 5926 5575 94

12/10/2001 142 2.07 0.05 10.02 0.42 20.42 0.75 5478 5760 105

12/11/2001 143 2.11 0.04 9.82 0.38 19.70 0.28 5353 5505 103

12/12/2001 144 1.97 0.10 10.34 0.47 20.80 0.11 5614 5610 100

12/13/2001 145 2.00 0.09 10.41 0.15 21.36 0.19 5818 5890 101

12/14/2001 146 2.02 0.02 10.75 0.05 21.47 0.08 5769 5650 98

12/17/2001 147 2.08 0.02 10.72 0.06 21.24 0.20 5817 5830 100

12/18/2001 148 2.05 0.13 9.79 0.05 21.59 0.22 5714 5760 101

12/19/2001 149 2.00 0.12 9.99 0.39 20.07 0.99 5500 5640 103

12/20/2001 150 1.94 0.06 9.86 0.16 19.82 0.32 5391 5850 109

12/21/2001 151 1.99 0.10 10.13 0.34 19.68 0.49 5373 5540 103

12/24/2001 152 1.90 0.07 9.92 0.01 20.67 0.46 5452 5390 99

12/25/2001 ** Holiday Holiday Holiday Holiday

12/26/2001 153 1.98 0.04 10.02 0.24 20.78 0.25 5507 5365 97

12/27/2001 154 1.96 0.06 10.69 0.14 21.66 0.27 5727 5560 97

12/28/2001 155 2.05 0.05 10.35 0.36 21.17 0.12 5625 5500 98

12/31/2001 156 2.03 0.12 10.48 0.16 21.74 0.07 5735 5710 100

1/1/2002 ** Holiday Holiday Holiday Holiday

1/2/2002 157 2.01 0.02 9.92 0.05 21.45 0.25 5635 5520 98

1/3/2002 158 1.95 0.04 10.44 0.11 21.34 0.25 5662 5475 97

1/4/2002 159 2.11 0.06 10.47 0.11 21.63 0.11 5664 5630 99

1/7/2002 160 2.04 0.03 10.78 0.03 21.43 0.05 5761 5650 98

1/8/2002 161 2.01 0.03 10.67 0.04 21.76 0.15 5754 5505 96

1/9/2002 162 2.02 0.08 10.75 0.13 21.48 0.28 5639 5425 96

1/10/2002 163 2.04 0.05 10.40 0.51 20.55 0.33 5393 5375 100

1/11/2002 164 1.93 0.01 10.84 0.06 21.04 0.03 5538 5250 95

1/14/2002 165 1.99 0.02 10.85 0.18 21.77 0.16 5692 5275 93

1/15/2002 166 1.90 0.07 10.12 0.68 21.35 0.58 5434 5240 96

1/16/2002 167 2.15 0.06 10.64 0.12 21.05 0.54 5526 5320 96

1/17/2002 168 1.99 0.07 10.93 0.19 19.55 0.24 5599 4970 89

1/18/2002 169 1.99 0.06 10.46 0.01 21.18 0.23 5785 5720 99

1/21/2002 170 2.10 0.07 10.11 0.02 20.96 0.07 5721 5825 102

1/22/2002 171 2.14 0.01 10.38 0.19 21.68 0.17 5875 5975 102

1/23/2002 172 1.99 0.01 9.37 0.04 20.55 0.05 5471 5600 102

1/24/2002 173 2.01 0.01 10.05 0.13 20.55 0.20 5320 5390 101

1/25/2002 174 2.06 0.03 10.43 0.03 21.43 0.12 5606 5690 101

1/28/2002 175 1.93 0.05 9.77 0.18 21.50 0.23 5460 5585 102

1/29/2002 176 2.07 0.01 10.38 0.05 20.10 0.08 5356 5385 101

1/30/2002 177 2.09 0.01 10.30 0.01 21.25 0.03 5540 5635 102

1/31/2002 178 2.00 0.01 10.35 0.06 21.50 0.35 5749 5815 101

2/1/2002 179 2.12 0.06 10.21 0.05 21.04 0.13 5340 5390 101

2/4/2002 180 2.07 0.03 10.07 0.07 21.01 0.09 5493 5645 103

2/5/2002 181 2.13 0.08 10.03 0.24 21.59 0.41 5496 5595 102

2/6/2002 182 1.86 0.03 9.27 0.20 19.92 1.47 5160 5335 103

2/7/2002 183 2.03 0.06 9.81 0.09 19.12 0.11 5533 5665 102

2/8/2002 184 2.09 0.06 9.39 0.10 19.00 0.09 5369 5585 104

2/11/2002 185 2.01 0.01 9.96 0.08 21.73 0.01 5672 5750 101

2/12/2002 186 2.05 0.09 9.91 0.39 20.63 0.23 5666 5775 102

2/13/2002 187 2.12 0.04 9.31 0.09 20.45 0.49 5571 5930 106

2/14/2002 188 1.94 0.06 9.27 0.07 19.85 0.19 5424 5640 104

2/15/2002 189 1.94 0.03 9.36 0.02 20.97 0.03 5667 5770 102

2/18/2002 190 2.07 0.07 9.76 0.17 20.64 0.33 5667 5750 101

2/19/2002 191 2.07 0.08 9.94 0.23 20.55 0.32 5650 5650 100

2/20/2002 192 2.00 0.01 10.65 0.11 21.26 0.33 5875 5910 101

2/21/2002 193 2.05 0.08 10.51 0.11 20.96 0.16 5857 5855 100

2/22/2002 194 2.05 0.04 9.93 0.04 21.05 0.20 5763 5660 98

2/25/2002 195 2.12 0.06 10.12 0.27 21.70 0.05 5747 5610 98

2/26/2002 196 2.00 0.13 10.35 0.41 20.98 0.47 5673 5540 98

2/27/2002 197 1.95 0.02 10.00 0.08 20.93 0.17 5720 5685 99

Study Number FY01-013

E-35
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

2/28/2002 198 2.16 0.01 10.48 0.04 19.34 0.03 5484 5495 100

3/1/2002 199 2.03 0.11 10.42 0.07 20.51 0.22 5173 5255 102

3/4/2002 200 2.06 0.03 9.74 0.18 21.02 0.03 5244 5275 101

3/5/2002 201 2.12 0.06 10.13 0.07 21.12 0.02 5312 5330 100

3/6/2002 202 2.08 0.07 9.54 0.05 20.44 0.47 5079 5165 102

3/7/2002 203 2.07 0.02 9.99 0.05 20.82 0.41 5177 5195 100

3/8/2002 204 2.06 0.06 10.38 0.03 21.22 0.30 5237 5280 101

3/11/2002 205 1.95 0.02 10.24 0.31 19.46 0.09 5169 5505 107

3/12/2002 206 1.97 0.03 10.35 0.04 19.60 0.27 5215 5505 106

3/13/2002 207 2.07 0.06 10.24 0.08 19.47 0.18 5170 5610 109

3/14/2002 208 1.92 0.06 10.67 0.08 19.85 0.34 5299 5655 107

3/15/2002 209 2.10 0.05 10.88 0.12 18.78 0.16 5230 5775 110

3/18/2002 210 1.91 0.02 10.06 0.29 20.79 0.08 5152 5235 102

3/19/2002 211 2.12 0.08 10.40 0.24 20.97 0.28 5267 5345 101

3/20/2002 212 2.14 0.01 10.30 0.03 21.36 0.23 5308 5360 101

3/21/2002 213 1.86 0.02 10.05 0.18 20.58 0.36 5122 5130 100

3/22/2002 214 2.10 0.06 10.27 0.05 21.52 0.09 5313 5365 101

3/25/2002 215 1.98 0.04 10.37 0.08 21.35 0.03 5281 5450 103

3/26/2002 216 2.04 0.02 9.43 0.12 20.04 0.22 5092 5310 104

3/27/2002 217 2.08 0.08 9.87 0.11 20.84 0.06 5316 5540 104

3/28/2002 218 2.04 0.10 9.61 0.11 20.16 0.04 5193 5410 104

3/29/2002 219 2.03 0.05 10.11 0.03 18.86 0.10 5110 5345 105

4/1/2002 220 1.88 0.01 10.18 0.07 19.55 0.11 5265 5320 101

4/2/2002 221 1.96 0.10 10.76 0.04 20.72 0.12 5555 5750 104

4/3/2002 222 1.96 0.03 10.36 0.05 20.30 0.07 5454 5570 102

4/4/2002 223 1.94 0.02 9.84 0.20 19.47 0.13 5214 5360 103

4/5/2002 224 2.06 0.04 9.84 0.06 20.07 0.14 5354 5485 102

4/8/2002 225 2.07 0.01 10.28 0.03 20.51 0.03 5490 5575 102

4/9/2002 226 1.90 0.03 9.39 0.02 20.40 0.15 5283 5390 102

4/10/2002 227 2.06 0.03 9.65 0.11 21.51 0.03 5542 5680 102

4/11/2002 228 1.99 0.04 9.34 0.08 20.77 0.06 5440 5460 100

4/12/2002 229 2.09 0.02 10.07 0.03 20.19 0.05 5437 5440 100

4/15/2002 230 2.08 0.01 9.94 0.23 20.96 0.16 5516 5580 101

4/16/2002 231 2.10 0.02 10.02 0.04 21.67 0.08 5331 5370 101

4/17/2002 232 1.98 0.05 9.82 0.02 20.84 0.13 5145 5220 101

4/18/2002 233 2.00 0.03 10.01 0.07 21.00 0.08 5192 5275 102

4/19/2002 234 2.08 0.08 10.52 0.38 20.78 0.14 5251 5325 101

4/22/2002 235 1.96 0.02 9.70 0.10 20.85 0.10 5402 5525 102

4/23/2002 236 1.97 0.02 9.89 0.05 20.02 0.02 5292 5330 101

4/24/2002 237 2.10 0.08 10.42 0.28 20.62 0.05 5484 5540 101

4/25/2002 238 2.11 0.02 10.17 0.09 20.35 0.21 5401 5495 102

4/26/2002 239 2.08 0.06 9.88 0.07 20.67 0.15 5446 5470 100

4/29/2002 240 2.14 0.10 9.58 0.14 20.53 0.03 5483 5475 100

4/30/2002 241 2.08 0.03 9.85 0.11 21.07 0.12 5641 5640 100

5/1/2002 242 2.03 0.08 10.41 0.13 21.07 0.06 5672 5535 98

5/2/2002 243 1.91 0.04 9.98 0.03 20.18 0.08 5440 5335 98

5/3/2002 244 1.95 0.05 9.89 0.16 19.97 0.34 5197 5300 102

5/6/2002 245 1.99 0.04 9.74 0.01 21.15 0.03 5488 5630 103

5/7/2002 246 1.99 0.03 10.15 0.10 20.41 0.01 5473 5510 101

5/8/2002 247 1.90 0.01 9.79 0.02 21.20 0.19 5493 5600 102

5/9/2002 248 2.10 0.04 10.00 0.04 20.66 0.03 5477 5545 101

5/10/2002 249 1.95 0.07 9.41 0.33 20.22 0.37 5255 5360 102

5/13/2002 250 2.04 0.06 9.26 0.07 21.04 0.11 5409 5440 101

5/14/2002 251 2.09 0.04 9.87 0.01 20.89 0.02 5486 5525 101

5/15/2002 252 1.97 0.06 9.44 0.07 20.08 0.44 5241 5130 98

5/16/2002 253 2.13 0.04 9.92 0.03 20.82 0.04 5559 5415 97

5/17/2002 254 2.04 0.05 9.69 0.10 20.95 0.35 5478 5295 97

5/20/2002 255 2.03 0.02 9.74 0.03 21.05 0.10 5513 5330 97

5/21/2002 256 1.98 0.03 10.06 0.12 20.73 0.64 5477 5455 100

5/22/2002 257 2.17 0.00 9.78 0.13 20.77 0.08 5513 5270 96

5/23/2002 258 2.09 0.03 10.32 0.09 21.39 0.07 5680 5495 97

5/24/2002 259 1.94 0.05 9.58 0.21 20.89 0.25 5467 5345 98

5/27/2002 260 2.08 0.02 10.32 0.03 21.25 0.10 5707 5495 96

5/28/2002 261 1.91 0.05 10.29 0.03 21.84 0.08 5782 5615 97

5/29/2002 262 1.99 0.14 9.65 0.26 19.87 0.15 5381 5132 95

5/30/2002 263 2.02 0.10 9.42 0.46 20.13 0.35 5394 5250 97

5/31/2002 264 2.02 0.03 10.12 0.14 21.63 0.04 5679 5415 95

Study Number FY01-013

E-36
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

6/3/2002 265 1.97 0.03 9.90 0.07 20.86 0.19 5575 5335 96

6/4/2002 266 1.90 0.08 9.34 0.07 20.71 0.03 5502 5280 96

6/5/2002 267 1.91 0.03 10.11 0.06 21.45 0.09 5640 5320 94

6/6/2002 268 1.92 0.02 10.08 0.09 20.57 0.34 5380 5130 95

6/7/2002 269 2.02 0.05 9.55 0.01 21.06 0.11 5310 5050 95

6/10/2002 270 2.03 0.05 10.14 0.05 21.42 0.01 5454 5285 97

6/11/2002 271 2.06 0.05 10.10 0.06 20.82 0.03 5372 5370 100

6/12/2002 272 1.92 0.03 9.83 0.11 20.77 0.29 5274 5205 99

6/13/2002 273 2.01 0.09 9.47 0.05 20.47 0.11 5276 5205 99

6/14/2002 274 2.04 0.01 9.55 0.06 20.39 0.08 5316 5245 99

6/17/2002 275 2.01 0.03 10.26 0.09 20.85 0.05 5504 5460 99

6/18/2002 276 2.10 0.01 9.81 0.24 20.15 0.04 5357 5390 101

6/19/2002 277 2.08 0.03 9.85 0.04 19.92 0.05 5361 5250 98

6/20/2002 278 2.16 0.01 9.61 0.03 20.17 0.09 5302 5160 97

6/21/2002 279 2.11 0.01 9.91 0.05 21.23 0.10 5404 5310 98

6/24/2002 280 1.94 0.05 10.04 0.08 20.68 0.18 5472 5385 98

6/25/2002 281 2.03 0.02 10.55 0.04 20.76 0.09 5533 5480 99

6/26/2002 282 1.98 0.06 9.84 0.07 19.73 0.18 5322 5335 100

6/27/2002 283 2.17 0.01 9.45 0.06 20.08 0.19 5332 5305 99

6/28/2002 284 2.14 0.03 9.92 0.17 20.35 0.24 5413 5450 101

7/1/2002 285 1.99 0.04 9.80 0.12 21.20 0.23 5409 5405 100

7/2/2002 286 2.12 0.05 10.02 0.09 21.43 0.17 5489 5415 99

7/3/2002 287 1.90 0.01 9.99 0.04 20.61 0.05 5368 5290 99

7/4/2002 ** Holiday Holiday Holiday Holiday

7/5/2002 288 2.05 0.02 9.84 0.14 20.69 0.18 5443 5360 98

7/8/2002 289 2.06 0.02 9.47 0.07 21.01 0.15 5375 5280 98

7/9/2002 290 2.09 0.08 9.89 0.18 20.54 0.27 5425 5295 98

7/10/2002 291 2.01 0.05 9.98 0.15 21.40 0.21 5496 5420 99

7/11/2002 292 2.06 0.03 10.51 0.05 21.19 0.24 5545 5470 99

7/12/2002 293 2.09 0.02 10.01 0.07 21.08 0.04 5403 5380 100

7/15/2002 294 2.11 0.03 10.16 0.08 20.52 0.34 5425 5315 98

7/16/2002 295 2.04 0.13 9.81 0.03 20.77 0.09 5385 5275 98

7/17/2002 296 1.86 0.04 9.74 0.02 20.62 0.11 5287 5230 99

7/18/2002 297 2.03 0.15 9.54 0.26 19.88 0.92 5188 5025 97

7/19/2002 298 2.00 0.09 9.74 0.04 20.32 0.41 5312 5125 96

7/22/2002 299 1.96 0.13 10.23 0.11 19.82 0.08 5259 5005 95

7/23/2002 300 2.10 0.06 10.48 0.25 20.95 0.35 5496 5225 95

7/24/2002 301 2.01 0.05 10.78 0.15 21.71 0.15 5655 5355 95

7/25/2002 302 1.94 0.02 10.79 0.03 21.03 0.23 5496 5230 95

7/26/2002 303 1.86 0.06 10.52 0.13 20.09 0.52 5220 5035 96

7/29/2002 304 2.02 0.05 10.57 0.07 19.64 0.31 5343 5285 99

7/30/2002 305 2.10 0.04 10.55 0.06 18.83 0.08 5241 5210 99

7/31/2002 306 1.98 0.01 9.69 0.28 19.90 0.06 5233 5160 99

8/1/2002 307 1.99 0.04 9.96 0.14 20.59 0.25 5339 5235 98

8/2/2002 308 2.01 0.02 9.46 0.42 20.07 0.10 5332 5235 98

8/5/2002 309 1.94 0.04 9.50 0.08 20.50 0.09 5108 4890 96

8/6/2002 310 2.00 0.09 10.08 0.09 21.09 0.13 5346 5165 97

8/7/2002 311 1.94 0.05 9.91 0.31 19.81 0.54 5070 4895 97

8/8/2002 312 1.94 0.03 9.56 0.07 21.65 0.07 5309 5100 96

8/9/2002 313 2.15 0.02 10.23 0.08 21.24 0.08 5317 5090 96

8/12/2002 314 2.07 0.03 9.69 0.02 18.53 0.25 5236 5620 107

8/13/2002 315 1.96 0.07 10.12 0.21 20.87 0.23 5484 5315 97

8/14/2002 316 2.11 0.09 9.78 0.10 19.28 0.72 5143 5620 109

8/15/2002 317 2.09 0.05 10.43 0.36 21.10 0.55 5609 5525 99

8/16/2002 318 2.04 0.04 9.51 0.45 20.70 0.41 5285 5095 96

8/19/2002 319 1.95 0.04 10.44 0.10 21.05 0.05 5281 4930 93

8/20/2002 320 2.02 0.06 9.88 0.04 21.55 0.06 5254 4960 94

8/21/2002 321 1.99 0.06 10.51 0.13 20.57 0.16 5218 4940 95

8/22/2002 322 2.10 0.04 10.50 0.05 21.17 0.35 5357 5040 94

8/23/2002 323 2.01 0.05 10.32 0.04 21.02 0.04 5280 5020 95

8/26/2002 324 1.92 0.01 10.26 0.04 21.14 0.08 5377 5020 93

8/27/2002 325 2.09 0.04 9.92 0.15 21.05 0.27 5339 5140 96

8/28/2002 326 2.07 0.04 10.56 0.06 21.20 0.04 5464 5110 94

8/29/2002 327 2.13 0.03 10.10 0.08 20.49 0.07 5290 4990 94

8/30/2002 328 2.01 0.01 10.62 0.03 21.18 0.09 5524 5170 94

9/2/2002 329 1.95 0.07 10.03 0.37 20.49 0.64 5037 4850 96

9/3/2002 330 2.07 0.03 10.21 0.14 19.20 0.12 5018 4915 98

Study Number FY01-013

E-37
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

9/4/2002 331 2.00 0.01 9.44 0.09 20.54 0.03 5065 5215 103

9/5/2002 332 1.98 0.02 9.69 0.05 19.41 0.08 5007 5080 101

9/6/2002 333 2.03 0.03 10.24 0.04 21.28 0.38 5388 5135 95

9/9/2002 334 1.94 0.02 10.56 0.02 20.72 0.11 5377 5245 98

9/10/2002 335 1.99 0.01 9.96 0.08 21.38 0.17 5397 4990 92

9/11/2002 336 1.87 0.08 10.40 0.01 21.27 0.26 5438 5145 95

9/12/2002 337 2.00 0.03 10.08 0.04 19.89 0.20 5176 4835 93

9/13/2002 338 2.12 0.05 10.00 0.06 21.53 0.12 5462 5115 94

9/16/2002 339 1.96 0.02 10.15 0.03 21.28 0.03 5428 5160 95

9/17/2002 340 2.07 0.12 9.34 0.07 20.08 1.01 5242 4985 95

9/18/2002 341 2.07 0.02 9.83 0.13 19.26 0.12 5491 5290 96

9/19/2002 342 1.93 0.02 9.43 0.03 19.32 0.12 5328 5285 99

9/20/2002 343 1.96 0.07 9.78 0.02 19.44 0.06 5310 5260 99

9/23/2002 344 1.91 0.01 9.33 0.02 20.15 0.21 5466 5280 97

9/24/2002 345 1.90 0.02 9.70 0.16 19.63 0.05 5426 5230 96

9/25/2002 346 2.03 0.09 9.61 0.14 19.92 0.08 5505 5250 95

9/26/2002 347 2.01 0.05 9.92 0.04 19.43 0.18 5472 5305 97

9/27/2002 348 2.09 0.07 9.72 0.06 19.56 0.55 5516 5375 97

9/30/2002 349 2.02 0.01 9.43 0.03 20.09 0.05 5398 5330 99

10/1/2002 350 1.89 0.03 10.09 0.05 19.61 0.24 5410 5410 100

10/2/2002 351 1.94 0.03 9.98 0.02 20.09 0.02 5487 5420 99

10/3/2002 352 1.94 0.02 9.96 0.03 20.16 0.03 5505 5445 99

10/4/2002 353 2.03 0.01 9.87 0.12 19.72 0.22 5394 5280 98

10/7/2002 354 2.11 0.03 9.74 0.07 19.68 0.06 5405 5285 98

10/8/2002 355 2.10 0.05 10.27 0.10 19.53 0.11 5450 5400 99

10/9/2002 356 2.16 0.02 10.02 0.01 19.86 0.16 5463 5375 98

10/10/2002 357 2.10 0.02 9.73 0.07 18.65 0.19 5146 5140 100

10/11/2002 358 1.90 0.01 9.31 0.05 18.44 0.12 5015 5075 101

10/14/2002 359 2.12 0.04 10.15 0.05 19.58 0.14 5430 5370 99

10/15/2002 360 1.98 0.02 10.18 0.07 19.45 0.04 5429 5415 100

10/16/2002 361 2.03 0.04 9.54 0.31 19.15 0.05 5285 5220 99

10/17/2002 362 2.02 0.02 9.81 0.06 19.96 0.16 5513 5605 102

10/18/2002 363 2.05 0.02 9.53 0.17 20.09 0.09 5419 5455 101

10/21/2002 364 1.99 0.03 9.56 0.04 20.06 0.08 5430 5480 101

10/22/2002 365 1.99 0.09 9.99 0.15 19.69 0.48 5432 5505 101

10/23/2002 366 1.96 0.03 10.13 0.04 20.07 0.16 5487 5550 101

10/24/2002 367 2.16 0.02 10.47 0.04 18.95 0.08 5391 5420 101

10/25/2002 368 2.06 0.03 9.45 0.02 19.62 0.08 5317 5465 103

10/28/2002 369 1.93 0.01 9.93 0.04 19.98 0.03 5449 5670 104

10/29/2002 370 2.07 0.02 9.99 0.06 19.87 0.03 5464 5665 104

10/30/2002 371 2.06 0.07 10.29 0.12 19.77 0.08 5492 5320 97

10/31/2002 372 2.07 0.01 9.88 0.10 20.29 0.05 5503 5670 103

11/1/2002 373 1.99 0.01 9.83 0.14 19.53 0.06 5312 5330 100

11/4/2002 374 2.05 0.01 10.33 0.08 19.74 0.13 5469 5580 102

11/5/2002 375 2.02 0.01 9.78 0.08 19.74 0.07 5355 5480 102

11/6/2002 376 1.98 0.02 9.84 0.03 20.04 0.10 5415 5550 102

11/7/2002 377 1.97 0.03 10.09 0.04 20.11 0.05 5456 5595 103

11/8/2002 378 1.90 0.02 10.23 0.03 19.89 0.05 5429 5725 105

11/11/2002 379 1.95 0.01 9.58 0.02 21.03 0.06 5365 5595 104

11/12/2002 380 2.16 0.01 10.30 0.11 20.23 0.10 5443 5600 103

11/13/2002 381 2.08 0.01 9.45 0.04 21.16 0.04 5364 5565 104

11/14/2002 382 1.96 0.02 10.43 0.02 20.66 0.08 5448 5535 102

11/15/2002 383 2.05 0.02 10.19 0.04 20.46 0.02 5392 5515 102

11/18/2002 384 2.05 0.02 10.49 0.01 20.48 0.06 5528 5565 101

11/19/2002 385 2.06 0.06 10.02 0.03 19.82 0.02 5339 5345 100

11/20/2002 386 1.88 0.02 10.49 0.01 19.99 0.02 5405 5370 99

11/21/2002 387 1.94 0.11 10.22 0.07 20.08 0.09 5385 5365 100

11/22/2002 388 1.88 0.01 9.70 0.08 20.39 0.05 5422 5445 100

11/25/2002 389 2.05 0.03 10.31 0.06 21.10 0.09 5567 5650 101

11/26/2002 390 1.92 0.06 9.91 0.06 20.51 0.10 5389 5370 100

11/27/2002 391 2.00 0.01 10.15 0.09 20.50 0.06 5443 5330 98

11/28/2002 ** Holiday Holiday Holiday Holiday

11/29/2002 392 2.09 0.01 10.14 0.04 19.44 0.03 5342 5475 102

12/2/2002 393 1.99 0.03 10.04 0.05 20.51 0.03 5487 5510 100

12/3/2002 394 1.92 0.06 10.53 0.17 19.68 0.09 5393 5415 100

12/4/2002 395 1.86 0.02 10.22 0.07 19.56 0.11 5286 5290 100

12/5/2002 396 1.98 0.02 9.44 0.21 19.65 0.06 5182 5170 100

Study Number FY01-013

E-38
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

12/6/2002 397 1.87 0.02 9.68 0.02 20.52 0.08 5377 5310 99

12/9/2002 398 2.10 0.01 9.56 0.35 20.32 0.37 5318 5330 100

12/10/2002 399 1.97 0.07 9.88 0.05 19.44 0.02 5210 5245 101

12/11/2002 400 1.96 0.10 9.65 0.13 20.72 0.14 5388 5460 101

12/12/2002 401 2.04 0.04 9.72 0.20 20.41 0.09 5323 5405 102

12/13/2002 402 1.99 0.07 9.87 0.18 19.76 0.26 5252 5325 101

12/16/2002 403 1.97 0.02 10.03 0.04 19.69 0.36 5323 5390 101

12/17/2002 404 2.14 0.04 9.62 0.12 19.81 0.53 5297 5380 102

12/18/2002 405 2.08 0.03 9.82 0.19 20.13 0.14 5366 5400 101

12/19/2002 406 2.06 0.03 9.69 0.12 19.60 0.13 5280 5195 98

12/20/2002 407 2.12 0.00 10.00 0.07 19.85 0.05 5403 5370 99

12/23/2002 408 1.96 0.09 9.81 0.10 19.54 0.40 5178 5355 103

12/24/2002 409 1.96 0.02 9.76 0.17 19.37 0.16 5171 5265 102

12/25/2002 ** Holiday Holiday Holiday Holiday

12/26/2002 410 2.01 0.03 9.75 0.06 20.02 0.48 5269 5360 102

12/27/2002 411 1.99 0.07 9.86 0.20 19.68 0.31 5248 5235 100

12/30/2002 412 2.00 0.04 9.57 0.31 19.71 0.48 5266 5120 97

12/31/2002 413 1.99 0.03 9.35 0.16 20.34 0.48 5335 5230 98

1/1/2003 ** Holiday Holiday Holiday Holiday

1/2/2003 414 2.07 0.04 10.17 0.23 21.00 0.37 5597 5490 98

1/3/2003 415 2.11 0.03 10.22 0.06 19.61 0.21 5335 5335 100

1/6/2003 416 2.04 0.01 9.74 0.14 20.11 0.20 5254 5165 98

1/7/2003 417 2.04 0.08 9.63 0.24 19.97 0.37 5247 5115 97

1/8/2003 418 2.11 0.01 10.40 0.09 20.44 0.05 5464 5325 97

1/9/2003 419 2.14 0.01 10.56 0.03 20.22 0.13 5472 5410 99

1/10/2003 420 2.09 0.03 10.18 0.02 20.46 0.02 5414 5355 99

1/13/2003 421 2.01 0.04 10.46 0.07 19.81 0.50 5318 5140 97

1/14/2003 422 1.96 0.05 10.16 0.33 19.82 0.19 5243 5155 98

1/15/2003 423 2.01 0.06 9.93 0.41 20.14 0.19 5375 5525 103

1/16/2003 424 1.98 0.02 9.97 0.22 19.49 0.42 5223 5415 104

1/17/2003 425 2.03 0.04 9.60 0.25 19.69 0.20 5196 5560 107

1/20/2003 426 2.10 0.04 9.61 0.08 20.23 0.10 5282 5750 109

1/21/2003 427 2.00 0.01 9.82 0.09 19.80 0.06 5231 5590 107

1/22/2003 428 2.02 0.06 9.70 0.17 19.23 0.58 5126 5405 105

1/23/2003 429 1.98 0.06 9.59 0.29 19.82 0.47 5195 5665 109

1/24/2003 430 1.99 0.04 10.36 0.13 19.20 0.08 5175 5535 107

1/27/2003 431 2.07 0.06 10.31 0.45 20.07 0.32 5345 5420 101

1/28/2003 432 1.91 0.03 9.70 0.05 20.51 0.06 5287 5430 103

1/29/2003 433 2.11 0.04 10.23 0.01 20.05 0.06 5330 5460 102

1/30/2003 434 1.89 0.03 10.47 0.04 20.58 0.07 5418 5550 102

1/31/2003 435 2.04 0.08 9.76 0.05 19.34 0.55 5152 5250 102

2/3/2003 436 2.05 0.05 9.95 0.19 19.99 0.14 5260 5470 104

2/4/2003 437 2.09 0.10 9.91 0.18 19.23 0.49 5128 5395 105

2/5/2003 438 2.06 0.04 9.90 0.47 19.33 0.37 5139 5430 106

2/6/2003 439 1.97 0.07 9.52 0.25 19.88 0.13 5137 5415 105

2/7/2003 440 2.10 0.07 9.58 0.14 20.39 0.07 5277 5530 105

2/10/2003 441 2.00 0.02 9.90 0.07 21.20 0.01 5425 5620 104

2/11/2003 442 1.90 0.05 10.30 0.07 20.68 0.08 5478 5650 103

2/12/2003 443 1.97 0.06 9.71 0.17 19.79 0.36 5231 5400 103

2/13/2003 444 1.99 0.01 10.12 0.02 19.34 0.22 5217 5360 103

2/14/2003 445 2.01 0.02 9.80 0.06 20.36 0.02 5423 5655 104

2/17/2003 446 2.05 0.02 9.62 0.08 18.88 0.04 5173 5450 105

2/18/2003 447 1.90 0.08 9.91 0.10 19.23 0.11 5269 5515 105

2/19/2003 448 2.05 0.14 9.79 0.17 18.94 0.39 5253 5450 104

2/20/2003 449 1.88 0.03 10.28 0.14 19.36 0.08 5376 5605 104

2/21/2003 450 2.05 0.05 9.68 0.22 20.54 0.20 5274 5420 103

2/24/2003 451 2.08 0.02 10.26 0.03 19.70 0.11 5159 5475 106

2/25/2003 452 1.99 0.07 9.61 0.24 19.48 0.35 5121 5395 105

2/26/2003 453 1.94 0.06 9.77 0.29 19.69 0.28 5179 5390 104

2/27/2003 454 1.94 0.03 9.90 0.29 19.91 0.21 5242 5435 104

2/28/2003 455 2.00 0.03 9.49 0.06 20.42 0.04 5294 5585 105

3/3/2002 456 1.96 0.02 9.56 0.26 20.10 0.18 5190 5440 105

3/4/2002 457 2.04 0.01 10.02 0.16 20.59 0.14 5352 5520 103

3/5/2002 458 1.99 0.04 9.80 0.20 19.94 0.27 5205 5405 104

3/6/2002 459 2.00 0.04 9.79 0.02 20.80 0.02 5317 5525 104

3/7/2002 460 1.94 0.04 10.66 0.29 21.64 0.25 5598 5730 102

3/10/2003 461 2.09 0.03 9.62 0.16 19.53 0.06 5205 5335 102

Study Number FY01-013

E-39
GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev

Anticipated 

Usage (g)

Actual 

Usage (g)

% Usage 

(Actual / 

Date Anticipated)

Exposure 

Day

Chamber 6 (2g/m Nominal Usage (Mass Balance) 3) Chamber 7 (10 g/m3) Chamber 8 (20g/m3)

3/11/2003 462 1.99 0.08 9.48 0.16 20.22 0.15 5280 5380 102

3/12/2003 463 1.93 0.08 9.63 0.23 19.63 0.43 5208 5320 102

3/13/2003 464 2.06 0.01 9.60 0.15 19.60 0.40 5210 5310 102

3/14/2003 465 1.99 0.04 9.56 0.10 19.62 0.39 5168 5285 102

3/17/2003 466 1.96 0.02 9.60 0.12 19.93 0.07 5315 5610 106

3/18/2003 467 2.07 0.03 9.98 0.13 20.37 0.19 5339 5600 105

3/19/2003 468 1.97 0.03 9.56 0.20 20.15 0.15 5232 5420 104

3/20/2003 469 1.97 0.06 9.38 0.08 20.99 0.08 5340 5490 103

3/21/2003 470 2.05 0.03 9.76 0.18 20.04 0.15 5229 5525 106

3/24/2003 471 1.97 0.03 10.31 0.41 20.26 0.17 5276 5395 102

3/25/2003 472 2.02 0.04 9.91 0.18 20.48 0.13 5267 5320 101

3/26/2003 473 2.00 0.06 10.27 0.22 20.13 0.27 5242 5160 98

3/27/2003 474 1.95 0.03 10.01 0.13 19.74 0.58 5278 5210 99

3/28/2003 475 1.98 0.01 9.78 0.29 20.05 0.10 5308 5190 98

3/31/2003 476 2.03 0.06 9.82 0.24 19.20 0.27 5138 5250 102

4/1/2003 477 1.97 0.07 9.67 0.30 19.97 0.40 5236 5420 104

4/2/2003 478 2.05 0.08 9.76 0.29 19.62 0.15 5165 5230 101

4/3/2003 479 2.00 0.15 9.69 0.23 19.78 0.19 5221 5420 104

4/4/2003 480 1.97 0.02 9.72 0.10 19.50 0.06 5137 5310 103

4/7/2003 481 1.97 0.05 9.71 0.20 21.04 0.06 5391 5510 102

4/8/2003 482 1.97 0.09 10.09 0.09 19.69 0.34 5230 5330 102

4/9/2003 483 2.01 0.02 10.42 0.06 20.19 0.06 5491 5555 101

4/10/2003 484 1.97 0.07 9.81 0.19 19.90 0.28 5218 5370 103

4/11/2003 485 2.06 0.04 9.90 0.06 20.57 0.06 5393 5515 102

4/14/2003 486 2.13 0.03 10.29 0.02 20.29 0.22 5454 5755 106

4/15/2003 487 2.12 0.01 9.95 0.24 19.43 0.34 5263 5474 104

4/16/2003 488 2.02 0.03 10.05 0.09 20.60 0.05 5452 5465 100

4/17/2003 489 1.95 0.01 10.07 0.26 20.68 0.21 5455 5530 101

4/18/2003 490 2.08 0.01 10.13 0.17 19.87 0.36 5326 5325 100

4/21/2003 491 2.06 0.04 10.10 0.13 19.85 0.45 5285 5325 101

4/22/2003 492 1.97 0.02 10.06 0.04 19.98 0.38 5283 5345 101

4/23/2003 493 1.99 0.03 9.80 0.04 20.16 0.30 5287 5410 102

4/24/2003 494 1.96 0.07 9.87 0.23 19.73 0.28 5216 5090 98

4/25/2003 495 2.05 0.06 9.73 0.14 19.94 0.27 5249 5085 97

4/28/2003 496 2.02 0.02 9.56 0.66 19.53 1.05 5107 4930 97

4/29/2003 497 2.03 0.02 9.97 0.13 20.10 0.06 5271 5370 102

4/30/2003 498 2.01 0.10 10.27 0.30 19.87 0.33 5277 5175 98

5/1/2003 499 2.01 0.03 9.81 0.12 19.93 0.17 5213 5090 98

5/2/2003 500 2.03 0.01 9.69 0.12 20.36 0.11 5293 5135 97

5/5/2003 501 2.13 0.04 10.16 0.05 20.55 0.34 5408 5230 97

5/6/2003 502 1.99 0.03 10.38 0.27 19.53 0.19 5230 5270 101

5/7/2003 503 2.00 0.06 9.88 0.16 19.72 0.34 5188 5125 99

5/8/2003 504 2.03 0.04 9.97 0.04 20.16 0.07 5288 5140 97

5/9/2003 505 2.06 0.02 9.91 0.10 19.97 0.06 5254 5105 97

5/12/2003 506 1.99 0.11 9.77 0.11 19.59 0.11 5154 4965 96

5/13/2003 507 2.08 0.03 9.84 0.05 20.01 0.04 5246 5030 96

5/14/2003 508 2.02 0.07 9.74 0.04 19.77 0.06 5185 5325 103

5/15/2003 509 2.01 0.02 9.52 0.50 19.30 0.48 5075 5280 104

5/16/2003 510 2.09 0.03 10.04 0.15 19.94 0.52 5271 5465 104

5/19/2003 511 2.08 0.03 10.11 0.08 20.48 0.21 5251 5500 105

5/20/2003 512 2.13 0.01 9.80 0.30 20.74 0.17 5248 5365 102

5/21/2003 513 2.09 0.01 9.75 0.28 20.02 0.17 5203 5365 103

5/22/2003 514 2.05 0.01 10.09 0.59 20.56 0.78 5331 5525 104

5/23/2003 515 2.04 0.03 10.07 0.52 20.81 0.24 5380 5605 104

5/26/2003 516 2.01 0.05 10.07 0.09 19.84 0.13 5155 5295 103

5/27/2003 517 1.99 0.03 10.08 0.12 20.54 0.40 5265 5465 104

5/28/2003 518 2.06 0.04 9.89 0.23 20.35 0.13 5241 5445 104

5/29/2003 519 2.02 0.01 9.91 0.15 19.93 0.34 5312 5555 105

5/30/2003 520 1.94 0.03 9.85 0.42 19.90 0.15 5286 5515 104

Average 2.02 10.00 20.29 5413 5359 99

STDEV 0.07 0.37 0.74 211 234 4

% Target 100.82 99.98 101.45

*11/28/01 (Exposure Day 134). Did not expose for a full day because of fluctuations in the chamber supply air. We exposed for approximately 40 minutes 

at average concentrations of 1.53 g/m3

, 7.88 g/m3, and 13.62 g/m3. The supply air system was repaired and normal exposures were conducted the 

following day.

Study Number FY01-013

E-40
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-6 Summary of GMVC Room Air Sampling Results 

E-41
Summary of GMVC Room Air Sampling Results

Date Exposure 

Day

Measured 

Room Air 

Conc. (g/m3

)

Stdev.

Sample 

Time 

(min)

9/13/2001 81 0.02 0.01 20

11/13/2001 124 0.5 0.02 13

11/14/2001 125 0.31 0.01 21

2/5/2002 181 -0.2 0.04 18

4/29/2002 240 0.14 0.02 30

7/22/2002 299 0.06 0.01 30

10/14/2002 359 0.11 0.06 20

1/2/2003 414 -0.06 0.02 20

5/28/2003 518 0.07 0.01 20

* Samples taken using the Low Miran during last part of exposure day

Study Number FY01-013

E-42
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-7 Aerosol Scientist’s Report 

E-43
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-44

Study Number FY01-013 

Study Title: 211(b) Chronic Carcinogenicity Study Gasoline MTBE Vapor Condensate 

(GMVC) 

LRRI Protocol Number: FY01-013 

Appendix E-7 

AERSOSOL SCIENTIST’S REPORT 

Edward B. Barr, MSEE Date 

Aerosol Scientist 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-45

METHOD 

Test Substance Identification, Source, and Storage

Gasoline MTBE Vapor Condensate (GMVC; Lot Number API 00-02) was prepared and 

supplied in 420-pound and 20-pound gas cylinders by Chevron Research and Technology Center 

(CRTC; Richmond, CA). Original characterization of the test substance was performed by 

CRTC. The reference gas chromatographic profile of the 19 key components was provided by 

ExxonMobil Biomedical Sciences, Inc. (EMBSI), Annandale, NJ. Twenty-pound cylinders and 

some 420-pound cylinders were stored at ambient temperature in a storage building dedicated for 

that purpose at the Lovelace Respiratory Research Institute (LRRI). The remaining 420-pound 

cylinders were stored in an outside, controlled area at ambient temperature. The test substance 

was transferred, as needed, from the 420-pound to the 20-pound cylinders. Only authorized 

personnel were allowed access to the test substance. Receipt, use, and inventory of this test 

substance were documented. 

Analysis. Before dispensing GMVC from each 420 pound tank, a liquid sample was transferred 

from the 420-pound tank to a small glass vial with a crimp top. A 50 μL sample of liquid was 

injected into a Tedlar bag for gas chromatographic analysis at LRRI. The analytical method is 

described under Section “Qualitative Analysis of the Hydrocarbon Composition of the Test 

Substance and Exposure Atmosphere by Gas Chromatography.” 

Reserve Sample. The Sponsor-contracted archives have retained samples of the test substance. 

Exposure System

The exposure system consisted of four level [low, mid, and high target concentration 

levels and control (air only)] H-2000 whole-body chambers [Lab Products, Inc., Seaford, DE], 

the vapor generation system, and the on-line gas analysis system [Miran infrared spectrometers]. 

Figure E-1 is a schematic representation of a typical H-2000 chamber in the exposure system. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-46

MAIN EXHAUST DUCT

MAIN SUPPLY AIR

DUCT

H-2000

EXPOSURE

CHAMBER

CHAMBER

DILUTION

Vapor

Generation

System

CHAMBER

EXHAUST

2" Delivery Line

MIRAN

Infrared

Spectrometer

Figure E-1. Gasoline MTBE Vapor Exposure System 

Figure E-2 shows the layout of the four chamber system in room 408 and the adjacent 

room housing the Miran 1A infrared spectrometers and other equipment. The chamber system 

was housed in a separate room for safety requirements. Room 408 was modified to meet 

National Fire Protection Association (NFPA) requirements for class I liquids. Electrical 

equipment was excluded from use in room 408, so the Miran 1A infrared spectrometers used for 

analyzing the chamber atmospheres and other electrical equipment were operated in a separate 

room. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-47

Gasoline MTBE Vapor Condensate

Room 408

Miran

MIR6

Table

Miran

MIR7

Table

Miran

MIR8

Table

N2 N2

N2 N2

Control

Cabinet Computer

Change

Chamber

Change

Chamber

Control

CBR5

High Level

CBR8

Mid Level

CBR7

Low Level

CBR6

SS

Flex

Freezer

FR409

Monitoring & Controls

Room 409

MobileTedlar

Bag Setup

Ar He H2

GC1

GC2

Ar He H2

Computer

Miran

MIR1 LN2

LNT1

LN2

LNT2

Generator

Cabinet

20# Gas Tank

Work Table

Figure E-2. Gasoline Vapor Condensate Exposure System Room Layout 

H-2000 Whole-Body Chambers. The rats were housed 24 hours per day during quarantine and 

exposure in the H-2000 whole-body inhalation chambers (Figure E-1). Rats were exposed 6 

hours/day (plus 14 minutes, the time for the vapor concentration to reach T90), 5 days/week for 

104 weeks (520 exposure days). Initially, all rats were housed separately in 3.8-inch wide by 

11-inch long by 8-inch high compartments within stainless steel baskets. When male rats 

reached 400 g they were transferred to baskets with 5.7-inch by 11-inch by 8-inch compartments. 

Each chamber contained six baskets. 

The chambers and cage racks were washed weekly. The cage racks were rotated 

clockwise weekly when the rats were transferred from the dirty to the clean chamber. 

The chambers were held at approximately 1 inch of water negative pressure with respect 

to the exposure room, and the chamber flow rates were maintained at 12 to 15 air changes per 

hour (400–500 liters per minute [LPM]). Chamber temperatures were maintained at 20° to 24°C. 

Temperature, relative humidity, and chamber air flow rates were continuously monitored 24 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-48

hours per day. Values for the three parameters were recorded at 30-minute intervals by a 

computer-based monitoring system. Oxygen concentration in the chambers was maintained at 

19%. This parameter was checked daily but not recorded. 

A 12-hour light cycle was maintained with lights on at 0600. Light levels in the exposure 

room and noise levels in the chambers were determined periodically. 

Vapor Generation System. A schematic of the vapor generation system is shown in Figure E-3. 

The daily supply of GMVC for each exposure chamber was contained in 20-pound gas storage 

cylinders. Exposure atmospheres were generated by controlling the flow of pressurized GMVC 

through a rotameter, into a heated stainless steel transfer line where the GMVC was completely 

vaporized. Chamber concentrations were controlled by adjusting the flow rates of the GMVC 

and dilution air rate. Chamber exhaust was carried to a thermal oxidizer on the roof of the 

exposure facility where it was burned. 

On-line Gas Analysis System. Chamber atmospheres were monitored continuously by Miran 1A 

infrared spectrometers (Foxboro Wilks, Foxboro, CT). The high-, mid-, and low-level exposure 

chambers were each monitored with their own analyzer. The analyzers for the high-, mid-, and 

low-level chambers underwent weekly five-point calibrations and daily one-point calibration 

checks using test substance. A fourth analyzer was devoted to monitoring the control chamber, 

the room air, and the hood enclosing the 20-pound tank of test substance. This Miran underwent 

a three-point calibration periodically. The Miran 1A analyzers dedicated to the mid- and highlevel chambers were calibrated over a range of 6–35 g/m3

. The Miran 1A analyzers for the 

control chamber and the low-level chamber were calibrated over a concentration range of 

1–7 g/m3

. 

The absorbance signals, recorded continuously from the first 2 hours, second 2 hours, and 

third 2 hours, were averaged to provide three concentration values for each chamber each 

exposure day. The mean of the three values from each exposure chamber was reported as the 

day’s exposure concentration for that chamber. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-49

Gasoline MTBE Vapor Condensate Vapor Generator

Sight

Bowl

Bypass

To Main

Exhaust

Duct

GMVC

Vapor and

Air Mixture

To CBR6

Bench Scale

Gasoline

MTBE

Vapor

Condensat

e

P

Liquid

Pressurizing

N2 (60-80 psig)

Nitrogen

Carrier Gas

Pneumatic

Shutoff

Pressure Valve

Gauge

GMVC

Rotameter

Nitrogen

Rotameter

Heat Exchanger

(Vaporizer)

Orifice

Meter

Low Level

Chamber

Supply Air

Mid Level

Chamber

Supply Air

High Level

Chamber

Supply Air

GMVC

Vapor and

Air Mixture

To CBR7

GMVC

Vapor and

Air Mixture

To CBR8 Dilution

Tee

Liquid GMVC Line

Nitrogen Line

GMVC Vapor Line

Chamber

Bypass

(3-way Valve)

Hot

Water

Retur

n

Hot

Water

In

Heat Exchanger

(Vaporizer)

Heat Exchanger

(Vaporizer)

Dilution

Tee

Dilution

Tee

Nitrogen

Rotameter

Nitrogen

Rotameter

Hot

Water

Return

Hot Water

Return

Hot Water

In

Hot Water

In

Sight

Bowl

Sight

Bowl

Orifice

Meter

Orifice

Meter

Chamber

Bypass

(3-way Valve)

Chamber

Bypass

(3-way Valve)

GMVC

Rotameter

GMVC

Rotameter

Figure E-3. Vapor Generator for GMVC 

Qualitative Assessment of Exposure Atmospheres. The qualitative composition of the exposure 

atmosphere in each chamber was determined weekly by gas chromatography using a Shimadzu 

Model GC-17A/FID (Columbia, MD). Exposure atmosphere samples were collected from the 

chambers into Tedlar sampling bags each week. The atmosphere samples were transferred from 

the sampling bags directly to the sampling loop of the GC. The percent peak area of each of 19 

components was compared to the EMBSI hydrocarbon profile. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-50

Qualitative Analysis of the Hydrocarbon Composition of the Test Substance and Exposure 

Atmosphere by Gas Chromatography

The hydrocarbon profile of the test substance and the exposure atmosphere was 

determined using a Shimadzu Model GC-17A/FID (Columbia, MD) equipped with a Petrocol 

DH150 capillary column (Supelco, 150 m × 0.25 mm ID, 1.0 μm film thickness). The 

chromatographic method was adapted from that used by EMBSI and is summarized in Table 

E-1. To validate the system before the exposures began, the retention times and relative peak 

intensities of 19 standards of the 19 major components in the test substance were determined. 

Each standard vapor was prepared in the concentration expected in the test substance as 

determined by EMBSI (see Appendix B) and injected on the GC. These standards and their 

relative peak intensities as expected in GMVC are listed in Table E-2. The gas chromatographic 

profile of the 19 major peaks (retention time and relative peak area) was compared with that 

originally determined for the GMVC by EMBSI and subsequently used as the benchmark for 

comparison of the profiles obtained on test substance and exposure atmosphere samples. 

Two types of performance checks on the gas chromatograph were conducted during the 

study. Each week during the study, the retention times of eight representative components were 

determined using a certified mixture containing 760 ppm butane, 2270 ppm isopentane, 160 ppm 

trans-2-pentene, 430 ppm 2-methylpentane, 220 ppm hexane, 90 ppm 2,4-dimethylpentane, 

100 ppm 2-methylhexane, and 220 ppm isooctane in nitrogen (Matheson Tri-Gas, Irving TX). In 

addition, one-point performance qualifications were performed on each day in which chamber 

profiles were analyzed. The one-point check was performed using a certified standard of 840 

ppm butane in N2 (Matheson Tri-Gas, Irving, TX). 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-51

Table E-1. Gas Chromatograph Operating Conditions for Vapor Condensate Analysis 

Analytical Column: Supelco PetrocolTM DH150 

(150 m × 0.25mm) 1.0 μm film thickness 

Oven Temperature Program: 

Initial Temp 35°C 

Initial Time 96 minutes 

Rate 1 5°C/min to 130°C 

Rate 2 20°C/min to 200°C 

Final Time 15 minutes 

Injector: 

Temperature 225°C 

Mode Split 

Ratio 111:1 

Injection Volume 500 μL (vapor) 

Detector: 

Type Flame Ionizing Detector (FID) 

Temperature 225°C 

Fuel Hydrogen @ 30–60 mL/min 

Oxidizer Air @ 300–600 mL/min 

Make-up Gas Helium @ 30 mL/min 

Table E-2. The Hydrocarbon Components of GMVC 

 and Their Relative Amounts in BGVC as 

 Determined by Gas Chromatography 

Component Area Percent 

Isobutane 2.2 

n-Butane 11.1 

Isopentane 31.0 

n-Pentane 9.1 

Trans-2-pentene 2.0 

2-Methyl-2-butene 2.9 

MtBE 21.3 

2,3-Dimethylbutane 0.9 

2-Methylpentane 4.5 

3-Methylpentane 2.6 

n-Hexane 2.1 

Methylcyclopentane 1.1 

2,4-Dimethylpentane 0.9 

Benzene 1.5 

2-Methylhexane 1.0 

2,3-Dimethylpentane 1.0 

3-Methylhexane 1.1 

Isooctane 1.2 

Toluene 2.5 

Totals 100 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-52

Computer Environmental Monitoring System

A general layout of the Computer Environmental Monitoring System (CEMS) is shown 

in Figure E-4. The system is comprised of a computer, LabVIEW data acquisition software, 

input/output (I/O) hardware, transducers, and instruments. LabVIEW serves as the interface 

between the operator and the monitoring system. The computer executes the LabVIEW 

monitoring program and performs data acquisition, data storage, and directs communications via 

data acquisition, serial interface, and signal conditioning hardware. LabVIEW (version 6.0, 

National Instruments Corporation, Austin, TX) is a software program that was used to develop 

the automation, control, and monitoring application for this study. The LabVIEW application 

(“Gas Condensate CEMS”) acquires the signals from the exposure system transducers via I/O 

hardware that converts the transducer signals to voltage measurements. The LabVIEW 

application then converts the voltage measurements to physical parameters (i.e., temperature, 

pressure, flow, RH). 

Computer and

Data Acquisiton

software

[LabVIEW]

I/O Hardare Transducers/

Instruments

Figure E-4. Computer Environmental Monitoring System 

Chamber and room temperatures were measured using calibrated series 400 thermistor 

probes (Omega Engineering, Stamford, CN), chamber humidities were measured by model 

5103VHH calibrated RH sensors (Thermalogic, Hudson, MA), and pressures measured by series 

PX41 and PX163 calibrated pressure transducers (Omega Engineering, Stamford, CN). Flows 

were calculated from pressure differential measurements across 2-inch orifice meters. The 

acquired parameters were summarized by the LabVIEW application in a summary data file each 

day, and the mean, minimum, maximum, and standard deviation of each environmental 

parameter is written to the file every 30 minutes. The LabVIEW application also is used to start 

and stop the exposures and to record average vapor concentrations every 2 hours to a data file. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-53

RESULTS 

Pre-exposure Characterization

The exposure system was tested prior to animal exposures. Characterization included the 

following: 1) within-day and between-day consistency of the hydrocarbon profile as determined 

by gas chromatography; 2) uniformity of the distribution of total vapor within each chamber; 

3) determination of the time for vapor concentration to achieve 90% of the equilibrium target 

value (T90); and 4) the exposure atmosphere in the animals’ breathing zone was also examined 

for the presence of aerosol particles using a TSI Scanning Mobility Particle Sizer (TSI Industries, 

Shoreview, MN). One time, prior to the initiation of animal exposures, the concentration of the 

test substance in the generator containment hood and in the exposure room were measured to 

ensure that the generator containment hood was operating satisfactorily. 

Three-Day Stability Evaluation and Nominal GMVC Usage. Before exposures were initiated the 

system was operated for 6 hours/day for 3 consecutive days to determine system stability. The 

concentration of vapor in each chamber was close to target and constant within each day, and the 

concentrations were reproducible from day to day (Table E-3). Gas chromatographic analysis of 

the chamber atmospheres indicated that the relative percentages of the major components were 

constant over the 3-day period. The percentages of actual GMVC usage/anticipated usage 

(nominal usage) on the 3 days of stability testing were 95, 97, and 90 for Days 1, 2, and 3, 

respectively. 

Table E-3. Results of 3-Day Stability Evaluations 

Target Exposure 

Concentration (g/m3

)/ 

Chamber number 

Achieved Concentration ± SD (n = 3) 

Day 

(5/17/01) 

Day 2 

(5/18/01) 

Day 3 

(5/19/01) 

2 (Chamber 6) 2.06 ± 0.04 1.97 ± 0.10 1.93 ± 0.05 

10 (Chamber 7) 9.45 ± 0.23 9.37 ± 0.15 9.37 ± 0.28 

20 (Chamber 8) 18.8 ± 0.28 18.9 ± 1.14 19.5 ± 0.37 

 

Homogeneity of Vapor Concentration. The homogeneity of vapor concentration throughout the 

exposure chambers was determined by conducting a chamber distribution study. The 

concentrations of GMVC were measured from four sampling ports located in front and four 

sampling ports located in the back of the chambers during an exposure day and compared to the 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-54

concentration obtained in a reference location within the chamber. The spatial variations 

measured in Chambers 6 (2 g/m3

), 7 (10 g/m3), and 8 (20 g/m3) were 3.0%, 1.3%, and 0.8%, 

respectively. These results indicate the vapor was distributed evenly within each of the 

chambers. 

T90 Determination. The amounts of time required to reach T90 were 13, 14.1, and 14.2 minutes 

for Chambers 6, 7, and 8, respectively. A T90 of 14 minutes was chosen for use with this study. 

Daily exposures periods to GMVC were then 6 hours and 14 minutes. 

Confirmation of the Absence of Aerosols. The particle concentrations of air inside Chamber 8, 

operated at a target concentration 20 g GMVC/m3

, and the control chamber (Chamber 5) were 

determined using a TSI Aerodynamic Particle Sizer (model 3321, TSI, Inc., St. Paul, MN). 

There was less than 1 particle per cubic centimeter air in the control and high-level chambers, 

indicating that there were no GMVC aerosols at the highest target vapor concentration used in 

this study. 

In-Study Data

Test Substance. The composition of the test substance remained acceptably constant throughout 

the study. Results of gas chromatography analyses of the test substance are provided in 

Appendix B. 

Chamber Distribution Evaluation During Exposures. During the second week of exposures, the 

uniformity of vapor distribution was re-evaluated to determine the distribution in the presence of 

the test animals. The spatial variations measured in Chambers 6 (low-level chamber, 2 g/m3

), 7 

(mid-level chamber, 10 g/m3

), and 8 (high-level chamber, 20 g/m3) were 2.8%, 0.86%, and 1.8%, 

respectively. These results indicated the vapor was distributed evenly within each of the 

chambers. 

Determination of Nominal Concentration. Daily nominal or “anticipated” usage was calculated 

by multiplying the average GMVC concentration in each chamber (low, mid, high; g/m3) by the 

total flow through each respective chamber ([L/min * min]/[1000 L/m3]) and then summing the 

values for all three chambers. This value was compared to the actual GMVC usage determined 

by taking the difference between the weight of the 20-pound cylinder before and after each 

exposure. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-55

Concentration of Test Substance in the Exposure Room. Concentration of the test substance in 

the exposure room was determined periodically during the study (at approximately 60-day 

intervals) using a Miran 1A Infrared Spectrometer (Foxboro Wilks, Foxboro, CT) operated using 

the same settings as used to monitor the low-level exposure chamber. 

Chamber Concentrations and Nominal Usage. The overall study means of the daily vapor 

concentrations achieved for the 2, 10, and 20 g GMVC/m3

 vapors are provided in Table E-4. 

The overall achieved means were within 2% of target for each exposure concentration. Thus, all 

future references to exposure concentration are in terms of target concentration. For the control 

chambers, concentrations of “zero” were obtained on all but 15 of the 520 exposure days. On 

these 15 days, the readings were below the lowest concentration on the standard curve used to 

calibrate the control chamber Miran 1A (1 g GMVC/m3

). Daily results are provided in Appendix 

E-5. Concentrations of GMVC in room air were below the concentration of the lowest standard 

used to calibrate the Miran 1A (1 g/m3; Appendix E-6). 

Table E-4. Summary of GMVC Vapor Concentrationsa

Target 

g GMVC/m3

 

Achieved Concentrations, 

g GMVC/m3 Percent of Target 

 0 < 1b NA 

 2 2.02 ± 0.07 101 

10 10.0 ± 0.37 100 

20 20.3 ± 0.74 101 

a

Results are the mean ± SD of vapor concentrations obtained in 520 

exposure days. 

b Concentrations of “zero” were obtained on all but 15 of the 520 

exposure days. On these 15 days, the readings were below the lowest 

concentration on the standard curve used to calibrate the control 

chamber Miran 1A (1 g GMVC/m3

). 

The overall average of the daily percent nominal usage was 99% ± 4%, indicating 

excellent agreement between anticipated and actual GMVC usage. 

Gas Chromatographic Profiles of GMVC Exposure Atmospheres

Gas chromatographic profiles were obtained from each exposure chamber weekly to 

assess whether the animals were exposed to the relative amounts of the same 19 major 

components throughout the study. The peak areas of the 19 major components were summed to 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

E-56

provide a “total peak area” for those components. The peak area of each of the components was 

divided by the total peak area for the components to obtain a relative peak area (in percent) for 

each of the components. These were compared to the reference values provided by EMBSI. 

Profiles remained acceptably constant throughout the study. Results are provided in Appendix F. 

Environmental Data

Results of analyses of the chamber environment are provided in Appendix G. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

F-1 

APPENDIX F 

WEEKLY GAS CHROMATOGRAPHIC PROFILES OF CHAMBER ATMOSPHERES 
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

5-23-01

Week 

Starting 

5-28-01

Week 

Starting 

5-23-01

Week 

Starting 

5-28-01

Week 

Starting 

5-23-01

Week 

Starting 

5-28-01

Isobutane 2.2 2.5 2.2 2.2 2.2 2.1 2.3n-butane 11.1 10.2 9.3 10.2 10.5 10.5 10.9Isopentane 31.0 26.9 26.6 30.1 30.2 30.7 31.5n-pentane 9.1 8.7 8.7 8.9 9.0 8.9 9.1trans-2-pentene 2.0 2.9 2.7 2.1 2.2 2.1 2.12-methyl-2-butene 2.9 3.9 3.7 2.9 2.9 2.9 3.1MTBE/2,3-dimethylbutaneMTBE 21.3 20.9 20.7 23.0 22.7 22.8 22.92,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 5.2 4.6 4.4 4.4 4.53-methylpentane 2.6 2.7 3.1 2.4 2.6 2.6 2.6n-hexane 2.1 2.2 2.5 2.1 2.2 2.2 2.0Methylcyclopentane 1.1 2.1 1.5 1.2 1.0 1.2 1.12,4-dimethylpentane 0.9 2.3 0.9 1.1 1.0 0.9 0.9Benzene 1.5 1.7 2.5 1.6 1.5 1.5 1.22-methylhexane 1.0 1.1 1.2 1.0 1.0 1.1 0.92,3-dimethylpentane 1.0 2.4 1.7 1.2 1.2 1.2 1.13-methylhexane 1.1 1.3 2.1 1.3 1.2 1.2 0.9Isooctane 1.2 0.7 1.9 1.3 1.4 1.5 1.2Toluene 2.5 2.0 2.5 1.8 1.7 1.3 0.8

Low (2.0g/m3) Mid (10g/m3) Mid (10g/m3)

May 2001

Study Number FY01-013

F-2
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

6-4-01

Week 

Starting 

6-11-01

Week 

Starting 

6-18-01

Week 

Starting 

6-25-01

Week 

Starting 

6-4-01

Week 

Starting 

6-11-01

Week 

Starting 

6-18-01

Week 

Starting 

6-25-01

Week 

Starting 

6-4-01

Week 

Starting 

6-11-01

Week 

Starting 

6-18-01

Week 

Starting 

6-25-01

Isobutane 2.2 2.6 2.2 2.3 2.2 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1n-butane 11.1 8.8 9.1 9.6 9.8 10.2 10.4 10.5 10.3 10.9 10.7 10.5 10.5Isopentane 31.0 24.9 26.0 26.8 26.2 29.9 30.0 30.2 29.8 31.9 31.1 30.7 30.6n-pentane 9.1 7.7 8.5 7.8 8.6 8.8 8.8 8.9 8.9 9.1 9.1 8.9 8.9trans-2-pentene 2.0 3.8 3.0 3.0 3.0 2.2 2.2 2.1 2.2 2.1 2.2 2.0 2.12-methyl-2-butene 2.9 4.0 4.3 3.7 3.6 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 20.9 21.8 21.0 19.0 22.6 23.4 21.9 22.4 23.0 22.5 22.3 22.32,3-dimethylbutane 0.9 0.9 0.9 0.9 0.8 1.0 1.0 0.9 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.3 4.9 4.3 4.9 4.5 4.4 4.6 4.5 4.4 4.5 4.5 4.43-methylpentane 2.6 2.9 2.9 2.7 2.7 2.5 2.5 2.6 2.7 2.5 2.5 2.6 2.6n-hexane 2.1 2.6 2.3 2.5 3.2 2.1 2.1 2.2 2.1 1.9 2.1 2.2 2.3Methylcyclopentane 1.1 1.8 1.4 1.7 1.7 1.2 1.1 1.2 1.2 1.0 1.1 1.2 1.22,4-dimethylpentane 0.9 2.0 1.5 1.0 0.9 1.0 1.1 1.0 1.0 1.1 1.0 0.9 1.0Benzene 1.5 2.0 2.2 1.8 2.4 2.0 1.8 1.7 2.0 1.1 1.5 1.6 1.72-methylhexane 1.0 2.0 1.0 1.4 1.9 1.0 1.0 1.0 1.1 0.9 1.0 1.0 1.02,3-dimethylpentane 1.0 2.7 2.2 2.2 2.3 1.3 1.2 1.3 1.3 1.0 1.1 1.1 1.13-methylhexane 1.1 1.5 1.8 1.6 1.0 1.1 1.2 1.2 1.1 1.0 1.1 1.2 1.2Isooctane 1.2 1.8 1.9 2.2 1.8 1.4 1.2 1.3 1.4 1.2 1.2 1.3 1.4Toluene 2.5 2.9 2.3 3.6 3.9 2.0 1.6 2.2 2.0 0.6 1.4 2.0 2.0

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

June 2001

Study Number FY01-013

F-3
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

7-2-01

Week 

Starting 

7-9-01

Week 

Starting 

7-16-01

Week 

Starting 

7-23-01

Week 

Starting 

7-30-01

Week 

Starting 

7-2-01

Week 

Starting 

7-9-01

Week 

Starting 

7-16-01

Week 

Starting 

7-23-01

Week 

Starting 

7-30-01

Week 

Starting 

7-2-01

Week 

Starting 

7-9-01

Week 

Starting 

7-16-01

Week 

Starting 

7-23-01

Week 

Starting 

7-30-01

Isobutane 2.2 2.7 2.0 2.8 2.4 2.1 2.2 2.2 2.1 2.1 2.1 2.2 1.8n-butane 11.1 8.8 8.1 10.0 10.1 10.0 10.4 10.4 10.2 10.3 10.3 10.6 8.8Isopentane 31.0 25.1 22.8 27.9 27.8 30.1 30.5 30.2 30.6 30.5 30.5 30.7 29.6n-pentane 9.1 8.6 7.1 8.8 8.3 8.8 9.0 8.9 8.8 8.9 8.9 8.9 8.6trans-2-pentene 2.0 3.7 2.8 2.7 2.2 2.1 2.1 2.2 2.0 2.1 2.1 2.1 2.02-methyl-2-butene 2.9 5.7 2.6 4.0 2.9 2.9 2.9 2.8 2.8 3.0 2.9 2.9 2.7MTBE/2,3-dimethylbutaneMTBE 21.3 19.9 19.7 20.4 22.5 22.7 22.6 22.3 23.9 22.6 22.5 22.4 25.32,3-dimethylbutane 0.9 0.8 0.8 0.9 0.9 1.0 1.0 0.9 1.0 1.0 0.9 0.9 1.12-methylpentane 4.5 4.8 5.4 4.2 4.6 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.93-methylpentane 2.6 3.1 2.6 2.2 2.6 2.6 2.6 2.7 2.6 2.6 2.4 2.6 2.7n-hexane 2.1 2.0 2.8 2.3 2.0 2.2 2.1 2.2 2.0 2.3 2.5 2.2 2.2Methylcyclopentane 1.1 1.9 2.1 1.9 1.3 1.2 1.2 1.2 1.1 1.1 1.0 1.1 1.12,4-dimethylpentane 0.9 1.2 4.7 1.3 1.4 1.0 0.9 1.1 1.0 1.0 0.9 1.0 1.1Benzene 1.5 2.1 1.9 1.8 1.6 1.6 1.9 1.8 1.4 1.6 1.6 1.6 1.32-methylhexane 1.0 1.3 1.2 1.4 1.0 1.1 1.1 1.0 1.0 1.0 1.2 1.0 1.22,3-dimethylpentane 1.0 2.0 1.3 2.7 1.4 1.3 1.2 1.1 1.1 1.2 1.4 1.1 1.33-methylhexane 1.1 1.2 4.6 1.0 1.9 1.2 1.2 1.1 1.1 1.2 1.2 1.1 1.3Isooctane 1.2 1.9 5.2 2.0 1.6 1.2 1.3 1.2 1.3 1.2 1.2 1.3 1.6Toluene 2.5 3.2 2.4 1.8 3.4 2.1 1.4 2.0 1.4 2.0 2.0 1.9 1.5

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

July 2001

Study Number FY01-013

F-4
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

8-6-01

Week 

Starting 

8-13-01

Week 

Starting 

8-20-01

Week 

Starting 

8-27-01

Week 

Starting 

8-6-01

Week 

Starting 

8-13-01

Week 

Starting 

8-20-01

Week 

Starting 

8-27-01

Week 

Starting 

8-6-01

Week 

Starting 

8-13-01

Week 

Starting 

8-20-01

Week 

Starting 

8-27-01

Isobutane 2.2 2.2 2.2 2.7 2.2 2.2 2.2 2.2 2.2 2.1 2.2 2.2 2.1n-butane 11.1 9.8 9.0 10.4 10.1 10.3 10.5 10.5 10.5 10.4 10.6 10.6 10.5Isopentane 31.0 27.4 26.4 28.6 28.5 30.0 30.1 30.1 30.3 30.4 30.5 30.5 30.5n-pentane 9.1 8.3 8.4 8.6 8.4 8.8 8.8 8.8 8.8 8.8 8.8 8.8 8.8trans-2-pentene 2.0 2.3 2.5 2.2 2.4 2.1 2.1 2.0 2.0 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 2.7 3.4 2.7 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 22.2 22.3 22.3 22.2 23.3 23.1 23.1 23.2 23.0 22.9 22.8 22.92,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 5.1 4.4 4.5 4.5 4.5 4.4 4.4 4.4 4.4 4.4 4.43-methylpentane 2.6 2.9 2.8 2.6 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 3.0n-hexane 2.1 2.6 2.2 2.1 2.2 2.1 2.1 2.1 2.1 2.3 2.1 2.2 2.2Methylcyclopentane 1.1 1.6 1.4 1.2 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.1 1.1 1.3 1.0 1.0 1.1 1.1 1.0 0.9 0.9 1.0Benzene 1.5 1.7 2.0 1.6 1.6 1.6 1.6 1.8 1.5 1.5 1.6 1.6 1.52-methylhexane 1.0 1.4 1.5 1.3 1.3 1.0 1.1 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.7 1.7 1.6 1.7 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.5 1.7 1.4 1.3 1.2 1.2 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.6 1.9 1.3 1.7 1.3 1.3 1.3 1.2 1.3 1.2 1.2 1.2Toluene 2.5 3.5 3.5 3.1 3.1 2.0 2.0 2.0 1.9 1.9 2.1 2.0 1.8

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

August 2001

Study Number FY01-013

F-5
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

9-3-01

Week 

Starting 

9-10-01

Week 

Starting 

9-17-01

Week 

Starting 

9-24-01

Week 

Starting 

9-3-01

Week 

Starting 

9-10-01

Week 

Starting 

9-17-01

Week 

Starting 

9-24-01

Week 

Starting 

9-3-01

Week 

Starting 

9-10-01

Week 

Starting 

9-17-01

Week 

Starting 

9-24-01

Isobutane 2.2 2.2 2.4 2.1 2.1 2.1 2.0 2.0 1.6 2.0n-butane 11.1 9.9 10.3 10.1 10.2 10.4 10.2 9.7 7.3 9.9Isopentane 31.0 28.4 29.3 28.7 30.4 31.2 30.1 30.4 28.8 30.3n-pentane 9.1 8.7 8.6 8.8 8.7 9.0 8.8 8.8 8.6 8.9trans-2-pentene 2.0 2.4 2.9 2.6 2.0 2.0 2.1 2.0 2.1 2.02-methyl-2-butene 2.9 2.9 3.2 3.1 2.8 2.9 2.9 2.7 2.5 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.8 20.6 22.3 23.3 23.4 23.4 23.9 25.5 23.52,3-dimethylbutane 0.9 1.0 0.9 0.9 1.0 1.0 1.0 1.0 1.1 1.02-methylpentane 4.5 4.9 4.5 4.4 4.5 4.6 4.5 4.6 5.4 4.63-methylpentane 2.6 3.0 2.6 2.7 2.6 2.6 2.6 2.7 3.2 2.6n-hexane 2.1 2.1 2.0 2.7 2.1 2.1 2.1 2.2 2.6 2.1Methylcyclopentane 1.1 1.4 1.2 1.2 1.2 1.0 1.1 1.1 1.3 1.12,4-dimethylpentane 0.9 1.1 2.2 1.6 1.0 0.9 1.0 1.2 1.1 1.1Benzene 1.5 1.7 1.2 2.4 1.8 1.2 1.5 1.4 1.2 1.52-methylhexane 1.0 1.2 1.0 1.1 1.0 0.9 1.0 1.1 1.0 1.02,3-dimethylpentane 1.0 1.4 1.8 1.3 1.1 1.1 1.2 1.2 1.8 1.13-methylhexane 1.1 1.2 1.2 1.1 1.1 1.0 1.2 1.2 1.3 1.1Isooctane 1.2 1.4 2.1 1.3 1.3 1.3 1.3 1.4 1.9 1.4Toluene 2.5 2.3 2.1 1.6 1.8 1.3 1.8 1.6 1.9 1.8

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

September 2001

Study Number FY01-013

F-6
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

10-01-01

Week 

Starting 

10-08-01

Week 

Starting 

10-15-01

Week 

Starting 

10-22-01

Week 

Starting 

10-29-

01

Week 

Starting 

10-01-01

Week 

Starting 

10-08-01

Week 

Starting 

10-15-

01

Week 

Starting 

10-22-

01

Week 

Starting 

10-29-

01

Week 

Starting 

10-01-01

Week 

Starting 

10-08-01

Week 

Starting 

10-15-01

Week 

Starting 

10-22-01

Week 

Starting 

10-29-01

Isobutane 2.2 2.3 2.6 2.0 2.1 1.9 2.0 2.1 2.1 2.1 2.0 2.0 2.1 2.1 2.2 1.9n-butane 11.1 9.0 9.7 9.8 10.3 9.7 10.0 10.5 10.2 10.3 10.0 10.2 10.4 10.4 10.4 9.1Isopentane 31.0 26.2 25.9 28.0 28.6 28.5 29.5 30.3 30.1 30.2 30.3 30.2 30.5 30.5 30.4 30.0n-pentane 9.1 8.5 8.2 8.4 8.5 8.8 8.8 8.9 8.8 8.9 8.9 9.0 8.9 8.9 8.9 8.8trans-2-pentene 2.0 3.3 2.6 3.0 1.9 2.5 2.1 2.0 2.0 1.9 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 3.0 3.7 3.5 2.9 3.0 2.8 3.0 2.8 2.9 2.8 2.9 2.9 3.0 2.9 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 21.0 21.5 22.8 22.8 22.0 22.8 22.9 23.8 23.2 23.8 22.8 22.9 23.1 22.9 24.32,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 5.3 4.3 4.9 4.7 4.6 4.5 4.5 4.5 4.6 4.5 4.5 4.5 4.5 4.73-methylpentane 2.6 2.7 2.6 3.2 2.7 2.7 2.7 2.6 2.5 2.6 2.6 2.7 2.6 2.5 2.6 2.7n-hexane 2.1 2.6 2.2 2.1 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.2 2.1 2.1 2.1 2.2Methylcyclopentane 1.1 1.4 2.0 1.4 1.3 1.3 1.3 1.1 1.1 1.2 1.2 1.2 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.7 1.6 1.1 1.6 1.5 1.5 0.9 0.9 1.0 1.0 1.0 0.9 0.9 1.0 1.0Benzene 1.5 2.0 1.8 2.1 1.6 1.8 1.7 1.8 1.8 1.6 1.5 1.6 1.6 1.6 1.6 1.62-methylhexane 1.0 1.6 1.8 1.0 1.3 1.3 1.1 0.9 1.0 0.9 0.9 1.1 1.0 1.0 1.0 1.12,3-dimethylpentane 1.0 2.1 2.1 1.4 1.4 1.3 1.3 1.1 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.23-methylhexane 1.1 2.3 1.5 1.2 1.2 1.3 1.2 1.1 1.1 1.2 1.1 1.2 1.1 1.1 1.1 1.2Isooctane 1.2 2.1 1.9 1.4 1.3 1.7 1.3 1.2 1.2 1.2 1.3 1.3 1.2 1.2 1.2 1.4Toluene 2.5 2.8 2.1 2.4 2.3 2.8 2.0 2.0 2.1 2.1 1.9 2.0 2.1 2.0 2.1 1.8

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

October 2001

Study Number FY01-013

F-7
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

11-5-01

Week 

Starting 

11-12-01

Week 

Starting 

11-19-01

Week 

Starting 

11-26-01

Week 

Starting 

11-5-01

Week 

Starting 

11-12-01

Week 

Starting 

11-19-01

Week 

Starting 

11-26-01

Week 

Starting 

11-5-01

Week 

Starting 

11-12-01

Week 

Starting 

11-19-01

Week 

Starting 

11-26-01

Isobutane 2.2 2.1 2.3 2.2 2.1 2.0 2.1 1.8 2.0 2.0 2.1 2.0 2.0n-butane 11.1 10.1 9.4 9.7 10.1 10.1 10.3 9.2 10.0 10.2 10.4 10.3 10.1Isopentane 31.0 29.6 25.6 28.0 29.1 30.4 30.3 36.1 30.2 30.4 30.6 30.5 30.3n-pentane 9.1 8.7 8.0 8.5 8.7 8.9 8.9 9.6 8.9 8.9 8.9 9.0 8.9trans-2-pentene 2.0 2.0 3.0 2.3 2.0 2.0 2.0 2.4 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.1 2.9 2.8 2.9 2.9 2.5 2.9 2.9 2.9 2.9 3.0MTBE/2,3-dimethylbutaneMTBE 21.3 23.0 21.2 22.4 23.4 23.5 23.1 19.8 23.9 22.9 22.8 22.9 23.02,3-dimethylbutane 0.9 1.0 0.9 0.9 1.0 1.0 1.0 0.8 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 4.3 4.7 4.5 4.6 4.5 4.1 4.6 4.5 4.5 4.5 4.53-methylpentane 2.6 2.6 2.6 2.8 2.6 2.6 2.6 2.3 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.4 2.2 2.3 2.2 2.1 2.1 1.9 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.5 1.3 1.2 1.1 1.1 1.0 1.1 1.2 1.1 1.1 1.12,4-dimethylpentane 0.9 1.0 1.6 1.2 1.1 1.0 0.9 0.9 1.0 1.0 0.9 0.9 0.9Benzene 1.5 1.7 2.6 2.1 1.7 1.5 1.5 1.9 1.5 1.6 1.6 1.6 1.62-methylhexane 1.0 1.1 1.9 1.4 1.0 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.3 2.0 1.8 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.2 2.7 1.4 1.5 1.1 1.1 1.1 1.1 1.2 1.2 1.1 1.2Isooctane 1.2 1.5 2.0 1.8 1.5 1.3 1.2 1.2 1.2 1.3 1.3 1.3 1.3Toluene 2.5 2.0 3.2 2.3 2.2 1.8 2.1 1.8 1.9 2.1 2.0 2.0 2.1

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

November 2001

Study Number FY01-013

F-8
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

12-03-01

Week 

Starting 

12-10-01

Week 

Starting 

12-17-01

Week 

Starting 

12-24-01

Week 

Starting 

12-31-01

Week 

Starting 

12-03-01

Week 

Starting 

12-10-01

Week 

Starting 

12-17-01

Week 

Starting 

12-24-01

Week 

Starting 

12-31-01

Week 

Starting 

12-03-01

Week 

Starting 

12-10-01

Week 

Starting 

12-17-01

Week 

Starting 

12-24-01

Week 

Starting 

12-31-01

Isobutane 2.2 2.2 1.8 1.9 2.0 2.1 2.1 1.9 2.1 2.1 2.1 2.1 1.8 2.1 2.1 2.1n-butane 11.1 9.8 9.1 9.1 9.9 10.3 10.2 9.8 10.2 10.2 10.2 10.3 9.2 10.3 10.4 10.3Isopentane 31.0 28.6 28.7 26.1 29.0 28.9 30.3 30.3 29.6 30.3 30.5 30.4 29.4 30.2 30.7 30.2n-pentane 9.1 8.5 8.8 8.2 8.7 8.6 8.9 8.9 8.9 8.9 8.9 8.9 8.9 8.9 9.0 8.9trans-2-pentene 2.0 2.2 2.2 3.0 2.1 2.3 2.0 2.0 2.4 2.0 2.0 2.0 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 3.1 2.8 3.3 2.9 3.0 2.8 2.9 3.1 2.9 2.9 3.0 3.0 3.0 2.9 3.0MTBE/2,3-dimethylbutaneMTBE 21.3 23.0 22.8 21.9 23.7 22.3 23.6 23.7 22.8 23.2 23.2 22.9 23.4 22.7 22.6 22.82,3-dimethylbutane 0.9 1.0 1.0 0.9 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.5 4.7 4.5 4.5 4.5 4.6 4.5 4.5 4.6 4.5 4.7 4.5 4.5 4.53-methylpentane 2.6 2.5 2.6 3.0 2.7 3.0 2.6 2.6 2.5 2.6 2.6 2.6 2.8 2.6 2.6 2.6n-hexane 2.1 2.2 2.5 2.8 2.1 2.0 2.1 2.2 2.2 2.1 2.1 2.1 2.3 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.3 1.7 1.2 1.3 1.1 1.1 1.2 1.1 1.1 1.1 1.2 1.2 1.1 1.22,4-dimethylpentane 0.9 2.0 1.2 1.1 1.4 1.2 1.0 1.0 1.1 0.9 1.0 1.0 1.1 1.0 0.9 1.0Benzene 1.5 1.9 1.8 2.0 1.6 1.7 1.5 1.8 1.9 1.8 1.5 1.6 1.7 1.7 1.6 1.62-methylhexane 1.0 1.1 1.4 1.6 1.1 1.2 1.0 1.0 0.9 1.0 0.9 1.0 1.1 1.1 1.0 1.12,3-dimethylpentane 1.0 1.5 1.4 2.3 1.2 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.1 1.1 1.23-methylhexane 1.1 1.4 1.5 2.0 1.2 1.3 1.1 1.1 1.3 1.1 1.2 1.1 1.2 1.2 1.1 1.2Isooctane 1.2 1.3 1.6 2.0 1.3 1.6 1.2 1.2 1.2 1.2 1.3 1.3 1.4 1.3 1.3 1.3Toluene 2.5 2.0 2.9 2.4 2.3 2.4 1.9 1.9 1.9 2.1 1.8 2.1 2.3 2.0 2.1 1.9

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

December 2001

Study Number FY01-013

F-9
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

1-7-02

Week 

Starting 

1-14-02

Week 

Starting 

1-21-02

Week 

Starting 

1-28-02

Week 

Starting 

1-7-02

Week 

Starting 

1-14-02

Week 

Starting 

1-21-02

Week 

Starting 

1-28-02

Week 

Starting 

1-7-02

Week 

Starting 

1-14-02

Week 

Starting 

1-21-02

Week 

Starting 

1-28-02

Isobutane 2.2 2.3 2.1 2.1 2.2 2.1 2.1 2.2 2.1 2.1 2.2 2.1 2.1n-butane 11.1 10.1 9.9 10.1 10.4 10.3 10.3 10.3 10.1 10.4 10.4 10.3 10.3Isopentane 31.0 29.0 28.6 29.1 28.7 30.4 30.3 29.9 30.3 30.6 30.6 30.5 30.4n-pentane 9.1 8.5 8.8 8.6 8.8 8.9 8.9 8.9 8.9 9.0 8.9 8.9 8.9trans-2-pentene 2.0 2.1 2.3 1.9 2.5 2.0 2.0 2.2 2.0 2.0 2.0 2.0 2.12-methyl-2-butene 2.9 2.8 3.1 2.9 3.1 2.9 2.9 2.9 2.9 2.9 2.9 3.0 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.0 22.5 23.2 22.6 22.9 23.1 22.9 23.5 22.7 22.6 22.8 22.72,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.5 4.7 4.6 4.5 4.5 4.6 4.5 4.5 4.5 4.5 4.63-methylpentane 2.6 2.7 2.7 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.2 2.2 2.3 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.3 1.2 1.2 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.22,4-dimethylpentane 0.9 1.3 1.4 1.1 1.5 0.9 0.9 1.0 1.0 1.0 0.9 1.0 1.0Benzene 1.5 2.0 1.7 1.5 1.6 1.8 1.8 1.9 1.5 1.6 1.6 1.6 1.62-methylhexane 1.0 1.1 1.2 1.2 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 2.1 1.3 1.3 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.3 1.4 1.3 1.4 1.1 1.1 1.1 1.1 1.2 1.1 1.2 1.2Isooctane 1.2 1.3 1.5 1.5 1.4 1.2 1.2 1.2 1.2 1.3 1.3 1.2 1.3Toluene 2.5 2.4 2.4 2.4 1.8 2.1 2.0 2.0 1.9 2.0 2.0 1.9 2.0

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

January 2002

Study Number FY01-013

F-10
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

2-4-02

Week 

Starting 

2-11-02

Week 

Starting 

2-18-02

Week 

Starting 

2-25-02

Week 

Starting 

2-4-02

Week 

Starting 

2-11-02

Week 

Starting 

2-18-02

Week 

Starting 

2-25-02

Week 

Starting 

2-4-02

Week 

Starting 

2-11-02

Week 

Starting 

2-18-02

Week 

Starting 

2-25-02

Isobutane 2.2 2.2 2.1 2.7 2.1 2.1 2.1 2.1 1.8 2.1 2.1 2.0 2.1n-butane 11.1 10.6 10.0 10.0 9.9 10.3 10.2 10.2 9.3 10.2 10.2 9.9 10.5Isopentane 31.0 29.8 29.5 27.4 29.2 30.4 30.3 30.3 29.4 30.5 30.5 30.7 32.5n-pentane 9.1 8.9 8.9 8.5 8.6 8.9 8.9 8.9 8.8 8.9 8.9 8.9 9.3trans-2-pentene 2.0 2.2 2.2 3.2 2.1 2.0 2.0 2.1 2.0 2.0 2.0 2.0 2.12-methyl-2-butene 2.9 3.2 3.3 3.5 3.0 2.9 2.9 3.0 2.9 3.0 3.0 3.0 3.0MTBE/2,3-dimethylbutaneMTBE 21.3 21.9 21.2 19.8 21.7 23.0 22.7 22.7 23.3 22.8 22.8 23.2 22.82,3-dimethylbutane 0.9 0.9 0.9 0.8 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 4.7 5.2 4.7 4.5 4.5 4.6 4.7 4.5 4.5 4.6 4.43-methylpentane 2.6 2.6 2.8 2.8 2.9 2.6 2.6 2.6 2.7 2.6 2.6 2.7 2.5n-hexane 2.1 2.2 2.1 2.7 2.2 2.1 2.2 2.1 2.3 2.1 2.1 2.2 1.9Methylcyclopentane 1.1 1.2 1.4 1.4 1.3 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.02,4-dimethylpentane 0.9 0.9 1.2 1.4 1.3 0.9 1.0 1.1 1.0 0.9 0.9 1.0 0.8Benzene 1.5 1.7 1.6 1.9 1.8 1.6 1.9 1.6 1.8 1.9 1.6 1.5 1.52-methylhexane 1.0 1.1 1.3 2.5 1.2 1.0 1.0 1.0 1.1 1.0 1.0 1.0 0.72,3-dimethylpentane 1.0 1.3 1.3 1.7 1.3 1.1 1.1 1.1 1.3 1.1 1.1 1.1 0.83-methylhexane 1.1 1.2 1.4 1.0 1.4 1.1 1.1 1.1 1.3 1.1 1.1 1.2 0.8Isooctane 1.2 1.4 1.6 1.3 1.7 1.2 1.2 1.2 1.5 1.3 1.3 1.3 0.9Toluene 2.5 2.2 2.5 2.2 2.9 2.1 2.3 2.2 2.6 2.0 2.1 1.7 1.2

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

February 2002

Study Number FY01-013

F-11
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

3-4-02

Week 

Starting 

3-11-02

Week 

Starting 

3-18-02

Week 

Starting 

3-25-02

Week 

Starting 

3-4-02

Week 

Starting 

3-11-02

Week 

Starting 

3-18-02

Week 

Starting 

3-25-02

Week 

Starting 

3-4-02

Week 

Starting 

3-11-02

Week 

Starting 

3-18-02

Week 

Starting 

3-25-02

Isobutane 2.2 2.1 2.1 2.2 2.2 2.1 2.1 2.2 2.2 2.0 2.1 2.2 2.2n-butane 11.1 9.9 10.0 10.8 10.1 10.2 10.3 10.5 10.6 9.7 10.3 10.5 10.7Isopentane 31.0 28.3 29.1 29.4 30.4 30.3 30.4 30.6 30.6 30.4 30.4 30.6 30.8n-pentane 9.1 8.7 8.7 8.7 9.4 8.9 8.9 8.9 9.0 8.9 9.1 8.9 9.0trans-2-pentene 2.0 2.3 2.0 2.3 3.1 2.0 2.0 1.9 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 3.0 2.9 3.0 3.0 2.9 3.0 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 21.2 21.8 20.7 20.7 22.8 22.8 22.7 22.4 23.3 22.4 22.4 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.4 4.6 4.5 4.4 4.5 4.5 4.5 4.5 4.7 4.5 4.5 4.53-methylpentane 2.6 2.5 2.7 2.6 2.5 2.6 2.6 2.6 2.6 2.7 2.6 2.6 2.6n-hexane 2.1 2.1 2.3 2.2 2.1 2.1 2.1 2.1 2.1 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.6 1.3 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.3 1.7 1.1 1.1 1.0 1.0 1.0 1.0 0.9 0.9 0.9Benzene 1.5 1.8 1.9 1.7 1.6 1.6 1.6 1.5 1.5 1.5 2.0 1.6 1.62-methylhexane 1.0 1.2 1.1 1.3 1.2 1.0 1.0 1.0 1.0 1.1 1.0 1.0 1.02,3-dimethylpentane 1.0 1.2 1.3 1.3 1.2 1.1 1.1 1.1 1.1 1.2 1.1 1.1 1.13-methylhexane 1.1 4.6 1.3 1.2 1.2 1.1 1.1 1.1 1.1 1.2 1.1 1.2 1.1Isooctane 1.2 1.4 1.5 1.8 1.4 1.2 1.2 1.2 1.2 1.3 1.2 1.3 1.2Toluene 2.5 2.2 2.6 2.5 2.1 2.2 2.2 2.0 2.0 1.9 2.3 2.0 2.0

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

March 2002

Study Number FY01-013

F-12
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

4-1-02

Week 

Starting 

4-8-02

Week 

Starting 

4-15-02

Week 

Starting 

4-22-02

Week 

Starting 

4-29-02

Week 

Starting 

4-1-02

Week 

Starting 

4-8-02

Week 

Starting 

4-15-02

Week 

Starting 

4-22-02

Week 

Starting 

4-29-02

Week 

Starting 

4-1-02

Week 

Starting 

4-8-02

Week 

Starting 

4-15-02

Week 

Starting 

4-22-02

Week 

Starting 

4-29-02

Isobutane 2.2 2.3 2.6 2.2 2.3 2.3 2.1 2.2 2.1 2.2 2.2 2.0 2.1 2.2 2.2 2.2n-butane 11.1 10.4 10.7 10.6 10.5 10.6 10.4 10.7 10.3 10.4 10.6 9.8 10.1 10.6 10.6 10.7Isopentane 31.0 29.7 30.0 30.2 29.8 29.8 30.6 30.5 30.6 30.4 30.3 30.3 30.6 30.6 30.5 30.6n-pentane 9.1 8.8 8.9 9.0 8.7 8.9 8.9 8.9 8.9 8.9 9.0 8.9 8.9 8.9 8.9 8.9trans-2-pentene 2.0 2.0 2.2 2.2 2.6 2.2 1.9 2.0 2.1 2.1 2.1 2.0 1.9 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.1 3.0 2.9 3.0 2.9 2.9 2.9 2.8 2.9 2.8 2.9 3.0 3.0 3.0MTBE/2,3-dimethylbutaneMTBE 21.3 22.3 21.0 21.5 21.1 21.1 22.7 22.4 22.8 22.7 22.3 23.1 22.9 22.4 22.4 22.32,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 1.0 0.9 1.0 1.0 0.9 1.0 1.0 0.9 0.9 0.92-methylpentane 4.5 4.5 4.4 4.5 4.5 4.6 4.6 4.5 4.6 4.6 4.5 4.7 4.6 4.5 4.5 4.53-methylpentane 2.6 2.6 2.7 2.6 2.9 2.7 2.6 2.6 2.6 2.6 2.6 2.7 2.7 2.6 2.6 2.6n-hexane 2.1 2.2 2.1 2.3 2.2 2.1 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.2 1.2 1.2 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.2 1.2 1.1 1.1 1.1 1.0 1.0 0.9 0.8 0.9 1.0 1.1 0.9 0.9 1.0Benzene 1.5 1.7 1.7 1.6 1.8 1.8 1.5 1.6 1.5 1.5 1.8 1.7 1.5 1.6 1.6 1.62-methylhexane 1.0 1.2 1.0 1.1 1.1 1.1 1.0 0.9 1.0 1.0 0.9 1.1 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.1 1.1 1.1 1.4 1.4 1.1 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.3 1.4 1.2 1.2 1.2 1.1 1.1 1.1 1.2 1.1 1.2 1.2 1.1 1.1 1.1Isooctane 1.2 1.4 1.5 1.3 1.4 1.5 1.2 1.2 1.2 1.2 1.2 1.3 1.3 1.3 1.3 1.3Toluene 2.5 2.2 2.3 2.4 2.3 2.5 2.0 2.1 2.0 2.0 2.1 1.9 1.9 2.1 2.1 2.1

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

April 2002

Study Number FY01-013

F-13
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

5-6-02

Week 

Starting 

5-13-02

Week 

Starting 

5-20-02

Week 

Starting 

5-27-02

Week 

Starting 

5-6-02

Week 

Starting 

5-13-02

Week 

Starting 

5-20-02

Week 

Starting 

5-27-02

Week 

Starting 

5-6-02

Week 

Starting 

5-13-02

Week 

Starting 

5-20-02

Week 

Starting 

5-27-02

Isobutane 2.2 2.3 2.4 2.3 2.4 2.2 2.2 2.3 2.3 2.2 2.3 2.2 2.2n-butane 11.1 10.6 10.5 10.6 11.3 10.6 10.8 10.7 10.6 10.6 11.0 10.8 10.7Isopentane 31.0 29.9 29.6 29.0 30.1 30.4 30.6 30.4 29.9 30.5 30.9 30.5 30.9n-pentane 9.1 9.0 9.3 8.9 8.8 8.9 8.9 9.0 8.9 8.9 9.0 8.9 9.0trans-2-pentene 2.0 2.8 2.6 2.9 2.7 2.1 2.0 2.1 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 3.0 3.1 3.2 2.9 2.9 3.0 3.1 3.0 3.0 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 20.8 20.8 21.0 20.4 22.2 22.2 22.1 21.8 22.2 22.1 22.1 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.92-methylpentane 4.5 4.4 4.6 4.5 4.5 4.5 4.5 4.4 4.5 4.5 4.5 4.5 4.53-methylpentane 2.6 2.6 2.6 2.5 2.6 2.6 2.6 2.5 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.1 2.2 2.2 2.2 2.1 2.1 2.1 2.2 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.3 1.3 1.1 1.2 1.1 1.1 1.2 1.1 1.1 1.2 1.12,4-dimethylpentane 0.9 1.2 1.2 1.0 1.2 0.9 0.9 0.9 1.0 0.9 0.9 1.0 0.9Benzene 1.5 2.2 1.6 2.2 2.1 1.8 1.8 1.8 1.9 1.6 1.6 1.6 1.62-methylhexane 1.0 0.9 1.2 1.1 1.1 1.0 1.0 1.0 1.1 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.1 1.3 1.4 1.4 1.1 1.1 1.1 1.3 1.1 1.0 1.1 1.13-methylhexane 1.1 1.2 1.1 1.3 1.3 1.1 1.1 1.1 1.2 1.1 1.1 1.2 1.1Isooctane 1.2 1.4 1.4 1.5 1.3 1.2 1.2 1.2 1.3 1.3 1.2 1.2 1.3Toluene 2.5 2.4 2.1 2.2 1.8 2.1 2.0 2.1 2.1 2.1 1.9 2.1 2.0

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

May2002

Study Number FY01-013

F-14
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

6-03-02

Week 

Starting 

6-10-02

Week 

Starting 

6-17-02

Week 

Starting 

6-24-02

Week 

Starting 

6-03-02

Week 

Starting 

6-10-02

Week 

Starting 

6-17-02

Week 

Starting 

6-24-02

Week 

Starting 

6-03-02

Week 

Starting 

6-10-02

Week 

Starting 

6-17-02

Week 

Starting 

6-24-02

Isobutane 2.2 2.4 2.1 2.4 2.3 2.3 2.2 2.3 2.1 2.3 2.1 2.3 2.1n-butane 11.1 9.9 10.3 10.6 10.1 11.0 10.4 10.9 10.4 11.4 10.1 11.0 10.0Isopentane 31.0 27.3 28.7 29.1 28.6 30.9 30.3 30.6 30.6 31.8 30.7 31.4 30.4n-pentane 9.1 8.5 8.5 8.9 8.6 8.9 8.8 8.9 8.8 9.0 8.8 8.9 8.8trans-2-pentene 2.0 2.2 2.1 2.2 2.3 2.0 2.0 2.1 2.0 2.0 1.9 2.0 1.92-methyl-2-butene 2.9 2.9 2.8 2.8 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 22.6 22.5 22.6 22.2 23.3 23.7 23.1 23.4 22.8 23.9 22.8 23.62,3-dimethylbutane 0.9 1.0 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 4.6 4.4 4.5 4.5 4.5 4.4 4.6 4.3 4.5 4.4 4.63-methylpentane 2.6 2.9 2.5 2.5 2.5 2.5 2.6 2.5 2.6 2.5 2.6 2.5 2.6n-hexane 2.1 2.2 2.3 2.1 2.2 2.0 2.1 2.1 2.1 2.0 2.1 2.0 2.1Methylcyclopentane 1.1 1.2 1.5 1.3 1.3 1.1 1.1 1.1 1.1 1.0 1.1 1.1 1.12,4-dimethylpentane 0.9 1.3 1.7 1.1 1.1 0.9 1.0 0.9 1.0 0.9 1.0 0.9 1.0Benzene 1.5 2.2 1.7 3.8 1.8 1.4 1.4 1.4 1.4 1.3 1.6 1.4 1.72-methylhexane 1.0 1.4 1.1 1.2 1.4 0.9 1.0 0.9 1.0 0.9 1.0 0.9 1.12,3-dimethylpentane 1.0 1.8 1.3 1.5 2.3 1.1 1.1 1.1 1.1 1.0 1.1 1.0 1.13-methylhexane 1.1 1.4 1.3 1.3 1.2 1.1 1.1 1.1 1.1 1.0 1.1 1.0 1.1Isooctane 1.2 1.7 1.5 1.6 1.6 1.1 1.2 1.2 1.2 1.1 1.2 1.2 1.3Toluene 2.5 2.5 2.4 1.9 2.0 1.3 1.8 1.7 1.8 0.9 1.4 1.4 1.7

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

June 2002

Study Number FY01-013

F-15
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

7-01-02

Week 

Starting 

7-08-02

Week 

Starting 

7-15-02

Week 

Starting 

7-22-02

Week 

Starting 

7-29-02

Week 

Starting 

7-01-02

Week 

Starting 

7-08-02

Week 

Starting 

7-15-02

Week 

Starting 

7-22-02

Week 

Starting 

7-29-02

Week 

Starting 

7-01-02

Week 

Starting 

7-08-02

Week 

Starting 

7-15-02

Week 

Starting 

7-22-02

Week 

Starting 

7-29-02

Isobutane 2.2 2.3 2.4 2.4 2.4 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.1n-butane 11.1 10.1 10.5 11.1 10.4 10.2 10.6 10.6 10.7 10.6 10.5 10.9 10.9 10.8 10.8 10.1Isopentane 31.0 28.3 28.7 30.4 28.3 28.5 30.2 30.4 30.2 30.3 30.5 31.1 31.2 31.0 30.8 30.5n-pentane 9.1 8.5 8.4 9.3 8.4 8.7 8.8 8.8 8.8 8.8 8.8 8.9 8.9 8.9 8.9 8.8trans-2-pentene 2.0 2.1 2.5 3.0 2.2 2.4 2.0 2.1 2.2 2.1 2.0 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 2.9 2.8 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.9 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 22.3 22.6 19.8 22.2 21.6 22.7 22.7 22.9 22.9 23.6 22.5 22.5 22.7 22.6 23.62,3-dimethylbutane 0.9 0.9 1.0 0.8 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.4 4.5 4.3 4.5 4.5 4.4 4.5 4.4 4.5 4.5 4.4 4.4 4.4 4.4 4.63-methylpentane 2.6 2.7 2.8 2.2 2.7 2.6 2.6 2.6 2.5 2.6 2.6 2.5 2.5 2.5 2.5 2.6n-hexane 2.1 2.3 2.2 1.9 2.7 2.3 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.1Methylcyclopentane 1.1 1.4 1.3 1.4 1.1 1.3 1.1 1.1 1.1 1.1 1.0 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.1 2.1 1.3 1.3 1.0 0.9 1.1 1.0 1.1 1.0 0.9 1.0 0.9 1.0Benzene 1.5 1.8 1.7 1.8 2.3 1.9 1.9 1.8 1.5 1.8 1.4 1.5 1.5 1.5 1.6 1.42-methylhexane 1.0 1.2 1.4 1.1 1.3 1.4 1.1 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.02,3-dimethylpentane 1.0 1.6 1.4 1.4 1.6 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.0 1.0 1.1 1.13-methylhexane 1.1 1.5 1.2 1.2 1.5 1.8 1.1 1.1 1.1 1.1 1.0 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.7 1.4 1.3 1.3 1.4 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.3Toluene 2.5 3.0 2.2 2.0 2.2 2.9 2.1 2.0 2.0 2.0 1.6 1.7 1.7 1.7 2.0 1.8

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

July 2002

Study Number FY01-013

F-16
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

8-05-02

Week 

Starting 

8-12-02

Week 

Starting 

8-19-02

Week 

Starting 

8-26-02

Week 

Starting 

8-05-02

Week 

Starting 

8-12-02

Week 

Starting 

8-19-02

Week 

Starting 

8-26-02

Week 

Starting 

8-05-02

Week 

Starting 

8-12-02

Week 

Starting 

8-19-02

Week 

Starting 

8-26-02

Isobutane 2.2 2.0 2.3 2.1 2.3 2.2 2.2 2.2 2.2 2.2 2.1 2.2 2.2n-butane 11.1 10.0 10.7 10.0 10.0 10.5 10.6 10.5 10.5 10.8 10.2 10.8 10.7Isopentane 31.0 28.3 28.3 27.1 27.5 30.8 30.6 30.3 30.5 31.0 30.5 31.0 30.9n-pentane 9.1 8.5 8.3 8.1 8.3 8.8 8.9 8.8 8.9 8.9 8.8 8.9 8.9trans-2-pentene 2.0 2.3 2.0 2.8 2.6 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.7 2.9 2.9 3.0 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 22.2 22.0 21.3 21.2 23.3 23.3 22.9 23.2 22.7 23.5 22.6 22.92,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.4 4.6 4.4 4.9 4.5 4.5 4.4 4.5 4.4 4.5 4.4 4.43-methylpentane 2.6 2.6 2.5 2.8 2.6 2.6 2.7 2.6 2.6 2.5 2.6 2.5 2.5n-hexane 2.1 2.4 2.2 2.2 2.3 2.1 2.1 2.1 2.1 2.0 2.1 2.0 2.0Methylcyclopentane 1.1 1.2 1.4 1.4 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.5 1.6 1.3 2.4 0.9 0.9 1.0 0.7 0.9 0.9 1.0 0.9Benzene 1.5 2.1 1.4 1.9 1.7 1.4 1.4 1.8 1.4 1.5 1.6 1.5 1.52-methylhexane 1.0 1.2 1.1 1.7 1.3 0.9 1.0 1.0 1.0 1.0 1.0 0.9 1.02,3-dimethylpentane 1.0 1.6 1.7 2.3 1.9 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.13-methylhexane 1.1 1.4 1.7 1.9 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.7 1.9 1.9 1.5 1.2 1.2 1.2 1.1 1.2 1.3 1.2 1.2Toluene 2.5 2.9 2.3 3.0 2.6 1.7 1.7 2.2 1.9 1.8 1.7 1.8 1.8

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

August 2002

Study Number FY01-013

F-17
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

9-2-02

Week 

Starting 

9-9-02

Week 

Starting 

9-16-02

Week 

Starting 

9-23-02

Week 

Starting 

9-30-02

Week 

Starting 

9-2-02

Week 

Starting 

9-9-02

Week 

Starting 

9-16-02

Week 

Starting 

9-23-02

Week 

Starting 

9-30-02

Week 

Starting 

9-2-02

Week 

Starting 

9-9-02

Week 

Starting 

9-16-02

Week 

Starting 

9-23-02

Week 

Starting 

9-30-02

Isobutane 2.2 2.5 2.1 2.3 2.2 2.5 2.2 2.2 2.0 2.1 2.1 2.3 2.1 2.0 2.1 2.2n-butane 11.1 9.6 9.8 10.2 9.7 9.8 10.5 10.7 10.0 10.4 10.2 11.0 10.0 9.6 10.5 10.4Isopentane 31.0 26.4 28.4 28.1 27.5 27.5 30.2 30.3 30.5 30.4 30.1 30.7 30.6 30.3 31.0 30.7n-pentane 9.1 8.4 8.4 8.8 8.7 8.2 8.8 8.8 8.8 8.9 8.8 8.9 8.8 8.8 8.9 8.9trans-2-pentene 2.0 2.9 2.1 2.9 2.8 2.5 2.0 1.9 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.7 2.6 2.9 2.8 2.7 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 21.7 22.5 22.9 22.0 21.7 22.8 22.8 23.9 23.2 23.0 22.5 23.7 24.0 22.9 22.82,3-dimethylbutane 0.9 0.9 0.9 1.0 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.4 5.0 4.4 5.0 4.4 4.4 4.4 4.6 4.5 4.5 4.4 4.6 4.6 4.4 4.43-methylpentane 2.6 2.8 3.0 2.5 2.5 2.7 2.6 2.5 2.6 2.6 2.6 2.5 2.6 2.7 2.6 2.6n-hexane 2.1 2.1 2.2 2.3 2.1 2.3 2.1 2.1 2.1 2.1 2.1 2.0 2.1 2.2 2.1 2.1Methylcyclopentane 1.1 1.4 1.2 1.4 1.6 1.5 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.2 1.1 1.12,4-dimethylpentane 0.9 2.5 1.0 1.0 1.1 2.3 1.0 1.0 1.0 0.9 1.0 0.9 1.0 0.8 1.0 1.0Benzene 1.5 2.0 1.7 2.0 2.0 1.8 1.8 1.8 1.3 1.9 1.8 1.8 1.4 1.4 1.5 1.62-methylhexane 1.0 1.2 1.3 1.1 1.3 1.2 1.0 1.0 1.0 1.0 1.1 0.9 1.0 1.0 0.9 1.02,3-dimethylpentane 1.0 1.9 2.0 1.7 1.7 2.0 1.1 1.1 1.1 1.0 1.3 1.0 1.1 1.2 1.0 1.13-methylhexane 1.1 1.6 1.3 1.2 1.6 1.5 1.0 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.1 1.1Isooctane 1.2 1.6 1.9 1.3 1.7 2.1 1.2 1.2 1.3 1.2 1.2 1.2 1.3 1.4 1.2 1.3Toluene 2.5 3.5 2.6 2.0 2.6 2.5 2.1 2.1 1.7 2.0 2.2 1.9 1.7 1.9 1.7 1.9

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

September 2002

Study Number FY01-013

F-18
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

10-7-02

Week 

Starting 

10-14-02

Week 

Starting 

10-21-02

Week 

Starting 

10-28-02

Week 

Starting 

10-7-02

Week 

Starting 

10-14-02

Week 

Starting 

10-21-02

Week 

Starting 

10-28-02

Week 

Starting 

10-7-02

Week 

Starting 

10-14-02

Week 

Starting 

10-21-02

Week 

Starting 

10-28-02

Isobutane 2.2 2.3 2.0 2.1 1.9 2.0 2.1 2.0 2.1 1.9 2.1 2.1 2.1n-butane 11.1 9.8 10.1 9.5 9.0 9.9 10.3 10.1 10.1 9.5 10.4 10.3 10.3Isopentane 31.0 28.1 28.3 27.6 25.7 30.2 30.1 30.2 30.1 30.2 30.7 30.9 31.0n-pentane 9.1 8.6 8.7 8.8 7.9 8.8 8.7 8.8 8.8 8.8 8.8 8.9 8.9trans-2-pentene 2.0 2.5 2.6 2.6 2.2 2.0 1.9 2.1 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 2.7 2.9 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.9 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 23.2 22.1 21.7 24.9 23.5 23.0 23.1 22.7 24.0 23.1 23.0 23.12,3-dimethylbutane 0.9 1.0 0.9 0.9 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.7 4.6 5.4 4.5 4.5 4.5 4.5 4.7 4.5 4.5 4.53-methylpentane 2.6 2.6 2.7 2.7 2.8 2.6 2.6 2.6 2.6 2.6 2.5 2.6 2.6n-hexane 2.1 2.2 2.2 2.6 1.9 2.1 2.1 2.1 2.1 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.4 1.4 1.5 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.2 1.1 1.5 3.2 1.1 1.1 0.9 1.0 0.9 0.9 0.8 1.0Benzene 1.5 1.9 1.8 2.2 2.0 1.5 1.8 1.8 1.5 1.5 1.6 1.6 1.52-methylhexane 1.0 1.0 1.2 1.4 1.0 1.0 1.0 1.0 1.1 1.1 1.0 1.0 0.92,3-dimethylpentane 1.0 1.3 1.6 1.8 1.3 1.1 1.2 1.1 1.1 1.2 1.1 1.1 1.13-methylhexane 1.1 1.3 1.4 1.7 1.4 1.2 1.1 1.2 2.3 1.2 1.1 1.1 1.1Isooctane 1.2 1.6 1.5 1.4 1.4 1.3 1.3 1.3 1.1 1.4 1.3 1.2 1.2Toluene 2.5 2.8 2.8 2.8 2.4 2.1 2.1 2.2 2.0 1.9 1.9 1.8 1.6

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

October 2002

Study Number FY01-013

F-19
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

11-4-02

Week 

Starting 

11-11-02

Week 

Starting 

11-18-02

Week 

Starting 

11-25-02

Week 

Starting 

11-4-02

Week 

Starting 

11-11-02

Week 

Starting 

11-18-02

Week 

Starting 

11-25-02

Week 

Starting 

11-4-02

Week 

Starting 

11-11-02

Week 

Starting 

11-18-02

Week 

Starting 

11-25-02

Isobutane 2.2 2.1 2.1 2.5 2.1 2.0 2.0 2.0 2.0 2.1 1.9 1.9 2.1n-butane 11.1 9.5 9.8 9.6 9.5 9.8 9.9 9.8 9.9 10.3 9.4 9.2 10.3Isopentane 31.0 27.5 27.7 27.1 26.6 30.0 30.3 30.3 30.1 30.7 30.1 30.0 30.7n-pentane 9.1 8.4 8.5 8.5 8.7 9.0 8.8 8.9 9.0 9.0 8.8 8.8 8.9trans-2-pentene 2.0 2.7 2.6 3.1 2.7 2.2 2.0 2.1 2.1 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 3.3 4.0 3.0 2.9 2.8 2.9 2.9 2.9 2.8 2.8 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.6 23.2 22.5 22.4 23.5 23.4 23.6 23.4 22.8 23.9 24.2 22.72,3-dimethylbutane 0.9 1.0 1.0 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.6 4.4 4.7 4.6 4.6 4.6 4.7 4.5 4.7 4.8 4.53-methylpentane 2.6 2.6 2.4 2.4 2.7 2.7 2.6 2.7 2.7 2.6 2.7 2.7 2.6n-hexane 2.1 2.1 2.0 2.0 2.1 2.1 2.2 2.1 2.2 2.1 2.1 2.2 2.1Methylcyclopentane 1.1 1.3 1.3 1.9 1.5 1.1 1.2 1.2 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.6 1.3 1.8 1.8 1.0 1.3 1.0 0.9 1.0 1.0 1.0 1.0Benzene 1.5 2.1 2.0 1.7 2.6 1.4 1.4 1.5 1.5 1.6 1.6 1.4 1.62-methylhexane 1.0 1.2 1.4 1.4 1.3 0.9 0.9 1.0 1.0 1.0 1.2 1.1 1.02,3-dimethylpentane 1.0 1.5 1.6 1.7 1.7 1.1 1.2 1.2 1.3 1.1 1.2 1.2 1.13-methylhexane 1.1 1.7 1.6 1.2 1.4 1.2 1.2 1.1 1.2 1.2 1.2 1.2 1.2Isooctane 1.2 1.7 1.5 1.4 1.9 1.3 1.3 1.3 1.2 1.3 1.4 1.4 1.2Toluene 2.5 2.9 2.3 2.0 2.5 2.1 1.9 1.9 2.0 1.9 1.9 1.8 2.0

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

November 2002

Study Number FY01-013

F-20
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

12-2-02

Week 

Starting 

12-9-02

Week 

Starting 

12-16-02

Week 

Starting 

12-23-02

Week 

Starting 

12-30-

02

Week 

Starting 

12-2-02

Week 

Starting 

12-9-02

Week 

Starting 

12-16-

02

Week 

Starting 

12-23-

02

Week 

Starting 

12-30-

02

Week 

Starting 

12-2-02

Week 

Starting 

12-9-02

Week 

Starting 

12-16-02

Week 

Starting 

12-23-02

Week 

Starting 

12-30-02

Isobutane 2.2 2.2 2.6 2.0 2.1 2.2 2.1 1.8 2.0 2.1 2.1 2.1 1.8 2.1 2.1 2.0n-butane 11.1 10.0 9.5 9.6 9.6 9.8 10.2 9.4 10.1 10.1 10.1 10.3 9.5 10.3 10.4 10.2Isopentane 31.0 27.9 28.2 27.7 27.5 28.7 30.4 30.0 30.2 30.4 30.3 30.8 30.6 31.0 30.9 30.7n-pentane 9.1 8.9 8.6 8.5 8.4 8.7 8.9 9.0 8.9 9.0 9.0 9.0 9.0 9.0 9.0 9.0trans-2-pentene 2.0 2.6 2.7 2.8 2.0 2.5 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.12-methyl-2-butene 2.9 2.8 2.9 2.8 2.8 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.9 21.9 22.8 22.8 21.8 23.1 23.4 22.9 22.9 23.0 22.7 23.3 22.8 22.6 22.62,3-dimethylbutane 0.9 1.0 0.9 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.4 4.4 4.6 4.4 4.6 4.6 4.6 4.6 4.6 4.6 4.7 4.5 4.5 4.53-methylpentane 2.6 2.7 2.5 2.5 2.6 2.8 2.6 2.7 2.6 2.7 2.6 2.6 2.7 2.6 2.6 2.6n-hexane 2.1 2.2 2.1 2.4 2.3 2.2 2.1 2.2 2.1 2.2 2.1 2.1 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.1 1.3 1.2 1.5 1.3 1.1 1.2 1.2 1.2 1.1 1.1 1.2 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.3 1.0 1.2 1.2 0.9 1.0 1.0 0.9 1.0 0.9 1.0 1.0 0.9 0.9Benzene 1.5 1.9 1.7 2.1 1.9 2.1 1.5 1.6 1.5 1.5 1.6 1.6 1.6 1.5 1.6 1.62-methylhexane 1.0 1.3 1.4 1.4 1.3 1.5 1.0 1.0 1.0 0.9 1.0 1.0 1.1 1.0 1.0 1.02,3-dimethylpentane 1.0 1.7 1.6 2.0 1.5 1.3 1.1 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.3 1.5 1.6 1.3 1.4 1.1 1.3 1.2 1.1 1.1 1.1 1.2 1.1 1.1 1.2Isooctane 1.2 1.7 1.4 1.5 2.9 1.6 1.2 1.3 1.3 1.3 1.2 1.3 1.3 1.2 1.2 1.2Toluene 2.5 2.1 3.6 2.8 2.8 2.7 2.0 2.2 2.2 2.1 2.2 1.9 1.9 1.6 1.9 2.1

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

December 2002

Study Number FY01-013

F-21
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

1-6-03

Week 

Starting 

1-13-03

Week 

Starting 

1-20-03

Week 

Starting 

1-27-03

Week 

Starting 

1-6-03

Week 

Starting 

1-13-03

Week 

Starting 

1-20-03

Week 

Starting 

1-27-03

Week 

Starting 

1-6-03

Week 

Starting 

1-13-03

Week 

Starting 

1-20-03

Week 

Starting 

1-27-03

Isobutane 2.2 2.1 2.2 2.1 2.2 2.0 2.0 2.1 2.2 2.0 2.0 2.1 2.1n-butane 11.1 9.4 9.1 10.0 10.0 10.1 9.9 10.2 10.5 10.2 10.2 10.0 10.6Isopentane 31.0 27.9 27.3 28.4 27.5 30.7 30.2 30.3 30.5 30.8 30.7 30.8 31.1n-pentane 9.1 8.5 8.7 8.8 8.8 8.9 8.9 8.8 8.9 9.0 8.9 8.9 9.0trans-2-pentene 2.0 2.4 2.3 2.4 2.5 2.2 2.2 1.9 2.1 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 2.9 3.3 3.3 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 23.3 22.7 22.3 22.6 23.6 23.3 23.3 23.0 22.9 22.8 22.8 22.62,3-dimethylbutane 0.9 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.9 4.5 4.4 4.6 4.6 4.6 4.7 4.6 4.6 4.6 4.6 4.53-methylpentane 2.6 2.8 3.1 2.6 2.5 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.2 2.3 2.3 2.1 2.1 2.2 2.2 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.4 1.2 1.5 1.1 1.2 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.0 1.9 1.3 1.1 0.9 1.0 1.0 0.7 1.0 1.0 0.9 0.9Benzene 1.5 1.8 2.0 1.9 2.0 1.4 1.5 1.5 1.5 1.6 1.6 1.5 1.52-methylhexane 1.0 1.1 1.0 1.1 1.3 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.3 1.9 1.3 1.9 1.1 1.3 1.2 1.2 1.1 1.1 1.1 1.13-methylhexane 1.1 1.9 1.4 1.4 1.4 1.1 1.0 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.6 1.4 1.4 1.3 1.2 1.2 1.2 1.2 1.2 1.3 1.3 1.2Toluene 2.5 2.7 2.8 2.8 2.7 1.5 2.0 2.1 2.0 1.8 2.0 1.9 1.7

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

January 2003

Study Number FY01-013

F-22
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

2-3-03

Week 

Starting 

2-10-03

Week 

Starting 

2-17-03

Week 

Starting 

2-24-03

Week 

Starting 

2-3-03

Week 

Starting 

2-10-03

Week 

Starting 

2-17-03

Week 

Starting 

2-24-03

Week 

Starting 

2-3-03

Week 

Starting 

2-10-03

Week 

Starting 

2-17-03

Week 

Starting 

2-24-03

Isobutane 2.2 2.0 2.7 2.2 2.2 2.1 2.1 2.2 2.1 2.1 2.1 2.2 2.1n-butane 11.1 9.5 9.9 9.8 10.1 10.2 10.2 10.6 10.3 10.4 10.0 10.8 10.0Isopentane 31.0 27.1 27.4 27.1 28.5 30.3 30.3 30.5 30.3 30.7 30.7 30.9 30.7n-pentane 9.1 8.9 8.6 8.6 8.5 8.9 8.8 8.9 8.9 8.9 8.9 9.0 8.9trans-2-pentene 2.0 3.2 2.3 2.6 2.0 2.1 2.0 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 3.0 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.8 2.9 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 22.7 22.1 21.7 21.8 23.3 23.2 22.7 23.0 22.7 23.4 22.3 23.32,3-dimethylbutane 0.9 1.0 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.02-methylpentane 4.5 4.7 4.7 4.3 4.5 4.6 4.6 4.5 4.6 4.5 4.7 4.4 4.63-methylpentane 2.6 2.7 2.7 2.8 3.1 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.7n-hexane 2.1 2.1 2.2 2.5 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.4 1.2 1.3 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.4 1.2 1.1 0.9 1.0 1.0 1.0 1.0 1.0 0.9 1.0Benzene 1.5 1.8 1.7 1.8 2.1 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.62-methylhexane 1.0 1.4 1.4 1.6 1.2 1.0 1.0 1.0 0.9 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.8 1.9 1.8 1.5 1.2 1.2 1.1 1.2 1.1 1.1 1.1 1.13-methylhexane 1.1 1.7 1.5 1.7 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.2 1.5 1.8 1.7 1.3 1.2 1.2 1.3 1.3 1.3 1.2 1.3Toluene 2.5 3.1 2.9 3.3 2.9 2.0 2.1 2.1 2.0 2.0 1.5 1.9 1.5

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

February 2003

Study Number FY01-013

F-23
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

3-3-03

Week 

Starting 

3-10-03

Week 

Starting 

3-17-03

Week 

Starting 

3-24-03

Week 

Starting 

3-31-03

Week 

Starting 

3-3-03

Week 

Starting 

3-10-03

Week 

Starting 

3-17-03

Week 

Starting 

3-24-03

Week 

Starting 

3-31-03

Week 

Starting 

3-3-03

Week 

Starting 

3-10-03

Week 

Starting 

3-17-03

Week 

Starting 

3-24-03

Week 

Starting 

3-31-03

Isobutane 2.2 2.1 2.3 2.2 2.4 2.1 2.2 2.1 2.2 2.2 2.2 2.2 2.1 2.3 2.2 2.2n-butane 11.1 9.8 10.1 10.5 9.9 10.4 10.5 10.2 10.7 10.6 10.6 10.7 10.1 10.9 10.8 10.7Isopentane 31.0 28.0 28.3 28.8 28.0 28.5 30.3 30.4 30.5 30.4 30.5 30.9 30.8 31.0 31.0 30.7n-pentane 9.1 8.9 8.4 8.9 8.4 8.7 8.8 8.9 8.8 8.9 8.9 8.9 8.9 8.9 8.9 8.9trans-2-pentene 2.0 2.7 2.3 2.3 2.4 2.6 2.1 2.0 2.0 2.1 2.1 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.4 2.9 3.3 3.5 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.4 22.3 22.1 21.5 21.9 22.7 23.2 22.5 22.4 22.7 22.4 23.3 22.3 22.3 22.42,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 1.0 1.0 0.9 0.9 1.0 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.4 4.6 4.4 4.5 4.6 4.5 4.6 4.5 4.5 4.5 4.5 4.6 4.5 4.5 4.53-methylpentane 2.6 2.7 2.5 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.2 2.3 2.1 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.3 1.2 1.6 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.2 1.1 1.0 1.4 1.2 1.0 1.0 1.0 1.0 0.8 1.0 0.9 0.8 0.9 0.9Benzene 1.5 2.1 1.8 1.9 1.8 2.3 1.5 1.4 1.6 1.5 1.6 1.6 1.4 1.5 1.5 1.62-methylhexane 1.0 1.4 1.1 1.1 1.1 1.2 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.4 1.4 1.3 1.6 1.3 1.1 1.2 1.1 1.2 1.1 1.0 1.1 1.1 1.1 1.13-methylhexane 1.1 1.4 1.4 1.3 1.7 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.5 1.7 1.4 1.9 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.3 1.2 1.2 1.2Toluene 2.5 2.8 2.7 2.9 2.8 2.5 2.1 2.0 2.2 2.2 2.1 1.9 1.6 1.9 1.8 2.1

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

March 2003

Study Number FY01-013

F-24
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

4-7-03

Week 

Starting 

4-14-03

Week 

Starting 

4-21-03

Week 

Starting 

4-28-03

Week 

Starting 

4-7-03

Week 

Starting 

4-14-03

Week 

Starting 

4-21-03

Week 

Starting 

4-28-03

Week 

Starting 

4-7-03

Week 

Starting 

4-14-03

Week 

Starting 

4-21-03

Week 

Starting 

4-28-03

Isobutane 2.2 2.4 2.3 2.2 2.5 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.3n-butane 11.1 10.5 10.4 10.4 10.2 10.6 10.7 10.6 10.8 10.9 10.9 10.8 10.9Isopentane 31.0 28.6 29.1 28.6 28.3 30.5 30.6 30.7 30.7 30.8 31.0 30.8 31.0n-pentane 9.1 8.9 8.6 8.5 8.5 8.9 8.9 8.9 8.9 8.9 8.9 8.9 8.9trans-2-pentene 2.0 2.6 2.4 2.3 2.2 2.1 2.1 2.0 2.0 2.0 2.1 2.0 2.02-methyl-2-butene 2.9 3.8 3.4 3.5 3.3 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 21.6 22.1 22.2 22.0 22.9 22.5 22.9 22.6 22.3 22.3 22.3 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 0.9 1.0 1.0 0.9 0.9 0.9 0.92-methylpentane 4.5 4.5 4.5 4.5 4.4 4.5 4.5 4.5 4.5 4.4 4.5 4.5 4.43-methylpentane 2.6 2.6 2.5 2.6 2.7 2.6 2.6 2.6 2.6 2.5 2.5 2.6 2.5n-hexane 2.1 2.1 2.2 2.3 2.3 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.2 1.5 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.4 1.2 1.3 1.0 0.9 0.9 0.9 0.9 0.9 0.9 0.9 1.0Benzene 1.5 1.6 1.9 1.8 2.0 1.5 1.5 1.4 1.5 1.6 1.6 1.6 1.62-methylhexane 1.0 1.3 1.2 1.2 1.4 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.5 1.3 1.3 1.5 1.2 1.1 1.1 1.1 1.0 1.0 1.1 1.13-methylhexane 1.1 1.2 1.1 1.5 1.3 1.1 1.1 1.0 1.0 1.1 1.1 1.1 1.1Isooctane 1.2 1.4 1.6 1.4 1.5 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2Toluene 2.5 2.3 2.2 2.1 2.6 1.9 2.1 1.8 2.0 2.0 1.9 2.0 1.9

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

April 2003

Study Number FY01-013

F-25
Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Weekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)

Component Target

Week 

Starting 

5-5-03

Week 

Starting 

5-12-03

Week 

Starting 

5-19-03

Week 

Starting 

5-26-03

Week 

Starting 

5-5-03

Week 

Starting 

5-12-03

Week 

Starting 

5-19-03

Week 

Starting 

5-26-03

Week 

Starting 

5-5-03

Week 

Starting 

5-12-03

Week 

Starting 

5-19-03

Week 

Starting 

5-26-03

Isobutane 2.2 2.2 2.2 2.4 2.4 2.2 2.1 2.1 2.2 2.2 2.2 2.2 2.2n-butane 11.1 10.2 10.2 10.6 10.2 10.6 10.1 10.5 10.3 10.9 10.7 10.8 10.7Isopentane 31.0 28.9 28.3 29.1 28.5 30.5 30.4 30.2 30.2 31.1 31.0 31.0 30.8n-pentane 9.1 8.6 8.7 8.6 8.7 8.9 8.8 8.8 8.9 9.0 9.0 9.0 8.9trans-2-pentene 2.0 2.6 2.2 2.3 2.4 2.1 1.9 2.1 2.2 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.5 3.2 3.0 2.9 3.3 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 21.7 21.5 21.2 21.8 22.4 23.0 22.1 22.7 22.3 22.4 22.3 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 1.0 0.9 1.0 0.9 0.9 0.9 0.92-methylpentane 4.5 4.6 4.7 4.5 5.2 4.5 4.7 4.7 4.6 4.4 4.5 4.5 4.53-methylpentane 2.6 2.5 2.5 2.8 2.7 2.6 2.7 2.7 2.7 2.5 2.6 2.6 2.6n-hexane 2.1 2.2 2.2 2.2 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.4 1.4 1.1 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.0 1.2 1.0 0.9 1.0 1.1 1.0 0.9 0.9 0.9 0.9Benzene 1.5 2.1 2.2 1.8 2.1 1.6 1.4 1.6 1.4 1.5 1.5 1.5 1.52-methylhexane 1.0 1.2 1.3 1.1 1.1 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.02,3-dimethylpentane 1.0 1.3 1.6 1.6 1.6 1.1 1.3 1.2 1.3 1.0 1.1 1.1 1.13-methylhexane 1.1 1.2 1.4 1.4 1.4 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.1Isooctane 1.2 1.8 1.6 1.2 1.2 1.2 1.3 1.2 1.3 1.2 1.2 1.2 1.3Toluene 2.5 2.4 2.7 2.7 2.5 2.2 1.9 2.3 2.0 1.8 1.8 1.8 1.9

Low (2.0g/m3) Mid (10g/m3) High (20g/m3)

May 2003

Study Number FY01-013

F-26
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

G-1 

APPENDIX G 

ENVIRONMENTAL DATA 

G-1 Light and Sound Measurements 

G-2 Monthly Summaries of Chamber Flow, Relative Humidity, and 

Temperature 

G-3 Monthly Summaries of Percent Time Environmental Conditions 

were Out of Specified Ranges 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

G-1 Light and Sound Measurements 

G-2
Light and Sound Measurements FY01-013 

Date Chamber 5 (Control) Chamber 6 (2 g/m3) Chamber 7 (10 g/m3) Chamber 8 (20 g/m3) 

Decibels Foot 

Candles 

Decibels Foot 

Candles 

Decibels Foot 

Candles 

Decibels Foot 

Candles 

3/15/01 81 40 77 30 74 45 73.5 44 5/16/01 ND 40 ND 20 ND 35 ND 51 5/18/01 84 31 80 13 80 28 80 24 10/2/01 76 30.1 76 13.5 72 27.8 77 24.2 5/13/02 79 25 74 13 77 26.5 75 24.8 8/15/02 80 23.3 72 12.5 74 22 72.5 18 1/14/03 82 28.6 74 16.1 76 22.2 75 22.1 5/23/03 82 30 76 15 77 28 78 23 aND. No value recorded. Measurements of both sound and light were recorded two days later. 

Study Number FY01-013

G-3
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

G-2 Monthly Summaries of Chamber Flow, Relative Humidity, and Temperature 

G-4
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 5 (Control)

Month Year Mean SD Max* Min*

May 2001 440 9 451 428

June 2001 462 23 499 430

July 2001 447 12 475 429

August 2001 447 12 476 423

September 2001 457 11 479 443

October 2001 454 13 476 431

November 2001 473 12 491 448

December 2001 455 10 468 427

January 2002 436 16 470 412

February 2002 479 22 522 443

March 2002 476 34 530 416

April 2002 430 6 443 416

May 2002 452 14 486 431

June 2002 449 9 469 433

July 2002 471 15 504 443

August 2002 443 16 500 419

September 2002 428 7 441 415

October 2002 432 7 445 416

November 2002 440 7 459 430

December 2002 437 7 454 423

January 2003 451 15 473 422

February 2003 446 4 456 438

March 2003 441 8 456 416

April 2003 449 9 463 436

May 2003 448 8 464 439

*Min and Max of daily averages

G-5
MTBE Protocol No. FY01-013 Reviewed By:_____________

Summary of Relative Humidity Data (%RH)

Chamber 5 (Control)

Month Year Mean SD Max* Min*

May 2001 71 6 85 65

June 2001 73 8 84 51

July 2001 69 7 79 55

August 2001 68 6 78 58

September 2001 65 7 77 53

October 2001 55 12 74 30

November 2001 50 6 62 39

December 2001 48 8 72 38

January 2002 52 8 73 41

February 2002 39 6 49 24

March 2002 38 5 50 30

April 2002 42 6 61 30

May 2002 58 9 72 37

June 2002 67 4 75 56

July 2002 66 5 75 57

August 2002 67 5 84 59

September 2002 69 5 78 60

October 2002 63 11 84 45

November 2002 43 10 66 29

December 2002 40 4 50 34

January 2003 44 4 53 38

February 2003 41 8 60 28

March 2003 37 8 52 21

April 2003 32 9 50 17

May 2003 41 13 59 17

*Min and Max of daily averages

G-6
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data (o

C)

Chamber 5 (Control)

Month Year Mean SD Max* Min*

May 2001 22 1 24 22

June 2001 23 1 24 21

July 2001 22 0 23 21

August 2001 22 1 23 21

September 2001 22 1 23 21

October 2001 22 1 23 21

November 2001 22 1 23 21

December 2001 22 1 23 21

January 2002 21 1 23 20

February 2002 22 1 23 20

March 2002 22 1 24 21

April 2002 22 0 23 21

May 2002 22 0 23 21

June 2002 22 0 22 21

July 2002 22 0 23 22

August 2002 22 0 23 21

September 2002 22 0 22 21

October 2002 22 0 23 21

November 2002 23 1 23 21

December 2002 23 0 23 22

January 2003 22 0 23 21

February 2003 21 0 22 21

March 2003 22 1 23 20

April 2003 21 0 22 21

May 2003 22 0 22 21

*Min and Max of daily averages

G-7
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 6 (2g/m3

)

Month Year Mean SD Max* Min*

May 2001 451 23 467 411

June 2001 466 4 478 456

July 2001 465 12 484 443

August 2001 455 7 470 437

September 2001 459 6 467 446

October 2001 454 11 471 434

November 2001 450 22 484 419

December 2001 456 7 475 447

January 2002 451 19 494 423

February 2002 490 28 539 438

March 2002 439 15 452 368

April 2002 441 6 460 432

May 2002 444 18 474 395

June 2002 452 5 466 441

July 2002 473 16 501 450

August 2002 455 24 497 430

September 2002 453 24 485 413

October 2002 460 23 489 411

November 2002 462 7 479 453

December 2002 469 11 492 453

January 2003 460 6 468 451

February 2003 455 6 475 450

March 2003 441 13 477 420

April 2003 445 3 453 440

May 2003 443 3 447 438

*Min and Max of daily average

G-8
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Relative Humidity Data (%RH)

Chamber 6 (2g/m3

)

Month Year Mean SD Max* Min*

May 2001 67 5 77 62

June 2001 78 4 85 71

July 2001 71 2 75 67

August 2001 69 3 74 64

September 2001 69 6 78 58

October 2001 59 9 72 47

November 2001 60 8 73 46

December 2001 57 6 72 47

January 2002 54 7 65 38

February 2002 45 9 59 25

March 2002 44 6 57 34

April 2002 46 10 71 29

May 2002 58 9 74 35

June 2002 57 1 57 51

July 2002 57 1 57 52

August 2002 57 1 58 55

September 2002 57 0 57 55

October 2002 57 2 57 47

November 2002 41 5 52 33

December 2002 41 4 48 34

January 2003 46 6 57 36

February 2003 45 5 54 36

March 2003 41 9 55 24

April 2003 43 6 55 34

May 2003 50 9 61 32

*Min and Max of daily average

G-9
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data (o

C)

Chamber 6 (2g/m3

)

Month Year Mean SD Max* Min*

May 2001 25 0 26 24

June 2001 24 1 25 22

July 2001 22 0 23 22

August 2001 23 0 23 22

September 2001 23 0 23 22

October 2001 23 0 23 22

November 2001 23 0 23 22

December 2001 22 1 23 21

January 2002 22 0 23 22

February 2002 22 1 23 19

March 2002 22 0 23 22

April 2002 22 0 23 22

May 2002 22 0 23 21

June 2002 22 0 23 21

July 2002 22 0 23 21

August 2002 22 1 23 21

September 2002 22 1 23 21

October 2002 22 1 23 21

November 2002 22 0 23 22

December 2002 22 0 22 21

January 2003 22 1 22 21

February 2003 22 0 23 21

March 2003 22 0 23 21

April 2003 22 1 22 21

May 2003 22 0 23 21

*Min and Max of daily average

G-10
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 7 (10g/m3

)

Month Year Mean SD Max* Min*

May 2001 437 15 459 411

June 2001 452 9 470 437

July 2001 448 10 466 430

August 2001 446 9 472 428

September 2001 455 10 476 441

October 2001 444 11 461 421

November 2001 444 20 476 418

December 2001 438 5 447 431

January 2002 451 13 472 425

February 2002 481 33 546 429

March 2002 422 12 442 383

April 2002 440 17 497 410

May 2002 456 12 483 426

June 2002 470 9 491 457

July 2002 421 18 495 421

August 2002 448 10 465 429

September 2002 433 13 459 396

October 2002 440 6 452 430

November 2002 432 8 445 419

December 2002 444 6 458 436

January 2003 442 8 456 428

February 2003 434 4 439 424

March 2003 437 9 460 424

April 2003 430 5 438 422

May 2003 429 3 434 423

*Min and Max of daily averages

G-11
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Relative Humidity Data (%RH)

Chamber 7 (10g/m3

)

Month Year Mean SD Max* Min*

May 2001 60 3 66 54

June 2001 71 9 83 52

July 2001 64 4 72 57

August 2001 67 4 75 59

September 2001 65 4 70 55

October 2001 54 11 73 38

November 2001 55 10 70 36

December 2001 52 6 69 43

January 2002 50 5 59 42

February 2002 40 9 56 25

March 2002 39 5 46 26

April 2002 44 12 75 27

May 2002 56 11 71 36

June 2002 65 7 77 50

July 2002 70 3 75 64

August 2002 70 7 82 58

September 2002 72 5 82 64

October 2002 59 7 72 48

November 2002 41 7 58 30

December 2002 40 5 48 33

January 2003 45 12 79 33

February 2003 41 6 57 29

March 2003 40 9 62 27

April 2003 36 5 52 27

May 2003 45 10 60 27

*Min and Max of daily averages

G-12
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data (o

C)

Chamber 7 (10g/m3

)

Month Year Mean SD Max* Min*

May 2001 24 0 25 24

June 2001 24 1 26 23

July 2001 23 0 23 22

August 2001 23 0 23 22

September 2001 23 0 23 22

October 2001 23 0 23 22

November 2001 23 0 24 23

December 2001 22 1 24 22

January 2002 22 0 23 22

February 2002 22 1 23 21

March 2002 22 0 23 22

April 2002 23 0 23 22

May 2002 22 0 23 22

June 2002 22 0 23 21

July 2002 22 1 23 21

August 2002 22 1 23 20

September 2002 22 1 23 21

October 2002 22 1 23 21

November 2002 23 0 23 22

December 2002 22 1 23 21

January 2003 22 1 23 21

February 2003 22 0 23 22

March 2003 22 0 23 21

April 2003 21 0 22 21

May 2003 22 0 23 21

*Min and Max of daily averages

G-13
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 8 (20g/m3

)

Month Year Mean SD Max* Min*

May 2001 444 9 452 429

June 2001 452 4 460 444

July 2001 452 7 462 440

August 2001 453 12 474 426

September 2001 480 19 516 447

October 2001 476 15 510 458

November 2001 470 19 491 409

December 2001 461 9 475 449

January 2002 448 7 456 430

February 2002 457 17 487 433

March 2002 437 22 471 368

April 2002 457 13 473 422

May 2002 458 6 476 449

June 2002 439 15 474 413

July 2002 439 15 476 420

August 2002 444 19 483 422

September 2002 444 23 486 414

October 2002 457 4 464 452

November 2002 443 10 456 429

December 2002 437 4 444 430

January 2003 430 4 440 424

February 2003 432 17 459 386

March 2003 437 17 458 390

April 2003 437 4 444 431

May 2003 431 6 434 422

*Min and Max of daily averages

G-14
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Relative Humidity Data (%RH)

Chamber 8 (20g/m3

)

Month Year Mean SD Max* Min*

May 2001 62 5 73 58

June 2001 72 6 81 61

July 2001 64 2 68 57

August 2001 65 2 69 59

September 2001 60 4 68 48

October 2001 53 10 70 31

November 2001 52 6 63 37

December 2001 50 7 68 39

January 2002 49 6 58 38

February 2002 49 11 73 30

March 2002 45 5 56 38

April 2002 46 5 61 38

May 2002 56 7 68 36

June 2002 66 6 76 56

July 2002 71 3 77 65

August 2002 66 3 73 60

September 2002 68 5 82 64

October 2002 59 6 69 47

November 2002 48 7 65 38

December 2002 44 6 57 34

January 2003 47 4 54 39

February 2003 49 6 66 38

March 2003 43 9 60 28

April 2003 42 5 51 33

May 2003 49 10 59 31

*Min and Max of daily averages

G-15
MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data (o

C)

Chamber 8 (20g/m3

)

Month Year Mean SD Max* Min*

May 2001 23 1 24 22

June 2001 23 1 25 21

July 2001 22 0 23 21

August 2001 22 0 23 21

September 2001 22 0 22 21

October 2001 22 0 23 21

November 2001 22 0 23 22

December 2001 22 1 23 21

January 2002 22 1 23 21

February 2002 21 1 22 20

March 2002 21 1 23 20

April 2002 22 0 23 20

May 2002 23 0 23 21

June 2002 22 0 23 21

July 2002 22 1 23 21

August 2002 22 1 23 20

September 2002 22 1 23 21

October 2002 22 1 22 21

November 2002 22 1 22 20

December 2002 22 1 23 20

January 2003 21 0 22 21

February 2003 21 0 22 20

March 2003 21 1 23 20

April 2003 21 0 22 21

May 2003 21 0 22 21

*Min and Max of daily averages

G-16
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

G-3 Monthly Summaries of Percent Time Environmental Conditions 

were Out of Specified Ranges 

G-17
Study Number FY01-013

G-18
Study Number FY01-013

G-19
Study Number FY01-013

G-20
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

H-1 

APPENDIX H 

INDIVIDUAL ANIMAL DISPOSITION 

H-1 Males 

H-2 Females 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

H-1 Males 

H-2
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 1 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6831E401 1 M Dosing phase 25-Mar-03 12:45 128 21-Mar-03 668 u Sacrificed moribund 350.8 C C 6831E402 1 M Dosing phase 12-Dec-02 13:56 128 12-Dec-02 569 u Sacrificed moribund 375.6 C C 6831E403 1 M Dosing phase 28-Jan-03 09:10 8 21-Jan-03 609 u Sacrificed moribund 276.1 C C 6831E404 1 M Dosing phase 03-Mar-03 16:53 128 27-Feb-03 646 u Sacrificed moribund 494.2 C C 6831E405 1 M Dosing phase 18-Mar-03 10:28 8 14-Mar-03 661 u Sacrificed moribund 311.3 C C 6831E406 1 M Dosing phase 03-Jun-03 15:54 128 13-May-03 721 u Sacrificed moribund 224.4 C C 6831E407 1 M Dosing phase 04-Jun-03 13:52 128 28-May-03 736 s Final phase sacrifice 403.2 C C 6831E408 1 M Dosing phase 20-Dec-01 14:18 128 17-Dec-01 209 u Sacrificed moribund 312.1 C - 6831E409 1 M Dosing phase 13-Feb-03 16:55 128 12-Feb-03 631 u Sacrificed moribund 300.4 C C 6831E410 1 M Dosing phase 25-Feb-03 13:18 8 25-Feb-03 644 u Sacrificed moribund 369.2 C C 6831E411 1 M Dosing phase 01-Apr-03 11:25 8 28-Mar-03 675 u Sacrificed moribund 339.4 C C 6831E412 1 M Dosing phase 12-Dec-02 13:38 128 01-Dec-02 558 u Sacrificed moribund 331.9 C C 6831E413 1 M Dosing phase 09-Jun-03 08:20 -1 29-May-03 737 s Final phase sacrifice 379.5 C C 6831E414 1 M Dosing phase 29-Jan-03 11:03 8 28-Jan-03 616 u Sacrificed moribund 255.3 C C 6831E415 1 M Dosing phase 09-Jun-03 08:30 -1 27-May-03 735 s Final phase sacrifice 395.5 C C 6831E416 1 M Dosing phase 25-Mar-03 13:06 128 19-Mar-03 666 u Sacrificed moribund 385.4 C C 6831E417 1 M Dosing phase 28-May-03 16:51 128 26-May-03 734 u Sacrificed moribund 372.5 C C 6831E418 1 M Dosing phase 09-Jun-03 16:41 128 29-May-03 737 s Final phase sacrifice 398.8 C C 6831E419 1 M Dosing phase 21-Apr-03 17:09 128 17-Apr-03 695 u Sacrificed moribund 359.2 C C 6831E420 1 M Dosing phase 24-Apr-03 17:19 128 24-Apr-03 702 u Sacrificed moribund 355.4 C C 6831E421 1 M Dosing phase 20-Dec-02 11:37 -1 19-Dec-02 576 u Sacrificed moribund 385.2 C C 6831E422 1 M Dosing phase 09-Jun-03 16:42 128 30-May-03 738 s Final phase sacrifice 384.3 C C 6831E423 1 M Dosing phase 10-Jan-03 16:20 128 09-Jan-03 597 u Sacrificed moribund 381.1 C C 6831E424 1 M Dosing phase 10-Feb-03 09:41 -1 07-Feb-03 626 u Sacrificed moribund 365.0 C C 6831E425 1 M Dosing phase 11-Feb-03 11:03 8 10-Feb-03 629 u Found Dead 434.1 C C 6831E426 1 M Dosing phase 08-May-03 16:30 128 02-May-03 710 u Sacrificed moribund 282.1 C C 6831E427 1 M Dosing phase 21-May-03 16:27 128 21-May-03 729 u Sacrificed moribund 294.9 C C 6831E428 1 M Dosing phase 10-Feb-03 09:56 -1 10-Feb-03 629 u Sacrificed moribund 355.2 C C 6831E429 1 M Dosing phase 18-Mar-03 10:29 8 14-Mar-03 661 u Sacrificed moribund 352.3 C C 6831E430 1 M Dosing phase 10-Mar-03 16:56 128 04-Mar-03 651 u Sacrificed moribund 327.7 C C 6831E431 1 M Dosing phase 28-Aug-02 09:17 8 15-Jun-02 389 u Sacrificed moribund 346.8 C C 6831E432 1 M Dosing phase 06-Mar-03 16:10 128 06-Mar-03 653 u Sacrificed moribund 379.0 C C 6831E433 1 M Dosing phase 01-Apr-03 11:26 8 28-Mar-03 675 u Sacrificed moribund 311.2 C C 6831E434 1 M Dosing phase 06-Mar-03 16:42 128 05-Mar-03 652 u Sacrificed moribund 317.5 C C 6831E435 1 M Dosing phase 09-Jun-03 16:42 128 30-May-03 738 s Final phase sacrifice 355.1 C C 6831E436 1 M Dosing phase 09-Jun-03 16:42 128 30-May-03 738 s Final phase sacrifice 393.1 C C 6831E437 1 M Dosing phase 09-Jun-03 16:43 128 27-May-03 735 s Final phase sacrifice 398.3 C C 6831E438 1 M Dosing phase 04-Apr-03 16:56 128 02-Apr-03 680 u Sacrificed moribund 331.8 C C 6831E439 1 M Dosing phase 23-May-02 14:25 128 22-May-02 365 u Sacrificed moribund 417.3 C C 6831E440 1 M Dosing phase 04-Jun-03 13:57 128 28-May-03 736 s Final phase sacrifice 396.8 C C 6831E441 1 M Dosing phase 10-Feb-03 10:25 8 05-Feb-03 624 u Sacrificed moribund 366.9 C C 6831E442 1 M Dosing phase 04-Jun-03 13:58 128 28-May-03 736 s Final phase sacrifice 383.6 C C 6831E443 1 M Dosing phase 09-Jun-03 16:43 128 29-May-03 737 s Final phase sacrifice 404.7 C C 6831E444 1 M Dosing phase 18-Mar-03 10:30 8 14-Mar-03 661 u Sacrificed moribund 331.1 C C 6831E445 1 M Dosing phase 10-Feb-03 10:21 8 05-Feb-03 624 u Sacrificed moribund 369.9 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-3
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6831E446 1 M Dosing phase 09-Jun-03 16:43 128 27-May-03 735 s Final phase sacrifice 352.3 C C 6831E447 1 M Dosing phase 21-Feb-03 16:35 128 21-Feb-03 640 u Sacrificed moribund 353.4 C C 6831E448 1 M Dosing phase 09-Jun-03 16:44 128 27-May-03 735 s Final phase sacrifice 396.0 C C 6831E449 1 M Dosing phase 09-Jun-03 16:44 128 29-May-03 737 s Final phase sacrifice 418.7 C C 6831E450 1 M Dosing phase 06-Jan-03 15:17 -1 24-Dec-02 581 u Sacrificed moribund 440.7 C C 6833F501 2 M Dosing phase 25-Feb-03 13:17 8 24-Feb-03 643 u Found Dead 357.8 C C 6833F502 2 M Dosing phase 04-Jun-03 14:18 128 30-May-03 738 s Final phase sacrifice 384.3 C C 6833F503 2 M Dosing phase 20-May-03 12:06 128 20-May-03 728 u Found Dead 328.8 C C 6833F504 2 M Dosing phase 04-Apr-03 17:09 128 04-Apr-03 682 u Sacrificed moribund 344.8 C C 6833F505 2 M Dosing phase 04-Jun-03 14:18 128 30-May-03 738 s Final phase sacrifice 400.1 C C 6833F506 2 M Dosing phase 21-Feb-03 16:40 128 21-Feb-03 640 u Sacrificed moribund 299.2 C C 6833F507 2 M Dosing phase 18-Mar-03 10:30 8 14-Mar-03 661 u Sacrificed moribund 367.4 C C 6833F508 2 M Dosing phase 09-Jun-03 16:49 128 27-May-03 735 s Final phase sacrifice 387.3 C C 6833F509 2 M Dosing phase 07-Jan-03 10:09 -1 31-Dec-02 588 u Sacrificed moribund 503.4 C C 6833F510 2 M Dosing phase 03-Mar-03 16:28 128 26-Feb-03 645 u Sacrificed moribund 314.7 C C 6833F511 2 M Dosing phase 09-Jun-03 16:49 128 27-May-03 735 s Final phase sacrifice 411.5 C C 6833F512 2 M Dosing phase 19-Sep-02 14:24 128 17-Sep-02 483 u Sacrificed moribund 306.8 C C 6833F513 2 M Dosing phase 09-Jun-03 16:50 128 29-May-03 737 s Final phase sacrifice 280.5 C C 6833F514 2 M Dosing phase 06-Jan-03 14:29 8 20-Dec-02 577 u Sacrificed moribund 395.1 C C 6833F515 2 M Dosing phase 22-Nov-02 15:32 8 20-Nov-02 547 u Sacrificed moribund 352.0 C C 6833F516 2 M Dosing phase 04-Jun-03 14:21 128 30-May-03 738 s Final phase sacrifice 377.9 C C 6833F517 2 M Dosing phase 18-Feb-03 13:24 8 14-Feb-03 633 u Sacrificed moribund 408.0 C C 6833F518 2 M Dosing phase 03-Mar-03 17:03 128 28-Feb-03 647 u Sacrificed moribund 407.4 C C 6833F519 2 M Dosing phase 04-Jun-03 14:22 128 30-May-03 738 s Final phase sacrifice 416.2 C C 6833F520 2 M Dosing phase 29-May-03 17:19 128 21-May-03 729 u Sacrificed moribund 324.1 C C 6833F521 2 M Dosing phase 09-Jun-03 16:50 128 28-May-03 736 s Final phase sacrifice 335.6 C C 6833F522 2 M Dosing phase 16-Apr-03 17:29 128 11-Apr-03 689 u Sacrificed moribund 377.2 C C 6833F523 2 M Dosing phase 09-Jun-03 16:50 128 28-May-03 736 s Final phase sacrifice 408.3 C C 6833F524 2 M Dosing phase 25-Jun-02 14:28 128 21-Jun-02 395 u Found Dead 479.0 C C 6833F525 2 M Dosing phase 09-Jun-03 16:51 128 29-May-03 737 s Final phase sacrifice 393.6 C C 6833F526 2 M Dosing phase 09-Jun-03 16:51 128 28-May-03 736 s Final phase sacrifice 362.5 C C 6833F527 2 M Dosing phase 20-Dec-02 11:37 -1 19-Dec-02 576 u Sacrificed moribund 357.5 C C 6833F528 2 M Dosing phase 19-Sep-02 14:32 128 12-Sep-02 478 u Sacrificed moribund 309.8 C C 6833F529 2 M Dosing phase 30-Sep-02 09:14 128 20-Sep-02 486 u Sacrificed moribund 444.5 C C 6833F530 2 M Dosing phase 07-May-03 17:31 128 29-Apr-03 707 u Sacrificed moribund 329.6 C C 6833F531 2 M Dosing phase 21-Apr-03 17:13 128 17-Apr-03 695 u Sacrificed moribund 355.2 C C 6833F532 2 M Dosing phase 05-Sep-02 08:59 8 28-Aug-02 463 u Sacrificed moribund 314.7 C C 6833F533 2 M Dosing phase 07-Jan-03 10:09 -1 31-Dec-02 588 u Sacrificed moribund 388.3 C C 6833F534 2 M Dosing phase 25-Feb-03 13:18 8 25-Feb-03 644 u Sacrificed moribund 247.0 C C 6833F535 2 M Dosing phase 11-Jun-03 08:03 8 28-May-03 736 s Final phase sacrifice 409.1 C C 6833F536 2 M Dosing phase 09-Jun-03 16:51 128 29-May-03 737 s Final phase sacrifice 340.7 C C 6833F537 2 M Dosing phase 18-Feb-03 13:24 8 14-Feb-03 633 u Sacrificed moribund 338.3 C C 6833F538 2 M Dosing phase 21-Apr-03 16:45 128 18-Apr-03 696 u Sacrificed moribund 369.0 C C 6833F539 2 M Dosing phase 26-Mar-03 18:25 128 26-Mar-03 673 u Sacrificed moribund 259.2 C C 6833F540 2 M Dosing phase 09-Aug-02 13:29 128 07-Aug-02 442 u Sacrificed moribund 300.4 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-4
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 3 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6833F541 2 M Dosing phase 11-Mar-03 13:09 8 07-Mar-03 654 u Found Dead 379.4 C C 6833F542 2 M Dosing phase 09-Jun-03 16:51 128 27-May-03 735 s Final phase sacrifice 365.4 C C 6833F543 2 M Dosing phase 06-Mar-03 16:53 128 05-Mar-03 652 u Sacrificed moribund 325.3 C C 6833F544 2 M Dosing phase 25-Mar-03 12:47 128 21-Mar-03 668 u Sacrificed moribund 352.7 C C 6833F545 2 M Dosing phase 13-Dec-02 11:59 8 15-Nov-02 542 u Sacrificed moribund 367.1 C C 6833F546 2 M Dosing phase 09-May-03 13:16 8 29-Apr-03 707 u Sacrificed moribund 350.7 C C 6833F547 2 M Dosing phase 04-Jun-03 14:27 128 30-May-03 738 s Final phase sacrifice 366.3 C C 6833F548 2 M Dosing phase 14-Apr-03 16:50 128 09-Apr-03 687 u Sacrificed moribund 472.7 C C 6833F549 2 M Dosing phase 21-Feb-03 16:31 128 20-Feb-03 639 u Found Dead 288.9 C C 6833F550 2 M Dosing phase 09-Jun-03 16:52 128 27-May-03 735 s Final phase sacrifice 368.4 C C 6835G601 3 M Dosing phase 04-Jun-03 14:28 128 28-May-03 736 s Final phase sacrifice 382.8 C C 6835G602 3 M Dosing phase 09-Jun-03 16:45 128 29-May-03 737 s Final phase sacrifice 368.3 C C 6835G603 3 M Dosing phase 09-Jun-03 16:45 128 27-May-03 735 s Final phase sacrifice 375.0 C C 6835G604 3 M Dosing phase 11-Mar-03 13:02 8 10-Mar-03 657 u Sacrificed moribund 334.8 C C 6835G605 3 M Dosing phase 09-Jun-03 16:45 128 29-May-03 737 s Final phase sacrifice 354.7 C C 6835G606 3 M Dosing phase 07-Jan-03 10:08 -1 31-Dec-02 588 u Sacrificed moribund 411.5 C C 6835G607 3 M Dosing phase 04-Jun-03 14:31 128 28-May-03 736 s Final phase sacrifice 372.0 C C 6835G608 3 M Dosing phase 21-Apr-03 17:45 128 16-Apr-03 694 u Sacrificed moribund 319.0 C C 6835G609 3 M Dosing phase 09-Jun-03 16:45 128 30-May-03 738 s Final phase sacrifice 394.9 C C 6835G610 3 M Dosing phase 09-Jun-03 16:46 128 29-May-03 737 s Final phase sacrifice 368.2 C C 6835G611 3 M Dosing phase 09-Aug-02 13:24 128 02-Aug-02 437 u Sacrificed moribund 290.7 C C 6835G612 3 M Dosing phase 18-Feb-03 13:22 8 14-Feb-03 633 u Sacrificed moribund 317.1 C C 6835G613 3 M Dosing phase 09-Jun-03 16:46 128 27-May-03 735 s Final phase sacrifice 374.6 C C 6835G614 3 M Dosing phase 09-Jun-03 16:47 128 27-May-03 735 s Final phase sacrifice 389.1 C C 6835G615 3 M Dosing phase 09-Jun-03 16:47 128 29-May-03 737 s Final phase sacrifice 349.7 C C 6835G616 3 M Dosing phase 21-Apr-03 17:42 128 21-Apr-03 699 u Sacrificed moribund 350.1 C C 6835G617 3 M Dosing phase 09-Jun-03 16:47 128 27-May-03 735 s Final phase sacrifice 359.5 C C 6835G618 3 M Dosing phase 18-Feb-03 13:17 8 07-Feb-03 626 u Sacrificed moribund 333.2 C C 6835G619 3 M Dosing phase 18-Feb-03 13:22 8 14-Feb-03 633 u Sacrificed moribund 321.5 C C 6835G620 3 M Dosing phase 18-Feb-03 13:17 8 07-Feb-03 626 u Sacrificed moribund 334.6 C C 6835G621 3 M Dosing phase 09-Jun-03 16:47 128 30-May-03 738 s Final phase sacrifice 350.0 C C 6835G622 3 M Dosing phase 23-May-03 17:23 128 22-May-03 730 u Sacrificed moribund 312.8 C C 6835G623 3 M Dosing phase 07-Nov-02 14:45 -1 06-Nov-02 533 u Sacrificed moribund 381.3 C C 6835G624 3 M Dosing phase 25-Mar-03 13:10 128 19-Mar-03 666 u Sacrificed moribund 310.6 C C 6835G625 3 M Dosing phase 04-Mar-03 13:40 8 04-Mar-03 651 u Found Dead 323.9 C C 6835G626 3 M Dosing phase 01-Apr-03 11:44 -1 28-Mar-03 675 u Sacrificed moribund 347.1 C C 6835G627 3 M Dosing phase 12-May-03 11:30 -1 05-Apr-03 683 u Found Dead 372.8 C C 6835G628 3 M Dosing phase 09-Jun-03 16:48 128 30-May-03 738 s Final phase sacrifice 378.2 C C 6835G629 3 M Dosing phase 06-Mar-03 16:14 128 06-Mar-03 653 u Sacrificed moribund 316.6 C C 6835G630 3 M Dosing phase 09-Jun-03 16:48 128 27-May-03 735 s Final phase sacrifice 366.6 C C 6835G631 3 M Dosing phase 21-Apr-03 17:18 128 17-Apr-03 695 u Sacrificed moribund 362.6 C C 6835G632 3 M Dosing phase 14-Apr-03 16:58 128 09-Apr-03 687 u Sacrificed moribund 323.8 C C 6835G633 3 M Dosing phase 16-Apr-03 17:30 128 11-Apr-03 689 u Sacrificed moribund 420.2 C C 6835G634 3 M Dosing phase 09-Jun-03 16:48 128 27-May-03 735 s Final phase sacrifice 396.2 C C 6835G635 3 M Dosing phase 18-Feb-03 13:18 8 07-Feb-03 626 u Sacrificed moribund 307.0 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-5
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 4 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6835G636 3 M Dosing phase 03-Feb-03 09:11 8 02-Feb-03 621 u Found Dead 297.7 C C 6835G637 3 M Dosing phase 03-Mar-03 16:31 128 26-Feb-03 645 u Sacrificed moribund 326.4 C C 6835G638 3 M Dosing phase 04-Jun-03 14:37 128 28-May-03 736 s Final phase sacrifice 392.6 C C 6835G639 3 M Dosing phase 04-Jun-03 14:37 128 28-May-03 736 s Final phase sacrifice 383.2 C C 6835G640 3 M Dosing phase 20-Dec-02 11:38 -1 19-Dec-02 576 u Sacrificed moribund 291.4 C C 6835G641 3 M Dosing phase 18-Mar-03 10:31 8 14-Mar-03 661 u Sacrificed moribund 349.9 C C 6835G642 3 M Dosing phase 25-Mar-03 12:52 128 21-Mar-03 668 u Sacrificed moribund 334.1 C C 6835G643 3 M Dosing phase 28-Jan-03 08:47 -1 15-Jan-03 603 u Sacrificed moribund 407.3 C C 6835G644 3 M Dosing phase 07-Nov-02 13:43 -1 22-Oct-02 518 u Sacrificed moribund 353.4 C C 6835G645 3 M Dosing phase 21-May-03 16:39 128 21-May-03 729 u Sacrificed moribund 323.0 C C 6835G646 3 M Dosing phase 21-Feb-03 16:51 128 21-Feb-03 640 u Sacrificed moribund 356.0 C C 6835G647 3 M Dosing phase 04-Jun-03 14:38 128 28-May-03 736 s Final phase sacrifice 401.1 C C 6835G648 3 M Dosing phase 09-Jun-03 16:48 128 29-May-03 737 s Final phase sacrifice 268.6 C C 6835G649 3 M Dosing phase 09-Jun-03 16:49 128 29-May-03 737 s Final phase sacrifice 349.5 C C 6835G650 3 M Dosing phase 10-Feb-03 10:31 8 06-Feb-03 625 u Sacrificed moribund 341.9 C C 6837H701 4 M Dosing phase 21-Apr-03 17:26 128 17-Apr-03 695 u Sacrificed moribund 253.6 C C 6837H702 4 M Dosing phase 04-Jun-03 14:03 128 27-May-03 735 s Final phase sacrifice 382.2 C C 6837H703 4 M Dosing phase 18-Mar-03 10:28 8 14-Mar-03 661 u Sacrificed moribund 435.2 C C 6837H704 4 M Dosing phase 09-Jun-03 16:52 128 30-May-03 738 s Final phase sacrifice 397.1 C C 6837H705 4 M Dosing phase 09-Jun-03 16:53 128 30-May-03 738 s Final phase sacrifice 399.2 C C 6837H706 4 M Dosing phase 09-Jun-03 16:53 128 30-May-03 738 s Final phase sacrifice 356.7 C C 6837H707 4 M Dosing phase 06-Mar-03 16:46 128 05-Mar-03 652 u Sacrificed moribund 353.8 C C 6837H708 4 M Dosing phase 09-Jun-03 16:53 128 29-May-03 737 s Final phase sacrifice 346.6 C C 6837H709 4 M Dosing phase 11-Mar-03 13:03 8 10-Mar-03 657 u Sacrificed moribund 362.3 C C 6837H710 4 M Dosing phase 14-Apr-03 16:28 128 10-Apr-03 688 u Sacrificed moribund 305.8 C C 6837H711 4 M Dosing phase 29-Apr-03 17:32 128 25-Apr-03 703 u Sacrificed moribund 358.8 C C 6837H712 4 M Dosing phase 03-Feb-03 10:27 8 22-Jan-03 610 u Sacrificed moribund 348.6 C C 6837H713 4 M Dosing phase 09-May-03 16:21 128 08-May-03 716 u Sacrificed moribund 301.4 C C 6837H714 4 M Dosing phase 09-Jun-03 16:53 128 28-May-03 736 s Final phase sacrifice 335.0 C C 6837H715 4 M Dosing phase 10-Feb-03 09:48 -1 07-Feb-03 626 u Sacrificed moribund 365.1 C C 6837H716 4 M Dosing phase 08-May-03 10:26 -1 05-Sep-02 471 u Sacrificed moribund 411.5 C C 6837H717 4 M Dosing phase 09-Jun-03 16:54 128 29-May-03 737 s Final phase sacrifice 371.8 C C 6837H718 4 M Dosing phase 20-May-03 12:52 8 19-May-03 727 u Found Dead 349.8 C C 6837H719 4 M Dosing phase 07-Nov-02 14:36 -1 22-Oct-02 518 u Sacrificed moribund 365.4 C C 6837H720 4 M Dosing phase 18-Feb-03 13:23 8 14-Feb-03 633 u Sacrificed moribund 301.7 C C 6837H721 4 M Dosing phase 09-May-03 16:40 128 14-Apr-03 692 u Sacrificed moribund 362.5 C C 6837H722 4 M Dosing phase 04-Jun-03 14:08 128 27-May-03 735 s Final phase sacrifice 335.5 C C 6837H723 4 M Dosing phase 06-Jan-03 10:30 8 24-Dec-02 581 u Sacrificed moribund 333.5 C C 6837H724 4 M Dosing phase 09-Jun-03 16:54 128 28-May-03 736 s Final phase sacrifice 351.4 C C 6837H725 4 M Dosing phase 09-Jun-03 16:54 128 28-May-03 736 s Final phase sacrifice 271.3 C C 6837H726 4 M Dosing phase 04-Jun-03 14:11 128 27-May-03 735 s Final phase sacrifice 376.6 C C 6837H727 4 M Dosing phase 11-Mar-03 13:04 8 10-Mar-03 657 u Sacrificed moribund 304.8 C C 6837H728 4 M Dosing phase 04-Jun-03 14:11 128 27-May-03 735 s Final phase sacrifice 348.4 C C 6837H729 4 M Dosing phase 04-Jun-03 14:12 128 27-May-03 735 s Final phase sacrifice 355.9 C C 6837H730 4 M Dosing phase 24-Apr-03 17:28 128 24-Apr-03 702 u Sacrificed moribund 334.0 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-6
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 5 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6837H731 4 M Dosing phase 06-Mar-03 16:50 128 05-Mar-03 652 u Sacrificed moribund 304.6 C C 6837H732 4 M Dosing phase 06-Jan-03 15:43 -1 30-Dec-02 587 u Found Dead 378.8 C C 6837H733 4 M Dosing phase 10-Jan-03 16:33 128 09-Jan-03 597 u Sacrificed moribund 298.5 C C 6837H734 4 M Dosing phase 24-Apr-03 17:29 128 24-Apr-03 702 u Sacrificed moribund 316.5 C C 6837H735 4 M Dosing phase 09-Jun-03 16:54 128 28-May-03 736 s Final phase sacrifice 357.6 C C 6837H736 4 M Dosing phase 09-Jun-03 16:55 128 29-May-03 737 s Final phase sacrifice 371.5 C C 6837H737 4 M Dosing phase 06-Mar-03 16:52 128 05-Mar-03 652 u Sacrificed moribund 323.8 C C 6837H738 4 M Dosing phase 24-Apr-03 17:31 128 24-Apr-03 702 u Sacrificed moribund 330.4 C C 6837H739 4 M Dosing phase 09-Jun-03 16:55 128 28-May-03 736 s Final phase sacrifice 371.6 C C 6837H740 4 M Dosing phase 21-Feb-03 16:55 128 21-Feb-03 640 u Sacrificed moribund 315.5 C C 6837H741 4 M Dosing phase 09-Jun-03 16:55 128 29-May-03 737 s Final phase sacrifice 361.3 C C 6837H742 4 M Dosing phase 10-Jan-03 16:24 128 09-Jan-03 597 u Sacrificed moribund 307.8 C C 6837H743 4 M Dosing phase 09-May-03 16:33 128 08-May-03 716 u Sacrificed moribund 301.2 C C 6837H744 4 M Dosing phase 04-Sep-02 13:41 128 03-Sep-02 469 u Sacrificed moribund 296.4 C C 6837H745 4 M Dosing phase 25-Mar-03 12:28 128 24-Mar-03 671 u Sacrificed moribund 273.9 C C 6837H746 4 M Dosing phase 03-Mar-03 16:40 128 26-Feb-03 645 u Sacrificed moribund 287.8 C C 6837H747 4 M Dosing phase 09-Jun-03 16:55 128 30-May-03 738 s Final phase sacrifice 365.8 C C 6837H748 4 M Dosing phase 06-Jan-03 15:36 -1 30-Dec-02 587 u Sacrificed moribund 364.1 C C 6837H749 4 M Dosing phase 09-Jun-03 16:56 128 29-May-03 737 s Final phase sacrifice 328.0 C C 6837H750 4 M Dosing phase 14-Apr-03 17:01 128 09-Apr-03 687 u Sacrificed moribund 305.6 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-7
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

H-2 Females 

H-8
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 1 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6832E451 1 F Dosing phase 13-Jun-03 12:31 128 03-Jun-03 735 s Final phase sacrifice 290.9 C C 6832E452 1 F Dosing phase 13-Jun-03 12:31 128 03-Jun-03 735 s Final phase sacrifice 265.5 C C 6832E453 1 F Dosing phase 08-May-03 17:11 128 06-May-03 707 u Sacrificed moribund 219.3 C C 6832E454 1 F Dosing phase 03-Feb-03 10:42 8 31-Jan-03 612 u Found Dead 273.6 C C 6832E455 1 F Dosing phase 14-Apr-03 16:32 128 09-Apr-03 680 u Sacrificed moribund 279.2 C C 6832E456 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 272.8 C C 6832E457 1 F Dosing phase 10-Jan-03 16:45 128 07-Jan-03 588 u Sacrificed moribund 201.2 C C 6832E458 1 F Dosing phase 04-Jun-03 14:40 128 02-Jun-03 734 s Final phase sacrifice 257.4 C C 6832E459 1 F Dosing phase 18-Feb-03 13:19 8 14-Feb-03 626 u Sacrificed moribund 223.0 C C 6832E460 1 F Dosing phase 13-Jun-03 12:39 128 04-Jun-03 736 s Final phase sacrifice 277.6 C C 6832E461 1 F Dosing phase 04-Jun-03 14:41 128 02-Jun-03 734 s Final phase sacrifice 300.6 C C 6832E462 1 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 304.3 C C 6832E463 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 277.1 C C 6832E464 1 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 217.4 C C 6832E465 1 F Dosing phase 10-Jan-03 16:49 128 07-Jan-03 588 u Sacrificed moribund 192.6 C - 6832E466 1 F Dosing phase 16-Apr-03 17:25 128 11-Apr-03 682 u Sacrificed moribund 237.0 C C 6832E467 1 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 301.9 C - 6832E468 1 F Dosing phase 14-Apr-03 16:34 128 09-Apr-03 680 u Sacrificed moribund 260.6 C C 6832E469 1 F Dosing phase 21-Feb-03 16:29 128 20-Feb-03 632 u Sacrificed moribund 201.9 C C 6832E470 1 F Dosing phase 22-Nov-02 15:30 8 20-Nov-02 540 u Sacrificed moribund 239.4 C C 6832E471 1 F Dosing phase 04-Apr-03 17:00 128 02-Apr-03 673 u Sacrificed moribund 236.9 C C 6832E472 1 F Dosing phase 13-Jun-03 12:17 128 06-Jun-03 738 s Final phase sacrifice 165.8 C C 6832E473 1 F Dosing phase 18-Mar-03 10:16 8 17-Mar-03 657 u Found Dead 227.3 C C 6832E474 1 F Dosing phase 21-Feb-03 16:21 128 20-Feb-03 632 u Sacrificed moribund 189.3 C C 6832E475 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 260.0 C C 6832E476 1 F Dosing phase 23-May-03 17:29 128 22-May-03 723 u Sacrificed moribund 259.5 C C 6832E477 1 F Dosing phase 10-Jan-03 16:53 128 07-Jan-03 588 u Found Dead 187.7 C C 6832E478 1 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 263.4 C C 6832E479 1 F Dosing phase 09-May-03 16:35 128 08-May-03 709 u Sacrificed moribund 263.3 C C 6832E480 1 F Dosing phase 01-Apr-03 11:29 8 29-Mar-03 669 u Found Dead 225.3 C C 6832E481 1 F Dosing phase 29-Apr-02 15:15 -1 10-Apr-02 316 u Sacrificed moribund 203.4 C C 6832E482 1 F Dosing phase 11-Mar-03 13:09 8 07-Mar-03 647 u Sacrificed moribund 250.2 C C 6832E483 1 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 271.8 C C 6832E484 1 F Dosing phase 25-Mar-03 13:02 128 19-Mar-03 659 u Sacrificed moribund 212.8 C C 6832E485 1 F Dosing phase 03-Oct-02 16:19 128 24-Sep-02 483 u Sacrificed moribund 211.2 C C 6832E486 1 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 265.4 C - 6832E487 1 F Dosing phase 10-Jan-03 17:01 128 08-Jan-03 589 u Sacrificed moribund 226.0 C C 6832E488 1 F Dosing phase 14-Apr-03 16:26 128 10-Apr-03 681 u Sacrificed moribund 220.2 C C 6832E489 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 263.9 C C 6832E490 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 223.6 C C 6832E491 1 F Dosing phase 09-Apr-03 16:56 128 07-Apr-03 678 u Sacrificed moribund 217.6 C C 6832E492 1 F Dosing phase 29-Oct-02 15:49 8 23-Oct-02 512 u Sacrificed moribund 186.5 C C 6832E493 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 230.8 C C 6832E494 1 F Dosing phase 25-Feb-03 13:20 8 25-Feb-03 637 u Sacrificed moribund 276.5 C C 6832E495 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 301.6 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-9
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6832E496 1 F Dosing phase 25-Feb-03 13:21 8 25-Feb-03 637 u Sacrificed moribund 200.1 C C 6832E497 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 269.1 C C 6832E498 1 F Dosing phase 04-Jun-03 14:42 128 02-Jun-03 734 s Final phase sacrifice 254.1 C - 6832E499 1 F Dosing phase 12-Dec-02 13:52 128 12-Dec-02 562 u Sacrificed moribund 248.6 C C 6832E500 1 F Dosing phase 04-Jun-03 14:42 128 02-Jun-03 734 s Final phase sacrifice 303.6 C C 6834F551 2 F Dosing phase 04-Jun-03 14:43 128 02-Jun-03 734 s Final phase sacrifice 280.6 C C 6834F552 2 F Dosing phase 06-Jan-03 14:54 -1 24-Dec-02 574 u Sacrificed moribund 229.7 C C 6834F553 2 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 278.5 C C 6834F554 2 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 281.2 C - 6834F555 2 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 297.4 C C 6834F556 2 F Dosing phase 04-Apr-03 16:48 128 01-Apr-03 672 u Sacrificed moribund 225.7 C C 6834F557 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 264.6 C C 6834F558 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 263.2 C C 6834F559 2 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 245.3 C C 6834F560 2 F Dosing phase 04-Jun-03 14:44 128 02-Jun-03 734 s Final phase sacrifice 283.1 C - 6834F561 2 F Dosing phase 04-Jun-03 14:45 128 02-Jun-03 734 s Final phase sacrifice 277.0 C C 6834F562 2 F Dosing phase 03-Oct-02 16:23 128 29-Sep-02 488 u Sacrificed moribund 238.4 C C 6834F563 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 288.7 C C 6834F564 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 221.5 C C 6834F565 2 F Dosing phase 03-Mar-03 17:20 128 28-Feb-03 640 u Sacrificed moribund 268.4 C C 6834F566 2 F Dosing phase 07-Nov-02 13:05 -1 19-Oct-02 508 u Sacrificed moribund 226.8 C C 6834F567 2 F Dosing phase 12-May-03 10:54 8 09-May-03 710 u Sacrificed moribund 282.2 C C 6834F568 2 F Dosing phase 10-Jan-03 17:06 128 08-Jan-03 589 u Sacrificed moribund 203.6 C C 6834F569 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 312.4 C C 6834F570 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 268.6 C C 6834F571 2 F Dosing phase 23-May-03 17:27 128 22-May-03 723 u Sacrificed moribund 211.9 C C 6834F572 2 F Dosing phase 21-Apr-03 17:32 128 17-Apr-03 688 u Sacrificed moribund 256.4 C C 6834F573 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 258.5 C C 6834F574 2 F Dosing phase 04-Jun-03 14:45 128 02-Jun-03 734 s Final phase sacrifice 265.2 C C 6834F575 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 309.2 C C 6834F576 2 F Dosing phase 16-Apr-03 17:32 128 14-Apr-03 685 u Found Dead 212.6 C C 6834F577 2 F Dosing phase 08-May-03 16:53 128 07-May-03 708 u Sacrificed moribund 248.1 C C 6834F578 2 F Dosing phase 25-Mar-03 12:36 128 24-Mar-03 664 u Sacrificed moribund 218.3 C C 6834F579 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 299.6 C C 6834F580 2 F Dosing phase 04-Jun-03 14:46 128 02-Jun-03 734 s Final phase sacrifice 296.3 C C 6834F581 2 F Dosing phase 28-May-03 17:04 128 28-May-03 729 u Sacrificed moribund 207.5 C C 6834F582 2 F Dosing phase 25-Feb-03 13:19 8 24-Feb-03 636 u Sacrificed moribund 248.6 C C 6834F583 2 F Dosing phase 04-Jun-03 14:46 128 02-Jun-03 734 s Final phase sacrifice 276.2 C - 6834F584 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 258.5 C C 6834F585 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 234.6 C C 6834F586 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 286.9 C C 6834F587 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 282.6 C - 6834F588 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 267.6 C - 6834F589 2 F Dosing phase 14-Apr-03 16:36 128 09-Apr-03 680 u Sacrificed moribund 267.9 C C 6834F590 2 F Dosing phase 21-May-02 11:05 8 14-May-02 350 u Sacrificed moribund 234.0 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-10
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 3 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6834F591 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 256.1 C C 6834F592 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 274.7 C C 6834F593 2 F Dosing phase 28-May-03 16:49 128 24-May-03 725 u Found Dead 257.4 C C 6834F594 2 F Dosing phase 10-Jan-03 17:11 128 08-Jan-03 589 u Sacrificed moribund 299.0 C C 6834F595 2 F Dosing phase 03-Oct-02 16:30 128 29-Sep-02 488 u Sacrificed moribund 214.2 C C 6834F596 2 F Dosing phase 04-Jun-03 14:47 128 02-Jun-03 734 s Final phase sacrifice 262.2 C C 6834F597 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 280.2 C - 6834F598 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 252.7 C - 6834F599 2 F Dosing phase 12-Dec-02 13:17 128 11-Dec-02 561 u Sacrificed moribund 200.0 C C 6834F600 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 280.6 C C 6836G651 3 F Dosing phase 04-Jun-03 14:47 128 02-Jun-03 734 s Final phase sacrifice 262.8 C C 6836G652 3 F Dosing phase 04-Jun-03 14:48 128 02-Jun-03 734 s Final phase sacrifice 277.7 C C 6836G653 3 F Dosing phase 03-Oct-02 16:36 128 30-Sep-02 489 u Sacrificed moribund 207.9 C C 6836G654 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 238.3 C C 6836G655 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 259.9 C C 6836G656 3 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 277.7 C - 6836G657 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 263.5 C C 6836G658 3 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 274.9 C - 6836G659 3 F Dosing phase 29-May-03 16:58 128 29-May-03 730 u Sacrificed moribund 232.0 C C 6836G660 3 F Dosing phase 04-Jun-03 14:48 128 02-Jun-03 734 s Final phase sacrifice 295.8 C C 6836G661 3 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 242.0 C C 6836G662 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 234.8 C - 6836G663 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 258.5 C C 6836G664 3 F Dosing phase 16-Dec-02 14:23 8 12-Dec-02 562 u Sacrificed moribund 223.0 C C 6836G665 3 F Dosing phase 07-Nov-02 13:57 -1 22-Oct-02 511 u Found Dead 191.0 C C 6836G666 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 226.0 C C 6836G667 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 271.4 C C 6836G668 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 212.8 C C 6836G669 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 256.3 C C 6836G670 3 F Dosing phase 04-Jun-03 14:49 128 02-Jun-03 734 s Final phase sacrifice 267.4 C C 6836G671 3 F Dosing phase 12-Dec-02 13:42 128 28-Nov-02 548 u Found Dead 240.6 C C 6836G672 3 F Dosing phase 04-Jun-03 14:49 128 02-Jun-03 734 s Final phase sacrifice 283.2 C C 6836G673 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 242.1 C C 6836G674 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 287.6 C C 6836G675 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 257.6 C C 6836G676 3 F Dosing phase 18-Mar-03 10:18 8 14-Mar-03 654 u Sacrificed moribund 232.8 C C 6836G677 3 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 268.4 C C 6836G678 3 F Dosing phase 29-Apr-03 17:36 128 25-Apr-03 696 u Sacrificed moribund 235.4 C C 6836G679 3 F Dosing phase 18-Mar-03 10:20 8 14-Mar-03 654 u Sacrificed moribund 217.4 C C 6836G680 3 F Dosing phase 06-Mar-03 17:17 128 05-Mar-03 645 u Sacrificed moribund 213.1 C C 6836G681 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 272.3 C C 6836G682 3 F Dosing phase 11-Mar-03 13:10 8 07-Mar-03 647 u Sacrificed moribund 223.1 C C 6836G683 3 F Dosing phase 08-May-03 16:34 128 01-May-03 702 u Sacrificed moribund 240.7 C C 6836G684 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 287.6 C C 6836G685 3 F Dosing phase 22-Nov-02 15:31 8 20-Nov-02 540 u Sacrificed moribund 186.6 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-11
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 4 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6836G686 3 F Dosing phase 04-Jun-03 14:50 128 02-Jun-03 734 s Final phase sacrifice 231.0 C C 6836G687 3 F Dosing phase 14-Apr-03 16:40 128 09-Apr-03 680 u Sacrificed moribund 223.0 C C 6836G688 3 F Dosing phase 26-Mar-03 18:27 128 26-Mar-03 666 u Sacrificed moribund 246.4 C C 6836G689 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 241.1 C C 6836G690 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 236.8 C C 6836G691 3 F Dosing phase 30-Aug-01 12:40 128 28-Aug-01 91 u Sacrificed moribund 156.8 C - 6836G692 3 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 244.1 C C 6836G693 3 F Dosing phase 25-Mar-03 13:12 128 18-Mar-03 658 u Found Dead 260.8 C C 6836G694 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 255.8 C C 6836G695 3 F Dosing phase 25-Mar-03 12:38 128 21-Mar-03 661 u Sacrificed moribund 204.4 C C 6836G696 3 F Dosing phase 30-Aug-01 12:39 128 28-Aug-01 91 u Sacrificed moribund 175.2 C - 6836G697 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 252.0 C C 6836G698 3 F Dosing phase 14-Feb-03 11:42 8 13-Feb-03 625 u Sacrificed moribund 226.0 C C 6836G699 3 F Dosing phase 24-Sep-01 14:00 128 20-Sep-01 114 u Sacrificed moribund 153.9 C C 6836G700 3 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 209.6 C C 6838H751 4 F Dosing phase 25-Mar-03 13:04 128 19-Mar-03 659 u Sacrificed moribund 197.9 C C 6838H752 4 F Dosing phase 21-Apr-03 16:58 128 16-Apr-03 687 u Sacrificed moribund 216.2 C C 6838H753 4 F Dosing phase 03-Jun-03 15:49 128 14-May-03 715 u Sacrificed moribund 188.8 C C 6838H754 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 267.9 C C 6838H755 4 F Dosing phase 04-Jun-03 14:51 128 02-Jun-03 734 s Final phase sacrifice 229.6 C C 6838H756 4 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 250.7 C C 6838H757 4 F Dosing phase 09-May-03 13:10 8 30-Apr-03 701 u Sacrificed moribund 183.6 C C 6838H758 4 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 247.8 C C 6838H759 4 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 230.5 C C 6838H760 4 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 245.1 C - 6838H761 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 244.4 C C 6838H762 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 237.7 C C 6838H763 4 F Dosing phase 03-Oct-02 16:53 128 01-Oct-02 490 u Sacrificed moribund 229.8 C C 6838H764 4 F Dosing phase 07-Nov-02 14:43 -1 06-Nov-02 526 u Sacrificed moribund 186.0 C C 6838H765 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 259.5 C - 6838H766 4 F Dosing phase 19-Sep-02 14:00 128 19-Sep-02 478 u Sacrificed moribund 198.3 C C 6838H767 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 251.5 C C 6838H768 4 F Dosing phase 13-Jun-03 12:44 128 04-Jun-03 736 s Final phase sacrifice 242.4 C C 6838H769 4 F Dosing phase 13-Jun-03 12:43 128 04-Jun-03 736 s Final phase sacrifice 232.5 C C 6838H770 4 F Dosing phase 25-Mar-03 12:41 128 21-Mar-03 661 u Sacrificed moribund 198.8 C C 6838H771 4 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 217.7 C C 6838H772 4 F Dosing phase 28-May-03 16:54 128 28-May-03 729 u Sacrificed moribund 185.1 C C 6838H773 4 F Dosing phase 04-Jun-03 14:51 128 02-Jun-03 734 s Final phase sacrifice 256.8 C C 6838H774 4 F Dosing phase 03-Oct-02 16:34 128 30-Sep-02 489 u Sacrificed moribund 190.1 C C 6838H775 4 F Dosing phase 21-Apr-03 17:36 128 17-Apr-03 688 u Sacrificed moribund 191.6 C C 6838H776 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 261.4 C C 6838H777 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 242.5 C C 6838H778 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 218.1 C C 6838H779 4 F Dosing phase 04-Jun-03 14:52 128 02-Jun-03 734 s Final phase sacrifice 265.1 C C 6838H780 4 F Dosing phase 04-Jun-03 14:52 128 02-Jun-03 734 s Final phase sacrifice 236.3 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-12
 Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 5 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Date and Time Oper. Date of Phase Death Term. Body Number Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs 6838H781 4 F Dosing phase 13-Jun-03 12:43 128 04-Jun-03 736 s Final phase sacrifice 244.3 C - 6838H782 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 240.3 C C 6838H783 4 F Dosing phase 12-May-03 10:51 8 09-May-03 710 u Sacrificed moribund 196.1 C C 6838H784 4 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 202.7 C - 6838H785 4 F Dosing phase 19-Sep-02 14:26 128 17-Sep-02 476 u Sacrificed moribund 230.0 C C 6838H786 4 F Dosing phase 19-May-03 16:24 128 15-May-03 716 u Found Dead 240.4 C C 6838H787 4 F Dosing phase 13-Jun-03 12:43 128 04-Jun-03 736 s Final phase sacrifice 266.0 C C 6838H788 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 244.1 C C 6838H789 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 247.7 C - 6838H790 4 F Dosing phase 04-Jun-03 14:53 128 02-Jun-03 734 s Final phase sacrifice 238.2 C C 6838H791 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 265.6 C C 6838H792 4 F Dosing phase 29-May-03 17:01 128 29-May-03 730 u Sacrificed moribund 199.7 C C 6838H793 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 231.8 C C 6838H794 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 258.7 C - 6838H795 4 F Dosing phase 19-May-03 16:22 128 15-May-03 716 u Found Dead 219.8 C C 6838H796 4 F Dosing phase 13-Jun-03 12:44 128 04-Jun-03 736 s Final phase sacrifice 240.6 C - 6838H797 4 F Dosing phase 28-Jan-03 09:17 8 24-Jan-03 605 u Sacrificed moribund 223.3 C C 6838H798 4 F Dosing phase 13-Jun-03 12:30 128 05-Jun-03 737 s Final phase sacrifice 256.0 C C 6838H799 4 F Dosing phase 13-Jun-03 12:30 128 05-Jun-03 737 s Final phase sacrifice 215.8 C C 6838H800 4 F Dosing phase 04-Jun-03 14:54 128 02-Jun-03 734 s Final phase sacrifice 247.9 C C Note: * = pretest animal no. P = partial data. C = complete data. - = no data.

Study Number FY01-013

H-13
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

I-1 

APPENDIX I 

INDIVIDUAL ANIMAL IN-LIFE BODY WEIGHTS 

I-1 Males – Individual Animal Body Weight Data 

I-2 Males – Summary Statistics - Body Weight Data 

I-3 Females – Individual Animal Body Weight Data 

I-4 Females – Summary Statistics - Body Weight Data 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

I-1 Males 

Individual Animal Body Weight Data 

I-2
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 1 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 M a l e A n i m a l s 6831E401 1 187.6 195.9 219.1 234.5 250.3 260.1 270.3 283.2 296.3 302.6 302.0 314.7 321.8 6831E402 195.5 206.4 220.7 239.1 249.7 263.4 269.2 282.0 291.8 297.5 299.7 311.5 313.8 6831E403 174.0 177.4 196.4 212.8 228.7 237.4 245.3 255.1 265.6 273.0 282.7 290.7 296.9 6831E404 190.4 194.3 212.4 229.3 245.6 258.6 264.9 280.2 289.1 299.1 309.7 325.8 326.9 6831E405 181.4 184.0 202.7 213.7 217.8 233.8 236.9 249.7 258.4 265.6 272.8 285.9 288.9 6831E406 184.7 191.2 200.0 208.1 215.0 219.8 223.8 243.2 248.4 253.5 261.2 272.9 280.5 6831E407 181.8 193.8 214.4 230.8 243.5 257.4 263.0 278.1 288.2 298.8 301.3 308.5 317.8 6831E408 189.7 194.7 222.9 237.2 257.5 267.9 280.2 293.8 300.0 306.7 319.6 334.2 340.8 6831E409 189.0 195.8 214.7 229.1 243.9 255.7 265.6 283.3 290.7 290.9 299.6 314.2 316.2 6831E410 185.7 204.1 226.2 241.8 258.1 273.2 282.6 292.6 302.8 312.3 317.7 331.0 340.7 6831E411 182.2 188.5 203.4 226.1 243.0 259.4 269.4 284.7 289.4 302.1 311.9 328.1 334.1 6831E412 185.4 193.0 211.1 225.1 236.2 253.5 262.2 273.1 285.0 286.4 294.8 306.5 313.4 6831E413 160.0 161.9 176.6 192.7 199.8 221.9 228.7 245.2 252.8 260.7 270.8 282.0 291.8 6831E414 189.3 201.9 222.0 242.8 255.8 267.4 274.2 283.5 296.7 308.6 314.1 314.5 321.3 6831E415 180.0 184.1 206.4 222.6 232.3 244.1 255.0 271.1 282.1 290.8 302.0 311.7 314.3 6831E416 191.9 197.0 220.4 239.1 248.8 264.4 271.3 288.3 290.8 298.7 306.5 319.1 323.5 6831E417 178.8 189.9 208.3 230.1 237.2 251.1 259.0 274.1 284.3 293.6 303.0 312.1 319.5 6831E418 177.1 182.4 201.5 230.1 246.6 255.3 266.7 280.5 292.0 299.0 305.9 317.9 323.3 6831E419 199.0 195.9 227.2 252.4 274.5 290.9 301.0 316.8 325.6 336.0 344.3 357.0 367.2 6831E420 180.1 183.8 199.5 219.8 232.2 245.6 256.7 268.1 275.9 277.0 285.9 299.5 304.5 6831E421 186.0 186.3 203.0 227.2 243.5 258.7 269.2 276.3 285.8 292.4 301.0 312.9 317.2 6831E422 185.3 182.8 199.8 221.4 228.4 243.6 250.2 262.9 274.2 279.8 287.6 301.7 301.2 6831E423 183.5 167.2 186.5 207.3 216.4 222.9 227.4 242.2 256.0 261.2 272.7 285.0 293.3 6831E424 186.6 171.1 198.4 229.2 239.8 249.5 257.9 269.4 279.9 287.1 294.2 304.9 309.7 6831E425 193.9 177.4 211.5 239.7 252.5 265.6 271.9 284.6 301.4 307.5 310.4 319.3 326.7 6831E426 186.7 171.5 194.9 214.7 221.4 225.8 228.6 241.4 255.3 260.0 266.1 278.2 282.6 6831E427 173.3 184.1 193.5 214.0 230.5 243.4 248.8 266.0 274.8 283.8 289.6 301.1 307.0 6831E428 179.7 177.7 191.2 214.2 222.9 235.4 244.5 259.4 272.2 277.0 282.8 291.8 300.0 6831E429 192.6 202.2 229.2 252.4 262.8 273.7 284.0 305.3 310.5 321.3 325.3 335.5 334.6 6831E430 188.5 187.0 227.7 244.9 257.8 272.0 283.3 295.0 309.3 310.5 321.2 328.0 333.1 6831E431 185.8 190.2 207.4 229.2 248.2 264.3 272.3 286.1 297.8 310.3 324.5 339.2 341.9 6831E432 182.0 166.0 196.1 221.0 234.2 242.5 255.1 265.6 280.2 282.6 288.1 301.5 305.5 6831E433 185.9 173.4 195.8 218.4 231.1 240.7 246.5 263.0 280.2 280.3 288.2 302.7 309.4 6831E434 193.2 180.8 214.2 243.1 250.5 260.6 272.6 283.5 279.6 301.8 305.3 328.5 328.3 6831E435 189.1 192.6 208.9 226.3 242.4 246.1 249.4 264.5 272.9 279.2 285.2 298.3 300.2 6831E436 182.3 192.1 209.3 229.6 242.6 250.9 254.8 265.7 278.1 288.1 288.6 292.3 306.6 6831E437 173.3 179.4 201.4 215.6 232.6 241.9 250.4 264.4 278.2 283.0 285.8 292.6 296.4 6831E438 193.9 200.1 218.8 239.4 253.7 266.7 272.8 281.8 293.7 302.1 314.4 320.9 324.0 6831E439 176.1 181.1 192.3 207.5 219.3 228.0 237.9 248.8 257.9 265.0 274.0 286.3 292.2 6831E440 185.0 197.4 209.0 219.1 235.5 241.5 250.1 268.9 284.5 292.9 300.8 316.5 326.4 6831E441 180.7 188.8 197.2 211.4 224.6 231.6 238.8 251.4 261.3 271.9 275.6 289.3 292.2 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-3
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 M a l e A n i m a l s 6831E442 1 181.6 201.5 214.8 236.0 259.6 273.0 281.7 291.7 298.6 311.4 320.4 334.7 336.5 6831E443 183.5 193.4 209.5 229.2 238.9 249.6 255.1 264.8 275.0 284.8 288.1 295.8 301.8 6831E444 174.0 179.3 196.3 215.8 234.1 237.7 247.4 259.1 273.4 279.7 281.2 290.1 297.6 6831E445 203.3 216.3 239.3 259.1 270.6 282.0 286.3 299.0 310.8 314.9 319.3 330.9 335.3 6831E446 178.6 186.8 203.5 228.4 246.2 259.1 264.2 277.7 295.2 304.9 314.3 327.1 334.3 6831E447 186.3 194.2 212.4 221.3 234.5 243.3 257.6 274.2 283.1 290.6 296.5 308.4 312.0 6831E448 170.9 173.6 185.4 192.3 203.9 213.6 219.9 233.8 248.8 255.5 266.1 276.1 284.3 6831E449 196.8 210.3 224.2 245.0 265.7 279.7 288.1 299.3 312.4 315.9 322.7 335.7 346.3 6831E450 179.5 187.7 197.7 213.0 225.9 237.9 243.4 261.9 268.1 276.9 282.2 294.3 299.4 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 184.4 188.2 207.5 226.5 239.7 251.2 259.1 272.7 283.1 290.5 297.6 309.1 314.7 Sdevs 7.8 11.5 12.9 14.3 16.1 17.3 18.2 17.8 17.5 18.3 18.4 19.0 18.8 6833F501 2 185.6 197.1 211.5 232.0 245.7 258.3 266.0 277.7 287.4 298.7 306.8 317.3 321.8 6833F502 177.0 196.2 212.2 232.3 245.7 258.3 266.8 279.2 283.2 285.2 293.9 300.6 307.8 6833F503 174.8 188.8 203.6 228.5 241.6 251.6 262.6 273.0 279.6 285.9 290.2 299.7 308.6 6833F504 190.4 204.5 222.4 241.0 254.8 265.0 275.5 286.5 299.3 303.6 316.4 323.9 327.0 6833F505 188.7 206.6 221.9 241.1 254.7 266.8 277.5 287.9 296.2 303.6 318.0 328.7 337.4 6833F506 191.3 200.2 221.2 238.9 251.5 258.4 271.3 279.0 287.1 290.5 302.7 306.3 311.9 6833F507 172.5 174.2 182.9 196.7 204.5 212.3 218.9 237.1 241.6 252.5 259.3 274.3 277.4 6833F508 188.3 194.1 203.0 222.0 234.7 249.5 260.3 272.6 282.4 289.8 302.0 309.6 314.7 6833F509 192.1 202.3 219.2 235.7 253.0 263.1 271.2 287.2 292.8 300.0 312.7 320.6 324.1 6833F510 181.7 196.5 213.1 230.5 241.5 253.7 264.9 275.7 280.9 287.2 291.7 300.6 305.5 6833F511 183.9 199.7 215.8 234.7 257.6 266.7 280.5 297.2 302.4 311.2 320.3 327.3 336.7 6833F512 184.6 188.1 200.6 215.3 227.8 239.4 244.2 261.4 265.1 269.4 277.6 290.8 293.9 6833F513 166.0 168.6 177.6 190.2 205.0 214.4 228.7 244.2 253.1 258.6 266.8 270.2 278.8 6833F514 164.5 174.7 189.9 209.1 223.6 226.0 239.8 253.4 265.8 273.4 280.8 293.2 299.5 6833F515 177.8 196.2 212.7 229.2 243.1 253.0 263.1 278.8 287.8 292.4 298.0 316.3 327.6 6833F516 192.6 202.1 215.5 232.0 248.8 260.8 270.5 288.0 291.5 298.1 303.1 315.5 324.0 6833F517 182.6 196.1 212.2 230.7 245.3 258.3 268.6 282.7 291.7 295.2 304.7 313.3 315.0 6833F518 171.9 183.2 196.8 214.5 234.1 247.0 260.1 273.1 284.9 293.0 300.4 312.8 318.2 6833F519 192.3 207.3 229.9 247.4 260.8 274.0 284.9 294.8 308.8 333.7 326.5 338.7 342.9 6833F520 187.2 203.9 223.8 243.1 254.0 267.8 276.7 287.4 300.0 323.7 313.2 323.3 327.0 6833F521 180.5 196.5 215.2 228.0 242.3 254.5 263.1 273.2 280.8 302.1 295.0 300.7 305.9 6833F522 176.6 186.6 201.4 210.9 225.4 237.9 250.0 257.5 266.7 294.3 288.7 291.5 304.2 6833F523 179.2 184.4 198.2 207.7 214.4 222.7 236.3 250.2 260.8 285.6 277.4 284.1 299.1 6833F524 197.2 217.8 236.2 255.2 265.7 283.1 290.1 303.5 308.0 332.3 326.9 336.5 342.8 6833F525 185.7 198.7 219.0 243.5 255.5 270.7 279.5 292.2 300.2 327.0 324.3 330.0 335.6 6833F526 182.1 190.7 213.4 232.0 245.5 255.0 267.0 276.2 286.9 306.8 297.6 303.6 311.9 6833F527 163.5 176.8 190.8 208.9 222.3 233.0 239.1 247.3 253.8 275.7 263.2 277.5 287.1 6833F528 171.2 178.2 186.7 208.5 223.6 234.4 243.2 253.7 263.8 290.5 278.9 286.7 297.1 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-4
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 3 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 M a l e A n i m a l s 6833F529 2 181.3 202.0 210.7 225.9 242.2 251.8 261.9 277.0 285.5 295.2 305.0 312.7 315.7 6833F530 189.4 196.2 209.5 223.1 238.2 247.5 258.2 272.7 281.3 284.3 293.6 301.1 311.6 6833F531 157.2 179.8 204.5 220.9 237.4 248.2 261.6 274.3 285.8 292.1 306.8 315.2 322.2 6833F532 183.2 199.3 211.4 227.1 236.0 244.0 250.1 264.5 271.9 276.6 282.9 290.3 298.3 6833F533 189.6 211.2 228.5 242.9 255.6 269.6 273.3 278.0 288.1 293.6 299.3 308.1 310.4 6833F534 163.3 172.5 177.6 191.1 203.8 213.0 222.8 235.1 242.5 250.1 262.5 269.9 274.6 6833F535 190.0 199.6 150.3 208.5 231.6 255.8 267.8 278.0 292.0 302.8 311.4 320.6 325.4 6833F536 176.8 186.5 203.5 219.3 236.5 244.7 255.6 264.4 273.3 296.1 283.0 289.2 298.4 6833F537 179.1 188.2 198.5 213.4 227.6 241.3 251.5 268.0 280.7 308.6 300.1 309.8 322.1 6833F538 185.7 189.9 202.9 223.7 241.2 250.2 259.8 271.2 286.6 308.3 304.9 307.9 312.4 6833F539 205.3 219.1 236.3 259.9 271.0 278.0 285.3 298.8 305.2 328.3 319.9 328.6 336.1 6833F540 189.7 195.7 202.2 222.8 235.3 250.3 262.1 277.9 288.7 310.6 302.7 315.7 325.5 6833F541 191.0 206.5 220.4 241.3 251.6 264.6 273.2 284.0 288.8 308.7 304.0 315.6 316.1 6833F542 167.0 169.3 181.0 198.0 212.6 224.3 236.7 249.2 258.5 284.8 272.5 284.8 293.0 6833F543 174.8 189.2 206.8 226.5 237.5 249.6 236.5 272.7 281.8 304.3 289.2 294.3 301.3 6833F544 178.2 192.3 206.9 224.5 242.8 248.5 278.4 285.3 308.4 294.8 307.7 317.7 6833F545 191.1 205.4 220.8 240.3 253.8 262.6 278.2 292.1 296.9 325.6 318.4 329.1 336.4 6833F546 185.2 199.1 215.4 237.9 250.6 262.0 272.9 293.4 290.4 311.9 298.4 311.1 315.3 6833F547 182.0 184.4 201.2 209.6 221.3 230.1 243.1 251.8 263.4 286.2 282.1 285.2 291.1 6833F548 177.4 193.2 212.7 233.2 249.0 257.7 268.5 276.7 284.8 307.6 296.2 306.8 306.9 6833F549 189.2 199.4 218.4 237.1 252.0 256.3 269.6 280.5 293.4 299.3 303.3 310.7 312.3 6833F550 194.3 202.4 224.7 236.6 247.9 260.3 263.7 273.5 282.1 281.8 287.8 294.5 298.7 (n) 50 50 50 50 50 50 49 50 50 50 50 50 50 Means 182.1 193.8 207.8 226.1 240.0 250.9 260.7 273.7 282.2 296.5 297.1 306.1 312.5 Sdevs 9.8 11.6 16.2 15.6 15.6 16.4 16.6 15.9 15.7 18.5 16.7 17.0 16.6 6835G601 3 184.0 190.3 202.4 220.9 233.8 245.2 253.6 265.8 275.9 287.2 292.7 305.7 312.4 6835G602 178.8 189.9 208.8 230.1 246.5 258.7 269.5 279.5 289.0 292.5 302.4 308.8 317.9 6835G603 190.9 193.0 201.1 220.7 233.3 247.5 257.3 266.9 275.9 284.0 291.7 299.7 303.5 6835G604 188.6 195.4 211.4 235.5 244.4 255.9 265.4 276.3 287.6 292.1 296.2 309.0 315.8 6835G605 172.8 180.7 200.2 217.2 230.3 245.4 253.7 265.3 274.0 282.2 290.8 299.6 304.0 6835G606 211.4 227.1 250.8 272.5 289.6 305.8 316.7 330.0 340.2 348.5 357.8 367.3 379.6 6835G607 179.5 185.0 198.0 213.6 218.8 225.2 235.2 238.6 250.6 256.1 259.8 273.8 282.4 6835G608 200.3 204.9 220.7 236.4 244.0 255.6 267.6 277.5 285.7 288.5 297.7 307.4 315.2 6835G609 187.4 191.2 208.2 227.7 237.8 255.5 267.4 283.0 288.0 297.6 306.5 315.1 327.8 6835G610 181.9 192.6 213.5 229.5 247.1 262.1 275.9 273.2 292.2 299.4 306.7 315.0 324.0 6835G611 176.7 182.3 195.2 216.7 232.8 246.4 260.8 257.7 280.2 286.9 296.2 303.4 313.1 6835G612 195.4 208.4 224.0 246.6 258.1 274.9 284.9 298.0 308.5 317.5 325.1 338.4 339.0 6835G613 170.1 174.7 185.8 210.7 221.9 240.5 249.9 264.2 274.0 284.4 294.8 302.5 305.5 6835G614 195.2 203.4 223.9 240.8 255.0 265.7 272.8 282.1 295.5 305.4 312.3 320.7 327.1 6835G615 180.2 187.3 196.2 210.3 223.3 235.9 248.0 257.6 273.6 278.0 285.0 293.1 298.1 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-5
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 4 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 M a l e A n i m a l s 6835G616 3 186.1 197.7 216.9 231.5 237.9 253.8 265.4 274.7 284.3 288.3 295.9 306.5 312.0 6835G617 179.9 188.6 199.6 210.2 223.5 238.9 249.4 265.2 273.2 280.2 288.7 298.6 301.0 6835G618 178.0 184.3 196.8 213.1 224.9 233.2 243.1 259.0 272.9 276.3 280.4 286.6 298.2 6835G619 188.4 194.8 205.8 226.2 238.5 251.9 263.9 275.3 278.3 286.9 295.9 310.0 311.1 6835G620 188.5 196.2 211.6 226.6 234.5 255.0 263.2 276.9 282.3 290.0 298.7 310.5 317.2 6835G621 159.9 163.0 179.0 198.7 212.4 228.0 237.5 251.4 261.7 273.6 281.8 290.3 298.8 6835G622 178.3 182.9 195.1 209.8 223.4 233.1 240.9 253.0 260.7 271.5 277.4 282.9 289.0 6835G623 194.9 201.7 220.9 236.8 251.7 262.9 272.4 285.0 289.9 298.0 306.2 307.9 318.4 6835G624 175.6 180.3 192.1 205.7 215.5 225.4 232.1 243.9 249.0 255.1 266.1 270.6 279.2 6835G625 178.5 186.1 203.2 224.1 238.5 253.4 263.0 273.1 281.9 290.5 294.6 306.6 314.7 6835G626 176.9 181.9 193.1 206.7 217.0 229.5 239.1 251.4 257.4 265.5 272.1 280.4 287.5 6835G627 169.2 178.8 190.9 212.0 229.8 242.8 254.7 267.0 277.2 287.1 296.5 305.6 311.7 6835G628 184.8 195.6 209.7 227.7 243.2 257.3 266.1 276.8 286.5 290.7 301.2 309.7 310.6 6835G629 195.1 209.1 217.6 236.7 253.4 266.9 275.5 285.0 299.3 303.2 315.7 323.6 324.0 6835G630 193.3 209.8 228.1 242.8 270.6 264.7 270.5 281.5 290.9 294.0 296.2 305.8 310.6 6835G631 196.8 218.8 234.9 258.2 257.2 292.5 306.1 317.3 328.9 336.4 342.0 359.6 367.6 6835G632 205.0 212.7 224.5 238.8 252.7 254.6 265.3 279.6 289.8 298.8 304.8 309.7 319.3 6835G633 186.0 187.9 195.7 207.3 219.4 230.4 245.3 259.4 275.9 281.3 288.2 297.9 303.8 6835G634 196.2 209.6 217.6 239.9 252.1 265.8 275.4 285.3 299.6 302.5 311.0 323.9 330.1 6835G635 182.2 190.6 207.5 221.3 232.5 245.8 256.1 264.7 273.2 277.7 288.9 296.5 303.0 6835G636 191.2 197.8 224.4 245.6 263.6 276.0 286.3 296.6 312.3 317.8 334.4 344.7 352.4 6835G637 183.4 193.7 211.9 234.9 244.2 256.9 265.6 275.7 288.1 291.3 307.4 314.1 321.5 6835G638 174.1 188.3 201.2 218.9 232.1 242.8 260.5 273.0 282.1 285.9 294.1 309.2 318.9 6835G639 188.0 203.5 222.3 236.9 250.2 265.7 279.0 282.3 291.2 302.9 306.7 320.7 324.4 6835G640 177.0 185.9 202.2 211.6 222.7 239.9 240.8 249.5 262.7 265.4 275.9 283.5 291.1 6835G641 184.4 196.3 216.5 231.8 244.5 252.0 260.1 270.4 281.3 289.6 295.4 305.8 309.0 6835G642 196.0 211.0 226.6 244.9 257.7 274.3 278.7 290.2 303.3 308.9 315.7 324.3 331.3 6835G643 171.1 183.5 198.6 216.8 226.1 239.8 247.3 256.5 268.4 274.7 281.8 287.2 293.0 6835G644 197.7 211.6 217.7 238.3 249.8 259.6 264.9 276.6 280.2 290.1 298.5 305.0 309.2 6835G645 188.7 194.2 201.3 214.2 222.0 242.5 248.3 257.0 267.2 275.9 280.9 294.3 299.1 6835G646 195.3 208.7 221.1 228.4 247.4 259.6 268.2 281.2 293.5 301.4 310.4 321.1 332.1 6835G647 169.8 185.8 199.7 215.9 226.3 235.5 254.1 256.5 264.8 275.2 285.7 294.8 299.6 6835G648 171.5 188.1 202.7 217.6 230.4 237.9 245.5 262.1 278.1 287.9 292.0 296.8 301.8 6835G649 165.3 174.4 189.2 209.6 217.8 229.5 238.3 250.5 260.9 264.0 272.8 279.2 287.2 6835G650 166.1 171.7 184.1 197.8 206.6 215.5 221.8 233.1 241.3 250.1 259.6 270.4 271.5 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 184.1 193.4 208.0 225.3 237.7 250.7 260.5 271.0 281.6 288.6 296.6 305.9 312.3 Sdevs 10.9 12.9 14.3 15.3 16.5 17.4 17.8 17.9 18.3 18.3 18.7 19.6 20.2 6837H701 4 169.9 185.0 200.8 224.5 238.0 253.1 267.2 279.2 295.3 306.7 319.7 327.7 334.3 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-6
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 5 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 M a l e A n i m a l s 6837H702 4 184.9 189.1 205.3 225.7 241.8 254.2 266.3 275.8 290.4 298.6 312.0 315.5 329.4 6837H703 180.0 191.8 211.5 234.3 249.3 267.2 276.2 287.9 299.7 313.0 323.1 328.0 331.9 6837H704 134.2 177.8 201.8 215.7 230.0 242.2 255.6 267.9 278.7 287.7 293.6 301.2 307.4 6837H705 182.1 194.7 210.7 230.9 243.1 259.0 267.4 283.6 292.9 303.6 316.8 320.9 328.8 6837H706 190.4 195.6 205.9 225.5 239.4 256.0 267.6 277.6 286.6 297.0 308.6 320.5 326.5 6837H707 183.3 191.1 203.8 219.9 230.9 245.0 253.8 262.9 272.1 282.9 289.4 298.4 301.7 6837H708 174.9 181.3 197.2 212.5 224.6 235.9 248.0 255.4 269.9 279.6 281.7 289.2 294.0 6837H709 187.9 203.3 214.8 233.4 248.1 258.5 269.2 280.2 290.3 299.8 309.5 310.8 317.6 6837H710 180.2 180.2 188.5 208.8 224.6 231.8 250.0 262.6 277.1 280.8 294.8 307.2 311.3 6837H711 183.2 199.0 219.4 235.6 252.4 266.6 278.5 291.9 300.4 309.5 318.1 328.0 333.3 6837H712 173.5 182.1 191.3 212.1 222.2 240.7 250.3 262.3 273.7 281.2 288.5 296.2 298.1 6837H713 194.9 205.0 222.9 243.6 255.6 263.6 275.1 288.4 294.2 299.6 308.9 314.9 314.9 6837H714 168.8 172.4 185.5 205.7 218.1 229.3 238.2 251.1 262.6 268.1 277.4 287.2 291.1 6837H715 185.5 199.9 215.0 237.6 248.4 259.2 270.2 280.4 294.1 310.4 317.4 321.6 323.0 6837H716 174.9 187.6 202.8 216.4 226.9 239.3 246.7 259.1 266.7 274.8 277.6 288.9 292.5 6837H717 189.8 209.3 224.2 243.2 254.4 266.2 279.7 291.0 298.5 308.7 314.6 321.6 330.9 6837H718 168.7 166.5 183.5 199.4 211.2 221.2 234.0 246.5 262.2 264.8 272.4 284.0 287.6 6837H719 167.7 175.0 191.0 206.5 223.3 234.8 242.4 256.9 265.9 270.8 286.1 290.6 302.1 6837H720 172.7 174.1 183.9 198.2 203.2 215.4 222.5 233.5 243.4 249.7 255.7 261.2 267.3 6837H721 193.6 200.4 212.4 236.9 249.4 264.2 273.0 282.3 292.7 296.7 305.4 312.7 316.0 6837H722 173.8 180.8 195.7 211.7 222.1 238.2 247.3 256.1 269.1 276.5 286.8 295.8 303.6 6837H723 177.4 186.3 200.2 217.7 226.4 242.3 252.6 264.5 275.0 279.8 292.7 302.3 304.0 6837H724 198.2 212.0 227.1 244.7 253.5 270.3 280.4 294.8 310.2 317.8 326.0 339.0 345.0 6837H725 178.5 161.4 179.6 204.8 217.8 231.0 242.6 253.6 265.5 274.6 283.3 288.0 294.0 6837H726 182.0 190.9 201.5 217.3 226.8 239.5 248.7 258.2 266.6 272.8 278.8 288.0 293.0 6837H727 171.9 178.7 196.3 220.3 231.8 243.8 257.2 270.3 286.9 291.6 300.5 310.6 319.2 6837H728 166.0 168.6 179.6 202.0 213.5 221.1 228.8 239.8 249.9 259.1 266.3 273.1 279.9 6837H729 192.9 200.2 214.1 227.1 236.5 246.3 253.5 266.9 278.1 279.9 288.3 293.5 298.2 6837H730 179.4 190.5 201.0 213.2 224.0 234.0 243.3 260.5 271.2 275.6 284.3 291.8 295.3 6837H731 186.4 190.3 200.3 215.0 224.9 238.8 249.9 259.5 271.6 275.8 284.1 290.5 298.4 6837H732 195.7 205.1 217.8 234.7 243.9 257.9 266.8 278.0 293.7 299.7 306.6 316.8 321.5 6837H733 182.9 187.9 201.3 216.2 228.9 237.7 245.8 259.2 267.9 271.8 279.8 288.2 293.1 6837H734 176.8 182.6 196.5 210.1 219.3 226.5 234.3 244.6 259.6 261.2 271.8 281.2 282.6 6837H735 160.2 164.3 175.8 192.0 201.2 210.1 220.9 231.3 245.7 251.6 259.2 270.3 278.8 6837H736 166.7 106.6 165.5 198.0 224.6 241.7 252.3 262.5 275.7 280.6 294.9 304.3 311.9 6837H737 182.5 200.5 215.7 236.3 245.2 254.5 263.9 274.1 287.6 289.9 298.4 305.2 312.6 6837H738 162.0 104.1 161.0 193.5 219.5 234.2 245.7 257.8 268.5 275.3 287.0 293.7 312.9 6837H739 184.8 189.3 199.5 210.0 213.9 227.9 235.8 243.0 259.9 266.7 279.2 284.0 298.3 6837H740 180.2 191.0 209.5 229.9 242.3 261.7 270.5 285.5 290.8 296.7 309.9 322.5 332.5 6837H741 179.7 189.3 198.2 215.3 233.6 242.7 257.0 270.1 274.9 286.4 293.7 302.3 309.9 6837H742 191.1 199.3 211.3 224.4 235.4 244.6 254.2 260.6 275.5 279.4 287.7 296.4 296.4 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-7
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 6 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 M a l e A n i m a l s 6837H743 4 170.3 172.3 188.2 206.4 219.0 226.4 237.1 251.5 263.8 271.6 278.6 291.5 300.3 6837H744 159.4 183.7 199.4 215.8 226.8 235.4 249.9 257.2 270.8 277.4 287.6 296.0 303.0 6837H745 170.1 183.7 197.8 213.4 224.9 235.9 247.4 258.2 267.3 278.5 284.6 295.7 299.1 6837H746 181.4 196.7 204.7 223.1 235.4 247.3 257.5 268.0 281.0 288.3 298.0 310.4 317.0 6837H747 187.7 193.9 200.9 213.0 221.7 232.4 245.7 255.3 264.5 269.5 283.9 298.1 302.3 6837H748 178.6 183.6 193.9 211.7 219.7 231.1 241.8 245.5 261.4 265.8 273.8 282.8 287.5 6837H749 159.1 164.6 172.3 181.3 193.3 202.6 212.0 221.6 232.7 239.1 248.2 257.4 263.9 6837H750 179.8 190.3 195.7 204.3 214.7 226.7 237.4 243.8 256.8 263.6 273.9 285.3 294.6 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 177.9 184.2 199.5 217.4 229.5 241.7 252.2 263.4 275.0 282.0 291.2 299.6 305.8 Sdevs 11.6 20.2 14.5 14.3 14.3 15.5 15.8 16.6 16.2 17.3 17.8 17.6 17.8 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-8
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 7 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 M a l e A n i m a l s 6831E401 1 325.0 346.7 358.5 373.8 379.4 395.3 399.1 399.4 407.8 421.1 422.9 426.8 430.1 6831E402 322.3 339.8 346.8 361.1 366.6 382.2 382.1 382.9 405.4 418.0 387.0 405.6 413.2 6831E403 300.9 316.7 331.3 347.2 353.7 366.5 367.0 373.0 386.5 390.8 359.4 385.9 377.8 6831E404 331.2 350.9 361.6 382.6 393.4 408.3 413.4 410.7 429.6 448.7 445.3 454.9 460.2 6831E405 294.5 315.1 323.6 346.3 353.1 371.6 370.6 375.8 393.0 399.0 404.6 415.1 409.4 6831E406 285.6 306.1 318.7 332.6 338.8 355.7 359.3 359.6 377.0 383.4 367.3 379.3 389.6 6831E407 322.1 342.1 352.9 360.1 378.4 390.0 389.0 397.3 420.9 416.1 411.9 420.1 423.0 6831E408 341.9 344.8 359.5 345.5 352.7 6831E409 323.6 340.7 356.1 370.6 376.4 382.9 388.4 401.7 410.1 419.6 419.0 431.6 435.0 6831E410 346.4 360.3 367.1 380.2 393.1 408.8 410.9 424.6 445.4 449.8 453.7 474.2 470.0 6831E411 341.8 361.0 374.3 384.1 393.2 401.8 403.8 404.2 418.5 431.0 431.5 446.0 450.7 6831E412 319.3 333.9 351.9 362.3 375.9 389.0 391.5 397.7 419.1 429.0 424.0 433.2 430.6 6831E413 300.2 330.9 353.1 367.3 386.2 410.9 399.4 406.4 420.2 429.9 419.7 435.2 428.3 6831E414 323.1 354.3 369.6 383.1 395.4 410.9 417.7 412.3 431.7 445.2 439.1 448.3 453.3 6831E415 329.6 339.9 351.1 371.6 379.4 383.2 395.0 401.8 403.6 419.4 417.2 426.0 430.5 6831E416 328.7 348.7 365.6 371.4 384.2 403.6 399.2 408.1 419.2 432.9 432.2 442.8 448.8 6831E417 328.4 344.2 357.7 376.5 374.8 388.6 394.0 401.3 414.1 428.8 429.0 442.4 448.0 6831E418 325.7 343.3 363.2 372.9 388.1 409.1 403.1 406.2 426.4 433.8 429.9 441.1 430.4 6831E419 372.2 390.6 399.4 416.1 437.6 457.5 431.9 458.3 474.1 454.3 481.7 490.5 482.5 6831E420 312.6 334.0 351.0 364.1 375.9 392.0 392.5 397.6 403.0 400.5 412.0 413.9 413.9 6831E421 312.9 349.6 367.4 377.6 393.9 413.5 418.0 427.6 436.3 441.1 444.8 452.6 457.6 6831E422 302.9 320.0 329.1 337.9 351.6 360.3 369.2 383.0 388.4 397.5 401.0 408.2 405.8 6831E423 296.6 315.0 335.9 354.5 369.8 383.7 390.6 398.5 400.9 415.4 425.0 428.2 427.6 6831E424 313.0 337.7 355.0 370.9 382.0 406.0 411.5 418.0 429.1 438.0 441.1 451.2 442.3 6831E425 332.6 362.4 376.8 394.9 408.8 430.9 434.8 444.1 451.0 462.9 469.0 477.5 472.6 6831E426 287.0 308.9 324.8 340.6 352.1 368.2 369.5 373.6 389.5 392.5 371.0 396.1 390.4 6831E427 316.2 338.3 349.8 366.5 378.7 400.5 393.5 404.2 395.0 413.5 410.5 424.0 421.0 6831E428 302.8 325.8 338.1 361.6 366.0 384.5 390.7 404.4 411.5 423.9 429.1 430.1 428.4 6831E429 340.3 359.1 377.6 390.3 405.9 427.8 427.2 442.4 452.3 461.3 466.7 475.7 472.7 6831E430 333.6 362.9 375.4 397.4 412.3 423.2 435.9 444.5 446.8 456.5 472.3 481.6 483.1 6831E431 352.4 372.3 385.7 394.5 402.7 426.2 407.9 431.6 424.6 439.8 410.8 6831E432 307.4 331.4 347.9 354.9 373.8 396.1 387.8 401.3 411.2 420.9 431.6 437.6 444.8 6831E433 312.5 335.2 355.9 372.7 382.8 398.7 401.6 411.2 420.3 429.8 432.9 436.1 429.0 6831E434 331.2 346.6 363.3 383.0 385.9 403.2 403.4 410.1 417.4 426.4 433.1 435.3 437.8 6831E435 301.0 327.5 341.6 355.2 363.7 375.0 376.9 387.4 398.8 409.7 411.0 414.6 416.9 6831E436 302.3 314.9 330.4 340.6 355.7 371.6 375.6 390.1 387.4 403.5 392.8 409.8 408.2 6831E437 299.5 331.7 336.2 349.8 357.0 374.3 376.8 382.5 389.1 401.0 407.2 421.3 416.2 6831E438 325.9 346.8 355.5 361.1 379.7 387.7 383.0 394.6 405.7 420.0 374.2 402.8 407.5 6831E439 295.0 320.6 336.9 355.3 361.8 373.0 384.0 383.8 391.1 404.7 6831E440 330.6 357.1 373.8 396.4 395.5 415.6 415.9 441.5 442.2 451.9 462.4 461.4 465.5 6831E441 301.0 328.9 336.1 349.7 354.5 375.5 384.8 391.5 410.9 419.8 423.8 435.8 446.1 Note: Data for Dosing phase

Study Number FY01-013

I-9
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 8 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 M a l e A n i m a l s 6831E442 1 341.6 362.1 374.1 381.9 386.3 410.2 415.0 430.0 437.9 447.9 454.0 466.5 470.9 6831E443 314.6 334.8 356.1 360.7 369.5 394.9 386.4 382.9 394.5 410.9 422.0 433.1 447.7 6831E444 306.5 323.7 337.0 347.8 357.9 378.7 373.5 370.4 377.3 397.1 399.4 405.2 412.2 6831E445 339.4 358.1 364.8 380.7 398.6 404.4 405.2 409.0 416.4 441.6 436.5 443.1 446.1 6831E446 339.2 363.5 381.6 391.3 399.3 416.4 414.0 426.8 444.3 458.5 452.9 466.9 468.3 6831E447 317.1 347.2 368.7 386.1 401.5 416.3 425.3 431.6 443.9 458.3 425.2 442.9 459.6 6831E448 288.4 317.1 336.0 353.3 360.0 370.4 373.8 377.4 386.7 392.9 398.0 408.5 405.5 6831E449 345.5 367.1 378.9 390.9 411.0 427.7 429.7 444.0 455.7 469.5 473.9 482.7 486.1 6831E450 302.8 330.9 344.5 363.1 375.8 394.0 384.3 404.5 413.3 421.0 429.1 433.9 442.7 (n) 50 50 50 50 50 49 49 49 49 49 48 47 47 Means 319.3 340.8 355.0 368.6 379.4 396.3 397.0 405.3 415.8 426.1 424.8 435.7 437.0 Sdevs 18.9 18.1 17.9 18.3 19.9 21.0 19.4 22.5 22.5 21.9 27.9 25.8 26.2 6833F501 2 327.9 347.6 356.5 373.9 383.7 382.8 394.7 390.7 399.9 405.2 406.4 415.6 406.8 6833F502 311.2 330.5 341.2 356.1 369.2 376.4 380.4 391.4 403.7 421.4 412.3 427.1 421.0 6833F503 313.1 333.9 339.8 348.6 368.6 376.8 383.1 378.7 396.6 406.7 406.0 420.6 411.3 6833F504 332.7 350.9 359.6 371.8 393.3 402.7 413.0 413.6 423.5 434.4 439.7 452.2 441.8 6833F505 337.5 357.4 365.9 374.2 382.9 400.2 405.2 411.3 421.2 432.3 437.1 442.8 431.1 6833F506 320.8 337.7 354.0 365.9 377.5 392.0 400.9 392.3 404.9 408.3 407.2 418.1 406.3 6833F507 278.2 305.7 320.4 329.3 344.1 358.8 362.3 370.2 386.1 395.7 402.7 410.6 412.7 6833F508 324.9 343.3 361.5 373.2 385.1 397.1 402.1 412.6 406.8 423.5 424.5 437.0 429.8 6833F509 325.1 345.2 361.6 375.4 386.2 397.0 402.5 404.1 416.6 435.0 430.3 443.7 425.7 6833F510 305.4 323.3 337.3 351.6 355.8 367.8 377.8 378.0 389.9 396.5 413.1 411.9 399.1 6833F511 338.3 361.7 371.0 383.6 405.8 419.1 424.2 428.0 441.8 463.2 462.2 470.3 466.3 6833F512 296.3 325.5 355.1 364.1 378.0 395.1 407.4 401.7 413.5 428.7 438.2 434.3 431.5 6833F513 286.4 312.7 323.6 339.4 342.3 361.7 366.7 357.3 379.6 385.1 383.8 394.2 376.6 6833F514 302.9 324.1 342.0 345.5 353.8 370.2 380.4 381.0 385.2 389.5 393.2 394.9 398.1 6833F515 330.9 349.4 370.4 375.0 382.8 402.6 409.5 408.3 421.2 427.3 424.8 432.2 430.1 6833F516 331.6 350.3 363.3 375.4 384.9 404.3 405.7 420.9 438.8 437.6 438.2 439.8 436.3 6833F517 324.0 339.4 356.7 378.3 379.6 397.7 403.7 412.4 421.7 430.2 426.3 430.0 433.6 6833F518 320.8 347.4 360.1 378.5 393.3 407.0 410.0 411.0 417.3 438.1 445.7 459.5 456.4 6833F519 350.4 370.3 381.6 397.5 410.8 427.0 435.6 434.3 440.2 454.1 461.9 473.4 470.2 6833F520 334.1 353.3 358.8 372.3 383.0 395.0 405.0 396.2 398.8 413.3 412.5 420.6 417.3 6833F521 311.3 330.5 338.9 349.5 356.9 373.7 384.8 390.7 396.9 411.4 406.8 408.2 409.5 6833F522 309.2 334.5 349.9 351.5 368.6 386.7 392.7 407.7 404.5 417.9 424.4 426.6 431.0 6833F523 309.3 336.0 357.6 367.5 383.9 385.1 400.1 406.9 419.6 427.6 431.7 437.4 447.7 6833F524 345.7 368.3 379.8 391.2 400.9 412.3 422.3 436.9 446.4 455.9 460.5 6833F525 341.7 363.6 369.2 384.4 399.3 415.4 412.7 427.1 436.7 448.6 443.0 456.7 449.2 6833F526 317.5 339.3 359.4 364.2 375.8 388.8 399.1 402.2 412.4 421.2 424.0 424.8 428.5 6833F527 287.9 315.4 335.5 353.0 367.1 379.6 387.2 385.7 388.6 393.1 401.7 390.2 407.0 6833F528 301.8 320.7 335.5 346.6 359.4 370.8 380.2 389.0 392.6 391.3 393.6 389.7 394.9 Note: Data for Dosing phase

Study Number FY01-013

I-10
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 9 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 M a l e A n i m a l s 6833F529 2 322.9 347.2 361.2 368.8 381.2 392.7 402.8 403.5 410.8 418.8 410.4 418.1 430.6 6833F530 317.5 337.8 352.3 363.6 374.6 388.1 386.5 396.0 401.1 408.9 412.7 421.0 426.1 6833F531 331.4 354.4 377.8 383.5 392.6 413.1 411.9 418.3 428.2 434.3 424.8 406.7 451.4 6833F532 303.1 328.7 343.3 354.4 364.1 376.0 380.5 387.0 403.5 414.1 421.7 419.4 426.8 6833F533 317.7 338.3 352.7 361.2 376.4 391.3 392.0 399.4 400.2 413.4 412.5 406.7 414.6 6833F534 279.7 306.9 329.7 335.4 348.0 361.6 370.8 390.0 383.6 387.2 397.8 391.0 405.4 6833F535 331.9 364.8 381.4 387.8 402.6 415.5 416.2 435.9 440.4 454.5 459.3 460.0 472.1 6833F536 306.5 318.5 329.4 337.5 355.2 363.5 365.0 375.3 381.4 391.7 397.0 395.6 404.2 6833F537 322.4 344.9 360.7 370.3 381.1 394.9 402.9 405.2 416.1 423.9 428.5 437.2 447.8 6833F538 319.8 334.0 354.2 355.0 364.4 384.7 385.3 388.9 399.8 415.9 413.8 401.8 410.9 6833F539 337.5 349.8 369.1 375.8 383.3 400.2 406.2 418.2 425.5 435.8 429.0 435.1 441.2 6833F540 327.3 350.1 366.1 379.7 388.2 403.3 410.7 420.9 429.3 439.7 440.4 444.6 413.6 6833F541 318.6 336.4 349.1 355.6 375.7 385.5 382.4 394.3 395.6 403.7 402.6 409.7 411.9 6833F542 296.8 316.4 332.5 344.3 351.9 363.2 370.3 374.0 383.9 391.2 386.7 396.9 396.1 6833F543 305.0 322.4 345.6 344.2 351.4 367.3 370.7 370.4 368.4 383.7 386.4 402.7 398.8 6833F544 317.4 341.4 358.4 358.9 374.3 394.1 393.6 393.5 402.6 415.2 422.8 431.2 425.0 6833F545 340.4 355.3 371.9 377.1 389.6 403.8 390.4 406.2 414.3 428.4 422.3 432.9 430.0 6833F546 317.4 345.6 351.4 360.8 375.4 395.2 390.7 400.6 409.4 425.1 422.5 430.3 427.7 6833F547 297.7 318.0 338.9 346.2 363.2 375.2 380.4 390.3 400.5 411.3 417.5 415.8 413.7 6833F548 310.4 336.0 342.8 354.0 373.4 390.7 398.8 405.3 410.0 427.7 432.7 438.6 438.0 6833F549 310.6 335.2 345.0 347.9 364.0 383.8 380.2 397.0 405.8 411.8 409.4 414.9 414.8 6833F550 298.2 324.4 342.9 352.2 370.3 385.6 389.5 397.3 413.7 424.7 420.6 424.0 422.9 (n) 50 50 50 50 50 50 50 50 50 50 50 49 49 Means 316.9 338.5 353.3 363.0 375.5 389.5 394.5 400.2 408.6 419.1 420.5 424.4 424.4 Sdevs 16.8 15.8 15.0 15.8 16.2 16.5 16.4 17.7 18.1 19.7 19.5 20.9 20.4 6835G601 3 310.4 337.6 339.6 354.1 357.8 379.2 382.2 374.6 387.4 401.0 401.6 405.5 398.1 6835G602 314.7 339.2 346.1 365.1 382.8 395.8 402.7 404.8 410.9 420.7 422.9 433.1 419.9 6835G603 309.2 334.5 344.1 354.7 370.5 388.4 391.1 398.1 405.7 417.9 417.5 430.5 426.0 6835G604 311.2 339.4 355.7 362.6 389.1 402.7 403.0 396.8 419.5 428.5 435.0 442.4 431.2 6835G605 303.6 335.9 348.5 361.3 374.8 385.6 382.8 394.9 404.1 413.5 415.1 423.6 416.5 6835G606 370.9 404.4 421.3 437.4 457.3 473.3 466.3 464.7 486.1 499.2 500.0 502.9 492.9 6835G607 280.5 311.0 322.6 339.8 356.4 369.5 376.2 375.7 388.7 395.1 399.3 404.5 403.3 6835G608 318.2 349.2 358.9 367.6 384.4 388.3 397.5 404.3 404.7 411.5 416.7 424.4 417.7 6835G609 326.1 351.6 372.4 383.9 399.9 412.6 411.1 429.9 444.5 452.8 452.1 457.3 454.2 6835G610 314.2 351.9 364.8 377.7 385.7 395.0 394.3 400.7 418.8 420.5 417.7 424.8 417.7 6835G611 303.7 327.8 341.4 353.7 366.6 380.1 382.4 381.8 394.6 410.7 407.1 423.6 381.5 6835G612 335.7 370.1 385.1 398.4 414.4 432.4 408.6 426.8 441.0 456.9 451.4 461.6 450.0 6835G613 309.8 335.9 349.3 354.8 376.8 385.3 384.0 388.3 396.4 413.4 410.9 414.9 415.1 6835G614 318.1 348.3 356.2 370.1 383.7 395.0 394.1 398.1 410.4 422.5 423.7 421.2 420.0 6835G615 299.3 325.1 345.5 354.8 369.1 388.7 395.8 408.5 410.5 413.1 418.0 425.5 430.1 Note: Data for Dosing phase

Study Number FY01-013

I-11
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 10 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 M a l e A n i m a l s 6835G616 3 307.9 336.9 352.1 365.0 379.3 394.0 390.2 400.8 411.5 416.7 416.5 421.6 417.2 6835G617 299.5 329.3 348.1 363.1 372.9 395.3 395.0 403.0 413.3 426.1 430.9 432.9 431.9 6835G618 300.0 329.3 351.2 355.0 369.7 383.2 383.6 398.7 401.0 418.9 422.1 424.9 428.7 6835G619 311.9 337.2 341.9 358.8 369.8 379.6 376.8 386.1 392.3 404.6 401.4 412.7 405.9 6835G620 318.2 341.8 355.0 364.7 383.8 390.4 392.9 402.8 405.9 414.3 422.2 424.4 422.9 6835G621 307.2 337.1 334.9 349.7 355.5 367.7 374.1 369.3 379.5 388.7 390.5 391.6 393.9 6835G622 295.1 315.6 329.8 334.8 343.8 349.2 349.6 358.5 368.5 374.9 377.8 388.5 378.3 6835G623 318.3 341.9 344.6 355.3 371.1 382.5 384.8 400.8 399.5 416.6 412.1 416.8 414.7 6835G624 278.9 302.4 315.3 326.4 343.2 353.3 352.4 372.2 366.7 378.9 383.8 390.5 387.5 6835G625 320.9 342.8 353.5 368.7 375.8 388.3 382.7 391.8 397.6 405.4 412.0 417.3 410.9 6835G626 296.7 318.8 330.4 347.4 359.4 372.5 363.5 381.9 389.1 390.1 391.5 390.6 393.7 6835G627 320.7 348.3 364.7 373.7 392.0 404.1 400.0 409.9 415.0 428.0 430.3 428.0 427.8 6835G628 320.0 339.0 348.0 360.2 381.1 383.2 387.2 385.1 399.2 408.5 416.4 415.1 415.7 6835G629 319.8 350.6 369.9 385.0 398.4 410.1 415.8 426.1 430.4 444.5 447.2 447.5 444.2 6835G630 310.0 329.8 338.3 345.4 357.7 377.1 373.2 383.8 389.4 394.0 405.6 409.0 400.1 6835G631 367.4 392.3 410.4 424.2 444.4 456.9 459.5 462.6 473.3 493.4 490.6 490.7 489.2 6835G632 318.7 344.5 359.4 371.2 386.0 390.9 397.2 406.5 416.3 434.3 436.9 439.2 434.2 6835G633 303.9 330.6 350.4 364.0 378.5 393.4 390.9 400.3 406.6 425.4 426.5 419.4 419.2 6835G634 334.1 349.5 368.8 379.1 394.9 410.4 410.7 416.8 419.3 419.4 429.1 434.6 437.3 6835G635 305.1 325.2 335.8 349.0 353.7 371.6 368.1 374.3 375.7 387.1 387.5 394.1 384.9 6835G636 353.9 383.0 397.2 417.7 422.0 442.9 439.6 450.9 458.2 463.4 467.7 459.5 461.1 6835G637 320.9 342.4 359.7 371.7 388.5 395.0 395.9 403.3 416.2 425.9 423.9 428.4 427.9 6835G638 311.3 335.0 345.2 358.4 374.0 386.8 381.7 381.0 393.2 406.0 411.2 405.1 402.9 6835G639 325.4 355.5 365.3 370.4 387.1 396.3 399.1 410.2 417.3 425.3 423.9 424.2 424.2 6835G640 297.4 313.3 331.0 338.2 356.5 357.1 361.8 377.3 376.6 387.4 387.4 385.9 387.2 6835G641 311.2 334.8 349.8 366.4 374.2 383.2 381.3 399.1 403.0 385.3 401.4 413.0 411.6 6835G642 332.5 353.3 365.0 377.2 392.7 398.8 403.4 416.0 424.8 438.3 436.8 438.8 435.5 6835G643 298.7 323.9 334.3 344.2 353.3 368.7 365.8 374.4 379.7 390.2 388.7 388.1 389.2 6835G644 314.6 330.7 338.1 346.9 364.3 380.3 384.8 389.0 402.7 426.6 413.9 423.2 419.3 6835G645 305.5 325.3 336.3 346.4 357.1 363.6 368.8 378.7 379.7 383.0 389.2 388.7 386.5 6835G646 336.2 363.6 366.9 386.6 404.7 420.6 419.3 427.0 436.3 451.7 460.5 458.5 452.8 6835G647 306.6 322.1 329.8 347.8 360.5 373.3 373.1 378.2 390.1 406.0 416.1 414.8 418.1 6835G648 309.7 330.9 344.0 355.2 375.3 384.8 383.3 400.8 411.9 427.4 433.0 437.9 440.7 6835G649 294.3 315.0 320.0 336.8 353.6 369.5 369.6 380.9 388.0 401.8 403.2 404.3 408.0 6835G650 277.1 306.4 319.8 335.1 350.7 363.7 366.2 371.1 374.2 384.8 386.8 388.8 402.4 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 313.5 338.8 351.1 363.5 377.9 390.2 390.3 398.3 406.5 417.0 419.3 422.9 419.6 Sdevs 18.4 19.8 21.1 21.9 23.0 23.9 22.8 22.7 24.6 26.3 25.5 24.9 24.6 6837H701 4 334.7 361.2 369.2 385.8 398.6 401.4 402.7 399.5 409.1 424.2 411.6 415.7 411.2 Note: Data for Dosing phase

Study Number FY01-013

I-12
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 11 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 M a l e A n i m a l s 6837H702 4 326.1 355.8 365.4 387.3 401.4 410.5 413.6 414.7 425.7 440.0 427.5 437.3 436.5 6837H703 335.2 363.4 374.7 387.6 404.4 416.3 417.9 423.2 439.8 455.5 434.4 445.5 448.0 6837H704 320.2 344.2 354.7 372.8 384.9 400.8 404.4 410.3 414.1 430.5 427.3 419.8 421.4 6837H705 335.2 360.0 369.4 383.8 394.4 419.3 417.0 424.9 437.1 446.2 443.2 447.9 444.2 6837H706 329.8 355.8 369.0 375.9 393.1 405.6 406.9 408.9 420.6 435.8 424.8 435.2 440.2 6837H707 303.8 329.6 342.8 357.1 370.0 381.7 389.3 390.9 404.1 407.1 401.4 397.1 408.2 6837H708 299.6 321.8 339.5 343.4 353.7 343.5 363.7 363.4 367.0 365.9 378.0 378.1 367.7 6837H709 316.6 339.8 354.9 363.1 373.4 386.6 390.4 388.9 406.0 415.3 417.3 413.9 410.9 6837H710 314.8 333.4 348.3 369.3 379.1 386.7 392.7 395.9 414.7 421.8 423.4 424.5 421.5 6837H711 330.9 349.1 363.9 379.8 391.9 409.3 405.9 410.4 426.1 448.5 443.4 439.9 445.6 6837H712 300.9 325.8 342.4 359.6 383.2 392.4 387.0 392.3 410.0 425.5 418.1 422.4 417.5 6837H713 322.5 338.7 349.4 364.8 377.6 392.6 390.3 392.9 401.0 412.0 411.2 411.2 402.7 6837H714 296.2 321.4 339.0 353.9 358.9 379.1 376.1 375.5 384.9 389.4 393.4 390.0 384.2 6837H715 327.5 355.4 372.8 383.7 390.4 406.4 402.6 407.4 417.5 418.6 426.7 429.5 428.7 6837H716 298.3 321.3 334.7 355.5 362.9 376.4 382.7 393.8 402.4 413.2 409.9 415.8 417.1 6837H717 332.8 359.8 376.7 390.9 401.4 411.8 411.0 424.0 431.2 444.3 449.1 446.8 445.1 6837H718 290.1 305.0 325.6 340.7 350.2 352.9 361.5 371.4 376.0 383.7 377.6 378.2 375.2 6837H719 300.1 324.1 334.1 352.1 364.3 380.9 380.1 387.9 400.0 414.4 405.1 407.6 405.6 6837H720 273.2 297.3 306.0 319.7 325.7 340.0 340.1 335.5 342.6 363.1 362.1 364.5 368.9 6837H721 323.8 342.5 352.0 363.9 366.7 379.1 378.9 390.4 396.9 402.8 402.2 408.7 400.5 6837H722 305.4 319.7 336.4 352.2 365.8 372.2 375.3 371.1 397.9 403.4 376.8 405.3 393.4 6837H723 309.4 327.9 338.5 352.1 367.8 375.0 380.3 388.3 396.8 410.2 414.5 418.3 411.1 6837H724 350.4 364.5 374.2 393.2 405.4 415.0 419.4 425.5 432.5 446.7 446.8 447.4 441.9 6837H725 297.0 318.8 333.5 341.9 350.2 359.7 362.9 372.8 377.2 390.3 390.9 389.7 392.1 6837H726 297.9 307.1 319.5 333.8 353.5 357.6 364.7 366.8 376.5 385.3 389.2 395.8 398.6 6837H727 327.6 353.9 366.6 383.1 387.0 404.3 400.2 404.1 398.7 422.0 414.6 419.6 407.4 6837H728 283.7 308.3 316.1 336.7 335.2 344.8 349.8 354.5 361.6 378.5 377.6 377.6 375.4 6837H729 299.3 311.2 329.1 340.1 355.1 361.4 368.5 380.2 378.4 401.9 404.8 413.1 408.9 6837H730 301.6 324.2 344.8 361.0 382.6 386.5 383.1 387.5 388.9 406.7 412.9 412.2 401.2 6837H731 306.8 320.4 330.9 345.9 357.5 367.9 376.2 373.7 392.6 393.8 394.5 388.9 381.1 6837H732 320.8 332.3 340.6 362.6 375.4 395.8 393.9 396.3 403.5 416.8 418.6 421.1 421.0 6837H733 290.7 306.9 315.5 317.6 327.7 340.6 340.8 350.4 344.6 353.5 351.8 356.1 352.9 6837H734 289.1 307.8 320.2 339.0 348.4 360.8 363.8 373.5 366.4 388.7 390.1 382.9 385.3 6837H735 281.0 307.1 333.6 350.1 348.2 362.9 366.6 377.0 374.6 390.2 384.8 391.5 398.3 6837H736 314.4 338.9 355.0 372.6 379.0 395.6 396.9 397.8 387.1 413.2 413.2 421.3 419.6 6837H737 316.0 334.9 350.7 362.5 367.6 377.7 379.1 381.4 389.0 400.8 401.7 384.9 397.5 6837H738 304.3 315.2 327.7 346.4 365.5 377.8 379.9 386.0 390.0 404.9 400.5 410.0 410.1 6837H739 295.6 315.6 334.7 348.2 355.9 372.7 377.8 389.7 374.8 394.3 394.6 393.2 394.8 6837H740 333.7 346.9 364.6 377.0 391.6 409.6 406.1 420.5 418.9 441.8 440.8 436.1 440.0 6837H741 307.7 325.4 335.3 352.3 365.9 373.1 383.6 388.6 388.9 407.3 409.4 409.5 406.5 6837H742 303.4 318.3 326.7 337.1 350.8 368.5 368.6 375.2 384.3 393.0 399.4 402.2 394.3 Note: Data for Dosing phase

Study Number FY01-013

I-13
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 12 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 M a l e A n i m a l s 6837H743 4 304.6 331.1 347.7 368.0 372.1 383.5 388.1 394.1 396.5 415.6 418.2 425.2 411.3 6837H744 306.4 322.6 333.9 344.1 353.8 371.7 371.6 378.4 384.7 394.5 392.4 391.8 386.2 6837H745 309.4 329.3 346.7 360.2 367.6 381.9 383.4 394.7 400.7 398.0 412.0 380.2 391.1 6837H746 318.7 339.0 357.5 374.0 380.4 391.7 385.8 398.7 404.8 418.4 422.1 400.5 411.6 6837H747 308.0 328.4 348.2 365.5 372.2 382.3 379.8 394.5 400.3 409.6 413.7 417.0 411.3 6837H748 296.0 318.0 337.0 356.4 363.4 382.1 376.2 377.4 388.0 403.8 382.6 407.6 401.6 6837H749 270.7 288.6 297.4 319.0 333.5 343.3 350.2 359.9 358.2 362.7 362.6 360.8 357.1 6837H750 297.0 326.3 344.5 358.4 365.8 381.8 381.6 390.9 390.5 404.4 417.3 414.2 422.1 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 309.2 329.9 343.8 358.8 369.4 381.4 383.4 389.0 395.5 408.2 406.7 408.1 406.5 Sdevs 17.2 18.5 18.5 18.8 19.7 21.1 19.2 19.6 22.1 23.2 22.2 22.8 23.0 Note: Data for Dosing phase

Study Number FY01-013

I-14
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 13 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 455 487 515 539 567 595 623 651 679 707 M a l e A n i m a l s 6831E401 1 424.7 432.4 425.1 416.8 409.3 406.8 402.6 391.2 6831E402 419.5 423.8 428.2 410.9 375.9 6831E403 389.2 390.4 388.5 376.9 375.5 354.7 6831E404 461.9 471.1 474.2 459.6 470.8 472.2 484.9 6831E405 413.9 419.8 421.4 410.6 408.7 402.3 403.5 375.8 6831E406 394.6 398.2 407.2 400.5 403.5 395.1 404.9 398.3 386.5 334.3 6831E407 416.8 419.4 427.6 413.9 417.6 417.4 414.8 413.7 412.2 409.4 6831E409 439.0 449.3 456.7 435.6 439.1 404.7 337.4 6831E410 477.1 475.3 477.2 449.3 455.0 454.1 445.9 6831E411 447.0 453.6 457.3 459.6 450.0 443.9 435.7 426.4 6831E412 439.7 440.1 434.4 450.7 6831E413 431.1 431.6 430.6 417.9 416.8 406.1 397.5 396.2 392.0 377.4 6831E414 454.4 445.2 454.7 437.2 424.6 413.7 6831E415 432.5 437.9 440.1 425.9 422.0 413.1 417.0 409.9 403.0 403.5 6831E416 454.6 459.2 430.1 433.8 436.5 425.5 419.8 408.1 6831E417 461.4 471.6 469.8 471.0 466.1 463.2 473.8 476.0 460.3 447.8 6831E418 434.0 439.6 436.3 428.6 434.8 429.0 426.6 424.8 420.8 403.0 6831E419 463.9 484.1 479.4 463.4 459.2 455.3 460.4 438.6 415.8 6831E420 416.8 415.2 409.4 392.1 396.0 394.1 381.4 382.9 373.2 6831E421 463.9 466.4 466.4 452.6 439.5 6831E422 408.9 412.8 415.0 408.4 406.2 410.9 402.9 401.3 391.9 392.1 6831E423 433.9 445.3 449.6 435.3 432.0 396.7 6831E424 445.5 439.3 442.7 403.1 425.8 419.7 378.1 6831E425 490.4 499.6 493.0 481.0 468.8 457.8 448.0 6831E426 405.3 410.3 415.5 406.0 396.6 400.5 394.7 387.0 382.7 304.6 6831E427 427.4 426.3 412.4 432.3 426.9 405.8 387.2 367.1 351.7 341.2 6831E428 433.2 430.3 430.4 409.7 405.1 404.7 366.1 6831E429 481.6 481.5 481.0 466.2 468.2 465.0 462.1 424.3 6831E430 493.2 491.6 482.1 477.0 469.7 455.7 459.1 324.4 6831E432 444.8 454.2 444.2 436.0 438.5 444.2 411.5 377.2 6831E433 438.2 436.7 444.2 424.7 422.0 405.3 384.8 347.6 6831E434 439.8 438.5 444.0 432.6 430.3 421.1 413.9 322.3 6831E435 421.3 426.0 426.3 413.2 407.9 411.3 406.8 398.3 389.7 363.8 6831E436 417.4 420.4 426.7 417.5 414.5 409.3 405.6 400.5 400.2 400.1 6831E437 424.3 438.7 429.7 425.2 425.2 429.3 417.9 417.2 404.3 409.7 6831E438 424.8 421.8 414.6 405.2 406.0 405.2 393.1 377.2 343.6 6831E440 482.3 483.1 485.6 469.2 471.8 455.9 444.8 438.2 433.1 420.1 6831E441 461.2 458.2 455.5 442.8 448.7 446.5 375.4 6831E442 482.3 479.9 472.5 463.5 465.1 464.1 457.3 442.8 434.4 416.5 6831E443 422.6 459.2 454.1 442.6 436.5 440.1 433.3 428.6 415.0 406.9 6831E444 422.5 428.2 425.2 416.2 408.6 412.1 409.0 367.9 Note: Data for Dosing phase

Study Number FY01-013

I-15
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 14 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 455 487 515 539 567 595 623 651 679 707 M a l e A n i m a l s 6831E445 1 443.3 446.7 443.0 431.7 435.4 424.6 372.5 6831E446 472.4 472.4 466.6 453.0 445.9 445.1 442.0 431.8 416.5 394.5 6831E447 464.3 468.6 463.1 450.4 455.5 449.0 429.2 6831E448 413.1 410.3 413.5 411.9 404.8 407.2 402.4 404.6 397.1 399.0 6831E449 489.7 498.3 484.5 472.5 474.4 466.1 460.5 449.4 433.6 428.9 6831E450 442.9 450.0 448.7 443.7 449.2 (n) 47 47 47 47 46 43 40 31 21 18 Means 441.8 445.8 444.2 433.6 431.3 425.7 416.6 401.6 402.7 391.8 Sdevs 26.1 26.6 25.0 24.6 25.9 26.1 32.5 34.7 27.6 35.7 6833F501 2 420.1 418.8 422.5 415.5 405.2 392.8 398.7 6833F502 434.4 436.1 429.5 421.2 426.1 415.0 411.4 396.6 389.3 384.7 6833F503 418.8 422.2 429.9 421.5 410.9 409.1 399.5 394.3 392.4 387.4 6833F504 444.2 444.8 445.3 435.7 430.2 421.6 417.4 408.4 345.8 6833F505 436.1 447.7 449.5 438.8 440.5 424.9 419.6 412.2 415.6 397.6 6833F506 404.2 413.6 412.6 404.7 403.0 399.3 386.2 6833F507 415.3 431.1 439.8 436.2 432.6 417.5 418.4 401.3 6833F508 435.8 427.8 435.8 430.3 429.2 414.2 407.2 398.6 392.0 380.4 6833F509 434.0 432.7 442.4 405.3 453.0 6833F510 409.7 412.3 415.7 403.8 394.3 389.9 383.3 6833F511 469.1 467.6 473.6 456.1 453.0 443.6 441.5 433.4 431.2 416.4 6833F512 430.1 6833F513 388.7 382.6 388.6 380.6 379.6 378.3 369.4 353.9 354.8 342.3 6833F514 392.3 399.4 404.5 395.8 390.0 6833F515 423.0 430.3 435.9 396.2 6833F516 435.9 445.9 447.3 436.3 421.2 417.0 412.3 405.9 395.6 388.5 6833F517 438.1 445.1 443.1 433.2 431.9 424.6 408.3 6833F518 467.6 473.2 469.9 457.6 456.3 435.4 434.1 6833F519 472.4 480.9 482.2 476.6 467.6 465.3 452.9 447.3 439.0 427.4 6833F520 418.2 422.4 422.6 414.7 405.7 401.7 398.6 389.6 384.3 372.9 6833F521 410.9 417.7 419.4 414.2 402.5 390.2 389.7 381.0 365.8 355.0 6833F522 434.8 441.0 442.5 439.2 426.3 413.3 414.9 415.7 393.0 6833F523 445.4 455.9 447.8 440.3 432.3 429.8 424.0 422.6 425.3 417.7 6833F525 449.2 459.1 453.1 451.2 444.2 433.3 430.6 431.4 435.4 412.8 6833F526 431.4 437.7 434.7 418.4 416.3 410.5 397.5 390.0 381.1 380.5 6833F527 395.5 396.6 388.8 380.2 360.6 6833F528 381.2 6833F529 429.0 6833F530 428.3 431.8 428.8 426.6 422.7 426.3 425.9 423.5 413.8 329.1 6833F531 453.4 459.2 458.7 449.6 435.0 434.3 429.4 419.7 413.1 6833F532 353.4 Note: Data for Dosing phase

Study Number FY01-013

I-16
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 15 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 455 487 515 539 567 595 623 651 679 707 M a l e A n i m a l s 6833F533 2 411.9 411.6 406.9 402.5 403.7 6833F534 404.0 414.1 415.5 408.4 401.1 395.3 377.3 6833F535 469.0 476.6 473.4 459.7 449.8 445.8 447.0 439.2 436.8 430.1 6833F536 408.0 413.1 409.4 405.2 399.0 398.3 395.4 390.3 393.0 367.9 6833F537 456.0 452.7 455.6 441.6 441.4 431.3 399.8 6833F538 416.7 421.7 416.0 402.6 395.8 393.9 396.8 386.0 391.4 6833F539 448.7 448.2 441.6 428.6 429.1 430.2 418.1 372.0 6833F541 412.3 414.7 407.4 396.9 391.7 386.9 382.6 370.7 6833F542 405.0 410.0 405.8 392.1 392.7 391.9 391.0 387.3 384.4 378.3 6833F543 401.8 408.7 407.4 399.2 393.8 395.0 401.5 325.8 6833F544 423.7 428.0 426.9 419.3 413.2 411.9 410.1 402.2 6833F545 424.2 426.8 423.9 374.1 6833F546 430.3 435.6 428.4 416.8 418.2 414.4 417.0 415.6 412.8 351.1 6833F547 420.1 419.5 419.4 414.3 405.3 398.9 396.3 391.7 388.6 374.2 6833F548 441.3 440.8 435.1 430.2 434.4 426.7 431.3 436.4 457.3 6833F549 409.6 418.6 410.3 406.0 406.5 397.5 385.5 6833F550 413.2 423.9 407.7 405.1 402.8 395.1 397.7 389.4 391.6 382.9 (n) 48 44 44 44 42 38 38 30 25 20 Means 424.9 431.8 430.8 420.1 417.8 413.2 408.4 401.1 400.9 383.9 Sdevs 23.8 21.6 22.1 22.9 23.0 19.4 19.7 26.2 26.9 27.6 6835G601 3 400.2 401.1 405.6 397.3 399.6 399.0 400.3 392.7 391.5 383.0 6835G602 420.2 411.1 420.0 409.3 415.4 403.2 405.6 405.3 403.8 389.7 6835G603 431.7 435.4 436.6 422.1 417.6 407.4 391.5 393.0 376.9 371.7 6835G604 429.5 433.0 439.6 430.8 428.1 423.7 421.5 349.6 6835G605 418.3 423.8 420.5 406.7 401.9 400.9 393.5 388.7 380.5 372.0 6835G606 498.4 489.2 487.4 475.6 456.6 6835G607 407.0 408.0 412.8 401.8 393.7 385.4 379.1 377.4 374.4 374.7 6835G608 419.4 421.5 418.1 410.5 394.0 403.5 404.9 402.6 403.5 6835G609 457.3 431.8 435.1 424.1 421.4 419.5 420.4 417.3 408.9 400.8 6835G610 415.8 419.7 417.6 408.2 398.4 384.4 384.5 376.4 375.7 374.0 6835G612 459.8 459.2 461.8 437.6 438.1 424.1 374.0 6835G613 409.5 417.5 410.2 407.4 402.3 398.0 395.0 390.9 382.7 378.4 6835G614 422.0 424.4 421.1 434.7 409.9 404.9 402.2 396.9 389.2 389.4 6835G615 432.3 430.7 422.4 415.3 407.9 407.2 397.4 392.4 387.8 382.8 6835G616 419.5 423.3 416.1 410.7 413.8 406.4 397.5 391.4 375.5 6835G617 433.5 443.8 441.1 432.0 413.0 416.8 409.5 402.3 400.1 392.4 6835G618 436.2 429.0 420.2 415.1 413.9 414.1 342.8 6835G619 415.9 419.6 423.7 409.9 409.3 409.1 382.7 6835G620 423.3 422.6 391.6 410.7 413.7 406.5 334.3 6835G621 394.3 386.4 411.1 379.4 380.4 372.2 366.2 371.8 362.5 354.9 Note: Data for Dosing phase

Study Number FY01-013

I-17
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 16 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 455 487 515 539 567 595 623 651 679 707 M a l e A n i m a l s 6835G622 3 385.7 386.7 400.0 388.3 382.6 381.0 374.7 377.5 372.5 372.5 6835G623 420.3 424.5 411.1 6835G624 394.1 399.7 400.0 397.0 393.6 392.1 386.0 380.3 6835G625 415.0 418.3 411.9 413.9 409.9 412.7 405.2 6835G626 398.6 396.8 398.2 391.4 389.7 380.8 378.0 374.0 6835G627 432.5 430.4 429.6 418.7 418.8 417.7 409.7 405.3 376.4 6835G628 415.6 423.7 421.1 413.0 406.0 406.0 405.5 401.9 394.2 388.8 6835G629 449.3 451.8 448.3 435.8 439.3 430.9 419.7 322.4 6835G630 407.6 412.3 412.3 402.6 398.5 395.1 389.3 384.5 381.1 374.6 6835G631 502.4 499.0 503.5 485.8 475.7 480.6 468.4 448.1 406.5 6835G632 444.3 453.8 450.0 441.0 431.8 425.1 403.9 393.3 370.7 6835G633 421.5 423.9 422.3 419.1 414.5 410.5 409.0 410.4 408.5 6835G634 439.4 443.3 439.8 427.1 423.0 410.3 420.1 413.6 407.1 395.5 6835G635 392.7 395.1 390.2 386.4 382.0 350.0 308.4 6835G636 463.1 464.6 456.9 452.6 430.2 392.7 6835G637 429.6 432.2 428.9 421.2 417.8 398.1 386.9 6835G638 408.5 418.5 415.4 403.2 402.1 403.5 396.5 394.5 399.1 391.3 6835G639 428.1 438.8 431.9 420.7 416.9 410.4 404.2 402.8 397.0 382.2 6835G640 386.4 385.1 382.8 380.6 349.8 6835G641 416.7 412.2 409.8 391.4 396.3 398.4 377.2 369.5 6835G642 435.0 429.0 431.2 413.6 410.7 408.0 387.5 376.3 6835G643 389.5 397.9 395.8 387.1 389.6 399.1 6835G644 428.0 422.5 378.6 6835G645 390.9 381.0 384.2 375.4 380.2 384.3 378.6 358.7 365.8 364.6 6835G646 455.1 444.6 457.8 434.7 435.2 429.8 423.8 6835G647 430.0 439.9 442.1 421.2 422.3 425.2 412.6 419.6 412.6 410.1 6835G648 446.5 449.2 449.3 435.1 431.9 425.2 418.1 418.0 412.2 385.0 6835G649 414.1 415.5 413.7 399.3 399.1 394.4 384.3 376.6 374.5 369.9 6835G650 409.9 415.1 419.7 410.5 401.2 395.3 344.7 (n) 49 49 49 47 47 45 43 34 28 22 Means 424.4 425.2 423.4 415.0 410.2 405.4 392.9 390.5 389.0 381.7 Sdevs 25.0 24.0 24.8 22.3 21.2 19.7 27.0 22.8 15.4 12.6 6837H701 4 418.7 419.8 424.0 403.2 402.4 376.5 381.6 369.2 341.0 6837H702 436.6 433.8 425.9 407.7 404.5 392.3 399.3 397.7 388.0 383.5 6837H703 444.6 459.8 460.8 446.8 447.9 425.8 406.1 435.9 6837H704 426.1 428.0 426.1 413.9 411.9 389.9 385.4 393.1 385.3 385.8 6837H705 445.7 454.6 450.1 436.4 429.8 419.2 426.8 419.4 413.4 404.2 6837H706 435.5 442.5 439.9 422.7 418.7 401.6 408.6 392.1 369.2 356.5 6837H707 410.3 409.5 414.5 392.4 381.8 375.9 386.4 339.3 Note: Data for Dosing phase

Study Number FY01-013

I-18
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 17 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 455 487 515 539 567 595 623 651 679 707 M a l e A n i m a l s 6837H708 4 378.3 374.4 385.3 371.4 366.8 357.6 360.6 360.0 353.0 353.6 6837H709 421.2 416.4 410.4 396.6 391.9 374.8 362.3 356.9 6837H710 416.9 423.8 418.2 393.5 383.5 348.2 344.3 336.4 309.7 6837H711 443.7 458.9 462.3 442.8 445.5 427.3 426.9 418.7 378.9 6837H712 418.6 421.3 422.5 407.6 402.5 368.9 6837H713 408.8 412.8 415.7 376.2 401.7 381.0 372.3 362.9 336.1 305.4 6837H714 388.3 388.9 390.7 376.5 370.3 361.1 362.7 357.3 346.9 339.1 6837H715 437.3 437.8 436.0 430.4 428.1 419.7 371.9 6837H716 419.5 6837H717 449.9 445.6 437.8 429.3 419.6 427.2 419.1 416.9 410.9 404.0 6837H718 379.4 381.5 377.7 366.5 363.7 360.9 357.5 351.3 355.2 349.4 6837H719 407.1 409.0 376.9 6837H720 372.1 374.0 370.0 349.5 361.8 358.2 335.0 6837H721 402.8 403.9 406.1 389.4 385.8 383.6 381.2 378.0 370.1 6837H722 404.3 398.5 404.1 386.5 386.9 371.2 378.6 377.8 370.5 353.4 6837H723 416.1 422.3 416.7 409.5 364.0 6837H724 446.8 445.3 443.7 433.1 425.0 424.9 420.4 408.1 397.6 377.0 6837H725 395.5 403.8 402.8 396.0 393.6 392.0 393.7 389.3 371.9 355.2 6837H726 403.6 402.6 402.7 387.6 385.7 385.9 384.7 392.6 384.7 375.9 6837H727 405.6 402.4 397.4 392.5 381.8 375.0 370.5 346.6 6837H728 376.9 378.8 372.2 366.9 358.2 361.1 353.7 339.0 335.5 333.7 6837H729 411.2 414.3 409.4 403.2 391.3 397.6 393.9 380.4 366.1 366.3 6837H730 412.4 417.0 409.1 401.6 386.1 399.6 392.8 389.7 380.6 6837H731 380.5 387.8 386.4 375.1 365.9 369.3 367.8 302.4 6837H732 432.4 420.6 419.3 401.8 389.7 6837H733 361.6 361.9 364.5 360.2 347.3 289.6 6837H734 390.2 388.8 382.3 376.2 372.0 373.9 364.1 365.9 344.8 6837H735 403.8 409.9 406.5 398.3 387.3 394.4 383.9 390.4 380.6 369.9 6837H736 419.3 421.8 419.1 409.6 397.6 406.8 392.6 394.3 387.3 385.5 6837H737 404.0 415.9 409.6 392.0 371.7 372.9 347.6 319.8 6837H738 407.7 417.6 408.1 398.2 392.5 396.5 395.1 387.1 381.7 6837H739 398.6 403.1 403.4 398.4 383.1 392.8 389.0 384.0 382.2 384.0 6837H740 438.9 440.9 439.4 430.7 419.2 418.7 381.9 6837H741 414.1 408.9 409.0 394.8 391.6 387.3 388.0 384.7 373.8 355.3 6837H742 374.7 390.6 390.3 392.7 321.3 301.3 6837H743 412.0 414.0 410.7 393.1 385.1 393.8 394.7 393.4 382.7 356.2 6837H744 342.1 6837H745 369.0 399.2 400.2 386.9 397.6 375.0 376.8 367.4 6837H746 416.1 418.7 421.5 407.0 397.4 395.6 371.9 6837H747 412.1 408.8 408.7 388.4 383.6 381.8 369.0 377.2 370.6 363.1 6837H748 406.9 408.6 392.2 379.7 369.8 Note: Data for Dosing phase

Study Number FY01-013

I-19
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 18 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 455 487 515 539 567 595 623 651 679 707 M a l e A n i m a l s 6837H749 4 354.4 358.0 354.6 342.4 342.0 336.6 340.0 338.2 342.9 320.0 6837H750 417.1 433.0 430.4 418.2 409.4 410.0 406.4 399.9 383.0 (n) 50 48 48 47 47 44 41 37 30 22 Means 407.8 412.3 409.7 397.3 389.7 383.0 381.6 376.0 369.8 362.6 Sdevs 24.9 23.6 23.9 23.1 25.5 29.3 22.6 29.1 23.2 24.7 Note: Data for Dosing phase

Study Number FY01-013

I-20
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

I-2 Males 

Summary Statistics - Body Weight Data 

I-21
 Lovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06

 Research Institute Study number: FY01013M Page: 1  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ D a y o f P h a s e  Group(s) 16! 7" 14 21 28 35 42 49 56 63 70 77 84 ----------------------------------------------------------------------------------------------------------------------------------- M a l e A n i m a l s  1 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 184.4 188.2 207.5 226.5 239.7 251.2 259.1 272.7 283.1 290.5 297.6 309.1 314.7  Sdevs 7.8 11.5 12.9 14.3 16.1 17.3 18.2 17.8 17.5 18.3 18.4 19.0 18.8  2 (N) 50 50 50 50 50 50 49 50 50 50 50 50 50 Means 182.1 193.8% 207.8 226.1 240.0 250.9 260.7 273.7 282.2 296.5 297.1 306.1 312.5  Sdevs 9.8 11.6 16.2 15.6 15.6 16.4 16.6 15.9 15.7 18.5 16.7 17.0 16.6  3 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 184.1 193.4% 208.0 225.3 237.7 250.7 260.5 271.0 281.6 288.6 296.6 305.9 312.3  Sdevs 10.9 12.9 14.3 15.3 16.5 17.4 17.8 17.9 18.3 18.3 18.7 19.6 20.2  4 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 177.9$ 184.2 199.5* 217.4+ 229.5+ 241.7* 252.2 263.4* 275.0* 282.0 291.2 299.6* 305.8*  Sdevs 11.6 20.2 14.5 14.3 14.3 15.5 15.8 16.6 16.2 17.3 17.8 17.6 17.8  ----------------------------------------------------------------------------------------------------------------------------------- Note: ! = Pretest phase; " = Dosing phase  *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance  %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance 

Study Number FY01-013

I-22
 Lovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06

 Research Institute Study number: FY01013M Page: 2  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ D a y o f P h a s e  Group(s) 91 119 147 175 203 231 259 287 315 343 371 399 427 ----------------------------------------------------------------------------------------------------------------------------------- M a l e A n i m a l s  1 (N) 50 50 50 50 50 49 49 49 49 49 48 47 47 Means 319.3 340.8 355.0 368.6 379.4 396.3 397.0 405.3 415.8 426.1 424.8 435.7 437.0  Sdevs 18.9 18.1 17.9 18.3 19.9 21.0 19.4 22.5 22.5 21.9 27.9 25.8 26.2  2 (N) 50 50 50 50 50 50 50 50 50 50 50 49 49 Means 316.9 338.5 353.3 363.0 375.5 389.5 394.5 400.2 408.6 419.1 420.5 424.4 424.4*  Sdevs 16.8 15.8 15.0 15.8 16.2 16.5 16.4 17.7 18.1 19.7 19.5 20.9 20.4  3 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 313.5 338.8 351.1 363.5 377.9 390.2 390.3 398.3 406.5 417.0 419.3 422.9* 419.6+  Sdevs 18.4 19.8 21.1 21.9 23.0 23.9 22.8 22.7 24.6 26.3 25.5 24.9 24.6  4 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 309.2* 329.9+ 343.8+ 358.8* 369.4* 381.4+ 383.4+ 389.0+ 395.5+ 408.2+ 406.7+ 408.1+ 406.5+  Sdevs 17.2 18.5 18.5 18.8 19.7 21.1 19.2 19.6 22.1 23.2 22.2 22.8 23.0  ----------------------------------------------------------------------------------------------------------------------------------- Note: Data for Dosing phase  *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance  %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance 

Study Number FY01-013

I-23
 Lovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06

 Research Institute Study number: FY01013M Page: 3  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ D a y o f P h a s e  Group(s) 455 487 515 539 567 595 623 651 679 707  ----------------------------------------------------------------------------------------------------------------------------------- M a l e A n i m a l s  1 (N) 47 47 47 47 46 43 40 31 21 18  Means 441.8 445.8 444.2 433.6 431.3 425.7 416.6 401.6 402.7 391.8  Sdevs 26.1 26.6 25.0 24.6 25.9 26.1 32.5 34.7 27.6 35.7  2 (N) 48 44 44 44 42 38 38 30 25 20  Means 424.9+ 431.8* 430.8* 420.1* 417.8* 413.2% 408.4 401.1 400.9 383.9  Sdevs 23.8 21.6 22.1 22.9 23.0 19.4 19.7 26.2 26.9 27.6  3 (N) 49 49 49 47 47 45 43 34 28 22  Means 424.4+ 425.2+ 423.4+ 415.0+ 410.2+ 405.4$ 392.9$ 390.5 389.0 381.7  Sdevs 25.0 24.0 24.8 22.3 21.2 19.7 27.0 22.8 15.4 12.6  4 (N) 50 48 48 47 47 44 41 37 30 22  Means 407.8+ 412.3+ 409.7+ 397.3+ 389.7+ 383.0$ 381.6$ 376.0+ 369.8$ 362.6$  Sdevs 24.9 23.6 23.9 23.1 25.5 29.3 22.6 29.1 23.2 24.7  ----------------------------------------------------------------------------------------------------------------------------------- Note: Data for Dosing phase  *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance  %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance 

Study Number FY01-013

I-24
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

I-3 Females 

Individual Animal Body Weight Data 

I-25
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 1 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 F e m a l e A n i m a l s 6832E451 1 122.4 129.0 142.9 152.9 159.5 166.5 166.5 172.1 172.6 177.4 178.5 181.2 186.2 6832E452 121.3 130.7 142.9 146.8 151.3 153.9 156.2 163.1 163.2 164.6 171.4 172.1 175.7 6832E453 130.3 139.4 152.9 154.6 159.8 165.1 166.2 171.4 170.1 174.6 177.9 180.3 184.0 6832E454 122.0 130.9 136.2 139.7 139.8 146.5 149.4 155.4 155.5 158.8 167.5 166.4 168.3 6832E455 128.1 140.4 146.2 153.8 165.0 164.9 172.0 175.0 181.9 180.1 185.9 188.3 190.4 6832E456 126.8 140.7 148.7 153.1 158.0 162.5 164.5 166.2 170.5 174.5 179.7 184.6 183.8 6832E457 122.9 136.1 146.6 149.6 142.9 152.4 160.2 164.1 170.0 170.1 176.1 178.7 179.4 6832E458 125.2 135.9 144.7 151.3 155.7 161.3 165.1 167.0 167.2 173.3 176.7 180.3 194.6 6832E459 131.2 137.2 148.7 151.9 158.3 165.7 166.8 169.4 170.7 177.0 182.5 186.1 193.6 6832E460 134.7 142.8 154.5 160.2 167.6 169.3 171.9 180.4 185.0 187.3 192.2 191.7 193.5 6832E461 126.1 134.4 146.7 150.5 159.4 167.3 168.5 174.7 176.9 176.8 188.9 190.5 195.6 6832E462 131.4 143.5 154.5 162.7 168.8 170.4 176.4 182.8 183.0 186.7 190.6 191.4 194.2 6832E463 135.5 140.6 151.3 157.1 162.7 166.8 172.8 177.7 178.6 182.9 188.6 191.4 193.2 6832E464 118.0 128.0 134.7 139.6 140.9 147.4 149.0 154.2 157.2 159.9 161.5 163.8 167.2 6832E465 123.1 131.2 143.5 153.0 161.9 166.1 169.8 172.6 175.0 177.3 177.4 181.8 183.7 6832E466 122.6 134.8 144.2 153.5 158.6 169.9 168.2 171.8 176.3 181.0 184.1 184.2 185.3 6832E467 136.0 147.7 152.5 159.4 164.6 167.2 173.6 177.3 178.5 184.3 188.1 192.8 195.2 6832E468 122.4 135.1 148.1 156.1 162.6 169.1 170.3 175.5 178.7 182.5 185.7 189.8 193.8 6832E469 120.5 132.9 140.9 150.8 155.7 160.4 162.8 171.4 176.2 177.5 183.4 185.6 190.0 6832E470 128.2 138.5 146.5 156.7 161.2 170.1 168.3 176.0 178.0 180.1 185.0 187.1 189.9 6832E471 126.5 131.3 141.4 146.3 152.9 158.2 162.4 167.5 167.6 173.4 175.8 177.0 183.9 6832E472 117.5 125.2 133.1 139.5 142.5 126.5 150.8 155.1 157.5 161.2 164.5 164.9 165.8 6832E473 120.8 132.8 143.8 148.1 154.2 158.4 164.1 166.7 169.8 176.6 177.3 181.0 180.4 6832E474 122.8 131.5 141.4 146.1 151.2 154.2 161.5 161.6 161.0 167.6 167.9 172.3 170.5 6832E475 121.5 131.4 140.3 136.6 135.4 152.1 159.9 157.6 164.4 162.9 176.4 180.1 175.4 6832E476 125.7 137.2 149.1 147.2 149.6 160.2 171.3 171.1 172.8 166.2 193.9 190.2 184.3 6832E477 126.3 133.5 146.6 154.1 160.2 163.7 167.9 174.2 175.0 179.1 184.5 188.4 188.7 6832E478 128.6 138.0 150.7 160.1 165.2 169.7 173.7 178.1 178.7 183.3 191.2 189.8 192.8 6832E479 127.9 140.8 154.3 164.6 172.1 178.2 179.3 184.1 185.4 190.1 194.8 198.0 199.2 6832E480 116.3 119.8 128.0 133.6 135.9 140.8 144.7 147.6 150.9 156.3 163.4 164.2 162.9 6832E481 132.2 136.9 145.7 156.9 159.3 164.5 165.8 171.7 174.6 177.2 183.1 192.6 188.3 6832E482 129.9 140.0 152.0 159.8 164.1 170.0 172.0 178.0 181.9 192.0 194.3 199.5 200.0 6832E483 121.2 127.8 134.6 143.6 146.9 152.1 157.0 160.2 160.8 169.4 174.7 176.4 178.4 6832E484 134.0 148.6 162.1 162.2 173.0 174.5 174.4 179.3 182.4 186.7 192.6 194.9 197.4 6832E485 133.9 144.5 158.3 168.9 172.2 172.9 172.6 176.0 176.1 179.4 188.6 187.0 190.0 6832E486 122.9 132.1 143.0 147.5 155.8 160.4 166.8 170.9 173.9 176.9 182.1 186.3 183.7 6832E487 120.1 131.5 141.2 146.5 150.7 156.7 160.5 166.3 168.5 170.7 183.7 181.0 180.9 6832E488 125.6 137.6 148.0 157.6 157.5 160.4 165.7 171.7 174.5 177.6 183.0 184.1 184.5 6832E489 121.9 134.2 145.9 154.4 155.8 158.1 163.4 167.4 170.3 172.7 174.7 175.6 175.2 6832E490 120.1 133.1 141.7 155.1 154.4 157.5 159.2 166.1 167.2 163.1 171.4 172.2 173.0 6832E491 119.0 133.0 142.9 156.5 160.8 164.0 168.9 176.3 176.7 183.2 189.3 188.9 192.6 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-26
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 F e m a l e A n i m a l s 6832E492 1 121.1 129.9 133.9 144.7 139.7 146.3 153.4 156.1 156.7 164.2 167.4 170.9 169.6 6832E493 130.2 139.1 152.0 164.5 165.5 170.3 174.2 178.9 178.7 187.8 188.4 187.6 190.0 6832E494 127.9 134.6 149.8 159.4 162.8 162.9 167.7 173.7 174.7 177.2 183.6 187.2 187.4 6832E495 123.4 139.0 148.5 165.6 166.7 174.1 179.5 185.9 187.5 195.2 198.4 203.8 200.5 6832E496 123.9 132.8 139.8 150.7 152.6 158.1 160.2 163.4 165.0 174.2 180.5 181.6 182.0 6832E497 127.8 134.1 145.4 155.9 154.9 158.7 161.5 169.6 172.0 178.2 183.9 187.9 186.9 6832E498 131.0 143.4 153.3 161.2 156.9 164.0 163.4 175.0 173.8 179.0 188.0 186.1 181.7 6832E499 112.9 124.2 130.8 143.2 140.0 142.2 145.4 152.2 154.8 162.2 166.6 167.4 169.3 6832E500 129.1 142.5 154.7 168.5 168.4 173.3 178.1 184.4 188.7 194.0 196.4 200.1 199.7 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 125.4 135.4 145.6 153.0 156.6 161.3 165.3 170.1 172.1 176.1 181.6 183.7 185.1 Sdevs 5.3 5.9 7.1 8.1 9.6 9.9 8.3 8.8 8.9 9.3 9.2 9.5 9.8 6834F551 2 124.5 139.1 149.3 167.8 166.7 171.2 176.1 179.6 182.7 189.7 191.2 195.6 193.3 6834F552 121.0 134.0 144.8 153.8 157.9 160.0 165.0 170.1 175.3 179.9 183.9 185.8 186.0 6834F553 127.5 140.3 150.1 163.3 162.9 165.4 172.6 177.4 181.8 169.9 189.8 190.7 191.8 6834F554 126.7 131.8 143.0 146.5 149.1 152.0 157.5 163.4 165.8 170.1 172.6 174.8 176.6 6834F555 128.4 139.5 145.5 155.8 162.0 161.4 169.9 174.8 179.8 182.1 184.6 187.6 189.0 6834F556 122.4 130.9 139.3 142.2 152.4 156.7 159.4 166.1 168.6 175.6 177.8 182.5 186.1 6834F557 116.1 126.7 144.2 150.3 156.6 159.7 163.2 172.6 173.8 179.6 179.5 182.0 185.9 6834F558 122.6 132.9 139.0 142.9 145.9 150.1 154.3 163.1 163.4 168.7 168.6 173.4 173.4 6834F559 122.1 130.7 138.5 147.1 148.4 152.0 157.2 162.8 164.6 171.3 173.6 174.8 175.4 6834F560 124.3 138.4 147.1 162.7 161.1 165.0 168.1 173.6 178.1 180.7 186.6 186.6 186.9 6834F561 121.1 131.5 142.9 149.4 155.4 156.9 161.2 168.7 170.1 177.1 180.0 181.2 184.0 6834F562 127.5 134.6 142.0 149.4 155.8 156.9 159.4 165.3 167.6 173.1 176.4 178.0 183.3 6834F563 123.4 135.0 143.1 149.8 146.7 159.2 165.3 169.0 176.4 185.7 184.2 187.1 189.9 6834F564 118.0 128.7 136.3 144.7 146.4 153.7 155.6 161.8 163.4 167.9 171.3 171.5 174.8 6834F565 124.2 138.7 143.8 155.2 159.1 164.9 168.9 178.6 177.2 183.0 186.6 189.5 203.4 6834F566 120.3 134.5 141.8 150.2 154.9 158.2 166.4 173.8 178.8 184.4 186.5 190.0 193.9 6834F567 126.5 138.0 147.3 160.7 165.7 165.8 172.8 177.8 178.1 187.3 185.3 189.4 193.8 6834F568 120.2 126.9 137.0 146.6 150.1 151.4 156.5 166.3 170.6 171.8 180.7 178.2 177.8 6834F569 129.8 143.3 157.4 170.9 173.3 175.8 183.0 187.6 191.7 190.6 192.9 191.5 192.2 6834F570 118.0 131.0 143.9 151.4 155.6 161.8 166.0 170.8 173.4 180.7 180.3 183.0 182.7 6834F571 119.5 128.9 137.9 144.6 145.2 152.9 159.1 162.2 165.0 168.3 173.8 173.4 175.7 6834F572 119.2 130.9 142.2 151.9 156.3 161.3 166.7 174.3 177.4 187.7 187.4 187.1 192.8 6834F573 123.2 132.7 140.9 151.0 152.4 158.8 163.3 164.6 166.0 169.5 168.0 174.8 175.3 6834F574 127.0 135.2 139.5 145.3 151.2 153.6 158.8 162.9 163.7 171.7 170.3 175.2 175.5 6834F575 126.7 140.2 150.3 157.8 164.6 173.5 173.2 179.4 182.0 186.7 191.3 195.5 193.0 6834F576 123.5 132.8 140.6 147.1 147.2 153.5 156.4 161.2 165.7 171.7 174.1 175.9 175.6 6834F577 118.7 134.4 149.5 161.6 169.3 170.6 176.0 178.7 183.0 186.5 190.7 195.8 191.9 6834F578 121.4 130.4 139.1 148.1 149.9 157.9 160.8 166.7 171.6 168.6 172.6 175.2 171.1 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-27
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 3 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 F e m a l e A n i m a l s 6834F579 2 125.8 135.5 145.9 155.7 159.3 164.2 166.0 173.5 175.9 182.3 186.5 190.2 190.2 6834F580 119.7 132.2 144.5 154.2 158.8 164.7 173.8 177.4 180.3 188.9 190.5 196.6 195.7 6834F581 121.4 135.2 145.0 155.4 160.4 163.9 172.1 173.9 175.7 183.9 183.5 187.8 192.6 6834F582 124.5 136.0 140.4 148.0 154.0 157.0 163.0 164.6 163.7 172.2 171.3 174.1 177.7 6834F583 115.0 128.0 146.4 153.0 156.9 161.2 165.6 168.4 172.6 176.2 179.5 184.0 182.3 6834F584 128.9 136.0 147.4 150.0 152.3 154.7 157.7 164.2 164.7 171.3 172.7 174.3 176.8 6834F585 120.0 131.9 141.9 148.5 150.0 157.4 161.0 166.9 171.2 174.9 180.7 182.1 184.0 6834F586 122.0 136.9 145.8 152.0 160.9 158.7 162.4 171.2 174.1 179.1 178.2 178.2 183.7 6834F587 126.1 140.3 148.8 155.4 168.8 166.8 169.1 174.8 178.1 184.9 184.3 184.1 186.6 6834F588 126.1 137.7 146.4 150.8 162.7 159.8 164.8 171.9 175.9 184.0 184.6 188.7 194.6 6834F589 131.9 145.2 156.9 159.8 147.8 171.6 172.9 179.3 184.1 189.4 193.7 195.2 199.4 6834F590 126.8 138.5 143.9 154.8 154.7 161.3 167.6 172.7 176.5 183.7 193.8 186.7 188.8 6834F591 121.0 136.2 144.8 155.3 138.7 154.8 160.3 163.8 173.6 175.9 176.7 183.6 183.6 6834F592 123.1 138.5 145.1 150.5 170.2 159.2 161.6 163.0 165.6 171.6 173.0 176.9 179.2 6834F593 124.8 141.9 146.5 150.6 149.4 157.8 159.4 171.2 173.2 174.2 179.6 179.1 184.1 6834F594 128.8 141.5 151.1 161.2 148.7 173.1 173.8 175.4 180.2 186.1 186.5 190.6 190.3 6834F595 129.1 141.1 148.5 157.0 153.6 162.4 165.8 170.6 174.6 177.9 179.6 180.9 178.7 6834F596 127.5 138.0 149.3 157.6 155.3 165.6 169.4 175.8 175.5 180.0 179.6 182.3 182.9 6834F597 116.3 129.6 141.7 151.1 145.7 154.4 161.6 165.7 171.3 177.8 177.1 183.9 181.5 6834F598 121.5 128.6 138.0 142.7 160.6 150.5 154.2 159.8 162.9 168.4 172.4 172.5 169.6 6834F599 127.1 137.6 149.8 157.5 148.8 166.1 171.5 178.4 179.9 186.2 187.8 187.3 189.3 6834F600 130.0 142.4 155.2 166.6 172.1 175.7 177.1 186.2 186.1 194.1 192.8 197.4 198.5 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 123.6 135.2 144.8 153.1 155.8 160.8 165.3 170.8 173.8 178.9 181.3 183.7 185.2 Sdevs 4.0 4.6 4.9 6.6 7.9 6.7 6.7 6.7 6.9 7.2 7.3 7.3 8.0 6836G651 3 128.2 141.0 150.2 155.0 162.0 167.7 171.4 172.8 177.6 183.1 186.4 183.4 186.7 6836G652 126.3 137.1 147.7 152.8 156.7 160.2 165.4 170.5 175.9 181.8 186.5 185.7 189.6 6836G653 113.9 126.3 131.8 138.4 142.9 147.6 155.4 158.5 164.2 169.3 172.1 171.6 170.6 6836G654 116.2 123.6 131.5 138.9 142.9 148.3 154.2 160.1 169.0 176.3 176.8 177.5 182.9 6836G655 133.2 137.6 144.5 149.7 156.3 161.7 165.2 173.1 175.4 177.2 181.8 188.6 190.5 6836G656 130.1 137.7 150.7 154.5 156.0 159.1 165.7 169.5 174.1 176.9 181.7 183.3 186.0 6836G657 127.5 138.6 146.0 149.4 158.6 158.3 164.3 168.2 168.1 178.7 178.9 179.6 181.8 6836G658 117.8 129.1 140.8 147.7 152.7 156.7 162.3 163.2 170.4 174.1 176.4 177.3 189.2 6836G659 124.9 139.2 147.5 147.6 158.1 161.9 170.6 171.9 175.9 184.0 183.5 187.2 189.2 6836G660 121.7 130.3 141.1 146.5 152.9 154.3 157.0 165.0 165.8 171.9 171.8 177.6 177.8 6836G661 126.8 134.6 140.5 145.0 147.4 151.8 156.0 159.6 161.3 166.8 168.8 174.2 176.0 6836G662 127.0 133.8 137.2 143.2 148.5 149.7 157.0 160.9 161.9 164.6 166.3 169.3 169.0 6836G663 126.3 142.5 148.5 154.9 159.6 160.0 165.8 169.2 172.4 176.6 178.0 182.3 186.7 6836G664 128.4 144.8 148.3 150.6 156.5 157.6 158.8 161.4 164.3 170.2 176.8 176.1 176.1 6836G665 115.9 120.8 125.3 132.2 134.6 135.3 140.1 144.5 145.4 153.8 153.5 154.4 153.5 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-28
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 4 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 F e m a l e A n i m a l s 6836G666 3 117.2 122.7 131.5 141.8 150.7 150.8 153.0 155.0 158.0 164.2 166.4 168.1 169.2 6836G667 116.2 124.2 130.6 138.9 140.2 142.9 144.9 153.5 156.4 163.1 165.8 164.5 165.3 6836G668 109.4 120.2 122.8 127.9 131.5 134.1 139.6 145.0 149.2 154.7 156.0 159.3 158.8 6836G669 123.6 130.1 138.6 143.3 149.1 150.2 160.2 158.3 163.7 167.5 171.3 171.8 174.7 6836G670 129.4 136.9 144.5 150.1 155.3 160.2 163.4 168.4 172.1 178.0 179.4 178.2 179.9 6836G671 113.5 127.8 132.9 134.6 143.0 145.6 150.7 155.2 154.3 159.6 162.3 166.1 166.8 6836G672 121.2 134.0 138.3 139.8 149.2 154.0 159.2 166.6 166.9 178.3 176.3 177.1 184.9 6836G673 117.8 124.5 130.1 136.1 140.7 139.6 144.7 148.2 151.8 157.4 157.8 160.0 164.7 6836G674 129.8 144.0 155.8 161.8 166.4 169.5 175.5 179.5 182.6 189.1 187.4 188.6 190.2 6836G675 119.3 132.4 139.6 143.2 147.9 150.1 156.4 159.1 165.2 166.9 172.1 171.4 172.5 6836G676 120.1 136.8 145.4 152.8 155.1 160.6 166.3 168.4 175.4 177.7 184.4 185.5 187.0 6836G677 123.8 136.7 144.2 155.2 161.3 161.6 170.5 169.6 174.1 183.3 186.3 187.4 189.0 6836G678 120.3 131.8 142.4 148.6 154.8 159.7 166.8 166.7 169.7 173.2 177.2 176.9 178.8 6836G679 126.2 136.7 145.9 158.9 164.6 164.7 167.1 171.4 171.3 179.1 178.4 179.4 181.1 6836G680 130.1 140.5 149.0 157.7 164.9 166.9 172.6 179.6 184.5 190.3 188.3 191.1 193.2 6836G681 131.2 144.2 155.3 159.2 164.6 169.1 176.3 177.9 182.5 188.1 194.2 195.5 198.0 6836G682 116.7 131.0 136.9 141.7 144.0 147.1 151.7 155.0 158.6 162.1 169.5 168.1 169.2 6836G683 126.2 140.0 146.7 146.1 156.6 162.5 165.2 166.7 173.9 180.4 178.8 179.5 179.1 6836G684 117.4 130.9 141.6 150.0 154.8 158.2 164.0 169.1 173.8 179.5 181.1 179.7 182.6 6836G685 121.5 131.6 139.1 144.7 150.3 153.4 155.4 161.5 162.8 165.4 169.7 171.1 175.7 6836G686 124.7 137.9 148.2 153.2 161.5 166.7 172.5 179.6 181.6 184.8 186.4 189.7 192.0 6836G687 129.1 142.9 152.7 164.3 168.2 170.4 177.2 183.6 184.9 187.0 189.7 190.0 192.5 6836G688 127.4 140.5 149.7 154.5 162.6 167.3 171.9 178.5 181.5 186.0 189.2 190.8 195.5 6836G689 115.7 125.2 136.2 140.7 148.0 151.4 154.0 159.4 159.1 167.5 169.3 170.9 171.3 6836G690 124.6 135.8 147.8 153.8 157.6 159.9 164.4 166.0 169.5 173.9 176.8 178.8 179.3 6836G691 121.1 135.3 144.5 149.1 155.6 161.2 163.7 169.8 177.8 182.8 181.9 184.2 188.7 6836G692 108.5 122.1 132.9 135.4 139.4 141.3 144.8 151.1 154.4 159.2 160.9 162.4 167.1 6836G693 138.9 151.3 161.3 169.0 170.6 174.6 178.8 181.5 184.6 187.8 192.1 193.1 193.2 6836G694 117.3 131.9 139.0 147.8 148.0 158.0 160.8 167.7 170.2 169.9 172.9 173.2 171.3 6836G695 124.9 135.8 144.5 149.6 153.2 156.4 158.3 162.6 166.5 172.2 172.8 172.6 174.0 6836G696 122.3 136.7 146.3 152.2 155.5 165.0 166.2 168.4 172.6 175.3 177.1 175.1 183.8 6836G697 122.1 133.7 138.6 142.2 145.5 151.7 154.3 159.6 163.2 164.6 167.6 171.1 171.1 6836G698 132.8 139.9 145.7 154.5 160.1 165.8 173.1 173.6 181.7 189.2 188.1 190.3 192.3 6836G699 126.7 134.1 141.7 145.2 148.2 150.9 158.7 141.5 166.5 178.7 181.3 184.6 185.1 6836G700 109.3 114.3 121.5 126.3 129.8 132.1 135.5 138.2 140.3 144.8 148.2 147.0 149.5 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 122.8 133.8 141.9 147.5 152.7 156.1 160.9 164.5 168.5 173.7 175.9 177.2 179.5 Sdevs 6.6 7.4 8.4 8.9 9.2 9.7 10.1 10.5 10.4 10.5 10.3 10.4 11.0 6838H751 4 125.4 129.4 139.4 140.5 144.2 148.1 151.1 157.4 161.7 162.9 165.8 166.3 170.8 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-29
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 5 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 F e m a l e A n i m a l s 6838H752 4 127.6 135.0 139.7 149.2 156.8 161.0 165.8 171.1 176.2 178.4 181.0 182.7 181.8 6838H753 124.0 129.6 142.7 142.3 149.3 151.2 152.2 157.7 160.8 165.6 167.5 170.4 170.7 6838H754 124.7 133.7 138.2 147.1 154.7 157.2 158.7 163.2 165.8 170.0 171.1 174.4 176.3 6838H755 116.4 119.0 126.1 130.3 132.3 136.5 138.5 140.2 141.3 147.5 151.4 152.2 155.6 6838H756 123.3 129.7 133.8 137.0 140.1 147.7 149.0 153.7 157.1 161.4 164.7 164.0 165.3 6838H757 120.6 130.2 139.4 145.7 152.0 154.6 156.0 161.1 162.4 168.0 170.2 171.1 173.0 6838H758 131.0 139.4 149.4 159.3 167.0 168.6 172.4 177.8 180.4 185.2 184.5 181.9 187.4 6838H759 120.1 126.1 130.9 136.0 145.2 148.7 149.9 154.9 158.2 164.1 165.3 164.1 168.2 6838H760 117.1 128.2 135.4 141.3 147.2 152.3 154.1 157.8 158.4 163.3 169.3 168.3 174.5 6838H761 121.8 128.0 134.7 142.1 147.4 153.3 147.8 160.0 160.8 166.8 170.1 170.8 173.2 6838H762 117.2 124.7 131.1 135.7 142.4 143.2 158.3 149.9 150.0 151.1 157.1 157.7 162.4 6838H763 119.5 129.4 136.1 141.6 145.1 154.9 160.3 161.7 165.2 170.4 172.6 178.2 177.8 6838H764 119.9 136.5 137.4 141.0 148.0 151.8 153.1 159.7 164.1 167.3 168.7 172.1 173.3 6838H765 127.9 136.4 145.3 153.5 161.5 164.2 171.9 176.4 177.1 184.7 182.3 186.4 193.4 6838H766 123.4 129.5 134.9 140.4 143.7 145.1 146.8 150.7 156.3 160.0 158.9 161.6 166.7 6838H767 122.9 131.8 134.9 143.3 147.2 149.0 150.2 157.0 160.5 163.4 164.8 165.2 168.3 6838H768 122.8 130.0 137.0 142.9 147.2 149.1 149.4 155.6 158.2 164.0 164.3 164.6 168.9 6838H769 114.7 121.8 126.0 131.9 140.1 143.4 145.8 150.6 154.7 160.6 161.0 164.9 165.7 6838H770 130.4 137.2 142.6 148.7 154.0 153.9 160.8 163.4 168.6 174.1 175.6 178.0 181.8 6838H771 110.5 118.6 123.7 128.6 138.0 140.9 144.0 151.6 153.0 158.1 159.1 162.3 165.7 6838H772 118.0 129.2 136.3 142.3 149.9 154.2 155.8 163.2 165.6 173.7 173.0 175.7 182.7 6838H773 122.1 131.5 135.1 141.2 148.7 150.6 151.7 157.9 160.8 167.5 168.3 169.6 171.1 6838H774 112.1 118.9 120.7 130.5 136.0 137.1 141.8 147.8 152.4 161.8 161.3 161.2 165.2 6838H775 115.0 125.5 130.6 138.1 146.9 146.8 150.3 153.7 155.6 162.5 163.1 166.4 165.7 6838H776 120.4 128.2 124.3 139.3 145.2 146.7 150.2 157.6 159.5 163.6 165.1 168.8 168.7 6838H777 112.2 117.2 124.0 129.5 139.2 144.1 143.3 150.0 153.7 158.7 158.9 159.8 160.4 6838H778 127.2 134.3 141.1 142.0 145.8 148.7 148.2 157.0 156.9 159.8 164.2 165.7 165.5 6838H779 129.4 132.5 135.5 145.5 152.1 157.5 158.0 160.1 165.5 168.6 176.2 172.0 176.0 6838H780 125.1 137.0 143.4 146.0 154.0 152.5 155.7 161.1 164.3 170.7 172.8 174.4 175.9 6838H781 125.3 131.9 140.4 142.8 151.2 154.6 159.3 164.1 169.8 173.6 179.2 178.9 176.7 6838H782 119.6 128.7 134.3 140.2 144.6 149.8 151.3 159.3 161.9 169.4 172.1 170.7 180.5 6838H783 125.5 135.3 138.6 150.3 155.4 158.4 161.5 167.1 169.8 176.9 179.3 178.4 179.9 6838H784 120.1 132.6 137.7 140.6 145.8 148.6 149.6 157.1 160.7 167.8 170.3 171.4 172.4 6838H785 128.8 134.5 142.9 149.1 154.3 158.6 164.6 169.1 175.4 180.4 182.7 184.6 185.4 6838H786 120.4 130.6 139.5 145.5 149.8 153.3 160.4 162.6 166.1 172.5 175.2 177.3 173.8 6838H787 128.0 138.2 141.0 151.2 154.1 159.2 162.9 165.3 170.6 177.9 181.2 182.6 180.9 6838H788 114.3 122.8 127.6 135.3 139.8 142.9 148.2 152.6 155.7 165.7 161.9 162.4 164.5 6838H789 124.3 134.2 142.7 149.9 158.2 159.5 164.9 170.7 175.7 181.4 187.4 188.1 183.6 6838H790 120.6 127.5 134.5 142.7 151.4 158.3 156.5 160.8 164.1 169.6 170.4 175.3 171.2 6838H791 118.8 127.1 132.7 141.3 149.2 150.6 153.9 157.6 163.5 167.7 167.0 171.7 177.0 6838H792 124.2 136.8 142.1 147.8 152.1 153.0 157.7 160.9 162.2 170.5 168.7 170.4 170.5 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-30
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 6 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84 F e m a l e A n i m a l s 6838H793 4 125.4 131.2 138.4 142.9 148.5 151.6 153.8 161.2 164.8 172.5 170.8 169.4 173.5 6838H794 122.8 133.3 138.9 142.3 150.6 154.0 153.9 160.3 160.3 165.2 167.2 167.0 167.4 6838H795 119.6 129.7 137.8 141.2 151.1 151.9 159.6 164.0 166.3 175.0 175.6 173.9 176.8 6838H796 121.0 128.8 136.1 140.2 147.3 150.6 156.9 158.7 163.7 171.8 172.0 172.7 172.5 6838H797 120.1 127.5 136.1 142.3 152.4 152.2 152.4 157.6 161.8 170.6 171.2 167.5 176.0 6838H798 125.6 133.5 141.1 150.8 155.8 156.4 157.0 161.4 162.8 162.8 167.3 167.2 164.5 6838H799 116.2 125.2 129.1 131.8 136.6 139.2 142.5 148.7 153.1 159.5 161.9 163.5 165.9 6838H800 126.9 138.2 146.7 155.9 167.9 168.2 169.0 176.8 176.2 179.1 181.0 182.5 181.4 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 121.8 130.1 136.2 142.3 148.7 151.7 154.5 159.5 162.6 168.1 169.8 170.9 172.9 Sdevs 4.9 5.4 6.3 6.7 7.2 6.9 7.5 7.4 7.6 7.8 7.8 7.8 7.5 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

I-31
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 7 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 F e m a l e A n i m a l s 6832E451 1 189.5 195.5 200.9 210.0 211.9 215.4 219.2 222.1 228.3 236.0 250.8 249.8 263.2 6832E452 176.6 186.5 188.4 200.9 196.3 204.5 205.3 209.3 210.0 214.8 219.8 220.9 225.5 6832E453 181.9 190.5 194.6 204.7 207.6 209.7 209.6 214.4 223.5 226.7 233.7 231.1 232.9 6832E454 172.4 182.6 191.5 203.5 200.5 206.1 204.9 217.9 219.7 228.1 232.9 240.5 249.5 6832E455 193.0 195.7 204.2 216.8 209.8 218.0 218.9 224.3 229.3 234.8 236.3 239.7 254.3 6832E456 183.5 190.8 192.1 201.6 207.5 211.5 215.3 224.2 231.2 234.4 241.5 249.3 251.6 6832E457 179.9 187.8 189.7 198.1 201.6 202.0 202.4 208.5 212.0 213.3 217.1 223.1 230.8 6832E458 183.0 193.5 194.8 200.1 203.3 207.8 206.4 213.2 213.5 210.6 213.9 225.9 227.0 6832E459 193.6 202.3 212.5 220.4 221.1 221.4 222.3 226.7 227.6 235.0 239.0 246.3 240.9 6832E460 194.5 200.1 204.1 215.3 213.6 220.5 223.2 226.8 227.5 233.2 227.9 234.0 234.1 6832E461 198.8 203.6 206.4 216.5 211.7 222.6 221.5 226.1 226.6 235.2 241.2 241.1 251.6 6832E462 196.6 208.3 214.0 222.4 221.5 228.2 230.5 235.4 238.6 245.8 251.4 265.2 265.9 6832E463 199.9 210.1 207.9 217.4 220.9 226.7 224.8 229.2 233.0 232.5 239.0 242.2 247.1 6832E464 166.6 176.6 182.5 190.5 196.5 194.8 194.5 204.3 205.6 209.0 216.1 220.0 229.0 6832E465 182.8 192.7 194.9 197.2 205.1 201.0 202.3 209.3 208.9 213.9 214.7 215.7 215.5 6832E466 187.0 201.0 200.5 206.8 209.9 212.6 201.8 212.1 217.7 222.4 229.1 232.2 239.5 6832E467 196.0 206.9 212.3 215.8 219.9 219.3 223.5 232.3 232.8 240.3 251.9 261.3 276.9 6832E468 192.0 198.1 203.2 210.6 216.6 214.7 218.8 228.6 228.6 234.5 236.2 232.0 238.7 6832E469 187.1 194.4 202.8 210.4 207.3 210.1 209.5 214.5 213.9 221.1 226.1 223.3 223.8 6832E470 191.7 204.3 209.3 214.6 220.9 221.8 217.5 231.4 240.0 240.1 249.1 255.4 272.9 6832E471 183.5 198.1 198.0 207.9 209.8 212.0 211.7 213.8 215.1 220.3 225.2 229.4 235.2 6832E472 162.3 173.3 173.7 179.4 182.0 181.6 185.0 181.9 186.6 187.0 176.9 182.0 179.3 6832E473 182.2 194.4 199.2 210.1 211.3 214.4 220.2 223.6 231.4 228.3 240.4 241.9 252.1 6832E474 172.5 180.6 177.1 183.8 190.5 193.1 198.0 210.7 204.5 208.2 221.1 220.1 231.8 6832E475 175.0 191.8 193.0 199.0 201.6 205.6 208.9 213.5 214.3 213.7 218.2 223.9 228.0 6832E476 183.7 201.6 210.3 209.9 214.3 218.9 219.6 226.2 227.2 229.2 237.9 241.7 251.0 6832E477 189.6 198.5 202.9 213.5 214.9 216.2 215.9 214.6 219.6 225.2 228.8 232.0 244.9 6832E478 192.2 200.9 208.3 212.3 212.5 212.2 216.2 214.8 219.4 220.4 224.9 228.4 231.1 6832E479 201.4 208.6 210.5 218.8 221.4 222.4 222.0 225.8 229.1 233.0 240.0 245.4 254.7 6832E480 169.3 174.3 181.4 187.9 194.3 197.2 201.4 204.4 207.9 209.0 221.1 218.2 220.1 6832E481 196.5 196.8 198.6 207.7 212.9 212.7 215.7 212.0 207.7 6832E482 203.2 212.4 218.0 227.8 231.7 227.9 223.7 230.0 234.5 239.7 251.6 256.7 267.2 6832E483 177.6 188.7 194.2 200.5 201.2 200.4 205.2 211.7 212.7 223.1 231.7 241.0 247.0 6832E484 200.4 209.4 208.9 216.9 214.5 217.0 221.7 222.9 236.0 236.9 249.5 259.6 265.0 6832E485 190.2 201.6 206.4 216.4 217.8 221.8 220.6 221.5 222.6 235.3 240.8 254.3 252.1 6832E486 189.1 198.6 207.7 213.8 215.7 218.5 220.9 225.3 229.7 231.0 247.7 259.3 255.1 6832E487 186.0 198.6 201.3 205.9 211.4 215.2 215.9 224.3 220.0 224.3 226.4 233.3 240.0 6832E488 188.5 191.7 200.4 208.5 210.1 217.7 218.3 216.8 217.5 227.4 233.9 248.9 252.8 6832E489 181.3 195.5 199.3 205.0 202.2 205.0 212.3 216.9 217.7 226.6 227.1 222.8 223.5 6832E490 176.6 186.3 188.6 195.7 196.5 200.0 203.8 202.9 202.2 206.6 211.2 212.2 216.1 6832E491 194.3 200.5 203.1 212.9 217.2 218.9 221.3 226.9 223.6 232.8 239.2 242.6 247.3 Note: Data for Dosing phase

Study Number FY01-013

I-32
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 8 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 F e m a l e A n i m a l s 6832E492 1 168.9 180.3 183.8 191.7 190.3 189.9 201.3 202.9 206.1 205.1 210.7 211.3 217.0 6832E493 192.4 200.9 201.6 209.1 225.4 215.5 218.6 223.2 224.2 227.7 245.1 253.2 256.1 6832E494 187.1 195.6 198.7 207.5 211.7 212.7 218.5 224.4 226.7 223.8 240.0 251.7 265.1 6832E495 202.5 215.5 219.7 218.9 228.4 229.8 234.8 236.7 247.8 243.0 252.0 260.9 269.2 6832E496 185.7 193.9 197.6 196.4 211.3 210.7 210.5 214.4 214.5 219.1 223.5 229.3 239.1 6832E497 190.5 203.7 208.0 212.6 215.4 215.6 221.6 229.8 230.8 237.1 245.8 253.8 261.5 6832E498 182.6 200.2 199.9 201.4 214.6 212.4 214.7 222.2 219.4 220.7 228.5 227.4 229.5 6832E499 171.0 183.3 183.5 189.2 200.8 196.8 203.6 204.9 207.6 209.8 218.1 221.5 224.9 6832E500 200.7 214.4 216.9 222.0 237.4 227.5 236.4 240.7 250.1 259.8 272.2 280.0 287.3 (n) 50 50 50 50 50 50 50 50 50 49 49 49 49 Means 186.5 196.2 199.9 207.1 210.5 212.2 214.2 219.0 221.5 225.8 232.6 237.4 243.2 Sdevs 10.1 9.9 10.5 10.6 10.8 10.5 10.2 10.7 12.2 12.9 15.5 17.6 19.6 6834F551 2 195.3 202.1 210.4 209.0 213.8 216.7 215.2 218.8 220.1 226.9 231.9 229.8 236.9 6834F552 192.5 200.2 208.2 213.8 215.7 218.2 216.9 228.7 225.8 234.7 244.7 248.2 252.8 6834F553 197.3 199.4 206.0 208.3 211.0 215.4 215.7 216.8 220.7 226.6 231.9 230.4 238.1 6834F554 181.2 186.2 193.2 200.6 196.9 204.6 206.5 210.8 217.8 225.4 236.8 235.9 242.6 6834F555 194.4 194.8 200.5 201.0 214.3 211.2 225.2 226.1 221.7 231.6 239.0 243.5 245.9 6834F556 187.7 196.7 203.8 205.3 207.0 206.8 216.6 220.8 219.1 222.3 223.3 229.8 227.8 6834F557 191.0 194.0 202.7 207.5 208.0 203.4 213.8 220.7 220.1 223.8 224.8 231.9 233.7 6834F558 174.2 186.1 195.6 201.1 201.0 206.0 213.3 215.7 214.2 221.7 230.0 233.1 236.0 6834F559 178.5 185.7 188.9 197.0 197.5 203.1 203.7 206.7 198.9 206.7 209.6 214.1 216.5 6834F560 189.3 197.9 205.2 209.8 209.2 214.9 213.4 219.6 223.4 231.2 235.9 246.1 243.3 6834F561 188.6 200.3 203.3 209.1 209.1 210.5 215.0 220.4 221.5 220.7 230.1 230.3 239.3 6834F562 184.1 192.3 191.3 199.5 206.8 208.4 208.5 217.1 214.1 217.7 222.6 223.2 227.0 6834F563 195.1 209.2 206.7 212.2 216.4 215.7 216.9 223.5 231.2 223.0 229.5 236.2 237.4 6834F564 178.6 187.2 195.0 201.2 203.4 208.6 207.5 215.9 217.1 218.4 225.0 238.4 247.8 6834F565 201.1 215.0 217.0 227.3 237.0 232.9 242.9 244.7 247.3 249.3 259.1 279.5 299.0 6834F566 192.9 204.5 208.5 220.0 216.3 218.1 223.4 230.9 225.3 229.5 238.1 237.6 245.1 6834F567 194.5 203.4 207.0 212.6 218.4 220.3 224.8 229.2 227.0 235.5 243.9 247.1 251.9 6834F568 180.4 192.6 195.5 192.6 196.3 202.0 198.5 198.8 193.6 203.0 202.3 204.2 205.1 6834F569 194.5 204.9 211.2 220.3 218.3 227.7 224.7 232.1 236.0 242.0 244.2 247.6 251.6 6834F570 182.6 192.3 194.0 201.6 200.7 202.8 206.7 206.1 212.0 212.5 216.6 227.1 232.2 6834F571 181.7 188.7 198.0 201.2 200.0 206.1 205.7 212.1 220.4 229.4 234.1 238.2 241.2 6834F572 195.5 203.0 208.8 213.6 213.3 219.9 218.9 228.6 231.4 229.5 234.4 238.9 246.5 6834F573 181.1 190.4 191.2 197.7 200.3 201.8 205.3 212.1 210.1 213.3 221.3 219.7 223.7 6834F574 174.7 188.1 195.9 200.0 207.4 207.2 209.8 218.0 218.0 221.0 232.8 224.7 228.1 6834F575 201.3 203.8 214.4 215.9 216.1 221.1 228.2 238.9 240.5 243.8 256.8 263.5 268.4 6834F576 183.4 190.8 200.0 206.0 203.8 209.8 214.6 221.3 220.4 225.9 235.9 235.9 247.7 6834F577 193.4 204.2 213.8 213.2 216.8 222.1 220.5 232.5 227.9 233.9 239.8 247.7 251.5 6834F578 174.5 184.3 189.9 193.6 190.6 196.7 197.2 202.0 203.4 203.8 211.5 218.0 215.5 Note: Data for Dosing phase

Study Number FY01-013

I-33
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 9 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 F e m a l e A n i m a l s 6834F579 2 194.3 203.6 210.0 212.5 209.9 220.8 220.4 223.5 225.0 230.6 238.4 243.0 244.0 6834F580 196.3 207.6 213.8 219.3 221.0 216.8 221.2 224.8 228.0 227.8 235.3 242.9 254.2 6834F581 195.1 204.6 206.2 211.4 219.4 218.0 221.3 222.6 225.6 232.5 234.7 236.1 242.3 6834F582 177.2 187.0 190.9 197.8 199.3 197.7 203.4 212.4 218.8 212.9 216.4 214.3 220.1 6834F583 188.0 194.9 204.3 203.5 204.3 206.7 213.5 220.4 215.3 216.8 224.3 224.8 229.9 6834F584 179.5 192.4 196.4 201.6 203.7 207.6 208.1 224.9 222.2 221.1 230.7 233.8 247.9 6834F585 183.9 197.2 198.2 203.7 207.8 202.5 202.5 210.2 212.9 215.2 222.5 223.1 225.8 6834F586 186.2 193.8 199.8 204.4 212.4 210.8 209.3 219.4 221.5 221.6 232.5 237.1 246.9 6834F587 189.3 199.2 203.6 211.5 215.1 218.1 216.9 219.2 225.6 225.2 231.1 235.8 235.4 6834F588 198.5 208.1 209.8 219.0 217.4 222.4 221.6 226.6 228.5 235.6 251.7 252.2 251.4 6834F589 203.0 212.8 211.2 221.9 227.0 233.7 232.6 240.2 247.4 250.1 258.5 258.5 264.4 6834F590 192.0 201.6 213.0 212.3 217.1 225.3 222.8 233.3 227.3 234.0 6834F591 183.8 191.5 197.9 204.6 204.8 210.7 209.2 215.9 212.4 214.8 223.2 220.2 234.4 6834F592 187.8 194.9 199.4 207.4 212.6 213.0 219.9 225.2 230.7 223.4 235.8 243.4 260.4 6834F593 183.8 194.1 200.1 203.5 206.9 213.2 209.5 216.4 221.6 224.6 234.8 245.9 250.0 6834F594 189.3 200.7 208.1 211.2 216.2 218.7 213.5 226.4 228.6 226.1 242.9 256.9 263.0 6834F595 182.8 192.0 198.7 202.0 206.0 210.3 208.5 210.0 208.6 211.6 217.8 215.0 219.8 6834F596 187.1 191.3 201.7 204.6 208.3 210.1 214.8 218.6 219.8 222.5 230.9 236.1 241.7 6834F597 182.4 192.5 197.1 199.8 206.5 211.1 213.6 218.9 221.4 220.9 234.8 235.3 249.1 6834F598 175.3 183.9 188.5 197.2 195.7 202.1 203.8 206.5 207.4 207.9 216.2 217.6 219.8 6834F599 191.5 200.0 204.0 208.0 214.4 216.5 219.8 227.5 227.0 225.1 236.6 244.4 246.5 6834F600 195.0 209.3 211.0 216.9 221.8 222.3 229.7 230.5 247.4 258.7 267.0 270.7 268.5 (n) 50 50 50 50 50 50 50 50 50 50 49 49 49 Means 188.0 197.0 202.4 207.3 209.9 212.8 214.9 220.8 222.0 225.2 232.7 236.5 241.8 Sdevs 7.6 7.8 7.5 7.8 8.8 8.5 9.0 9.5 10.9 11.4 12.8 14.8 16.3 6836G651 3 188.6 197.7 198.1 208.5 207.7 214.7 214.4 225.7 221.5 224.5 229.3 232.6 229.6 6836G652 189.8 198.1 206.4 212.0 216.6 217.0 216.5 229.0 226.8 231.7 235.6 240.2 246.5 6836G653 174.1 181.4 185.9 196.7 199.8 198.8 199.9 207.3 209.0 211.3 219.6 218.2 221.0 6836G654 181.9 190.4 194.2 197.2 204.8 205.8 203.3 210.2 213.3 212.0 217.1 222.3 230.4 6836G655 191.9 200.5 203.2 210.2 211.0 214.8 213.7 219.1 221.0 224.7 231.5 236.9 246.8 6836G656 189.1 196.4 198.0 206.4 207.6 209.6 211.5 216.1 222.7 221.6 229.3 234.3 237.8 6836G657 182.5 189.7 191.8 198.7 208.0 207.8 210.0 219.9 218.0 223.8 223.6 233.6 238.8 6836G658 183.3 193.3 191.7 202.0 208.5 208.1 213.3 219.6 222.0 243.1 246.5 259.0 258.0 6836G659 192.0 196.6 202.2 206.3 212.9 217.0 213.2 222.3 218.3 220.4 225.6 234.7 242.0 6836G660 181.9 189.3 196.9 205.8 207.4 209.0 213.2 221.7 222.1 220.6 229.3 235.3 240.8 6836G661 177.3 188.4 192.4 207.9 202.2 204.2 203.9 211.4 209.9 209.2 204.7 215.4 214.0 6836G662 170.6 181.4 186.7 191.9 194.9 196.9 197.4 203.7 202.3 201.4 205.6 205.8 210.4 6836G663 186.7 202.7 206.7 208.3 217.9 219.0 216.6 221.9 219.3 223.8 229.5 230.4 233.1 6836G664 177.6 185.5 191.2 195.2 199.7 206.5 198.4 207.4 203.7 210.2 210.6 211.1 214.0 6836G665 156.1 161.8 169.0 170.6 174.9 180.6 179.4 187.4 186.6 182.0 189.8 207.2 211.5 Note: Data for Dosing phase

Study Number FY01-013

I-34
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 10 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 F e m a l e A n i m a l s 6836G666 3 168.8 174.8 180.9 185.5 194.5 194.9 197.3 199.6 203.6 204.8 213.5 224.4 225.6 6836G667 169.9 175.5 181.0 181.1 190.2 191.6 195.3 202.8 205.3 202.7 207.8 234.2 227.1 6836G668 160.0 171.5 172.7 179.5 187.9 182.5 187.8 190.6 191.7 193.4 196.5 204.2 204.7 6836G669 178.4 189.4 190.2 195.8 197.3 204.6 200.9 198.4 206.1 209.9 212.3 215.0 231.3 6836G670 186.1 193.9 197.5 201.6 205.6 213.3 208.2 215.5 220.2 217.2 218.9 226.1 234.9 6836G671 171.6 180.1 186.2 193.5 193.2 199.8 200.7 202.5 211.4 208.6 212.0 211.8 219.5 6836G672 184.2 194.1 200.1 211.3 213.8 218.1 215.5 223.4 226.0 225.6 234.4 240.3 246.7 6836G673 165.8 179.8 176.3 186.2 186.5 189.5 190.2 190.7 193.7 196.3 198.6 203.4 206.1 6836G674 197.2 199.5 207.2 217.1 215.4 220.5 218.5 224.0 228.2 228.8 232.9 234.2 241.8 6836G675 179.2 182.3 191.2 194.4 194.6 203.1 198.1 198.1 210.3 210.3 222.4 221.1 230.7 6836G676 194.1 197.1 207.0 211.8 216.5 218.4 217.7 219.7 227.5 227.1 240.9 245.7 259.2 6836G677 189.6 198.0 197.0 205.0 213.4 217.7 218.0 218.7 222.5 222.2 223.8 233.0 235.6 6836G678 182.6 189.0 191.9 194.0 205.7 205.9 200.1 199.3 203.0 205.8 204.8 211.1 209.5 6836G679 181.0 188.7 191.9 195.5 201.2 205.2 210.3 220.1 235.7 237.0 237.0 239.7 243.1 6836G680 193.1 205.9 206.8 209.9 215.8 217.3 218.2 220.4 222.4 223.6 224.0 232.6 228.9 6836G681 195.2 207.5 209.4 214.4 222.3 224.4 224.1 230.0 235.6 231.3 238.5 237.5 240.9 6836G682 170.5 182.1 187.7 198.0 199.4 204.1 203.8 212.7 217.2 213.1 217.0 219.5 219.6 6836G683 183.5 192.9 196.9 203.8 214.9 211.1 215.1 218.7 214.4 216.7 220.8 224.7 221.4 6836G684 186.6 191.6 196.1 198.0 209.1 221.4 219.7 225.4 224.0 230.3 232.5 238.2 246.7 6836G685 176.8 182.8 182.6 191.7 193.5 195.0 195.2 198.8 205.2 204.6 208.8 214.8 214.4 6836G686 193.2 199.9 205.1 209.1 213.0 216.4 215.3 222.0 226.0 226.4 229.4 232.2 235.3 6836G687 198.0 202.2 210.7 213.9 221.3 220.6 225.7 225.3 229.4 227.9 243.6 257.8 259.3 6836G688 197.6 202.6 198.9 206.7 213.8 216.8 215.6 221.4 222.5 219.1 229.6 235.5 236.0 6836G689 173.2 181.2 183.3 187.5 191.0 193.2 194.4 199.4 198.5 200.3 200.6 202.1 201.6 6836G690 180.7 186.3 189.3 196.9 195.3 201.0 199.9 204.5 207.4 210.1 210.4 213.1 212.1 6836G691 154.5 6836G692 166.5 178.9 179.4 186.8 191.8 195.8 198.9 203.8 211.3 208.5 218.4 228.2 232.0 6836G693 195.4 198.6 209.9 215.3 220.7 222.2 220.3 219.7 231.7 226.6 233.2 240.3 237.6 6836G694 173.7 184.6 179.9 188.0 194.0 197.0 195.6 202.9 204.9 203.6 206.8 216.8 216.4 6836G695 177.8 188.6 189.2 200.4 205.6 206.1 205.0 208.2 213.8 227.9 229.5 230.3 233.9 6836G696 173.7 6836G697 176.8 181.1 184.0 190.1 194.7 199.1 195.9 203.8 202.3 204.6 209.5 214.5 215.0 6836G698 196.7 204.6 208.0 210.5 223.9 217.4 223.8 227.4 230.0 228.1 235.3 237.7 233.9 6836G699 182.9 6836G700 154.8 163.3 171.2 180.0 186.5 190.9 188.4 196.5 193.7 188.1 196.7 202.2 201.5 (n) 50 47 47 47 47 47 47 47 47 47 47 47 47 Means 180.7 189.4 193.1 199.4 204.2 206.9 206.8 212.1 214.7 215.8 220.6 226.4 229.3 Sdevs 11.4 10.6 10.9 10.9 11.3 11.0 11.0 11.5 12.0 13.0 13.8 14.0 15.1 6838H751 4 171.5 181.9 186.4 199.2 196.2 198.4 199.6 203.0 205.5 212.3 209.9 214.7 216.3 Note: Data for Dosing phase

Study Number FY01-013

I-35
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 11 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 F e m a l e A n i m a l s 6838H752 4 183.1 190.8 193.4 210.0 202.3 204.5 203.8 207.6 209.3 215.2 217.2 222.9 228.0 6838H753 171.7 182.1 186.5 201.4 197.9 199.4 202.0 203.2 205.8 214.8 212.8 220.6 226.4 6838H754 177.6 184.7 184.5 196.1 190.6 193.8 200.1 201.5 207.0 209.6 210.7 210.9 212.5 6838H755 156.8 165.8 167.8 182.6 180.6 180.4 186.2 184.9 193.9 198.4 197.0 205.9 212.2 6838H756 167.1 173.7 178.0 189.4 191.2 191.1 191.6 194.4 199.5 203.5 206.2 215.1 217.1 6838H757 177.4 179.4 181.0 199.3 194.0 197.1 202.6 201.9 202.4 204.9 205.7 223.9 226.9 6838H758 191.2 197.3 199.4 219.4 211.0 209.3 211.0 214.6 216.7 221.6 223.1 229.8 222.3 6838H759 169.8 177.2 176.7 193.4 189.5 190.0 197.2 196.4 196.8 199.5 199.2 203.8 205.3 6838H760 173.6 182.0 181.9 193.0 198.3 198.6 201.0 202.1 206.0 211.2 210.3 215.1 214.4 6838H761 177.5 187.6 190.2 199.3 201.9 197.6 202.3 207.5 209.7 209.9 206.0 218.5 217.0 6838H762 161.9 168.9 172.0 179.9 184.4 185.1 187.7 189.4 194.8 200.4 200.3 204.7 205.1 6838H763 177.8 185.6 186.6 192.4 196.9 198.8 202.1 206.2 205.9 212.1 211.1 220.6 220.2 6838H764 174.0 180.3 185.0 186.7 194.5 194.1 196.3 197.0 199.8 202.8 202.3 206.5 208.3 6838H765 192.3 196.6 201.1 207.7 211.1 210.7 212.7 212.5 220.0 212.2 223.2 224.4 229.3 6838H766 163.4 172.0 178.3 184.7 188.0 189.6 192.6 193.4 195.7 199.4 199.4 207.3 216.8 6838H767 169.5 176.4 181.4 189.2 196.8 195.5 205.9 202.3 206.0 211.4 211.0 217.8 218.4 6838H768 169.9 172.8 176.3 181.3 190.1 189.4 191.2 192.4 188.1 194.3 193.6 199.0 196.8 6838H769 167.2 175.5 178.6 186.2 192.4 190.8 190.6 195.8 195.4 198.3 197.2 200.8 200.1 6838H770 181.9 193.3 194.8 198.4 208.7 207.9 207.8 211.1 211.1 213.5 218.4 222.9 225.4 6838H771 166.8 177.1 178.7 178.2 183.2 183.5 183.8 184.7 188.7 188.5 191.9 192.8 189.8 6838H772 182.9 188.8 192.1 197.5 206.4 208.6 206.9 208.7 209.9 217.3 218.8 221.2 218.0 6838H773 174.1 177.8 181.9 190.8 190.3 199.0 198.6 203.7 208.4 205.0 207.0 210.0 211.6 6838H774 167.3 168.5 174.3 182.4 180.7 184.5 185.0 185.4 193.7 187.9 188.9 198.4 197.5 6838H775 169.6 177.0 180.9 189.4 194.9 194.7 196.0 197.6 198.1 203.3 206.1 207.5 206.2 6838H776 172.6 183.9 188.2 195.1 198.2 193.4 199.2 202.3 209.5 209.3 209.2 220.3 219.2 6838H777 164.6 164.8 168.6 176.3 177.2 182.6 181.8 184.4 190.7 191.0 192.9 201.1 198.9 6838H778 168.3 174.2 178.6 184.5 188.1 192.7 192.8 187.8 191.6 196.7 197.0 204.6 203.3 6838H779 178.0 184.6 192.9 198.0 202.0 203.8 204.6 204.3 209.7 211.6 214.4 227.1 229.7 6838H780 176.8 181.8 189.6 193.9 198.4 199.3 196.8 200.8 201.0 200.2 207.6 205.9 208.0 6838H781 181.1 184.7 189.2 196.6 202.5 205.1 203.8 208.1 209.5 211.4 208.8 219.8 220.0 6838H782 175.3 181.7 185.1 193.4 193.5 193.7 193.9 193.7 198.4 198.7 195.7 205.8 208.6 6838H783 183.0 188.0 192.0 203.6 202.3 202.9 202.2 212.0 210.5 214.5 212.9 220.3 220.7 6838H784 176.0 178.6 186.6 191.1 193.8 197.1 199.4 199.7 203.5 205.0 206.4 209.1 208.0 6838H785 188.2 199.1 197.9 208.6 210.9 216.1 213.6 218.9 227.5 220.5 224.8 234.9 236.9 6838H786 179.3 186.2 190.4 193.7 200.2 203.9 199.3 202.5 201.7 208.8 210.8 213.0 212.0 6838H787 184.5 192.4 197.9 203.9 207.1 208.8 210.7 210.5 216.2 217.7 221.1 228.1 231.8 6838H788 165.0 175.0 182.9 189.0 190.3 194.5 192.3 195.0 196.5 199.5 200.3 212.9 218.2 6838H789 189.3 195.1 204.4 206.9 209.2 214.0 212.8 209.5 214.6 217.3 219.5 222.4 227.5 6838H790 173.3 184.6 188.9 193.2 198.1 200.8 196.9 198.9 201.1 201.2 202.3 205.0 209.4 6838H791 176.5 191.7 199.7 206.2 207.5 213.0 205.5 219.7 221.9 225.5 237.5 245.8 246.0 6838H792 174.6 185.8 190.5 198.2 200.3 202.9 202.5 208.1 207.3 212.5 212.7 217.4 217.3 Note: Data for Dosing phase

Study Number FY01-013

I-36
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 12 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 91 119 147 175 203 231 259 287 315 343 371 399 427 F e m a l e A n i m a l s 6838H793 4 175.6 187.2 188.7 196.8 201.0 205.3 208.2 210.2 213.7 215.5 216.2 222.6 224.6 6838H794 170.5 176.2 177.9 189.8 192.8 196.3 201.9 201.5 203.8 211.3 216.6 221.0 221.9 6838H795 181.6 184.4 187.9 192.0 195.7 196.9 198.9 206.0 206.7 208.3 211.1 210.4 210.4 6838H796 175.0 182.1 188.2 191.0 196.0 198.9 199.2 205.1 204.1 208.3 205.5 211.4 214.6 6838H797 174.1 182.1 185.4 198.4 199.1 200.3 196.5 207.9 207.2 212.7 209.6 221.0 228.8 6838H798 169.9 172.9 176.6 183.0 185.9 190.9 189.0 195.2 198.2 201.5 201.8 205.2 207.7 6838H799 168.7 178.1 182.0 184.3 188.7 187.2 186.6 192.1 201.7 202.9 209.4 222.0 219.2 6838H800 185.8 195.1 201.1 206.0 210.0 212.6 213.6 223.2 219.0 218.2 222.8 227.2 227.5 (n) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 174.9 182.1 186.0 194.0 196.4 198.1 199.1 201.9 204.7 207.3 208.7 215.0 216.2 Sdevs 7.7 8.2 8.5 9.1 8.4 8.6 8.1 9.2 8.7 8.6 9.8 10.4 11.0 Note: Data for Dosing phase

Study Number FY01-013

I-37
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 13 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 459 487 512 539 567 595 623 651 679 707 F e m a l e A n i m a l s 6832E451 1 271.9 282.5 279.5 272.4 278.9 278.0 284.0 285.7 285.1 282.8 6832E452 243.5 260.9 244.0 247.5 246.6 254.7 259.5 263.5 270.3 268.4 6832E453 242.1 250.6 239.8 245.2 243.6 251.2 248.0 249.7 246.3 217.8 6832E454 262.4 265.1 262.9 276.2 266.3 271.9 6832E455 279.5 288.2 286.7 287.6 289.3 290.1 294.8 298.5 281.4 6832E456 273.8 270.3 269.9 269.7 270.9 271.0 277.1 281.5 277.2 275.7 6832E457 246.7 249.7 246.2 252.2 264.0 6832E458 236.9 257.9 243.7 248.9 254.7 252.9 251.1 254.2 259.1 256.7 6832E459 252.1 263.1 257.9 254.4 273.6 263.8 229.5 6832E460 248.4 255.0 258.0 255.4 271.0 266.8 271.7 270.3 277.5 274.8 6832E461 260.1 281.0 279.4 284.6 286.5 290.3 293.5 301.1 299.7 297.6 6832E462 288.8 290.1 288.4 283.8 291.8 288.3 293.5 304.5 307.0 306.1 6832E463 244.9 255.2 256.8 255.5 271.8 270.6 271.6 279.6 283.4 280.0 6832E464 244.7 249.8 246.0 250.9 252.4 247.7 252.0 254.5 256.2 261.1 6832E465 221.7 225.7 225.5 221.3 225.8 6832E466 247.0 257.5 257.3 252.5 252.4 265.4 266.6 265.2 232.8 6832E467 288.8 288.4 294.5 290.8 286.7 295.0 300.5 305.1 308.3 304.2 6832E468 251.9 254.1 253.8 259.5 262.0 276.5 274.5 275.9 253.1 6832E469 236.9 232.4 232.7 240.2 242.0 243.2 236.7 6832E470 273.6 279.9 279.3 235.6 6832E471 252.6 253.4 255.9 254.5 256.3 260.2 266.1 268.0 6832E472 184.2 187.0 187.2 189.3 192.7 193.6 187.7 186.7 183.8 159.4 6832E473 276.8 280.0 274.9 277.5 283.3 294.0 289.6 266.4 6832E474 248.9 250.5 243.3 251.2 262.0 258.4 216.8 6832E475 244.5 249.5 245.5 251.7 253.1 257.3 260.3 262.3 260.2 260.1 6832E476 268.7 271.5 269.9 267.0 280.0 287.3 285.1 288.6 285.8 272.2 6832E477 250.8 265.9 259.0 255.4 259.8 6832E478 238.1 241.7 239.6 242.6 251.6 251.3 256.3 265.7 262.5 267.1 6832E479 276.7 276.4 282.0 276.2 286.6 279.0 285.0 286.9 284.2 262.4 6832E480 229.9 234.6 231.6 231.1 234.4 230.0 233.3 239.9 6832E482 289.8 294.5 289.8 294.3 291.7 291.3 297.2 6832E483 262.3 264.8 256.7 259.1 263.9 267.8 264.2 273.4 274.4 276.7 6832E484 272.7 278.0 276.8 273.0 273.9 267.9 255.7 213.1 6832E485 268.5 6832E486 258.5 257.8 258.6 260.5 258.2 259.2 256.5 265.6 265.3 262.5 6832E487 263.2 262.6 274.6 264.8 271.0 6832E488 269.8 271.6 276.9 273.7 271.8 269.6 260.5 266.3 223.7 6832E489 229.8 232.2 235.2 231.7 245.2 251.1 253.2 263.0 264.0 268.8 6832E490 223.9 223.7 233.3 221.7 233.0 237.5 241.3 252.6 232.7 239.5 6832E491 253.3 256.7 253.4 257.1 242.0 246.1 240.3 228.4 6832E492 226.6 226.9 185.9 Note: Data for Dosing phase

Study Number FY01-013

I-38
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 14 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 459 487 512 539 567 595 623 651 679 707 F e m a l e A n i m a l s 6832E493 1 281.9 284.9 282.4 282.2 289.5 289.1 284.6 290.1 287.7 286.6 6832E494 270.6 277.9 274.2 271.9 265.0 269.0 267.2 6832E495 282.3 288.6 288.5 296.2 292.2 293.6 296.5 296.9 298.4 299.2 6832E496 246.4 248.3 251.9 251.3 250.9 245.0 229.7 6832E497 279.2 278.4 274.9 277.1 269.9 276.4 271.5 271.7 272.0 266.5 6832E498 238.9 236.2 242.3 242.9 245.6 248.5 252.8 253.5 261.0 261.0 6832E499 235.5 246.1 240.1 243.1 6832E500 301.0 305.9 304.3 314.0 310.5 307.7 308.5 311.5 310.6 302.9 (n) 49 48 48 47 45 41 40 34 29 25 Means 255.9 260.5 258.1 259.5 263.7 266.1 264.1 268.8 269.1 268.4 Sdevs 22.0 22.4 24.4 22.5 21.5 21.6 25.4 26.2 27.6 30.4 6834F551 2 248.6 245.4 245.5 250.9 258.5 260.4 262.2 265.7 271.6 274.5 6834F552 262.6 271.2 269.3 269.8 258.6 6834F553 248.9 258.8 255.9 258.7 260.4 259.4 266.5 275.1 275.9 279.8 6834F554 263.8 265.1 258.2 268.4 271.4 277.3 279.7 284.0 281.1 285.4 6834F555 263.1 271.0 268.8 267.2 270.4 275.7 276.3 285.0 288.5 288.5 6834F556 238.4 244.7 238.1 249.7 249.6 259.2 264.9 261.1 6834F557 245.5 250.6 252.1 259.8 255.9 259.4 260.9 263.2 258.3 264.3 6834F558 255.8 263.4 251.0 251.3 253.7 258.0 265.2 269.3 268.3 266.1 6834F559 228.5 226.4 230.4 233.8 232.9 237.1 241.3 239.4 238.2 240.0 6834F560 259.7 266.5 263.9 272.7 268.1 275.2 272.6 282.4 283.1 277.8 6834F561 253.0 262.0 254.8 258.7 256.2 266.7 270.6 275.5 270.8 279.8 6834F562 240.3 235.0 6834F563 247.4 252.0 251.5 260.3 262.6 268.6 277.3 279.1 283.7 283.3 6834F564 247.9 259.0 257.3 263.9 252.2 257.1 266.4 271.2 260.6 261.4 6834F565 315.3 323.3 310.7 321.8 296.0 301.4 294.9 6834F566 252.1 248.5 267.1 6834F567 265.6 269.1 267.4 266.2 270.1 274.5 274.3 286.7 291.0 288.4 6834F568 213.5 217.1 211.9 216.4 218.0 6834F569 275.7 282.5 276.1 289.9 284.9 292.2 296.5 306.5 309.8 308.8 6834F570 255.2 266.3 256.3 256.5 253.1 255.5 256.5 259.1 258.1 260.5 6834F571 258.6 252.8 252.9 249.6 246.9 254.4 248.2 252.9 254.7 251.3 6834F572 267.6 273.6 271.0 270.6 279.7 277.9 278.0 281.1 282.2 6834F573 239.0 235.7 247.6 248.2 249.4 251.7 256.2 263.6 267.2 264.2 6834F574 244.3 239.9 239.9 237.6 247.7 251.9 259.7 265.2 269.4 263.6 6834F575 289.1 291.9 283.7 289.2 281.7 286.3 294.6 298.9 302.0 307.0 6834F576 261.9 270.0 262.6 263.0 272.0 272.4 274.4 279.7 250.9 6834F577 274.1 272.8 281.1 282.0 281.5 286.3 287.1 295.1 301.2 248.8 6834F578 227.8 222.6 224.3 239.4 236.0 242.6 247.6 244.0 6834F579 262.1 267.1 267.9 273.9 275.5 278.2 285.5 292.4 300.2 300.4 Note: Data for Dosing phase

Study Number FY01-013

I-39
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 15 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 459 487 512 539 567 595 623 651 679 707 F e m a l e A n i m a l s 6834F580 2 255.3 270.1 259.9 269.2 265.3 270.8 281.3 287.4 289.7 296.4 6834F581 269.4 266.8 261.8 274.3 278.4 276.3 280.0 280.2 282.1 278.5 6834F582 238.4 230.2 230.3 229.2 232.0 241.4 248.2 6834F583 248.7 246.1 251.6 251.5 253.2 263.0 267.0 269.0 277.2 276.3 6834F584 263.3 265.0 263.7 266.3 275.2 276.3 277.1 267.3 271.0 270.9 6834F585 245.5 237.3 243.5 236.9 232.2 236.3 237.2 243.2 246.5 247.5 6834F586 258.8 266.7 270.2 268.7 272.5 278.6 281.5 281.1 287.0 286.9 6834F587 250.7 255.6 257.8 256.4 265.9 264.3 272.3 270.6 276.6 280.1 6834F588 261.8 258.6 256.8 252.8 262.5 258.4 257.8 262.3 266.1 258.9 6834F589 279.8 285.3 292.3 285.8 290.4 291.0 291.5 292.9 274.1 6834F591 237.6 252.2 244.3 252.2 249.1 252.3 255.1 258.5 258.7 252.8 6834F592 262.9 275.3 268.3 276.1 268.4 273.1 280.0 284.7 283.6 282.0 6834F593 260.2 267.8 254.9 266.5 257.1 265.4 276.6 275.9 275.9 271.1 6834F594 282.2 279.4 277.6 287.3 280.7 6834F595 221.5 6834F596 248.1 257.4 255.7 261.6 259.5 265.5 266.2 264.7 264.2 255.2 6834F597 264.8 269.9 266.7 275.0 271.9 274.4 271.3 280.2 279.6 280.8 6834F598 229.7 230.3 231.0 235.4 236.9 241.1 244.4 255.5 258.8 262.1 6834F599 266.6 264.3 263.7 256.5 6834F600 281.5 283.9 274.1 277.5 271.1 277.3 280.6 283.8 282.2 283.4 (n) 49 48 47 46 45 42 42 40 38 35 Means 255.8 259.7 258.3 261.9 261.5 266.3 269.7 273.3 274.7 273.6 Sdevs 18.1 19.6 17.7 18.6 16.8 15.2 14.8 15.2 15.9 16.7 6836G651 3 252.1 247.3 250.7 249.2 252.4 266.1 258.0 259.1 262.9 261.7 6836G652 265.2 263.0 260.3 260.4 266.7 267.4 274.0 276.9 277.7 274.9 6836G653 229.8 205.2 6836G654 249.8 250.1 253.0 256.1 261.4 264.0 262.8 261.8 256.3 259.8 6836G655 252.4 253.7 257.2 250.2 252.9 255.9 262.0 257.1 265.5 262.3 6836G656 246.1 251.7 245.6 249.7 247.7 260.1 258.0 273.6 273.7 276.3 6836G657 248.2 250.4 246.4 254.4 253.3 258.5 252.9 263.9 262.8 263.5 6836G658 272.1 272.4 269.9 272.6 264.3 262.7 267.1 271.3 273.3 274.8 6836G659 256.8 260.3 252.3 262.1 259.4 263.8 260.4 265.4 261.5 265.7 6836G660 257.7 261.5 263.3 273.4 282.9 290.6 301.3 315.3 323.7 331.0 6836G661 216.5 214.9 217.6 219.3 217.4 227.4 228.4 236.4 238.3 244.8 6836G662 212.7 215.8 213.1 214.5 213.8 219.5 217.7 225.2 227.5 224.3 6836G663 240.0 239.4 233.6 238.9 238.4 255.1 252.4 252.4 261.4 257.5 6836G664 218.0 221.1 222.5 220.9 6836G665 219.9 211.0 226.6 6836G666 227.5 233.4 244.2 231.0 226.3 233.6 231.4 233.4 232.4 225.2 6836G667 236.0 247.2 244.3 256.5 252.5 257.2 259.8 262.6 273.1 266.7 Note: Data for Dosing phase

Study Number FY01-013

I-40
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 16 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 459 487 512 539 567 595 623 651 679 707 F e m a l e A n i m a l s 6836G668 3 206.2 213.2 205.8 207.9 212.1 208.0 213.0 218.9 218.4 210.3 6836G669 245.7 250.1 243.2 243.7 241.7 252.0 255.1 258.2 254.6 249.9 6836G670 249.3 251.1 244.0 250.7 253.6 259.0 263.1 264.4 264.2 264.6 6836G671 233.0 234.2 228.6 227.4 6836G672 267.4 273.8 268.4 274.1 270.4 276.7 278.3 281.6 285.3 279.1 6836G673 211.3 212.9 211.3 215.0 219.4 229.2 221.5 234.5 237.1 237.6 6836G674 259.6 262.4 256.8 264.5 270.3 271.8 273.8 278.0 277.6 273.6 6836G675 240.5 245.2 238.0 243.2 241.8 254.0 257.3 264.7 263.1 259.7 6836G676 263.3 268.9 269.4 273.9 270.0 272.6 273.8 239.6 6836G677 244.2 259.9 247.6 257.6 254.3 255.6 256.1 257.9 262.2 257.9 6836G678 215.8 216.0 217.0 218.2 219.2 228.6 223.8 229.5 230.1 6836G679 255.1 258.0 251.0 257.9 252.9 246.7 253.7 228.3 6836G680 239.0 239.0 240.7 243.0 243.9 253.6 266.0 6836G681 254.7 261.2 253.6 251.7 255.9 256.2 257.6 265.2 268.5 273.2 6836G682 230.0 233.3 235.8 237.3 238.9 257.1 248.0 6836G683 230.1 234.3 231.4 234.8 230.2 232.1 232.8 238.7 243.1 6836G684 269.0 262.4 265.9 271.3 274.9 274.4 275.2 284.9 292.3 293.9 6836G685 225.2 228.5 226.7 188.2 6836G686 246.8 246.6 247.7 247.8 250.2 253.3 257.1 252.6 271.2 242.9 6836G687 268.8 268.7 265.2 269.3 266.4 267.9 263.6 268.1 222.7 6836G688 245.0 253.2 251.7 252.4 259.4 255.5 253.2 252.6 6836G689 213.8 209.8 211.0 210.3 213.0 225.7 225.9 232.1 236.1 232.3 6836G690 219.1 219.2 219.5 217.2 217.6 220.6 219.2 222.2 225.4 221.2 6836G692 240.6 243.5 243.7 246.7 236.8 247.7 248.9 249.8 248.9 250.1 6836G693 249.2 252.7 251.9 254.2 250.0 261.4 261.2 261.4 6836G694 223.2 226.7 226.4 234.3 242.3 247.9 247.3 248.9 254.1 252.2 6836G695 240.9 251.9 248.4 252.0 244.2 248.1 216.5 218.3 6836G697 220.5 227.5 226.5 230.3 227.0 230.1 231.9 236.2 243.9 248.4 6836G698 245.9 252.8 249.9 255.1 255.2 260.0 222.6 6836G700 205.2 210.7 206.9 207.8 208.0 211.7 205.5 205.9 201.5 204.4 (n) 47 47 46 45 42 42 42 39 34 31 Means 239.6 241.8 241.0 243.3 245.5 250.9 249.7 252.5 255.6 256.1 Sdevs 18.3 19.4 17.8 20.9 19.3 18.6 21.2 22.1 24.2 25.2 6838H751 4 224.4 235.3 238.3 231.7 232.4 235.6 233.1 216.2 6838H752 235.9 243.7 241.2 241.0 238.0 240.2 246.6 246.5 240.1 6838H753 241.2 243.5 242.9 241.0 239.9 243.6 235.1 242.7 238.1 207.9 6838H754 221.2 219.9 224.9 226.7 234.1 243.1 242.4 251.4 257.4 263.2 6838H755 217.9 219.5 227.9 224.0 226.5 232.1 230.0 232.9 231.3 227.5 6838H756 226.5 238.5 236.4 231.6 240.8 240.0 238.6 249.8 250.8 251.3 Note: Data for Dosing phase

Study Number FY01-013

I-41
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 17 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 459 487 512 539 567 595 623 651 679 707 F e m a l e A n i m a l s 6838H757 4 230.2 233.9 233.0 232.0 233.7 226.2 224.0 227.8 217.5 6838H758 236.8 235.2 233.9 237.1 235.5 241.7 243.9 261.1 257.8 259.3 6838H759 209.0 208.2 210.9 209.7 212.1 211.3 211.8 216.3 221.9 232.5 6838H760 223.8 225.9 225.0 222.5 222.6 224.7 226.4 232.6 239.1 233.9 6838H761 224.0 222.3 223.9 236.7 226.6 231.1 231.9 234.5 238.7 242.6 6838H762 219.2 221.9 221.2 226.8 225.6 234.2 227.5 234.5 238.7 236.6 6838H763 235.6 245.2 6838H764 216.9 223.1 214.2 6838H765 234.4 241.4 235.6 236.5 236.7 242.7 240.1 257.7 255.5 260.9 6838H766 225.6 6838H767 234.0 248.6 238.1 241.9 252.3 246.2 241.2 254.8 253.9 247.1 6838H768 205.1 198.2 202.1 202.7 204.1 212.5 214.0 225.4 229.3 234.6 6838H769 203.1 209.5 208.4 207.3 209.5 216.6 221.1 221.7 225.6 229.4 6838H770 237.0 242.4 245.6 240.9 243.8 240.8 241.4 210.7 6838H771 198.9 198.6 199.9 199.6 198.5 201.6 208.7 210.7 208.4 208.7 6838H772 225.0 233.1 237.2 240.6 241.1 252.6 246.9 251.3 239.2 226.0 6838H773 225.2 221.7 226.3 233.6 224.7 241.0 236.0 242.9 247.6 255.0 6838H774 207.5 190.2 6838H775 211.4 212.3 214.6 213.2 209.7 216.7 228.3 221.0 211.9 6838H776 235.5 240.1 238.3 248.8 236.4 249.1 246.8 255.2 258.3 251.8 6838H777 225.5 221.7 219.6 213.0 223.8 224.9 227.8 228.5 236.8 236.0 6838H778 213.7 213.2 218.2 218.3 219.2 227.6 228.0 229.5 236.4 238.1 6838H779 242.2 245.6 243.8 238.7 246.6 251.3 248.3 250.1 256.8 263.3 6838H780 218.3 227.5 215.8 217.0 219.4 219.1 222.4 226.0 228.2 230.7 6838H781 233.8 246.1 233.4 238.9 238.8 244.4 241.5 245.0 250.1 252.0 6838H782 215.3 216.6 219.6 224.2 221.1 226.7 227.2 237.6 240.6 244.6 6838H783 231.5 240.9 239.2 242.3 236.8 243.0 243.9 244.3 237.8 196.2 6838H784 213.2 219.2 215.8 219.8 219.3 226.1 223.8 227.0 228.5 232.3 6838H785 256.3 6838H786 217.6 222.3 223.9 223.1 223.1 227.0 220.9 230.9 238.8 241.9 6838H787 217.7 257.2 253.3 247.0 247.5 256.0 255.2 254.6 257.0 257.5 6838H788 231.0 229.1 229.1 226.6 222.8 228.4 233.3 240.7 242.5 243.4 6838H789 242.7 250.6 243.2 240.2 240.5 241.4 247.6 251.9 248.6 248.6 6838H790 216.1 220.3 217.7 217.8 218.6 222.5 225.1 235.3 233.7 232.7 6838H791 261.8 266.3 259.0 265.7 259.5 268.8 266.6 263.2 258.0 272.7 6838H792 229.7 231.5 222.8 223.6 229.0 232.7 232.6 231.4 235.2 232.1 6838H793 229.8 229.5 234.8 231.7 227.6 235.9 232.5 234.9 230.7 233.7 6838H794 234.7 240.4 235.0 233.8 230.4 241.8 241.0 252.7 245.5 253.2 6838H795 219.9 225.7 225.6 231.8 230.3 230.1 233.3 234.9 229.1 224.5 6838H796 237.4 229.4 226.4 226.9 228.5 228.1 229.2 234.9 231.8 234.6 6838H797 245.9 246.0 242.0 245.6 243.0 241.8 Note: Data for Dosing phase

Study Number FY01-013

I-42
 Lovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 18 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic D a y o f P h a s e Animal Group 459 487 512 539 567 595 623 651 679 707 F e m a l e A n i m a l s 6838H798 4 210.3 218.6 215.5 213.7 211.5 223.2 218.4 230.8 234.3 238.0 6838H799 228.2 233.9 225.8 229.8 224.1 230.4 224.7 220.4 215.0 218.3 6838H800 235.0 236.9 235.5 235.6 236.2 239.2 238.8 240.2 238.0 241.3 (n) 50 48 46 45 45 45 44 44 42 39 Means 226.3 229.6 228.6 229.6 229.4 234.1 233.6 237.3 238.4 239.3 Sdevs 13.0 15.5 12.7 13.2 12.7 12.8 11.7 13.6 13.0 16.1 Note: Data for Dosing phase

Study Number FY01-013

I-43
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

I-4 Females 

Summary Statistics - Body Weight Data 

I-44
 Lovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06

 Research Institute Study number: FY01013F Page: 1  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ D a y o f P h a s e  Group(s) 16! 7" 14 21 28 35 42 49 56 63 70 77 84 ----------------------------------------------------------------------------------------------------------------------------------- F e m a l e A n i m a l s  1 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 125.4 135.4 145.6 153.0 156.6 161.3 165.3 170.1 172.1 176.1 181.6 183.7 185.1  Sdevs 5.3 5.9 7.1 8.1 9.6 9.9 8.3 8.8 8.9 9.3 9.2 9.5 9.8  2 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 123.6 135.2 144.8 153.1 155.8 160.8 165.3 170.8 173.8 178.9 181.3 183.7 185.2  Sdevs 4.0 4.6 4.9 6.6 7.9 6.7 6.7 6.7 6.9 7.2 7.3 7.3 8.0  3 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 122.8% 133.8 141.9% 147.5+ 152.7 156.1% 160.9% 164.5$ 168.5 173.7 175.9+ 177.2$ 179.5%  Sdevs 6.6 7.4 8.4 8.9 9.2 9.7 10.1 10.5 10.4 10.5 10.3 10.4 11.0  4 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 121.8$ 130.1$ 136.2$ 142.3+ 148.7+ 151.7$ 154.5$ 159.5$ 162.6$ 168.1$ 169.8+ 170.9$ 172.9$  Sdevs 4.9 5.4 6.3 6.7 7.2 6.9 7.5 7.4 7.6 7.8 7.8 7.8 7.5  ----------------------------------------------------------------------------------------------------------------------------------- Note: ! = Pretest phase; " = Dosing phase  *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance  %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance 

Study Number FY01-013

I-45
 Lovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06

 Research Institute Study number: FY01013F Page: 2  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ D a y o f P h a s e  Group(s) 91 119 147 175 203 231 259 287 315 343 371 399 427 ----------------------------------------------------------------------------------------------------------------------------------- F e m a l e A n i m a l s  1 (N) 50 50 50 50 50 50 50 50 50 49 49 49 49 Means 186.5 196.2 199.9 207.1 210.5 212.2 214.2 219.0 221.5 225.8 232.6 237.4 243.2  Sdevs 10.1 9.9 10.5 10.6 10.8 10.5 10.2 10.7 12.2 12.9 15.5 17.6 19.6  2 (N) 50 50 50 50 50 50 50 50 50 50 49 49 49 Means 188.0 197.0 202.4 207.3 209.9 212.8 214.9 220.8 222.0 225.2 232.7 236.5 241.8  Sdevs 7.6 7.8 7.5 7.8 8.8 8.5 9.0 9.5 10.9 11.4 12.8 14.8 16.3  3 (N) 50 47 47 47 47 47 47 47 47 47 47 47 47 Means 180.7$ 189.4+ 193.1$ 199.4+ 204.2+ 206.9* 206.8+ 212.1+ 214.7+ 215.8$ 220.6$ 226.4$ 229.3$  Sdevs 11.4 10.6 10.9 10.9 11.3 11.0 11.0 11.5 12.0 13.0 13.8 14.0 15.1  4 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50 Means 174.9$ 182.1+ 186.0$ 194.0+ 196.4+ 198.1+ 199.1+ 201.9+ 204.7+ 207.3$ 208.7$ 215.0$ 216.2$  Sdevs 7.7 8.2 8.5 9.1 8.4 8.6 8.1 9.2 8.7 8.6 9.8 10.4 11.0  ----------------------------------------------------------------------------------------------------------------------------------- Note: Data for Dosing phase  *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance  %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance 

Study Number FY01-013

I-46
 Lovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06

 Research Institute Study number: FY01013F Page: 3  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ D a y o f P h a s e  Group(s) 459 487 512 539 567 595 623 651 679 707  ----------------------------------------------------------------------------------------------------------------------------------- F e m a l e A n i m a l s  1 (N) 49 48 48 47 45 41 40 34 29 25  Means 255.9 260.5 258.1 259.5 263.7 266.1 264.1 268.8 269.1 268.4  Sdevs 22.0 22.4 24.4 22.5 21.5 21.6 25.4 26.2 27.6 30.4  2 (N) 49 48 47 46 45 42 42 40 38 35  Means 255.8 259.7 258.3 261.9 261.5 266.3 269.7 273.3 274.7 273.6  Sdevs 18.1 19.6 17.7 18.6 16.8 15.2 14.8 15.2 15.9 16.7  3 (N) 47 47 46 45 42 42 42 39 34 31  Means 239.6$ 241.8+ 241.0$ 243.3$ 245.5$ 250.9$ 249.7$ 252.5$ 255.6% 256.1  Sdevs 18.3 19.4 17.8 20.9 19.3 18.6 21.2 22.1 24.2 25.2  4 (N) 50 48 46 45 45 45 44 44 42 39  Means 226.3$ 229.6+ 228.6$ 229.6$ 229.4$ 234.1$ 233.6$ 237.3$ 238.4$ 239.3$  Sdevs 13.0 15.5 12.7 13.2 12.7 12.8 11.7 13.6 13.0 16.1  ----------------------------------------------------------------------------------------------------------------------------------- Note: Data for Dosing phase  *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance  %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance 

Study Number FY01-013

I-47
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

J-1 

APPENDIX J 

INDIVIDUAL ANIMAL SUMMARIES OF CLINICAL OBSERVATIONS 

J-1 Males 

J-2 Females 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

J-1 Males 

J-2
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 1 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6831E401 1 Hair/skin/Jaundiced (yellow tinge to skin) 665" Hair/skin/Skin growth (small) 609"-665 6831E402 1 Hair/skin/Jaundiced (yellow tinge to skin) 567" Hair/skin/Sore (superficial wound/lesion) 546"-567 6831E403 1 Hair/skin/Jaundiced (yellow tinge to skin) 602"-609 Hair/skin/Pallor (pale/grey tinge to skin) 539", 595 6831E404 1 Hair/skin/Sore (superficial wound/lesion) 519"-644 Tissue mass/Body dorsal 455"-467, 560-630 Tissue mass/Body ventral 637"-644 6831E405 1 Appendages/injured/Left-rear-foot-injured 567"-602 Hair/skin/Jaundiced (yellow tinge to skin) 658" Hair/skin/Skin growth (small) 602"-630 Toes/Injured toes 112"-119 6831E406 1 Eyes/Left eye red discharge 406", 700-721 Hair/skin/Jaundiced (yellow tinge to skin) 721" Hair/skin/Pallor (pale/grey tinge to skin) 707"-714 Hair/skin/Skin growth (small) 630", 679 Toes/Injured toes 112", 154, 189-203 None/Dead 728" 6831E407 1 Appendages/injured/Right-front-foot-injured 259"-294 Eyes/Left eye red discharge 294", 343-385, 413-480, 495-509, 519-539 550, 580, 609, 651-658, 679-728 Hair/skin/Skin growth (small) 616"-714 Tissue mass/Body dorsal 474"-480 Toes/Injured toes 112"-119, 147-175, 189-196, 231 6831E408 1 Toes/Injured toes 112"-119, 154-161, 189-203 None/Dead 210" 6831E409 1 Hair/skin/Skin growth (small) 546"-630 Hair/skin/Sore (superficial wound/lesion) 495"-519 Movements/activity/Hypoactivity 616"-630 Tissue mass/Body dorsal 392"-420, 441, 474-480 Tissue mass/Body ventral 455"-467 Toes/Injured toes 112"-119, 189-196 Total body/Emaciated 616"-630 6831E410 1 Appendages/injured/Tail injured 474"-480 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-3
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 2 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6831E410 1 Eyes/Right eye red discharge 474"-480, 495-580, 602-637 Hair/skin/Jaundiced (yellow tinge to skin) 637" Hair/skin/Skin growth (small) 546"-637 Toes/Injured toes 455"-467 6831E411 1 Eyes/Right eye red discharge 539" Hair/skin/Jaundiced (yellow tinge to skin) 672" Hair/skin/Skin growth (small) 602"-672 Hair/skin/Sore (superficial wound/lesion) 502"-539 Tissue mass/Body dorsal 420"-467 6831E412 1 Tissue mass/Body ventral 546"-550 Toes/Injured toes 287"-301 Toes/Missing toes 406" None/Dead 560"-567 6831E413 1 Feces/urine/Urine stain 448", 509-515 Hair/skin/Pallor (pale/grey tinge to skin) 707"-714 Hair/skin/Skin growth (small) 546"-616, 630-700 Tissue mass/Genital area 525"-539 6831E414 1 Eyes/Left eye red discharge 36"-63, 84-91, 140, 182, 203-210, 238-245 406-434, 448-455, 474-480, 515-539, 580-609 Hair/skin/Pallor (pale/grey tinge to skin) 609" Hair/skin/Skin growth (small) 546"-609 None/Dead 616" 6831E415 1 Hair/skin/Skin growth (small) 546"-728 Tissue mass/Body ventral 595"-609 6831E416 1 Eyes/Right eye red discharge 315"-322 Hair/skin/Jaundiced (yellow tinge to skin) 665" Hair/skin/Pallor (pale/grey tinge to skin) 658" Hair/skin/Skin growth (small) 546"-567, 609-616, 630-665 Tissue mass/Body ventral 502"-539 6831E417 1 Appendages/injured/Left-front-foot-injured 259" Appendages/injured/Right-front-foot-injured 259" Appendages/injured/Left-rear-foot-injured 133"-140, 364 Appendages/injured/Tail injured 210"-218 Eyes/Right eye red discharge 336", 357 Hair/skin/Pallor (pale/grey tinge to skin) 728" Hair/skin/Skin growth (small) 560"-728 Toes/Injured toes 189"-218, 301-322 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-4
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 3 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6831E418 1 Hair/skin/Skin growth (small) 546"-728 Toes/Injured toes 189"-196 6831E419 1 Appendages/injured/Right-rear-foot-injured 546"-560 Eyes/Left eye red discharge 98"-480, 515-693 Hair/skin/Jaundiced (yellow tinge to skin) 679"-693 Hair/skin/Skin growth (small) 546"-693 Toes/Injured toes 308"-322 6831E420 1 Appendages/injured/Left-front-foot-injured 455" Appendages/injured/Right-front-foot-injured 455" Appendages/injured/Left-rear-foot-injured 525"-567 Feces/urine/Urine stain 112", 509 Eyes/Left eye red discharge 495" Hair/skin/Jaundiced (yellow tinge to skin) 686"-700 Hair/skin/Skin growth (small) 546"-595, 644-700 Tissue mass/Body ventral 602"-609 Toes/Injured toes 343" Toes/Missing toes 336" Total body/Emaciated 700" 6831E421 1 Hair/skin/Jaundiced (yellow tinge to skin) 574" 6831E422 1 Eyes/Right eye red discharge 259"-364, 413-467, 488-495 Hair/skin/Skin growth (small) 546"-728 Hair/skin/Sore (superficial wound/lesion) 502"-515 6831E423 1 Eyes/Left eye red discharge 406" Hair/skin/Jaundiced (yellow tinge to skin) 595" Hair/skin/Skin growth (small) 580"-595 Tissue mass/Body dorsal 455"-467 6831E424 1 Feces/urine/Urine stain 273"-357, 385-623 Eyes/Left eye red discharge 57"-78, 140-147, 218, 238-245, 301-371 385-467, 488-515, 525-616 Hair/skin/Pallor (pale/grey tinge to skin) 623" 6831E425 1 Appendages/injured/Right-rear-foot-injured 441"-467 Hair/skin/Skin growth (small) 580"-616 6831E426 1 Hair/skin/Jaundiced (yellow tinge to skin) 707" Hair/skin/Pallor (pale/grey tinge to skin) 700" Hair/skin/Skin growth (small) 574"-707 Tissue mass/Body dorsal 488" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-5
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 4 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6831E426 1 Tissue mass/Body ventral 546"-567 None/Dead 714" 6831E427 1 Appendages/injured/Left-rear-foot-injured 686"-707 Ears/nose/Red nasal discharge 154" Eyes/Right eye red discharge 495" Hair/skin/Pallor (pale/grey tinge to skin) 721"-728 Hair/skin/Skin growth (small) 574"-623, 644-658 6831E428 1 Hair/skin/Pallor (pale/grey tinge to skin) 623" Hair/skin/Skin growth (small) 574" Hair/skin/Sore (superficial wound/lesion) 525"-567 Tissue mass/Body dorsal 515" 6831E429 1 Hair/skin/Pallor (pale/grey tinge to skin) 658" Hair/skin/Skin growth (small) 550"-616, 644-658 Toes/Injured toes 189"-203 6831E430 1 Eyes/Corneal opacity left eye 189"-480, 495-651 Eyes/Micro-ophthalmia left eye 161"-182 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Skin growth (small) 580"-616 Hair/skin/Sore (superficial wound/lesion) 546"-574 6831E431 1 Total body/Emaciated 385" None/Dead 392"-399 6831E432 1 Eyes/Left eye red discharge 57"-78, 140-147, 182, 210-218, 315-329 427-480, 495 Eyes/Right eye red discharge 98" Hair/skin/Jaundiced (yellow tinge to skin) 630", 651 Hair/skin/Pallor (pale/grey tinge to skin) 616"-623, 637-644 Hair/skin/Skin growth (small) 587"-651 Toes/Injured toes 112" 6831E433 1 Feces/urine/Urine stain 350"-357 Eyes/Right eye red discharge 84", 105, 119-140, 218-231, 259-294, 308-329 378-413, 448-480, 546-567, 602-672 Hair/skin/Jaundiced (yellow tinge to skin) 658"-672 Hair/skin/Pallor (pale/grey tinge to skin) 644"-651 Hair/skin/Skin growth (small) 580"-672 Toes/Injured toes 182" 6831E434 1 Appendages/injured/Tail injured 378" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-6
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 5 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6831E434 1 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Skin growth (small) 580"-616 Toes/Injured toes 182", 210-218 Total body/Emaciated 651" 6831E435 1 Eyes/Left eye red discharge 119", 413, 546 Eyes/Right eye red discharge 78", 140, 161-175, 218, 231, 259-301, 315-329 385, 434, 448, 467-474, 488-495, 509, 532 550-587, 616-721 Hair/skin/Pallor (pale/grey tinge to skin) 728" Hair/skin/Skin growth (small) 546"-728 Tissue mass/Body ventral 679"-714 Toes/Injured toes 154"-175 6831E436 1 Appendages/missing/Tail missing (tip/portion) 371"-480, 495-728 Feces/urine/Urine stain 329"-357, 434-480, 495, 532-587 Hair/skin/Skin growth (small) 602"-616, 665-728 6831E437 1 Hair/skin/Skin growth (small) 546"-728 Tissue mass/Body ventral 672"-693 6831E438 1 Hair/skin/Jaundiced (yellow tinge to skin) 651"-679 Hair/skin/Skin growth (small) 602"-616 Tissue mass/Body dorsal 560"-679 6831E439 1 Tissue mass/Body dorsal 315"-364 6831E440 1 Eyes/Left eye red discharge 154"-175, 502-519 Eyes/Right eye red discharge 98"-105, 182-189, 308-336, 378-385, 399-420 441-480, 525-539, 609-728 Hair/skin/Skin growth (small) 550"-728 Tissue mass/Body dorsal 665"-728 6831E441 1 Eyes/Left eye red discharge 595"-623 Eyes/Right eye red discharge 495", 515-623 Hair/skin/Jaundiced (yellow tinge to skin) 623" Hair/skin/Skin growth (small) 574"-623 Hair/skin/Sore (superficial wound/lesion) 515" 6831E442 1 Hair/skin/Skin growth (small) 602"-679, 721-728 Toes/Injured toes 287"-336 6831E443 1 Eyes/Left eye red discharge 495" Eyes/Right eye red discharge 189"-196, 329-336, 385, 434-448, 515-519 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-7
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 6 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6831E443 1 Eyes/Right eye red discharge 539, 616-637, 672-693, 707 Hair/skin/Skin growth (small) 580"-728 Hair/skin/Sore (superficial wound/lesion) 532"-574 6831E444 1 Eyes/Right eye red discharge 126"-133, 218-231, 399-658 Hair/skin/Pallor (pale/grey tinge to skin) 651"-658 Hair/skin/Sore (superficial wound/lesion) 532"-539, 580-658 Tissue mass/Body ventral 301" Toes/Injured toes 287"-329 Total body/Emaciated 651"-658 6831E445 1 Eyes/Left eye red discharge 495"-502 Eyes/Corneal opacity left eye 609"-623 Hair/skin/Jaundiced (yellow tinge to skin) 623" Hair/skin/Skin growth (small) 587"-623 Tissue mass/Right-front-leg/foot 98"-133 6831E446 1 Hair/skin/Skin growth (small) 602"-728 Hair/skin/Sore (superficial wound/lesion) 679"-728 Tissue mass/Body ventral 495"-509 6831E447 1 Hair/skin/Jaundiced (yellow tinge to skin) 637" 6831E448 1 Appendages/injured/Left-rear-foot-injured 161" Eyes/Corneal opacity right eye 686"-707 Hair/skin/Skin growth (small) 602"-728 6831E449 1 Eyes/Right eye red discharge 189", 399-448, 467-679, 693-728 Hair/skin/Skin growth (small) 602"-728 6831E450 1 Appendages/injured/Left-rear-foot-injured 406" Feces/urine/Urine stain 252"-364, 385-413 Eyes/Left eye red discharge 78", 98-105 Hair/skin/Jaundiced (yellow tinge to skin) 580" Toes/Injured toes 154"-189 None/Dead 587" 6833F501 2 Hair/skin/Skin growth (small) 623"-637 6833F502 2 Appendages/injured/Tail injured 140" Eyes/Left eye red discharge 364"-686, 700-714 Hair/skin/Skin growth (small) 574"-623 Hair/skin/Sore (superficial wound/lesion) 665"-686, 721-728 Tissue mass/Body ventral 630"-658 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-8
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 7 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6833F502 2 Tissue mass/Tail 700"-714 6833F503 2 Feces/urine/Urine stain 133"-196, 301-364 Hair/skin/Jaundiced (yellow tinge to skin) 721" Hair/skin/Skin growth (small) 546"-721 6833F504 2 Appendages/injured/Left-front-foot-injured 550"-587 Eyes/Left eye red discharge 98"-126, 140-182, 245-252, 266-273, 301 343-364, 378-385, 399-406, 434-474, 488-509 525-539, 560-679 Eyes/Right eye red discharge 546" Hair/skin/Jaundiced (yellow tinge to skin) 679" Hair/skin/Pallor (pale/grey tinge to skin) 665"-672 Hair/skin/Skin growth (small) 580"-679 6833F505 2 Appendages/injured/Tail injured 343"-350 Eyes/Left eye red discharge 91", 140-161, 182, 210-218, 308-728 Hair/skin/Skin growth (small) 595"-630 Tissue mass/Tail 371"-616 6833F506 2 Feces/urine/Urine stain 630"-637 Hair/skin/Jaundiced (yellow tinge to skin) 637" Hair/skin/Skin growth (small) 574"-616 Toes/Injured toes 455"-467 6833F507 2 Hair/skin/Jaundiced (yellow tinge to skin) 651"-658 Hair/skin/Skin growth (small) 574"-658 6833F508 2 Appendages/injured/Right-rear-foot-injured 480"-488 Appendages/injured/Tail injured 495"-509, 574-686 Hair/skin/Pallor (pale/grey tinge to skin) 721" Hair/skin/Skin growth (small) 602"-700 Hair/skin/Sore (superficial wound/lesion) 495"-502 Tissue mass/Right-rear-leg/foot 509" Toes/Injured toes 467" 6833F509 2 Swelling/Swollen abdomen 574"-587 6833F510 2 Eyes/Left eye red discharge 637"-644 Eyes/Right eye red discharge 126", 154-161, 364-609, 623-644 Hair/skin/Skin growth (small) 595"-644 Tissue mass/Face 644" 6833F511 2 Ears/nose/Injured nose 63"-70 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-9
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 8 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6833F511 2 Eyes/Right eye red discharge 36"-70 Hair/skin/Skin growth (small) 595"-728 6833F512 2 Hair/skin/Jaundiced (yellow tinge to skin) 480" Tissue mass/Body ventral 392"-399 6833F513 2 Feces/urine/Urine stain 329"-343, 515-519 Hair/skin/Pallor (pale/grey tinge to skin) 728" Hair/skin/Skin growth (small) 546"-595 Tissue mass/Body ventral 602"-728 Tissue mass/Genital area 539" 6833F514 2 Eyes/Left eye red discharge 364", 399-406, 427-467, 495, 509 Hair/skin/Sore (superficial wound/lesion) 539"-574 None/Dead 580"-587 6833F515 2 Appendages/injured/Tail injured 308"-488 Feces/urine/Urine stain 112", 133-225, 238-546 Hair/skin/Jaundiced (yellow tinge to skin) 546" 6833F516 2 Feces/urine/Urine stain 112", 133-161, 182-287, 301-364, 385, 399-467 488-539, 550 Hair/skin/Skin growth (small) 623"-728 Hair/skin/Sore (superficial wound/lesion) 546"-567 6833F517 2 Feces/urine/Urine stain 112", 133-161, 182-287, 336-364, 448-467 495 Hair/skin/Pallor (pale/grey tinge to skin) 623"-630 Toes/Missing toes 406" 6833F518 2 Discolor/Body-dorsal 509"-602 Hair/skin/Dermatitis 609"-644 Hair/skin/Ulcer (open sore,skin broken) 560"-644 Tissue mass/Body ventral 644" 6833F519 2 Appendages/injured/Left-rear-foot-injured 580"-587, 714-728 Feces/urine/Urine stain 378", 495-519 6833F520 2 Hair/skin/Pallor (pale/grey tinge to skin) 721"-728 Hair/skin/Skin growth (small) 693" 6833F521 2 Eyes/Left eye red discharge 210"-225, 308-322, 343-413, 427-441, 455-495 515-532, 574-580, 609-623, 693-700, 714-728 Hair/skin/Skin growth (small) 644"-651 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-10
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 9 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6833F521 2 Toes/Injured toes 413" 6833F522 2 Eyes/Right eye red discharge 231" Hair/skin/Jaundiced (yellow tinge to skin) 679"-686 Hair/skin/Skin growth (small) 595"-616, 637-651, 665-686 Tissue mass/Body dorsal 686" None/Dead 693" 6833F523 2 Appendages/injured/Tail injured 218"-238 Appendages/missing/Tail missing (tip/portion) 245"-728 Feces/urine/Urine stain 112", 154-182 Hair/skin/Sore (superficial wound/lesion) 728" 6833F524 2 None/Dead 399" 6833F525 2 Appendages/injured/Tail injured 378"-385 Hair/skin/Skin growth (small) 580"-595 Hair/skin/Sore (superficial wound/lesion) 502"-574 Tissue mass/Tail 392"-474 6833F526 2 Feces/urine/Urine stain 133"-147, 182, 238-574, 587-595, 651-658 672-686 6833F527 2 Eyes/Left eye red discharge 364", 378, 495, 550 Hair/skin/Pallor (pale/grey tinge to skin) 574" Hair/skin/Skin growth (small) 550"-574 6833F528 2 Appendages/injured/Right-rear-leg-injured 154"-161 Hair/skin/Jaundiced (yellow tinge to skin) 474" None/Dead 480" 6833F529 2 Feces/urine/Urine stain 189"-203, 231-480 Tissue mass/Body dorsal 474"-480 None/Dead 488"-495 6833F530 2 Appendages/injured/Tail injured 455"-474 Hair/skin/Jaundiced (yellow tinge to skin) 707" Hair/skin/Skin growth (small) 580"-700 Hair/skin/Sore (superficial wound/lesion) 519"-700 None/Dead 714" 6833F531 2 Ears/nose/Injured nose 98" Feces/urine/Urine stain 140"-147, 364 Eyes/Left eye red discharge 57"-84, 105-119, 133-140, 218, 231-245 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-11
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 10 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6833F531 2 Eyes/Left eye red discharge 350-495, 539-546, 560-595 Eyes/Right eye red discharge 42"-98, 112-161, 189-693 Hair/skin/Pallor (pale/grey tinge to skin) 686"-693 Hair/skin/Skin growth (small) 602"-651 Hair/skin/Sore (superficial wound/lesion) 532"-623 6833F532 2 Total body/Emaciated 455" None/Dead 467" 6833F533 2 Hair/skin/Jaundiced (yellow tinge to skin) 587" 6833F534 2 Eyes/Left eye red discharge 57"-78, 225 Eyes/Right eye red discharge 105"-112, 609 Hair/skin/Jaundiced (yellow tinge to skin) 637" Hair/skin/Skin growth (small) 602"-637 6833F535 2 Hair/skin/Skin growth (small) 602"-728 Hair/skin/Sore (superficial wound/lesion) 532" Tissue mass/Genital area 539" Total body/Dehydrated 14" 6833F536 2 Hair/skin/Skin growth (small) 623" 6833F537 2 Hair/skin/Jaundiced (yellow tinge to skin) 630" Hair/skin/Pallor (pale/grey tinge to skin) 623" 6833F538 2 Hair/skin/Jaundiced (yellow tinge to skin) 693" Hair/skin/Pallor (pale/grey tinge to skin) 679"-686 Hair/skin/Skin growth (small) 574"-693 Hair/skin/Sore (superficial wound/lesion) 539"-693 6833F539 2 Eyes/Left eye red discharge 665"-672 Hair/skin/Skin growth (small) 550"-672 Hair/skin/Sore (superficial wound/lesion) 644"-672 Tissue mass/Body ventral 539"-546 Total body/Emaciated 672" 6833F540 2 Feces/urine/Urine stain 364", 434-441 Eyes/Left eye red discharge 126"-196, 218 Eyes/Right eye red discharge 119"-147, 231-273, 308-315, 329 Hair/skin/Jaundiced (yellow tinge to skin) 441" 6833F541 2 Normal throughout interval Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-12
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 11 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6833F542 2 Eyes/Right eye red discharge 658"-728 Hair/skin/Skin growth (small) 550"-602, 616-728 Toes/Injured toes 112" 6833F543 2 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Skin growth (small) 550"-651 Tissue mass/Body dorsal 616"-651 Tissue mass/Body ventral 644"-651 6833F544 2 Hair/skin/Jaundiced (yellow tinge to skin) 665" Hair/skin/Skin growth (small) 609"-665 6833F545 2 Feces/urine/Urine stain 189"-203, 231-322 Hair/skin/Jaundiced (yellow tinge to skin) 539" None/Dead 546"-567 6833F546 2 Hair/skin/Alopecia 630"-707 Hair/skin/Pallor (pale/grey tinge to skin) 707" Hair/skin/Skin growth (small) 616"-707 Total body/Emaciated 707" None/Dead 714" 6833F547 2 Feces/urine/Urine stain 721"-728 Eyes/Right eye red discharge 218", 231-238, 308-329, 364, 378-385, 434-637 658-728 6833F548 2 Feces/urine/Urine stain 238"-322, 343-357, 413 Eyes/Left eye red discharge 168"-175 Hair/skin/Skin growth (small) 574"-609, 623-630 Tissue mass/Body ventral 644"-686 6833F549 2 Eyes/Left eye red discharge 84"-91, 105-112, 126-133, 154-175, 189-218 273, 308-378, 413-467, 509-519, 532-539 567-637 Eyes/Right eye red discharge 392"-399 Hair/skin/Jaundiced (yellow tinge to skin) 637" Hair/skin/Skin growth (small) 602"-637 6833F550 2 Feces/urine/Urine stain 231"-357, 441-467, 502-525, 539 Eyes/Left eye red discharge 98", 196-203 Hair/skin/Skin growth (small) 623"-728 6835G601 3 Feces/urine/Urine stain 231"-357, 434-467 Eyes/Corneal opacity left eye 665"-728 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-13
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 12 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6835G601 3 Hair/skin/Skin growth (small) 644"-658 6835G602 3 Appendages/injured/Right-rear-foot-injured 480" Feces/urine/Constipation 434"-448 Eyes/Right eye red discharge 357", 413-420, 441-448, 480-488, 509-546 567-574, 595, 658-665 Hair/skin/Skin growth (small) 644"-672, 700-721 Tissue mass/Body ventral 616" 6835G603 3 Hair/skin/Skin growth (small) 616", 637-721 6835G604 3 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Skin growth (small) 574"-595, 623-651 6835G605 3 Eyes/Left eye red discharge 728" Hair/skin/Skin growth (small) 580"-728 6835G606 3 Appendages/injured/Right-rear-foot-injured 385"-427 Feces/urine/Diarrhea 488" Hair/skin/Pallor (pale/grey tinge to skin) 580"-587 Hair/skin/Skin growth (small) 574"-587 Hair/skin/Sore (superficial wound/lesion) 574"-587 6835G607 3 Appendages/injured/Right-rear-foot-injured 427" Eyes/Right eye red discharge 140", 252 Hair/skin/Skin growth (small) 574"-728 Hair/skin/Sore (superficial wound/lesion) 700"-728 Toes/Injured toes 210"-218, 329-343 6835G608 3 Hair/skin/Jaundiced (yellow tinge to skin) 686"-693 Hair/skin/Pallor (pale/grey tinge to skin) 679" Hair/skin/Skin growth (small) 580"-693 Tissue mass/Body ventral 539"-574 Toes/Injured toes 210" 6835G609 3 Eyes/Right eye red discharge 495"-714, 728 Hair/skin/Skin growth (small) 602"-728 Tissue mass/Tail 455"-480 6835G610 3 Eyes/Left eye red discharge 336", 357-519, 532-714 Eyes/Right eye red discharge 651"-700 Hair/skin/Skin growth (small) 602"-616, 644-714 Tissue mass/Body ventral 406"-434, 474-488 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-14
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 13 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6835G611 3 None/Dead 441" 6835G612 3 Eyes/Right eye red discharge 495"-630 Hair/skin/Jaundiced (yellow tinge to skin) 623"-630 Hair/skin/Sore (superficial wound/lesion) 546"-609 6835G613 3 Eyes/Right eye red discharge 532" Hair/skin/Skin growth (small) 546"-700, 721-728 Toes/Injured toes 218"-238 6835G614 3 Hair/skin/Skin growth (small) 546"-651, 665-728 6835G615 3 Eyes/Left eye red discharge 480", 519, 546-644, 665-693, 728 Hair/skin/Skin growth (small) 602"-728 Hair/skin/Sore (superficial wound/lesion) 532"-728 Tissue mass/Body dorsal 488"-728 6835G616 3 Appendages/injured/Right-rear-foot-injured 98"-105 Appendages/injured/Tail injured 474"-480 Hair/skin/Pallor (pale/grey tinge to skin) 679"-693 Hair/skin/Sore (superficial wound/lesion) 519"-665 6835G617 3 Appendages/injured/Tail injured 36"-161, 225-480, 550-637 Hair/skin/Skin growth (small) 580"-728 Hair/skin/Sore (superficial wound/lesion) 519"-595 Tissue mass/Body ventral 546"-574 Tissue mass/Tail 441"-467 6835G618 3 Hair/skin/Jaundiced (yellow tinge to skin) 623" Hair/skin/Skin growth (small) 560"-623 None/Dead 630" 6835G619 3 Feces/urine/Urine stain 133", 154-161, 182-210, 231-467, 480-488 532-630 Hair/skin/Jaundiced (yellow tinge to skin) 630" 6835G620 3 Hair/skin/Jaundiced (yellow tinge to skin) 616"-623 Hair/skin/Skin growth (small) 546"-623 None/Dead 630" 6835G621 3 Hair/skin/Skin growth (small) 602"-728 6835G622 3 Eyes/Left eye red discharge 112"-126, 140, 154-161, 218, 231-259, 294-301 350-364, 378-385, 420, 441-448, 474-480 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-15
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 14 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6835G622 3 Eyes/Left eye red discharge 539-630, 644-728 Hair/skin/Jaundiced (yellow tinge to skin) 728" Hair/skin/Skin growth (small) 574"-728 6835G623 3 Eyes/Right eye red discharge 49"-78, 112 Tissue mass/Body dorsal 502"-532 6835G624 3 Appendages/injured/Right-front-foot-injured 119" Eyes/Left eye red discharge 364", 539 Hair/skin/Jaundiced (yellow tinge to skin) 665" Hair/skin/Skin growth (small) 602"-630 6835G625 3 Feces/urine/Urine stain 329"-350, 385, 434 Eyes/Left eye red discharge 231", 259, 273, 308-315, 595-609, 637-644 Hair/skin/Pallor (pale/grey tinge to skin) 644" 6835G626 3 Hair/skin/Pallor (pale/grey tinge to skin) 672" Hair/skin/Skin growth (small) 574"-672 Tissue mass/Body ventral 539"-567 6835G627 3 Feces/urine/Urine stain 350"-364 Hair/skin/Jaundiced (yellow tinge to skin) 672"-679 Hair/skin/Skin growth (small) 644"-679 None/Dead 686"-714 6835G628 3 Feces/urine/Urine stain 560" Hair/skin/Skin growth (small) 574"-580, 700-728 6835G629 3 Hair/skin/Jaundiced (yellow tinge to skin) 637", 651 Hair/skin/Pallor (pale/grey tinge to skin) 644" Hair/skin/Abscess(puss filled mass/wound) 420" Hair/skin/Skin growth (small) 567"-651 6835G630 3 Eyes/Left eye red discharge 98"-119, 140-147, 385, 399, 420, 480 Hair/skin/Skin growth (small) 644"-651 Toes/Injured toes 336"-343 6835G631 3 Appendages/injured/Right-front-foot-injured 672"-693 Feces/urine/Urine stain 133"-161, 266-287, 308-364, 392-474, 488-623 Eyes/Right eye red discharge 210", 455-474, 488-502, 519-546, 651-658 Hair/skin/Jaundiced (yellow tinge to skin) 686"-693 Tissue mass/Body ventral 587"-693 Tissue mass/Right-front-leg/foot 392" Toes/Injured toes 385"-406 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-16
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 15 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6835G632 3 Hair/skin/Jaundiced (yellow tinge to skin) 686" Hair/skin/Pallor (pale/grey tinge to skin) 679" Hair/skin/Skin growth (small) 644"-686 Hair/skin/Sore (superficial wound/lesion) 539"-587 6835G633 3 Hair/skin/Skin growth (small) 546"-623, 637-693 Tissue mass/Body ventral 658"-693 6835G634 3 Appendages/injured/Left-rear-foot-injured 550"-580 Hair/skin/Skin growth (small) 609"-728 Hair/skin/Sore (superficial wound/lesion) 539"-595 Tissue mass/Body ventral 672"-693 6835G635 3 Eyes/Bulging left eye 609"-616 Eyes/Corneal opacity left eye 609"-616 Eyes/Missing left eye 623" Hair/skin/Skin growth (small) 616" Tissue mass/Face 623" None/Dead 630" 6835G636 3 Appendages/injured/Left-rear-foot-injured 580"-616 Feces/urine/Urine stain 133", 154-210, 231-364, 385-595 Hair/skin/Jaundiced (yellow tinge to skin) 616" Hair/skin/Sore (superficial wound/lesion) 595"-616 6835G637 3 Eyes/Right eye red discharge 225", 280-287, 308-644 Hair/skin/Pallor (pale/grey tinge to skin) 644" Hair/skin/Skin growth (small) 574"-644 Respiration/Wheezing 623"-644 Total body/Emaciated 644" 6835G638 3 Hair/skin/Skin growth (small) 539"-728 6835G639 3 Hair/skin/Skin growth (small) 550"-658, 686-728 Tissue mass/Body ventral 539"-546 6835G640 3 Hair/skin/Jaundiced (yellow tinge to skin) 574" Hair/skin/Pallor (pale/grey tinge to skin) 567" Tissue mass/Body ventral 392", 539-574 Tissue mass/Right-front-leg/foot 392" 6835G641 3 Appendages/injured/Tail injured 225"-280, 294-480 Eyes/Right eye red discharge 658" Hair/skin/Pallor (pale/grey tinge to skin) 658" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-17
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 16 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6835G641 3 Hair/skin/Skin growth (small) 644"-658 Hair/skin/Sore (superficial wound/lesion) 519"-616 6835G642 3 Appendages/injured/Left-rear-foot-injured 140"-161 Hair/skin/Jaundiced (yellow tinge to skin) 665" Hair/skin/Pallor (pale/grey tinge to skin) 658" Hair/skin/Skin growth (small) 595"-665 6835G643 3 Eyes/Right eye red discharge 161"-175, 329-336, 371, 413, 441-448, 474-495 525-574, 602 Tissue mass/Body dorsal 519"-602 None/Dead 609" 6835G644 3 Eyes/Left eye red discharge 189"-196, 385, 399, 420-434 Hair/skin/Jaundiced (yellow tinge to skin) 515" None/Dead 519"-532 6835G645 3 Appendages/injured/Tail injured 343"-392 Appendages/missing/Tail missing (tip/portion) 399"-728 Eyes/Left eye red discharge 273"-280, 308-336 Eyes/Right eye red discharge 371" Eyes/Corneal opacity right eye 378"-728 Hair/skin/Skin growth (small) 574"-728 Movements/activity/Limb paralysis 728" 6835G646 3 Appendages/injured/Right-rear-foot-injured 602"-616 Hair/skin/Jaundiced (yellow tinge to skin) 637" Hair/skin/Skin growth (small) 574"-637 6835G647 3 Hair/skin/Skin growth (small) 560"-616, 644-728 6835G648 3 Eyes/Corneal opacity left eye 595"-728 Hair/skin/Skin growth (small) 686"-728 6835G649 3 Hair/skin/Skin growth (small) 574"-616, 665-728 Hair/skin/Sore (superficial wound/lesion) 539" Tissue mass/Body ventral 707"-728 6835G650 3 Appendages/injured/Right-front-foot-injured 609"-623 Hair/skin/Skin growth (small) 602"-623 Hair/skin/Sore (superficial wound/lesion) 525"-567 Movements/activity/Hypoactivity 616"-623 Total body/Emaciated 616"-623 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-18
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 17 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H701 4 Appendages/injured/Tail ring lesions 406"-467 Feces/urine/Urine stain 308"-371, 385-574, 587-623 Eyes/Right eye red discharge 378", 623 Eyes/Micro-ophthalmia right eye 371" Hair/skin/Jaundiced (yellow tinge to skin) 686"-693 Hair/skin/Pallor (pale/grey tinge to skin) 672"-679 Hair/skin/Skin growth (small) 623"-693 6837H702 4 Appendages/injured/Tail injured 392"-448, 707-728 Hair/skin/Skin growth (small) 595"-728 Hair/skin/Sore (superficial wound/lesion) 532"-616 Tissue mass/Body dorsal 467" Tissue mass/Body ventral 474" 6837H703 4 Appendages/injured/Left-front-foot-injured 651"-658 Feces/urine/Urine stain 480" Swelling/Swollen abdomen 560"-595, 658 6837H704 4 Appendages/injured/Tail ring lesions 406"-467 Feces/urine/Urine stain 329"-350, 385, 406-480, 495-567 Hair/skin/Skin growth (small) 574"-602, 623-728 Hair/skin/Sore (superficial wound/lesion) 560"-567 Tissue mass/Body ventral 686"-728 6837H705 4 Hair/skin/Skin growth (small) 550"-728 6837H706 4 Appendages/injured/Right-rear-foot-injured 161" Feces/urine/Urine stain 112", 133, 231-287, 308-480, 495-602 Eyes/Right eye red discharge 49"-78 Hair/skin/Pallor (pale/grey tinge to skin) 714"-728 Hair/skin/Skin growth (small) 595"-602, 616, 630-728 6837H707 4 Appendages/injured/Left-front-foot-injured 161" Appendages/injured/Left-rear-foot-injured 616" Appendages/injured/Tail injured 364"-474 Eyes/Left eye red discharge 133"-161 Eyes/Right eye red discharge 119", 140, 406-420, 495 Hair/skin/Jaundiced (yellow tinge to skin) 644"-651 Hair/skin/Skin growth (small) 550"-587 Tissue mass/Body ventral 595"-651 Toes/Injured toes 336"-343 6837H708 4 Appendages/injured/Left-rear-foot-injured 161", 539-567 Appendages/injured/Tail ring lesions 406" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-19
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 18 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H708 4 Hair/skin/Jaundiced (yellow tinge to skin) 721" Hair/skin/Pallor (pale/grey tinge to skin) 728" Hair/skin/Skin growth (small) 602"-616 6837H709 4 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Sore (superficial wound/lesion) 644"-651 6837H710 4 Hair/skin/Jaundiced (yellow tinge to skin) 672" Hair/skin/Pallor (pale/grey tinge to skin) 679" Hair/skin/Sore (superficial wound/lesion) 602"-686 Respiration/Wheezing 623"-686 Toes/Injured toes 420" Total body/Emaciated 686" 6837H711 4 Appendages/injured/Left-rear-foot-injured 392"-399 Appendages/injured/Tail ring lesions 406"-474 Feces/urine/Urine stain 665"-700 Hair/skin/Jaundiced (yellow tinge to skin) 672"-700 Hair/skin/Skin growth (small) 560"-700 Toes/Injured toes 420" Total body/Emaciated 700" None/Dead 707" 6837H712 4 Appendages/injured/Left-front-foot-injured 364" Hair/skin/Jaundiced (yellow tinge to skin) 609" Hair/skin/Skin growth (small) 546"-609 None/Dead 616" 6837H713 4 Hair/skin/Jaundiced (yellow tinge to skin) 707"-714 Hair/skin/Pallor (pale/grey tinge to skin) 686"-700 Hair/skin/Skin growth (small) 546"-550, 587-714 Hair/skin/Sore (superficial wound/lesion) 519" Tissue mass/Body ventral 474"-515 6837H714 4 Tissue mass/Genital area 519"-728 6837H715 4 Appendages/injured/Tail injured 392"-467 Feces/urine/Urine stain 231" Eyes/Left eye red discharge 154"-161, 182-218 Hair/skin/Skin growth (small) 595" Total body/Emaciated 623" 6837H716 4 Appendages/injured/Tail injured 273"-413, 427-467 Eyes/Left eye red discharge 168" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-20
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 19 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H716 4 Tissue mass/Face 441"-467 Tissue mass/Tail 420" None/Dead 474" 6837H717 4 Hair/skin/Skin growth (small) 595", 609-721 6837H718 4 Eyes/Left eye red discharge 49"-78, 218, 259-315, 371, 420-434, 480 495-707 Eyes/Right eye red discharge 448", 488 Hair/skin/Skin growth (small) 546"-574, 595-721 Hair/skin/Sore (superficial wound/lesion) 595"-616 Tissue mass/Body ventral 651"-721 Tissue mass/Genital area 519"-539 6837H719 4 Hair/skin/Jaundiced (yellow tinge to skin) 515" None/Dead 519"-532 6837H720 4 Hair/skin/Jaundiced (yellow tinge to skin) 630" Hair/skin/Skin growth (small) 546"-630 Tissue mass/Genital area 539" 6837H721 4 Appendages/injured/Tail ring lesions 406"-467 Feces/urine/Urine stain 133", 182-210, 231-580 Eyes/Left eye red discharge 182"-196, 308-315, 580-595, 623-686 Eyes/Right eye red discharge 245", 336-350, 378, 488, 665-686 Hair/skin/Skin growth (small) 616", 644-686 None/Dead 693"-714 6837H722 4 Hair/skin/Jaundiced (yellow tinge to skin) 728" Hair/skin/Pallor (pale/grey tinge to skin) 721" Hair/skin/Skin growth (small) 546"-728 6837H723 4 Eyes/Left eye red discharge 49"-91, 140-161, 182-580 Hair/skin/Jaundiced (yellow tinge to skin) 580" Hair/skin/Pallor (pale/grey tinge to skin) 567"-574 None/Dead 587" 6837H724 4 Hair/skin/Skin growth (small) 587"-728 6837H725 4 Eyes/Corneal opacity right eye 550"-728 Hair/skin/Jaundiced (yellow tinge to skin) 721"-728 Hair/skin/Pallor (pale/grey tinge to skin) 707"-714 Hair/skin/Skin growth (small) 546"-728 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-21
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 20 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H726 4 Hair/skin/Skin growth (small) 609"-616, 665-686, 721-728 Toes/Injured toes 112"-119, 210 6837H727 4 Appendages/injured/Left-rear-foot-injured 587" Appendages/injured/Tail ring lesions 406"-480 Feces/urine/Urine stain 231"-371, 392-480 Eyes/Right eye red discharge 210", 225-651 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Sore (superficial wound/lesion) 539"-616 Tissue mass/Genital area 580"-587 6837H728 4 Appendages/injured/Tail ring lesions 406"-441 Eyes/Left eye red discharge 84"-98, 112, 245-280, 308-441, 455-480 509-728 Eyes/Right eye red discharge 57"-78 Hair/skin/Pallor (pale/grey tinge to skin) 693" Hair/skin/Skin growth (small) 550"-721 6837H729 4 Eyes/Right eye red discharge 509"-728 Hair/skin/Skin growth (small) 560"-728 6837H730 4 Hair/skin/Jaundiced (yellow tinge to skin) 700" Hair/skin/Skin growth (small) 560"-700 6837H731 4 Appendages/injured/Tail injured 140"-147 Feces/urine/Urine stain 336"-371, 385-420, 441-467 Eyes/Left eye red discharge 474"-651 Eyes/Right eye red discharge 539"-567, 580-651 Hair/skin/Jaundiced (yellow tinge to skin) 651" Hair/skin/Pallor (pale/grey tinge to skin) 644" Total body/Emaciated 651" 6837H732 4 Hair/skin/Skin growth (small) 546"-580 Hair/skin/Sore (superficial wound/lesion) 495"-580 Tissue mass/Genital area 539" Tissue mass/Tail 455"-474 None/Dead 587" 6837H733 4 Appendages/injured/Left-front-foot-injured 480" Appendages/injured/Right-front-foot-injured 480" Appendages/injured/Left-rear-foot-injured 480" Appendages/injured/Right-rear-foot-injured 480" Hair/skin/Jaundiced (yellow tinge to skin) 595" Hair/skin/Pallor (pale/grey tinge to skin) 580"-587 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-22
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 21 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H733 4 Toes/Injured toes 112"-119 6837H734 4 Eyes/Right eye red discharge 49"-63 Hair/skin/Jaundiced (yellow tinge to skin) 700" Hair/skin/Pallor (pale/grey tinge to skin) 679" Hair/skin/Skin growth (small) 546"-700 Hair/skin/Sore (superficial wound/lesion) 616" Tissue mass/Genital area 406"-448 6837H735 4 Hair/skin/Skin growth (small) 550"-728 Tissue mass/Body dorsal 420" 6837H736 4 Hair/skin/Skin growth (small) 546"-728 Tissue mass/Genital area 539" Total body/Dehydrated 7" 6837H737 4 Appendages/injured/Right-rear-foot-injured 616" Eyes/Right eye red discharge 105"-112, 140-147 Hair/skin/Jaundiced (yellow tinge to skin) 630"-651 Hair/skin/Pallor (pale/grey tinge to skin) 616" Hair/skin/Skin growth (small) 574"-651 Hair/skin/Sore (superficial wound/lesion) 525"-616 6837H738 4 Appendages/injured/Tail ring lesions 406"-467 Hair/skin/Jaundiced (yellow tinge to skin) 700" Hair/skin/Pallor (pale/grey tinge to skin) 665"-672, 693 Total body/Dehydrated 7" 6837H739 4 Hair/skin/Skin growth (small) 550"-616, 644-728 6837H740 4 Appendages/injured/Left-rear-foot-injured 392"-427 Feces/urine/Urine stain 231"-609 Eyes/Right eye red discharge 161", 357-364, 488-637 Hair/skin/Jaundiced (yellow tinge to skin) 637" Tissue mass/Body dorsal 532"-637 Tissue mass/Body ventral 515"-519 6837H741 4 Eyes/Right eye red discharge 448"-455, 539-567, 623-651, 686-728 Hair/skin/Skin growth (small) 721" 6837H742 4 Eyes/Right eye red discharge 49"-57 Hair/skin/Jaundiced (yellow tinge to skin) 595" Hair/skin/Pallor (pale/grey tinge to skin) 580"-587 Hair/skin/Skin growth (small) 546"-595 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-23
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 22 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H743 4 Appendages/injured/Tail injured 488"-502 Appendages/missing/Tail missing (tip/portion) 532"-714 Hair/skin/Jaundiced (yellow tinge to skin) 707"-714 Hair/skin/Skin growth (small) 560"-714 6837H744 4 Eyes/Left eye red discharge 133", 308-315, 357, 385-392, 406-467 Eyes/Right eye red discharge 49"-78, 189-210, 225-245, 259-467 Hair/skin/Jaundiced (yellow tinge to skin) 467" 6837H745 4 Appendages/injured/Tail ring lesions 406"-474 Feces/urine/Bloody feces 539" Eyes/Left eye red discharge 602" Eyes/Right eye red discharge 119"-133, 154-595, 609-665 Hair/skin/Pallor (pale/grey tinge to skin) 630", 658-665 Hair/skin/Skin growth (small) 550"-665 Hair/skin/Sore (superficial wound/lesion) 519"-616 Total body/Emaciated 665" 6837H746 4 Eyes/Left eye red discharge 364"-371, 385-420, 448, 474, 488-525, 550 567, 595-609 Hair/skin/Jaundiced (yellow tinge to skin) 637"-644 Hair/skin/Skin growth (small) 602"-609 6837H747 4 Hair/skin/Jaundiced (yellow tinge to skin) 658" Hair/skin/Pallor (pale/grey tinge to skin) 665" Hair/skin/Skin growth (small) 560"-728 Toes/Injured toes 112" 6837H748 4 Eyes/Left eye red discharge 308"-315, 371, 392-399, 434, 502-515 Eyes/Right eye red discharge 218", 392-399 Hair/skin/Pallor (pale/grey tinge to skin) 580" Hair/skin/Skin growth (small) 560"-580 Tissue mass/Body dorsal 420"-434 Tissue mass/Genital area 539" None/Dead 587" 6837H749 4 Appendages/injured/Tail injured 455"-467 Eyes/Left eye red discharge 273"-728 Eyes/Right eye red discharge 42"-63, 78-728 Hair/skin/Pallor (pale/grey tinge to skin) 672"-728 Hair/skin/Skin growth (small) 602"-728 6837H750 4 Appendages/injured/Tail ring lesions 406"-467 Hair/skin/Jaundiced (yellow tinge to skin) 679"-686 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-24
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013M Page: 23 Dates 22-May-01 to 20-May-03 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6837H750 4 Hair/skin/Skin growth (small) 546"-686 Movements/activity/Hypoactivity 686" Toes/Injured toes 105"-112, 308-322 Total body/Emaciated 686" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-25
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

J-2 Females 

J-26
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 1 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6832E451 1 Feces/urine/Urine stain 218"-364, 442-448, 502, 518-525, 573 Eyes/Left eye red discharge 63"-448, 467-728 6832E452 1 Eyes/Left eye red discharge 700"-707 Eyes/Micro-ophthalmia left eye 182"-211 Tissue mass/Body ventral 532"-543 6832E453 1 Appendages/missing/Tail missing (tip/portion) 322"-420 Feces/urine/Urine stain 105"-329, 616 Feces/urine/Red Vaginal Discharge 707" Eyes/Left eye red discharge 378", 434-448, 473, 518, 532-539 Eyes/Corneal opacity left eye 539"-707 Hair/skin/Pallor (pale/grey tinge to skin) 686", 707 6832E454 1 Appendages/injured/Tail injured 119"-154, 252-427, 467-609 6832E455 1 Feces/urine/Red Vaginal Discharge 679" 6832E456 1 Feces/urine/Urine stain 266"-315 Eyes/Left eye red discharge 35"-56, 84-112, 133-154, 336, 364, 378 400-420, 442, 502-512 Eyes/Right eye red discharge 175"-182, 218-280, 294, 392-413, 427-448 467-488, 525-532, 543, 560-567, 580-616 644-672, 693-700 6832E457 1 Eyes/Left eye red discharge 29"-42, 218-224, 238-343, 357-364, 378-420 473-532, 560, 580-588 Eyes/Right eye red discharge 42" Hair/skin/Jaundiced (yellow tinge to skin) 588" 6832E458 1 Eyes/Left eye red discharge 378"-400, 413-448, 488-512, 693 Eyes/Right eye red discharge 400", 679-686 Toes/Injured toes 147"-154 6832E459 1 Appendages/missing/Tail missing (tip/portion) 595"-623 Eyes/Right eye red discharge 336", 378-392, 467, 488, 508-518, 560-567 Tissue mass/Body ventral 609"-623 6832E460 1 Tissue mass/Genital area 679"-693 6832E461 1 Feces/urine/Urine stain 147"-154, 182-448, 467-543 Eyes/Left eye red discharge 42"-56, 77-98, 133-140, 161-203, 218-357 371-448, 467-573, 595-707, 721-728 Eyes/Corneal opacity left eye 364", 413-420 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-27
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 2 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6832E461 1 Tissue mass/Body ventral 707" 6832E462 1 Feces/urine/Urine stain 133"-161 6832E463 1 Eyes/Left eye red discharge 42", 133-154, 218-266, 294, 364-448, 543 6832E464 1 Feces/urine/Urine stain 126"-133, 147-357, 406-434 Feces/urine/Red Vaginal Discharge 392" 6832E465 1 Appendages/injured/Left-rear-foot-injured 231"-245 Appendages/injured/Right-rear-foot-injured 231"-245 Appendages/injured/Right-front-leg-injured 588" Ears/nose/Red nasal discharge 231" Feces/urine/Urine stain 133", 147-245, 336-357, 588 Eyes/Left eye red discharge 364"-420, 434 Hair/skin/Sore (superficial wound/lesion) 580"-588 Total body/Dehydrated 588" 6832E466 1 Appendages/injured/Left-front-foot-injured 406"-420 Hair/skin/Jaundiced (yellow tinge to skin) 679" None/Dead 686" 6832E467 1 Eyes/Left eye red discharge 196"-211 6832E468 1 Appendages/injured/Tail injured 371"-385 Feces/urine/Urine stain 364" Movements/activity/Limb paralysis 679" 6832E469 1 Feces/urine/Urine stain 133"-161, 322-364, 392-400 Hair/skin/Jaundiced (yellow tinge to skin) 630" Total body/Emaciated 630" 6832E470 1 Feces/urine/Urine stain 91", 119, 147-154 Eyes/Right eye red discharge 350"-357 Hair/skin/Jaundiced (yellow tinge to skin) 539" 6832E471 1 Eyes/Right eye red discharge 84"-294, 308-448, 467-672 Hair/skin/Jaundiced (yellow tinge to skin) 672" Hair/skin/Pallor (pale/grey tinge to skin) 665" 6832E472 1 Appendages/injured/Right-rear-foot-injured 91" Appendages/injured/Tail injured 371"-385 Feces/urine/Urine stain 364", 413-420, 448 Eyes/Left eye red discharge 105", 287-357, 378-448, 467-588, 616-623 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-28
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 3 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6832E472 1 Eyes/Left eye red discharge 658 Eyes/Right eye red discharge 266"-357, 378-448, 467-481, 532-543, 573-623 658 Hair/skin/Pallor (pale/grey tinge to skin) 686"-707 Toes/Injured toes 182" Total body/Emaciated 686"-728 6832E473 1 Hair/skin/Pallor (pale/grey tinge to skin) 651" 6832E474 1 Appendages/injured/Left-rear-foot-injured 91" Eyes/Left eye red discharge 488"-630 Hair/skin/Jaundiced (yellow tinge to skin) 630" Hair/skin/Pallor (pale/grey tinge to skin) 623" Toes/Injured toes 105"-112 6832E475 1 Appendages/injured/Right-front-foot-injured 91" Eyes/Left eye red discharge 211"-364, 385-448, 473-714 6832E476 1 Appendages/injured/Left-rear-foot-injured 91" Appendages/injured/Right-rear-foot-injured 91" Feces/urine/Urine stain 147"-154, 189-203, 252-301, 350-364, 406-473 532-543, 609, 714-721 Eyes/Right eye red discharge 364" Eyes/Corneal opacity right eye 460"-721 Hair/skin/Jaundiced (yellow tinge to skin) 721" 6832E477 1 Appendages/injured/Tail injured 467"-518 Eyes/Left eye red discharge 42" Toes/Injured toes 329" None/Dead 588" 6832E478 1 Feces/urine/Urine stain 91"-112, 126-448, 473-616 Eyes/Left eye red discharge 266"-448, 467-665, 728 Eyes/Corneal opacity left eye 672"-700 6832E479 1 Feces/urine/Urine stain 133", 231-245, 357-364, 442-448 Eyes(continued)/Corneal defect right eye 182"-211 6832E480 1 Eyes/Left eye red discharge 287"-294, 322-448, 467-508, 539-543, 602-630 Eyes/Right eye red discharge 161", 211-294, 322-448, 467-665 6832E481 1 Feces/urine/Urine stain 126"-133, 231-308 Feces/urine/Red Vaginal Discharge 315" Eyes/Left eye red discharge 42"-71, 98-112, 133, 161, 211-231, 252-315 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-29
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 4 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6832E481 1 None/Dead 322"-329 6832E482 1 Feces/urine/Urine stain 231"-350, 371-378, 406-448, 488 Eyes/Right eye red discharge 392"-400, 413-434, 488-502 Hair/skin/Jaundiced (yellow tinge to skin) 644" Hair/skin/Pallor (pale/grey tinge to skin) 637" 6832E483 1 Appendages/injured/Right-rear-foot-injured 231"-245 Eyes/Left eye red discharge 112"-126, 182-203, 218, 231, 609 Eyes/Right eye red discharge 112"-161, 182-203, 218-224, 336-413, 434-448 518-595, 616-623 6832E484 1 Hair/skin/Jaundiced (yellow tinge to skin) 658" Hair/skin/Pallor (pale/grey tinge to skin) 644"-651 6832E485 1 Appendages/injured/Right-rear-foot-injured 91" Eyes/Left eye red discharge 218"-273, 287-294, 308-448, 467-481 Hair/skin/Jaundiced (yellow tinge to skin) 481" Toes/Injured toes 473"-481 None/Dead 488" 6832E486 1 Appendages/injured/Left-rear-foot-injured 460"-481 Appendages/injured/Right-rear-foot-injured 560" Feces/urine/Urine stain 133"-203, 218-364, 392-481 Eyes/Right eye red discharge 343"-364, 378-488, 512-602, 630, 658-665 714 6832E487 1 Appendages/injured/Left-rear-foot-injured 460" Feces/urine/Urine stain 133"-154, 182-203, 252-357, 448-467 Hair/skin/Pallor (pale/grey tinge to skin) 580"-588 6832E488 1 Feces/urine/Urine stain 336"-357, 467 Eyes/Right eye red discharge 672"-679 Hair/skin/Pallor (pale/grey tinge to skin) 679" 6832E489 1 Appendages/injured/Right-rear-foot-injured 460"-481 Eyes/Right eye red discharge 336"-658, 672-728 6832E490 1 Feces/urine/Urine stain 98"-203, 218-294, 336-392, 420-448 Eyes/Right eye red discharge 693", 728 Hair/skin/Pallor (pale/grey tinge to skin) 728" 6832E491 1 Appendages/injured/Tail injured 371"-378 None/Dead 679" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-30
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 5 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6832E492 1 Feces/urine/Urine stain 119"-133, 168-175 Eyes/Right eye red discharge 495"-512 None/Dead 518" 6832E493 1 Hair/skin/Pallor (pale/grey tinge to skin) 728" Swelling/Swollen abdomen 543"-588 6832E494 1 Feces/urine/Urine stain 231"-245 Eyes/Left eye red discharge 616"-630 Eyes/Right eye red discharge 71", 84, 105-119, 133-154, 218-224, 252-357 371-488, 512-567, 588-595, 609-630 Eyes/Micro-ophthalmia right eye 224" Hair/skin/Ulcer (open sore,skin broken) 539"-560 Tissue mass/Body ventral 567"-630 6832E495 1 Appendages/injured/Tail injured 147"-154 Feces/urine/Urine stain 329"-357, 442-467, 539-553 Eyes/Right eye red discharge 525"-609, 630-728 6832E496 1 Eyes/Right eye red discharge 539" Hair/skin/Pallor (pale/grey tinge to skin) 630" Total body/Emaciated 630" 6832E497 1 Appendages/injured/Left-front-foot-injured 543"-560 Appendages/injured/Tail injured 371"-385 Eyes/Left eye red discharge 448", 679-686, 700-707, 728 Eyes/Right eye red discharge 147"-154, 343-448, 481 6832E498 1 Appendages/injured/Tail injured 29"-71 Toes/Injured toes 29"-71 6832E499 1 Hair/skin/Pallor (pale/grey tinge to skin) 560" Tissue mass/Body ventral 553"-560 6832E500 1 Appendages/injured/Right-rear-foot-injured 91" Feces/urine/Urine stain 105"-154, 168-203, 218-392, 442-448 Swelling/Swollen abdomen 560"-588 6834F551 2 Appendages/injured/Right-rear-foot-injured 580"-609 Ears/nose/Injured nose 385" Feces/urine/Urine stain 119"-203, 224-357, 406-420, 442-448, 525-532 543-630, 644-714 Eyes/Left eye red discharge 71", 91-119, 336-357, 427-448, 473-630 Tissue mass/Body dorsal 728" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-31
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 6 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6834F551 2 Tissue mass/Body ventral 693"-714 6834F552 2 Eyes/Left eye red discharge 573" Eyes/Right eye red discharge 406"-448, 467-532, 573 Hair/skin/Pallor (pale/grey tinge to skin) 573" None/Dead 580" 6834F553 2 Appendages/injured/Right-front-foot-injured 567"-602 Feces/urine/Urine stain 133"-140, 245-357, 442-448 Eyes/Left eye red discharge 560"-595 Toes/Injured toes 182" 6834F554 2 Ears/nose/Red nasal discharge 182" Feces/urine/Urine stain 105"-161, 224-357, 385, 406-427, 442-448 Eyes/Left eye red discharge 442"-448 Eyes/Right eye red discharge 400" Toes/Injured toes 182" 6834F555 2 Feces/urine/Urine stain 119", 133-161, 308, 413-427, 448 Eyes/Left eye red discharge 35"-56 Eyes/Right eye red discharge 42"-98, 147-161, 231-245, 336-343, 385-420 Eyes/Corneal opacity right eye 658"-728 Swelling/Swollen abdomen 567"-588 6834F556 2 Appendages/injured/Right-rear-foot-injured 406"-420 Feces/urine/Red Vaginal Discharge 651"-672 Eyes/Left eye red discharge 434"-448, 467-495, 588-616, 630, 672 Eyes/Right eye red discharge 350"-357, 392-420, 442-448, 532-539, 672 Hair/skin/Pallor (pale/grey tinge to skin) 658"-672 Toes/Injured toes 182"-203 6834F557 2 Feces/urine/Urine stain 91", 126, 322-357 Eyes/Left eye red discharge 371"-413, 473-481, 679-707 Swelling/Swollen abdomen 567"-580 Toes/Injured toes 105"-112 6834F558 2 Appendages/injured/Left-front-foot-injured 406" Appendages/injured/Right-front-foot-injured 406"-427 Feces/urine/Urine stain 126"-400, 413-448, 473-532 Eyes/Left eye red discharge 385" 6834F559 2 Appendages/injured/Right-rear-foot-injured 406"-448 Appendages/missing/Tail missing (most/entire) 315"-448, 467-728 Feces/urine/Urine stain 91", 119-357, 406-420, 442-448, 658-665 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-32
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 7 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6834F559 2 Eyes/Left eye red discharge 350"-357, 378-448, 532-543, 616, 637-651 6834F560 2 Appendages/missing/Tail missing (tip/portion) 336"-442 Feces/urine/Urine stain 119"-154, 168-364, 378-448, 467-543, 567-623 637-651, 700 Eyes/Right eye red discharge 161", 336-350, 364-400, 413-442, 467-488 512-560 6834F561 2 Eyes/Left eye red discharge 126"-203, 218-400, 460-473, 518-543, 588-595 616, 644-651 Eyes/Right eye red discharge 42"-50, 84-105, 218-315, 392-400, 413-467 707-728 6834F562 2 Feces/urine/Diarrhea 488" Feces/urine/Excessive urination 488" Feces/urine/Red urine 473" Feces/urine/Urine stain 105"-154, 182-329, 420 Eyes/Right eye red discharge 105"-154, 175-238, 329, 371, 385-400, 413-448 473-488 Hair/skin/Pallor (pale/grey tinge to skin) 488" 6834F563 2 Eyes/Left eye red discharge 460", 512, 532-543 Eyes/Right eye red discharge 322"-539, 553-728 Swelling/Swollen abdomen 573"-588 Tissue mass/Body dorsal 644"-728 6834F564 2 Feces/urine/Urine stain 322"-357, 413-420, 488-512 Eyes/Left eye red discharge 385"-448, 481, 518-616 Eyes/Right eye red discharge 460"-473, 488-512 Swelling/Swollen abdomen 567"-588 6834F565 2 Swelling/Swollen abdomen 539"-560 Tissue mass/Neck 623"-637 Tissue mass/Body ventral 567"-637 6834F566 2 Feces/urine/Red Vaginal Discharge 508" None/Dead 518"-525 6834F567 2 Feces/urine/Urine stain 161"-357, 420-427, 442-448, 616-637 Tissue mass/Body ventral 580"-707 Toes/Injured toes 105"-119 6834F568 2 Feces/urine/Urine stain 182"-203, 273-588 Eyes/Left eye red discharge 154", 231, 245-406, 427-488, 502-508, 518-543 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-33
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 8 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6834F568 2 Eyes/Right eye red discharge 196"-203, 218-231, 364-371, 400-420, 434-448 488, 502-512 Hair/skin/Jaundiced (yellow tinge to skin) 588" 6834F569 2 Eyes/Left eye red discharge 460"-473, 539-543, 721-728 Swelling/Swollen abdomen 560"-588, 686-728 6834F570 2 Feces/urine/Urine stain 294"-357, 406-448, 481-525, 560-623 Toes/Injured toes 301" 6834F571 2 Feces/urine/Urine stain 147"-154, 168-203, 231-287, 301-357, 371-448 473-567, 644-651, 665-686, 707-721 Feces/urine/Red Vaginal Discharge 294" Eyes/Left eye red discharge 196"-203, 231, 245, 273-448, 473-637, 651-672 686 Eyes/Right eye red discharge 196"-203, 322-400, 420-448, 467-637, 651-672 686-693, 707-721 Hair/skin/Jaundiced (yellow tinge to skin) 721" 6834F572 2 Eyes/Corneal opacity right eye 119"-448, 467-686 Eyes/Micro-ophthalmia right eye 371"-448 Hair/skin/Jaundiced (yellow tinge to skin) 686" Hair/skin/Pallor (pale/grey tinge to skin) 679" Swelling/Swollen abdomen 567"-588, 665-672 6834F573 2 Feces/urine/Urine stain 273"-301 Eyes/Right eye red discharge 77"-154, 196-315, 329-357, 371-448, 473-481 495-602, 623, 658-686 6834F574 2 Feces/urine/Urine stain 161"-357, 406-448, 502-512, 539-580, 721 6834F575 2 Swelling/Swollen abdomen 539"-588 6834F576 2 Appendages/injured/Tail injured 336"-448 Feces/urine/Urine stain 133", 161-357 Hair/skin/Pallor (pale/grey tinge to skin) 679" Hair/skin/Sore (superficial wound/lesion) 658"-679 Swelling/Swollen abdomen 567"-588 Tissue mass/Body dorsal 539"-651, 672-679 Toes/Injured toes 105"-112 None/Dead 686" 6834F577 2 Appendages/injured/Tail injured 371"-385 Appendages/missing/Tail missing (tip/portion) 392"-448, 467-707 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-34
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 9 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6834F577 2 Feces/urine/Diarrhea 707" Feces/urine/Urine stain 105"-112, 126-203, 294-315, 336-357 Hair/skin/Skin growth (small) 686"-707 Hair/skin/Sore (superficial wound/lesion) 495"-609, 623-651 6834F578 2 Feces/urine/Urine stain 294"-357, 400-448, 467-532, 560-588 Eyes/Left eye red discharge 406", 448, 481-495, 518, 532, 580-588 Eyes/Right eye red discharge 91"-119, 133, 147-154, 238-266, 406, 420-427 488-495, 616-623, 637-658 6834F579 2 Eyes/Left eye red discharge 182"-203, 231, 378, 420-427, 467-473, 488-532 630 6834F580 2 Hair/skin/Sore (superficial wound/lesion) 679" Swelling/Swollen abdomen 539"-543, 714-728 6834F581 2 Feces/urine/Urine stain 224"-245, 420, 442-448, 721-728 Eyes/Left eye red discharge 105"-112, 161, 182-273, 294, 357, 378-392 Hair/skin/Jaundiced (yellow tinge to skin) 728" Hair/skin/Pallor (pale/grey tinge to skin) 721" 6834F582 2 Feces/urine/Urine stain 442"-448 Eyes/Left eye red discharge 182", 442-448 Eyes/Right eye red discharge 273", 294-301, 336-357, 371-427, 467-495 525, 539, 580-602, 616 6834F583 2 Eyes/Left eye red discharge 161" 6834F584 2 Eyes/Left eye red discharge 686", 700-707 Eyes/Right eye red discharge 385", 602-637, 658-721 6834F585 2 Eyes/Left eye red discharge 84"-98, 119-133, 154-273, 378-448, 467-488 512-543 Eyes/Right eye red discharge 442" Eyes/Corneal opacity left eye 218"-448, 467-728 6834F586 2 Normal throughout interval 6834F587 2 Feces/urine/Urine stain 91"-112, 133, 168-182, 336-357, 400-448 488-580 Swelling/Swollen abdomen 560" 6834F588 2 Eyes/Left eye red discharge 84", 133, 218-245, 343-385, 400 Eyes/Right eye red discharge 442" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-35
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 10 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6834F588 2 Hair/skin/Sore (superficial wound/lesion) 721"-728 6834F589 2 Feces/urine/Red Vaginal Discharge 658", 679 Hair/skin/Pallor (pale/grey tinge to skin) 679" Swelling/Swollen abdomen 588" 6834F590 2 Feces/urine/Urine stain 119"-182, 224-315 Feces/urine/Prolapsed uterus 350" 6834F591 2 Appendages/injured/Left-front-foot-injured 91" Appendages/injured/Right-front-foot-injured 91" Feces/urine/Urine stain 119", 133-357, 442-448 Eyes/Right eye red discharge 364", 392-448, 467-488, 502-543, 602, 630 679 Toes/Injured toes 112" 6834F592 2 Feces/urine/Urine stain 133"-420, 434-448, 495-553 6834F593 2 Feces/urine/Urine stain 126", 161-308 Eyes/Left eye red discharge 126"-140, 218, 231-400, 413-448, 467-488 512, 539-553, 609-637, 658, 714 None/Dead 728" 6834F594 2 Eyes/Left eye red discharge 231", 343, 364, 385-448, 467-588 Eyes/Right eye red discharge 231"-448, 467-495, 512-580 Swelling/Swollen abdomen 539"-588 Tissue mass/Genital area 567"-588 6834F595 2 Appendages/missing/Tail missing (tip/portion) 322"-448 Feces/urine/Urine stain 301"-357, 427-448 Feces/urine/Red Vaginal Discharge 294", 392 None/Dead 488" 6834F596 2 Eyes/Left eye red discharge 105"-119, 245-448, 473-488, 543-553 Eyes/Right eye red discharge 218"-364, 400-448, 467-728 6834F597 2 Eyes/Left eye red discharge 161" Eyes/Right eye red discharge 400", 658-665, 679-693, 728 Swelling/Swollen abdomen 543" 6834F598 2 Appendages/injured/Right-rear-foot-injured 91" Feces/urine/Urine stain 420" Eyes/Left eye red discharge 512"-525, 553-560 Eyes/Right eye red discharge 336"-378, 420-448, 488-495, 525, 553, 595 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-36
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 11 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6834F598 2 Eyes/Right eye red discharge 630-637, 658-686, 707-728 6834F599 2 Feces/urine/Urine stain 126"-133, 147-154, 168-175, 224-329 Eyes/Left eye red discharge 133", 161, 364-378, 406-427, 532-560 Hair/skin/Jaundiced (yellow tinge to skin) 560" Hair/skin/Pallor (pale/grey tinge to skin) 553"-560 Swelling/Swollen abdomen 543"-560 6834F600 2 Normal throughout interval 6836G651 3 Feces/urine/Urine stain 442" Eyes/Left eye red discharge 434"-442, 502-508, 525 Eyes/Right eye red discharge 616" 6836G652 3 Appendages/injured/Tail injured 413" Feces/urine/Urine stain 105"-119, 133, 147-203, 224-357 Eyes/Left eye red discharge 532" 6836G653 3 Appendages/injured/Tail injured 413"-448 Eyes/Left eye red discharge 63", 84-448, 467-488 Eyes/Right eye red discharge 350"-448, 467-488 Respiration/Dyspnea (labored breathing) 488" 6836G654 3 Eyes/Left eye red discharge 329" Eyes/Right eye red discharge 218"-448, 467-728 6836G655 3 Feces/urine/Urine stain 140", 161-203, 350-357, 406-448, 512 Eyes/Left eye red discharge 119"-154, 182-203, 218-406, 420-448, 467-707 728 Eyes/Micro-ophthalmia left eye 105" 6836G656 3 Eyes/Right eye red discharge 196"-218, 385-392, 413, 427-448, 467, 532-560 616-623 6836G657 3 Appendages/injured/Right-front-foot-injured 467" Eyes/Left eye red discharge 133"-140, 385, 488-512, 532-560, 658, 693-700 714-728 Eyes/Right eye red discharge 371"-448, 473-728 6836G658 3 Feces/urine/Urine stain 105", 147-154, 168-175, 189-357, 442 6836G659 3 Appendages/injured/Tail injured 175"-231 Feces/urine/Urine stain 182"-245, 329-357, 442-448 Eyes/Left eye red discharge 672" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-37
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 12 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6836G659 3 Hair/skin/Jaundiced (yellow tinge to skin) 728" Hair/skin/Pallor (pale/grey tinge to skin) 721" 6836G660 3 Eyes/Left eye red discharge 532"-573, 609 Eyes/Right eye red discharge 133"-140, 196-203, 413-420, 467, 539-543 616-637 Swelling/Swollen abdomen 567"-588, 665-728 6836G661 3 Appendages/injured/Right-rear-foot-injured 364"-371 Eyes/Right eye red discharge 460" Eyes/Micro-ophthalmia right eye 231" 6836G662 3 Feces/urine/Urine stain 147"-161, 182-357, 413-420, 460, 543-560 Eyes/Right eye red discharge 460", 473-553, 595, 609-672, 700 6836G663 3 Eyes/Left eye red discharge 273"-413, 442-448, 488-623, 644-658, 672-679 728 Eyes/Right eye red discharge 473"-481 Hair/skin/Sore (superficial wound/lesion) 525"-623 6836G664 3 Feces/urine/Urine stain 133", 147-357, 427-448, 473-560 Feces/urine/Red Vaginal Discharge 385"-406 Eyes/Left eye red discharge 133", 413-420, 434-442 Eyes/Right eye red discharge 322"-336, 413-448, 473-543 6836G665 3 Appendages/injured/Right-front-foot-injured 91" Eyes/Left eye red discharge 502"-512 Eyes/Right eye red discharge 413"-420 Hair/skin/Sore (superficial wound/lesion) 512" Toes/Injured toes 98" None/Dead 518"-525 6836G666 3 Eyes/Left eye red discharge 329"-357, 481-525, 573-728 Eyes/Right eye red discharge 609" Hair/skin/Skin growth (small) 467"-508, 532-609 Tissue mass/Face 343"-448 6836G667 3 Feces/urine/Urine stain 161" Eyes/Left eye red discharge 488"-512, 543, 567-580 6836G668 3 Normal throughout interval 6836G669 3 Appendages/injured/Left-rear-foot-injured 406"-442 Feces/urine/Cloudy urine 105"-112 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-38
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 13 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6836G669 3 Feces/urine/Urine stain 133", 147-154, 609 Eyes/Left eye red discharge 35"-71, 133, 385-481, 525-532, 658-665 Eyes/Right eye red discharge 686" 6836G670 3 Eyes/Left eye red discharge 406"-420 Eyes/Right eye red discharge 42"-71, 294-392, 427-467, 488, 525-588 644-665, 714-721 6836G671 3 Eyes/Left eye red discharge 406" Eyes/Right eye red discharge 280"-287, 301-315, 385-420, 442-488, 512-518 539 None/Dead 553"-560 6836G672 3 Eyes/Right eye red discharge 224"-245, 273-442, 473-560, 595-602, 616-728 Tissue mass/Body ventral 721"-728 6836G673 3 Feces/urine/Urine stain 280" Eyes/Left eye red discharge 280" Eyes/Right eye red discharge 280" Total body/Dehydrated 280" 6836G674 3 Appendages/injured/Left-front-foot-injured 91" Eyes/Left eye red discharge 105", 400-481, 525-543, 616-623 Eyes/Right eye red discharge 280"-357, 371-488, 512-553, 567-595, 616-623 651, 672-686, 707-714 6836G675 3 Feces/urine/Urine stain 413"-420, 442-460 Eyes/Left eye red discharge 84"-105, 119-364, 385-518, 532-602, 616-630 658 Eyes/Right eye red discharge 133"-140, 218-287, 308-400, 442-460, 567-580 Eyes/Corneal opacity left eye 721"-728 6836G676 3 Appendages/injured/Left-rear-foot-injured 448"-460 Appendages/injured/Right-rear-foot-injured 595"-609 Feces/urine/Urine stain 91"-98, 161-273, 287-357, 371-460, 488-495 512-580 Feces/urine/Red Vaginal Discharge 448"-460 Eyes/Left eye red discharge 400" Eyes/Right eye red discharge 231"-245, 413-427, 616-623 Hair/skin/Pallor (pale/grey tinge to skin) 651" Hair/skin/Sore (superficial wound/lesion) 525"-623 Oral cavity/dental/tissue mass 133"-140 Oral cavity/dental/Sore 147"-154 6836G677 3 Normal throughout interval Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-39
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 14 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6836G678 3 Eyes/Left eye red discharge 105"-112, 413-420, 434, 448-481, 518-532 553-580, 616-637 Eyes/Right eye red discharge 105"-112, 343-532, 553-623 Tissue mass/Genital area 532"-693 None/Dead 700" 6836G679 3 Eyes/Right eye red discharge 273"-357, 406-420, 488, 539-560, 573-580 630-644 Hair/skin/Pallor (pale/grey tinge to skin) 651" Hair/skin/Skin growth (small) 637"-651 6836G680 3 Eyes/Left eye red discharge 413"-442, 580-588 Eyes/Right eye red discharge 442" Hair/skin/Jaundiced (yellow tinge to skin) 644" Hair/skin/Pallor (pale/grey tinge to skin) 637" 6836G681 3 Normal throughout interval 6836G682 3 Eyes/Left eye red discharge 385"-392 Hair/skin/Jaundiced (yellow tinge to skin) 644" 6836G683 3 Feces/urine/Urine stain 560" Eyes/Right eye red discharge 442" 6836G684 3 Feces/urine/Urine stain 518" Eyes/Right eye red discharge 322"-357, 385-473 6836G685 3 Hair/skin/Jaundiced (yellow tinge to skin) 539" 6836G686 3 Eyes/Right eye red discharge 133", 196-203, 231-728 Hair/skin/Pallor (pale/grey tinge to skin) 728" 6836G687 3 Feces/urine/Urine stain 91"-98, 119, 133-203, 224-357, 400-448 488-495, 539-560 Hair/skin/Jaundiced (yellow tinge to skin) 679" Tissue mass/Body ventral 672"-679 6836G688 3 Appendages/injured/Right-front-foot-injured 665" Ears/nose/Red nasal discharge 658" Hair/skin/Pallor (pale/grey tinge to skin) 658" 6836G689 3 Feces/urine/Urine stain 133", 336-357, 413-460, 525-560, 573-580 665 Eyes/Right eye red discharge 336"-343, 357, 371-728 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-40
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 15 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6836G689 3 Hair/skin/Skin growth (small) 539"-580 Hair/skin/Sore (superficial wound/lesion) 512"-532, 595-728 6836G690 3 Eyes/Left eye red discharge 133", 154, 273-280, 413-442, 467-481, 495-512 539-693, 707-728 Hair/skin/Sore (superficial wound/lesion) 512" Toes/Injured toes 147"-154 6836G691 3 Ears/nose/Injured nose 91" Eyes/Left eye red discharge 91" Respiration/Dyspnea (labored breathing) 91" 6836G692 3 Normal throughout interval 6836G693 3 Eyes/Left eye red discharge 308"-473, 488, 512-525, 539-580, 595-637 Eyes/Right eye red discharge 196"-218, 616-623 None/Dead 658" 6836G694 3 Feces/urine/Urine stain 350"-357, 488, 560 Eyes/Left eye red discharge 161", 287-315, 371-609 Eyes/Right eye red discharge 357", 385-460, 488-532 6836G695 3 Eyes/Left eye red discharge 630"-658 Eyes/Right eye red discharge 616"-658 Hair/skin/Pallor (pale/grey tinge to skin) 630"-658 6836G696 3 Ears/nose/Injured nose 91" Eyes/Left eye red discharge 91" Respiration/Dyspnea (labored breathing) 91" 6836G697 3 Eyes/Left eye red discharge 161", 189-728 Eyes/Right eye red discharge 287", 385-420, 434-442, 467-488, 512-595 Hair/skin/Skin growth (small) 665"-728 Tissue mass/Body dorsal 700"-728 6836G698 3 Feces/urine/Urine stain 105"-112, 126-154, 168-357, 413-460, 488-623 Eyes/Left eye red discharge 392"-420, 442, 467-508, 525-560, 573-580 602-623 Eyes/Right eye red discharge 385"-488, 518-588, 602-623 Hair/skin/Jaundiced (yellow tinge to skin) 623" Hair/skin/Alopecia 119" 6836G699 3 Eyes/Left eye red discharge 50"-56 Eyes/Corneal opacity left eye 91"-112 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-41
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 16 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6836G699 3 Oral cavity/dental/Malocclusion/overgrown teeth 112" Oral cavity/dental/Broken teeth 56" Total body/Skinny 50"-56 6836G700 3 Feces/urine/Urine stain 400" Eyes/Left eye red discharge 602" Hair/skin/Pallor (pale/grey tinge to skin) 119" 6838H751 4 Appendages/injured/Tail injured 448"-658 Eyes/Left eye red discharge 71", 105, 119, 231-238, 336-658 Eyes/Right eye red discharge 71", 231-539, 560-567, 588-602, 616-623 637-658 Hair/skin/Pallor (pale/grey tinge to skin) 651"-658 Total body/Emaciated 651"-658 6838H752 4 Eyes/Left eye red discharge 273", 287-329, 364, 400, 442-448 Eyes/Right eye red discharge 364", 385-392, 413-448, 495-508 Hair/skin/Jaundiced (yellow tinge to skin) 679"-686 Hair/skin/Skin growth (small) 508"-512 6838H753 4 Appendages/injured/Right-rear-foot-injured 448"-460 Feces/urine/Urine stain 714"-721 Feces/urine/Red Vaginal Discharge 707" Eyes/Left eye red discharge 252"-266, 371-495 Eyes/Right eye red discharge 119", 133-154, 252-266, 392-427, 460 None/Dead 728" 6838H754 4 Appendages/injured/Left-rear-foot-injured 448"-460 Appendages/injured/Tail injured 400"-442 Appendages/injured/Tail ring lesions 442"-467 Appendages/missing/Tail missing (tip/portion) 502"-728 Feces/urine/Urine stain 133", 168-203, 218-364, 413-721 Eyes/Left eye red discharge 133", 322-357, 378-392, 406-420, 442-467 630-644 6838H755 4 Eyes/Left eye red discharge 378"-400, 442, 539-686, 700-728 Eyes/Right eye red discharge 357", 371, 406-434, 448-518, 539-580, 616-630 651-665 6838H756 4 Appendages/missing/Tail missing (tip/portion) 378"-728 Eyes/Left eye red discharge 231"-273, 308-357, 385-400, 420-481, 588-602 6838H757 4 Eyes/Left eye red discharge 196"-211, 252-273, 350-400, 427, 460-467 539, 560-567, 616, 644-658 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-42
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 17 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6838H757 4 Eyes/Right eye red discharge 392", 406, 434-442, 467, 512-573, 616 644-658, 672-700 Hair/skin/Jaundiced (yellow tinge to skin) 693"-700 Hair/skin/Pallor (pale/grey tinge to skin) 679"-686 Toes/Injured toes 329" Toes/Missing toes 336"-427 None/Dead 707" 6838H758 4 Eyes/Left eye red discharge 427", 637-693 Hair/skin/Sore (superficial wound/lesion) 707" 6838H759 4 Appendages/injured/Left-rear-foot-injured 91" Eyes/Left eye red discharge 707"-728 Eyes/Right eye red discharge 133", 252-273, 400, 442-460, 543-553, 630-665 686-693 Toes/Injured toes 329"-350 6838H760 4 Eyes/Left eye red discharge 161", 273, 467-693, 714-728 Eyes/Right eye red discharge 273" 6838H761 4 Appendages/injured/Tail injured 658"-707 Eyes/Left eye red discharge 442" Eyes/Right eye red discharge 161", 442 6838H762 4 Feces/urine/Urine stain 287"-364, 420-460, 473-508, 518-532, 580 Eyes/Left eye red discharge 385"-543, 580, 630-637, 665-728 6838H763 4 Feces/urine/Urine stain 126"-133, 336-357 Feces/urine/Red Vaginal Discharge 473" Eyes/Right eye red discharge 287"-294 6838H764 4 Feces/urine/Urine stain 322"-357, 525 Eyes/Left eye red discharge 442"-525 Hair/skin/Jaundiced (yellow tinge to skin) 525" 6838H765 4 Eyes/Right eye red discharge 543"-553, 602-693, 707-721 6838H766 4 Hair/skin/Jaundiced (yellow tinge to skin) 473" 6838H767 4 Feces/urine/Urine stain 672" Eyes/Left eye red discharge 385" Eyes/Right eye red discharge 543"-700 Eyes/Corneal opacity right eye 63"-728 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-43
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 18 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6838H768 4 Eyes/Right eye red discharge 442" 6838H769 4 Feces/urine/Urine stain 147"-588, 609, 651 6838H770 4 Appendages/injured/Left-rear-foot-injured 460" Appendages/injured/Right-rear-foot-injured 460" Eyes/Right eye red discharge 71", 133-154, 385-460 Hair/skin/Jaundiced (yellow tinge to skin) 658" Hair/skin/Pallor (pale/grey tinge to skin) 651" 6838H771 4 Eyes/Left eye red discharge 434" 6838H772 4 Appendages/injured/Left-rear-foot-injured 91" Feces/urine/Urine stain 126"-154, 168-175, 189-203, 224-364, 392-488 567, 707-728 Eyes/Right eye red discharge 512"-672 Hair/skin/Jaundiced (yellow tinge to skin) 700"-728 Tissue mass/Body ventral 679"-714 6838H773 4 Appendages/injured/Tail injured 218"-224 Eyes/Left eye red discharge 385"-400 Tissue mass/Body ventral 658"-686 Tissue mass/Genital area 693"-728 6838H774 4 Eyes/Left eye red discharge 273", 481-488 Hair/skin/Alopecia 467"-488 6838H775 4 Eyes/Left eye red discharge 133", 224, 336-357, 385-413, 442-467, 488-644 Eyes/Right eye red discharge 686" Hair/skin/Jaundiced (yellow tinge to skin) 686" 6838H776 4 Appendages/injured/Right-front-foot-injured 231"-245 Appendages/injured/Left-rear-foot-injured 161" Eyes/Left eye red discharge 413" Eyes/Right eye red discharge 406"-460, 473-637, 658-728 Toes/Injured toes 168"-175 6838H777 4 Appendages/injured/Left-front-foot-injured 140"-154 Eyes/Left eye red discharge 161", 378-473 Eyes/Right eye red discharge 406", 518 Eyes/Corneal opacity left eye 211"-728 Toes/Injured toes 112"-119 6838H778 4 Eyes/Left eye red discharge 488"-495 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-44
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 19 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6838H778 4 Eyes/Right eye red discharge 420"-442 Hair/skin/Pallor (pale/grey tinge to skin) 728" Hair/skin/Sore (superficial wound/lesion) 525" 6838H779 4 Feces/urine/Urine stain 133", 147-154, 168-560, 580-588 Eyes/Left eye red discharge 364"-525 6838H780 4 Feces/urine/Urine stain 658"-665 Eyes/Left eye red discharge 385"-488, 588-630, 665, 686 Eyes/Right eye red discharge 488", 553-560 6838H781 4 Eyes/Left eye red discharge 567"-580 6838H782 4 Feces/urine/Urine stain 168"-203, 252-364, 392-473, 488, 502-560 588, 609-630 Eyes/Left eye red discharge 161", 543-553, 728 Tissue mass/Body ventral 714"-728 6838H783 4 Feces/urine/Urine stain 273"-473, 488-623, 637-686 Eyes/Left eye red discharge 336"-343, 400, 420-427, 488, 518-573, 630 651-672, 686-707 Eyes/Right eye red discharge 336"-343, 406, 467-473, 488, 567, 637 Hair/skin/Jaundiced (yellow tinge to skin) 700" Hair/skin/Pallor (pale/grey tinge to skin) 707" 6838H784 4 Feces/urine/Urine stain 322"-336 Eyes/Left eye red discharge 442", 481 Eyes/Right eye red discharge 161" Toes/Injured toes 105"-112 6838H785 4 Eyes/Left eye red discharge 218"-473 Eyes/Right eye red discharge 231", 252-336, 350-357, 371-392, 413-473 Hair/skin/Jaundiced (yellow tinge to skin) 473" 6838H786 4 Feces/urine/Red urine 488"-495, 588 Feces/urine/Urine stain 119", 133, 147-364, 400-481, 502-609 Feces/urine/Red Vaginal Discharge 602" Eyes/Left eye red discharge 413", 473-543, 560 6838H787 4 Feces/urine/Urine stain 273"-350, 442, 532 Eyes/Left eye red discharge 442"-460 Eyes/Right eye red discharge 442" 6838H788 4 Feces/urine/Urine stain 357" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-45
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 20 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6838H788 4 Eyes/Left eye red discharge 196"-211, 252-273, 350, 467-495, 518-658 672-728 Eyes/Right eye red discharge 539"-609 6838H789 4 Appendages/injured/Tail injured 467"-488 Feces/urine/Urine stain 231"-266 Eyes/Left eye red discharge 133", 350-357, 371-488, 532, 560, 580-609 644-679 Eyes/Right eye red discharge 350"-357, 413-420, 658-728 6838H790 4 Appendages/injured/Left-rear-foot-injured 238"-266 Feces/urine/Urine stain 147"-357, 371-560, 623 Eyes/Right eye red discharge 413"-420, 467-560, 580-602, 630-637, 658 6838H791 4 Appendages/injured/Tail injured 29"-119, 147-154, 218-224, 336-481 Appendages/injured/Tail ring lesions 442"-460 Eyes/Right eye red discharge 400" Toes/Injured toes 413"-427 6838H792 4 Eyes/Right eye red discharge 385"-392 Hair/skin/Jaundiced (yellow tinge to skin) 714"-728 Toes/Injured toes 98" 6838H793 4 Appendages/injured/Tail injured 371"-442 Feces/urine/Urine stain 442", 567 Eyes/Left eye red discharge 161", 385-442, 467 6838H794 4 Feces/urine/Urine stain 679"-686 Eyes/Left eye red discharge 392", 406, 420-442 Eyes/Right eye red discharge 84", 518, 573-616 Eyes/Left eye closed 385" Hair/skin/Alopecia 105"-112 6838H795 4 Appendages/injured/Left-rear-foot-injured 400" Feces/urine/Urine stain 126", 147-154, 224-329, 350-357, 442-460 693-700 Eyes/Left eye red discharge 161", 442 Eyes/Right eye red discharge 616" 6838H796 4 Appendages/injured/Tail injured 481"-495 Feces/urine/Urine stain 119"-126, 147-161, 224-357, 427-495, 518-637 658, 679-714 Feces/urine/Red Vaginal Discharge 448" Eyes/Right eye red discharge 140", 329, 364, 392-481, 495, 518-637 Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-46
 Lovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04

 Research Institute Study number: FY01013F Page: 21 Dates 29-May-01 to 27-May-03 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group Observation Days observed 6838H796 4 Eyes/Right eye red discharge 658-728 6838H797 4 Eyes/Left eye red discharge 273", 336-350, 406, 567-573 Eyes/Right eye red discharge 42"-112, 140, 273-280, 385-560, 573-602 6838H798 4 Appendages/injured/Tail injured 413"-460 Feces/urine/Urine stain 91"-728 Eyes/Right eye red discharge 385"-392, 413-434, 573-630 Eyes/Corneal opacity left eye 413"-728 Hair/skin/Skin growth (small) 686"-728 Tissue mass/Genital area 721"-728 6838H799 4 Ears/nose/Injured nose 147"-154, 385-392 6838H800 4 Eyes/Left eye red discharge 686" Note: ! = Pretest phase; " = Dosing phase

Study Number FY01-013

J-47
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

K-1 

APPENDIX K 

BODY AND ORGAN WEIGHTS AT NECROPSY 

K-1 Absolute Organ Weights, Male and Female, Final Sacrifice 

K-2 Percent Organ to Body Weight, Male and Female, Final Sacrifice 

K-3 Percent Organ to Brain Weight, Male and Female, Final Sacrifice 

K-4 Absolute Organ Weights, Male and Female, Euthanized Rats 

K-5 Percent Organ to Body Weight, Male and Female, Euthanized Rats 

K-6 Percent Organ to Brain Weight, Male and Female, Euthanized Rats 

K-7 Organ Weights for Animals that Died 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-1 Absolute Organ Weights, Male and Female, Final Sacrifice 

K-2
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs M a l e A n i m a l s 6831E407/M 1/1 403.2 0.077 2.185 0.765 1.389 3.157 15.081 1.863 6831E413/M 1/1 379.5 0.078 2.123 0.284 1.165 2.588 14.429 1.827 6831E415/M 1/1 395.5 0.064 2.085 0.518 1.102 2.941 22.487 2.220 6831E418/M 1/1 398.8 0.075 2.168 0.628 1.268 3.057 14.154 1.863 6831E422/M 1/1 384.3 0.054 2.075 0.731 1.122 2.873 13.236 1.722 6831E435/M 1/1 355.1 0.077 2.039 0.777 1.291 3.273 16.985 1.735 6831E436/M 1/1 393.1 0.069 2.054 0.342 1.153 2.916 15.136 1.639 6831E437/M 1/1 398.3 0.075 2.130 0.978 1.223 2.718 12.255 1.735 6831E440/M 1/1 396.8 0.440 2.107 0.376 1.231 2.870 14.131 1.809 6831E442/M 1/1 383.6 0.096 2.089 0.494 1.082 3.339 30.447 2.505 6831E443/M 1/1 404.7 0.069 2.080 0.457 1.162 2.796 13.070 1.668 6831E446/M 1/1 352.3 0.059 2.038 0.472 1.234 2.681 15.988 2.446 6831E448/M 1/1 396.0 0.060 2.042 0.495 1.020 2.638 12.794 1.771 6831E449/M 1/1 418.7 0.080 2.180 0.370 1.321 2.836 14.940 2.040 M e a n: 390.0 0.098 2.100 0.549 1.197 2.906 16.081 1.917 Standard deviation: 18.2 0.099 0.051 0.200 0.101 0.230 4.838 0.281 Number of observ. : (14) (14) (14) (14) (14) (14) (14) (14) 6833F502/M 2/1 384.3 0.084 2.125 0.359 1.345 2.804 13.466 1.808 6833F505/M 2/1 400.1 0.060 1.999 0.391 1.227 2.953 15.398 1.922 6833F508/M 2/1 387.3 0.071 2.070 0.620 1.257 2.929 13.579 2.162 6833F511/M 2/1 411.5 0.068 2.142 0.396 1.324 2.909 14.293 2.005 6833F513/M 2/1 280.5 0.072 2.021 0.350 1.034 2.558 11.897 2.992 6833F516/M 2/1 377.9 0.073 2.049 0.425 1.083 2.595 17.607 2.553 6833F519/M 2/1 416.2 0.066 2.094 0.435 1.362 3.182 13.189 1.969 6833F521/M 2/1 335.6 0.082 2.052 0.385 1.254 2.633 19.093 3.870 6833F523/M 2/1 408.3 0.052 2.069 0.477 1.087 2.757 12.645 2.182 6833F525/M 2/1 393.6 1.742 2.097 0.369 1.199 3.369 17.624 2.495 6833F526/M 2/1 362.5 0.086 2.041 0.519 1.141 3.960 17.942 2.503 6833F535/M 2/1 409.1 0.071 2.069 0.383 1.197 3.133 13.062 2.270 6833F536/M 2/1 340.7 0.071 2.090 0.561 1.141 2.635 11.522 1.650 6833F542/M 2/1 365.4 0.067 2.028 0.478 1.151 2.682 12.958 1.813 6833F547/M 2/1 366.3 0.069 1.993 0.483 1.242 2.892 13.078 1.741 6833F550/M 2/1 368.4 0.066 2.059 0.337 1.084 4.855 18.891 1.853 M e a n: 375.5 0.175 2.062 0.436 1.196 3.053 14.765 2.237 Standard deviation: 35.2 0.418 0.042 0.081 0.099 0.598 2.589 0.566 Number of observ. : (16) (16) (16) (16) (16) (16) (16) (16) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-3
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6835G601/M 3/1 382.8 0.050 2.077 0.397 0.992 2.717 12.481 1.859 6835G602/M 3/1 368.3 0.112 2.100 0.353 1.200 3.096 14.508 2.100 6835G603/M 3/1 375.0 0.062 2.028 0.331 1.051 2.857 13.108 1.878 6835G605/M 3/1 354.7 0.096 2.026 0.362 1.225 3.018 14.370 2.858 6835G607/M 3/1 372.0 0.068 2.059 0.377 1.136 3.061 14.932 1.689 6835G609/M 3/1 394.9 0.071 2.173 0.399 1.253 3.072 14.141 1.959 6835G610/M 3/1 368.2 0.064 2.137 0.325 1.123 2.714 12.084 2.010 6835G613/M 3/1 374.6 0.063 2.070 0.365 1.187 2.648 12.740 1.909 6835G614/M 3/1 389.1 0.072 2.090 0.591 1.456 3.088 14.386 1.974 6835G615/M 3/1 349.7 0.073 2.090 0.392 1.116 3.219 16.784 3.213 6835G617/M 3/1 359.5 0.088 1.989 0.407 1.148 3.122 13.169 1.705 6835G621/M 3/1 350.0 0.094 2.053 0.389 1.053 2.609 13.974 1.739 6835G628/M 3/1 378.2 0.067 2.043 0.412 1.302 2.799 13.500 1.965 6835G630/M 3/1 366.6 0.077 2.074 0.301 1.095 2.824 13.706 2.013 6835G634/M 3/1 396.2 0.069 2.124 0.543 1.323 3.401 16.109 2.022 6835G638/M 3/1 392.6 0.068 2.135 0.498 1.535 3.154 16.469 2.495 6835G639/M 3/1 383.2 0.080 2.015 0.404 1.290 2.880 14.085 2.629 6835G647/M 3/1 401.1 0.070 2.099 0.474 1.209 2.818 15.258 1.847 6835G648/M 3/1 268.6 0.076 2.001 0.574 1.006 3.395 13.383 2.427 6835G649/M 3/1 349.5 0.072 2.066 0.421 1.132 2.707 14.052 1.773 M e a n: 368.7 0.075 2.072 0.416% 1.192 2.960 14.162 2.103 Standard deviation: 28.5 0.014 0.048 0.081 0.140 0.236 1.268 0.411 Number of observ. : (20) (20) (20) (20) (20) (20) (20) (20) 6837H702/M 4/1 382.2 0.073 2.102 0.428 1.160 3.075 14.279 1.976 6837H704/M 4/1 397.1 0.073 2.076 0.541 1.206 2.818 14.026 1.704 6837H705/M 4/1 399.2 0.067 2.167 0.453 1.223 3.699 18.642 3.669 6837H706/M 4/1 356.7 0.070 2.117 0.571 1.217 3.199 14.762 1.936 6837H708/M 4/1 346.6 0.064 1.966 0.312 1.054 3.024 22.278 2.364 6837H714/M 4/1 335.0 0.067 2.032 0.452 0.974 2.967 14.172 1.667 6837H717/M 4/1 371.8 0.076 1.974 0.398 1.177 3.435 12.522 1.905 6837H722/M 4/1 335.5 0.070 2.074 0.392 1.006 2.950 21.799 3.291 6837H724/M 4/1 351.4 0.070 2.132 0.383 1.271 3.993 16.022 2.710 6837H725/M 4/1 271.3 0.091 1.988 0.443 1.040 3.077 17.512 2.725 6837H726/M 4/1 376.6 0.081 2.055 0.351 1.129 2.942 15.164 1.859 6837H728/M 4/1 348.4 0.060 1.978 0.301 1.068 2.578 14.001 1.664 6837H729/M 4/1 355.9 0.071 2.078 0.342 1.151 2.620 13.647 1.922 6837H735/M 4/1 357.6 0.076 2.061 0.527 1.103 2.833 13.693 1.774 6837H736/M 4/1 371.5 0.076 2.024 0.605 1.244 3.245 15.902 1.946 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-4
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6837H739/M 4/1 371.6 0.056 2.041 0.535 1.164 2.937 13.007 1.788 6837H741/M 4/1 361.3 0.079 2.000 0.380 1.113 2.744 14.641 1.908 6837H747/M 4/1 365.8 0.096 2.119 0.433 1.155 3.273 16.088 1.726 6837H749/M 4/1 328.0 0.055 2.050 0.305 1.092 2.622 11.872 1.889 M e a n: 357.0+ 0.072 2.054* 0.429 1.134 3.054 15.475 2.128 Standard deviation: 28.4 0.010 0.058 0.092 0.082 0.365 2.832 0.570 Number of observ. : (19) (19) (19) (19) (19) (19) (19) (19) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-5
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 4 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen M a l e A n i m a l s 6831E407/M 1/1 403.2 1.198 3.905 6831E413/M 1/1 379.5 1.802 5.707 6831E415/M 1/1 395.5 4.540 14.307 6831E418/M 1/1 398.8 2.320 4.868 6831E422/M 1/1 384.3 2.251 4.134 6831E435/M 1/1 355.1 1.624 2.760 6831E436/M 1/1 393.1 1.667 4.818 6831E437/M 1/1 398.3 1.309 2.923 6831E440/M 1/1 396.8 1.076 2.071 6831E442/M 1/1 383.6 7.643 5.291 6831E443/M 1/1 404.7 1.661 4.881 6831E446/M 1/1 352.3 4.662 2.641 6831E448/M 1/1 396.0 2.389 5.345 6831E449/M 1/1 418.7 1.810 8.908 M e a n: 390.0 2.568 5.183 Standard deviation: 18.2 1.831 3.133 Number of observ. : (14) (14) (14) 6833F502/M 2/1 384.3 1.854 6.828 6833F505/M 2/1 400.1 1.839 8.886 6833F508/M 2/1 387.3 1.783 5.970 6833F511/M 2/1 411.5 1.719 7.054 6833F513/M 2/1 280.5 5.401 1.575 6833F516/M 2/1 377.9 6.050 6.591 6833F519/M 2/1 416.2 1.982 5.173 6833F521/M 2/1 335.6 20.968 3.212 6833F523/M 2/1 408.3 3.037 5.249 6833F525/M 2/1 393.6 3.886 4.371 6833F526/M 2/1 362.5 4.917 4.200 6833F535/M 2/1 409.1 4.343 5.318 6833F536/M 2/1 340.7 0.956 4.302 6833F542/M 2/1 365.4 1.865 4.645 6833F547/M 2/1 366.3 1.208 3.821 6833F550/M 2/1 368.4 2.079 8.859 M e a n: 375.5 3.993 5.378 Standard deviation: 35.2 4.794 1.948 Number of observ. : (16) (16) (16) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-6
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 5 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6835G601/M 3/1 382.8 1.599 10.187 6835G602/M 3/1 368.3 2.412 9.180 6835G603/M 3/1 375.0 1.846 2.816 6835G605/M 3/1 354.7 9.039 3.063 6835G607/M 3/1 372.0 1.270 5.616 6835G609/M 3/1 394.9 2.114 9.009 6835G610/M 3/1 368.2 2.150 9.405 6835G613/M 3/1 374.6 1.613 7.676 6835G614/M 3/1 389.1 1.543 7.271 6835G615/M 3/1 349.7 10.668 3.631 6835G617/M 3/1 359.5 2.434 2.183 6835G621/M 3/1 350.0 1.832 7.621 6835G628/M 3/1 378.2 1.297 6.559 6835G630/M 3/1 366.6 2.737 4.122 6835G634/M 3/1 396.2 2.057 4.417 6835G638/M 3/1 392.6 4.180 6.398 6835G639/M 3/1 383.2 2.829 5.872 6835G647/M 3/1 401.1 1.397 7.126 6835G648/M 3/1 268.6 3.024 3.771 6835G649/M 3/1 349.5 3.861 3.995 M e a n: 368.7 2.995 5.996 Standard deviation: 28.5 2.489 2.419 Number of observ. : (20) (20) (20) 6837H702/M 4/1 382.2 2.074 9.060 6837H704/M 4/1 397.1 2.239 4.011 6837H705/M 4/1 399.2 8.413 4.497 6837H706/M 4/1 356.7 1.411 2.680 6837H708/M 4/1 346.6 13.658 8.015 6837H714/M 4/1 335.0 0.914 8.264 6837H717/M 4/1 371.8 1.868 6.365 6837H722/M 4/1 335.5 19.599 1.947 6837H724/M 4/1 351.4 2.348 4.761 6837H725/M 4/1 271.3 20.175 2.031 6837H726/M 4/1 376.6 1.523 10.830 6837H728/M 4/1 348.4 1.366 9.114 6837H729/M 4/1 355.9 3.987 6.645 6837H735/M 4/1 357.6 1.689 7.052 6837H736/M 4/1 371.5 0.756 7.363 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-7
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 6 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6837H739/M 4/1 371.6 1.405 6.749 6837H741/M 4/1 361.3 3.900 7.623 6837H747/M 4/1 365.8 1.788 6.609 6837H749/M 4/1 328.0 1.634 6.537 M e a n: 357.0+ 4.776 6.324 Standard deviation: 28.4 6.159 2.448 Number of observ. : (19) (19) (19) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-8
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries F e m a l e A n i m a l s 6832E451/F 1/1 290.9 0.069 1.874 1.031 1.932 10.320 1.452 0.092 6832E452/F 1/1 265.5 0.076 1.896 0.910 1.915 8.751 1.276 0.130 6832E456/F 1/1 272.8 0.069 1.821 0.929 1.821 9.353 1.367 0.087 6832E458/F 1/1 257.4 0.054 1.858 0.873 1.732 8.619 1.206 0.110 6832E460/F 1/1 277.6 0.066 1.883 0.933 1.840 9.696 1.354 0.094 6832E461/F 1/1 300.6 0.076 1.955 1.135 2.027 10.562 1.328 0.097 6832E462/F 1/1 304.3 0.070 1.915 0.853 2.087 12.338 1.907 0.104 6832E463/F 1/1 277.1 0.072 1.952 0.933 1.901 10.556 1.873 0.093 6832E464/F 1/1 217.4 0.061 1.833 0.938 1.809 6.630 2.025 0.070 6832E467/F 1/1 301.9 0.068 1.894 0.903 1.898 9.325 1.428 0.115 6832E472/F 1/1 165.8 0.075 1.746 0.881 3.437 6.561 1.250 0.087 6832E475/F 1/1 260.0 0.059 1.948 0.813 1.794 7.974 1.322 0.113 6832E478/F 1/1 263.4 0.056 1.915 0.807 1.885 8.604 1.292 0.101 6832E483/F 1/1 271.8 0.063 1.849 0.820 1.725 8.851 1.251 0.121 6832E486/F 1/1 265.4 0.058 1.858 0.852 1.865 8.641 1.325 0.098 6832E489/F 1/1 263.9 0.068 1.944 0.858 1.850 8.490 1.214 0.094 6832E490/F 1/1 223.6 0.052 1.898 0.925 1.811 11.856 2.951 0.071 6832E493/F 1/1 230.8 0.064 1.946 0.991 2.005 10.077 2.948 0.035 6832E495/F 1/1 301.6 0.083 1.980 1.061 2.082 9.832 1.501 0.549 6832E497/F 1/1 269.1 0.063 1.811 0.909 1.740 9.759 1.458 0.093 6832E498/F 1/1 254.1 0.063 1.988 0.874 1.782 7.261 1.227 0.106 6832E500/F 1/1 303.6 0.063 1.900 1.044 1.993 9.295 1.413 0.105 M e a n: 265.4 0.066 1.894 0.922 1.951 9.243 1.562 0.117 Standard deviation: 33.3 0.008 0.060 0.085 0.348 1.452 0.503 0.099 Number of observ. : (22) (22) (22) (22) (22) (22) (22) (22) 6834F551/F 2/1 280.6 0.049 1.874 0.810 1.973 10.661 1.421 0.099 6834F553/F 2/1 278.5 0.069 1.940 0.890 1.982 8.888 1.346 0.104 6834F554/F 2/1 281.2 0.060 1.853 0.880 1.918 9.170 1.439 0.106 6834F555/F 2/1 297.4 0.071 1.894 0.914 1.943 9.952 1.431 0.148 6834F557/F 2/1 264.6 0.056 1.905 0.966 1.940 8.148 1.307 0.136 6834F558/F 2/1 263.2 0.066 1.833 0.923 1.944 10.176 1.225 0.107 6834F559/F 2/1 245.3 0.069 1.865 0.911 1.805 7.877 1.243 0.107 6834F560/F 2/1 283.1 0.060 1.937 0.894 2.025 8.558 1.336 0.096 6834F561/F 2/1 277.0 0.066 1.814 0.913 2.000 9.070 1.342 0.115 6834F563/F 2/1 288.7 0.074 1.864 1.043 2.109 10.619 1.259 0.133 6834F564/F 2/1 221.5 0.059 1.783 0.781 1.945 7.715 1.193 0.117 6834F569/F 2/1 312.4 0.081 1.912 0.974 2.028 11.000 1.315 0.116 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-9
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6834F570/F 2/1 268.6 0.060 1.924 0.783 1.834 9.343 1.281 0.122 6834F573/F 2/1 258.5 0.060 1.819 0.850 1.795 8.141 1.244 0.069 6834F574/F 2/1 265.2 0.062 1.817 0.847 1.869 8.390 1.299 0.111 6834F575/F 2/1 309.2 0.067 1.913 0.878 2.059 9.295 1.350 0.107 6834F579/F 2/1 299.6 0.071 1.912 1.013 2.202 12.317 1.680 0.112 6834F580/F 2/1 296.3 0.064 1.893 0.899 1.964 8.956 1.214 0.112 6834F583/F 2/1 276.2 0.056 1.917 1.003 1.878 8.571 1.453 0.142 6834F584/F 2/1 258.5 0.049 1.885 0.841 1.159 23.096 1.549 0.184 6834F585/F 2/1 234.6 0.057 1.891 0.964 1.788 8.638 1.851 0.097 6834F586/F 2/1 286.9 0.073 1.858 0.821 1.849 8.973 1.326 0.103 6834F587/F 2/1 282.6 0.062 1.921 0.966 1.951 8.796 1.319 0.118 6834F588/F 2/1 267.6 0.048 1.701 0.980 1.767 8.660 1.360 0.126 6834F591/F 2/1 256.1 0.062 1.907 0.897 1.922 8.576 1.357 0.109 6834F592/F 2/1 274.7 0.057 1.869 0.900 1.867 8.069 1.367 0.108 6834F596/F 2/1 262.2 0.065 1.862 0.830 1.889 11.183 1.271 0.434 6834F597/F 2/1 280.2 0.066 1.886 0.843 1.842 8.743 1.359 0.133 6834F598/F 2/1 252.7 0.057 1.856 0.809 1.908 8.509 1.233 0.088 6834F600/F 2/1 280.6 0.063 1.946 0.788 1.854 9.964 1.603 0.132 M e a n: 273.5 0.063 1.875 0.894 1.900 9.668 1.366 0.126 Standard deviation: 20.4 0.008 0.052 0.072 0.171 2.759 0.145 0.062 Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30) 6836G651/F 3/1 262.8 0.065 1.900 0.892 2.080 9.121 1.315 0.080 6836G652/F 3/1 277.7 0.067 1.919 0.827 1.936 9.920 1.391 0.125 6836G654/F 3/1 238.3 0.065 1.831 0.855 2.056 9.973 1.192 0.061 6836G655/F 3/1 259.9 0.074 1.883 0.847 2.097 10.385 1.398 0.076 6836G656/F 3/1 277.7 0.063 1.858 0.849 1.952 8.622 1.255 0.083 6836G657/F 3/1 263.5 0.059 1.839 0.911 1.931 8.523 1.247 0.112 6836G658/F 3/1 274.9 0.061 1.888 0.919 1.977 9.044 1.216 0.088 6836G660/F 3/1 295.8 0.086 1.878 0.965 2.105 20.228 1.736 0.094 6836G661/F 3/1 242.0 0.044 1.872 1.025 1.846 8.977 1.432 0.421 6836G662/F 3/1 234.8 0.066 1.923 0.838 1.753 7.870 1.206 0.094 6836G663/F 3/1 258.5 0.051 1.855 0.849 1.899 9.525 1.310 0.098 6836G666/F 3/1 226.0 0.054 1.914 0.813 1.694 7.733 1.165 0.083 6836G667/F 3/1 271.4 0.066 1.811 0.806 1.744 8.448 1.278 0.110 6836G668/F 3/1 212.8 0.172 1.852 0.831 1.615 6.904 1.090 0.127 6836G669/F 3/1 256.3 0.057 1.805 1.022 1.998 10.512 1.439 0.103 6836G670/F 3/1 267.4 0.058 1.849 0.856 2.104 9.011 1.235 0.091 6836G672/F 3/1 283.2 0.066 1.850 0.944 1.788 8.869 1.186 0.106 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-10
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6836G673/F 3/1 242.1 0.051 1.848 0.895 1.664 7.308 1.321 0.113 6836G674/F 3/1 287.6 0.064 1.903 0.880 2.030 9.768 1.300 0.092 6836G675/F 3/1 257.6 0.052 1.890 0.993 1.987 11.252 1.996 0.122 6836G677/F 3/1 268.4 0.062 1.938 0.794 1.950 8.928 1.268 0.103 6836G681/F 3/1 272.3 0.063 1.927 1.099 1.960 8.460 1.261 0.117 6836G684/F 3/1 287.6 0.065 1.978 0.872 1.919 9.125 1.270 0.128 6836G686/F 3/1 231.0 0.075 1.925 0.986 2.364 10.609 2.675 0.102 6836G689/F 3/1 241.1 0.060 1.857 0.847 1.849 8.139 1.230 0.097 6836G690/F 3/1 236.8 0.056 1.823 0.836 1.849 8.875 1.192 0.110 6836G692/F 3/1 244.1 0.055 1.813 0.820 1.706 8.416 1.266 0.075 6836G694/F 3/1 255.8 0.057 1.842 0.838 1.806 9.304 1.460 0.070 6836G697/F 3/1 252.0 0.068 1.841 0.842 2.010 8.485 1.339 0.135 6836G700/F 3/1 209.6 0.065 1.828 0.730 1.580 6.587 1.126 1.002 M e a n: 256.3 0.066 1.871 0.883 1.908 9.297 1.360 0.141 Standard deviation: 21.9 0.022 0.043 0.081 0.171 2.322 0.305 0.174 Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30) 6838H754/F 4/1 267.9 0.055 1.865 1.086 1.945 9.362 1.316 0.124 6838H755/F 4/1 229.6 0.049 1.786 0.775 2.366 7.711 1.108 0.096 6838H756/F 4/1 250.7 0.057 1.803 0.905 1.809 8.085 1.136 0.089 6838H758/F 4/1 247.8 0.062 1.861 0.904 2.164 8.813 1.297 0.124 6838H759/F 4/1 230.5 0.074 1.869 0.832 1.954 8.936 1.413 0.174 6838H760/F 4/1 245.1 0.060 1.885 0.909 1.892 8.921 1.333 0.104 6838H761/F 4/1 244.4 0.070 1.888 0.881 1.920 9.530 1.360 0.118 6838H762/F 4/1 237.7 0.057 1.829 0.894 1.920 8.646 1.304 0.078 6838H765/F 4/1 259.5 0.050 1.894 1.019 2.000 9.208 1.526 0.086 6838H767/F 4/1 251.5 0.059 1.893 0.794 1.895 8.634 1.403 0.090 6838H768/F 4/1 242.4 0.062 1.865 0.930 1.901 10.119 1.316 0.091 6838H769/F 4/1 232.5 0.050 1.885 0.795 1.745 7.909 1.191 0.098 6838H771/F 4/1 217.7 0.052 1.891 0.772 1.671 7.602 1.178 0.111 6838H773/F 4/1 256.8 0.060 1.835 0.782 1.892 9.364 1.235 0.102 6838H776/F 4/1 261.4 0.076 1.921 0.975 2.090 9.261 1.277 0.088 6838H777/F 4/1 242.5 0.058 1.704 0.890 1.853 8.051 1.159 0.107 6838H778/F 4/1 218.1 0.054 1.811 1.009 1.836 8.259 2.364 0.108 6838H779/F 4/1 265.1 0.060 1.836 0.896 2.017 8.468 1.281 0.103 6838H780/F 4/1 236.3 0.060 1.880 0.897 1.899 12.439 1.536 0.156 6838H781/F 4/1 244.3 0.050 1.878 0.934 1.891 8.720 1.280 0.110 6838H782/F 4/1 240.3 0.069 1.810 0.933 1.842 8.641 1.146 0.115 6838H784/F 4/1 202.7 0.061 1.935 0.834 1.689 5.137 1.264 0.090 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-11
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 4 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6838H787/F 4/1 266.0 0.072 1.867 0.802 2.198 11.416 1.727 0.116 6838H788/F 4/1 244.1 0.053 1.782 0.766 1.859 9.184 1.169 0.107 6838H789/F 4/1 247.7 0.056 1.928 0.957 1.997 8.518 1.366 0.148 6838H790/F 4/1 238.2 0.026 1.861 1.049 1.867 8.661 1.321 0.106 6838H791/F 4/1 265.6 0.057 1.893 0.987 2.142 11.866 2.178 0.075 6838H793/F 4/1 231.8 0.051 1.837 0.853 1.956 11.979 1.673 0.090 6838H794/F 4/1 258.7 0.066 1.846 0.843 1.965 8.605 1.213 0.111 6838H796/F 4/1 240.6 0.055 1.856 0.848 1.958 8.097 1.253 0.099 6838H798/F 4/1 256.0 0.057 1.878 0.808 1.920 9.152 1.196 0.098 6838H799/F 4/1 215.8 0.059 1.862 0.767 1.604 7.680 1.193 0.075 6838H800/F 4/1 247.9 0.062 1.832 0.837 2.140 11.218 1.616 0.094 M e a n: 243.6$ 0.058$ 1.857* 0.884 1.933 9.036 1.374 0.105 Standard deviation: 15.7 0.009 0.046 0.086 0.155 1.452 0.278 0.022 Number of observ. : (33) (33) (33) (33) (33) (33) (33) (33) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-12
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 5 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen F e m a l e A n i m a l s 6832E451/F 1/1 290.9 0.896 0.592 6832E452/F 1/1 265.5 0.986 0.623 6832E456/F 1/1 272.8 2.478 0.983 6832E458/F 1/1 257.4 0.592 0.646 6832E460/F 1/1 277.6 1.318 3.997 6832E461/F 1/1 300.6 0.764 0.728 6832E462/F 1/1 304.3 1.789 0.754 6832E463/F 1/1 277.1 4.344 0.732 6832E464/F 1/1 217.4 4.264 0.609 6832E467/F 1/1 301.9 0.744 0.573 6832E472/F 1/1 165.8 0.552 0.736 6832E475/F 1/1 260.0 0.600 0.509 6832E478/F 1/1 263.4 0.670 0.809 6832E483/F 1/1 271.8 0.601 0.607 6832E486/F 1/1 265.4 0.721 0.554 6832E489/F 1/1 263.9 0.536 0.811 6832E490/F 1/1 223.6 4.246 0.595 6832E493/F 1/1 230.8 15.518 0.517 6832E495/F 1/1 301.6 0.665 0.975 6832E497/F 1/1 269.1 1.997 0.842 6832E498/F 1/1 254.1 0.500 0.823 6832E500/F 1/1 303.6 1.635 0.527 M e a n: 265.4 2.110 0.843 Standard deviation: 33.3 3.251 0.718 Number of observ. : (22) (22) (22) 6834F551/F 2/1 280.6 1.344 0.678 6834F553/F 2/1 278.5 0.899 0.576 6834F554/F 2/1 281.2 0.517 0.536 6834F555/F 2/1 297.4 0.861 0.680 6834F557/F 2/1 264.6 0.592 1.306 6834F558/F 2/1 263.2 0.795 0.726 6834F559/F 2/1 245.3 0.807 0.591 6834F560/F 2/1 283.1 0.634 0.617 6834F561/F 2/1 277.0 0.815 0.924 6834F563/F 2/1 288.7 0.649 1.310 6834F564/F 2/1 221.5 0.572 0.487 6834F569/F 2/1 312.4 0.771 0.801 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-13
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 6 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6834F570/F 2/1 268.6 2.156 0.709 6834F573/F 2/1 258.5 0.626 0.774 6834F574/F 2/1 265.2 0.617 0.985 6834F575/F 2/1 309.2 1.030 1.460 6834F579/F 2/1 299.6 4.593 0.635 6834F580/F 2/1 296.3 1.260 0.733 6834F583/F 2/1 276.2 0.609 0.880 6834F584/F 2/1 258.5 2.657 0.885 6834F585/F 2/1 234.6 1.469 0.770 6834F586/F 2/1 286.9 0.783 0.595 6834F587/F 2/1 282.6 0.854 0.623 6834F588/F 2/1 267.6 0.697 0.745 6834F591/F 2/1 256.1 1.207 0.667 6834F592/F 2/1 274.7 0.721 0.573 6834F596/F 2/1 262.2 0.729 0.746 6834F597/F 2/1 280.2 0.631 0.667 6834F598/F 2/1 252.7 0.522 0.839 6834F600/F 2/1 280.6 2.074 0.620 M e a n: 273.5 1.083 0.771 Standard deviation: 20.4 0.842 0.232 Number of observ. : (30) (30) (30) 6836G651/F 3/1 262.8 0.645 1.139 6836G652/F 3/1 277.7 1.535 0.615 6836G654/F 3/1 238.3 0.848 0.583 6836G655/F 3/1 259.9 1.405 0.585 6836G656/F 3/1 277.7 0.718 0.858 6836G657/F 3/1 263.5 0.615 0.620 6836G658/F 3/1 274.9 0.963 0.534 6836G660/F 3/1 295.8 2.544 0.734 6836G661/F 3/1 242.0 0.955 3.095 6836G662/F 3/1 234.8 0.615 0.731 6836G663/F 3/1 258.5 0.702 0.699 6836G666/F 3/1 226.0 0.393 0.677 6836G667/F 3/1 271.4 0.638 1.299 6836G668/F 3/1 212.8 0.338 1.095 6836G669/F 3/1 256.3 0.670 1.372 6836G670/F 3/1 267.4 0.689 0.829 6836G672/F 3/1 283.2 1.147 0.569 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-14
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 7 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6836G673/F 3/1 242.1 0.530 1.148 6836G674/F 3/1 287.6 0.697 0.881 6836G675/F 3/1 257.6 3.393 0.707 6836G677/F 3/1 268.4 0.758 0.675 6836G681/F 3/1 272.3 0.589 0.911 6836G684/F 3/1 287.6 0.830 0.621 6836G686/F 3/1 231.0 2.587 0.765 6836G689/F 3/1 241.1 0.828 0.913 6836G690/F 3/1 236.8 0.635 1.078 6836G692/F 3/1 244.1 0.508 0.543 6836G694/F 3/1 255.8 1.738 0.730 6836G697/F 3/1 252.0 0.641 0.949 6836G700/F 3/1 209.6 0.463 3.191 M e a n: 256.3 0.987 0.972 Standard deviation: 21.9 0.714 0.632 Number of observ. : (30) (30) (30) 6838H754/F 4/1 267.9 0.578 0.674 6838H755/F 4/1 229.6 0.727 0.659 6838H756/F 4/1 250.7 0.686 0.585 6838H758/F 4/1 247.8 0.760 0.855 6838H759/F 4/1 230.5 1.062 0.960 6838H760/F 4/1 245.1 0.667 0.728 6838H761/F 4/1 244.4 2.194 0.785 6838H762/F 4/1 237.7 1.199 0.694 6838H765/F 4/1 259.5 0.564 0.970 6838H767/F 4/1 251.5 4.216 1.220 6838H768/F 4/1 242.4 1.189 0.648 6838H769/F 4/1 232.5 0.564 2.009 6838H771/F 4/1 217.7 0.483 0.663 6838H773/F 4/1 256.8 0.658 0.852 6838H776/F 4/1 261.4 0.841 0.693 6838H777/F 4/1 242.5 0.800 0.556 6838H778/F 4/1 218.1 8.518 0.706 6838H779/F 4/1 265.1 0.865 0.563 6838H780/F 4/1 236.3 2.942 2.121 6838H781/F 4/1 244.3 0.576 0.679 6838H782/F 4/1 240.3 0.515 0.594 6838H784/F 4/1 202.7 0.445 0.598 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-15
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 8 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6838H787/F 4/1 266.0 1.822 0.906 6838H788/F 4/1 244.1 0.638 0.599 6838H789/F 4/1 247.7 0.698 0.706 6838H790/F 4/1 238.2 0.605 0.738 6838H791/F 4/1 265.6 12.388 0.716 6838H793/F 4/1 231.8 2.487 0.851 6838H794/F 4/1 258.7 0.652 0.946 6838H796/F 4/1 240.6 0.696 0.700 6838H798/F 4/1 256.0 0.630 0.718 6838H799/F 4/1 215.8 0.505 0.522 6838H800/F 4/1 247.9 3.306 1.049 M e a n: 243.6$ 1.681 0.826 Standard deviation: 15.7 2.486 0.356 Number of observ. : (33) (33) (33) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-16
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-2 Percent Organ to Body Weight, Male and Female, Final Sacrifice 

K-17
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs M a l e A n i m a l s 6831E407/M 1/1 403.2 0.019 0.542 0.190 0.344 0.783 3.740 0.462 6831E413/M 1/1 379.5 0.021 0.559 0.075 0.307 0.682 3.802 0.481 6831E415/M 1/1 395.5 0.016 0.527 0.131 0.279 0.744 5.685 0.561 6831E418/M 1/1 398.8 0.019 0.544 0.157 0.318 0.767 3.549 0.467 6831E422/M 1/1 384.3 0.014 0.540 0.190 0.292 0.748 3.444 0.448 6831E435/M 1/1 355.1 0.022 0.574 0.219 0.364 0.922 4.784 0.489 6831E436/M 1/1 393.1 0.018 0.522 0.087 0.293 0.742 3.850 0.417 6831E437/M 1/1 398.3 0.019 0.535 0.246 0.307 0.682 3.077 0.436 6831E440/M 1/1 396.8 0.111 0.531 0.095 0.310 0.723 3.561 0.456 6831E442/M 1/1 383.6 0.025 0.545 0.129 0.282 0.871 7.938 0.653 6831E443/M 1/1 404.7 0.017 0.514 0.113 0.287 0.691 3.229 0.412 6831E446/M 1/1 352.3 0.017 0.578 0.134 0.350 0.761 4.538 0.694 6831E448/M 1/1 396.0 0.015 0.516 0.125 0.258 0.666 3.231 0.447 6831E449/M 1/1 418.7 0.019 0.521 0.088 0.316 0.677 3.568 0.487 M e a n: 390.0 0.025 0.539 0.141 0.308 0.747 4.143 0.494 Standard deviation: 18.2 0.025 0.020 0.052 0.030 0.074 1.302 0.085 Number of observ. : (14) (14) (14) (14) (14) (14) (14) (14) 6833F502/M 2/1 384.3 0.022 0.553 0.093 0.350 0.730 3.504 0.470 6833F505/M 2/1 400.1 0.015 0.500 0.098 0.307 0.738 3.849 0.480 6833F508/M 2/1 387.3 0.018 0.535 0.160 0.325 0.756 3.506 0.558 6833F511/M 2/1 411.5 0.017 0.521 0.096 0.322 0.707 3.474 0.487 6833F513/M 2/1 280.5 0.026 0.720 0.125 0.369 0.912 4.241 1.067 6833F516/M 2/1 377.9 0.019 0.542 0.112 0.287 0.687 4.659 0.676 6833F519/M 2/1 416.2 0.016 0.503 0.105 0.327 0.764 3.169 0.473 6833F521/M 2/1 335.6 0.024 0.611 0.115 0.374 0.784 5.688 1.153 6833F523/M 2/1 408.3 0.013 0.507 0.117 0.266 0.675 3.097 0.534 6833F525/M 2/1 393.6 0.443 0.533 0.094 0.305 0.856 4.477 0.634 6833F526/M 2/1 362.5 0.024 0.563 0.143 0.315 1.092 4.949 0.690 6833F535/M 2/1 409.1 0.017 0.506 0.094 0.293 0.766 3.193 0.555 6833F536/M 2/1 340.7 0.021 0.613 0.165 0.335 0.773 3.382 0.484 6833F542/M 2/1 365.4 0.018 0.555 0.131 0.315 0.734 3.547 0.496 6833F547/M 2/1 366.3 0.019 0.544 0.132 0.339 0.790 3.570 0.475 6833F550/M 2/1 368.4 0.018 0.559 0.091 0.294 1.318 5.128 0.503 M e a n: 375.5 0.046 0.554 0.117 0.320 0.818 3.965 0.609 Standard deviation: 35.2 0.106 0.056 0.024 0.029 0.167 0.793 0.209 Number of observ. : (16) (16) (16) (16) (16) (16) (16) (16) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-18
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6835G601/M 3/1 382.8 0.013 0.543 0.104 0.259 0.710 3.260 0.486 6835G602/M 3/1 368.3 0.030 0.570 0.096 0.326 0.841 3.939 0.570 6835G603/M 3/1 375.0 0.017 0.541 0.088 0.280 0.762 3.495 0.501 6835G605/M 3/1 354.7 0.027 0.571 0.102 0.345 0.851 4.052 0.806 6835G607/M 3/1 372.0 0.018 0.553 0.101 0.305 0.823 4.014 0.454 6835G609/M 3/1 394.9 0.018 0.550 0.101 0.317 0.778 3.581 0.496 6835G610/M 3/1 368.2 0.017 0.580 0.088 0.305 0.737 3.282 0.546 6835G613/M 3/1 374.6 0.017 0.553 0.097 0.317 0.707 3.401 0.510 6835G614/M 3/1 389.1 0.019 0.537 0.152 0.374 0.794 3.697 0.507 6835G615/M 3/1 349.7 0.021 0.598 0.112 0.319 0.920 4.799 0.919 6835G617/M 3/1 359.5 0.024 0.553 0.113 0.319 0.869 3.663 0.474 6835G621/M 3/1 350.0 0.027 0.587 0.111 0.301 0.745 3.992 0.497 6835G628/M 3/1 378.2 0.018 0.540 0.109 0.344 0.740 3.569 0.520 6835G630/M 3/1 366.6 0.021 0.566 0.082 0.299 0.770 3.738 0.549 6835G634/M 3/1 396.2 0.017 0.536 0.137 0.334 0.858 4.065 0.510 6835G638/M 3/1 392.6 0.017 0.544 0.127 0.391 0.803 4.195 0.636 6835G639/M 3/1 383.2 0.021 0.526 0.105 0.337 0.752 3.675 0.686 6835G647/M 3/1 401.1 0.017 0.523 0.118 0.301 0.703 3.804 0.461 6835G648/M 3/1 268.6 0.028 0.745 0.214 0.375 1.264 4.983 0.904 6835G649/M 3/1 349.5 0.021 0.591 0.120 0.324 0.775 4.021 0.507 M e a n: 368.7 0.020 0.565% 0.114 0.324 0.810 3.861 0.577% Standard deviation: 28.5 0.005 0.047 0.029 0.032 0.122 0.443 0.142 Number of observ. : (20) (20) (20) (20) (20) (20) (20) (20) 6837H702/M 4/1 382.2 0.019 0.550 0.112 0.304 0.805 3.736 0.517 6837H704/M 4/1 397.1 0.018 0.523 0.136 0.304 0.710 3.532 0.429 6837H705/M 4/1 399.2 0.017 0.543 0.113 0.306 0.927 4.670 0.919 6837H706/M 4/1 356.7 0.020 0.594 0.160 0.341 0.897 4.139 0.543 6837H708/M 4/1 346.6 0.018 0.567 0.090 0.304 0.873 6.428 0.682 6837H714/M 4/1 335.0 0.020 0.606 0.135 0.291 0.886 4.230 0.498 6837H717/M 4/1 371.8 0.020 0.531 0.107 0.317 0.924 3.368 0.512 6837H722/M 4/1 335.5 0.021 0.618 0.117 0.300 0.879 6.497 0.981 6837H724/M 4/1 351.4 0.020 0.607 0.109 0.362 1.136 4.559 0.771 6837H725/M 4/1 271.3 0.034 0.733 0.163 0.383 1.134 6.456 1.005 6837H726/M 4/1 376.6 0.022 0.546 0.093 0.300 0.781 4.027 0.494 6837H728/M 4/1 348.4 0.017 0.568 0.086 0.307 0.740 4.019 0.478 6837H729/M 4/1 355.9 0.020 0.584 0.096 0.323 0.736 3.835 0.540 6837H735/M 4/1 357.6 0.021 0.576 0.147 0.308 0.792 3.829 0.496 6837H736/M 4/1 371.5 0.020 0.545 0.163 0.335 0.874 4.281 0.524 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-19
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6837H739/M 4/1 371.6 0.015 0.549 0.144 0.313 0.790 3.500 0.481 6837H741/M 4/1 361.3 0.022 0.554 0.105 0.308 0.760 4.053 0.528 6837H747/M 4/1 365.8 0.026 0.579 0.118 0.316 0.895 4.398 0.472 6837H749/M 4/1 328.0 0.017 0.625 0.093 0.333 0.799 3.620 0.576 M e a n: 357.0+ 0.020 0.579$ 0.120 0.319 0.860$ 4.378 0.602% Standard deviation: 28.4 0.004 0.048 0.026 0.023 0.118 0.991 0.181 Number of observ. : (19) (19) (19) (19) (19) (19) (19) (19) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-20
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 4 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen M a l e A n i m a l s 6831E407/M 1/1 403.2 0.297 0.968 6831E413/M 1/1 379.5 0.475 1.504 6831E415/M 1/1 395.5 1.148 3.617 6831E418/M 1/1 398.8 0.582 1.221 6831E422/M 1/1 384.3 0.586 1.076 6831E435/M 1/1 355.1 0.457 0.777 6831E436/M 1/1 393.1 0.424 1.226 6831E437/M 1/1 398.3 0.329 0.734 6831E440/M 1/1 396.8 0.271 0.522 6831E442/M 1/1 383.6 1.993 1.379 6831E443/M 1/1 404.7 0.410 1.206 6831E446/M 1/1 352.3 1.323 0.750 6831E448/M 1/1 396.0 0.603 1.350 6831E449/M 1/1 418.7 0.432 2.128 M e a n: 390.0 0.666 1.318 Standard deviation: 18.2 0.489 0.774 Number of observ. : (14) (14) (14) 6833F502/M 2/1 384.3 0.482 1.777 6833F505/M 2/1 400.1 0.460 2.221 6833F508/M 2/1 387.3 0.460 1.542 6833F511/M 2/1 411.5 0.418 1.714 6833F513/M 2/1 280.5 1.925 0.561 6833F516/M 2/1 377.9 1.601 1.744 6833F519/M 2/1 416.2 0.476 1.243 6833F521/M 2/1 335.6 6.247 0.957 6833F523/M 2/1 408.3 0.744 1.286 6833F525/M 2/1 393.6 0.987 1.110 6833F526/M 2/1 362.5 1.356 1.159 6833F535/M 2/1 409.1 1.062 1.300 6833F536/M 2/1 340.7 0.281 1.263 6833F542/M 2/1 365.4 0.510 1.271 6833F547/M 2/1 366.3 0.330 1.043 6833F550/M 2/1 368.4 0.564 2.405 M e a n: 375.5 1.119 1.412 Standard deviation: 35.2 1.451 0.470 Number of observ. : (16) (16) (16) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-21
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 5 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6835G601/M 3/1 382.8 0.418 2.661 6835G602/M 3/1 368.3 0.655 2.493 6835G603/M 3/1 375.0 0.492 0.751 6835G605/M 3/1 354.7 2.549 0.864 6835G607/M 3/1 372.0 0.341 1.510 6835G609/M 3/1 394.9 0.535 2.281 6835G610/M 3/1 368.2 0.584 2.554 6835G613/M 3/1 374.6 0.431 2.049 6835G614/M 3/1 389.1 0.397 1.869 6835G615/M 3/1 349.7 3.050 1.038 6835G617/M 3/1 359.5 0.677 0.607 6835G621/M 3/1 350.0 0.523 2.177 6835G628/M 3/1 378.2 0.343 1.734 6835G630/M 3/1 366.6 0.746 1.124 6835G634/M 3/1 396.2 0.519 1.115 6835G638/M 3/1 392.6 1.065 1.630 6835G639/M 3/1 383.2 0.738 1.532 6835G647/M 3/1 401.1 0.348 1.777 6835G648/M 3/1 268.6 1.126 1.404 6835G649/M 3/1 349.5 1.105 1.143 M e a n: 368.7 0.832 1.616 Standard deviation: 28.5 0.720 0.617 Number of observ. : (20) (20) (20) 6837H702/M 4/1 382.2 0.543 2.371 6837H704/M 4/1 397.1 0.564 1.010 6837H705/M 4/1 399.2 2.107 1.127 6837H706/M 4/1 356.7 0.396 0.751 6837H708/M 4/1 346.6 3.941 2.313 6837H714/M 4/1 335.0 0.273 2.467 6837H717/M 4/1 371.8 0.502 1.712 6837H722/M 4/1 335.5 5.841 0.580 6837H724/M 4/1 351.4 0.668 1.355 6837H725/M 4/1 271.3 7.438 0.749 6837H726/M 4/1 376.6 0.404 2.876 6837H728/M 4/1 348.4 0.392 2.616 6837H729/M 4/1 355.9 1.120 1.867 6837H735/M 4/1 357.6 0.472 1.972 6837H736/M 4/1 371.5 0.204 1.982 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-22
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 6 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6837H739/M 4/1 371.6 0.378 1.816 6837H741/M 4/1 361.3 1.080 2.110 6837H747/M 4/1 365.8 0.489 1.807 6837H749/M 4/1 328.0 0.498 1.993 M e a n: 357.0+ 1.437 1.762 Standard deviation: 28.4 2.046 0.667 Number of observ. : (19) (19) (19) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-23
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries F e m a l e A n i m a l s 6832E451/F 1/1 290.9 0.024 0.644 0.354 0.664 3.548 0.499 0.032 6832E452/F 1/1 265.5 0.029 0.714 0.343 0.721 3.296 0.481 0.049 6832E456/F 1/1 272.8 0.025 0.667 0.341 0.667 3.428 0.501 0.032 6832E458/F 1/1 257.4 0.021 0.722 0.339 0.673 3.348 0.469 0.043 6832E460/F 1/1 277.6 0.024 0.678 0.336 0.663 3.492 0.488 0.034 6832E461/F 1/1 300.6 0.025 0.650 0.378 0.674 3.513 0.442 0.032 6832E462/F 1/1 304.3 0.023 0.629 0.280 0.686 4.054 0.627 0.034 6832E463/F 1/1 277.1 0.026 0.704 0.337 0.686 3.810 0.676 0.034 6832E464/F 1/1 217.4 0.028 0.843 0.431 0.832 3.050 0.931 0.032 6832E467/F 1/1 301.9 0.023 0.627 0.299 0.629 3.089 0.473 0.038 6832E472/F 1/1 165.8 0.045 1.053 0.531 2.073 3.957 0.754 0.052 6832E475/F 1/1 260.0 0.023 0.749 0.313 0.690 3.066 0.508 0.043 6832E478/F 1/1 263.4 0.021 0.727 0.306 0.716 3.266 0.490 0.038 6832E483/F 1/1 271.8 0.023 0.680 0.302 0.635 3.257 0.460 0.045 6832E486/F 1/1 265.4 0.022 0.700 0.321 0.703 3.255 0.499 0.037 6832E489/F 1/1 263.9 0.026 0.737 0.325 0.701 3.218 0.460 0.036 6832E490/F 1/1 223.6 0.023 0.849 0.414 0.810 5.302 1.320 0.032 6832E493/F 1/1 230.8 0.028 0.843 0.429 0.869 4.366 1.277 0.015 6832E495/F 1/1 301.6 0.028 0.657 0.352 0.690 3.260 0.498 0.182 6832E497/F 1/1 269.1 0.023 0.673 0.338 0.647 3.627 0.542 0.035 6832E498/F 1/1 254.1 0.025 0.782 0.344 0.701 2.858 0.483 0.042 6832E500/F 1/1 303.6 0.021 0.626 0.344 0.656 3.061 0.465 0.035 M e a n: 265.4 0.025 0.725 0.353 0.763 3.506 0.606 0.043 Standard deviation: 33.3 0.005 0.100 0.056 0.299 0.542 0.252 0.032 Number of observ. : (22) (22) (22) (22) (22) (22) (22) (22) 6834F551/F 2/1 280.6 0.017 0.668 0.289 0.703 3.799 0.506 0.035 6834F553/F 2/1 278.5 0.025 0.697 0.320 0.712 3.192 0.483 0.037 6834F554/F 2/1 281.2 0.021 0.659 0.313 0.682 3.261 0.512 0.038 6834F555/F 2/1 297.4 0.024 0.637 0.307 0.653 3.347 0.481 0.050 6834F557/F 2/1 264.6 0.021 0.720 0.365 0.733 3.079 0.494 0.051 6834F558/F 2/1 263.2 0.025 0.696 0.351 0.739 3.866 0.465 0.041 6834F559/F 2/1 245.3 0.028 0.760 0.371 0.736 3.211 0.507 0.044 6834F560/F 2/1 283.1 0.021 0.684 0.316 0.715 3.023 0.472 0.034 6834F561/F 2/1 277.0 0.024 0.655 0.330 0.722 3.274 0.484 0.042 6834F563/F 2/1 288.7 0.026 0.646 0.361 0.731 3.679 0.436 0.046 6834F564/F 2/1 221.5 0.027 0.805 0.353 0.878 3.483 0.539 0.053 6834F569/F 2/1 312.4 0.026 0.612 0.312 0.649 3.521 0.421 0.037 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-24
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6834F570/F 2/1 268.6 0.022 0.716 0.292 0.683 3.479 0.477 0.045 6834F573/F 2/1 258.5 0.023 0.704 0.329 0.694 3.149 0.481 0.027 6834F574/F 2/1 265.2 0.023 0.685 0.319 0.705 3.164 0.490 0.042 6834F575/F 2/1 309.2 0.022 0.619 0.284 0.666 3.006 0.437 0.035 6834F579/F 2/1 299.6 0.024 0.638 0.338 0.735 4.111 0.561 0.037 6834F580/F 2/1 296.3 0.022 0.639 0.303 0.663 3.022 0.410 0.038 6834F583/F 2/1 276.2 0.020 0.694 0.363 0.680 3.103 0.526 0.051 6834F584/F 2/1 258.5 0.019 0.729 0.325 0.448 8.934 0.599 0.071 6834F585/F 2/1 234.6 0.024 0.806 0.411 0.762 3.682 0.789 0.041 6834F586/F 2/1 286.9 0.025 0.648 0.286 0.644 3.127 0.462 0.036 6834F587/F 2/1 282.6 0.022 0.680 0.342 0.690 3.113 0.467 0.042 6834F588/F 2/1 267.6 0.018 0.636 0.366 0.660 3.236 0.508 0.047 6834F591/F 2/1 256.1 0.024 0.745 0.350 0.750 3.349 0.530 0.043 6834F592/F 2/1 274.7 0.021 0.680 0.328 0.680 2.938 0.498 0.039 6834F596/F 2/1 262.2 0.025 0.710 0.317 0.720 4.265 0.485 0.166 6834F597/F 2/1 280.2 0.024 0.673 0.301 0.657 3.120 0.485 0.047 6834F598/F 2/1 252.7 0.023 0.734 0.320 0.755 3.367 0.488 0.035 6834F600/F 2/1 280.6 0.022 0.694 0.281 0.661 3.552 0.571 0.047 M e a n: 273.5 0.023 0.689 0.328 0.697 3.548 0.502 0.047 Standard deviation: 20.4 0.002 0.049 0.031 0.067 1.069 0.068 0.024 Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30) 6836G651/F 3/1 262.8 0.025 0.723 0.339 0.792 3.471 0.500 0.030 6836G652/F 3/1 277.7 0.024 0.691 0.298 0.697 3.572 0.501 0.045 6836G654/F 3/1 238.3 0.027 0.768 0.359 0.863 4.185 0.500 0.026 6836G655/F 3/1 259.9 0.028 0.724 0.326 0.807 3.996 0.538 0.029 6836G656/F 3/1 277.7 0.023 0.669 0.306 0.703 3.105 0.452 0.030 6836G657/F 3/1 263.5 0.022 0.698 0.346 0.733 3.234 0.473 0.043 6836G658/F 3/1 274.9 0.022 0.687 0.334 0.719 3.290 0.442 0.032 6836G660/F 3/1 295.8 0.029 0.635 0.326 0.712 6.839 0.587 0.032 6836G661/F 3/1 242.0 0.018 0.774 0.424 0.763 3.710 0.592 0.174 6836G662/F 3/1 234.8 0.028 0.819 0.357 0.746 3.351 0.514 0.040 6836G663/F 3/1 258.5 0.020 0.718 0.328 0.735 3.684 0.507 0.038 6836G666/F 3/1 226.0 0.024 0.847 0.360 0.750 3.422 0.516 0.037 6836G667/F 3/1 271.4 0.024 0.667 0.297 0.643 3.113 0.471 0.041 6836G668/F 3/1 212.8 0.081 0.870 0.390 0.759 3.244 0.512 0.060 6836G669/F 3/1 256.3 0.022 0.704 0.399 0.780 4.102 0.562 0.040 6836G670/F 3/1 267.4 0.022 0.691 0.320 0.787 3.369 0.462 0.034 6836G672/F 3/1 283.2 0.023 0.653 0.333 0.631 3.132 0.419 0.037 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-25
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6836G673/F 3/1 242.1 0.021 0.763 0.370 0.687 3.019 0.546 0.047 6836G674/F 3/1 287.6 0.022 0.662 0.306 0.706 3.397 0.452 0.032 6836G675/F 3/1 257.6 0.020 0.734 0.385 0.771 4.368 0.775 0.047 6836G677/F 3/1 268.4 0.023 0.722 0.296 0.727 3.326 0.472 0.038 6836G681/F 3/1 272.3 0.023 0.708 0.404 0.720 3.106 0.463 0.043 6836G684/F 3/1 287.6 0.023 0.688 0.303 0.667 3.173 0.442 0.045 6836G686/F 3/1 231.0 0.032 0.833 0.427 1.023 4.592 1.158 0.044 6836G689/F 3/1 241.1 0.025 0.770 0.351 0.767 3.376 0.510 0.040 6836G690/F 3/1 236.8 0.024 0.770 0.353 0.781 3.748 0.503 0.046 6836G692/F 3/1 244.1 0.023 0.743 0.336 0.699 3.447 0.519 0.031 6836G694/F 3/1 255.8 0.022 0.720 0.328 0.706 3.637 0.571 0.027 6836G697/F 3/1 252.0 0.027 0.731 0.334 0.798 3.368 0.531 0.054 6836G700/F 3/1 209.6 0.031 0.872 0.348 0.754 3.143 0.537 0.478 M e a n: 256.3 0.026 0.735 0.346 0.747 3.617 0.534 0.058 Standard deviation: 21.9 0.011 0.063 0.036 0.072 0.726 0.135 0.083 Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30) 6838H754/F 4/1 267.9 0.021 0.696 0.405 0.726 3.494 0.491 0.046 6838H755/F 4/1 229.6 0.021 0.778 0.338 1.030 3.358 0.483 0.042 6838H756/F 4/1 250.7 0.023 0.719 0.361 0.722 3.225 0.453 0.036 6838H758/F 4/1 247.8 0.025 0.751 0.365 0.873 3.557 0.523 0.050 6838H759/F 4/1 230.5 0.032 0.811 0.361 0.848 3.876 0.613 0.075 6838H760/F 4/1 245.1 0.024 0.769 0.371 0.772 3.640 0.544 0.042 6838H761/F 4/1 244.4 0.029 0.772 0.360 0.786 3.899 0.556 0.048 6838H762/F 4/1 237.7 0.024 0.770 0.376 0.808 3.638 0.549 0.033 6838H765/F 4/1 259.5 0.019 0.730 0.393 0.771 3.549 0.588 0.033 6838H767/F 4/1 251.5 0.023 0.753 0.316 0.754 3.433 0.558 0.036 6838H768/F 4/1 242.4 0.026 0.769 0.384 0.784 4.174 0.543 0.038 6838H769/F 4/1 232.5 0.022 0.811 0.342 0.751 3.402 0.512 0.042 6838H771/F 4/1 217.7 0.024 0.869 0.355 0.768 3.492 0.541 0.051 6838H773/F 4/1 256.8 0.023 0.715 0.305 0.737 3.646 0.481 0.040 6838H776/F 4/1 261.4 0.029 0.735 0.373 0.800 3.543 0.489 0.034 6838H777/F 4/1 242.5 0.024 0.703 0.367 0.764 3.319 0.478 0.044 6838H778/F 4/1 218.1 0.025 0.830 0.463 0.842 3.786 1.084 0.050 6838H779/F 4/1 265.1 0.023 0.693 0.338 0.761 3.194 0.483 0.039 6838H780/F 4/1 236.3 0.025 0.796 0.380 0.804 5.264 0.650 0.066 6838H781/F 4/1 244.3 0.020 0.769 0.382 0.774 3.569 0.524 0.045 6838H782/F 4/1 240.3 0.029 0.753 0.388 0.766 3.595 0.477 0.048 6838H784/F 4/1 202.7 0.030 0.955 0.412 0.833 2.535 0.624 0.044 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-26
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 4 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6838H787/F 4/1 266.0 0.027 0.702 0.302 0.826 4.293 0.649 0.044 6838H788/F 4/1 244.1 0.022 0.730 0.314 0.761 3.762 0.479 0.044 6838H789/F 4/1 247.7 0.023 0.778 0.386 0.806 3.439 0.551 0.060 6838H790/F 4/1 238.2 0.011 0.781 0.440 0.784 3.636 0.555 0.044 6838H791/F 4/1 265.6 0.021 0.713 0.372 0.807 4.468 0.820 0.028 6838H793/F 4/1 231.8 0.022 0.792 0.368 0.844 5.168 0.722 0.039 6838H794/F 4/1 258.7 0.026 0.714 0.326 0.760 3.326 0.469 0.043 6838H796/F 4/1 240.6 0.023 0.771 0.352 0.814 3.365 0.521 0.041 6838H798/F 4/1 256.0 0.022 0.734 0.316 0.750 3.575 0.467 0.038 6838H799/F 4/1 215.8 0.027 0.863 0.355 0.743 3.559 0.553 0.035 6838H800/F 4/1 247.9 0.025 0.739 0.338 0.863 4.525 0.652 0.038 M e a n: 243.6$ 0.024 0.766 0.364 0.795 3.706 0.566 0.043 Standard deviation: 15.7 0.004 0.056 0.036 0.058 0.540 0.123 0.010 Number of observ. : (33) (33) (33) (33) (33) (33) (33) (33) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-27
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 5 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen F e m a l e A n i m a l s 6832E451/F 1/1 290.9 0.308 0.204 6832E452/F 1/1 265.5 0.371 0.235 6832E456/F 1/1 272.8 0.908 0.360 6832E458/F 1/1 257.4 0.230 0.251 6832E460/F 1/1 277.6 0.475 1.440 6832E461/F 1/1 300.6 0.254 0.242 6832E462/F 1/1 304.3 0.588 0.248 6832E463/F 1/1 277.1 1.568 0.264 6832E464/F 1/1 217.4 1.961 0.280 6832E467/F 1/1 301.9 0.246 0.190 6832E472/F 1/1 165.8 0.333 0.444 6832E475/F 1/1 260.0 0.231 0.196 6832E478/F 1/1 263.4 0.254 0.307 6832E483/F 1/1 271.8 0.221 0.223 6832E486/F 1/1 265.4 0.272 0.209 6832E489/F 1/1 263.9 0.203 0.307 6832E490/F 1/1 223.6 1.899 0.266 6832E493/F 1/1 230.8 6.723 0.224 6832E495/F 1/1 301.6 0.220 0.323 6832E497/F 1/1 269.1 0.742 0.313 6832E498/F 1/1 254.1 0.197 0.324 6832E500/F 1/1 303.6 0.538 0.174 M e a n: 265.4 0.852 0.319 Standard deviation: 33.3 1.419 0.258 Number of observ. : (22) (22) (22) 6834F551/F 2/1 280.6 0.479 0.242 6834F553/F 2/1 278.5 0.323 0.207 6834F554/F 2/1 281.2 0.184 0.191 6834F555/F 2/1 297.4 0.290 0.229 6834F557/F 2/1 264.6 0.224 0.494 6834F558/F 2/1 263.2 0.302 0.276 6834F559/F 2/1 245.3 0.329 0.241 6834F560/F 2/1 283.1 0.224 0.218 6834F561/F 2/1 277.0 0.294 0.334 6834F563/F 2/1 288.7 0.225 0.454 6834F564/F 2/1 221.5 0.258 0.220 6834F569/F 2/1 312.4 0.247 0.256 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-28
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 6 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6834F570/F 2/1 268.6 0.803 0.264 6834F573/F 2/1 258.5 0.242 0.299 6834F574/F 2/1 265.2 0.233 0.371 6834F575/F 2/1 309.2 0.333 0.472 6834F579/F 2/1 299.6 1.533 0.212 6834F580/F 2/1 296.3 0.425 0.247 6834F583/F 2/1 276.2 0.220 0.319 6834F584/F 2/1 258.5 1.028 0.342 6834F585/F 2/1 234.6 0.626 0.328 6834F586/F 2/1 286.9 0.273 0.207 6834F587/F 2/1 282.6 0.302 0.220 6834F588/F 2/1 267.6 0.260 0.278 6834F591/F 2/1 256.1 0.471 0.260 6834F592/F 2/1 274.7 0.262 0.209 6834F596/F 2/1 262.2 0.278 0.285 6834F597/F 2/1 280.2 0.225 0.238 6834F598/F 2/1 252.7 0.207 0.332 6834F600/F 2/1 280.6 0.739 0.221 M e a n: 273.5 0.395 0.282 Standard deviation: 20.4 0.293 0.080 Number of observ. : (30) (30) (30) 6836G651/F 3/1 262.8 0.245 0.433 6836G652/F 3/1 277.7 0.553 0.221 6836G654/F 3/1 238.3 0.356 0.245 6836G655/F 3/1 259.9 0.541 0.225 6836G656/F 3/1 277.7 0.259 0.309 6836G657/F 3/1 263.5 0.233 0.235 6836G658/F 3/1 274.9 0.350 0.194 6836G660/F 3/1 295.8 0.860 0.248 6836G661/F 3/1 242.0 0.395 1.279 6836G662/F 3/1 234.8 0.262 0.311 6836G663/F 3/1 258.5 0.272 0.270 6836G666/F 3/1 226.0 0.174 0.300 6836G667/F 3/1 271.4 0.235 0.479 6836G668/F 3/1 212.8 0.159 0.515 6836G669/F 3/1 256.3 0.261 0.535 6836G670/F 3/1 267.4 0.258 0.310 6836G672/F 3/1 283.2 0.405 0.201 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-29
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 7 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6836G673/F 3/1 242.1 0.219 0.474 6836G674/F 3/1 287.6 0.242 0.306 6836G675/F 3/1 257.6 1.317 0.274 6836G677/F 3/1 268.4 0.282 0.251 6836G681/F 3/1 272.3 0.216 0.335 6836G684/F 3/1 287.6 0.289 0.216 6836G686/F 3/1 231.0 1.120 0.331 6836G689/F 3/1 241.1 0.343 0.379 6836G690/F 3/1 236.8 0.268 0.455 6836G692/F 3/1 244.1 0.208 0.222 6836G694/F 3/1 255.8 0.679 0.285 6836G697/F 3/1 252.0 0.254 0.377 6836G700/F 3/1 209.6 0.221 1.522 M e a n: 256.3 0.383 0.391 Standard deviation: 21.9 0.275 0.293 Number of observ. : (30) (30) (30) 6838H754/F 4/1 267.9 0.216 0.252 6838H755/F 4/1 229.6 0.317 0.287 6838H756/F 4/1 250.7 0.274 0.233 6838H758/F 4/1 247.8 0.307 0.345 6838H759/F 4/1 230.5 0.461 0.416 6838H760/F 4/1 245.1 0.272 0.297 6838H761/F 4/1 244.4 0.898 0.321 6838H762/F 4/1 237.7 0.504 0.292 6838H765/F 4/1 259.5 0.217 0.374 6838H767/F 4/1 251.5 1.676 0.485 6838H768/F 4/1 242.4 0.490 0.267 6838H769/F 4/1 232.5 0.243 0.864 6838H771/F 4/1 217.7 0.222 0.305 6838H773/F 4/1 256.8 0.256 0.332 6838H776/F 4/1 261.4 0.322 0.265 6838H777/F 4/1 242.5 0.330 0.229 6838H778/F 4/1 218.1 3.905 0.324 6838H779/F 4/1 265.1 0.326 0.212 6838H780/F 4/1 236.3 1.245 0.897 6838H781/F 4/1 244.3 0.236 0.278 6838H782/F 4/1 240.3 0.214 0.247 6838H784/F 4/1 202.7 0.220 0.295 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-30
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 8 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6838H787/F 4/1 266.0 0.685 0.341 6838H788/F 4/1 244.1 0.261 0.245 6838H789/F 4/1 247.7 0.282 0.285 6838H790/F 4/1 238.2 0.254 0.310 6838H791/F 4/1 265.6 4.664 0.270 6838H793/F 4/1 231.8 1.073 0.367 6838H794/F 4/1 258.7 0.252 0.366 6838H796/F 4/1 240.6 0.289 0.291 6838H798/F 4/1 256.0 0.246 0.280 6838H799/F 4/1 215.8 0.234 0.242 6838H800/F 4/1 247.9 1.334 0.423 M e a n: 243.6$ 0.689 0.341 Standard deviation: 15.7 1.003 0.152 Number of observ. : (33) (33) (33) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-31
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-3 Percent Organ to Brain Weight, Male and Female, Final Sacrifice 

K-32
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs M a l e A n i m a l s 6831E407/M 1/1 403.2 3.524 100.000 35.011 63.570 144.485 690.206 85.263 6831E413/M 1/1 379.5 3.674 100.000 13.377 54.875 121.903 679.651 86.057 6831E415/M 1/1 395.5 3.070 100.000 24.844 52.854 141.055 1078.513 106.475 6831E418/M 1/1 398.8 3.459 100.000 28.967 58.487 141.006 652.860 85.932 6831E422/M 1/1 384.3 2.602 100.000 35.229 54.072 138.458 637.880 82.988 6831E435/M 1/1 355.1 3.776 100.000 38.107 63.315 160.520 833.006 85.091 6831E436/M 1/1 393.1 3.359 100.000 16.650 56.134 141.967 736.904 79.796 6831E437/M 1/1 398.3 3.521 100.000 45.915 57.418 127.606 575.352 81.455 6831E440/M 1/1 396.8 20.883 100.000 17.845 58.424 136.213 670.669 85.857 6831E442/M 1/1 383.6 4.596 100.000 23.648 51.795 159.837 1457.492 119.914 6831E443/M 1/1 404.7 3.317 100.000 21.971 55.865 134.423 628.365 80.192 6831E446/M 1/1 352.3 2.895 100.000 23.160 60.550 131.551 784.495 120.020 6831E448/M 1/1 396.0 2.938 100.000 24.241 49.951 129.187 626.543 86.729 6831E449/M 1/1 418.7 3.670 100.000 16.972 60.596 130.092 685.321 93.578 M e a n: 390.0 4.663 100.000 26.138 56.993 138.450 766.947 91.382 Standard deviation: 18.2 4.693 0.000 9.394 4.133 11.172 234.397 13.819 Number of observ. : (14) (14) (14) (14) (14) (14) (14) (14) 6833F502/M 2/1 384.3 3.953 100.000 16.894 63.294 131.953 633.694 85.082 6833F505/M 2/1 400.1 3.002 100.000 19.560 61.381 147.724 770.285 96.148 6833F508/M 2/1 387.3 3.430 100.000 29.952 60.725 141.498 655.990 104.444 6833F511/M 2/1 411.5 3.175 100.000 18.487 61.811 135.808 667.274 93.604 6833F513/M 2/1 280.5 3.563 100.000 17.318 51.163 126.571 588.669 148.046 6833F516/M 2/1 377.9 3.563 100.000 20.742 52.855 126.647 859.297 124.597 6833F519/M 2/1 416.2 3.152 100.000 20.774 65.043 151.958 629.847 94.031 6833F521/M 2/1 335.6 3.996 100.000 18.762 61.111 128.314 930.458 188.596 6833F523/M 2/1 408.3 2.513 100.000 23.055 52.537 133.253 611.165 105.462 6833F525/M 2/1 393.6 83.071 100.000 17.597 57.177 160.658 840.439 118.979 6833F526/M 2/1 362.5 4.214 100.000 25.429 55.904 194.023 879.079 122.636 6833F535/M 2/1 409.1 3.432 100.000 18.511 57.854 151.426 631.320 109.715 6833F536/M 2/1 340.7 3.397 100.000 26.842 54.593 126.077 551.292 78.947 6833F542/M 2/1 365.4 3.304 100.000 23.570 56.755 132.249 638.955 89.398 6833F547/M 2/1 366.3 3.462 100.000 24.235 62.318 145.108 656.197 87.356 6833F550/M 2/1 368.4 3.205 100.000 16.367 52.647 235.794 917.484 89.995 M e a n: 375.5 8.402 100.000 21.131 57.948 148.066 716.340 108.565 Standard deviation: 35.2 19.916 0.000 3.984 4.391 29.120 127.367 27.970 Number of observ. : (16) (16) (16) (16) (16) (16) (16) (16) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-33
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6835G601/M 3/1 382.8 2.407 100.000 19.114 47.761 130.814 600.915 89.504 6835G602/M 3/1 368.3 5.333 100.000 16.810 57.143 147.429 690.857 100.000 6835G603/M 3/1 375.0 3.057 100.000 16.321 51.824 140.878 646.351 92.604 6835G605/M 3/1 354.7 4.738 100.000 17.868 60.464 148.963 709.279 141.066 6835G607/M 3/1 372.0 3.303 100.000 18.310 55.172 148.664 725.206 82.030 6835G609/M 3/1 394.9 3.267 100.000 18.362 57.662 141.371 650.759 90.152 6835G610/M 3/1 368.2 2.995 100.000 15.208 52.550 127.000 565.466 94.057 6835G613/M 3/1 374.6 3.043 100.000 17.633 57.343 127.923 615.459 92.222 6835G614/M 3/1 389.1 3.445 100.000 28.278 69.665 147.751 688.325 94.450 6835G615/M 3/1 349.7 3.493 100.000 18.756 53.397 154.019 803.062 153.732 6835G617/M 3/1 359.5 4.424 100.000 20.463 57.717 156.963 662.092 85.721 6835G621/M 3/1 350.0 4.579 100.000 18.948 51.291 127.082 680.662 84.705 6835G628/M 3/1 378.2 3.279 100.000 20.166 63.730 137.004 660.793 96.182 6835G630/M 3/1 366.6 3.713 100.000 14.513 52.797 136.162 660.849 97.059 6835G634/M 3/1 396.2 3.249 100.000 25.565 62.288 160.122 758.427 95.198 6835G638/M 3/1 392.6 3.185 100.000 23.326 71.897 147.728 771.382 116.862 6835G639/M 3/1 383.2 3.970 100.000 20.050 64.020 142.928 699.007 130.471 6835G647/M 3/1 401.1 3.335 100.000 22.582 57.599 134.254 726.918 87.994 6835G648/M 3/1 268.6 3.798 100.000 28.686 50.275 169.665 668.816 121.289 6835G649/M 3/1 349.5 3.485 100.000 20.378 54.792 131.026 680.155 85.818 M e a n: 368.7 3.605 100.000 20.067% 57.469 142.887 683.239 101.556 Standard deviation: 28.5 0.697 0.000 3.899 6.335 11.804 57.029 20.173 Number of observ. : (20) (20) (20) (20) (20) (20) (20) (20) 6837H702/M 4/1 382.2 3.473 100.000 20.362 55.186 146.289 679.305 94.006 6837H704/M 4/1 397.1 3.516 100.000 26.060 58.092 135.742 675.626 82.081 6837H705/M 4/1 399.2 3.092 100.000 20.904 56.437 170.697 860.268 169.312 6837H706/M 4/1 356.7 3.307 100.000 26.972 57.487 151.110 697.307 91.450 6837H708/M 4/1 346.6 3.255 100.000 15.870 53.611 153.815 1133.164 120.244 6837H714/M 4/1 335.0 3.297 100.000 22.244 47.933 146.014 697.441 82.037 6837H717/M 4/1 371.8 3.850 100.000 20.162 59.625 174.012 634.347 96.505 6837H722/M 4/1 335.5 3.375 100.000 18.901 48.505 142.237 1051.061 158.679 6837H724/M 4/1 351.4 3.283 100.000 17.964 59.615 187.289 751.501 127.111 6837H725/M 4/1 271.3 4.577 100.000 22.284 52.314 154.779 880.885 137.072 6837H726/M 4/1 376.6 3.942 100.000 17.080 54.939 143.163 737.908 90.462 6837H728/M 4/1 348.4 3.033 100.000 15.217 53.994 130.334 707.836 84.125 6837H729/M 4/1 355.9 3.417 100.000 16.458 55.390 126.083 656.737 92.493 6837H735/M 4/1 357.6 3.688 100.000 25.570 53.518 137.458 664.386 86.075 6837H736/M 4/1 371.5 3.755 100.000 29.891 61.462 160.326 785.672 96.146 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-34
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6837H739/M 4/1 371.6 2.744 100.000 26.213 57.031 143.900 637.286 87.604 6837H741/M 4/1 361.3 3.950 100.000 19.000 55.650 137.200 732.050 95.400 6837H747/M 4/1 365.8 4.530 100.000 20.434 54.507 154.460 759.226 81.454 6837H749/M 4/1 328.0 2.683 100.000 14.878 53.268 127.902 579.122 92.146 M e a n: 357.0+ 3.514 100.000 20.867 55.188 148.569% 753.744 103.390 Standard deviation: 28.4 0.509 0.000 4.369 3.448 16.102 140.921 26.354 Number of observ. : (19) (19) (19) (19) (19) (19) (19) (19) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-35
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 4 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen M a l e A n i m a l s 6831E407/M 1/1 403.2 54.828 178.719 6831E413/M 1/1 379.5 84.880 268.818 6831E415/M 1/1 395.5 217.746 686.187 6831E418/M 1/1 398.8 107.011 224.539 6831E422/M 1/1 384.3 108.482 199.229 6831E435/M 1/1 355.1 79.647 135.360 6831E436/M 1/1 393.1 81.159 234.567 6831E437/M 1/1 398.3 61.455 137.230 6831E440/M 1/1 396.8 51.068 98.291 6831E442/M 1/1 383.6 365.869 253.279 6831E443/M 1/1 404.7 79.856 234.663 6831E446/M 1/1 352.3 228.754 129.588 6831E448/M 1/1 396.0 116.993 261.753 6831E449/M 1/1 418.7 83.028 408.624 M e a n: 390.0 122.912 246.489 Standard deviation: 18.2 88.492 148.817 Number of observ. : (14) (14) (14) 6833F502/M 2/1 384.3 87.247 321.318 6833F505/M 2/1 400.1 91.996 444.522 6833F508/M 2/1 387.3 86.135 288.406 6833F511/M 2/1 411.5 80.252 329.318 6833F513/M 2/1 280.5 267.244 77.932 6833F516/M 2/1 377.9 295.266 321.669 6833F519/M 2/1 416.2 94.651 247.039 6833F521/M 2/1 335.6 1021.832 156.530 6833F523/M 2/1 408.3 146.786 253.697 6833F525/M 2/1 393.6 185.312 208.441 6833F526/M 2/1 362.5 240.911 205.781 6833F535/M 2/1 409.1 209.908 257.032 6833F536/M 2/1 340.7 45.742 205.837 6833F542/M 2/1 365.4 91.963 229.043 6833F547/M 2/1 366.3 60.612 191.721 6833F550/M 2/1 368.4 100.971 430.257 M e a n: 375.5 194.177 260.534 Standard deviation: 35.2 233.918 94.668 Number of observ. : (16) (16) (16) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-36
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 5 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6835G601/M 3/1 382.8 76.986 490.467 6835G602/M 3/1 368.3 114.857 437.143 6835G603/M 3/1 375.0 91.026 138.856 6835G605/M 3/1 354.7 446.150 151.185 6835G607/M 3/1 372.0 61.680 272.754 6835G609/M 3/1 394.9 97.285 414.588 6835G610/M 3/1 368.2 100.608 440.103 6835G613/M 3/1 374.6 77.923 370.821 6835G614/M 3/1 389.1 73.828 347.895 6835G615/M 3/1 349.7 510.431 173.732 6835G617/M 3/1 359.5 122.373 109.754 6835G621/M 3/1 350.0 89.235 371.213 6835G628/M 3/1 378.2 63.485 321.047 6835G630/M 3/1 366.6 131.967 198.746 6835G634/M 3/1 396.2 96.846 207.957 6835G638/M 3/1 392.6 195.785 299.672 6835G639/M 3/1 383.2 140.397 291.414 6835G647/M 3/1 401.1 66.556 339.495 6835G648/M 3/1 268.6 151.124 188.456 6835G649/M 3/1 349.5 186.883 193.369 M e a n: 368.7 144.771 287.933 Standard deviation: 28.5 120.685 113.072 Number of observ. : (20) (20) (20) 6837H702/M 4/1 382.2 98.668 431.018 6837H704/M 4/1 397.1 107.852 193.208 6837H705/M 4/1 399.2 388.233 207.522 6837H706/M 4/1 356.7 66.651 126.594 6837H708/M 4/1 346.6 694.710 407.681 6837H714/M 4/1 335.0 44.980 406.693 6837H717/M 4/1 371.8 94.630 322.442 6837H722/M 4/1 335.5 944.986 93.877 6837H724/M 4/1 351.4 110.131 223.311 6837H725/M 4/1 271.3 1014.839 102.163 6837H726/M 4/1 376.6 74.112 527.007 6837H728/M 4/1 348.4 69.060 460.769 6837H729/M 4/1 355.9 191.867 319.779 6837H735/M 4/1 357.6 81.951 342.164 6837H736/M 4/1 371.5 37.352 363.785 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-37
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 6 Scheduled Sacrifices FS Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6837H739/M 4/1 371.6 68.839 330.671 6837H741/M 4/1 361.3 195.000 381.150 6837H747/M 4/1 365.8 84.379 311.892 6837H749/M 4/1 328.0 79.707 318.878 M e a n: 357.0+ 234.102 308.979 Standard deviation: 28.4 305.078 122.086 Number of observ. : (19) (19) (19) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-38
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries F e m a l e A n i m a l s 6832E451/F 1/1 290.9 3.682 100.000 55.016 103.095 550.694 77.481 4.909 6832E452/F 1/1 265.5 4.008 100.000 47.996 101.002 461.551 67.300 6.857 6832E456/F 1/1 272.8 3.789 100.000 51.016 100.000 513.619 75.069 4.778 6832E458/F 1/1 257.4 2.906 100.000 46.986 93.219 463.886 64.909 5.920 6832E460/F 1/1 277.6 3.505 100.000 49.549 97.716 514.923 71.907 4.992 6832E461/F 1/1 300.6 3.887 100.000 58.056 103.683 540.256 67.928 4.962 6832E462/F 1/1 304.3 3.655 100.000 44.543 108.982 644.282 99.582 5.431 6832E463/F 1/1 277.1 3.689 100.000 47.797 97.387 540.779 95.953 4.764 6832E464/F 1/1 217.4 3.328 100.000 51.173 98.691 361.702 110.475 3.819 6832E467/F 1/1 301.9 3.590 100.000 47.677 100.211 492.344 75.396 6.072 6832E472/F 1/1 165.8 4.296 100.000 50.458 196.850 375.773 71.592 4.983 6832E475/F 1/1 260.0 3.029 100.000 41.735 92.094 409.343 67.864 5.801 6832E478/F 1/1 263.4 2.924 100.000 42.141 98.433 449.295 67.467 5.274 6832E483/F 1/1 271.8 3.407 100.000 44.348 93.294 478.691 67.658 6.544 6832E486/F 1/1 265.4 3.122 100.000 45.856 100.377 465.070 71.313 5.274 6832E489/F 1/1 263.9 3.498 100.000 44.136 95.165 436.728 62.449 4.835 6832E490/F 1/1 223.6 2.740 100.000 48.736 95.416 624.658 155.479 3.741 6832E493/F 1/1 230.8 3.289 100.000 50.925 103.032 517.832 151.490 1.799 6832E495/F 1/1 301.6 4.192 100.000 53.586 105.152 496.566 75.808 27.727 6832E497/F 1/1 269.1 3.479 100.000 50.193 96.080 538.874 80.508 5.135 6832E498/F 1/1 254.1 3.169 100.000 43.964 89.638 365.241 61.720 5.332 6832E500/F 1/1 303.6 3.316 100.000 54.947 104.895 489.211 74.368 5.526 M e a n: 265.4 3.477 100.000 48.674 103.382 487.787 82.442 6.113 Standard deviation: 33.3 0.411 0.000 4.349 21.414 73.459 25.995 4.937 Number of observ. : (22) (22) (22) (22) (22) (22) (22) (22) 6834F551/F 2/1 280.6 2.615 100.000 43.223 105.283 568.890 75.827 5.283 6834F553/F 2/1 278.5 3.557 100.000 45.876 102.165 458.144 69.381 5.361 6834F554/F 2/1 281.2 3.238 100.000 47.491 103.508 494.873 77.658 5.720 6834F555/F 2/1 297.4 3.749 100.000 48.258 102.587 525.449 75.554 7.814 6834F557/F 2/1 264.6 2.940 100.000 50.709 101.837 427.717 68.609 7.139 6834F558/F 2/1 263.2 3.601 100.000 50.355 106.056 555.156 66.830 5.837 6834F559/F 2/1 245.3 3.700 100.000 48.847 96.783 422.359 66.649 5.737 6834F560/F 2/1 283.1 3.098 100.000 46.154 104.543 441.817 68.973 4.956 6834F561/F 2/1 277.0 3.638 100.000 50.331 110.254 500.000 73.980 6.340 6834F563/F 2/1 288.7 3.970 100.000 55.955 113.144 569.689 67.543 7.135 6834F564/F 2/1 221.5 3.309 100.000 43.803 109.086 432.698 66.910 6.562 6834F569/F 2/1 312.4 4.236 100.000 50.941 106.067 575.314 68.776 6.067 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-39
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6834F570/F 2/1 268.6 3.119 100.000 40.696 95.322 485.603 66.580 6.341 6834F573/F 2/1 258.5 3.299 100.000 46.729 98.681 447.554 68.389 3.793 6834F574/F 2/1 265.2 3.412 100.000 46.615 102.862 461.750 71.491 6.109 6834F575/F 2/1 309.2 3.502 100.000 45.897 107.632 485.886 70.570 5.593 6834F579/F 2/1 299.6 3.713 100.000 52.981 115.167 644.195 87.866 5.858 6834F580/F 2/1 296.3 3.381 100.000 47.491 103.751 473.112 64.131 5.917 6834F583/F 2/1 276.2 2.921 100.000 52.321 97.966 447.105 75.796 7.407 6834F584/F 2/1 258.5 2.599 100.000 44.615 61.485 1225.252 82.175 9.761 6834F585/F 2/1 234.6 3.014 100.000 50.978 94.553 456.795 97.885 5.130 6834F586/F 2/1 286.9 3.929 100.000 44.187 99.516 482.939 71.367 5.544 6834F587/F 2/1 282.6 3.227 100.000 50.286 101.562 457.887 68.662 6.143 6834F588/F 2/1 267.6 2.822 100.000 57.613 103.880 509.112 79.953 7.407 6834F591/F 2/1 256.1 3.251 100.000 47.037 100.787 449.712 71.159 5.716 6834F592/F 2/1 274.7 3.050 100.000 48.154 99.893 431.728 73.141 5.778 6834F596/F 2/1 262.2 3.491 100.000 44.576 101.450 600.591 68.260 23.308 6834F597/F 2/1 280.2 3.499 100.000 44.698 97.667 463.574 72.057 7.052 6834F598/F 2/1 252.7 3.071 100.000 43.588 102.802 458.459 66.433 4.741 6834F600/F 2/1 280.6 3.237 100.000 40.493 95.272 512.025 82.374 6.783 M e a n: 273.5 3.340 100.000 47.697 101.385 515.513 72.833 6.744 Standard deviation: 20.4 0.388 0.000 4.042 9.040 145.286 7.328 3.318 Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30) 6836G651/F 3/1 262.8 3.421 100.000 46.947 109.474 480.053 69.211 4.211 6836G652/F 3/1 277.7 3.491 100.000 43.095 100.886 516.936 72.486 6.514 6836G654/F 3/1 238.3 3.550 100.000 46.696 112.288 544.675 65.101 3.332 6836G655/F 3/1 259.9 3.930 100.000 44.981 111.365 551.514 74.243 4.036 6836G656/F 3/1 277.7 3.391 100.000 45.694 105.059 464.047 67.546 4.467 6836G657/F 3/1 263.5 3.208 100.000 49.538 105.003 463.458 67.809 6.090 6836G658/F 3/1 274.9 3.231 100.000 48.676 104.714 479.025 64.407 4.661 6836G660/F 3/1 295.8 4.579 100.000 51.384 112.087 1077.104 92.439 5.005 6836G661/F 3/1 242.0 2.350 100.000 54.754 98.611 479.541 76.496 22.489 6836G662/F 3/1 234.8 3.432 100.000 43.578 91.160 409.256 62.715 4.888 6836G663/F 3/1 258.5 2.749 100.000 45.768 102.372 513.477 70.620 5.283 6836G666/F 3/1 226.0 2.821 100.000 42.476 88.506 404.023 60.867 4.336 6836G667/F 3/1 271.4 3.644 100.000 44.506 96.300 466.483 70.569 6.074 6836G668/F 3/1 212.8 9.287 100.000 44.870 87.203 372.786 58.855 6.857 6836G669/F 3/1 256.3 3.158 100.000 56.621 110.693 582.382 79.723 5.706 6836G670/F 3/1 267.4 3.137 100.000 46.295 113.791 487.345 66.793 4.922 6836G672/F 3/1 283.2 3.568 100.000 51.027 96.649 479.405 64.108 5.730 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-40
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6836G673/F 3/1 242.1 2.760 100.000 48.431 90.043 395.455 71.483 6.115 6836G674/F 3/1 287.6 3.363 100.000 46.243 106.674 513.295 68.313 4.834 6836G675/F 3/1 257.6 2.751 100.000 52.540 105.132 595.344 105.608 6.455 6836G677/F 3/1 268.4 3.199 100.000 40.970 100.619 460.681 65.428 5.315 6836G681/F 3/1 272.3 3.269 100.000 57.032 101.713 439.024 65.439 6.072 6836G684/F 3/1 287.6 3.286 100.000 44.085 97.017 461.325 64.206 6.471 6836G686/F 3/1 231.0 3.896 100.000 51.221 122.805 551.117 138.961 5.299 6836G689/F 3/1 241.1 3.231 100.000 45.611 99.569 438.288 66.236 5.223 6836G690/F 3/1 236.8 3.072 100.000 45.858 101.426 486.835 65.387 6.034 6836G692/F 3/1 244.1 3.034 100.000 45.229 94.098 464.203 69.829 4.137 6836G694/F 3/1 255.8 3.094 100.000 45.494 98.046 505.103 79.262 3.800 6836G697/F 3/1 252.0 3.694 100.000 45.736 109.180 460.891 72.732 7.333 6836G700/F 3/1 209.6 3.556 100.000 39.934 86.433 360.339 61.597 54.814 M e a n: 256.3 3.505 100.000 47.176 101.964 496.780 72.616 7.550 Standard deviation: 21.9 1.171 0.000 4.232 8.703 123.142 15.686 9.509 Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30) 6838H754/F 4/1 267.9 2.949 100.000 58.231 104.290 501.984 70.563 6.649 6838H755/F 4/1 229.6 2.744 100.000 43.393 132.475 431.747 62.038 5.375 6838H756/F 4/1 250.7 3.161 100.000 50.194 100.333 448.419 63.006 4.936 6838H758/F 4/1 247.8 3.332 100.000 48.576 116.282 473.563 69.694 6.663 6838H759/F 4/1 230.5 3.959 100.000 44.516 104.548 478.117 75.602 9.310 6838H760/F 4/1 245.1 3.183 100.000 48.223 100.371 473.263 70.716 5.517 6838H761/F 4/1 244.4 3.708 100.000 46.663 101.695 504.767 72.034 6.250 6838H762/F 4/1 237.7 3.116 100.000 48.879 104.975 472.717 71.296 4.265 6838H765/F 4/1 259.5 2.640 100.000 53.801 105.597 486.167 80.570 4.541 6838H767/F 4/1 251.5 3.117 100.000 41.944 100.106 456.101 74.115 4.754 6838H768/F 4/1 242.4 3.324 100.000 49.866 101.930 542.574 70.563 4.879 6838H769/F 4/1 232.5 2.653 100.000 42.175 92.573 419.576 63.183 5.199 6838H771/F 4/1 217.7 2.750 100.000 40.825 88.366 402.010 62.295 5.870 6838H773/F 4/1 256.8 3.270 100.000 42.616 103.106 510.300 67.302 5.559 6838H776/F 4/1 261.4 3.956 100.000 50.755 108.798 482.093 66.476 4.581 6838H777/F 4/1 242.5 3.404 100.000 52.230 108.744 472.477 68.016 6.279 6838H778/F 4/1 218.1 2.982 100.000 55.715 101.380 456.046 130.536 5.964 6838H779/F 4/1 265.1 3.268 100.000 48.802 109.858 461.220 69.771 5.610 6838H780/F 4/1 236.3 3.191 100.000 47.713 101.011 661.649 81.702 8.298 6838H781/F 4/1 244.3 2.662 100.000 49.734 100.692 464.324 68.158 5.857 6838H782/F 4/1 240.3 3.812 100.000 51.547 101.768 477.403 63.315 6.354 6838H784/F 4/1 202.7 3.152 100.000 43.101 87.287 265.478 65.323 4.651 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-41
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 4 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6838H787/F 4/1 266.0 3.856 100.000 42.957 117.729 611.462 92.501 6.213 6838H788/F 4/1 244.1 2.974 100.000 42.985 104.321 515.376 65.600 6.004 6838H789/F 4/1 247.7 2.905 100.000 49.637 103.579 441.805 70.851 7.676 6838H790/F 4/1 238.2 1.397 100.000 56.368 100.322 465.395 70.983 5.696 6838H791/F 4/1 265.6 3.011 100.000 52.139 113.154 626.836 115.055 3.962 6838H793/F 4/1 231.8 2.776 100.000 46.434 106.478 652.096 91.072 4.899 6838H794/F 4/1 258.7 3.575 100.000 45.666 106.446 466.143 65.710 6.013 6838H796/F 4/1 240.6 2.963 100.000 45.690 105.496 436.261 67.511 5.334 6838H798/F 4/1 256.0 3.035 100.000 43.024 102.236 487.327 63.685 5.218 6838H799/F 4/1 215.8 3.169 100.000 41.192 86.144 412.460 64.071 4.028 6838H800/F 4/1 247.9 3.384 100.000 45.688 116.812 612.336 88.210 5.131 M e a n: 243.6$ 3.133$ 100.000 47.615 104.209 486.954 73.986 5.683 Standard deviation: 15.7 0.483 0.000 4.625 8.959 77.866 14.988 1.154 Number of observ. : (33) (33) (33) (33) (33) (33) (33) (33) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-42
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 5 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen F e m a l e A n i m a l s 6832E451/F 1/1 290.9 47.812 31.590 6832E452/F 1/1 265.5 52.004 32.859 6832E456/F 1/1 272.8 136.079 53.981 6832E458/F 1/1 257.4 31.862 34.769 6832E460/F 1/1 277.6 69.995 212.268 6832E461/F 1/1 300.6 39.079 37.238 6832E462/F 1/1 304.3 93.420 39.373 6832E463/F 1/1 277.1 222.541 37.500 6832E464/F 1/1 217.4 232.624 33.224 6832E467/F 1/1 301.9 39.282 30.253 6832E472/F 1/1 165.8 31.615 42.153 6832E475/F 1/1 260.0 30.801 26.129 6832E478/F 1/1 263.4 34.987 42.245 6832E483/F 1/1 271.8 32.504 32.829 6832E486/F 1/1 265.4 38.805 29.817 6832E489/F 1/1 263.9 27.572 41.718 6832E490/F 1/1 223.6 223.709 31.349 6832E493/F 1/1 230.8 797.431 26.567 6832E495/F 1/1 301.6 33.586 49.242 6832E497/F 1/1 269.1 110.271 46.494 6832E498/F 1/1 254.1 25.151 41.398 6832E500/F 1/1 303.6 86.053 27.737 M e a n: 265.4 110.781 44.579 Standard deviation: 33.3 167.421 38.179 Number of observ. : (22) (22) (22) 6834F551/F 2/1 280.6 71.718 36.179 6834F553/F 2/1 278.5 46.340 29.691 6834F554/F 2/1 281.2 27.901 28.926 6834F555/F 2/1 297.4 45.459 35.903 6834F557/F 2/1 264.6 31.076 68.556 6834F558/F 2/1 263.2 43.372 39.607 6834F559/F 2/1 245.3 43.271 31.689 6834F560/F 2/1 283.1 32.731 31.853 6834F561/F 2/1 277.0 44.928 50.937 6834F563/F 2/1 288.7 34.818 70.279 6834F564/F 2/1 221.5 32.081 27.314 6834F569/F 2/1 312.4 40.324 41.893 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-43
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 6 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6834F570/F 2/1 268.6 112.058 36.850 6834F573/F 2/1 258.5 34.415 42.551 6834F574/F 2/1 265.2 33.957 54.210 6834F575/F 2/1 309.2 53.842 76.320 6834F579/F 2/1 299.6 240.220 33.211 6834F580/F 2/1 296.3 66.561 38.722 6834F583/F 2/1 276.2 31.768 45.905 6834F584/F 2/1 258.5 140.955 46.950 6834F585/F 2/1 234.6 77.684 40.719 6834F586/F 2/1 286.9 42.142 32.024 6834F587/F 2/1 282.6 44.456 32.431 6834F588/F 2/1 267.6 40.976 43.798 6834F591/F 2/1 256.1 63.293 34.976 6834F592/F 2/1 274.7 38.577 30.658 6834F596/F 2/1 262.2 39.151 40.064 6834F597/F 2/1 280.2 33.457 35.366 6834F598/F 2/1 252.7 28.125 45.205 6834F600/F 2/1 280.6 106.578 31.860 M e a n: 273.5 57.408 41.155 Standard deviation: 20.4 43.752 12.323 Number of observ. : (30) (30) (30) 6836G651/F 3/1 262.8 33.947 59.947 6836G652/F 3/1 277.7 79.990 32.048 6836G654/F 3/1 238.3 46.313 31.841 6836G655/F 3/1 259.9 74.615 31.067 6836G656/F 3/1 277.7 38.644 46.179 6836G657/F 3/1 263.5 33.442 33.714 6836G658/F 3/1 274.9 51.006 28.284 6836G660/F 3/1 295.8 135.463 39.084 6836G661/F 3/1 242.0 51.015 165.331 6836G662/F 3/1 234.8 31.981 38.014 6836G663/F 3/1 258.5 37.844 37.682 6836G666/F 3/1 226.0 20.533 35.371 6836G667/F 3/1 271.4 35.229 71.728 6836G668/F 3/1 212.8 18.251 59.125 6836G669/F 3/1 256.3 37.119 76.011 6836G670/F 3/1 267.4 37.263 44.835 6836G672/F 3/1 283.2 62.000 30.757 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-44
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 7 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6836G673/F 3/1 242.1 28.680 62.121 6836G674/F 3/1 287.6 36.626 46.295 6836G675/F 3/1 257.6 179.524 37.407 6836G677/F 3/1 268.4 39.112 34.830 6836G681/F 3/1 272.3 30.566 47.276 6836G684/F 3/1 287.6 41.962 31.395 6836G686/F 3/1 231.0 134.390 39.740 6836G689/F 3/1 241.1 44.588 49.165 6836G690/F 3/1 236.8 34.833 59.133 6836G692/F 3/1 244.1 28.020 29.950 6836G694/F 3/1 255.8 94.354 39.631 6836G697/F 3/1 252.0 34.818 51.548 6836G700/F 3/1 209.6 25.328 174.562 M e a n: 256.3 52.582 52.136 Standard deviation: 21.9 37.585 34.443 Number of observ. : (30) (30) (30) 6838H754/F 4/1 267.9 30.992 36.139 6838H755/F 4/1 229.6 40.705 36.898 6838H756/F 4/1 250.7 38.048 32.446 6838H758/F 4/1 247.8 40.838 45.943 6838H759/F 4/1 230.5 56.822 51.364 6838H760/F 4/1 245.1 35.385 38.621 6838H761/F 4/1 244.4 116.208 41.578 6838H762/F 4/1 237.7 65.555 37.944 6838H765/F 4/1 259.5 29.778 51.214 6838H767/F 4/1 251.5 222.715 64.448 6838H768/F 4/1 242.4 63.753 34.745 6838H769/F 4/1 232.5 29.920 106.578 6838H771/F 4/1 217.7 25.542 35.061 6838H773/F 4/1 256.8 35.858 46.431 6838H776/F 4/1 261.4 43.779 36.075 6838H777/F 4/1 242.5 46.948 32.629 6838H778/F 4/1 218.1 470.348 38.984 6838H779/F 4/1 265.1 47.113 30.664 6838H780/F 4/1 236.3 156.489 112.819 6838H781/F 4/1 244.3 30.671 36.155 6838H782/F 4/1 240.3 28.453 32.818 6838H784/F 4/1 202.7 22.997 30.904 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-45
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 8 Scheduled Sacrifices FS Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6838H787/F 4/1 266.0 97.590 48.527 6838H788/F 4/1 244.1 35.802 33.614 6838H789/F 4/1 247.7 36.203 36.618 6838H790/F 4/1 238.2 32.509 39.656 6838H791/F 4/1 265.6 654.411 37.824 6838H793/F 4/1 231.8 135.384 46.326 6838H794/F 4/1 258.7 35.320 51.246 6838H796/F 4/1 240.6 37.500 37.716 6838H798/F 4/1 256.0 33.546 38.232 6838H799/F 4/1 215.8 27.121 28.034 6838H800/F 4/1 247.9 180.459 57.260 M e a n: 243.6$ 90.447 44.409 Standard deviation: 15.7 133.066 18.723 Number of observ. : (33) (33) (33) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-46
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-4 Absolute Organ Weights, Male and Female, Euthanized Rats 

K-47
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs M a l e A n i m a l s 6831E401/M 1/1 350.8 0.067 2.189 0.638 1.271 2.753 18.056 3.101 6831E402/M 1/1 375.6 0.054 NT 1.014 1.285 2.751 13.564 3.020 6831E403/M 1/1 276.1 0.064 2.003 0.423 1.119 2.426 10.792 3.106 6831E404/M 1/1 494.2 0.071 2.094 0.881 1.380 2.824 15.373 2.889 6831E405/M 1/1 311.3 0.056 2.075 0.357 1.718 2.595 10.311 3.020 6831E406/M 1/1 224.4 0.095 1.974 0.731 0.976 1.930 4.063 1.383 6831E408/M 1/1 312.1 0.051 2.105 0.816 0.866 2.157 7.247 1.155 6831E409/M 1/1 300.4 0.069 2.094 0.554 0.842 2.464 11.069 2.218 6831E410/M 1/1 369.2 0.118 2.087 0.567 1.358 3.031 19.129 3.000 6831E411/M 1/1 339.4 0.064 2.078 0.440 1.098 2.920 19.761 3.954 6831E412/M 1/1 331.9 0.077 1.994 0.350 0.961 2.031 8.317 1.352 6831E414/M 1/1 255.3 0.109 2.105 0.536 1.181 2.465 7.873 3.661 6831E416/M 1/1 385.4 0.079 2.057 0.507 1.151 2.962 17.859 4.139 6831E417/M 1/1 372.5 0.072 2.055 0.902 1.257 2.590 10.233 1.764 6831E419/M 1/1 359.2 0.066 2.189 0.315 1.495 3.114 15.481 4.936 6831E420/M 1/1 355.4 0.065 1.983 0.472 1.066 2.720 12.879 2.606 6831E421/M 1/1 385.2 0.064 2.098 0.797 1.336 3.013 12.585 4.092 6831E423/M 1/1 381.1 0.061 2.135 0.834 1.203 2.721 13.786 3.266 6831E424/M 1/1 365.0 0.106 2.132 0.547 1.186 2.756 14.755 3.113 6831E426/M 1/1 282.1 0.077 2.076 0.413 1.363 2.563 9.207 3.273 6831E427/M 1/1 294.9 0.072 2.110 0.468 1.461 2.745 16.057 5.844 6831E428/M 1/1 355.2 0.071 2.023 0.562 1.232 2.457 10.804 2.004 6831E429/M 1/1 352.3 0.077 2.159 0.471 1.402 2.836 15.320 3.052 6831E430/M 1/1 327.7 0.074 2.083 0.466 1.240 2.340 7.638 2.530 6831E431/M 1/1 346.8 0.056 2.255 0.931 1.166 2.429 8.002 1.433 6831E432/M 1/1 379.0 0.047 2.047 0.505 1.439 2.869 17.505 3.255 6831E433/M 1/1 311.2 0.061 2.011 0.569 1.033 2.400 9.705 1.556 6831E434/M 1/1 317.5 0.093 2.020 0.594 1.221 3.216 12.553 1.681 6831E438/M 1/1 331.8 0.074 2.135 0.500 1.286 3.117 18.231 3.183 6831E439/M 1/1 417.3 0.029 1.965 1.138 1.053 2.513 13.050 1.473 6831E441/M 1/1 366.9 0.064 2.177 0.869 1.338 2.953 11.189 3.081 6831E444/M 1/1 331.1 0.085 2.011 0.574 1.072 2.575 16.132 3.394 6831E445/M 1/1 369.9 0.061 2.067 0.452 1.477 2.811 12.286 3.499 6831E447/M 1/1 353.4 0.062 2.044 0.521 1.174 2.587 19.636 3.600 6831E450/M 1/1 440.7 0.052 2.011 1.033 1.214 2.759 15.438 2.210 M e a n: 346.4 0.070 2.078 0.621 1.226 2.668 13.025 2.881 Standard deviation: 50.7 0.018 0.068 0.215 0.186 0.299 3.997 1.053 Number of observ. : (35) (35) (34) (35) (35) (35) (35) (35) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-48
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6833F504/M 2/1 344.8 0.408 2.188 0.369 1.283 2.980 20.773 3.603 6833F506/M 2/1 299.2 0.050 2.124 0.358 1.267 2.799 13.412 3.670 6833F507/M 2/1 367.4 0.067 2.048 0.615 1.392 2.877 16.133 3.189 6833F509/M 2/1 503.4 0.100 2.054 1.178 1.334 2.646 10.207 1.709 6833F510/M 2/1 314.7 0.079 2.057 0.433 1.220 2.539 8.993 1.614 6833F512/M 2/1 306.8 0.055 2.079 0.567 1.393 2.774 10.773 3.015 6833F514/M 2/1 395.1 0.040 1.986 0.810 1.134 2.886 13.112 1.860 6833F515/M 2/1 352.0 0.069 2.111 0.706 1.064 2.731 14.976 2.789 6833F517/M 2/1 408.0 0.047 2.142 0.735 1.344 2.979 18.906 3.348 6833F518/M 2/1 407.4 0.083 2.155 0.421 1.410 3.064 16.277 2.784 6833F520/M 2/1 324.1 0.112 2.056 0.518 1.441 4.755 16.535 2.587 6833F522/M 2/1 377.2 0.082 2.086 0.428 1.299 2.893 17.617 2.854 6833F527/M 2/1 357.5 0.072 1.972 0.903 1.193 2.994 15.175 2.008 6833F528/M 2/1 309.8 0.044 1.911 0.616 1.159 2.571 9.672 2.735 6833F529/M 2/1 444.5 0.066 2.055 0.909 1.257 2.697 12.470 1.640 6833F530/M 2/1 329.6 0.055 2.077 0.593 1.306 3.177 11.588 2.180 6833F531/M 2/1 355.2 0.082 2.117 0.621 1.323 2.640 10.398 1.685 6833F532/M 2/1 314.7 0.061 2.076 0.870 1.235 2.563 16.010 6.447 6833F533/M 2/1 388.3 0.054 2.036 0.820 1.861 3.611 23.559 2.372 6833F534/M 2/1 247.0 0.047 1.993 0.431 1.332 2.378 11.087 2.822 6833F537/M 2/1 338.3 0.062 2.130 0.432 0.967 2.901 10.246 4.123 6833F538/M 2/1 369.0 0.066 2.087 0.514 1.345 2.805 9.488 3.811 6833F539/M 2/1 259.2 0.093 2.088 0.445 1.041 2.184 5.004 1.475 6833F540/M 2/1 300.4 0.066 2.155 1.029 1.285 2.863 9.134 2.912 6833F543/M 2/1 325.3 0.061 1.990 0.338 0.924 3.166 14.003 7.326 6833F544/M 2/1 352.7 0.115 1.957 0.432 1.957 2.719 19.204 2.962 6833F545/M 2/1 367.1 0.105 2.015 0.716 1.555 2.832 20.436 3.346 6833F546/M 2/1 350.7 0.077 1.994 0.341 1.168 4.144 14.791 2.855 6833F548/M 2/1 472.7 0.103 2.231 0.500 1.443 3.444 20.929 2.750 M e a n: 354.6 0.083 2.068 0.609 1.308 2.952% 14.169 2.982 Standard deviation: 56.9 0.066 0.073 0.222 0.220 0.511 4.439 1.294 Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29) 6835G604/M 3/1 334.8 0.086 2.045 0.383 1.183 4.068 14.831 12.192 6835G606/M 3/1 411.5 0.077 2.164 0.657 1.414 3.384 17.916 3.296 6835G608/M 3/1 319.0 0.065 2.109 0.339 1.925 3.072 14.188 3.425 6835G611/M 3/1 290.7 0.096 2.132 0.671 1.229 2.722 9.697 2.837 6835G612/M 3/1 317.1 0.097 2.133 0.379 1.240 2.696 13.715 3.837 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-49
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6835G616/M 3/1 350.1 0.079 2.093 0.381 1.426 3.154 18.545 2.912 6835G618/M 3/1 333.2 0.064 2.105 0.519 1.405 3.009 15.624 3.645 6835G619/M 3/1 321.5 0.106 2.126 0.399 1.376 2.973 14.882 2.455 6835G620/M 3/1 334.6 0.060 2.102 0.326 1.374 3.046 18.077 3.961 6835G622/M 3/1 312.8 0.101 2.094 0.343 1.206 2.920 13.806 3.501 6835G623/M 3/1 381.3 0.056 1.963 0.932 0.996 2.589 10.735 1.753 6835G624/M 3/1 310.6 0.054 2.011 0.376 1.100 2.539 11.563 2.475 6835G626/M 3/1 347.1 0.054 2.126 0.416 1.218 3.293 15.272 2.513 6835G629/M 3/1 316.6 0.097 2.117 0.498 1.191 2.823 12.467 2.638 6835G631/M 3/1 362.6 0.079 2.103 0.395 1.502 3.095 18.217 3.681 6835G632/M 3/1 323.8 0.062 2.065 0.366 1.207 2.672 11.730 2.627 6835G633/M 3/1 420.2 0.064 2.032 0.450 1.102 2.977 16.475 1.907 6835G635/M 3/1 307.0 0.097 2.150 0.389 1.368 2.718 12.549 1.955 6835G637/M 3/1 326.4 0.068 1.963 0.420 1.020 2.620 13.268 3.350 6835G640/M 3/1 291.4 0.068 2.026 0.515 1.137 2.628 13.620 3.804 6835G641/M 3/1 349.9 0.070 2.088 0.459 1.381 3.146 17.440 2.426 6835G642/M 3/1 334.1 0.085 2.077 0.503 1.493 3.088 19.408 3.470 6835G643/M 3/1 407.3 0.070 2.182 0.661 1.126 2.832 14.897 1.639 6835G644/M 3/1 353.4 0.062 2.064 0.768 1.358 2.640 14.950 2.947 6835G645/M 3/1 323.0 0.079 2.079 0.539 1.212 2.698 11.354 1.599 6835G646/M 3/1 356.0 0.228 2.023 0.389 1.325 3.409 20.089 3.383 6835G650/M 3/1 341.9 0.094 1.979 0.848 1.291 2.893 11.282 1.549 M e a n: 339.9 0.082 2.080 0.493* 1.289 2.952$ 14.689 3.177 Standard deviation: 33.5 0.033 0.058 0.162 0.187 0.332 2.837 1.951 Number of observ. : (27) (27) (27) (27) (27) (27) (27) (27) 6837H701/M 4/1 253.6 0.099 1.936 0.319 1.277 3.963 12.811 2.753 6837H703/M 4/1 435.2 0.089 2.047 0.634 1.172 2.976 16.387 1.810 6837H707/M 4/1 353.8 0.176 2.044 0.464 1.667 3.290 16.235 2.636 6837H709/M 4/1 362.3 0.049 2.046 0.430 1.249 3.339 21.619 2.819 6837H710/M 4/1 305.8 0.070 2.057 0.511 1.184 2.892 10.710 2.318 6837H711/M 4/1 358.8 0.104 2.001 0.690 1.232 2.941 13.089 1.775 6837H712/M 4/1 348.6 0.058 2.063 0.627 0.913 10.570 12.507 1.666 6837H713/M 4/1 301.4 0.119 1.993 0.587 1.245 4.506 16.514 2.528 6837H715/M 4/1 365.1 0.074 2.149 0.408 1.340 3.469 22.555 3.104 6837H716/M 4/1 411.5 0.071 2.070 1.033 1.004 3.006 14.766 1.809 6837H719/M 4/1 365.4 0.050 1.977 0.784 1.272 3.029 15.246 2.630 6837H720/M 4/1 301.7 0.053 2.074 0.331 1.158 2.740 14.915 2.507 6837H721/M 4/1 362.5 0.083 2.077 0.425 1.150 3.121 13.846 1.613 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-50
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 4 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6837H723/M 4/1 333.5 0.066 2.025 0.596 0.999 2.869 15.792 3.120 6837H727/M 4/1 304.8 0.068 1.962 0.334 1.612 2.935 13.028 2.648 6837H730/M 4/1 334.0 0.073 2.111 0.461 1.408 2.720 10.924 1.843 6837H731/M 4/1 304.6 0.028 2.045 0.475 0.981 2.743 14.176 3.262 6837H733/M 4/1 298.5 0.056 2.048 0.621 1.038 2.505 16.073 3.204 6837H734/M 4/1 316.5 0.096 2.031 0.382 1.172 3.114 21.333 3.271 6837H737/M 4/1 323.8 0.069 2.024 0.311 1.456 2.932 16.198 3.144 6837H738/M 4/1 330.4 0.062 2.052 0.596 1.392 2.903 13.475 2.708 6837H740/M 4/1 315.5 0.080 2.193 0.357 1.255 2.660 15.411 2.811 6837H742/M 4/1 307.8 0.058 1.978 0.472 1.108 2.727 21.298 3.605 6837H743/M 4/1 301.2 0.066 2.094 0.438 1.304 3.120 11.742 2.743 6837H744/M 4/1 296.4 0.055 1.943 0.698 1.243 2.833 13.204 3.294 6837H745/M 4/1 273.9 0.082 2.029 0.389 1.282 2.520 7.694 2.533 6837H746/M 4/1 287.8 0.606 2.016 0.636 1.120 2.866 12.264 4.145 6837H748/M 4/1 364.1 0.080 1.997 0.713 1.361 3.308 19.882 2.814 6837H750/M 4/1 305.6 0.077 2.046 0.390 1.113 3.146 16.136 3.436 M e a n: 328.4 0.094 2.039 0.521 1.231 3.301% 15.167 2.709 Standard deviation: 39.6 0.102 0.056 0.167 0.175 1.457 3.519 0.626 Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-51
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 5 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen M a l e A n i m a l s 6831E401/M 1/1 350.8 9.782 3.260 6831E402/M 1/1 375.6 17.452 3.016 6831E403/M 1/1 276.1 15.750 2.903 6831E404/M 1/1 494.2 2.033 4.266 6831E405/M 1/1 311.3 7.921 1.652 6831E406/M 1/1 224.4 0.477 2.313 6831E408/M 1/1 312.1 0.654 3.008 6831E409/M 1/1 300.4 3.669 2.315 6831E410/M 1/1 369.2 20.943 2.546 6831E411/M 1/1 339.4 11.696 1.642 6831E412/M 1/1 331.9 0.602 2.212 6831E414/M 1/1 255.3 0.492 1.971 6831E416/M 1/1 385.4 22.346 2.131 6831E417/M 1/1 372.5 1.489 2.974 6831E419/M 1/1 359.2 11.185 2.085 6831E420/M 1/1 355.4 8.490 4.617 6831E421/M 1/1 385.2 15.749 2.566 6831E423/M 1/1 381.1 13.603 2.651 6831E424/M 1/1 365.0 8.662 2.687 6831E426/M 1/1 282.1 10.465 2.315 6831E427/M 1/1 294.9 9.566 1.005 6831E428/M 1/1 355.2 2.000 2.783 6831E429/M 1/1 352.3 14.355 2.518 6831E430/M 1/1 327.7 0.798 2.355 6831E431/M 1/1 346.8 0.772 3.161 6831E432/M 1/1 379.0 24.221 1.985 6831E433/M 1/1 311.2 1.702 4.691 6831E434/M 1/1 317.5 0.726 2.204 6831E438/M 1/1 331.8 9.366 1.246 6831E439/M 1/1 417.3 0.919 3.417 6831E441/M 1/1 366.9 10.929 2.666 6831E444/M 1/1 331.1 13.234 1.908 6831E445/M 1/1 369.9 13.445 3.330 6831E447/M 1/1 353.4 11.908 1.704 6831E450/M 1/1 440.7 3.734 3.036 M e a n: 346.4 8.604 2.604 Standard deviation: 50.7 6.952 0.828 Number of observ. : (35) (35) (35) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-52
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 6 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6833F504/M 2/1 344.8 17.111 1.936 6833F506/M 2/1 299.2 15.090 2.374 6833F507/M 2/1 367.4 15.252 2.295 6833F509/M 2/1 503.4 1.672 2.570 6833F510/M 2/1 314.7 1.005 3.036 6833F512/M 2/1 306.8 6.982 1.550 6833F514/M 2/1 395.1 4.743 2.630 6833F515/M 2/1 352.0 9.800 2.188 6833F517/M 2/1 408.0 24.850 3.378 6833F518/M 2/1 407.4 2.709 3.237 6833F520/M 2/1 324.1 4.522 2.717 6833F522/M 2/1 377.2 12.163 2.405 6833F527/M 2/1 357.5 19.662 2.527 6833F528/M 2/1 309.8 8.750 2.183 6833F529/M 2/1 444.5 1.324 4.658 6833F530/M 2/1 329.6 1.585 2.329 6833F531/M 2/1 355.2 0.925 2.040 6833F532/M 2/1 314.7 6.546 2.738 6833F533/M 2/1 388.3 20.713 2.925 6833F534/M 2/1 247.0 1.669 2.056 6833F537/M 2/1 338.3 9.728 1.848 6833F538/M 2/1 369.0 20.739 2.719 6833F539/M 2/1 259.2 0.550 2.667 6833F540/M 2/1 300.4 12.451 2.414 6833F543/M 2/1 325.3 1.195 2.089 6833F544/M 2/1 352.7 19.119 4.019 6833F545/M 2/1 367.1 25.728 2.209 6833F546/M 2/1 350.7 5.966 3.492 6833F548/M 2/1 472.7 5.726 6.463 M e a n: 354.6 9.596 2.748 Standard deviation: 56.9 7.945 0.972 Number of observ. : (29) (29) (29) 6835G604/M 3/1 334.8 4.439 3.400 6835G606/M 3/1 411.5 11.745 3.463 6835G608/M 3/1 319.0 10.677 5.436 6835G611/M 3/1 290.7 9.603 2.555 6835G612/M 3/1 317.1 10.715 3.569 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-53
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 7 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6835G616/M 3/1 350.1 15.014 2.017 6835G618/M 3/1 333.2 13.403 2.220 6835G619/M 3/1 321.5 6.475 2.828 6835G620/M 3/1 334.6 13.601 1.733 6835G622/M 3/1 312.8 9.584 3.810 6835G623/M 3/1 381.3 1.134 2.795 6835G624/M 3/1 310.6 9.125 2.089 6835G626/M 3/1 347.1 3.818 4.092 6835G629/M 3/1 316.6 13.756 1.591 6835G631/M 3/1 362.6 5.476 3.138 6835G632/M 3/1 323.8 7.594 2.125 6835G633/M 3/1 420.2 3.558 6.831 6835G635/M 3/1 307.0 1.077 NT 6835G637/M 3/1 326.4 4.382 2.427 6835G640/M 3/1 291.4 21.296 2.467 6835G641/M 3/1 349.9 16.627 3.294 6835G642/M 3/1 334.1 7.449 3.708 6835G643/M 3/1 407.3 1.308 5.181 6835G644/M 3/1 353.4 10.510 2.754 6835G645/M 3/1 323.0 0.887 4.991 6835G646/M 3/1 356.0 21.891 2.893 6835G650/M 3/1 341.9 0.995 2.911 M e a n: 339.9 8.746 3.243 Standard deviation: 33.5 5.964 1.244 Number of observ. : (27) (27) (26) 6837H701/M 4/1 253.6 1.142 4.186 6837H703/M 4/1 435.2 2.411 2.042 6837H707/M 4/1 353.8 24.826 1.443 6837H709/M 4/1 362.3 16.549 1.939 6837H710/M 4/1 305.8 1.664 4.055 6837H711/M 4/1 358.8 1.350 4.210 6837H712/M 4/1 348.6 1.084 3.025 6837H713/M 4/1 301.4 3.950 1.946 6837H715/M 4/1 365.1 13.526 2.601 6837H716/M 4/1 411.5 1.018 3.598 6837H719/M 4/1 365.4 19.724 2.965 6837H720/M 4/1 301.7 10.114 2.527 6837H721/M 4/1 362.5 1.269 6.211 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-54
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 8 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6837H723/M 4/1 333.5 15.525 1.658 6837H727/M 4/1 304.8 12.195 2.346 6837H730/M 4/1 334.0 1.369 5.812 6837H731/M 4/1 304.6 5.152 2.346 6837H733/M 4/1 298.5 11.018 1.961 6837H734/M 4/1 316.5 5.461 4.232 6837H737/M 4/1 323.8 15.703 1.346 6837H738/M 4/1 330.4 7.892 2.607 6837H740/M 4/1 315.5 8.076 2.414 6837H742/M 4/1 307.8 15.130 1.685 6837H743/M 4/1 301.2 7.466 4.213 6837H744/M 4/1 296.4 11.692 2.049 6837H745/M 4/1 273.9 0.465 2.934 6837H746/M 4/1 287.8 7.929 1.268 6837H748/M 4/1 364.1 14.579 2.452 6837H750/M 4/1 305.6 9.684 NT M e a n: 328.4 8.550 2.860 Standard deviation: 39.6 6.573 1.275 Number of observ. : (29) (29) (28) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-55
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries F e m a l e A n i m a l s 6832E453/F 1/1 219.3 0.059 1.874 0.827 1.761 13.580 2.049 0.149 6832E455/F 1/1 279.2 0.070 1.901 0.969 1.877 9.411 1.419 0.126 6832E457/F 1/1 201.2 0.077 1.949 0.952 1.881 7.826 1.869 0.064 6832E459/F 1/1 223.0 0.070 1.931 0.942 1.698 19.564 2.491 0.069 6832E465/F 1/1 192.6 0.065 1.859 0.855 1.557 4.828 0.969 0.054 6832E466/F 1/1 237.0 0.053 1.911 1.010 1.737 9.505 1.871 0.131 6832E468/F 1/1 260.6 0.057 1.977 1.064 1.824 7.881 1.378 0.111 6832E469/F 1/1 201.9 0.071 1.832 0.950 2.041 6.956 1.640 0.093 6832E470/F 1/1 239.4 0.055 1.913 0.825 1.680 11.924 3.381 0.086 6832E471/F 1/1 236.9 0.057 1.866 1.141 1.880 11.599 2.997 0.082 6832E474/F 1/1 189.3 0.054 2.018 0.993 1.765 8.193 2.036 0.062 6832E476/F 1/1 259.5 0.067 1.903 1.038 2.028 13.141 2.965 0.035 6832E479/F 1/1 263.3 0.071 1.949 1.282 1.950 9.869 2.131 0.103 6832E481/F 1/1 203.4 0.066 1.854 0.809 1.589 7.212 1.228 0.184 6832E482/F 1/1 250.2 0.071 1.974 1.192 2.257 14.427 2.649 0.077 6832E484/F 1/1 212.8 0.055 1.912 1.196 2.219 10.267 2.731 0.048 6832E485/F 1/1 211.2 0.068 1.813 1.027 1.876 12.211 2.263 0.102 6832E487/F 1/1 226.0 0.067 1.930 0.825 1.687 12.808 2.153 0.058 6832E488/F 1/1 220.2 0.074 1.839 0.999 1.962 7.663 1.148 0.079 6832E491/F 1/1 217.6 0.085 1.993 1.018 2.167 11.452 2.390 0.060 6832E492/F 1/1 186.5 0.055 1.831 0.691 1.382 5.019 0.959 0.066 6832E494/F 1/1 276.5 0.053 1.899 1.071 1.779 8.133 1.179 0.083 6832E496/F 1/1 200.1 0.057 1.839 1.127 1.996 8.842 2.402 0.092 6832E499/F 1/1 248.6 0.049 1.819 0.798 1.670 10.709 1.434 0.097 M e a n: 227.4 0.064 1.899 0.983 1.844 10.126 1.989 0.088 Standard deviation: 27.6 0.009 0.058 0.146 0.212 3.277 0.685 0.034 Number of observ. : (24) (24) (24) (24) (24) (24) (24) (24) 6834F552/F 2/1 229.7 0.067 1.930 1.130 1.933 9.866 2.547 0.066 6834F556/F 2/1 225.7 0.085 1.866 1.061 1.720 7.343 1.389 0.037 6834F562/F 2/1 238.4 0.054 1.035 0.777 1.838 6.790 1.191 0.095 6834F565/F 2/1 268.4 0.056 1.932 0.963 1.846 10.202 1.160 0.137 6834F566/F 2/1 226.8 0.085 1.904 0.870 1.786 7.510 1.300 0.104 6834F567/F 2/1 282.2 0.078 1.913 1.008 2.171 11.802 1.476 0.138 6834F568/F 2/1 203.6 0.070 1.835 0.764 1.454 12.199 1.823 0.555 6834F571/F 2/1 211.9 0.060 1.874 1.226 1.906 9.289 2.661 0.058 6834F572/F 2/1 256.4 0.051 1.827 0.995 2.014 8.841 1.613 0.125 6834F577/F 2/1 248.1 0.094 1.953 0.933 1.941 9.489 2.334 0.097 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-56
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6834F578/F 2/1 218.3 0.068 1.826 0.797 1.758 6.495 1.209 0.074 6834F581/F 2/1 207.5 0.064 1.943 1.193 2.040 8.358 2.150 0.098 6834F582/F 2/1 248.6 0.074 1.847 0.837 1.666 7.649 1.170 0.062 6834F589/F 2/1 267.9 0.077 1.991 1.121 1.991 9.316 2.582 0.152 6834F590/F 2/1 234.0 0.076 1.947 0.831 2.019 8.314 1.247 0.152 6834F594/F 2/1 299.0 0.054 1.885 0.911 1.845 10.570 1.171 0.108 6834F595/F 2/1 214.2 0.091 1.977 0.710 1.650 6.592 1.210 0.101 6834F599/F 2/1 200.0 0.073 1.777 1.151 1.967 6.822 3.218 0.153 M e a n: 237.8 0.071 1.848 0.960 1.864 8.747 1.747 0.128 Standard deviation: 28.3 0.013 0.211 0.160 0.172 1.739 0.660 0.112 Number of observ. : (18) (18) (18) (18) (18) (18) (18) (18) 6836G653/F 3/1 207.9 0.084 1.879 0.892 1.416 6.856 1.277 0.116 6836G659/F 3/1 232.0 0.049 1.922 1.057 2.088 9.467 3.251 0.072 6836G664/F 3/1 223.0 0.044 1.870 0.862 1.850 7.449 1.315 0.056 6836G676/F 3/1 232.8 0.069 1.942 1.005 1.988 11.130 2.743 0.092 6836G678/F 3/1 235.4 0.066 1.882 0.787 1.970 8.714 1.668 0.127 6836G679/F 3/1 217.4 0.064 1.851 0.769 1.824 7.610 1.214 0.065 6836G680/F 3/1 213.1 0.055 1.951 1.283 2.137 9.056 2.880 0.026 6836G682/F 3/1 223.1 0.069 1.866 0.952 1.736 15.168 3.080 0.300 6836G683/F 3/1 240.7 0.053 1.916 0.970 1.747 7.473 1.190 0.163 6836G685/F 3/1 186.6 0.064 1.891 0.932 1.676 7.213 1.881 0.037 6836G687/F 3/1 223.0 0.079 1.962 1.012 2.142 11.239 1.869 0.065 6836G688/F 3/1 246.4 0.060 1.920 0.938 2.104 10.718 2.452 0.109 6836G691/F 3/1 156.8 0.093 1.743 0.612 1.265 5.034 1.090 0.083 6836G695/F 3/1 204.4 0.067 2.060 0.894 1.937 8.129 1.209 0.072 6836G696/F 3/1 175.2 0.065 1.665 0.590 1.302 6.162 0.935 0.087 6836G698/F 3/1 226.0 0.052 1.842 0.845 1.926 8.064 1.731 0.084 6836G699/F 3/1 153.9 0.054 1.777 0.516 1.195 4.320 0.982 0.089 M e a n: 211.6 0.064 1.879 0.877 1.783 8.459 1.810 0.097 Standard deviation: 27.9 0.013 0.090 0.187 0.314 2.594 0.781 0.062 Number of observ. : (17) (17) (17) (17) (17) (17) (17) (17) 6838H751/F 4/1 197.9 0.066 1.902 0.774 2.111 24.354 4.074 0.064 6838H752/F 4/1 216.2 0.074 1.853 0.904 2.156 17.154 3.248 0.331 6838H753/F 4/1 188.8 0.088 1.853 0.734 2.636 6.476 3.319 0.061 6838H757/F 4/1 183.6 0.023 1.845 1.032 1.807 6.749 1.962 0.120 6838H763/F 4/1 229.8 0.076 1.859 0.715 1.770 6.901 1.105 0.092 6838H764/F 4/1 186.0 0.060 1.930 0.856 1.590 8.068 2.123 0.086 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-57
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6838H766/F 4/1 198.3 0.065 1.847 1.230 1.743 13.194 2.328 0.056 6838H770/F 4/1 198.8 0.051 1.804 1.192 2.158 9.384 2.238 0.026 6838H772/F 4/1 185.1 0.041 1.869 0.930 1.978 7.823 1.963 0.046 6838H774/F 4/1 190.1 0.048 1.815 0.743 1.445 8.637 2.081 0.051 6838H775/F 4/1 191.6 0.068 1.902 0.933 2.167 7.998 1.965 0.054 6838H783/F 4/1 196.1 0.069 1.744 0.754 2.072 9.072 1.145 0.080 6838H785/F 4/1 230.0 0.061 1.886 0.854 1.888 10.372 2.524 0.128 6838H792/F 4/1 199.7 0.050 1.865 1.077 2.085 9.105 2.394 0.066 6838H797/F 4/1 223.3 0.171 1.816 0.987 1.916 11.415 2.662 0.110 M e a n: 201.0+ 0.067 1.853% 0.914 1.968 10.447 2.342 0.091 Standard deviation: 16.0 0.033 0.046 0.164 0.286 4.747 0.776 0.072 Number of observ. : (15) (15) (15) (15) (15) (15) (15) (15) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-58
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 4 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen F e m a l e A n i m a l s 6832E453/F 1/1 219.3 3.201 2.838 6832E455/F 1/1 279.2 1.025 NT 6832E457/F 1/1 201.2 7.608 0.520 6832E459/F 1/1 223.0 22.379 0.879 6832E465/F 1/1 192.6 0.489 0.865 6832E466/F 1/1 237.0 7.533 0.896 6832E468/F 1/1 260.6 1.389 0.694 6832E469/F 1/1 201.9 6.239 1.279 6832E470/F 1/1 239.4 8.409 0.461 6832E471/F 1/1 236.9 8.992 0.437 6832E474/F 1/1 189.3 4.961 0.451 6832E476/F 1/1 259.5 14.677 0.597 6832E479/F 1/1 263.3 7.731 0.579 6832E481/F 1/1 203.4 1.085 NT 6832E482/F 1/1 250.2 12.009 0.473 6832E484/F 1/1 212.8 1.819 0.525 6832E485/F 1/1 211.2 7.873 1.502 6832E487/F 1/1 226.0 18.072 0.826 6832E488/F 1/1 220.2 0.641 0.452 6832E491/F 1/1 217.6 12.931 0.810 6832E492/F 1/1 186.5 0.454 0.717 6832E494/F 1/1 276.5 0.857 0.537 6832E496/F 1/1 200.1 6.146 0.743 6832E499/F 1/1 248.6 10.111 0.639 M e a n: 227.4 6.943 0.805 Standard deviation: 27.6 5.928 0.528 Number of observ. : (24) (24) (22) 6834F552/F 2/1 229.7 6.415 0.724 6834F556/F 2/1 225.7 1.951 15.618 6834F562/F 2/1 238.4 0.571 1.144 6834F565/F 2/1 268.4 0.669 0.663 6834F566/F 2/1 226.8 1.357 7.544 6834F567/F 2/1 282.2 3.049 0.636 6834F568/F 2/1 203.6 7.143 0.672 6834F571/F 2/1 211.9 7.282 0.482 6834F572/F 2/1 256.4 16.685 0.759 6834F577/F 2/1 248.1 0.833 0.996 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-59
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 5 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6834F578/F 2/1 218.3 0.614 0.717 6834F581/F 2/1 207.5 7.529 0.563 6834F582/F 2/1 248.6 1.668 28.077 6834F589/F 2/1 267.9 6.510 9.492 6834F590/F 2/1 234.0 0.639 NT 6834F594/F 2/1 299.0 0.546 0.512 6834F595/F 2/1 214.2 0.411 1.723 6834F599/F 2/1 200.0 6.733 0.663 M e a n: 237.8 3.923 4.176 Standard deviation: 28.3 4.281 7.468 Number of observ. : (18) (18) (17) 6836G653/F 3/1 207.9 0.631 0.705 6836G659/F 3/1 232.0 14.041 0.494 6836G664/F 3/1 223.0 1.283 1.117 6836G676/F 3/1 232.8 10.824 1.351 6836G678/F 3/1 235.4 1.174 1.471 6836G679/F 3/1 217.4 0.532 0.448 6836G680/F 3/1 213.1 9.238 0.792 6836G682/F 3/1 223.1 6.951 1.095 6836G683/F 3/1 240.7 0.478 19.307 6836G685/F 3/1 186.6 6.049 0.574 6836G687/F 3/1 223.0 6.402 0.570 6836G688/F 3/1 246.4 6.811 0.731 6836G691/F 3/1 156.8 0.346 0.546 6836G695/F 3/1 204.4 0.427 0.447 6836G696/F 3/1 175.2 0.372 0.408 6836G698/F 3/1 226.0 4.538 1.115 6836G699/F 3/1 153.9 0.410 0.250 M e a n: 211.6 4.147 1.848 Standard deviation: 27.9 4.363 4.513 Number of observ. : (17) (17) (17) 6838H751/F 4/1 197.9 1.322 0.577 6838H752/F 4/1 216.2 8.120 2.570 6838H753/F 4/1 188.8 0.899 10.751 6838H757/F 4/1 183.6 5.112 0.710 6838H763/F 4/1 229.8 0.589 21.352 6838H764/F 4/1 186.0 2.415 0.680 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-60
 Lovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 6 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6838H766/F 4/1 198.3 12.559 0.668 6838H770/F 4/1 198.8 4.392 1.004 6838H772/F 4/1 185.1 2.453 0.620 6838H774/F 4/1 190.1 5.702 0.681 6838H775/F 4/1 191.6 3.654 0.732 6838H783/F 4/1 196.1 0.678 0.450 6838H785/F 4/1 230.0 5.651 0.718 6838H792/F 4/1 199.7 13.648 0.577 6838H797/F 4/1 223.3 7.103 0.578 M e a n: 201.0+ 4.953 2.845 Standard deviation: 16.0 4.060 5.746 Number of observ. : (15) (15) (15) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-61
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-5 Percent Organ to Body Weight, Male and Female, Euthanized Rats 

K-62
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs M a l e A n i m a l s 6831E401/M 1/1 350.8 0.019 0.624 0.182 0.362 0.785 5.147 0.884 6831E402/M 1/1 375.6 0.014 NT 0.270 0.342 0.732 3.611 0.804 6831E403/M 1/1 276.1 0.023 0.725 0.153 0.405 0.879 3.908 1.125 6831E404/M 1/1 494.2 0.014 0.424 0.178 0.279 0.571 3.110 0.585 6831E405/M 1/1 311.3 0.018 0.667 0.115 0.552 0.834 3.312 0.970 6831E406/M 1/1 224.4 0.042 0.880 0.326 0.435 0.860 1.811 0.616 6831E408/M 1/1 312.1 0.016 0.674 0.261 0.277 0.691 2.322 0.370 6831E409/M 1/1 300.4 0.023 0.697 0.184 0.280 0.820 3.685 0.738 6831E410/M 1/1 369.2 0.032 0.565 0.154 0.368 0.821 5.181 0.812 6831E411/M 1/1 339.4 0.019 0.612 0.130 0.324 0.860 5.823 1.165 6831E412/M 1/1 331.9 0.023 0.601 0.105 0.290 0.612 2.506 0.407 6831E414/M 1/1 255.3 0.043 0.825 0.210 0.463 0.966 3.084 1.434 6831E416/M 1/1 385.4 0.020 0.534 0.132 0.299 0.768 4.633 1.074 6831E417/M 1/1 372.5 0.019 0.552 0.242 0.337 0.695 2.747 0.474 6831E419/M 1/1 359.2 0.018 0.609 0.088 0.416 0.867 4.310 1.374 6831E420/M 1/1 355.4 0.018 0.558 0.133 0.300 0.765 3.624 0.733 6831E421/M 1/1 385.2 0.017 0.545 0.207 0.347 0.782 3.267 1.062 6831E423/M 1/1 381.1 0.016 0.560 0.219 0.316 0.714 3.617 0.857 6831E424/M 1/1 365.0 0.029 0.584 0.150 0.325 0.755 4.042 0.853 6831E426/M 1/1 282.1 0.027 0.736 0.146 0.483 0.908 3.263 1.160 6831E427/M 1/1 294.9 0.024 0.716 0.159 0.495 0.931 5.445 1.982 6831E428/M 1/1 355.2 0.020 0.570 0.158 0.347 0.692 3.042 0.564 6831E429/M 1/1 352.3 0.022 0.613 0.134 0.398 0.805 4.348 0.866 6831E430/M 1/1 327.7 0.023 0.636 0.142 0.378 0.714 2.331 0.772 6831E431/M 1/1 346.8 0.016 0.650 0.268 0.336 0.700 2.307 0.413 6831E432/M 1/1 379.0 0.012 0.540 0.133 0.380 0.757 4.618 0.859 6831E433/M 1/1 311.2 0.020 0.646 0.183 0.332 0.771 3.118 0.500 6831E434/M 1/1 317.5 0.029 0.636 0.187 0.385 1.013 3.953 0.529 6831E438/M 1/1 331.8 0.022 0.643 0.151 0.388 0.939 5.494 0.959 6831E439/M 1/1 417.3 0.007 0.471 0.273 0.252 0.602 3.127 0.353 6831E441/M 1/1 366.9 0.017 0.593 0.237 0.365 0.805 3.050 0.840 6831E444/M 1/1 331.1 0.026 0.607 0.173 0.324 0.778 4.873 1.025 6831E445/M 1/1 369.9 0.016 0.559 0.122 0.399 0.760 3.321 0.946 6831E447/M 1/1 353.4 0.018 0.578 0.147 0.332 0.732 5.557 1.019 6831E450/M 1/1 440.7 0.012 0.456 0.234 0.275 0.626 3.503 0.501 M e a n: 346.4 0.021 0.614 0.180 0.360 0.780 3.745 0.846 Standard deviation: 50.7 0.007 0.094 0.056 0.068 0.103 1.045 0.341 Number of observ. : (35) (35) (34) (35) (35) (35) (35) (35) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-63
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6833F504/M 2/1 344.8 0.118 0.635 0.107 0.372 0.864 6.025 1.045 6833F506/M 2/1 299.2 0.017 0.710 0.120 0.423 0.935 4.483 1.227 6833F507/M 2/1 367.4 0.018 0.557 0.167 0.379 0.783 4.391 0.868 6833F509/M 2/1 503.4 0.020 0.408 0.234 0.265 0.526 2.028 0.339 6833F510/M 2/1 314.7 0.025 0.654 0.138 0.388 0.807 2.858 0.513 6833F512/M 2/1 306.8 0.018 0.678 0.185 0.454 0.904 3.512 0.983 6833F514/M 2/1 395.1 0.010 0.503 0.205 0.287 0.730 3.319 0.471 6833F515/M 2/1 352.0 0.020 0.600 0.201 0.302 0.776 4.255 0.792 6833F517/M 2/1 408.0 0.012 0.525 0.180 0.329 0.730 4.634 0.821 6833F518/M 2/1 407.4 0.020 0.529 0.103 0.346 0.752 3.995 0.683 6833F520/M 2/1 324.1 0.035 0.634 0.160 0.445 1.467 5.102 0.798 6833F522/M 2/1 377.2 0.022 0.553 0.113 0.344 0.767 4.670 0.757 6833F527/M 2/1 357.5 0.020 0.552 0.253 0.334 0.837 4.245 0.562 6833F528/M 2/1 309.8 0.014 0.617 0.199 0.374 0.830 3.122 0.883 6833F529/M 2/1 444.5 0.015 0.462 0.205 0.283 0.607 2.806 0.369 6833F530/M 2/1 329.6 0.017 0.630 0.180 0.396 0.964 3.516 0.662 6833F531/M 2/1 355.2 0.023 0.596 0.175 0.372 0.743 2.927 0.474 6833F532/M 2/1 314.7 0.019 0.660 0.276 0.392 0.815 5.088 2.049 6833F533/M 2/1 388.3 0.014 0.524 0.211 0.479 0.930 6.067 0.611 6833F534/M 2/1 247.0 0.019 0.807 0.175 0.539 0.963 4.489 1.143 6833F537/M 2/1 338.3 0.018 0.630 0.128 0.286 0.858 3.029 1.219 6833F538/M 2/1 369.0 0.018 0.566 0.139 0.364 0.760 2.571 1.033 6833F539/M 2/1 259.2 0.036 0.805 0.172 0.402 0.842 1.930 0.569 6833F540/M 2/1 300.4 0.022 0.717 0.343 0.428 0.953 3.041 0.969 6833F543/M 2/1 325.3 0.019 0.612 0.104 0.284 0.973 4.304 2.252 6833F544/M 2/1 352.7 0.033 0.555 0.122 0.555 0.771 5.445 0.840 6833F545/M 2/1 367.1 0.029 0.549 0.195 0.424 0.771 5.567 0.911 6833F546/M 2/1 350.7 0.022 0.569 0.097 0.333 1.182 4.217 0.814 6833F548/M 2/1 472.7 0.022 0.472 0.106 0.305 0.729 4.427 0.582 M e a n: 354.6 0.024 0.597 0.172 0.375 0.847 4.002 0.870 Standard deviation: 56.9 0.019 0.092 0.058 0.074 0.172 1.117 0.428 Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29) 6835G604/M 3/1 334.8 0.026 0.611 0.114 0.353 1.215 4.429 3.641 6835G606/M 3/1 411.5 0.019 0.526 0.160 0.344 0.822 4.354 0.801 6835G608/M 3/1 319.0 0.020 0.661 0.106 0.603 0.963 4.448 1.074 6835G611/M 3/1 290.7 0.033 0.733 0.231 0.423 0.936 3.336 0.976 6835G612/M 3/1 317.1 0.031 0.673 0.120 0.391 0.850 4.325 1.210 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-64
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6835G616/M 3/1 350.1 0.023 0.598 0.109 0.407 0.901 5.297 0.832 6835G618/M 3/1 333.2 0.019 0.632 0.156 0.422 0.903 4.689 1.094 6835G619/M 3/1 321.5 0.033 0.661 0.124 0.428 0.925 4.628 0.764 6835G620/M 3/1 334.6 0.018 0.628 0.097 0.411 0.910 5.403 1.184 6835G622/M 3/1 312.8 0.032 0.669 0.110 0.386 0.934 4.414 1.119 6835G623/M 3/1 381.3 0.015 0.515 0.244 0.261 0.679 2.815 0.460 6835G624/M 3/1 310.6 0.017 0.647 0.121 0.354 0.817 3.723 0.797 6835G626/M 3/1 347.1 0.016 0.613 0.120 0.351 0.949 4.400 0.724 6835G629/M 3/1 316.6 0.031 0.669 0.157 0.376 0.892 3.937 0.833 6835G631/M 3/1 362.6 0.022 0.580 0.109 0.414 0.854 5.024 1.015 6835G632/M 3/1 323.8 0.019 0.638 0.113 0.373 0.825 3.623 0.811 6835G633/M 3/1 420.2 0.015 0.484 0.107 0.262 0.708 3.921 0.454 6835G635/M 3/1 307.0 0.032 0.700 0.127 0.446 0.885 4.088 0.637 6835G637/M 3/1 326.4 0.021 0.601 0.129 0.313 0.803 4.065 1.026 6835G640/M 3/1 291.4 0.023 0.695 0.177 0.390 0.902 4.674 1.305 6835G641/M 3/1 349.9 0.020 0.597 0.131 0.395 0.899 4.985 0.693 6835G642/M 3/1 334.1 0.025 0.622 0.151 0.447 0.924 5.809 1.039 6835G643/M 3/1 407.3 0.017 0.536 0.162 0.276 0.695 3.658 0.402 6835G644/M 3/1 353.4 0.018 0.584 0.217 0.384 0.747 4.230 0.834 6835G645/M 3/1 323.0 0.024 0.644 0.167 0.375 0.835 3.515 0.495 6835G646/M 3/1 356.0 0.064 0.568 0.109 0.372 0.957 5.642 0.950 6835G650/M 3/1 341.9 0.027 0.579 0.248 0.378 0.846 3.300 0.453 M e a n: 339.9 0.024 0.617 0.145* 0.383 0.873$ 4.323 0.949 Standard deviation: 33.5 0.010 0.059 0.044 0.066 0.105 0.736 0.594 Number of observ. : (27) (27) (27) (27) (27) (27) (27) (27) 6837H701/M 4/1 253.6 0.039 0.763 0.126 0.504 1.563 5.052 1.086 6837H703/M 4/1 435.2 0.020 0.470 0.146 0.269 0.684 3.765 0.416 6837H707/M 4/1 353.8 0.050 0.578 0.131 0.471 0.930 4.588 0.745 6837H709/M 4/1 362.3 0.014 0.565 0.119 0.345 0.922 5.968 0.778 6837H710/M 4/1 305.8 0.023 0.673 0.167 0.387 0.946 3.502 0.758 6837H711/M 4/1 358.8 0.029 0.558 0.192 0.343 0.820 3.647 0.495 6837H712/M 4/1 348.6 0.017 0.592 0.180 0.262 3.032 3.588 0.478 6837H713/M 4/1 301.4 0.039 0.661 0.195 0.413 1.495 5.480 0.839 6837H715/M 4/1 365.1 0.020 0.589 0.112 0.367 0.950 6.177 0.850 6837H716/M 4/1 411.5 0.017 0.503 0.251 0.244 0.731 3.589 0.440 6837H719/M 4/1 365.4 0.014 0.541 0.215 0.348 0.829 4.173 0.720 6837H720/M 4/1 301.7 0.018 0.687 0.110 0.384 0.908 4.944 0.831 6837H721/M 4/1 362.5 0.023 0.573 0.117 0.317 0.861 3.820 0.445 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-65
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 4 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6837H723/M 4/1 333.5 0.020 0.607 0.179 0.300 0.860 4.736 0.936 6837H727/M 4/1 304.8 0.022 0.644 0.110 0.529 0.963 4.275 0.869 6837H730/M 4/1 334.0 0.022 0.632 0.138 0.422 0.814 3.271 0.552 6837H731/M 4/1 304.6 0.009 0.671 0.156 0.322 0.901 4.654 1.071 6837H733/M 4/1 298.5 0.019 0.686 0.208 0.348 0.839 5.385 1.073 6837H734/M 4/1 316.5 0.030 0.642 0.121 0.370 0.984 6.740 1.033 6837H737/M 4/1 323.8 0.021 0.625 0.096 0.450 0.905 5.002 0.971 6837H738/M 4/1 330.4 0.019 0.621 0.180 0.421 0.879 4.079 0.820 6837H740/M 4/1 315.5 0.025 0.695 0.113 0.398 0.843 4.884 0.891 6837H742/M 4/1 307.8 0.019 0.643 0.153 0.360 0.886 6.920 1.171 6837H743/M 4/1 301.2 0.022 0.695 0.145 0.433 1.036 3.899 0.911 6837H744/M 4/1 296.4 0.019 0.656 0.236 0.419 0.956 4.455 1.111 6837H745/M 4/1 273.9 0.030 0.741 0.142 0.468 0.920 2.809 0.925 6837H746/M 4/1 287.8 0.211 0.700 0.221 0.389 0.996 4.261 1.440 6837H748/M 4/1 364.1 0.022 0.548 0.196 0.374 0.908 5.460 0.773 6837H750/M 4/1 305.6 0.025 0.670 0.128 0.364 1.030 5.281 1.125 M e a n: 328.4 0.030 0.629 0.158 0.380 1.013$ 4.635+ 0.847 Standard deviation: 39.6 0.036 0.069 0.043 0.069 0.428 1.019 0.249 Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-66
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 5 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen M a l e A n i m a l s 6831E401/M 1/1 350.8 2.788 0.929 6831E402/M 1/1 375.6 4.646 0.803 6831E403/M 1/1 276.1 5.703 1.051 6831E404/M 1/1 494.2 0.411 0.863 6831E405/M 1/1 311.3 2.544 0.531 6831E406/M 1/1 224.4 0.213 1.031 6831E408/M 1/1 312.1 0.210 0.964 6831E409/M 1/1 300.4 1.221 0.771 6831E410/M 1/1 369.2 5.672 0.690 6831E411/M 1/1 339.4 3.446 0.484 6831E412/M 1/1 331.9 0.181 0.666 6831E414/M 1/1 255.3 0.193 0.772 6831E416/M 1/1 385.4 5.798 0.553 6831E417/M 1/1 372.5 0.400 0.798 6831E419/M 1/1 359.2 3.114 0.581 6831E420/M 1/1 355.4 2.389 1.299 6831E421/M 1/1 385.2 4.089 0.666 6831E423/M 1/1 381.1 3.569 0.696 6831E424/M 1/1 365.0 2.373 0.736 6831E426/M 1/1 282.1 3.709 0.821 6831E427/M 1/1 294.9 3.244 0.341 6831E428/M 1/1 355.2 0.563 0.783 6831E429/M 1/1 352.3 4.075 0.715 6831E430/M 1/1 327.7 0.244 0.719 6831E431/M 1/1 346.8 0.223 0.911 6831E432/M 1/1 379.0 6.390 0.524 6831E433/M 1/1 311.2 0.547 1.507 6831E434/M 1/1 317.5 0.229 0.694 6831E438/M 1/1 331.8 2.823 0.375 6831E439/M 1/1 417.3 0.220 0.819 6831E441/M 1/1 366.9 2.979 0.727 6831E444/M 1/1 331.1 3.997 0.576 6831E445/M 1/1 369.9 3.634 0.900 6831E447/M 1/1 353.4 3.370 0.482 6831E450/M 1/1 440.7 0.847 0.689 M e a n: 346.4 2.459 0.756 Standard deviation: 50.7 1.937 0.235 Number of observ. : (35) (35) (35) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-67
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 6 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6833F504/M 2/1 344.8 4.963 0.562 6833F506/M 2/1 299.2 5.043 0.793 6833F507/M 2/1 367.4 4.151 0.625 6833F509/M 2/1 503.4 0.332 0.511 6833F510/M 2/1 314.7 0.319 0.965 6833F512/M 2/1 306.8 2.276 0.505 6833F514/M 2/1 395.1 1.200 0.666 6833F515/M 2/1 352.0 2.784 0.622 6833F517/M 2/1 408.0 6.091 0.828 6833F518/M 2/1 407.4 0.665 0.795 6833F520/M 2/1 324.1 1.395 0.838 6833F522/M 2/1 377.2 3.224 0.638 6833F527/M 2/1 357.5 5.500 0.707 6833F528/M 2/1 309.8 2.824 0.705 6833F529/M 2/1 444.5 0.298 1.048 6833F530/M 2/1 329.6 0.481 0.707 6833F531/M 2/1 355.2 0.260 0.574 6833F532/M 2/1 314.7 2.080 0.870 6833F533/M 2/1 388.3 5.334 0.753 6833F534/M 2/1 247.0 0.676 0.832 6833F537/M 2/1 338.3 2.876 0.546 6833F538/M 2/1 369.0 5.620 0.737 6833F539/M 2/1 259.2 0.212 1.029 6833F540/M 2/1 300.4 4.145 0.804 6833F543/M 2/1 325.3 0.367 0.642 6833F544/M 2/1 352.7 5.421 1.140 6833F545/M 2/1 367.1 7.008 0.602 6833F546/M 2/1 350.7 1.701 0.996 6833F548/M 2/1 472.7 1.211 1.367 M e a n: 354.6 2.706 0.773 Standard deviation: 56.9 2.166 0.203 Number of observ. : (29) (29) (29) 6835G604/M 3/1 334.8 1.326 1.015 6835G606/M 3/1 411.5 2.854 0.842 6835G608/M 3/1 319.0 3.347 1.704 6835G611/M 3/1 290.7 3.303 0.879 6835G612/M 3/1 317.1 3.379 1.126 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-68
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 7 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6835G616/M 3/1 350.1 4.288 0.576 6835G618/M 3/1 333.2 4.023 0.666 6835G619/M 3/1 321.5 2.014 0.880 6835G620/M 3/1 334.6 4.065 0.518 6835G622/M 3/1 312.8 3.064 1.218 6835G623/M 3/1 381.3 0.297 0.733 6835G624/M 3/1 310.6 2.938 0.673 6835G626/M 3/1 347.1 1.100 1.179 6835G629/M 3/1 316.6 4.344 0.502 6835G631/M 3/1 362.6 1.510 0.865 6835G632/M 3/1 323.8 2.345 0.656 6835G633/M 3/1 420.2 0.847 1.626 6835G635/M 3/1 307.0 0.351 NT 6835G637/M 3/1 326.4 1.343 0.744 6835G640/M 3/1 291.4 7.308 0.847 6835G641/M 3/1 349.9 4.752 0.941 6835G642/M 3/1 334.1 2.230 1.110 6835G643/M 3/1 407.3 0.321 1.272 6835G644/M 3/1 353.4 2.974 0.779 6835G645/M 3/1 323.0 0.275 1.545 6835G646/M 3/1 356.0 6.148 0.813 6835G650/M 3/1 341.9 0.291 0.851 M e a n: 339.9 2.631 0.945% Standard deviation: 33.5 1.842 0.324 Number of observ. : (27) (27) (26) 6837H701/M 4/1 253.6 0.450 1.651 6837H703/M 4/1 435.2 0.554 0.469 6837H707/M 4/1 353.8 7.016 0.408 6837H709/M 4/1 362.3 4.568 0.535 6837H710/M 4/1 305.8 0.544 1.326 6837H711/M 4/1 358.8 0.376 1.173 6837H712/M 4/1 348.6 0.311 0.868 6837H713/M 4/1 301.4 1.311 0.646 6837H715/M 4/1 365.1 3.704 0.712 6837H716/M 4/1 411.5 0.247 0.874 6837H719/M 4/1 365.4 5.398 0.811 6837H720/M 4/1 301.7 3.352 0.838 6837H721/M 4/1 362.5 0.350 1.714 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-69
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 8 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6837H723/M 4/1 333.5 4.656 0.497 6837H727/M 4/1 304.8 4.001 0.770 6837H730/M 4/1 334.0 0.410 1.740 6837H731/M 4/1 304.6 1.691 0.770 6837H733/M 4/1 298.5 3.691 0.657 6837H734/M 4/1 316.5 1.725 1.337 6837H737/M 4/1 323.8 4.849 0.416 6837H738/M 4/1 330.4 2.389 0.789 6837H740/M 4/1 315.5 2.560 0.765 6837H742/M 4/1 307.8 4.916 0.548 6837H743/M 4/1 301.2 2.479 1.399 6837H744/M 4/1 296.4 3.945 0.691 6837H745/M 4/1 273.9 0.170 1.071 6837H746/M 4/1 287.8 2.755 0.441 6837H748/M 4/1 364.1 4.004 0.673 6837H750/M 4/1 305.6 3.169 NT M e a n: 328.4 2.607 0.878 Standard deviation: 39.6 1.916 0.398 Number of observ. : (29) (29) (28) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-70
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries F e m a l e A n i m a l s 6832E453/F 1/1 219.3 0.027 0.855 0.377 0.803 6.193 0.934 0.068 6832E455/F 1/1 279.2 0.025 0.681 0.347 0.672 3.371 0.508 0.045 6832E457/F 1/1 201.2 0.038 0.969 0.473 0.935 3.889 0.929 0.032 6832E459/F 1/1 223.0 0.031 0.866 0.422 0.761 8.774 1.117 0.031 6832E465/F 1/1 192.6 0.034 0.965 0.444 0.808 2.506 0.503 0.028 6832E466/F 1/1 237.0 0.022 0.806 0.426 0.733 4.010 0.789 0.055 6832E468/F 1/1 260.6 0.022 0.759 0.408 0.700 3.024 0.529 0.043 6832E469/F 1/1 201.9 0.035 0.907 0.470 1.011 3.445 0.812 0.046 6832E470/F 1/1 239.4 0.023 0.799 0.345 0.702 4.980 1.412 0.036 6832E471/F 1/1 236.9 0.024 0.788 0.482 0.793 4.895 1.265 0.035 6832E474/F 1/1 189.3 0.029 1.066 0.525 0.933 4.329 1.076 0.033 6832E476/F 1/1 259.5 0.026 0.733 0.400 0.781 5.063 1.142 0.013 6832E479/F 1/1 263.3 0.027 0.740 0.487 0.741 3.748 0.809 0.039 6832E481/F 1/1 203.4 0.032 0.911 0.398 0.781 3.545 0.604 0.090 6832E482/F 1/1 250.2 0.028 0.789 0.476 0.902 5.766 1.059 0.031 6832E484/F 1/1 212.8 0.026 0.898 0.562 1.043 4.824 1.283 0.023 6832E485/F 1/1 211.2 0.032 0.858 0.486 0.888 5.780 1.071 0.048 6832E487/F 1/1 226.0 0.030 0.854 0.365 0.746 5.667 0.953 0.026 6832E488/F 1/1 220.2 0.034 0.835 0.454 0.891 3.480 0.521 0.036 6832E491/F 1/1 217.6 0.039 0.916 0.468 0.996 5.262 1.098 0.028 6832E492/F 1/1 186.5 0.029 0.982 0.371 0.741 2.692 0.514 0.035 6832E494/F 1/1 276.5 0.019 0.687 0.387 0.643 2.942 0.426 0.030 6832E496/F 1/1 200.1 0.028 0.919 0.563 0.997 4.419 1.200 0.046 6832E499/F 1/1 248.6 0.020 0.732 0.321 0.672 4.308 0.577 0.039 M e a n: 227.4 0.028 0.846 0.436 0.820 4.455 0.881 0.039 Standard deviation: 27.6 0.005 0.099 0.066 0.119 1.391 0.298 0.016 Number of observ. : (24) (24) (24) (24) (24) (24) (24) (24) 6834F552/F 2/1 229.7 0.029 0.840 0.492 0.841 4.294 1.109 0.029 6834F556/F 2/1 225.7 0.038 0.827 0.470 0.762 3.253 0.615 0.016 6834F562/F 2/1 238.4 0.023 0.434 0.326 0.771 2.848 0.500 0.040 6834F565/F 2/1 268.4 0.021 0.720 0.359 0.688 3.802 0.432 0.051 6834F566/F 2/1 226.8 0.037 0.840 0.384 0.788 3.312 0.573 0.046 6834F567/F 2/1 282.2 0.028 0.678 0.357 0.769 4.182 0.523 0.049 6834F568/F 2/1 203.6 0.034 0.901 0.375 0.714 5.991 0.895 0.273 6834F571/F 2/1 211.9 0.028 0.884 0.578 0.899 4.383 1.256 0.027 6834F572/F 2/1 256.4 0.020 0.713 0.388 0.786 3.448 0.629 0.049 6834F577/F 2/1 248.1 0.038 0.787 0.376 0.782 3.825 0.941 0.039 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-71
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6834F578/F 2/1 218.3 0.031 0.836 0.365 0.805 2.975 0.554 0.034 6834F581/F 2/1 207.5 0.031 0.937 0.575 0.983 4.029 1.036 0.047 6834F582/F 2/1 248.6 0.030 0.743 0.337 0.670 3.077 0.471 0.025 6834F589/F 2/1 267.9 0.029 0.743 0.418 0.743 3.477 0.964 0.057 6834F590/F 2/1 234.0 0.032 0.832 0.355 0.863 3.553 0.533 0.065 6834F594/F 2/1 299.0 0.018 0.630 0.305 0.617 3.535 0.392 0.036 6834F595/F 2/1 214.2 0.042 0.923 0.331 0.770 3.078 0.565 0.047 6834F599/F 2/1 200.0 0.037 0.889 0.576 0.984 3.412 1.609 0.077 M e a n: 237.8 0.030 0.786 0.409 0.791 3.693% 0.755 0.056 Standard deviation: 28.3 0.007 0.124 0.090 0.097 0.730 0.335 0.056 Number of observ. : (18) (18) (18) (18) (18) (18) (18) (18) 6836G653/F 3/1 207.9 0.040 0.904 0.429 0.681 3.298 0.614 0.056 6836G659/F 3/1 232.0 0.021 0.829 0.456 0.900 4.081 1.401 0.031 6836G664/F 3/1 223.0 0.020 0.838 0.387 0.830 3.340 0.590 0.025 6836G676/F 3/1 232.8 0.030 0.834 0.432 0.854 4.780 1.178 0.040 6836G678/F 3/1 235.4 0.028 0.799 0.334 0.837 3.701 0.708 0.054 6836G679/F 3/1 217.4 0.029 0.851 0.354 0.839 3.500 0.558 0.030 6836G680/F 3/1 213.1 0.026 0.915 0.602 1.003 4.249 1.351 0.012 6836G682/F 3/1 223.1 0.031 0.836 0.427 0.778 6.798 1.380 0.134 6836G683/F 3/1 240.7 0.022 0.796 0.403 0.726 3.105 0.494 0.068 6836G685/F 3/1 186.6 0.034 1.013 0.499 0.898 3.865 1.008 0.020 6836G687/F 3/1 223.0 0.035 0.880 0.454 0.961 5.040 0.838 0.029 6836G688/F 3/1 246.4 0.024 0.779 0.381 0.854 4.349 0.995 0.044 6836G691/F 3/1 156.8 0.059 1.111 0.390 0.807 3.210 0.695 0.053 6836G695/F 3/1 204.4 0.033 1.008 0.437 0.948 3.977 0.591 0.035 6836G696/F 3/1 175.2 0.037 0.951 0.337 0.743 3.518 0.534 0.050 6836G698/F 3/1 226.0 0.023 0.815 0.374 0.852 3.569 0.766 0.037 6836G699/F 3/1 153.9 0.035 1.155 0.335 0.776 2.807 0.638 0.058 M e a n: 211.6 0.031 0.901 0.414 0.840 3.952 0.844 0.046 Standard deviation: 27.9 0.009 0.112 0.068 0.085 0.943 0.315 0.027 Number of observ. : (17) (17) (17) (17) (17) (17) (17) (17) 6838H751/F 4/1 197.9 0.033 0.961 0.391 1.067 12.308 2.059 0.032 6838H752/F 4/1 216.2 0.034 0.857 0.418 0.997 7.934 1.502 0.153 6838H753/F 4/1 188.8 0.047 0.981 0.389 1.396 3.429 1.758 0.032 6838H757/F 4/1 183.6 0.013 1.005 0.562 0.984 3.676 1.069 0.065 6838H763/F 4/1 229.8 0.033 0.809 0.311 0.770 3.003 0.481 0.040 6838H764/F 4/1 186.0 0.032 1.038 0.460 0.855 4.337 1.141 0.046 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-72
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6838H766/F 4/1 198.3 0.033 0.931 0.620 0.879 6.652 1.174 0.028 6838H770/F 4/1 198.8 0.026 0.907 0.600 1.085 4.720 1.126 0.013 6838H772/F 4/1 185.1 0.022 1.010 0.502 1.069 4.226 1.061 0.025 6838H774/F 4/1 190.1 0.025 0.955 0.391 0.760 4.543 1.095 0.027 6838H775/F 4/1 191.6 0.035 0.993 0.487 1.131 4.174 1.026 0.028 6838H783/F 4/1 196.1 0.035 0.889 0.385 1.057 4.626 0.584 0.041 6838H785/F 4/1 230.0 0.027 0.820 0.371 0.821 4.510 1.097 0.056 6838H792/F 4/1 199.7 0.025 0.934 0.539 1.044 4.560 1.199 0.033 6838H797/F 4/1 223.3 0.077 0.813 0.442 0.858 5.112 1.192 0.049 M e a n: 201.0+ 0.033 0.927 0.458 0.985$ 5.187 1.171* 0.045 Standard deviation: 16.0 0.014 0.075 0.091 0.167 2.315 0.389 0.033 Number of observ. : (15) (15) (15) (15) (15) (15) (15) (15) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-73
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 4 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen F e m a l e A n i m a l s 6832E453/F 1/1 219.3 1.460 1.294 6832E455/F 1/1 279.2 0.367 NT 6832E457/F 1/1 201.2 3.781 0.258 6832E459/F 1/1 223.0 10.036 0.394 6832E465/F 1/1 192.6 0.254 0.449 6832E466/F 1/1 237.0 3.178 0.378 6832E468/F 1/1 260.6 0.533 0.266 6832E469/F 1/1 201.9 3.090 0.633 6832E470/F 1/1 239.4 3.512 0.193 6832E471/F 1/1 236.9 3.795 0.184 6832E474/F 1/1 189.3 2.621 0.238 6832E476/F 1/1 259.5 5.655 0.230 6832E479/F 1/1 263.3 2.936 0.220 6832E481/F 1/1 203.4 0.533 NT 6832E482/F 1/1 250.2 4.799 0.189 6832E484/F 1/1 212.8 0.855 0.247 6832E485/F 1/1 211.2 3.727 0.711 6832E487/F 1/1 226.0 7.996 0.365 6832E488/F 1/1 220.2 0.291 0.205 6832E491/F 1/1 217.6 5.942 0.372 6832E492/F 1/1 186.5 0.243 0.385 6832E494/F 1/1 276.5 0.310 0.194 6832E496/F 1/1 200.1 3.071 0.371 6832E499/F 1/1 248.6 4.067 0.257 M e a n: 227.4 3.044 0.365 Standard deviation: 27.6 2.575 0.250 Number of observ. : (24) (24) (22) 6834F552/F 2/1 229.7 2.792 0.315 6834F556/F 2/1 225.7 0.864 6.920 6834F562/F 2/1 238.4 0.239 0.480 6834F565/F 2/1 268.4 0.249 0.247 6834F566/F 2/1 226.8 0.598 3.327 6834F567/F 2/1 282.2 1.080 0.225 6834F568/F 2/1 203.6 3.508 0.330 6834F571/F 2/1 211.9 3.436 0.227 6834F572/F 2/1 256.4 6.507 0.296 6834F577/F 2/1 248.1 0.336 0.401 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-74
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 5 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6834F578/F 2/1 218.3 0.281 0.328 6834F581/F 2/1 207.5 3.629 0.271 6834F582/F 2/1 248.6 0.671 11.294 6834F589/F 2/1 267.9 2.430 3.543 6834F590/F 2/1 234.0 0.273 NT 6834F594/F 2/1 299.0 0.183 0.171 6834F595/F 2/1 214.2 0.192 0.804 6834F599/F 2/1 200.0 3.367 0.332 M e a n: 237.8 1.702 1.736 Standard deviation: 28.3 1.810 3.058 Number of observ. : (18) (18) (17) 6836G653/F 3/1 207.9 0.303 0.339 6836G659/F 3/1 232.0 6.053 0.213 6836G664/F 3/1 223.0 0.575 0.501 6836G676/F 3/1 232.8 4.649 0.580 6836G678/F 3/1 235.4 0.499 0.625 6836G679/F 3/1 217.4 0.245 0.206 6836G680/F 3/1 213.1 4.335 0.372 6836G682/F 3/1 223.1 3.115 0.491 6836G683/F 3/1 240.7 0.199 8.021 6836G685/F 3/1 186.6 3.242 0.308 6836G687/F 3/1 223.0 2.871 0.256 6836G688/F 3/1 246.4 2.764 0.297 6836G691/F 3/1 156.8 0.221 0.348 6836G695/F 3/1 204.4 0.209 0.219 6836G696/F 3/1 175.2 0.212 0.233 6836G698/F 3/1 226.0 2.008 0.493 6836G699/F 3/1 153.9 0.266 0.162 M e a n: 211.6 1.869 0.804 Standard deviation: 27.9 1.917 1.865 Number of observ. : (17) (17) (17) 6838H751/F 4/1 197.9 0.668 0.292 6838H752/F 4/1 216.2 3.756 1.189 6838H753/F 4/1 188.8 0.476 5.693 6838H757/F 4/1 183.6 2.784 0.387 6838H763/F 4/1 229.8 0.256 9.292 6838H764/F 4/1 186.0 1.298 0.366 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-75
 Lovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 6 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6838H766/F 4/1 198.3 6.332 0.337 6838H770/F 4/1 198.8 2.209 0.505 6838H772/F 4/1 185.1 1.325 0.335 6838H774/F 4/1 190.1 2.999 0.358 6838H775/F 4/1 191.6 1.907 0.382 6838H783/F 4/1 196.1 0.346 0.229 6838H785/F 4/1 230.0 2.457 0.312 6838H792/F 4/1 199.7 6.836 0.289 6838H797/F 4/1 223.3 3.181 0.259 M e a n: 201.0+ 2.455 1.348 Standard deviation: 16.0 2.004 2.596 Number of observ. : (15) (15) (15) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-76
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-6 Percent Organ to Brain Weight, Male and Female, Euthanized Rats 

K-77
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs M a l e A n i m a l s 6831E401/M 1/1 350.8 3.061 100.000 29.146 58.063 125.765 824.852 141.663 6831E402/M 1/1 375.6 NT 6831E403/M 1/1 276.1 3.195 100.000 21.118 55.866 121.118 538.792 155.067 6831E404/M 1/1 494.2 3.391 100.000 42.073 65.903 134.862 734.145 137.966 6831E405/M 1/1 311.3 2.699 100.000 17.205 82.795 125.060 496.916 145.542 6831E406/M 1/1 224.4 4.813 100.000 37.031 49.443 97.771 205.826 70.061 6831E408/M 1/1 312.1 2.423 100.000 38.765 41.140 102.470 344.276 54.869 6831E409/M 1/1 300.4 3.295 100.000 26.457 40.210 117.670 528.606 105.922 6831E410/M 1/1 369.2 5.654 100.000 27.168 65.069 145.232 916.579 143.747 6831E411/M 1/1 339.4 3.080 100.000 21.174 52.839 140.520 950.962 190.279 6831E412/M 1/1 331.9 3.862 100.000 17.553 48.195 101.856 417.101 67.803 6831E414/M 1/1 255.3 5.178 100.000 25.463 56.105 117.102 374.014 173.919 6831E416/M 1/1 385.4 3.841 100.000 24.648 55.955 143.996 868.206 201.215 6831E417/M 1/1 372.5 3.504 100.000 43.893 61.168 126.034 497.956 85.839 6831E419/M 1/1 359.2 3.015 100.000 14.390 68.296 142.257 707.218 225.491 6831E420/M 1/1 355.4 3.278 100.000 23.802 53.757 137.166 649.471 131.417 6831E421/M 1/1 385.2 3.051 100.000 37.989 63.680 143.613 599.857 195.043 6831E423/M 1/1 381.1 2.857 100.000 39.063 56.347 127.447 645.714 152.974 6831E424/M 1/1 365.0 4.972 100.000 25.657 55.629 129.268 692.073 146.013 6831E426/M 1/1 282.1 3.709 100.000 19.894 65.655 123.459 443.497 157.659 6831E427/M 1/1 294.9 3.412 100.000 22.180 69.242 130.095 760.995 276.967 6831E428/M 1/1 355.2 3.510 100.000 27.781 60.900 121.453 534.058 99.061 6831E429/M 1/1 352.3 3.566 100.000 21.816 64.937 131.357 709.588 141.362 6831E430/M 1/1 327.7 3.553 100.000 22.372 59.530 112.338 366.683 121.459 6831E431/M 1/1 346.8 2.483 100.000 41.286 51.707 107.716 354.856 63.548 6831E432/M 1/1 379.0 2.296 100.000 24.670 70.298 140.156 855.154 159.013 6831E433/M 1/1 311.2 3.033 100.000 28.294 51.367 119.344 482.596 77.374 6831E434/M 1/1 317.5 4.604 100.000 29.406 60.446 159.208 621.436 83.218 6831E438/M 1/1 331.8 3.466 100.000 23.419 60.234 145.995 853.911 149.087 6831E439/M 1/1 417.3 1.476 100.000 57.913 53.588 127.888 664.122 74.962 6831E441/M 1/1 366.9 2.940 100.000 39.917 61.461 135.645 513.964 141.525 6831E444/M 1/1 331.1 4.227 100.000 28.543 53.307 128.046 802.188 168.772 6831E445/M 1/1 369.9 2.951 100.000 21.867 71.456 135.994 594.388 169.279 6831E447/M 1/1 353.4 3.033 100.000 25.489 57.436 126.566 960.665 176.125 6831E450/M 1/1 440.7 2.586 100.000 51.367 60.368 137.195 767.678 109.896 M e a n: 346.4 3.412 100.000 29.377 58.894 128.284 625.834 138.063 Standard deviation: 50.7 0.867 0.000 10.095 8.553 13.808 193.580 49.938 Number of observ. : (35) (34) (34) (34) (34) (34) (34) (34) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-78
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6833F504/M 2/1 344.8 18.647 100.000 16.865 58.638 136.197 949.406 164.671 6833F506/M 2/1 299.2 2.354 100.000 16.855 59.652 131.780 631.450 172.787 6833F507/M 2/1 367.4 3.271 100.000 30.029 67.969 140.479 787.744 155.713 6833F509/M 2/1 503.4 4.869 100.000 57.352 64.946 128.822 496.933 83.204 6833F510/M 2/1 314.7 3.841 100.000 21.050 59.310 123.432 437.190 78.464 6833F512/M 2/1 306.8 2.646 100.000 27.273 67.003 133.430 518.182 145.022 6833F514/M 2/1 395.1 2.014 100.000 40.786 57.100 145.317 660.222 93.656 6833F515/M 2/1 352.0 3.269 100.000 33.444 50.403 129.370 709.427 132.117 6833F517/M 2/1 408.0 2.194 100.000 34.314 62.745 139.076 882.633 156.303 6833F518/M 2/1 407.4 3.852 100.000 19.536 65.429 142.181 755.313 129.188 6833F520/M 2/1 324.1 5.447 100.000 25.195 70.088 231.274 804.232 125.827 6833F522/M 2/1 377.2 3.931 100.000 20.518 62.272 138.686 844.535 136.817 6833F527/M 2/1 357.5 3.651 100.000 45.791 60.497 151.826 769.523 101.826 6833F528/M 2/1 309.8 2.302 100.000 32.234 60.649 134.537 506.122 143.119 6833F529/M 2/1 444.5 3.212 100.000 44.234 61.168 131.241 606.813 79.805 6833F530/M 2/1 329.6 2.648 100.000 28.551 62.879 152.961 557.920 104.959 6833F531/M 2/1 355.2 3.873 100.000 29.334 62.494 124.705 491.167 79.594 6833F532/M 2/1 314.7 2.938 100.000 41.908 59.489 123.459 771.195 310.549 6833F533/M 2/1 388.3 2.652 100.000 40.275 91.405 177.358 1157.122 116.503 6833F534/M 2/1 247.0 2.358 100.000 21.626 66.834 119.318 556.297 141.596 6833F537/M 2/1 338.3 2.911 100.000 20.282 45.399 136.197 481.033 193.568 6833F538/M 2/1 369.0 3.162 100.000 24.629 64.447 134.403 454.624 182.607 6833F539/M 2/1 259.2 4.454 100.000 21.312 49.856 104.598 239.655 70.642 6833F540/M 2/1 300.4 3.063 100.000 47.749 59.629 132.854 423.852 135.128 6833F543/M 2/1 325.3 3.065 100.000 16.985 46.432 159.095 703.668 368.141 6833F544/M 2/1 352.7 5.876 100.000 22.075 100.000 138.937 981.298 151.354 6833F545/M 2/1 367.1 5.211 100.000 35.534 77.171 140.546 1014.194 166.055 6833F546/M 2/1 350.7 3.862 100.000 17.101 58.576 207.824 741.775 143.180 6833F548/M 2/1 472.7 4.617 100.000 22.411 64.680 154.370 938.100 123.263 M e a n: 354.6 4.007 100.000 29.491 63.350 142.906$ 685.228 144.333 Standard deviation: 56.9 2.992 0.000 10.890 11.255 25.374 212.442 63.668 Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29) 6835G604/M 3/1 334.8 4.205 100.000 18.729 57.848 198.924 725.232 596.186 6835G606/M 3/1 411.5 3.558 100.000 30.360 65.342 156.377 827.911 152.311 6835G608/M 3/1 319.0 3.082 100.000 16.074 91.275 145.661 672.736 162.399 6835G611/M 3/1 290.7 4.503 100.000 31.473 57.645 127.674 454.831 133.068 6835G612/M 3/1 317.1 4.548 100.000 17.768 58.134 126.395 642.991 179.887 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-79
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6835G616/M 3/1 350.1 3.774 100.000 18.204 68.132 150.693 886.049 139.130 6835G618/M 3/1 333.2 3.040 100.000 24.656 66.746 142.945 742.233 173.159 6835G619/M 3/1 321.5 4.986 100.000 18.768 64.722 139.840 700.000 115.475 6835G620/M 3/1 334.6 2.854 100.000 15.509 65.366 144.910 859.991 188.440 6835G622/M 3/1 312.8 4.823 100.000 16.380 57.593 139.446 659.312 167.192 6835G623/M 3/1 381.3 2.853 100.000 47.478 50.739 131.890 546.867 89.302 6835G624/M 3/1 310.6 2.685 100.000 18.697 54.699 126.256 574.988 123.073 6835G626/M 3/1 347.1 2.540 100.000 19.567 57.291 154.892 718.344 118.203 6835G629/M 3/1 316.6 4.582 100.000 23.524 56.259 133.349 588.899 124.610 6835G631/M 3/1 362.6 3.757 100.000 18.783 71.422 147.171 866.239 175.036 6835G632/M 3/1 323.8 3.002 100.000 17.724 58.450 129.395 568.039 127.215 6835G633/M 3/1 420.2 3.150 100.000 22.146 54.232 146.506 810.778 93.848 6835G635/M 3/1 307.0 4.512 100.000 18.093 63.628 126.419 583.674 90.930 6835G637/M 3/1 326.4 3.464 100.000 21.396 51.961 133.469 675.904 170.657 6835G640/M 3/1 291.4 3.356 100.000 25.420 56.120 129.714 672.261 187.759 6835G641/M 3/1 349.9 3.352 100.000 21.983 66.140 150.671 835.249 116.188 6835G642/M 3/1 334.1 4.092 100.000 24.218 71.883 148.676 934.425 167.068 6835G643/M 3/1 407.3 3.208 100.000 30.293 51.604 129.789 682.722 75.115 6835G644/M 3/1 353.4 3.004 100.000 37.209 65.795 127.907 724.322 142.781 6835G645/M 3/1 323.0 3.800 100.000 25.926 58.297 129.774 546.128 76.912 6835G646/M 3/1 356.0 11.270 100.000 19.229 65.497 168.512 993.030 167.227 6835G650/M 3/1 341.9 4.750 100.000 42.850 65.235 146.185 570.086 78.272 M e a n: 339.9 3.954 100.000 23.795 61.928 141.979$ 706.046 153.016 Standard deviation: 33.5 1.632 0.000 8.155 8.381 15.940 134.204 95.551 Number of observ. : (27) (27) (27) (27) (27) (27) (27) (27) 6837H701/M 4/1 253.6 5.114 100.000 16.477 65.961 204.700 661.725 142.200 6837H703/M 4/1 435.2 4.348 100.000 30.972 57.255 145.383 800.537 88.422 6837H707/M 4/1 353.8 8.611 100.000 22.701 81.556 160.959 794.276 128.963 6837H709/M 4/1 362.3 2.395 100.000 21.017 61.046 163.196 1056.647 137.781 6837H710/M 4/1 305.8 3.403 100.000 24.842 57.560 140.593 520.661 112.688 6837H711/M 4/1 358.8 5.197 100.000 34.483 61.569 146.977 654.123 88.706 6837H712/M 4/1 348.6 2.811 100.000 30.393 44.256 512.361 606.253 80.756 6837H713/M 4/1 301.4 5.971 100.000 29.453 62.469 226.091 828.600 126.844 6837H715/M 4/1 365.1 3.443 100.000 18.986 62.355 161.424 1049.558 144.439 6837H716/M 4/1 411.5 3.430 100.000 49.903 48.502 145.217 713.333 87.391 6837H719/M 4/1 365.4 2.529 100.000 39.656 64.340 153.212 771.169 133.030 6837H720/M 4/1 301.7 2.555 100.000 15.960 55.834 132.112 719.142 120.878 6837H721/M 4/1 362.5 3.996 100.000 20.462 55.368 150.265 666.635 77.660 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-80
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 4 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Heart Liver No/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs 6837H723/M 4/1 333.5 3.259 100.000 29.432 49.333 141.679 779.852 154.074 6837H727/M 4/1 304.8 3.466 100.000 17.023 82.161 149.592 664.016 134.964 6837H730/M 4/1 334.0 3.458 100.000 21.838 66.698 128.849 517.480 87.305 6837H731/M 4/1 304.6 1.369 100.000 23.227 47.971 134.132 693.203 159.511 6837H733/M 4/1 298.5 2.734 100.000 30.322 50.684 122.314 784.814 156.445 6837H734/M 4/1 316.5 4.727 100.000 18.808 57.706 153.324 1050.369 161.054 6837H737/M 4/1 323.8 3.409 100.000 15.366 71.937 144.862 800.297 155.336 6837H738/M 4/1 330.4 3.021 100.000 29.045 67.836 141.472 656.676 131.969 6837H740/M 4/1 315.5 3.648 100.000 16.279 57.228 121.295 702.736 128.181 6837H742/M 4/1 307.8 2.932 100.000 23.862 56.016 137.867 1076.744 182.255 6837H743/M 4/1 301.2 3.152 100.000 20.917 62.273 148.997 560.745 130.993 6837H744/M 4/1 296.4 2.831 100.000 35.924 63.973 145.805 679.568 169.532 6837H745/M 4/1 273.9 4.041 100.000 19.172 63.184 124.199 379.202 124.840 6837H746/M 4/1 287.8 30.060 100.000 31.548 55.556 142.163 608.333 205.605 6837H748/M 4/1 364.1 4.006 100.000 35.704 68.152 165.648 995.594 140.911 6837H750/M 4/1 305.6 3.763 100.000 19.062 54.399 153.763 788.661 167.937 M e a n: 328.4 4.610 100.000 25.615 60.454 162.016% 744.171* 133.127 Standard deviation: 39.6 5.072 0.000 8.330 8.911 70.816 172.255 31.712 Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-81
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 5 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen M a l e A n i m a l s 6831E401/M 1/1 350.8 446.871 148.926 6831E402/M 1/1 375.6 6831E403/M 1/1 276.1 786.320 144.933 6831E404/M 1/1 494.2 97.087 203.725 6831E405/M 1/1 311.3 381.735 79.614 6831E406/M 1/1 224.4 24.164 117.173 6831E408/M 1/1 312.1 31.069 142.898 6831E409/M 1/1 300.4 175.215 110.554 6831E410/M 1/1 369.2 1003.498 121.993 6831E411/M 1/1 339.4 562.849 79.018 6831E412/M 1/1 331.9 30.191 110.933 6831E414/M 1/1 255.3 23.373 93.634 6831E416/M 1/1 385.4 1086.339 103.597 6831E417/M 1/1 372.5 72.457 144.720 6831E419/M 1/1 359.2 510.964 95.249 6831E420/M 1/1 355.4 428.139 232.829 6831E421/M 1/1 385.2 750.667 122.307 6831E423/M 1/1 381.1 637.143 124.169 6831E424/M 1/1 365.0 406.285 126.032 6831E426/M 1/1 282.1 504.094 111.513 6831E427/M 1/1 294.9 453.365 47.630 6831E428/M 1/1 355.2 98.863 137.568 6831E429/M 1/1 352.3 664.891 116.628 6831E430/M 1/1 327.7 38.310 113.058 6831E431/M 1/1 346.8 34.235 140.177 6831E432/M 1/1 379.0 1183.244 96.971 6831E433/M 1/1 311.2 84.635 233.267 6831E434/M 1/1 317.5 35.941 109.109 6831E438/M 1/1 331.8 438.689 58.361 6831E439/M 1/1 417.3 46.768 173.893 6831E441/M 1/1 366.9 502.021 122.462 6831E444/M 1/1 331.1 658.081 94.878 6831E445/M 1/1 369.9 650.460 161.103 6831E447/M 1/1 353.4 582.583 83.366 6831E450/M 1/1 440.7 185.679 150.970 M e a n: 346.4 400.477 125.096 Standard deviation: 50.7 332.180 41.734 Number of observ. : (35) (34) (34) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-82
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 6 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6833F504/M 2/1 344.8 782.038 88.483 6833F506/M 2/1 299.2 710.452 111.770 6833F507/M 2/1 367.4 744.727 112.061 6833F509/M 2/1 503.4 81.402 125.122 6833F510/M 2/1 314.7 48.858 147.594 6833F512/M 2/1 306.8 335.835 74.555 6833F514/M 2/1 395.1 238.822 132.427 6833F515/M 2/1 352.0 464.235 103.648 6833F517/M 2/1 408.0 1160.131 157.703 6833F518/M 2/1 407.4 125.708 150.209 6833F520/M 2/1 324.1 219.942 132.150 6833F522/M 2/1 377.2 583.078 115.292 6833F527/M 2/1 357.5 997.059 128.144 6833F528/M 2/1 309.8 457.876 114.233 6833F529/M 2/1 444.5 64.428 226.667 6833F530/M 2/1 329.6 76.312 112.133 6833F531/M 2/1 355.2 43.694 96.363 6833F532/M 2/1 314.7 315.318 131.888 6833F533/M 2/1 388.3 1017.338 143.664 6833F534/M 2/1 247.0 83.743 103.161 6833F537/M 2/1 338.3 456.714 86.761 6833F538/M 2/1 369.0 993.723 130.283 6833F539/M 2/1 259.2 26.341 127.730 6833F540/M 2/1 300.4 577.773 112.019 6833F543/M 2/1 325.3 60.050 104.975 6833F544/M 2/1 352.7 976.955 205.365 6833F545/M 2/1 367.1 1276.824 109.628 6833F546/M 2/1 350.7 299.198 175.125 6833F548/M 2/1 472.7 256.656 289.691 M e a n: 354.6 464.663 132.719 Standard deviation: 56.9 386.620 44.754 Number of observ. : (29) (29) (29) 6835G604/M 3/1 334.8 217.066 166.259 6835G606/M 3/1 411.5 542.745 160.028 6835G608/M 3/1 319.0 506.259 257.753 6835G611/M 3/1 290.7 450.422 119.841 6835G612/M 3/1 317.1 502.344 167.323 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-83
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 7 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6835G616/M 3/1 350.1 717.344 96.369 6835G618/M 3/1 333.2 636.722 105.463 6835G619/M 3/1 321.5 304.563 133.020 6835G620/M 3/1 334.6 647.050 82.445 6835G622/M 3/1 312.8 457.689 181.948 6835G623/M 3/1 381.3 57.769 142.384 6835G624/M 3/1 310.6 453.754 103.879 6835G626/M 3/1 347.1 179.586 192.474 6835G629/M 3/1 316.6 649.787 75.154 6835G631/M 3/1 362.6 260.390 149.215 6835G632/M 3/1 323.8 367.748 102.906 6835G633/M 3/1 420.2 175.098 336.171 6835G635/M 3/1 307.0 50.093 NT 6835G637/M 3/1 326.4 223.230 123.637 6835G640/M 3/1 291.4 1051.135 121.767 6835G641/M 3/1 349.9 796.312 157.759 6835G642/M 3/1 334.1 358.642 178.527 6835G643/M 3/1 407.3 59.945 237.443 6835G644/M 3/1 353.4 509.205 133.430 6835G645/M 3/1 323.0 42.665 240.067 6835G646/M 3/1 356.0 1082.106 143.005 6835G650/M 3/1 341.9 50.278 147.095 M e a n: 339.9 420.368 155.975 Standard deviation: 33.5 289.464 59.301 Number of observ. : (27) (27) (26) 6837H701/M 4/1 253.6 58.988 216.219 6837H703/M 4/1 435.2 117.782 99.756 6837H707/M 4/1 353.8 1214.579 70.597 6837H709/M 4/1 362.3 808.847 94.770 6837H710/M 4/1 305.8 80.895 197.132 6837H711/M 4/1 358.8 67.466 210.395 6837H712/M 4/1 348.6 52.545 146.631 6837H713/M 4/1 301.4 198.194 97.642 6837H715/M 4/1 365.1 629.409 121.033 6837H716/M 4/1 411.5 49.179 173.816 6837H719/M 4/1 365.4 997.673 149.975 6837H720/M 4/1 301.7 487.657 121.842 6837H721/M 4/1 362.5 61.098 299.037 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-84
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 8 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Testes No/sex Subgroup Body wt. (g) Spleen 6837H723/M 4/1 333.5 766.667 81.877 6837H727/M 4/1 304.8 621.560 119.572 6837H730/M 4/1 334.0 64.851 275.320 6837H731/M 4/1 304.6 251.932 114.719 6837H733/M 4/1 298.5 537.988 95.752 6837H734/M 4/1 316.5 268.882 208.370 6837H737/M 4/1 323.8 775.840 66.502 6837H738/M 4/1 330.4 384.600 127.047 6837H740/M 4/1 315.5 368.263 110.078 6837H742/M 4/1 307.8 764.914 85.187 6837H743/M 4/1 301.2 356.543 201.194 6837H744/M 4/1 296.4 601.750 105.455 6837H745/M 4/1 273.9 22.918 144.603 6837H746/M 4/1 287.8 393.304 62.897 6837H748/M 4/1 364.1 730.045 122.784 6837H750/M 4/1 305.6 473.314 NT M e a n: 328.4 420.954 140.007 Standard deviation: 39.6 325.797 61.350 Number of observ. : (29) (29) (28) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-85
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries F e m a l e A n i m a l s 6832E453/F 1/1 219.3 3.148 100.000 44.130 93.970 724.653 109.338 7.951 6832E455/F 1/1 279.2 3.682 100.000 50.973 98.738 495.055 74.645 6.628 6832E457/F 1/1 201.2 3.951 100.000 48.846 96.511 401.539 95.895 3.284 6832E459/F 1/1 223.0 3.625 100.000 48.783 87.934 1013.154 129.001 3.573 6832E465/F 1/1 192.6 3.497 100.000 45.992 83.755 259.710 52.125 2.905 6832E466/F 1/1 237.0 2.773 100.000 52.852 90.895 497.384 97.907 6.855 6832E468/F 1/1 260.6 2.883 100.000 53.819 92.261 398.634 69.702 5.615 6832E469/F 1/1 201.9 3.876 100.000 51.856 111.408 379.694 89.520 5.076 6832E470/F 1/1 239.4 2.875 100.000 43.126 87.820 623.314 176.738 4.496 6832E471/F 1/1 236.9 3.055 100.000 61.147 100.750 621.597 160.611 4.394 6832E474/F 1/1 189.3 2.676 100.000 49.207 87.463 405.996 100.892 3.072 6832E476/F 1/1 259.5 3.521 100.000 54.545 106.569 690.541 155.807 1.839 6832E479/F 1/1 263.3 3.643 100.000 65.777 100.051 506.362 109.338 5.285 6832E481/F 1/1 203.4 3.560 100.000 43.635 85.707 388.997 66.235 9.924 6832E482/F 1/1 250.2 3.597 100.000 60.385 114.336 730.851 134.195 3.901 6832E484/F 1/1 212.8 2.877 100.000 62.552 116.057 536.977 142.835 2.510 6832E485/F 1/1 211.2 3.751 100.000 56.646 103.475 673.525 124.821 5.626 6832E487/F 1/1 226.0 3.472 100.000 42.746 87.409 663.627 111.554 3.005 6832E488/F 1/1 220.2 4.024 100.000 54.323 106.688 416.694 62.425 4.296 6832E491/F 1/1 217.6 4.265 100.000 51.079 108.731 574.611 119.920 3.011 6832E492/F 1/1 186.5 3.004 100.000 37.739 75.478 274.113 52.376 3.605 6832E494/F 1/1 276.5 2.791 100.000 56.398 93.681 428.278 62.085 4.371 6832E496/F 1/1 200.1 3.100 100.000 61.283 108.537 480.805 130.614 5.003 6832E499/F 1/1 248.6 2.694 100.000 43.870 91.809 588.730 78.835 5.333 M e a n: 227.4 3.347 100.000 51.738 97.085 532.285 104.476 4.648 Standard deviation: 27.6 0.468 0.000 7.308 10.670 169.006 35.502 1.852 Number of observ. : (24) (24) (24) (24) (24) (24) (24) (24) 6834F552/F 2/1 229.7 3.472 100.000 58.549 100.155 511.192 131.969 3.420 6834F556/F 2/1 225.7 4.555 100.000 56.860 92.176 393.516 74.437 1.983 6834F562/F 2/1 238.4 5.217 100.000 75.072 177.585 656.039 115.072 9.179 6834F565/F 2/1 268.4 2.899 100.000 49.845 95.549 528.054 60.041 7.091 6834F566/F 2/1 226.8 4.464 100.000 45.693 93.803 394.433 68.277 5.462 6834F567/F 2/1 282.2 4.077 100.000 52.692 113.487 616.937 77.156 7.214 6834F568/F 2/1 203.6 3.815 100.000 41.635 79.237 664.796 99.346 30.245 6834F571/F 2/1 211.9 3.202 100.000 65.422 101.708 495.678 141.996 3.095 6834F572/F 2/1 256.4 2.791 100.000 54.461 110.235 483.908 88.287 6.842 6834F577/F 2/1 248.1 4.813 100.000 47.773 99.386 485.868 119.508 4.967 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-86
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6834F578/F 2/1 218.3 3.724 100.000 43.647 96.276 355.696 66.210 4.053 6834F581/F 2/1 207.5 3.294 100.000 61.400 104.992 430.160 110.654 5.044 6834F582/F 2/1 248.6 4.006 100.000 45.317 90.200 414.131 63.346 3.357 6834F589/F 2/1 267.9 3.867 100.000 56.303 100.000 467.906 129.684 7.634 6834F590/F 2/1 234.0 3.903 100.000 42.681 103.698 427.016 64.047 7.807 6834F594/F 2/1 299.0 2.865 100.000 48.329 97.878 560.743 62.122 5.729 6834F595/F 2/1 214.2 4.603 100.000 35.913 83.460 333.435 61.204 5.109 6834F599/F 2/1 200.0 4.108 100.000 64.772 110.692 383.906 181.092 8.610 M e a n: 237.8 3.871% 100.000 52.576 102.806 477.967 95.247 7.047 Standard deviation: 28.3 0.697 0.000 9.979 20.664 98.416 35.306 6.133 Number of observ. : (18) (18) (18) (18) (18) (18) (18) (18) 6836G653/F 3/1 207.9 4.470 100.000 47.472 75.359 364.875 67.962 6.173 6836G659/F 3/1 232.0 2.549 100.000 54.995 108.637 492.560 169.147 3.746 6836G664/F 3/1 223.0 2.353 100.000 46.096 98.930 398.342 70.321 2.995 6836G676/F 3/1 232.8 3.553 100.000 51.751 102.369 573.121 141.246 4.737 6836G678/F 3/1 235.4 3.507 100.000 41.817 104.676 463.018 88.629 6.748 6836G679/F 3/1 217.4 3.458 100.000 41.545 98.541 411.129 65.586 3.512 6836G680/F 3/1 213.1 2.819 100.000 65.761 109.534 464.172 147.617 1.333 6836G682/F 3/1 223.1 3.698 100.000 51.018 93.033 812.862 165.059 16.077 6836G683/F 3/1 240.7 2.766 100.000 50.626 91.180 390.031 62.109 8.507 6836G685/F 3/1 186.6 3.384 100.000 49.286 88.630 381.438 99.471 1.957 6836G687/F 3/1 223.0 4.027 100.000 51.580 109.174 572.834 95.260 3.313 6836G688/F 3/1 246.4 3.125 100.000 48.854 109.583 558.229 127.708 5.677 6836G691/F 3/1 156.8 5.336 100.000 35.112 72.576 288.812 62.536 4.762 6836G695/F 3/1 204.4 3.252 100.000 43.398 94.029 394.612 58.689 3.495 6836G696/F 3/1 175.2 3.904 100.000 35.435 78.198 370.090 56.156 5.225 6836G698/F 3/1 226.0 2.823 100.000 45.874 104.560 437.785 93.974 4.560 6836G699/F 3/1 153.9 3.039 100.000 29.038 67.248 243.106 55.262 5.008 M e a n: 211.6 3.415 100.000 46.451 94.486 448.060 95.690 5.166 Standard deviation: 27.9 0.741 0.000 8.522 13.862 130.829 39.674 3.311 Number of observ. : (17) (17) (17) (17) (17) (17) (17) (17) 6838H751/F 4/1 197.9 3.470 100.000 40.694 110.988 1280.442 214.196 3.365 6838H752/F 4/1 216.2 3.994 100.000 48.786 116.352 925.742 175.283 17.863 6838H753/F 4/1 188.8 4.749 100.000 39.611 142.256 349.487 179.115 3.292 6838H757/F 4/1 183.6 1.247 100.000 55.935 97.940 365.799 106.341 6.504 6838H763/F 4/1 229.8 4.088 100.000 38.462 95.212 371.221 59.441 4.949 6838H764/F 4/1 186.0 3.109 100.000 44.352 82.383 418.031 110.000 4.456 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-87
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Brain Kidneys Lungs No/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries 6838H766/F 4/1 198.3 3.519 100.000 66.594 94.369 714.348 126.042 3.032 6838H770/F 4/1 198.8 2.827 100.000 66.075 119.623 520.177 124.058 1.441 6838H772/F 4/1 185.1 2.194 100.000 49.759 105.832 418.566 105.029 2.461 6838H774/F 4/1 190.1 2.645 100.000 40.937 79.614 475.868 114.656 2.810 6838H775/F 4/1 191.6 3.575 100.000 49.054 113.933 420.505 103.312 2.839 6838H783/F 4/1 196.1 3.956 100.000 43.234 118.807 520.184 65.654 4.587 6838H785/F 4/1 230.0 3.234 100.000 45.281 100.106 549.947 133.828 6.787 6838H792/F 4/1 199.7 2.681 100.000 57.748 111.796 488.204 128.365 3.539 6838H797/F 4/1 223.3 9.416 100.000 54.350 105.507 628.579 146.586 6.057 M e a n: 201.0+ 3.647 100.000 49.392 106.315 563.140 126.127 4.932 Standard deviation: 16.0 1.811 0.000 9.081 15.804 249.853 40.813 3.897 Number of observ. : (15) (15) (15) (15) (15) (15) (15) (15) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-88
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 4 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen F e m a l e A n i m a l s 6832E453/F 1/1 219.3 170.811 151.441 6832E455/F 1/1 279.2 53.919 NT 6832E457/F 1/1 201.2 390.354 26.680 6832E459/F 1/1 223.0 1158.933 45.520 6832E465/F 1/1 192.6 26.304 46.530 6832E466/F 1/1 237.0 394.192 46.886 6832E468/F 1/1 260.6 70.258 35.104 6832E469/F 1/1 201.9 340.557 69.814 6832E470/F 1/1 239.4 439.571 24.098 6832E471/F 1/1 236.9 481.886 23.419 6832E474/F 1/1 189.3 245.837 22.349 6832E476/F 1/1 259.5 771.256 31.372 6832E479/F 1/1 263.3 396.665 29.708 6832E481/F 1/1 203.4 58.522 NT 6832E482/F 1/1 250.2 608.359 23.962 6832E484/F 1/1 212.8 95.136 27.458 6832E485/F 1/1 211.2 434.253 82.846 6832E487/F 1/1 226.0 936.373 42.798 6832E488/F 1/1 220.2 34.856 24.579 6832E491/F 1/1 217.6 648.821 40.642 6832E492/F 1/1 186.5 24.795 39.159 6832E494/F 1/1 276.5 45.129 28.278 6832E496/F 1/1 200.1 334.203 40.402 6832E499/F 1/1 248.6 555.855 35.129 M e a n: 227.4 363.202 42.644 Standard deviation: 27.6 307.168 28.581 Number of observ. : (24) (24) (22) 6834F552/F 2/1 229.7 332.383 37.513 6834F556/F 2/1 225.7 104.555 836.978 6834F562/F 2/1 238.4 55.169 110.531 6834F565/F 2/1 268.4 34.627 34.317 6834F566/F 2/1 226.8 71.271 396.219 6834F567/F 2/1 282.2 159.383 33.246 6834F568/F 2/1 203.6 389.264 36.621 6834F571/F 2/1 211.9 388.581 25.720 6834F572/F 2/1 256.4 913.246 41.544 6834F577/F 2/1 248.1 42.652 50.998 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-89
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 5 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6834F578/F 2/1 218.3 33.625 39.266 6834F581/F 2/1 207.5 387.494 28.976 6834F582/F 2/1 248.6 90.309 1520.141 6834F589/F 2/1 267.9 326.971 476.745 6834F590/F 2/1 234.0 32.820 NT 6834F594/F 2/1 299.0 28.966 27.162 6834F595/F 2/1 214.2 20.789 87.152 6834F599/F 2/1 200.0 378.897 37.310 M e a n: 237.8 210.611 224.732 Standard deviation: 28.3 231.151 400.890 Number of observ. : (18) (18) (17) 6836G653/F 3/1 207.9 33.582 37.520 6836G659/F 3/1 232.0 730.541 25.702 6836G664/F 3/1 223.0 68.610 59.733 6836G676/F 3/1 232.8 557.364 69.567 6836G678/F 3/1 235.4 62.380 78.162 6836G679/F 3/1 217.4 28.741 24.203 6836G680/F 3/1 213.1 473.501 40.595 6836G682/F 3/1 223.1 372.508 58.682 6836G683/F 3/1 240.7 24.948 1007.672 6836G685/F 3/1 186.6 319.884 30.354 6836G687/F 3/1 223.0 326.300 29.052 6836G688/F 3/1 246.4 354.740 38.073 6836G691/F 3/1 156.8 19.851 31.325 6836G695/F 3/1 204.4 20.728 21.699 6836G696/F 3/1 175.2 22.342 24.505 6836G698/F 3/1 226.0 246.363 60.532 6836G699/F 3/1 153.9 23.073 14.069 M e a n: 211.6 216.791 97.144 Standard deviation: 27.9 225.928 235.368 Number of observ. : (17) (17) (17) 6838H751/F 4/1 197.9 69.506 30.336 6838H752/F 4/1 216.2 438.208 138.694 6838H753/F 4/1 188.8 48.516 580.194 6838H757/F 4/1 183.6 277.073 38.482 6838H763/F 4/1 229.8 31.684 1148.575 6838H764/F 4/1 186.0 125.130 35.233 *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-90
 Lovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 6 Unscheduled Sacrifices U2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Animal Group/ Terminal Uterus No/sex Subgroup Body wt. (g) Spleen 6838H766/F 4/1 198.3 679.968 36.167 6838H770/F 4/1 198.8 243.459 55.654 6838H772/F 4/1 185.1 131.247 33.173 6838H774/F 4/1 190.1 314.160 37.521 6838H775/F 4/1 191.6 192.114 38.486 6838H783/F 4/1 196.1 38.876 25.803 6838H785/F 4/1 230.0 299.629 38.070 6838H792/F 4/1 199.7 731.796 30.938 6838H797/F 4/1 223.3 391.134 31.828 M e a n: 201.0+ 267.500 153.277 Standard deviation: 16.0 219.343 309.239 Number of observ. : (15) (15) (15) *(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance %($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

Study Number FY01-013

K-91
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

K-7 Organ Weights for Animals that Died 

K-92
 Lovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 1 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Terminal Organ Relative Relative Animal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of Brain No/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status 6831E425/M 1/1 10-Feb-03 629/# 11-Feb-03 11:03 10-Feb-03 8 Adrenal glands 434.1 0.100 0.023 4.42 HIGH 11-Feb-03 11:04 10-Feb-03 8 Brain 2.262 0.521 100.00 O

K

 11-Feb-03 11:04 10-Feb-03 8 Epididymis 0.667 0.154 29.49 O

K

 11-Feb-03 11:04 10-Feb-03 8 Heart 1.971 0.454 87.14 O

K

 11-Feb-03 11:04 10-Feb-03 8 Kidneys 3.767 0.868 166.53 O

K

 11-Feb-03 11:04 10-Feb-03 8 Liver 18.034 4.155 797.26 HIGH 11-Feb-03 11:04 10-Feb-03 8 Lungs 2.140 0.493 94.61 O

K

 11-Feb-03 11:04 10-Feb-03 8 Spleen 1.925 0.443 85.10 O

K

 11-Feb-03 11:04 10-Feb-03 8 Testes 3.742 0.862 165.43 HIGH 6833F501/M 2/1 24-Feb-03 643/# 27-Feb-03 16:49 24-Feb-03 128 Adrenal glands 357.8 0.041 0.011 1.88 O

K

 27-Feb-03 16:49 24-Feb-03 128 Brain 2.183 0.610 100.00 O

K

 27-Feb-03 16:52 24-Feb-03 128 Epididymis 0.481 0.134 22.03 O

K

 27-Feb-03 16:52 24-Feb-03 128 Heart 1.581 0.442 72.42 O

K

 27-Feb-03 16:52 24-Feb-03 128 Kidneys 3.835 1.072 175.68 O

K

 27-Feb-03 16:52 24-Feb-03 128 Liver 15.500 4.332 710.03 HIGH 27-Feb-03 16:52 24-Feb-03 128 Lungs 7.447 2.081 341.14 O

K

 27-Feb-03 16:52 24-Feb-03 128 Spleen 10.926 3.054 500.50 HIGH 27-Feb-03 16:52 24-Feb-03 128 Testes 3.181 0.889 145.72 HIGH 6833F503/M 2/1 20-May-03 728/# 20-May-03 12:06 20-May-03 128 Adrenal glands 328.8 0.054 0.016 2.49 O

K

 20-May-03 12:06 20-May-03 128 Brain 2.171 0.660 100.00 O

K

 20-May-03 12:06 20-May-03 128 Epididymis 0.434 0.132 19.99 O

K

 20-May-03 12:06 20-May-03 128 Heart 1.477 0.449 68.03 O

K

 20-May-03 12:06 20-May-03 128 Kidneys 3.483 1.059 160.43 O

K

 20-May-03 12:06 20-May-03 128 Liver 23.078 7.019 1063.01 HIGH 20-May-03 12:06 20-May-03 128 Lungs 5.920 1.801 272.69 O

K

 20-May-03 12:06 20-May-03 128 Spleen 13.861 4.216 638.46 HIGH 20-May-03 12:06 20-May-03 128 Testes 2.396 0.729 110.36 HIGH 6833F524/M 2/1 21-Jun-02 395/# 25-Jun-02 14:28 21-Jun-02 128 Adrenal glands 479.0 0.143 0.030 6.75 HIGH 25-Jun-02 14:28 21-Jun-02 128 Brain 2.117 0.442 100.00 LO

W

 25-Jun-02 14:29 21-Jun-02 128 Epididymis 1.730 0.361 81.72 O

K

 25-Jun-02 14:28 21-Jun-02 128 Heart 1.534 0.320 72.46 O

K

 25-Jun-02 14:28 21-Jun-02 128 Kidneys 3.981 0.831 188.05 O

K

 25-Jun-02 14:29 21-Jun-02 128 Liver 18.813 3.927 888.66 O

K

 25-Jun-02 14:29 21-Jun-02 128 Lungs 3.045 0.636 143.84 O

K

 25-Jun-02 14:29 21-Jun-02 128 Spleen 0.969 0.202 45.77 O

K

 25-Jun-02 14:29 21-Jun-02 128 Testes 3.615 0.755 170.76 HIGH 6833F541/M 2/1 07-Mar-03 654/# 17-Mar-03 16:50 07-Mar-03 128 Adrenal glands 379.4 0.070 0.018 3.22 O

K

 17-Mar-03 16:50 07-Mar-03 128 Brain 2.173 0.573 100.00 O

K

 17-Mar-03 16:50 07-Mar-03 128 Epididymis 0.527 0.139 24.25 O

K

 17-Mar-03 16:50 07-Mar-03 128 Heart 1.490 0.393 68.57 O

K

 17-Mar-03 16:50 07-Mar-03 128 Kidneys 3.740 0.986 172.11 O

K

 17-Mar-03 16:50 07-Mar-03 128 Liver 19.169 5.052 882.14 HIGH 17-Mar-03 16:50 07-Mar-03 128 Lungs 3.196 0.842 147.08 O

K

 Note: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

Study Number FY01-013

K-93
 Lovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 2 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Terminal Organ Relative Relative Animal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of Brain No/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status 6833F541/M 2/1 07-Mar-03 654/# 17-Mar-03 16:50 07-Mar-03 128 Spleen 379.4 2.829 0.746 130.19 HIGH 17-Mar-03 16:50 07-Mar-03 128 Testes 5.559 1.465 255.82 HIGH 6833F549/M 2/1 20-Feb-03 639/# 21-Feb-03 16:32 20-Feb-03 128 Adrenal glands 288.9 0.085 0.029 4.00 HIGH 21-Feb-03 16:32 20-Feb-03 128 Brain 2.125 0.736 100.00 O

K

 21-Feb-03 16:32 20-Feb-03 128 Epididymis 0.535 0.185 25.18 O

K

 21-Feb-03 16:32 20-Feb-03 128 Heart 1.361 0.471 64.05 O

K

 21-Feb-03 16:32 20-Feb-03 128 Kidneys 3.486 1.207 164.05 HIGH 21-Feb-03 16:32 20-Feb-03 128 Liver 13.182 4.563 620.33 HIGH 21-Feb-03 16:32 20-Feb-03 128 Lungs 4.343 1.503 204.38 O

K

 21-Feb-03 16:32 20-Feb-03 128 Spleen 7.839 2.713 368.89 HIGH 21-Feb-03 16:32 20-Feb-03 128 Testes 3.276 1.134 154.16 HIGH 6835G625/M 3/1 04-Mar-03 651/# 10-Mar-03 17:00 04-Mar-03 128 Adrenal glands 323.9 0.118 0.036 5.60 HIGH 10-Mar-03 17:00 04-Mar-03 128 Brain 2.106 0.650 100.00 O

K

 10-Mar-03 17:00 04-Mar-03 128 Epididymis 0.476 0.147 22.60 O

K

 10-Mar-03 17:00 04-Mar-03 128 Heart 1.402 0.433 66.57 O

K

 10-Mar-03 17:00 04-Mar-03 128 Kidneys 3.784 1.168 179.68 O

K

 10-Mar-03 17:00 04-Mar-03 128 Liver 20.970 6.474 995.73 HIGH 10-Mar-03 17:00 04-Mar-03 128 Lungs 5.059 1.562 240.22 O

K

 10-Mar-03 17:01 04-Mar-03 128 Spleen 9.653 2.980 458.36 HIGH 10-Mar-03 17:01 04-Mar-03 128 Testes 1.968 0.608 93.45 O

K

 6835G627/M 3/1 05-Apr-03 683/# 12-May-03 11:30 05-Apr-03 -1 Adrenal glands 372.8 0.180 0.048 8.38 HIGH 12-May-03 11:30 05-Apr-03 -1 Brain 2.147 0.576 100.00 O

K

 12-May-03 11:31 05-Apr-03 -1 Epididymis 0.483 0.130 22.50 O

K

 12-May-03 11:31 05-Apr-03 -1 Heart 1.926 0.517 89.71 O

K

 12-May-03 11:31 05-Apr-03 -1 Kidneys 5.269 1.414 245.41 HIGH 12-May-03 11:31 05-Apr-03 -1 Liver 22.671 6.082 1055.94 HIGH 12-May-03 11:31 05-Apr-03 -1 Lungs 3.727 1.000 173.59 O

K

 12-May-03 11:31 05-Apr-03 -1 Spleen 2.248 0.603 104.70 HIGH 12-May-03 11:31 05-Apr-03 -1 Testes 2.340 0.628 108.99 HIGH 6835G636/M 3/1 02-Feb-03 621/# 03-Feb-03 09:12 02-Feb-03 8 Adrenal glands 297.7 0.133 0.045 6.33 HIGH 03-Feb-03 09:12 02-Feb-03 8 Brain 2.100 0.705 100.00 O

K

 03-Feb-03 09:12 02-Feb-03 8 Epididymis 0.471 0.158 22.43 O

K

 03-Feb-03 09:12 02-Feb-03 8 Heart 1.897 0.637 90.33 HIGH 03-Feb-03 09:12 02-Feb-03 8 Kidneys 3.635 1.221 173.10 HIGH 03-Feb-03 09:12 02-Feb-03 8 Liver 15.909 5.344 757.57 HIGH 03-Feb-03 09:12 02-Feb-03 8 Lungs 4.159 1.397 198.05 O

K

 03-Feb-03 09:12 02-Feb-03 8 Spleen 5.744 1.929 273.52 HIGH 03-Feb-03 09:12 02-Feb-03 8 Testes 2.518 0.846 119.90 HIGH 6837H718/M 4/1 19-May-03 727/# 20-May-03 12:52 19-May-03 8 Adrenal glands 349.8 0.112 0.032 5.53 HIGH 20-May-03 12:52 19-May-03 8 Brain 2.027 0.579 100.00 O

K

 20-May-03 12:52 19-May-03 8 Epididymis 0.572 0.164 28.22 O

K

 20-May-03 12:52 19-May-03 8 Heart 1.625 0.464 80.17 O

K

 20-May-03 12:53 19-May-03 8 Kidneys 4.258 1.217 210.06 HIGH Note: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

Study Number FY01-013

K-94
 Lovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04

 Research Institute Study number: FY01013M Page: 3 Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic Terminal Organ Relative Relative Animal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of Brain No/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status 6837H718/M 4/1 19-May-03 727/# 20-May-03 12:53 19-May-03 8 Liver 349.8 18.253 5.217 900.49 HIGH 20-May-03 12:53 19-May-03 8 Lungs 2.694 0.770 132.91 O

K

 20-May-03 12:53 19-May-03 8 Spleen 0.548 0.157 27.04 LO

W

 20-May-03 12:54 19-May-03 8 Testes 7.728 2.209 381.25 HIGH 6837H732/M 4/1 30-Dec-02 587/# 06-Jan-03 15:52 30-Dec-02 -1 Adrenal glands 378.8 0.580 0.153 27.19 HIGH 06-Jan-03 15:52 30-Dec-02 -1 Brain 2.133 0.563 100.00 O

K

 06-Jan-03 15:52 30-Dec-02 -1 Epididymis 0.823 0.217 38.58 O

K

 06-Jan-03 15:52 30-Dec-02 -1 Heart 1.184 0.313 55.51 O

K

 06-Jan-03 15:52 30-Dec-02 -1 Kidneys 3.589 0.948 168.26 O

K

 06-Jan-03 15:52 30-Dec-02 -1 Liver 15.375 4.059 720.82 HIGH 06-Jan-03 15:52 30-Dec-02 -1 Lungs 6.445 1.702 302.16 O

K

 06-Jan-03 15:52 30-Dec-02 -1 Spleen 1.123 0.296 52.65 O

K

 06-Jan-03 15:52 30-Dec-02 -1 Testes 4.587 1.211 215.05 HIGH Note: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

Study Number FY01-013

K-95
 Lovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 1 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Terminal Organ Relative Relative Animal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of Brain No/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status 6832E454/F 1/1 31-Jan-03 612/# 03-Feb-03 10:43 31-Jan-03 8 Adrenal glands 273.6 0.066 0.024 3.63 HIGH 03-Feb-03 10:43 31-Jan-03 8 Brain 1.816 0.664 100.00 O

K

 03-Feb-03 10:43 31-Jan-03 8 Heart 1.058 0.387 58.26 O

K

 03-Feb-03 10:43 31-Jan-03 8 Kidneys 1.820 0.665 100.22 O

K

 03-Feb-03 10:43 31-Jan-03 8 Liver 10.435 3.814 574.61 O

K

 03-Feb-03 10:43 31-Jan-03 8 Lungs 1.948 0.712 107.27 O

K

 03-Feb-03 10:43 31-Jan-03 8 Ovaries 0.025 0.009 1.38 LO

W

 03-Feb-03 10:43 31-Jan-03 8 Spleen 5.293 1.934 291.46 HIGH 03-Feb-03 10:43 31-Jan-03 8 Uterus 0.520 0.190 28.63 O

K

 6832E473/F 1/1 17-Mar-03 657/# 25-Mar-03 13:15 17-Mar-03 128 Adrenal glands 227.3 0.053 0.023 2.76 HIGH 25-Mar-03 13:15 17-Mar-03 128 Brain 1.921 0.845 100.00 O

K

 25-Mar-03 13:15 17-Mar-03 128 Heart 0.703 0.309 36.60 O

K

 25-Mar-03 13:15 17-Mar-03 128 Kidneys 1.989 0.875 103.54 O

K

 25-Mar-03 13:15 17-Mar-03 128 Liver 9.117 4.011 474.60 HIGH 25-Mar-03 13:15 17-Mar-03 128 Lungs 1.887 0.830 98.23 O

K

 25-Mar-03 13:15 17-Mar-03 128 Ovaries 0.041 0.018 2.13 LO

W

 25-Mar-03 13:15 17-Mar-03 128 Spleen 0.435 0.191 22.64 LO

W

 25-Mar-03 13:15 17-Mar-03 128 Uterus 0.568 0.250 29.57 O

K

 6832E477/F 1/1 07-Jan-03 588/# 10-Jan-03 16:53 07-Jan-03 128 Adrenal glands 187.7 0.089 0.047 4.57 HIGH 10-Jan-03 16:53 07-Jan-03 128 Brain 1.947 1.037 100.00 HIGH 10-Jan-03 16:53 07-Jan-03 128 Heart 1.270 0.677 65.23 HIGH 10-Jan-03 16:53 07-Jan-03 128 Kidneys 2.133 1.136 109.55 O

K

 10-Jan-03 16:53 07-Jan-03 128 Liver 8.492 4.524 436.16 HIGH 10-Jan-03 16:53 07-Jan-03 128 Lungs 2.651 1.412 136.16 O

K

 10-Jan-03 16:53 07-Jan-03 128 Ovaries 0.148 0.079 7.60 HIGH 10-Jan-03 16:54 07-Jan-03 128 Spleen 4.814 2.564 247.25 HIGH 10-Jan-03 16:54 07-Jan-03 128 Uterus 0.596 0.317 30.61 O

K

 6832E480/F 1/1 29-Mar-03 669/# 01-Apr-03 12:10 29-Mar-03 128 Adrenal glands 225.3 0.065 0.029 3.47 HIGH 01-Apr-03 12:10 29-Mar-03 128 Brain 1.871 0.830 100.00 O

K

 01-Apr-03 12:11 29-Mar-03 128 Heart 0.850 0.377 45.43 O

K

 01-Apr-03 12:11 29-Mar-03 128 Kidneys 1.895 0.841 101.28 O

K

 01-Apr-03 12:11 29-Mar-03 128 Liver 7.095 3.149 379.21 O

K

 01-Apr-03 12:11 29-Mar-03 128 Lungs 1.998 0.887 106.79 O

K

 01-Apr-03 12:11 29-Mar-03 128 Ovaries 0.085 0.038 4.54 O

K

 01-Apr-03 12:11 29-Mar-03 128 Spleen 0.618 0.274 33.03 O

K

 01-Apr-03 12:11 29-Mar-03 128 Uterus 0.996 0.442 53.23 O

K

 6834F576/F 2/1 14-Apr-03 685/# 16-Apr-03 17:32 14-Apr-03 128 Adrenal glands 212.6 0.307 0.144 16.68 HIGH 16-Apr-03 17:32 14-Apr-03 128 Brain 1.841 0.866 100.00 O

K

 16-Apr-03 17:32 14-Apr-03 128 Heart 1.162 0.547 63.12 O

K

 16-Apr-03 17:32 14-Apr-03 128 Kidneys 2.148 1.010 116.68 O

K

 16-Apr-03 17:32 14-Apr-03 128 Liver 12.450 5.856 676.26 HIGH 16-Apr-03 17:32 14-Apr-03 128 Lungs 2.801 1.317 152.15 O

K

 16-Apr-03 17:32 14-Apr-03 128 Ovaries 0.089 0.042 4.83 O

K

 Note: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

Study Number FY01-013

K-96
 Lovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 2 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Terminal Organ Relative Relative Animal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of Brain No/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status 6834F576/F 2/1 14-Apr-03 685/# 16-Apr-03 17:32 14-Apr-03 128 Spleen 212.6 5.653 2.659 307.06 HIGH 16-Apr-03 17:32 14-Apr-03 128 Uterus 1.437 0.676 78.06 O

K

 6834F593/F 2/1 24-May-03 725/# 28-May-03 16:49 24-May-03 128 Adrenal glands 257.4 0.088 0.034 4.55 HIGH 28-May-03 16:49 24-May-03 128 Brain 1.936 0.752 100.00 O

K

 28-May-03 16:49 24-May-03 128 Heart 0.943 0.366 48.71 O

K

 28-May-03 16:49 24-May-03 128 Kidneys 2.335 0.907 120.61 O

K

 28-May-03 16:49 24-May-03 128 Liver 11.281 4.383 582.70 HIGH 28-May-03 16:49 24-May-03 128 Lungs 1.948 0.757 100.62 O

K

 28-May-03 16:49 24-May-03 128 Ovaries 0.073 0.028 3.77 LO

W

 28-May-03 16:49 24-May-03 128 Spleen 0.543 0.211 28.05 O

K

 28-May-03 16:49 24-May-03 128 Uterus 0.617 0.240 31.87 O

K

 6836G665/F 3/1 22-Oct-02 511/# 07-Nov-02 14:00 22-Oct-02 -1 Adrenal glands 191.0 0.049 0.026 2.36 HIGH 07-Nov-02 14:00 22-Oct-02 -1 Brain 2.078 1.088 100.00 HIGH 07-Nov-02 14:00 22-Oct-02 -1 Heart 0.718 0.376 34.55 O

K

 07-Nov-02 14:00 22-Oct-02 -1 Kidneys 1.758 0.921 84.60 O

K

 07-Nov-02 14:00 22-Oct-02 -1 Liver 8.383 4.390 403.42 HIGH 07-Nov-02 14:01 22-Oct-02 -1 Lungs 1.958 1.025 94.23 O

K

 07-Nov-02 14:01 22-Oct-02 -1 Ovaries 0.109 0.057 5.25 O

K

 07-Nov-02 14:01 22-Oct-02 -1 Spleen 0.355 0.186 17.08 LO

W

 13-Nov-02 10:26 22-Oct-02 -1 Uterus 0.425 0.223 20.45 O

K

 6836G671/F 3/1 28-Nov-02 548/# 12-Dec-02 13:42 28-Nov-02 128 Adrenal glands 240.6 0.057 0.024 3.06 HIGH 12-Dec-02 13:42 28-Nov-02 128 Brain 1.865 0.775 100.00 O

K

 12-Dec-02 13:42 28-Nov-02 128 Heart 0.757 0.315 40.59 O

K

 12-Dec-02 13:42 28-Nov-02 128 Kidneys 1.615 0.671 86.60 O

K

 12-Dec-02 13:42 28-Nov-02 128 Liver 9.343 3.883 500.97 O

K

 12-Dec-02 13:42 28-Nov-02 128 Lungs 1.155 0.480 61.93 O

K

 12-Dec-02 13:42 28-Nov-02 128 Ovaries 0.080 0.033 4.29 O

K

 12-Dec-02 13:42 28-Nov-02 128 Spleen 0.740 0.308 39.68 O

K

 12-Dec-02 13:42 28-Nov-02 128 Uterus 17.380 7.224 931.90 O

K

 6836G693/F 3/1 18-Mar-03 658/# 25-Mar-03 13:12 18-Mar-03 128 Adrenal glands 260.8 6.989 2.679 359.89 HIGH 25-Mar-03 13:12 18-Mar-03 128 Brain 1.942 0.745 100.00 O

K

 25-Mar-03 13:12 18-Mar-03 128 Heart 0.965 0.370 49.69 O

K

 25-Mar-03 13:12 18-Mar-03 128 Kidneys 2.331 0.894 120.03 O

K

 25-Mar-03 13:12 18-Mar-03 128 Liver 9.754 3.740 502.27 O

K

 25-Mar-03 13:12 18-Mar-03 128 Lungs 3.655 1.401 188.21 O

K

 25-Mar-03 13:12 18-Mar-03 128 Ovaries 0.093 0.036 4.79 O

K

 25-Mar-03 13:12 18-Mar-03 128 Spleen 0.471 0.181 24.25 LO

W

 25-Mar-03 13:13 18-Mar-03 128 Uterus 0.677 0.260 34.86 O

K

 6838H786/F 4/1 15-May-03 716/# 19-May-03 16:24 15-May-03 128 Adrenal glands 240.4 0.071 0.030 3.79 HIGH 19-May-03 16:24 15-May-03 128 Brain 1.872 0.779 100.00 O

K

 19-May-03 16:24 15-May-03 128 Heart 1.175 0.489 62.77 O

K

 19-May-03 16:24 15-May-03 128 Kidneys 1.803 0.750 96.31 O

K

 19-May-03 16:24 15-May-03 128 Liver 7.592 3.158 405.56 O

K

 Note: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

Study Number FY01-013

K-97
 Lovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04

 Research Institute Study number: FY01013F Page: 3 Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic Terminal Organ Relative Relative Animal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of Brain No/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status 6838H786/F 4/1 15-May-03 716/# 19-May-03 16:24 15-May-03 128 Lungs 240.4 1.793 0.746 95.78 O

K

 19-May-03 16:24 15-May-03 128 Ovaries 0.106 0.044 5.66 O

K

 19-May-03 16:24 15-May-03 128 Spleen 1.116 0.464 59.62 O

K

 19-May-03 16:24 15-May-03 128 Uterus 32.243 13.412 1722.38 O

K

 6838H795/F 4/1 15-May-03 716/# 19-May-03 16:22 15-May-03 128 Adrenal glands 219.8 0.068 0.031 3.51 HIGH 19-May-03 16:22 15-May-03 128 Brain 1.938 0.882 100.00 O

K

 19-May-03 16:22 15-May-03 128 Heart 0.857 0.390 44.22 O

K

 19-May-03 16:22 15-May-03 128 Kidneys 2.363 1.075 121.93 O

K

 19-May-03 16:22 15-May-03 128 Liver 9.829 4.472 507.17 HIGH 19-May-03 16:22 15-May-03 128 Lungs 2.250 1.024 116.10 O

K

 19-May-03 16:22 15-May-03 128 Ovaries 0.077 0.035 3.97 O

K

 19-May-03 16:22 15-May-03 128 Spleen 0.457 0.208 23.58 O

K

 19-May-03 16:22 15-May-03 128 Uterus 0.555 0.253 28.64 O

K

 Note: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

Study Number FY01-013

K-98
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

L-1 

APPENDIX L 

DIFFERENTIAL CELL COUNTS AND 

WHITE BLOOD CELL COUNT ESTIMATES 

L-1 12-Month Males 

L-2 12-Month Females 

L-3 18-Month Males 

L-4 18-Month Females 

L-5 24-Month Males 

L-6 24-Month Females 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

L-1 12-Month Males 

L-2
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E401-6831 38 0 55 4 3 0 0 0 0 14.0 5.3CONTROL E402-6831 30 0 67 1 2 0 0 0 0 18.0 5.4CONTROL E403-6831 21 0 74 4 1 0 0 0 1 10.0 2.1CONTROL E404-6831 22 0 73 4 1 0 0 0 0 7.0 1.5CONTROL E405-6831 16 0 82 2 0 0 0 0 0 6.0 1.0CONTROL E406-6831 29 0 65 4 2 0 0 0 0 8.0 2.3CONTROL E407-6831 33 1 59 4 3 0 0 0 1 10.0 3.3CONTROL E409-6831 21 0 78 1 0 0 0 0 2 7.0 1.5

CONTROL E410-6831 22 0 75 2 1 0 0 0 1 6 0 1 3 CONTROL E410-6831 22 0 75 2 1 0 0 0 1 6.0 1.3CONTROL E411-6831 28 0 71 0 1 0 0 0 1 10.0 2.8CONTROL E412-6831 31 0 67 1 1 0 0 0 0 4.0 1.2CONTROL E413-6831 26 0 72 2 0 0 0 0 2 7.0 1.8CONTROL E414-6831 33 0 61 4 2 0 0 0 0 10.0 3.3CONTROL E415-6831 26 0 67 5 2 0 0 0 0 4.0 1.0CONTROL E416-6831 41 0 56 3 0 0 0 0 0 8.0 3.3CONTROL E417-6831 24 0 72 1 3 0 0 0 0 7.0 1.7CONTROL E418-6831 44 0 51 3 2 0 0 0 0 8.0 3.5CONTROL E419-6831 38 0 59 0 3 0 0 0 0CONTROL E420-6831 36 0 61 3 0 0 0 0 0 20.0 7.2CONTROL E421-6831 44 0 47 4 4 1 0 0 0 6.0 2.6CONTROL E422-6831 27 0 71 1 1 0 0 0 0 8.0 2.2CONTROL E423-6831 29 0 62 4 5 0 0 0 0 12.0 3.5CONTROL E424-6831 47 0 45 5 3 0 0 0 0 15.0 7.1CONTROL E425-6831 27 0 68 4 1 0 0 0 2 6.0 1.6

1 of 12

Study Number FY01-013

L-3
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

CONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831

CONTROL E410-6831

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 

cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 7.7 0.6 0.4 0.0 0.0 0.0 2 00.0 12.1 0.2 0.4 0.0 0.0 0.0 2 00.0 7.4 0.4 0.1 0.0 0.0 0.0 2 00.0 5.1 0.3 0.1 0.0 0.0 0.0 2 00.0 4.9 0.1 0.0 0.0 0.0 0.0 2 00.0 5.2 0.3 0.2 0.0 0.0 0.0 2 00.1 5.9 0.4 0.3 0.0 0.0 0.0 2 00.0 5.5 0.1 0.0 0.0 0.0 0.0 2 0

0 0 4 5 0 1 0 1 0 0 0 0 0 0 2 0 CONTROL E410-6831

CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-6831

0.0 4.5 0.1 0.1 0.0 0.0 0.0 2 00.0 7.1 0.0 0.1 0.0 0.0 0.0 2 00.0 2.7 0.0 0.0 0.0 0.0 0.0 2 00.0 5.0 0.1 0.0 0.0 0.0 0.0 2 00.0 6.1 0.4 0.2 0.0 0.0 0.0 2 00.0 2.7 0.2 0.1 0.0 0.0 0.0 2 00.0 4.5 0.2 0.0 0.0 0.0 0.0 1 00.0 5.0 0.1 0.2 0.0 0.0 0.0 2 00.0 4.1 0.2 0.2 0.0 0.0 0.0 1 0

2 0

0.0 12.2 0.6 0.0 0.0 0.0 0.0 1 00.0 2.8 0.2 0.2 0.1 0.0 0.0 1 00.0 5.7 0.1 0.1 0.0 0.0 0.0 2 00.0 7.4 0.5 0.6 0.0 0.0 0.0 1 00.0 6.8 0.8 0.5 0.0 0.0 0.0 1 00.0 4.1 0.2 0.1 0.0 0.0 0.0 1 0

2 of 12

Study Number FY01-013

L-4
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

CONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831

CONTROL E410-6831

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

ADEQUATE CONTROL E410-6831

CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-6831

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE The smear was too thick for a WBC estimate to be madeADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

3 of 12

Study Number FY01-013

L-5
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E426-6831 21 0 69 8 2 0 0 0 1 8.0 1.7CONTROL E427-6831 40 0 54 6 0 0 0 0 0 10.4 4.2CONTROL E428-6831 44 0 50 5 1 0 0 0 0 9.2 4.0CONTROL E429-6831 25 0 70 4 1 0 0 0 0 10.0 2.5CONTROL E430-6831 22 0 75 3 0 0 0 0 0 10.0 2.2CONTROL E431-6831 46 0 46 5 3 0 0 0 0 19.3 8.9CONTROL E432-6831 28 0 68 3 1 0 0 0 0 12.0 3.4CONTROL E433-6831 31 0 66 2 1 0 0 0 2 14.0 4.3CONTROL E434-6831 32 0 61 2 5 0 0 0 0 14.5 4.6CONTROL E435-6831 34 0 60 4 2 0 0 0 0 14.4 4.9CONTROL E436-6831 27 0 66 5 2 0 0 0 0 14.0 3.8CONTROL E437-6831 31 0 64 4 1 0 0 0 0 10.4 3.2CONTROL E439-6831 36 0 59 4 1 0 0 0 0 12.8 4.6CONTROL E440-6831 30 0 62 4 4 0 0 0 0 14.4 4.3CONTROL E441-6831 21 0 72 4 3 0 0 0 2 6.0 1.3CONTROL E442-6831 22 0 75 3 0 0 0 0 1 9.2 2.0CONTROL E443-6831 37 0 57 3 3 0 0 0 0 12.8 4.7CONTROL E444-6831 28 0 69 2 1 0 0 0 0 14.8 4.1CONTROL E445-6831 27 0 69 3 1 0 0 0 0 10.5 2.8CONTROL E446-6831 35 0 59 5 1 0 0 0 0 9.6 3.4CONTROL E447-6831 28 0 65 5 2 0 0 0 0 8.0 2.2CONTROL E448-6831 36 0 61 3 0 0 0 0 0 10.4 3.7CONTROL E449-6831 27 0 65 3 4 1 0 0 0 15.2 4.1CONTROL E450-6831 41 0 54 4 1 0 0 0 0 10.4 4.3

HIGH H701-6837 48 1 44 4 3 0 0 0 0 13.2 6.3

4 of 12

Study Number FY01-013

L-6
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

CONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E431-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 

cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 5.5 0.6 0.2 0.0 0.0 0.0 1 00.0 5.6 0.6 0.0 0.0 0.0 0.0 1 00.0 4.6 0.5 0.1 0.0 0.0 0.0 1 00.0 7.0 0.4 0.1 0.0 0.0 0.0 1 00.0 7.5 0.3 0.0 0.0 0.0 0.0 1 00.0 8.9 1.0 0.6 0.0 0.0 0.0 1 00.0 8.2 0.4 0.1 0.0 0.0 0.0 1 00.0 9.2 0.3 0.1 0.0 0.0 0.0 1 00.0 8.8 0.3 0.7 0.0 0.0 0.0 1 0

CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E439-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831

HIGH H701-6837

0.0 8.6 0.6 0.3 0.0 0.0 0.0 1 00.0 9.2 0.7 0.3 0.0 0.0 0.0 1 00.0 6.7 0.4 0.1 0.0 0.0 0.0 1 00.0 7.6 0.5 0.1 0.0 0.0 0.0 1 00.0 8.9 0.6 0.6 0.0 0.0 0.0 1 00.0 4.3 0.2 0.2 0.0 0.0 0.0 1 00.0 6.9 0.3 0.0 0.0 0.0 0.0 1 00.0 7.3 0.4 0.4 0.0 0.0 0.0 1 00.0 10.2 0.3 0.1 0.0 0.0 0.0 1 00.0 7.2 0.3 0.1 0.0 0.0 0.0 1 00.0 5.7 0.5 0.1 0.0 0.0 0.0 1 00.0 5.2 0.4 0.2 0.0 0.0 0.0 1 00.0 6.3 0.3 0.0 0.0 0.0 0.0 1 00.0 9.9 0.5 0.6 0.2 0.0 0.0 1 00.0 5.6 0.4 0.1 0.0 0.0 0.0 1 00.1 5.8 0.5 0.4 0.0 0.0 0.0 1 0

5 of 12

Study Number FY01-013

L-7
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

CONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E431-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E439-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831

HIGH H701-6837

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE 1 macrophage was observed.ADEQUATEADEQUATE

6 of 12

Study Number FY01-013

L-8
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H702-6837 45 0 51 2 2 0 0 0 0 19.2 8.6HIGH H703-6837 22 0 70 3 5 0 0 0 0 11.2 2.5HIGH H704-6837 34 0 62 1 2 1 0 0 1 14.0 4.8HIGH H705-6837 39 1 57 3 0 0 0 0 0 17.2 6.7HIGH H706-6837 44 0 49 2 4 1 0 0 0 18.8 8.3HIGH H707-6837 35 0 55 3 6 1 0 0 1 22.4 7.8HIGH H708-6837 29 0 65 3 3 0 0 0 1 22.8 6.6HIGH H709-6837 41 1 51 3 4 0 0 0 0 23.6 9.7HIGH H710-6837 26 0 68 4 1 1 0 0 0 19.2 5.0HIGH H711-6837 34 0 64 2 0 0 0 0 1 15.2 5.2HIGH H712-6837 27 0 68 2 3 0 0 0 0 20.8 5.6HIGH H713-6837 44 1 50 3 2 0 0 0 0 29.6 13.0HIGH H714-6837 35 0 62 3 0 0 0 0 0 22.0 7.7HIGH H715-6837 43 0 50 4 3 0 0 0 0 8.8 3.8HIGH H716-6837 42 0 53 2 3 0 0 0 0 20.4 8.6HIGH H717-6837 39 0 55 3 3 0 0 0 1 15.6 6.1HIGH H718-6837 42 2 51 1 4 0 0 0 0 17.6 7.4HIGH H719-6837 42 0 53 2 3 0 0 0 0 16.8 7.1HIGH H720-6837 32 0 61 6 1 0 0 0 0 13.2 4.2HIGH H721-6837 38 0 55 4 3 0 0 0 1 15.6 5.9HIGH H722-6837 47 0 47 5 1 0 0 0 0 17.6 8.3HIGH H723-6837 46 0 50 3 1 0 0 0 2 21.2 9.8HIGH H724-6837 43 0 54 1 2 0 0 0 0 16.8 7.2HIGH H725-6837 37 0 57 5 1 0 0 0 0 16.0 5.9HIGH H726-6837 41 0 51 3 4 1 0 0 0 18.8 7.7

7 of 12

Study Number FY01-013

L-9
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

HIGH H702-6837HIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 

cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 9.8 0.4 0.4 0.0 0.0 0.0 1 00.0 7.8 0.3 0.6 0.0 0.0 0.0 1 00.0 8.7 0.1 0.3 0.1 0.0 0.0 1 00.2 9.8 0.5 0.0 0.0 0.0 0.0 1 00.0 9.2 0.4 0.8 0.2 0.0 0.0 1 00.0 12.3 0.7 1.3 0.2 0.0 0.0 1 00.0 14.8 0.7 0.7 0.0 0.0 0.0 1 00.2 12.0 0.7 0.9 0.0 0.0 0.0 1 00.0 13.1 0.8 0.2 0.2 0.0 0.0 1 0

HIGH H711-6837HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H716-6837HIGH H717-6837HIGH H718-6837HIGH H719-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837

0.0 9.7 0.3 0.0 0.0 0.0 0.0 1 00.0 14.1 0.4 0.6 0.0 0.0 0.0 1 00.3 14.8 0.9 0.6 0.0 0.0 0.0 1 00.0 13.6 0.7 0.0 0.0 0.0 0.0 1 00.0 4.4 0.4 0.3 0.0 0.0 0.0 1 00.0 10.8 0.4 0.6 0.0 0.0 0.0 1 00.0 8.6 0.5 0.5 0.0 0.0 0.0 1 00.4 9.0 0.2 0.7 0.0 0.0 0.0 1 00.0 8.9 0.3 0.5 0.0 0.0 0.0 1 00.0 8.1 0.8 0.1 0.0 0.0 0.0 1 00.0 8.6 0.6 0.5 0.0 0.0 0.0 1 00.0 8.3 0.9 0.2 0.0 0.0 0.0 1 00.0 10.6 0.6 0.2 0.0 0.0 0.0 1 00.0 9.1 0.2 0.3 0.0 0.0 0.0 1 00.0 9.1 0.8 0.2 0.0 0.0 0.0 1 00.0 9.6 0.6 0.8 0.2 0.0 0.0 1 0

8 of 12

Study Number FY01-013

L-10
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

HIGH H702-6837HIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

HIGH H711-6837HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H716-6837HIGH H717-6837HIGH H718-6837HIGH H719-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

9 of 12

Study Number FY01-013

L-11
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H727-6837 42 0 54 4 0 0 0 0 0 22.0 9.2HIGH H728-6837 31 1 59 6 3 0 0 0 0 11.6 3.6HIGH H729-6837 41 0 52 2 5 0 0 0 0 14.8 6.1HIGH H730-6837 57 0 37 3 3 0 0 0 0 20.0 11.4HIGH H731-6837 52 0 46 1 1 0 0 0 0 12.0 6.2HIGH H732-6837 42 0 52 5 1 0 0 0 0 16.0 6.7HIGH H733-6837 28 0 67 2 3 0 0 0 0 22.8 6.4HIGH H734-6837 42 0 48 7 2 1 0 0 1 22.4 9.4HIGH H735-6837 46 0 49 3 2 0 0 0 0 18 8 8 6 HIGH H735-6837 46 0 49 3 2 0 0 0 0 18.8 8.6HIGH H736-6837 41 0 56 2 1 0 0 0 0 17.6 7.2HIGH H737-6837 34 0 63 3 0 0 0 0 0 10.8 3.7HIGH H738-6837 45 0 50 3 2 0 0 0 0 16.0 7.2HIGH H739-6837 38 1 54 3 4 0 0 0 0 19.2 7.3HIGH H740-6837 28 2 63 5 2 0 0 0 0 16.0 4.5HIGH H741-6837 34 0 63 3 0 0 0 0 0 16.8 5.7HIGH H742-6837 31 0 63 5 1 0 0 0 0 15.6 4.8HIGH H743-6837 26 0 67 5 2 0 0 0 0 15.2 4.0HIGH H744-6837 32 0 60 6 2 0 0 0 0 15.0 4.8HIGH H745-6837 42 0 50 5 3 0 0 0 0 14.8 6.2HIGH H746-6837 31 0 62 7 0 0 0 0 1 15.4 4.8HIGH H747-6837 47 0 41 7 5 0 0 0 0 26.2 12.3HIGH H748-6837 57 0 37 4 2 0 0 0 0 23.2 13.2HIGH H749-6837 29 0 62 9 0 0 0 0 2 14.0 4.1HIGH H750-6837 34 0 61 4 1 0 0 0 0 13.2 4.5

10 of 12

Study Number FY01-013

L-12
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

HIGH H727-6837HIGH H728-6837HIGH H729-6837HIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGH H735-6837

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 

cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 11.9 0.9 0.0 0.0 0.0 0.0 1 00.1 6.8 0.7 0.3 0.0 0.0 0.0 1 00.0 7.7 0.3 0.7 0.0 0.0 0.0 1 00.0 7.4 0.6 0.6 0.0 0.0 0.0 1 00.0 5.5 0.1 0.1 0.0 0.0 0.0 1 00.0 8.3 0.8 0.2 0.0 0.0 0.0 1 00.0 15.3 0.5 0.7 0.0 0.0 0.0 1 00.0 10.8 1.6 0.4 0.2 0.0 0.0 1 00 0 9 2 0 6 0 4 0 0 0 0 0 0 1 0 HIGH H735-6837

HIGH H736-6837HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H744-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-6837

0.0 9.2 0.6 0.4 0.0 0.0 0.0 1 00.0 9.9 0.4 0.2 0.0 0.0 0.0 1 00.0 6.8 0.3 0.0 0.0 0.0 0.0 1 00.0 8.0 0.5 0.3 0.0 0.0 0.0 1 00.2 10.4 0.6 0.8 0.0 0.0 0.0 1 00.3 10.1 0.8 0.3 0.0 0.0 0.0 1 00.0 10.6 0.5 0.0 0.0 0.0 0.0 1 00.0 9.8 0.8 0.2 0.0 0.0 0.0 1 00.0 10.2 0.8 0.3 0.0 0.0 0.0 1 00.0 9.0 0.9 0.3 0.0 0.0 0.0 1 00.0 7.4 0.7 0.4 0.0 0.0 0.0 1 00.0 9.5 1.1 0.0 0.0 0.0 0.0 1 00.0 10.7 1.8 1.3 0.0 0.0 0.0 1 00.0 8.6 0.9 0.5 0.0 0.0 0.0 1 10.0 8.7 1.3 0.0 0.0 0.0 0.0 1 00.0 8.1 0.5 0.1 0.0 0.0 0.0 1 0

11 of 12

Study Number FY01-013

L-13
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Male Rats

GROUP ANIMAL

HIGH H727-6837HIGH H728-6837HIGH H729-6837HIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGH H735-6837

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE HIGH H735-6837

HIGH H736-6837HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H744-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-6837

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

12 of 12

Study Number FY01-013

L-14
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

L-2 12-Month Females 

L-15
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E451-6832 16 0 79 4 1 0 0 0 0 8.0 1.3CONTROL E452-6833 20 0 73 5 2 0 0 0 0 11.2 2.2CONTROL E453-6832 23 0 73 2 2 0 0 0 2 9.6 2.2CONTROL E454-6832 16 0 83 0 1 0 0 0 1 12.7 2.0CONTROL E455-6832 19 0 75 4 1 1 0 0 0 8.8 1.7CONTROL E456-6832 18 0 75 7 0 0 0 0 1 6.8 1.2CONTROL E457-6832 21 0 78 1 0 0 0 0 0 8.6 1.8CONTROL E458-6832 31 0 67 2 0 0 0 0 0 8.4 2.6CONTROL E459-6832 18 0 79 1 2 0 0 0 0 5.2 0.9CONTROL E460-6832 35 0 57 6 2 0 0 0 0 8.0 2.8CONTROL E461-6832 24 0 72 2 2 0 0 0 0 12.4 3.0CONTROL E462-6832 8 0 90 2 0 0 0 0 0 4.4 0.4

CONTROL E463-6832 24 0 70 4 2 0 0 0 2 5.8 1.4CONTROL E464-6832 18 0 78 3 1 0 0 0 0 6.4 1.2CONTROL E465-6832 27 0 64 7 2 0 0 0 1 8.4 2.3CONTROL E466-6832 28 0 65 6 1 0 0 0 0 9.6 2.7CONTROL E467-6832 26 0 66 5 2 1 0 0 0 8.0 2.1CONTROL E468-6832 21 0 74 4 1 0 0 0 0 6.6 1.4CONTROL E469-6832 15 0 76 5 4 0 0 0 0 8.4 1.3CONTROL E470-6832 26 0 69 1 4 0 0 0 0 8.8 2.3CONTROL E471-6832 40 0 56 3 1 0 0 0 0 9.2 3.7CONTROL E472-6832 36 0 62 2 0 0 0 0 1 7.6 2.7CONTROL E473-6832 24 0 65 4 6 1 0 0 0 8.4 2.0CONTROL E474-6832 23 0 72 2 2 1 0 0 0 8.0 1.8

1 of 12

Study Number FY01-013 L-16
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

CONTROL E451-6832CONTROL E452-6833CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E471-6832CONTROL E472-6832CONTROL E473-6832CONTROL E474-6832

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 6.3 0.3 0.1 0.0 0.0 0.0 1 00.0 8.2 0.6 0.2 0.0 0.0 0.0 1 00.0 7.0 0.2 0.2 0.0 0.0 0.0 1 00.0 10.5 0.0 0.1 0.0 0.0 0.0 1 00.0 6.6 0.4 0.1 0.1 0.0 0.0 1 00.0 5.1 0.5 0.0 0.0 0.0 0.0 1 00.0 6.7 0.1 0.0 0.0 0.0 0.0 1 00.0 5.6 0.2 0.0 0.0 0.0 0.0 1 00.0 4.1 0.1 0.1 0.0 0.0 0.0 1 00.0 4.6 0.5 0.2 0.0 0.0 0.0 1 00.0 8.9 0.2 0.2 0.0 0.0 0.0 1 00.0 4.0 0.1 0.0 0.0 0.0 0.0 1 00.0 4.1 0.2 0.1 0.0 0.0 0.0 1 00.0 5.0 0.2 0.1 0.0 0.0 0.0 1 00.0 5.4 0.6 0.2 0.0 0.0 0.0 1 00.0 6.2 0.6 0.1 0.0 0.0 0.0 1 00.0 5.3 0.4 0.2 0.1 0.0 0.0 1 00.0 4.9 0.3 0.1 0.0 0.0 0.0 1 00.0 6.4 0.4 0.3 0.0 0.0 0.0 1 00.0 6.1 0.4 0.4 0.0 0.0 0.0 1 00.0 5.2 0.3 0.1 0.0 0.0 0.0 1 00.0 4.7 0.2 0.0 0.0 0.0 0.0 1 00.0 5.5 0.3 0.5 0.1 0.0 0.0 0 00.0 5.8 0.2 0.2 0.1 0.0 0.0 1 0

2 of 12

Study Number FY01-013

L-17
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

CONTROL E451-6832CONTROL E452-6833CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E471-6832CONTROL E472-6832CONTROL E473-6832CONTROL E474-6832

Platelet 

Estimate 

(adequate, 

increased, 

decreased)

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

DECREASED

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

3 of 12

Study Number FY01-013

L-18
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E475-6832 34 0 63 1 2 0 0 0 0 8.0 2.7CONTROL E476-6832 21 0 70 6 3 0 0 0 0 11.2 2.4CONTROL E477-6832 18 0 78 3 1 0 0 0 0 9.6 1.7CONTROL E478-6832 32 0 64 3 1 0 0 0 0 10.0 3.2CONTROL E479-6832 18 0 76 5 1 0 0 0 0 11.2 2.0CONTROL E480-6832 17 0 75 6 2 0 0 0 0 10.8 1.8CONTROL E482-6832 17 0 77 6 0 0 0 0 0 8.4 1.4CONTROL E483-6832 20 0 73 5 2 0 0 0 0 8.8 1.8CONTROL E484-6832 14 0 78 6 1 1 0 0 1 11.6 1.6CONTROL E485-6832 20 0 77 3 0 0 0 0 0 8.8 1.8CONTROL E486-6832 21 0 76 2 1 0 0 0 0 9.6 2.0CONTROL E487-6832 28 0 68 2 2 0 0 0 0 6.8 1.9CONTROL E488-6832 20 0 76 2 2 0 0 0 1 6.8 1.4CONTROL E489-6832 15 0 81 4 0 0 0 0 0 8.0 1.2CONTROL E490-6832 22 0 72 4 1 1 0 0 0 10.0 2.2CONTROL E491-6832 28 0 70 2 0 0 0 0 0 7.2 2.0CONTROL E492-6832 12 0 86 1 1 0 0 0 4 4.8 0.6CONTROL E493-6832 35 0 58 5 2 0 0 0 0 12.0 4.2CONTROL E494-6832 18 0 75 7 0 0 0 0 1 6.8 1.2CONTROL E495-6832 37 0 55 7 1 0 0 0 0 11.2 4.1CONTROL E496-6832 25 0 70 3 1 1 0 0 0 13.6 3.4CONTROL E497-6832 35 0 58 4 3 0 0 0 0 8.8 3.1CONTROL E498-6832 38 0 58 3 0 1 0 0 0 13.2 5.0CONTROL E499-6832 23 0 71 4 2 0 0 0 0 12.0 2.8CONTROL E500-6832 15 0 79 2 4 0 0 0 0 8.4 1.3

4 of 12

Study Number FY01-013

L-19
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

CONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROL E480-6832CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E485-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E492-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E497-6832CONTROL E498-6832CONTROL E499-6832CONTROL E500-6832

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 5.0 0.1 0.2 0.0 0.0 0.0 00.0 7.8 0.7 0.3 0.0 0.0 0.0 1 00.0 7.5 0.3 0.1 0.0 0.0 0.0 1 00.0 6.4 0.3 0.1 0.0 0.0 0.0 1 00.0 8.5 0.6 0.1 0.0 0.0 0.0 1 00.0 8.1 0.6 0.2 0.0 0.0 0.0 1 00.0 6.5 0.5 0.0 0.0 0.0 0.0 1 00.0 6.4 0.4 0.2 0.0 0.0 0.0 1 00.0 9.0 0.7 0.1 0.1 0.0 0.0 1 00.0 6.8 0.3 0.0 0.0 0.0 0.0 1 00.0 7.3 0.2 0.1 0.0 0.0 0.0 1 00.0 4.6 0.1 0.1 0.0 0.0 0.0 1 00.0 5.2 0.1 0.1 0.0 0.0 0.0 1 00.0 6.5 0.3 0.0 0.0 0.0 0.0 1 00.0 7.2 0.4 0.1 0.1 0.0 0.0 1 00.0 5.0 0.1 0.0 0.0 0.0 0.0 1 00.0 4.1 0.0 0.0 0.0 0.0 0.0 1 00.0 7.0 0.6 0.2 0.0 0.0 0.0 1 00.0 5.1 0.5 0.0 0.0 0.0 0.0 1 00.0 6.2 0.8 0.1 0.0 0.0 0.0 1 00.0 9.5 0.4 0.1 0.1 0.0 0.0 1 00.0 5.1 0.4 0.3 0.0 0.0 0.0 1 00.0 7.7 0.4 0.0 0.1 0.0 0.0 1 00.0 8.5 0.5 0.2 0.0 0.0 0.0 1 00.0 6.6 0.2 0.3 0.0 0.0 0.0 1 0

5 of 12

Study Number FY01-013

L-20
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

CONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROL E480-6832CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E485-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E492-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E497-6832CONTROL E498-6832CONTROL E499-6832CONTROL E500-6832

Platelet 

Estimate 

(adequate, 

increased, 

decreased)

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

DECREASED

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

6 of 12

Study Number FY01-013

L-21
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H751-6838 26 0 70 1 3 0 0 0 0 6.8 1.8HIGH H752-6838 21 0 74 3 2 0 0 0 2 6.0 1.3HIGH H753-6838 27 0 67 5 1 0 0 0 0 7.6 2.1HIGH H754-6838 31 0 65 3 1 0 0 0 0 9.2 2.9HIGH H755-6838 33 2 61 3 1 0 0 0 0 10.8 3.6HIGH H756-6838 22 0 71 3 3 1 0 0 0 8.8 1.9HIGH H757-6838 31 0 59 7 3 0 0 0 0 5.6 1.7HIGH H758-6838 27 0 67 5 1 0 0 0 0 10.8 2.9HIGH H759-6838 24 0 74 0 2 0 0 0 0 4.8 1.2HIGH H760-6838 18 0 74 6 2 0 0 0 1 7.6 1.4HIGH H761-6838 22 0 70 6 2 0 0 0 0 6.8 1.5HIGH H762-6838 28 0 65 5 2 0 0 0 0 7.2 2.0HIGH H763-6838 29 0 64 4 3 0 0 0 0 5.2 1.5HIGH H764-6838 26 0 69 4 1 0 0 0 0 10.8 2.8HIGH H765-6838 21 0 71 4 4 0 0 0 0 5.4 1.1HIGH H766-6838 22 0 72 3 3 0 0 0 0 8.8 1.9HIGH H767-6838 20 0 74 6 0 0 0 0 0 7.2 1.4HIGH H768-6838 21 0 74 4 1 0 0 0 0 6.0 1.3HIGH H769-6838 27 0 72 0 1 0 0 0 0 11.2 3.0HIGH H770-6838 41 0 58 1 0 0 0 0 1 7.6 3.1HIGH H771-6838 37 0 61 1 1 0 0 0 0 8.0 3.0HIGH H772-6838 21 0 73 5 1 0 0 0 0HIGH H773-6838 29 0 65 5 1 0 0 0 0 10.0 2.9HIGH H774-6838 34 0 58 4 4 0 0 0 1 9.6 3.3HIGH H775-6838 21 0 73 4 2 0 0 0 0 10.0 2.1

7 of 12

Study Number FY01-013

L-22
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

HIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838HIGH H756-6838HIGH H757-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H763-6838HIGH H764-6838HIGH H765-6838HIGH H766-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H774-6838HIGH H775-6838

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 4.8 0.1 0.2 0.0 0.0 0.0 1 00.0 4.4 0.2 0.1 0.0 0.0 0.0 1 00.0 5.1 0.4 0.1 0.0 0.0 0.0 1 00.0 6.0 0.3 0.1 0.0 0.0 0.0 1 00.2 6.6 0.3 0.1 0.0 0.0 0.0 1 00.0 6.2 0.3 0.3 0.1 0.0 0.0 1 00.0 3.3 0.4 0.2 0.0 0.0 0.0 1 00.0 7.2 0.5 0.1 0.0 0.0 0.0 1 00.0 3.6 0.0 0.1 0.0 0.0 0.0 1 00.0 5.6 0.5 0.2 0.0 0.0 0.0 1 00.0 4.8 0.4 0.1 0.0 0.0 0.0 1 00.0 4.7 0.4 0.1 0.0 0.0 0.0 1 00.0 3.3 0.2 0.2 0.0 0.0 0.0 1 00.0 7.5 0.4 0.1 0.0 0.0 0.0 1 00.0 3.8 0.2 0.2 0.0 0.0 0.0 1 00.0 6.3 0.3 0.3 0.0 0.0 0.0 1 00.0 5.3 0.4 0.0 0.0 0.0 0.0 1 00.0 4.4 0.2 0.1 0.0 0.0 0.0 1 00.0 8.1 0.0 0.1 0.0 0.0 0.0 1 00.0 4.4 0.1 0.0 0.0 0.0 0.0 1 00.0 4.9 0.1 0.1 0.0 0.0 0.0 1 0

1 0

0.0 6.5 0.5 0.1 0.0 0.0 0.0 1 00.0 5.6 0.4 0.4 0.0 0.0 0.0 1 00.0 7.3 0.4 0.2 0.0 0.0 0.0 1 0

8 of 12

Study Number FY01-013

L-23
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

HIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838HIGH H756-6838HIGH H757-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H763-6838HIGH H764-6838HIGH H765-6838HIGH H766-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H774-6838HIGH H775-6838

Platelet 

Estimate 

(adequate, 

increased, 

decreased)

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

9 of 12

Study Number FY01-013

L-24
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H776-6838 18 0 74 4 4 0 0 0 0 9.6 1.7HIGH H777-6838 26 0 66 7 1 0 0 0 0 7.8 2.0HIGH H778-6838 22 0 74 3 1 0 0 0 0 6.8 1.5HIGH H779-6838 31 0 64 0 5 0 0 0 0 8.2 2.5HIGH H780-6838 33 0 56 6 5 0 0 0 0 10.4 3.4HIGH H781-6838 18 0 77 5 0 0 0 0 0 10.0 1.8HIGH H782-6838 17 0 77 4 2 0 0 0 0 8.4 1.4HIGH H783-6838 27 0 70 2 1 0 0 0 0 9.6 2.6HIGH H784-6838 17 0 82 0 1 0 0 0 0 8.8 1.5HIGH H785-6838 30 0 65 3 2 0 0 0 0 10.2 3.1HIGH H786-6838 25 0 70 4 1 0 0 0 0 8.0 2.0HIGH H787-6838 39 0 55 5 1 0 0 0 0 10.8 4.2HIGH H788-6838 22 0 70 4 4 0 0 0 1 7.2 1.6HIGH H789-6838 31 0 59 9 1 0 0 0 1 10.2 3.2HIGH H790-6838 20 0 76 1 3 0 0 0 1 8.8 1.8HIGH H791-6838 36 0 55 5 4 0 0 0 0 12.0 4.3HIGH H792-6838 21 0 75 1 3 0 0 0 0 10.0 2.1HIGH H793-6838 15 0 76 7 2 0 0 0 0 8.8 1.3HIGH H794-6838 24 0 73 3 0 0 0 0 1 8.0 1.9HIGH H795-6838 34 0 56 8 2 0 0 0 2 10.8 3.7HIGH H796-6838 38 0 53 5 4 0 0 0 1 8.8 3.3HIGH H797-6838 29 0 68 3 0 0 0 0 0 8.0 2.3HIGH H798-6838 29 0 68 2 1 0 0 0 0 8.8 2.6HIGH H799-6838 25 0 65 7 3 0 0 0 0 8.4 2.1HIGH H800-6838 26 0 68 4 2 0 0 0 1 9.8 2.5

10 of 12

Study Number FY01-013

L-25
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

HIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838HIGH H784-6838HIGH H785-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H794-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 7.1 0.4 0.4 0.0 0.0 0.0 1 00.0 5.1 0.5 0.1 0.0 0.0 0.0 1 00.0 5.0 0.2 0.1 0.0 0.0 0.0 1 00.0 5.2 0.0 0.4 0.0 0.0 0.0 1 00.0 5.8 0.6 0.5 0.0 0.0 0.0 1 00.0 7.7 0.5 0.0 0.0 0.0 0.0 1 00.0 6.5 0.3 0.2 0.0 0.0 0.0 1 00.0 6.7 0.2 0.1 0.0 0.0 0.0 1 00.0 7.2 0.0 0.1 0.0 0.0 0.0 1 00.0 6.6 0.3 0.2 0.0 0.0 0.0 1 00.0 5.6 0.3 0.1 0.0 0.0 0.0 1 00.0 5.9 0.5 0.1 0.0 0.0 0.0 1 00.0 5.0 0.3 0.3 0.0 0.0 0.0 1 00.0 6.0 0.9 0.1 0.0 0.0 0.0 1 00.0 6.7 0.1 0.3 0.0 0.0 0.0 1 00.0 6.6 0.6 0.5 0.0 0.0 0.0 1 00.0 7.5 0.1 0.3 0.0 0.0 0.0 1 00.0 6.7 0.6 0.2 0.0 0.0 0.0 1 00.0 5.8 0.2 0.0 0.0 0.0 0.0 1 00.0 6.0 0.9 0.2 0.0 0.0 0.0 1 00.0 4.7 0.4 0.4 0.0 0.0 0.0 1 00.0 5.4 0.2 0.0 0.0 0.0 0.0 1 00.0 6.0 0.2 0.1 0.0 0.0 0.0 1 00.0 5.5 0.6 0.3 0.0 0.0 0.0 1 00.0 6.7 0.4 0.2 0.0 0.0 0.0 1 0

11 of 12

Study Number FY01-013

L-26
LRRI Protocol FY01-013

 12 Month Differential Cell Counts for Females

GROUP ANIMAL

HIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838HIGH H784-6838HIGH H785-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H794-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838

Platelet 

Estimate 

(adequate, 

increased, 

decreased)

ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE

12 of 12

Study Number FY01-013

L-27
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

L-3 18-Month Males 

L-28
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E401-6831 34 0 56 6 4 0 0 0 0 14.4 4.9CONTROL E402-6831 17 0 80 2 1 0 0 0 10 28.4 4.8CONTROL E403-6831 18 0 72 6 4 0 0 0 2 7.6 1.4CONTROL E404-6831 37 0 58 4 1 0 0 0 3 10.8 4.0CONTROL E405-6831 21 0 74 3 2 0 0 0 2 8.4 1.8CONTROL E406-6831 44 1 46 6 3 0 0 0 3 18.8 8.3CONTROL E407-6831 41 0 51 7 1 0 0 0 2 12.0 4.9CONTROL E409-6831 35 0 58 5 2 0 0 0 1 9.2 3.2

CONTROL E410 6831 33 0 63 1 3 0 0 0 3 8 0 2 6 CONTROL E410-6831 33 0 63 1 3 0 0 0 3 8.0 2.6CONTROL E411-6831 38 0 58 3 1 0 0 0 1 10.8 4.1CONTROL E412-6831 37 0 51 6 6 0 0 0 0 14.4 5.3CONTROL E413-6831 25 0 70 2 3 0 0 0 2 7.2 1.8CONTROL E414-6831 25 0 70 4 1 0 0 0 0 19.2 4.8CONTROL E415-6831 20 0 76 1 3 0 0 0 1 8.0 1.6CONTROL E416-6831 30 0 59 6 4 1 0 0 8 10.0 3.0CONTROL E417-6831 51 0 47 2 0 0 0 0 1 10.0 5.1CONTROL E418-6831 34 0 57 7 2 0 0 0 0 14.0 4.8CONTROL E419-6831 28 1 65 4 2 0 0 0 0 10.4 2.9CONTROL E420-6831 44 0 49 5 2 0 0 0 2 11.2 4.9CONTROL E421-6831 12 0 79 5 4 0 0 0 0 18.4 2.2CONTROL E422-6831 39 0 54 6 1 0 0 0 1 15.2 5.9CONTROL E423-6831 26 0 66 4 4 0 0 0 2 11.2 2.9CONTROL E424-6831 60 0 30 9 1 0 0 0 0 29.6 17.8CONTROL E425-6831 37 0 56 4 3 0 0 0 0 13.2 4.9

1 of 12

Study Number FY01-013

L-29
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

CONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831

CONTROL E410 6831

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 8.1 0.9 0.6 0.0 0.0 0.0 1+ 00.0 22.7 0.6 0.3 0.0 0.0 0.0 3+ 2+0.0 5.5 0.5 0.3 0.0 0.0 0.0 1+ 00.0 6.3 0.4 0.1 0.0 0.0 0.0 1+ 00.0 6.2 0.3 0.2 0.0 0.0 0.0 1+ 00.2 8.6 1.1 0.6 0.0 0.0 0.0 1+ 00.0 6.1 0.8 0.1 0.0 0.0 0.0 1+ 00.0 5.3 0.5 0.2 0.0 0.0 0.0 1+ 0

0 0 5 0 0 1 0 2 0 0 0 0 0 0 1+ 0 CONTROL E410-6831

CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-6831

0.0 5.0 0.1 0.2 0.0 0.0 0.0 1+ 00.0 6.3 0.3 0.1 0.0 0.0 0.0 1+ 00.0 7.3 0.9 0.9 0.0 0.0 0.0 1+ 00.0 5.0 0.1 0.2 0.0 0.0 0.0 1+ 00.0 13.4 0.8 0.2 0.0 0.0 0.0 1+ 00.0 6.1 0.1 0.2 0.0 0.0 0.0 1+ 00.0 5.9 0.6 0.4 0.1 0.0 0.0 1+ 00.0 4.7 0.2 0.0 0.0 0.0 0.0 1+ 00.0 8.0 1.0 0.3 0.0 0.0 0.0 1+ 00.1 6.8 0.4 0.2 0.0 0.0 0.0 1+ 00.0 5.5 0.6 0.2 0.0 0.0 0.0 1+ 00.0 14.5 0.9 0.7 0.0 0.0 0.0 3+ 00.0 8.2 0.9 0.2 0.0 0.0 0.0 2+ 00.0 7.4 0.4 0.4 0.0 0.0 0.0 1+ 00.0 8.9 2.7 0.3 0.0 0.0 0.0 1+ 00.0 7.4 0.5 0.4 0.0 0.0 0.0 1+ 0

2 of 12

Study Number FY01-013

L-30
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

CONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831

CONTROL E410 6831

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequate

decreased

adequateadequateadequateadequateadequateadequate

adequate CONTROL E410-6831

CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-6831

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

3 of 12

Study Number FY01-013

L-31
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E426-6831 24 0 69 1 6 0 0 0 2 14.8 3.6CONTROL E427-6831 20 0 78 1 1 0 0 0 2 10.4 2.1CONTROL E428-6831 34 0 57 3 6 0 0 0 2 7.2 2.4CONTROL E429-6831 27 1 64 4 4 0 0 0 0 10.8 2.9CONTROL E430-6831 52 0 42 3 3 0 0 0 1 10.8 5.6CONTROL E432-6831 23 0 73 3 1 0 0 0 0 10.0 2.3CONTROL E433-6831 33 0 61 5 1 0 0 0 2 12.4 4.1CONTROL E434-6831 20 0 72 4 4 0 0 0 0 18.0 3.6CONTROL E435-6831 32 0 66 2 0 0 0 0 4 12.8 4.1CONTROL E436-6831 47 0 47 4 2 0 0 0 0 13.0 6.1CONTROL E437-6831 33 0 65 1 1 0 0 0 0 12.0 4.0CONTROL E438-6831 17 0 74 6 3 0 0 0 2 6.8 1.2CONTROL E440-6831 34 0 61 5 0 0 0 0 1 17.6 6.0CONTROL E441-6831 28 0 64 5 3 0 0 0 2 14.0 3.9CONTROL E442-6831 39 0 60 1 0 0 0 0 1 16.8 6.6CONTROL E443-6831 46 0 48 3 3 0 0 0 0 10.8 5.0CONTROL E444-6831 32 0 61 4 3 0 0 0 0 12.4 4.0CONTROL E445-6831 42 0 48 5 5 0 0 0 1 13.6 5.7CONTROL E446-6831 24 0 70 5 1 0 0 0 3 8.4 2.0CONTROL E447-6831 35 0 59 2 4 0 0 0 3 11.2 3.9CONTROL E448-6831 31 0 64 3 2 0 0 0 2 17.2 5.3CONTROL E449-6831 35 0 58 5 2 0 0 0 2 13.2 4.6CONTROL E450-6831 34 0 62 1 3 0 0 0 1 21.2 7.2

HIGH H701-6837 35 0 58 4 3 0 0 0 1 15.2 5.3HIGH H702-6837 52 1 43 1 3 0 0 0 5 10.0 5.2

4 of 12

Study Number FY01-013

L-32
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

CONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831CONTROL E435-6831

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 10.2 0.1 0.9 0.0 0.0 0.0 1+ 00.0 8.1 0.1 0.1 0.0 0.0 0.0 1+ 00.0 4.1 0.2 0.4 0.0 0.0 0.0 1+ 00.1 6.9 0.4 0.4 0.0 0.0 0.0 1+ 00.0 4.5 0.3 0.3 0.0 0.0 0.0 1+ 00.0 7.3 0.3 0.1 0.0 0.0 0.0 1+ 00.0 7.6 0.6 0.1 0.0 0.0 0.0 1+ 00.0 13.0 0.7 0.7 0.0 0.0 0.0 1+ 00.0 8.4 0.3 0.0 0.0 0.0 0.0 1+ 0

CONTROL E436-6831CONTROL E437-6831CONTROL E438-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831

HIGH H701-6837HIGH H702-6837

0.0 6.1 0.5 0.3 0.0 0.0 0.0 1+ 00.0 7.8 0.1 0.1 0.0 0.0 0.0 1+ 00.0 5.0 0.4 0.2 0.0 0.0 0.0 1+ 00.0 10.7 0.9 0.0 0.0 0.0 0.0 1+ 00.0 9.0 0.7 0.4 0.0 0.0 0.0 1+ 00.0 10.1 0.2 0.0 0.0 0.0 0.0 1+ 00.0 5.2 0.3 0.3 0.0 0.0 0.0 1+ 00.0 7.6 0.5 0.4 0.0 0.0 0.0 1+ 00.0 6.5 0.7 0.7 0.0 0.0 0.0 1+ 00.0 5.9 0.4 0.1 0.0 0.0 0.0 1+ 00.0 6.6 0.2 0.4 0.0 0.0 0.0 1+ 00.0 11.0 0.5 0.3 0.0 0.0 0.0 1+ 00.0 7.7 0.7 0.3 0.0 0.0 0.0 1+ 00.0 13.1 0.2 0.6 0.0 0.0 0.0 1+ 00.0 8.8 0.6 0.5 0.0 0.0 0.0 1+ 00.1 4.3 0.1 0.3 0.0 0.0 0.0 1+ 0

5 of 12

Study Number FY01-013

L-33
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

CONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831CONTROL E435-6831

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequateadequateadequateadequate

CONTROL E436-6831CONTROL E437-6831CONTROL E438-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831

HIGH H701-6837HIGH H702-6837

adequateadequate

decreased ss fibrin strands seen on slide. This would decrease the number of platelets seen on the slide.

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

6 of 12

Study Number FY01-013

L-34
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H703-6837 49 0 47 4 0 0 0 0 1 13.2 6.5HIGH H704-6837 50 0 45 3 2 0 0 0 1 13.0 6.5HIGH H705-6837 34 0 59 4 3 0 0 0 1 8.8 3.0HIGH H706-6837 46 0 47 4 3 0 0 0 1 17.2 7.9HIGH H707-6837 23 0 71 5 1 0 0 0 0 14.4 3.3HIGH H708-6837 55 0 42 1 2 0 0 0 1 13.2 7.3HIGH H709-6837 22 0 69 5 4 0 0 0 2 16.8 3.7HIGH H710-6837 40 0 51 7 2 0 0 0 1 27.6 11.0HIGH H711-6837 30 0 63 1 6 0 0 0 2 9.6 2.9HIGH H712-6837 45 0 48 5 2 0 0 0 0 13.2 5.9HIGH H713-6837 40 0 52 6 2 0 0 0 0 16.8 6.7HIGH H714-6837 35 0 61 1 3 0 0 0 0 15.2 5.3HIGH H715-6837 27 0 60 9 4 0 0 0 1 21.6 5.8HIGH H717-6837 45 0 53 2 0 0 0 0 3 10.0 4.5HIGH H718-6837 28 0 67 3 2 0 0 0 2 9.2 2.6HIGH H720-6837 25 0 70 3 2 0 0 0 0 22.0 5.5HIGH H721-6837 17 0 76 4 3 0 0 0 0 14.8 2.5HIGH H722-6837 66 0 30 3 1 0 0 0 2 36.4 24.0HIGH H723-6837 34 0 57 8 1 0 0 0 1 14.8 5.0HIGH H724-6837 37 0 59 4 0 0 0 0 2 9.6 3.6HIGH H725-6837 28 0 67 2 3 0 0 0 3 7.6 2.1HIGH H726-6837 36 0 59 3 2 0 0 0 1 7.2 2.6HIGH H727-6837 44 0 49 4 3 0 0 0 6 7.6 3.3HIGH H728-6837 26 0 66 5 3 0 0 0 0 14.4 3.7HIGH H729-6837 47 0 49 2 2 0 0 0 3 8.0 3.8

7 of 12

Study Number FY01-013

L-35
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

HIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837HIGH H711-6837

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 6.2 0.5 0.0 0.0 0.0 0.0 1+ 00.0 5.9 0.4 0.3 0.0 0.0 0.0 1+ 00.0 5.2 0.4 0.3 0.0 0.0 0.0 1+ 00.0 8.1 0.7 0.5 0.0 0.0 0.0 1+ 00.0 10.2 0.7 0.1 0.0 0.0 0.0 1+ 00.0 5.5 0.1 0.3 0.0 0.0 0.0 1+ 00.0 11.6 0.8 0.7 0.0 0.0 0.0 1+ 00.0 14.1 1.9 0.6 0.0 0.0 0.0 1+ 00.0 6.0 0.1 0.6 0.0 0.0 0.0 1+ 0

HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H717-6837HIGH H718-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H727-6837HIGH H728-6837HIGH H729-6837

0.0 6.3 0.7 0.3 0.0 0.0 0.0 1+ 00.0 8.7 1.0 0.3 0.0 0.0 0.0 1+ 00.0 9.3 0.2 0.5 0.0 0.0 0.0 1+ 00.0 13.0 1.9 0.9 0.0 0.0 0.0 1+ 00.0 5.3 0.2 0.0 0.0 0.0 0.0 1+ 00.0 6.2 0.3 0.2 0.0 0.0 0.0 1+ 00.0 15.4 0.7 0.4 0.0 0.0 0.0 1+ 00.0 11.2 0.6 0.4 0.0 0.0 0.0 1+ 00.0 10.9 1.1 0.4 0.0 0.0 0.0 1+ 00.0 8.4 1.2 0.1 0.0 0.0 0.0 1+ 00.0 5.7 0.4 0.0 0.0 0.0 0.0 1+ 00.0 5.1 0.2 0.2 0.0 0.0 0.0 1+ 00.0 4.2 0.2 0.1 0.0 0.0 0.0 1+ 00.0 3.7 0.3 0.2 0.0 0.0 0.0 1+ 00.0 9.5 0.7 0.4 0.0 0.0 0.0 1+ 00.0 3.9 0.2 0.2 0.0 0.0 0.0 1+ 0

8 of 12

Study Number FY01-013

L-36
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

HIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837HIGH H711-6837

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequateadequateadequateadequate

HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H717-6837HIGH H718-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H727-6837HIGH H728-6837HIGH H729-6837

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

9 of 12

Study Number FY01-013

L-37
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H730-6837 31 0 64 1 4 0 0 0 1 10.0 3.1HIGH H731-6837 27 0 66 4 3 0 0 0 1 13.6 3.7HIGH H732-6837 51 0 45 3 1 0 0 0 0 12.4 6.3HIGH H733-6837 30 0 60 5 5 0 0 0 0 12.8 3.8HIGH H734-6837 49 0 44 4 3 0 0 0 2 7.6 3.7HIGH H735-6837 36 0 60 2 2 0 0 0 2 9.6 3.5HIGH H736 6837 36 0 57 4 3 0 0 0 0 17 6 6 3 HIGH H736-6837 36 0 57 4 3 0 0 0 0 17.6 6.3HIGH H737-6837 71 0 27 2 0 0 0 0 1 22.8 16.2HIGH H738-6837 29 0 64 6 1 0 0 0 0 9.2 2.7HIGH H739-6837 38 0 59 2 1 0 0 0 0 11.2 4.3HIGH H740-6837 33 0 60 5 2 0 0 0 1 14.8 4.9HIGH H741-6837 52 0 39 5 4 0 0 0 4 6.0 3.1HIGH H742-6837 22 0 69 4 5 0 0 0 6 14.8 3.3HIGH H743-6837 48 0 46 5 1 0 0 0 0 10.8 5.2HIGH H745-6837 32 0 61 4 3 0 0 0 1 6.0 1.9HIGH H746-6837 32 0 61 4 3 0 0 0 2 9.6 3.1HIGH H747-6837 51 0 46 2 1 0 0 0 1 8.8 4.5HIGH H748-6837 35 0 64 0 1 0 0 0 2 5.6 2.0HIGH H749-6837 34 0 58 4 4 0 0 0 3 4.6 1.6HIGH H750-6837 40 0 53 2 5 0 0 0 4 4.4 1.8

10 of 12

Study Number FY01-013

L-38
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

HIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGH H735-6837HIGH H736 6837

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 6.4 0.1 0.4 0.0 0.0 0.0 1+ 00.0 9.0 0.5 0.4 0.0 0.0 0.0 1+ 00.0 5.6 0.4 0.1 0.0 0.0 0.0 1+ 00.0 7.7 0.6 0.6 0.0 0.0 0.0 1+ 00.0 3.3 0.3 0.2 0.0 0.0 0.0 1+ 00.0 5.8 0.2 0.2 0.0 0.0 0.0 1+ 00 0 10 0 0 7 0 5 0 0 0 0 0 0 1+ 0 HIGH H736-6837

HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-6837

0.0 10.0 0.7 0.5 0.0 0.0 0.0 1+ 00.0 6.2 0.5 0.0 0.0 0.0 0.0 1+ 00.0 5.9 0.6 0.1 0.0 0.0 0.0 1+ 00.0 6.6 0.2 0.1 0.0 0.0 0.0 1+ 00.0 8.9 0.7 0.3 0.0 0.0 0.0 1+ 00.0 2.3 0.3 0.2 0.0 0.0 0.0 1+ 00.0 10.2 0.6 0.7 0.0 0.0 0.0 1+ 00.0 5.0 0.5 0.1 0.0 0.0 0.0 1+ 00.0 3.7 0.2 0.2 0.0 0.0 0.0 1+ 00.0 5.9 0.4 0.3 0.0 0.0 0.0 1+ 00.0 4.0 0.2 0.1 0.0 0.0 0.0 1+ 00.0 3.6 0.0 0.1 0.0 0.0 0.0 1+ 00.0 2.7 0.2 0.2 0.0 0.0 0.0 1+ 00.0 2.3 0.1 0.2 0.0 0.0 0.0 1+ 0

11 of 12

Study Number FY01-013

L-39
LRRI Protocol FY01-013

 18 Month Differential Counts for Male Rats

GROUP ANIMAL

HIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGH H735-6837HIGH H736 6837

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequateadequate HIGH H736-6837

HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-6837

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

decreased ss fibrin strands seen on slide. This would decrease the number of platelets seen on the slide.

adequate

12 of 12

Study Number FY01-013

L-40
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

L-4 18-Month Females 

L-41
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E451-6832 19 0 77 3 1 0 0 0 0 4.0 0.8CONTROL E452-6832 37 0 58 3 2 0 0 0 2 4.0 1.5CONTROL E453-6832 29 0 64 4 3 0 0 0 1 4.0 1.2CONTROL E454-6832 14 0 84 0 2 0 0 0 6 2.0 0.3CONTROL E455-6832 24 0 68 5 3 0 0 0 6 5.6 1.3CONTROL E456-6832 24 0 75 0 1 0 0 0 1 3.4 0.8CONTROL E457-6832 19 0 75 3 2 0 1 0 2 4.8 0.9

CONTROL E458-6832 29 0 64 3 3 0 1 0 1 9.2 2.7CONTROL E459-6832 24 0 72 2 1 0 1 0 1 2.4 0.6CONTROL E460-6832 24 0 72 2 2 0 0 0 4 3.2 0.8CONTROL E461-6832 27 0 69 2 2 0 0 0 2 2.0 0.5CONTROL E462-6832 28 0 66 1 5 0 0 0 2 6.0 1.7CONTROL E463-6832 30 0 66 2 2 0 0 0 2 7.2 2.2CONTROL E464-6832 28 0 69 2 1 0 0 0 2 4.4 1.2CONTROL E465-6832 28 0 70 0 0 0 2 0 1 3.2 0.9CONTROL E466-6832 34 0 61 1 3 0 1 0 4 2.8 1.0CONTROL E467-6832 32 0 65 2 1 0 0 0 2 2.0 0.6CONTROL E468-6832 23 0 74 1 2 0 0 0 1 6.0 1.4CONTROL E469-6832 29 0 69 1 1 0 0 0 3 6.4 1.9CONTROL E470-6832 6 1 74 1 0 0 17 1 14CONTROL E472-6832 35 0 59 4 2 0 0 0 1 5.6 2.0

1 of 12

Study Number FY01-013

L-42
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

CONTROL E451-6832CONTROL E452-6832CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 3.1 0.1 0.0 0.0 0.0 0.0 1+ 00.0 2.3 0.1 0.1 0.0 0.0 0.0 1+ 2+0.0 2.6 0.2 0.1 0.0 0.0 0.0 1+ 00.0 1.7 0.0 0.0 0.0 0.0 0.0 1+ 00.0 3.8 0.3 0.2 0.0 0.0 0.0 1+ 00.0 2.6 0.0 0.0 0.0 0.0 0.0 1+ 00.0 3.6 0.1 0.1 0.0 0.0 0.0 1+ 0

CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E472-6832

0.0 5.9 0.3 0.3 0.0 0.1 0.0 1+ 00.0 1.7 0.0 0.0 0.0 0.0 0.0 1+ 00.0 2.3 0.1 0.1 0.0 0.0 0.0 1+ 00.0 1.4 0.0 0.0 0.0 0.0 0.0 1+ 00.0 4.0 0.1 0.3 0.0 0.0 0.0 1+ 00.0 4.8 0.1 0.1 0.0 0.0 0.0 1+ 00.0 3.0 0.1 0.0 0.0 0.0 0.0 1+ 00.0 2.2 0.0 0.0 0.0 0.1 0.0 1+ 00.0 1.7 0.0 0.1 0.0 0.0 0.0 1+ 00.0 1.3 0.0 0.0 0.0 0.0 0.0 1+ 00.0 4.4 0.1 0.1 0.0 0.0 0.0 1+ 00.0 4.4 0.1 0.1 0.0 0.0 0.0 1+ 0

2+ 1+

0.0 3.3 0.2 0.1 0.0 0.0 0.0 1+ 0

2 of 12

Study Number FY01-013

L-43
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

CONTROL E451-6832CONTROL E452-6832CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequateadequate

CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E472-6832

adequate

decreased Gross fibrin clots on slide. This would decrease the number of platelets seen on slide.

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

decreased Poor smear quality. Proper counting area for WBC estimate not present on slide.

adequate

3 of 12

Study Number FY01-013

L-44
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E473-6832 18 0 78 2 1 0 1 0 1 6.8 1.2CONTROL E474-6832 24 0 73 1 2 0 0 0 9 3.6 0.9CONTROL E475-6832 27 0 71 1 1 0 0 0 2 3.6 1.0CONTROL E476-6832 32 0 64 2 2 0 0 0 2 4.8 1.5CONTROL E477-6832 21 0 78 0 1 0 0 0 5 4.4 0.9CONTROL E478-6832 36 0 58 2 4 0 0 0 2CONTROL E479-6832 26 0 71 1 2 0 0 0 3 7.2 1.9CONTROL E480 6832 27 0 68 1 3 0 1 0 0 6 8 1 8 CONTROL E480-6832 27 0 68 1 3 0 1 0 0 6.8 1.8CONTROL E482-6832 25 0 71 2 0 0 2 0 5 4.0 1.0CONTROL E483-6832 37 0 60 0 3 0 0 0 12 3.2 1.2CONTROL E484-6832 17 0 80 3 0 0 0 0 3 4.0 0.7CONTROL E486-6832 24 0 74 1 1 0 0 0 4 8.0 1.9CONTROL E487-6832 18 0 75 3 1 0 3 0 2 9.2 1.7CONTROL E488-6832 28 0 68 2 2 0 0 0 1 7.6 2.1CONTROL E489-6832 29 0 64 3 4 0 0 0 2 6.4 1.9CONTROL E490-6832 38 0 58 1 3 0 0 0 9 4.4 1.7CONTROL E491-6832 22 0 74 2 2 0 0 0 0 5.4 1.2CONTROL E493-6832 35 0 58 4 3 0 0 0 3 3.2 1.1CONTROL E494-6832 45 3 47 4 1 0 0 0 4 4.8 2.2CONTROL E495-6832 31 0 64 4 1 0 0 0 3 5.2 1.6CONTROL E496-6832 46 0 48 5 1 0 0 0 9 4.4 2.0CONTROL E498-6832 40 0 58 1 1 0 0 0 1 2.6 1.0

4 of 12

Study Number FY01-013

L-45
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

CONTROL E473-6832CONTROL E474-6832CONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROL E480 6832

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 5.3 0.1 0.1 0.0 0.1 0.0 1+ 00.0 2.6 0.0 0.1 0.0 0.0 0.0 1+ 00.0 2.6 0.0 0.0 0.0 0.0 0.0 1+ 00.0 3.1 0.1 0.1 0.0 0.0 0.0 1+ 00.0 3.4 0.0 0.0 0.0 0.0 0.0 1+ 0

1+ 0

0.0 5.1 0.1 0.1 0.0 0.0 0.0 1+ 00 0 4 6 0 1 0 2 0 0 0 1 0 0 1+ 0 CONTROL E480-6832

CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E498-6832

0.0 4.6 0.1 0.2 0.0 0.1 0.0 1+ 00.0 2.8 0.1 0.0 0.0 0.1 0.0 1+ 00.0 1.9 0.0 0.1 0.0 0.0 0.0 1+ 00.0 3.2 0.1 0.0 0.0 0.0 0.0 1+ 00.0 5.9 0.1 0.1 0.0 0.0 0.0 1+ 00.0 6.9 0.3 0.1 0.0 0.3 0.0 1+ 00.0 5.2 0.2 0.2 0.0 0.0 0.0 1+ 00.0 4.1 0.2 0.3 0.0 0.0 0.0 1+ 00.0 2.6 0.0 0.1 0.0 0.0 0.0 1+ 00.0 4.0 0.1 0.1 0.0 0.0 0.0 1+ 00.0 1.9 0.1 0.1 0.0 0.0 0.0 1+ 00.1 2.3 0.2 0.0 0.0 0.0 0.0 2+ 00.0 3.3 0.2 0.1 0.0 0.0 0.0 1+ 00.0 2.1 0.2 0.0 0.0 0.0 0.0 1+ 00.0 1.5 0.0 0.0 0.0 0.0 0.0 1+ 0

5 of 12

Study Number FY01-013

L-46
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

CONTROL E473-6832CONTROL E474-6832CONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROL E480 6832

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequate Poor smear quality. Proper counting area for WBC estimate not present on slide.adequateadequate CONTROL E480-6832

CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E498-6832

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

6 of 12

Study Number FY01-013

L-47
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E499-6832 53 0 45 0 2 0 0 0 10 5.2 2.8CONTROL E500-6832 16 0 77 2 5 0 0 0 3 4.0 0.6

HIGH H751-6838 31 0 67 0 0 0 2 0 5 5.2 1.6HIGH H752-6838 32 0 65 3 0 0 0 0 2 4.8 1.5HIGH H753-6838 26 0 71 2 1 0 0 0 0 4.4 1.1HIGH H754-6838 16 0 78 2 4 0 0 0 1 3.0 0.5HIGH H755-6838 27 0 70 2 0 0 1 0 0 5.2 1.4

HIGH H756 6838 25 0 70 3 1 0 1 0 3 4 6 1 2 HIGH H756-6838 25 0 70 3 1 0 1 0 3 4.6 1.2HIGH H758-6838 16 0 79 3 2 0 0 0 4 4.6 0.7HIGH H759-6838 41 0 56 2 1 0 0 0 3 8.0 3.3HIGH H760-6838 18 0 79 2 0 0 1 0 2 5.0 0.9HIGH H761-6838 36 0 60 3 1 0 0 0 7 4.2 1.5HIGH H762-6838 32 0 65 2 0 0 1 0 0 6.4 2.0HIGH H765-6838 37 0 53 7 1 0 2 0 2 4.0 1.5HIGH H767-6838 31 0 63 3 3 0 0 0 7 3.6 1.1HIGH H768-6838 33 0 63 1 3 0 0 0 1 3.0 1.0HIGH H769-6838 22 0 74 3 1 0 0 0 5 3.4 0.7HIGH H770-6838 30 0 66 2 2 0 0 0 2 5.2 1.6HIGH H771-6838 29 0 61 4 4 0 2 0 2 3.2 0.9HIGH H772-6838 24 0 73 2 1 0 0 0 4 1.8 0.4HIGH H773-6838 23 0 74 2 1 0 0 0 1 2.8 0.6HIGH H775-6838 21 0 76 1 1 0 1 0 2 5.2 1.1

7 of 12

Study Number FY01-013

L-48
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

CONTROL E499-6832CONTROL E500-6832

HIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838

HIGH H756 6838

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 2.3 0.0 0.1 0.0 0.0 0.0 2+ 00.0 3.1 0.1 0.2 0.0 0.0 0.0 1+ 00.0 3.5 0.0 0.0 0.0 0.1 0.0 1+ 00.0 3.1 0.1 0.0 0.0 0.0 0.0 1+ 00.0 3.1 0.1 0.0 0.0 0.0 0.0 1+ 00.0 2.3 0.1 0.1 0.0 0.0 0.0 1+ 00.0 3.6 0.1 0.0 0.0 0.1 0.0 1+ 00 0 3 2 0 1 0 0 0 0 0 0 0 0 1+ 0 HIGH H756-6838

HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H775-6838

0.0 3.2 0.1 0.0 0.0 0.0 0.0 1+ 00.0 3.6 0.1 0.1 0.0 0.0 0.0 1+ 00.0 4.5 0.2 0.1 0.0 0.0 0.0 1+ 00.0 4.0 0.1 0.0 0.0 0.1 0.0 1+ 00.0 2.5 0.1 0.0 0.0 0.0 0.0 1+ 00.0 4.2 0.1 0.0 0.0 0.1 0.0 1+ 00.0 2.1 0.3 0.0 0.0 0.1 0.0 1+ 00.0 2.3 0.1 0.1 0.0 0.0 0.0 1+ 00.0 1.9 0.0 0.1 0.0 0.0 0.0 1+ 00.0 2.5 0.1 0.0 0.0 0.0 0.0 1+ 00.0 3.4 0.1 0.1 0.0 0.0 0.0 1+ 00.0 2.0 0.1 0.1 0.0 0.1 0.0 1+ 00.0 1.3 0.0 0.0 0.0 0.0 0.0 1+ 00.0 2.1 0.1 0.0 0.0 0.0 0.0 1+ 00.0 4.0 0.1 0.1 0.0 0.1 0.0 1+ 0

8 of 12

Study Number FY01-013

L-49
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

CONTROL E499-6832CONTROL E500-6832

HIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838

HIGH H756 6838

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

decreased

adequateadequateadequateadequateadequateadequate

adequate HIGH H756-6838

HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H775-6838

adequate

decreased

adequateadequateadequateadequate

decreased

adequateadequateadequateadequateadequateadequateadequateadequate

9 of 12

Study Number FY01-013

L-50
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H776-6838 18 0 81 1 0 0 0 0 2 5.5 1.0HIGH H777-6838 34 0 63 3 0 0 0 0 7 4.8 1.6HIGH H778-6838 32 1 62 4 0 0 1 0 2 8.2 2.6HIGH H779-6838 37 0 58 4 0 0 1 0 2 4.4 1.6HIGH H780-6838 26 0 66 5 3 0 0 0 1 6.0 1.6HIGH H781-6838 34 0 60 2 4 0 0 0 0 3.8 1.3HIGH H782-6838 24 0 72 4 0 0 0 0 6 5.4 1.3HIGH H783-6838 35 0 59 3 3 0 0 0 6 3.8 1.3HIGH H784-6838 45 0 52 2 1 0 0 0 4 4.2 1.9HIGH H786-6838 23 0 70 4 3 0 0 0 2 7.0 1.6HIGH H787-6838 22 0 70 6 2 0 0 0 2 3.2 0.7HIGH H788-6838 28 0 66 4 2 0 0 0 4 3.8 1.1HIGH H789-6838 29 0 65 2 2 0 2 0 1 5.0 1.5HIGH H790-6838 35 0 62 3 0 0 0 0 5 2.6 0.9HIGH H791-6838 30 0 63 4 2 0 1 0 3 7.6 2.3HIGH H792-6838 27 0 63 8 1 0 1 0 1 6.0 1.6HIGH H793-6838 20 0 70 7 3 0 0 0 2 4.4 0.9HIGH H795-6838 37 0 60 1 2 0 0 0 1 5.0 1.9HIGH H796-6838 40 0 57 2 1 0 0 0 1 7.2 2.9HIGH H797-6838 30 1 62 3 3 0 1 0 6 6.8 2.0HIGH H798-6838 16 0 76 7 0 0 1 0 1 6.0 1.0HIGH H799-6838 28 0 70 2 0 0 0 0 9 4.2 1.2HIGH H800-6838 24 0 73 2 1 0 0 0 1 4.6 1.1

10 of 12

Study Number FY01-013

L-51
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

HIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 4.5 0.1 0.0 0.0 0.0 0.0 1+ 00.0 3.0 0.1 0.0 0.0 0.0 0.0 3+ 2+0.1 5.1 0.3 0.0 0.0 0.1 0.0 1+ 00.0 2.6 0.2 0.0 0.0 0.0 0.0 1+ 00.0 4.0 0.3 0.2 0.0 0.0 0.0 1+ 00.0 2.3 0.1 0.2 0.0 0.0 0.0 1+ 00.0 3.9 0.2 0.0 0.0 0.0 0.0 1+ 00.0 2.2 0.1 0.1 0.0 0.0 0.0 1+ 0

HIGH H784-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838

0.0 2.2 0.1 0.0 0.0 0.0 0.0 1+ 00.0 4.9 0.3 0.2 0.0 0.0 0.0 1+ 00.0 2.2 0.2 0.1 0.0 0.0 0.0 1+ 00.0 2.5 0.2 0.1 0.0 0.0 0.0 1+ 00.0 3.3 0.1 0.1 0.0 0.1 0.0 1+ 00.0 1.6 0.1 0.0 0.0 0.0 0.0 1+ 00.0 4.8 0.3 0.2 0.0 0.1 0.0 1+ 00.0 3.8 0.5 0.1 0.0 0.1 0.0 1+ 00.0 3.1 0.3 0.1 0.0 0.0 0.0 1+ 00.0 3.0 0.1 0.1 0.0 0.0 0.0 1+ 00.0 4.1 0.1 0.1 0.0 0.0 0.0 1+ 00.1 4.2 0.2 0.2 0.0 0.1 0.0 1+ 00.0 4.6 0.4 0.0 0.0 0.1 0.0 1+ 00.0 2.9 0.1 0.0 0.0 0.0 0.0 1+ 00.0 3.4 0.1 0.0 0.0 0.0 0.0 1+ 0

11 of 12

Study Number FY01-013

L-52
LRRI Protocol FY01-013

 18 Month Differential Cell Counts for Female Rats

GROUP ANIMAL

HIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequateadequateadequate

HIGH H784-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

12 of 12

Study Number FY01-013

L-53
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

L-5 24-Month Males 

L-54
LRRI Protocol FY01-013

Final Differential Cell Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E407-6831 59 0 30 6 1 0 4 0 1 3.6 2.1CONTROL E413-6831 63 0 30 6 1 0 0 0 7 3.0 1.9CONTROL E415-6831 24 0 59 4 1 0 12 0 2 22.6 5.4CONTROL E418-6831 55 0 32 5 5 0 3 0 7 2.2 1.2CONTROL E422-6831 49 0 42 6 2 0 1 0 0 3.8 1.9CONTROL E435-6831 54 0 40 3 0 0 3 0 0 2.8 1.5CONTROL E436-6831 59 0 30 5 0 0 6 0 2 5.4 3.2CONTROL E437-6831 37 0 53 5 1 0 4 0 0 4.2 1.6CONTROL E440-6831 57 0 33 4 0 0 6 0 1 2.0 1.1CONTROL E442-6831 14 0 68 2 0 0 16 0 5 19.8 2.8CONTROL E443-6831 54 0 39 1 1 0 5 0 2 4.2 2.3CONTROL E446-6831 4 0 75 2 0 0 19 0 0 68.8 2.8CONTROL E448-6831 43 0 49 1 0 0 7 0 4 3.2 1.4CONTROL E449-6831 60 0 27 1 4 0 8 0 0 2.1 1.3

HIGH H702-6837 50 0 44 0 0 0 6 0 4 5.8 2.9HIGH H704-6837 42 0 44 3 1 0 10 0 4 2.6 1.1

1 of 6

Study Number FY01-013

L-55
LRRI Protocol FY01-013

Final Differential Cell Counts for Male Rats

GROUP ANIMAL

CONTROL E407-6831CONTROL E413-6831CONTROL E415-6831CONTROL E418-6831CONTROL E422-6831CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E440-6831CONTROL E442-6831CONTROL E443-6831CONTROL E446-6831CONTROL E448-6831CONTROL E449-6831

HIGH H702-6837HIGH H704-6837

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 1.1 0.2 0.0 0.0 0.1 0.0 1+ 00.0 0.9 0.2 0.0 0.0 0.0 0.0 1+ 00.0 13.3 0.9 0.2 0.0 2.7 0.0 1+ 00.0 0.7 0.1 0.1 0.0 0.1 0.0 1+ 00.0 1.6 0.2 0.1 0.0 0.0 0.0 1+ 00.0 1.1 0.1 0.0 0.0 0.1 0.0 1+ 00.0 1.6 0.3 0.0 0.0 0.3 0.0 1+ 00.0 2.2 0.2 0.0 0.0 0.2 0.0 1+ 00.0 0.7 0.1 0.0 0.0 0.1 0.0 1+ 00.0 13.5 0.4 0.0 0.0 3.2 0.0 2+ 2+0.0 1.6 0.0 0.0 0.0 0.2 0.0 1+ 00.0 51.6 1.4 0.0 0.0 13.1 0.0 2+ 2+0.0 1.6 0.0 0.0 0.0 0.2 0.0 1+ 00.0 0.6 0.0 0.1 0.0 0.2 0.0 1+ 00.0 2.6 0.0 0.0 0.0 0.3 0.0 1+ 00.0 1.1 0.1 0.0 0.0 0.3 0.0 1+ 0

2 of 6

Study Number FY01-013

L-56
LRRI Protocol FY01-013

Final Differential Cell Counts for Male Rats

GROUP ANIMAL

CONTROL E407-6831CONTROL E413-6831CONTROL E415-6831CONTROL E418-6831CONTROL E422-6831CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E440-6831CONTROL E442-6831CONTROL E443-6831CONTROL E446-6831CONTROL E448-6831CONTROL E449-6831

HIGH H702-6837HIGH H704-6837

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

decreased

adequateadequateadequateadequate

3 of 6

Study Number FY01-013

L-57
LRRI Protocol FY01-013

Final Differential Cell Counts for Male Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H705-6837 29 0 57 2 0 0 11 1 7 9.3 2.7HIGH H706-6837 60 0 34 1 1 0 4 0 0 3.6 2.2HIGH H708-6837 5 0 84 1 0 0 7 3 0 40.7 2.0HIGH H714-6837 54 0 41 2 1 0 2 0 1 4.1 2.2HIGH H717-6837 51 0 35 4 3 0 7 0 3 3.4 1.7HIGH H722-6837 6 0 84 0 0 0 10 0 0 48.8 2.9HIGH H724-6837 17 0 80 0 0 0 3 0 1 10.8 1.8HIGH H725-6837 7 0 85 0 0 0 7 1 4 362.0 25.3HIGH H726-6837 32 0 59 4 1 0 4 0 11 4.4 1.4HIGH H728-6837 47 0 49 1 0 0 3 0 1 2.8 1.3HIGH H729-6837 38 0 55 0 1 0 6 0 12 1.8 0.7HIGH H735-6837 46 0 47 0 1 0 6 0 5 1.6 0.7HIGH H736-6837 45 0 46 2 0 0 7 0 5 2.2 1.0HIGH H739-6837 62 0 27 2 2 0 7 0 6 4.0 2.5HIGH H741-6837 41 0 46 1 3 0 9 0 8 3.6 1.5HIGH H747-6837 64 0 28 3 3 0 2 0 6 3.0 1.9HIGH H749-6837 48 0 47 1 2 0 2 0 5 2.8 1.3

4 of 6

Study Number FY01-013

L-58
LRRI Protocol FY01-013

Final Differential Cell Counts for Male Rats

GROUP ANIMAL

HIGH H705-6837HIGH H706-6837HIGH H708-6837HIGH H714-6837HIGH H717-6837HIGH H722-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H728-6837HIGH H729-6837HIGH H735-6837HIGH H736-6837HIGH H739-6837HIGH H741-6837HIGH H747-6837HIGH H749-6837

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 5.3 0.2 0.0 0.0 1.0 0.1 2+ 2+0.0 1.2 0.0 0.0 0.0 0.1 0.0 1+ 00.0 34.2 0.4 0.0 0.0 2.8 1.2 2+ 2+0.0 1.7 0.1 0.0 0.0 0.1 0.0 1+ 00.0 1.2 0.1 0.1 0.0 0.2 0.0 1+ 00.0 41.0 0.0 0.0 0.0 4.9 0.0 2+ 2+0.0 8.6 0.0 0.0 0.0 0.3 0.0 1+ 00.0 307.7 0.0 0.0 0.0 25.3 3.6 2+ 2+0.0 2.6 0.2 0.0 0.0 0.2 0.0 1+ 00.0 1.4 0.0 0.0 0.0 0.1 0.0 1+ 00.0 1.0 0.0 0.0 0.0 0.1 0.0 1+ 00.0 0.8 0.0 0.0 0.0 0.1 0.0 1+ 00.0 1.0 0.0 0.0 0.0 0.2 0.0 1+ 00.0 1.1 0.1 0.1 0.0 0.3 0.0 1+ 00.0 1.7 0.0 0.1 0.0 0.3 0.0 1+ 00.0 0.8 0.1 0.1 0.0 0.1 0.0 1+ 00.0 1.3 0.0 0.1 0.0 0.1 0.0 1+ 0

5 of 6

Study Number FY01-013

L-59
LRRI Protocol FY01-013

Final Differential Cell Counts for Male Rats

GROUP ANIMAL

HIGH H705-6837HIGH H706-6837HIGH H708-6837HIGH H714-6837HIGH H717-6837HIGH H722-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H728-6837HIGH H729-6837HIGH H735-6837HIGH H736-6837HIGH H739-6837HIGH H741-6837HIGH H747-6837HIGH H749-6837

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequate

decreased

adequateadequate

decreased

adequate

decreased

adequateadequateadequateadequateadequateadequateadequateadequateadequate

6 of 6

Study Number FY01-013

L-60
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

L-6 24-Month Females 

L-61
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E451-6832 24 0 64 5 1 0 6 0 3 4.8 1.2CONTROL E452-6832 35 0 51 4 1 0 9 0 5 3.8 1.3CONTROL E456-6832 38 0 50 1 2 0 9 0 1 3.1 1.2CONTROL E458-6832 36 0 59 0 0 0 5 0 8 2.2 0.8CONTROL E460-6832 22 0 70 3 1 0 4 0 2 3.6 0.8

CONTROL E461 6832 24 0 64 2 4 0 6 0 3 4 2 1 0 CONTROL E461-6832 24 0 64 2 4 0 6 0 3 4.2 1.0CONTROL E462-6832 12 0 55 3 0 0 30 0 3 12.0 1.4CONTROL E463-6832 22 1 68 3 2 0 4 0 38 8.0 1.8CONTROL E464-6832 22 1 66 0 0 0 11 0 42 23.6 5.2CONTROL E467-6832 31 0 58 1 1 0 9 0 3 2.0 0.6CONTROL E472-6832 47 0 41 2 0 0 10 0 1 4.0 1.9CONTROL E475-6832 43 0 48 1 2 0 6 0 7 2.4 1.0CONTROL E478-6832 28 0 64 1 2 0 5 0 3 4.0 1.1CONTROL E483-6832 35 0 52 4 1 0 8 0 5 2.8 1.0CONTROL E486-6832 49 0 43 2 2 0 4 0 4 1.8 0.9CONTROL E489-6832 33 0 57 4 3 0 3 0 1 2.8 0.9CONTROL E490-6832 8 0 82 2 0 0 8 0 5 40.0 3.2CONTROL E493-6832 5 1 75 0 0 0 16 3 14 130.0 6.5

1 of 9

Study Number FY01-013

L-62
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

CONTROL E451-6832CONTROL E452-6832CONTROL E456-6832CONTROL E458-6832CONTROL E460-6832

CONTROL E461 6832

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 3.1 0.2 0.0 0.0 0.3 0.0 1+ 00.0 1.9 0.2 0.0 0.0 0.3 0.0 1+ 00.0 1.6 0.0 0.1 0.0 0.3 0.0 1+ 00.0 1.3 0.0 0.0 0.0 0.1 0.0 1+ 00.0 2.5 0.1 0.0 0.0 0.1 0.0 2+ 0

0 0 2 7 0 1 0 2 0 0 0 3 0 0 1+ 0 CONTROL E461-6832

CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E467-6832CONTROL E472-6832CONTROL E475-6832CONTROL E478-6832CONTROL E483-6832CONTROL E486-6832CONTROL E489-6832CONTROL E490-6832CONTROL E493-6832

0.0 2.7 0.1 0.2 0.0 0.3 0.0 1+ 00.0 6.6 0.4 0.0 0.0 3.6 0.0 1+ 00.1 5.4 0.2 0.2 0.0 0.3 0.0 3+ 2+0.2 15.6 0.0 0.0 0.0 2.6 0.0 3+ 2+0.0 1.2 0.0 0.0 0.0 0.2 0.0 1+ 00.0 1.6 0.1 0.0 0.0 0.4 0.0 1+ 00.0 1.2 0.0 0.0 0.0 0.1 0.0 1+ 00.0 2.6 0.0 0.1 0.0 0.2 0.0 1+ 00.0 1.5 0.1 0.0 0.0 0.2 0.0 1+ 00.0 0.8 0.0 0.0 0.0 0.1 0.0 1+ 00.0 1.6 0.1 0.1 0.0 0.1 0.0 1+ 00.0 32.8 0.8 0.0 0.0 3.2 0.0 3+ 2+1.3 97.5 0.0 0.0 0.0 20.8 3.9 3+ 2+

2 of 9

Study Number FY01-013

L-63
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

CONTROL E451-6832CONTROL E452-6832CONTROL E456-6832CONTROL E458-6832CONTROL E460-6832

CONTROL E461 6832

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequate

decreased Platelet decrease is due to miniclots in the sample.

adequateadequateadequate

adequate CONTROL E461-6832

CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E467-6832CONTROL E472-6832CONTROL E475-6832CONTROL E478-6832CONTROL E483-6832CONTROL E486-6832CONTROL E489-6832CONTROL E490-6832CONTROL E493-6832

adequateadequateadequate

decreased

adequateadequateadequateadequateadequateadequateadequateadequate

decreased

3 of 9

Study Number FY01-013

L-64
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

CONTROL E495-6832 28 0 60 1 1 0 10 0 6 4.0 1.1CONTROL E497-6832 40 0 46 4 2 0 8 0 6 2.8 1.1CONTROL E498-6832 34 0 59 0 3 0 4 0 9 1.8 0.6CONTROL E500-6832 46 0 43 0 1 0 10 0 1 2.6 1.2

HIGH H754-6838 49 0 41 2 0 1 7 0 7 3.0 1.5HIGH H755-6838 33 0 56 2 2 0 7 0 6 2.4 0.8HIGH H756-6838 23 0 67 3 3 0 4 0 5 2.2 0.5HIGH H758-6838 47 1 47 1 0 0 4 0 0 2.4 1.1HIGH H759-6838 62 0 27 5 3 0 3 0 2 4.6 2.9HIGH H760-6838 49 0 42 3 2 0 4 0 4 3.0 1.5HIGH H761-6838 10 0 62 4 0 0 21 3 2 4.0 0.4HIGH H762-6838 44 0 48 1 1 0 6 0 1 2.8 1.2HIGH H765-6838 40 0 54 0 2 0 4 0 7 3.2 1.3HIGH H767-6838 24 0 66 3 0 0 7 0 13 4.4 1.1HIGH H768-6838 33 0 60 1 1 0 5 0 3 3.2 1.1HIGH H769-6838 27 0 66 2 1 0 4 0 4 3.0 0.8HIGH H771-6838 38 0 58 3 0 0 1 0 5 1.6 0.6HIGH H773-6838 36 0 63 0 0 0 1 0 1 2.0 0.7HIGH H776-6838 50 0 48 1 1 0 0 0 2 1.4 0.7

4 of 9

Study Number FY01-013

L-65
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

CONTROL E495-6832CONTROL E497-6832CONTROL E498-6832CONTROL E500-6832

HIGH H754-6838HIGH H755-6838

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 2.4 0.0 0.0 0.0 0.4 0.0 1+ 00.0 1.3 0.1 0.1 0.0 0.2 0.0 1+ 00.0 1.1 0.0 0.1 0.0 0.1 0.0 1+ 00.0 1.1 0.0 0.0 0.0 0.3 0.0 1+ 00.0 1.2 0.1 0.0 0.0 0.2 0.0 1+ 00.0 1.3 0.0 0.0 0.0 0.2 0.0 1+ 0

HIGH H756-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H771-6838HIGH H773-6838HIGH H776-6838

0.0 1.5 0.1 0.1 0.0 0.1 0.0 1+ 00.0 1.1 0.0 0.0 0.0 0.1 0.0 1+ 00.0 1.2 0.2 0.1 0.0 0.1 0.0 1+ 00.0 1.3 0.1 0.1 0.0 0.1 0.0 1+ 00.0 2.5 0.2 0.0 0.0 0.8 0.1 2+ 1+0.0 1.3 0.0 0.0 0.0 0.2 0.0 1+ 00.0 1.7 0.0 0.1 0.0 0.1 0.0 1+ 00.0 2.9 0.1 0.0 0.0 0.3 0.0 1+ 00.0 1.9 0.0 0.0 0.0 0.2 0.0 1+ 00.0 2.0 0.1 0.0 0.0 0.1 0.0 1+ 00.0 0.9 0.0 0.0 0.0 0.0 0.0 1+ 00.0 1.3 0.0 0.0 0.0 0.0 0.0 1+ 00.0 0.7 0.0 0.0 0.0 0.0 0.0 1+ 0

5 of 9

Study Number FY01-013

L-66
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

CONTROL E495-6832CONTROL E497-6832CONTROL E498-6832CONTROL E500-6832

HIGH H754-6838HIGH H755-6838

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequate

HIGH H756-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H771-6838HIGH H773-6838HIGH H776-6838

adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate

6 of 9

Study Number FY01-013

L-67
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

NEUTROPHILS 

(%)

BAND 

NEUTROPHILS 

(%)

LYMPHOCYTES 

(%)

MONOCYTES 

(%)

EOSINOPHILS 

(%)

BASOPHILS 

(%)

ATYPICAL 

LYMPHS 

(%)

BLASTS 

(%)

NUCLEATED RBC 

(#/100 WBC)

WBC 

ESTIMATE 

(nX103 

cells/μl)

ABSOLUTE 

NEUTROPHILS 

(nX103 cells/μl)

HIGH H777-6838 33 0 60 3 1 0 3 0 4 2.6 0.9HIGH H778-6838 7 0 79 0 0 0 11 3 9 40.0 2.8HIGH H779-6838 33 0 64 0 0 0 3 0 1 2.4 0.8HIGH H780-6838 24 0 62 2 1 0 11 0 3 6.6 1.6HIGH H781-6838 32 0 60 2 0 0 6 0 1 2.0 0.6HIGH H782 6838 40 0 56 1 1 0 2 0 3 1 6 0 6 HIGH H782-6838 40 0 56 1 1 0 2 0 3 1.6 0.6HIGH H784-6838 71 0 25 2 0 0 2 0 1 2.8 2.0HIGH H787-6838 29 0 61 1 0 0 9 0 3 3.0 0.9HIGH H788-6838 46 0 46 2 0 0 6 0 3 4.0 1.8HIGH H789-6838 49 0 42 3 3 0 3 0 6 1.8 0.9HIGH H790-6838 61 0 31 6 0 0 2 0 5 3.0 1.8HIGH H791-6838 15 0 64 1 0 0 19 1 6 9.6 1.4HIGH H793-6838 26 0 52 7 0 0 12 3 16 8.8 2.3HIGH H794-6838 44 0 49 2 3 0 2 0 7 2.8 1.2HIGH H796-6838 36 0 58 0 0 0 6 0 3 2.0 0.7HIGH H798-6838 55 0 42 0 2 0 1 0 3 3.0 1.7HIGH H799-6838 49 1 48 1 0 0 1 0 6 1.8 0.9HIGH H800-6838 30 0 54 0 1 0 15 0 0 4.4 1.3

7 of 9

Study Number FY01-013

L-68
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782 6838

ABSOLUTE 

BAND 

NEUTROPHILS 

(nX103 cells/μl)

ABSOLUTE 

LYMPHOCYTES 

(nX103 cells/μl)

ABSOLUTE 

MONOCYTES 

(nX103 cells/μl)

ABSOLUTE 

EOSINOPHILS 

(nX103 cells/μl)

ABSOLUTE 

BASOPHILS 

(nX103 cells/μl)

ABSOLUTE 

ATYPICAL 

LYMPHS 

(nX103 cells/μl)

ABSOLUTE 

BLASTS 

(nX103 cells/μl)

POLYCHROMASIA 

(1+ - 4+)

ANISOCYTOSIS 

(0 - 4+)

0.0 1.6 0.1 0.0 0.0 0.1 0.0 1+ 00.0 31.6 0.0 0.0 0.0 4.4 1.2 2+ 2+0.0 1.5 0.0 0.0 0.0 0.1 0.0 1+ 00.0 4.1 0.1 0.1 0.0 0.7 0.0 1+ 00.0 1.2 0.0 0.0 0.0 0.1 0.0 1+ 00 0 0 9 0 0 0 0 0 0 0 0 0 0 1+ 0 HIGH H782-6838

HIGH H784-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H793-6838HIGH H794-6838HIGH H796-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838

0.0 0.9 0.0 0.0 0.0 0.0 0.0 1+ 00.0 0.7 0.1 0.0 0.0 0.1 0.0 1+ 00.0 1.8 0.0 0.0 0.0 0.3 0.0 1+ 00.0 1.8 0.1 0.0 0.0 0.2 0.0 1+ 00.0 0.8 0.1 0.1 0.0 0.1 0.0 1+ 00.0 0.9 0.2 0.0 0.0 0.1 0.0 1+ 00.0 6.1 0.1 0.0 0.0 1.8 0.1 2+ 2+0.0 4.6 0.6 0.0 0.0 1.1 0.3 1+ 00.0 1.4 0.1 0.1 0.0 0.1 0.0 1+ 00.0 1.2 0.0 0.0 0.0 0.1 0.0 1+ 00.0 1.3 0.0 0.1 0.0 0.0 0.0 1+ 00.0 0.9 0.0 0.0 0.0 0.0 0.0 1+ 00.0 2.4 0.0 0.0 0.0 0.7 0.0 1+ 0

8 of 9

Study Number FY01-013

L-69
LRRI Protocol FY01-013

Final Differential Counts for Female Rats

GROUP ANIMAL

HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782 6838

Platelet 

Estimate 

(adequate, 

increased, 

decreased) Comments

adequateadequateadequateadequateadequateadequate HIGH H782-6838

HIGH H784-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H793-6838HIGH H794-6838HIGH H796-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838

adequateadequateadequateadequateadequateadequateadequate 1 lymphocyte in the 100 cell differential demonstrated erythro-phagocytosisadequateadequateadequateadequateadequateadequate 2 lymphocytes in the 100 cell differential demonstrated erythro-phagocytosis

9 of 9

Study Number FY01-013

L-70
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

M-1 

APPENDIX M 

NEOPLASTIC AND NON-NEOPLASTIC LESIONS AND 

GROSS NECROPSY OBSERVATIONS IN MALE RATS 

M-1 Gross Necropsy Observations 

M-2 Lesion Incidence by Animal Number for Microscopic Observations 

M-3 Incidence Summary (with percentages) of Microscopic Observations 

M-4 Tabulated Incidence Summary of Non-neoplastic Lesions 

M-5 Lesion Incidence Summary with Average Severity Grades 

M-6 Raw Data 

M-7 Individual Animal Report of Correlated Gross and Microscopic Diagnoses 

M-8 Histological Comments on Tissue 

M-9 Summary of Missing Tissues 

M-10 Lesion Incidence Summary with K-S (comparison > control) 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-1 Gross Necropsy Observations 

M-2
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013M Page: 1  All Sacrifices  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Males --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Adrenal glands  Cyst ........................... 1 0 0 0  Discolored ..................... 1 0 0 1  Enlarged ....................... 2 2 5 4  Mass ........................... 0 1 0 0  Aorta  Enlarged ....................... 0 0 0 1  Brain  Deformity ...................... 6 1 2 3  Discolored ..................... 0 0 1 0  Cecum  Discolored ..................... 0 1 0 0  Colon  Mass ........................... 0 0 0 1  Duodenum  Discolored ..................... 0 0 0 1  Eyes/optic nerve  Crust .......................... 0 1 1 0  Small .......................... 1 0 0 0  Discolored ..................... 0 0 4 1  Heart  Discolored ..................... 0 1 0 0  Ileum  Mass ........................... 1 0 0 0  Discolored ..................... 0 1 0 0  Jejunum  Mass ........................... 2 0 0 0  Kidneys  Cyst ........................... 0 0 1 1  Enlarged ....................... 0 1 0 1  Mass ........................... 0 1 1 1  Nodule ......................... 0 1 2 0  Discolored ..................... 7 5 6 14 

Study Number FY01-013

M-3
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013M Page: 2  All Sacrifices  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Males --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Kidneys  Mineralization ................. 0 0 0 1  Liver  Cyst ........................... 0 0 1 1  Deformity ...................... 0 1 0 0  Enlarged ....................... 0 2 1 2  Hernia ......................... 1 0 0 2  Mass ........................... 2 1 2 0  Nodule ......................... 2 2 2 1  Thick .......................... 9 6 6 12  Discolored ..................... 9 13 13 11  Pituitary gland  Cyst ........................... 0 1 2 0  Deformity ...................... 0 0 1 0  Enlarged ....................... 3 0 0 4  Mass ........................... 4 3 0 1  Nodule ......................... 1 3 3 0  Discolored ..................... 7 4 7 4  Parathyroid  Enlarged ....................... 0 1 0 0  Salivary gland  Enlarged ....................... 0 0 1 0  Skin  Alopecia ....................... 0 1 0 0  Crust .......................... 1 3 3 1  Mass ........................... 2 3 4 1  Scar ........................... 0 1 0 0  Spleen  Cyst ........................... 0 1 0 0  Deformity ...................... 0 1 3 0  Discolored ..................... 6 2 2 5  Enlarged ....................... 25 28 29 25  Mass ........................... 0 0 1 1  Nodule ......................... 0 1 1 1  Stomach  Rupture ........................ 1 0 0 0 

Study Number FY01-013

M-4
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013M Page: 3  All Sacrifices  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Males --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Testes  Cyst ........................... 1 0 0 0  Enlarged ....................... 2 8 12 14  Fluid .......................... 0 1 0 0  Mass ........................... 6 7 2 5  Small .......................... 2 6 4 6  Discolored ..................... 37 34 47 38  Thyroid glands  Enlarged ....................... 1 1 3 2  Mass ........................... 0 3 1 1  Nodule ......................... 1 0 0 0  Discolored ..................... 1 1 1 0  Urinary bladder  Enlarged ....................... 0 0 0 1  Mass ........................... 1 0 0 0  Lungs  Discolored ..................... 17 23 17 15  Focus .......................... 0 1 0 0  Mass ........................... 1 3 0 1  Nodule ......................... 1 1 3 3  Epididymis  Enlarged ....................... 0 0 1 0  Nodule ......................... 0 0 0 1  Small .......................... 1 5 1 2  Discolored ..................... 0 1 1 1  Prostate  Enlarged ....................... 0 0 0 2  Discolored ..................... 0 1 0 0  Seminal vesicle  Enlarged ....................... 0 1 1 1  Mass ........................... 1 0 0 0  Small .......................... 5 2 9 6  Thick .......................... 0 0 1 0  Tail  Amputation ..................... 1 0 0 0  Crust .......................... 0 0 1 0 

Study Number FY01-013

M-5
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013M Page: 4  All Sacrifices  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Males --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Tail  Mass ........................... 0 1 0 0  Nodule ......................... 0 1 0 0  Bronchial (TBLN)  Enlarged ....................... 6 3 4 6  Discolored ..................... 1 2 0 2  Mandibular LN  Enlarged ....................... 6 2 4 2  Discolored ..................... 0 2 0 0  Mediastinal LN  Enlarged ....................... 7 3 8 2  Mass ........................... 1 0 0 0  Discolored ..................... 1 1 1 0  Mesenteric LN  Enlarged ....................... 1 2 2 1  Mammary gland  Mass ........................... 2 4 4 4  Discolored ..................... 0 0 1 1  Tiss.not specifi  Adhesion ....................... 0 1 0 0  Enlarged ....................... 0 0 0 1  Mass ........................... 1 1 2 3  Nodule ......................... 0 0 0 3  Perforation .................... 1 0 0 0  Thick .......................... 0 1 0 0  Discolored ..................... 0 0 1 1  Harderian gland  Enlarged ....................... 1 0 0 0  Discolored ..................... 0 1 0 0  Preputial gland  Enlarged ....................... 4 0 2 2  Mass ........................... 0 1 1 0  Pancreatic LN  Enlarged ....................... 5 2 2 4 

Study Number FY01-013

M-6
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013M Page: 5  All Sacrifices  Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Males --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Iliac LN  Enlarged ....................... 3 2 4 2  Lymph node other  Enlarged ....................... 6 6 10 7  Discolored ..................... 0 0 0 1  Cavities  Fluid .......................... 1 1 1 2  Popliteal LN  Enlarged ....................... 3 0 2 1  Discolored ..................... 0 0 0 1  Thymus  Mass ........................... 1 0 0 1  Discolored ..................... 0 0 0 2  Mediastinum  Mass ........................... 1 0 0 0  Mesentery  Mass ........................... 0 1 0 0  Nodule ......................... 0 0 1 1  Muscle, skeletal  Mass ........................... 0 2 0 0  Discolored ..................... 0 0 1 0  Bone, other  Enlarged ....................... 0 0 0 1  Mass ........................... 0 1 0 0  Zymbal's gland  Mass ........................... 0 0 0 1 

Study Number FY01-013

M-7
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Adrenal glands 

 Cyst 6831E440 

 Discolored 6831E434 6837H7

 Enlarged 6831E424 6833F504 6835G619 6837H7

 - 6831E444 6833F509 6835G625 6837H7

 - 6835G627 6837H7

 - 6835G636 6837H7

 - 6835G646 

 Mass 6833F525 

 

 Aorta 

 Enlarged 6837H7

 Brain 

 Deformity 6831E409 6833F531 6835G647 6837H7

 - 6831E414 6835G650 6837H7

 - 6831E417 6837H7

 - 6831E427 

 - 6831E434 

 - 6831E435 

 Discolored 6835G611 

 

 Cecum 

 Discolored 6833F530 

 Colon 

 Mass 6837H7

 Duodenum 

 Discolored 6837H7

 Eyes/optic nerve 

 Crust 6833F539 6835G615 

 Small 6831E430 

 Discolored 6835G601 6837H7

 - 6835G611 

 - 6835G636 

 - 6835G648 

 

 Heart 

 Discolored 6833F530 

M-8
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Ileum 

 Mass 6831E428 

 Discolored 6833F530 

 

 Jejunum 

 Mass 6831E412 

 - 6831E428 

 Kidneys 

 Cyst 6835G609 6837H7

 Enlarged 6833F520 6837H7

 Mass 6833F546 6835G604 6837H7

 Nodule 6833F543 6835G605 

 - 6835G608 

 Discolored 6831E417 6833F530 6835G602 6837H7

 - 6831E424 6833F540 6835G634 6837H7

 - 6831E424 6833F543 6835G636 6837H7

 - 6831E434 6833F545 6835G639 6837H7

 - 6831E435 6833F550 6835G647 6837H7

 - 6831E442 6835G648 6837H7

 - 6831E444 6837H7

 - 6837H7

 - 6837H7

 - 6837H7

 - 6837H7

 - 6837H7

 - 6837H7

 - 6837H7

 Mineralization 6837H7

 

 Liver 

 Cyst 6835G618 6837H7

 Deformity 6833F545 

 Enlarged 6833F503 6835G606 6837H7

 - 6833F533 6837H7

 Hernia 6831E418 6837H7

 - 6837H7

 Mass 6831E415 6833F520 6835G614 

 - 6831E442 6835G631 

 Nodule 6831E423 6833F511 6835G606 6837H7

 - 6831E427 6833F543 6835G607 

M-9
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Liver 

 Thick 6831E401 6833F501 6835G616 6837H7

 - 6831E416 6833F517 6835G620 6837H7

 - 6831E425 6833F521 6835G625 6837H7

 - 6831E427 6833F541 6835G627 6837H7

 - 6831E432 6833F544 6835G642 6837H7

 - 6831E438 6833F548 6835G646 6837H7

 - 6831E442 6837H7

 - 6831E444 6837H7

 - 6831E447 6837H7

 - 6837H7

 - 6837H7

 - 6837H7

 Discolored 6831E405 6833F506 6835G605 6837H7

 - 6831E410 6833F513 6835G611 6837H7

 - 6831E421 6833F518 6835G615 6837H7

 - 6831E428 6833F527 6835G622 6837H7

 - 6831E431 6833F530 6835G629 6837H7

 - 6831E434 6833F534 6835G632 6837H7

 - 6831E435 6833F535 6835G634 6837H7

 - 6831E445 6833F537 6835G637 6837H7

 - 6831E450 6833F538 6835G639 6837H7

 - 6833F542 6835G640 6837H7

 - 6833F544 6835G647 6837H7

 - 6833F549 6835G649 

 - 6833F550 6835G649 

 

 Pituitary gland 

 Cyst 6833F503 6835G627 

 - 6835G630 

 Deformity 6835G650 

 Enlarged 6831E414 6837H7

 - 6831E425 6837H7

 - 6831E427 6837H7

 - 6837H7

 Mass 6831E409 6833F520 6837H7

 - 6831E417 6833F531 

 - 6831E434 6833F546 

 - 6831E435 

 Nodule 6831E407 6833F537 6835G625 

 - 6833F547 6835G636 

 - 6833F549 6835G644 

M-10
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Pituitary gland 

 Discolored 6831E403 6833F507 6835G620 6837H7

 - 6831E410 6833F511 6835G627 6837H7

 - 6831E419 6833F516 6835G634 6837H7

 - 6831E420 6833F530 6835G637 6837H7

 - 6831E441 6835G638 

 - 6831E447 6835G641 

 - 6831E448 6835G647 

 

 Parathyroid 

 Enlarged 6833F550 

 Salivary gland 

 Enlarged 6835G604 

 Skin 

 Alopecia 6833F546 

 Crust 6831E438 6833F502 6835G615 6837H7

 - 6833F518 6835G623 

 - 6833F546 6835G631 

 Mass 6831E439 6833F510 6835G605 6837H7

 - 6831E440 6833F511 6835G607 

 - 6833F543 6835G614 

 - 6835G635 

 Scar 6833F519 

 

 Spleen 

 Cyst 6833F538 

 Deformity 6833F546 6835G605 

 - 6835G615 

 - 6835G630 

 Discolored 6831E410 6833F521 6835G631 6837H7

 - 6831E417 6833F544 6835G642 6837H7

 - 6831E422 6837H7

 - 6831E425 6837H7

 - 6831E426 6837H7

 - 6831E432 

 Enlarged 6831E401 6833F501 6835G605 6837H7

 - 6831E402 6833F503 6835G606 6837H7

 - 6831E403 6833F504 6835G608 6837H7

 - 6831E403 6833F506 6835G611 6837H7

 - 6831E405 6833F507 6835G612 6837H7

 - 6831E410 6833F512 6835G615 6837H7

 - 6831E411 6833F513 6835G616 6837H7

M-11
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Spleen 

 Enlarged 6831E415 6833F514 6835G617 6837H7

 - 6831E416 6833F515 6835G618 6837H7

 - 6831E419 6833F516 6835G619 6837H7

 - 6831E420 6833F517 6835G620 6837H7

 - 6831E421 6833F520 6835G622 6837H7

 - 6831E423 6833F521 6835G624 6837H7

 - 6831E424 6833F522 6835G625 6837H7

 - 6831E426 6833F526 6835G626 6837H7

 - 6831E427 6833F527 6835G629 6837H7

 - 6831E429 6833F528 6835G632 6837H7

 - 6831E432 6833F532 6835G633 6837H7

 - 6831E438 6833F533 6835G636 6837H7

 - 6831E441 6833F535 6835G637 6837H7

 - 6831E442 6833F537 6835G638 6837H7

 - 6831E444 6833F538 6835G639 6837H7

 - 6831E445 6833F540 6835G640 6837H7

 - 6831E446 6833F544 6835G641 6837H7

 - 6831E447 6833F545 6835G642 6837H7

 - 6833F546 6835G644 

 - 6833F548 6835G646 

 - 6833F549 6835G648 

 - 6835G649 

 Mass 6835G604 6837H7

 Nodule 6833F545 6835G640 6837H7

 

 Stomach 

 Rupture 6831E434 

 Testes 

 Cyst 6831E415 

 Enlarged 6831E418 6833F505 6835G601 6837H7

 - 6831E449 6833F510 6835G610 6837H7

 - 6833F511 6835G613 6837H7

 - 6833F516 6835G621 6837H7

 - 6833F519 6835G628 6837H7

 - 6833F536 6835G634 6837H7

 - 6833F544 6835G635 6837H7

 - 6833F550 6835G638 6837H7

 - 6835G645 6837H7

 - 6835G646 6837H7

 - 6835G647 6837H7

 - 6835G649 6837H7

 - 6837H7

M-12
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Testes 

 Enlarged 6837H7

 Fluid 6833F538 

 Mass 6831E402 6833F509 6835G606 6837H7

 - 6831E403 6833F515 6835G643 6837H7

 - 6831E421 6833F527 6837H7

 - 6831E421 6833F528 6837H7

 - 6831E423 6833F533 6837H7

 - 6831E441 6833F533 

 - 6833F545 

 Small 6831E415 6833F513 6835G604 6837H7

 - 6831E419 6833F519 6835G616 6837H7

 - 6833F520 6835G642 6837H7

 - 6833F525 6835G648 6837H7

 - 6833F531 6837H7

 - 6833F538 6837H7

 Discolored 6831E401 6833F501 6835G601 6837H7

 - 6831E404 6833F501 6835G602 6837H7

 - 6831E405 6833F502 6835G603 6837H7

 - 6831E406 6833F503 6835G604 6837H7

 - 6831E407 6833F504 6835G605 6837H7

 - 6831E410 6833F506 6835G607 6837H7

 - 6831E411 6833F507 6835G608 6837H7

 - 6831E412 6833F508 6835G609 6837H7

 - 6831E413 6833F511 6835G612 6837H7

 - 6831E414 6833F514 6835G613 6837H7

 - 6831E416 6833F516 6835G614 6837H7

 - 6831E419 6833F517 6835G615 6837H7

 - 6831E420 6833F518 6835G616 6837H7

 - 6831E420 6833F521 6835G617 6837H7

 - 6831E422 6833F522 6835G618 6837H7

 - 6831E424 6833F523 6835G619 6837H7

 - 6831E425 6833F523 6835G620 6837H7

 - 6831E426 6833F525 6835G622 6837H7

 - 6831E428 6833F526 6835G623 6837H7

 - 6831E429 6833F529 6835G624 6837H7

 - 6831E430 6833F534 6835G624 6837H7

 - 6831E432 6833F535 6835G625 6837H7

 - 6831E433 6833F536 6835G626 6837H7

 - 6831E433 6833F537 6835G627 6837H7

 - 6831E435 6833F538 6835G628 6837H7

 - 6831E436 6833F539 6835G629 6837H7

 - 6831E437 6833F541 6835G630 6837H7

 - 6831E440 6833F542 6835G631 6837H7

M-13
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Testes 

 Discolored 6831E442 6833F543 6835G632 6837H7

 - 6831E443 6833F544 6835G632 6837H7

 - 6831E444 6833F546 6835G633 6837H7

 - 6831E445 6833F547 6835G635 6837H7

 - 6831E446 6833F548 6835G636 6837H7

 - 6831E447 6833F549 6835G636 6837H7

 - 6831E448 6835G637 6837H7

 - 6831E449 6835G638 6837H7

 - 6831E450 6835G639 6837H7

 - 6835G640 6837H7

 - 6835G640 

 - 6835G642 

 - 6835G644 

 - 6835G645 

 - 6835G646 

 - 6835G647 

 - 6835G648 

 - 6835G649 

 - 6835G650 

 

 Thyroid glands 

 Enlarged 6831E430 6833F530 6835G614 6837H7

 - 6835G641 6837H7

 - 6835G646 

 Mass 6833F520 6835G637 6837H7

 - 6833F526 

 - 6833F550 

 Nodule 6831E422 

 Discolored 6831E446 6833F544 6835G632 

 

 Urinary bladder 

 Enlarged 6837H7

 Mass 6831E409 

 Lungs 

 Discolored 6831E401 6833F503 6835G601 6837H7

 - 6831E402 6833F504 6835G603 6837H7

 - 6831E402 6833F506 6835G606 6837H7

 - 6831E403 6833F507 6835G607 6837H7

 - 6831E410 6833F508 6835G610 6837H7

 - 6831E411 6833F514 6835G611 6837H7

 - 6831E414 6833F518 6835G613 6837H7

 - 6831E416 6833F521 6835G616 6837H7

M-14
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Lungs 

 Discolored 6831E420 6833F523 6835G620 6837H7

 - 6831E424 6833F524 6835G621 6837H7

 - 6831E429 6833F527 6835G624 6837H7

 - 6831E430 6833F530 6835G625 6837H7

 - 6831E439 6833F532 6835G636 6837H7

 - 6831E440 6833F535 6835G637 6837H7

 - 6831E441 6833F541 6835G639 6837H7

 - 6831E448 6833F544 6835G640 

 - 6831E450 6833F545 6835G644 

 - 6833F545 

 - 6833F546 

 - 6833F548 

 - 6833F549 

 - 6833F550 

 - 6833F550 

 Focus 6833F515 

 Mass 6831E427 6833F511 6837H7

 - 6833F518 

 - 6833F536 

 Nodule 6831E441 6833F543 6835G604 6837H7

 - 6835G615 6837H7

 - 6835G641 6837H7

 

 Epididymis 

 Enlarged 6835G645 

 Nodule 6837H7

 Small 6831E413 6833F506 6835G630 6837H7

 - 6833F525 6837H7

 - 6833F531 

 - 6833F539 

 - 6833F550 

 Discolored 6833F509 6835G625 6837H7

 

 Prostate 

 Enlarged 6837H7

 - 6837H7

 Discolored 6833F546 

 Seminal vesicle 

 Enlarged 6833F536 6835G648 6837H7

M-15
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Seminal vesicle 

 Mass 6831E427 

 Small 6831E415 6833F516 6835G603 6837H7

 - 6831E418 6833F527 6835G605 6837H7

 - 6831E436 6835G607 6837H7

 - 6831E439 6835G610 6837H7

 - 6831E440 6835G615 6837H7

 - 6835G617 6837H7

 - 6835G621 

 - 6835G622 

 - 6835G643 

 Thick 6835G604 

 

 Tail 

 Amputation 6831E436 

 Crust 6835G602 

 Mass 6833F521 

 Nodule 6833F505 

 

 Bronchial (TBLN) 

 Enlarged 6831E405 6833F501 6835G616 6837H7

 - 6831E411 6833F507 6835G631 6837H7

 - 6831E420 6833F515 6835G636 6837H7

 - 6831E421 6835G646 6837H7

 - 6831E429 6837H7

 - 6831E442 6837H7

 Discolored 6831E427 6833F532 6837H7

 - 6833F536 6837H7

 

 Mandibular LN 

 Enlarged 6831E407 6833F510 6835G604 6837H7

 - 6831E409 6833F515 6835G616 6837H7

 - 6831E420 6835G631 

 - 6831E422 6835G635 

 - 6831E427 

 - 6831E429 

 Discolored 6833F506 

 - 6833F541 

 

 Mediastinal LN 

 Enlarged 6831E410 6833F501 6835G602 6837H7

 - 6831E411 6833F515 6835G604 6837H7

 - 6831E420 6833F543 6835G612 

 - 6831E429 6835G616 

M-16
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Mediastinal LN 

 Enlarged 6831E442 6835G636 

 - 6831E444 6835G637 

 - 6831E446 6835G641 

 - 6835G644 

 Mass 6831E427 

 Discolored 6831E438 6833F509 6835G620 

 

 Mesenteric LN 

 Enlarged 6831E420 6833F515 6835G604 6837H7

 - 6833F543 6835G644 

 Mammary gland 

 Mass 6831E404 6833F518 6835G617 6837H7

 - 6831E435 6833F529 6835G633 6837H7

 - 6833F543 6835G643 6837H7

 - 6833F548 6835G649 6837H7

 Discolored 6835G631 6837H7

 

 Tiss.not specifi 

 Adhesion 6833F543 

 Enlarged 6837H7

 Mass 6831E406 6833F543 6835G602 6837H7

 - 6835G636 6837H7

 - 6837H7

 Nodule 6837H7

 - 6837H7

 - 6837H7

 Perforation 6831E406 

 Thick 6833F546 

 Discolored 6835G625 6837H7

 

 Harderian gland 

 Enlarged 6831E406 

 Discolored 6833F546 

 Preputial gland 

 Enlarged 6831E410 6835G605 6837H7

 - 6831E418 6835G621 6837H7

 - 6831E422 

 - 6831E443 

M-17
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013M Page

 All Sacrifices 

 Rat/F344/N Study start date: 23-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- M a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Preputial gland 

 Mass 6833F513 6835G608 

 

 Pancreatic LN 

 Enlarged 6831E411 6833F501 6835G604 6837H7

 - 6831E416 6833F533 6835G631 6837H7

 - 6831E424 6837H7

 - 6831E442 6837H7

 - 6831E447 

 

 Iliac LN 

 Enlarged 6831E411 6833F501 6835G629 6837H7

 - 6831E420 6833F515 6835G636 6837H7

 - 6831E442 6835G641 

 - 6835G644 

 

 Lymph node other 

 Enlarged 6831E416 6833F501 6835G602 6837H7

 - 6831E420 6833F515 6835G604 6837H7

 - 6831E420 6833F515 6835G604 6837H7

 - 6831E427 6833F515 6835G619 6837H7

 - 6831E429 6833F525 6835G620 6837H7

 - 6831E442 6833F531 6835G625 6837H7

 - 6835G629 6837H7

 - 6835G636 

 - 6835G641 

 - 6835G644 

 Discolored 6837H7

 

 Cavities 

 Fluid 6831E420 6833F530 6835G614 6837H7

 - 6837H7

 Popliteal LN 

 Enlarged 6831E420 6835G604 6837H7

 - 6831E435 6835G636 

 - 6831E442 

 Discolored 6837H7

 

 Thymus 

 Mass 6831E427 6837H7

M-18
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-2 Lesion Incidence by Animal Number for Microscopic Observations 

M-19
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Proliferative (including Neoplastic) Lesions 

M-20
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Hyperplasia, alveolar epithelial, focal 6831E402 6833F504 6835G624 6837H711 6831E410 6833F511 6835G629 6837H716 6831E429 6833F518 6837H724 6831E437 6833F520 6837H728 6831E441 6833F527 6831E444 6833F536 6831E446 6833F537 6831E448 Hyperplasia, alveolar epithelial, widespread 6831E416 6833F546 B-Adenoma, bronchiolo-alveolar 6831E441 6835G615 N-Sarcoma, histiocytic 6833F518 6833F543 N-Leukemia, mononuclear - capillary involvement 6831E401 6833F501 6835G605 6837H705 6831E402 6833F503 6835G606 6837H707 6831E403 6833F504 6835G608 6837H709 6831E405 6833F506 6835G610 6837H712 6831E409 6833F507 6835G611 6837H713 6831E410 6833F512 6835G612 6837H715 6831E411 6833F513 6835G615 6837H719 6831E415 6833F515 6835G616 6837H720 6831E416 6833F516 6835G618 6837H722 6831E419 6833F517 6835G619 6837H723 6831E420 6833F518 6835G620 6837H724 6831E421 6833F520 6835G622 6837H725 6831E423 6833F521 6835G624 6837H727 6831E424 6833F522 6835G625 6837H729 6831E426 6833F523 6835G626 6837H733 6831E429 6833F525 6835G627 6837H734 6831E438 6833F526 6835G629 6837H737 6831E441 6833F528 6835G630 6837H738 6831E442 6833F530 6835G631 6837H740 6831E444 6833F533 6835G632 6837H742 6831E445 6833F534 6835G633 6837H743 6831E446 6833F535 6835G636 6837H744 6831E447 6833F537 6835G637 6837H746 6831E450 6833F538 6835G638 6837H748 6833F540 6835G639 6837H750 6833F544 6835G640 6833F545 6835G641 6833F546 6835G642 6833F548 6835G644 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-21
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 6833F549 6835G646 6833F550 6835G648 6835G649 N-Leukemia, mononuclear - invasive involvement 6831E427 6833F532 6835G604 6837H708 Trachea ........................................Number examined: 50 49 50 50 Hyperplasia, epithelial 6831E430 6833F520 N-Leukemia, mononuclear 6831E420 6835G604 6831E438 Bronchial (TBLN) ...............................Number examined: 49 33 28 47 N-Sarcoma, histiocytic 6833F543 N-Leukemia, mononuclear 6831E405 6833F501 6835G604 6837H705 6831E411 6833F507 6835G616 6837H709 6831E416 6833F515 6835G626 6837H722 6831E420 6833F532 6835G631 6837H723 6831E421 6833F533 6835G636 6837H725 6831E427 6833F534 6835G644 6837H746 6831E429 6833F537 6835G646 6837H750 6831E442 6833F545 6831E446 6833F546 6831E447 Thyroid glands .................................Number examined: 50 35 31 50 Hyperplasia, C-cell, focal 6831E416 6833F538 6837H707 6831E417 6833F546 6837H714 6831E427 6837H726 6831E446 6837H729 6837H741 6837H746 6837H750 Hyperplasia, follicular cell 6835G614 B-Adenoma, C-cell 6831E403 6833F526 6835G616 6837H713 6831E432 6833F529 6835G632 6837H728 6831E442 6833F544 6835G641 6837H734 6833F550 6835G646 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-22
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thyroid glands .................................Number examined: 50 35 31 50 B-Adenoma, follicular cell 6831E430 6837H718 6831E448 6837H735 6837H743 M-Carcinoma, C-cell 6833F520 6833F530 M-Carcinoma, follicular cell 6831E422 6835G637 6837H710 6837H720 6837H735 Parathyroid ....................................Number examined: 45 33 30 46 Hyperplasia, diffuse 6837H701 Hyperplasia, focal 6837H740 6837H743 Aorta ..........................................Number examined: 50 34 30 50 N-Leukemia, mononuclear - invasive involvement 6831E427 Esophagus ......................................Number examined: 50 33 30 50 Larynx .........................................Number examined: 50 49 50 50 Hyperplasia, epithelial 6831E401 6833F501 6835G604 6837H701 6831E402 6833F504 6835G608 6837H702 6831E403 6833F508 6835G613 6837H703 6831E404 6833F511 6835G614 6837H704 6831E409 6833F513 6835G618 6837H705 6831E410 6833F517 6835G619 6837H706 6831E411 6833F518 6835G620 6837H707 6831E413 6833F520 6835G622 6837H708 6831E417 6833F525 6835G626 6837H709 6831E418 6833F527 6835G627 6837H713 6831E420 6833F531 6835G632 6837H714 6831E421 6833F538 6835G635 6837H722 6831E423 6833F546 6835G636 6837H723 6831E426 6833F547 6835G649 6837H724 6831E431 6833F548 6835G650 6837H730 6831E432 6837H734 6831E434 6837H738 6831E435 6837H740 6831E437 6837H741 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-23
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Larynx .........................................Number examined: 50 49 50 50 6831E438 6837H742 6831E444 6837H743 6831E446 6837H746 6831E447 6837H747 6831E448 6837H749 Salivary gland .................................Number examined: 50 34 30 50 M-Leukemia, mononuclear 6835G604 6837H750 6835G627 Mandibular LN ..................................Number examined: 40 32 30 48 Hyperplasia, lymphoid 6831E409 6835G635 N-Leukemia, mononuclear 6831E410 6833F501 6835G604 6837H708 6831E411 6833F506 6835G608 6837H709 6831E415 6833F515 6835G616 6837H712 6831E416 6833F517 6835G622 6837H722 6831E420 6833F532 6835G627 6837H723 6831E424 6833F534 6835G631 6837H724 6831E427 6833F537 6835G636 6837H725 6831E429 6833F540 6835G641 6837H733 6831E438 6833F545 6835G644 6837H740 6831E442 6833F546 6831E444 6831E446 6831E447 Liver ..........................................Number examined: 50 40 38 50 Hyperplasia, biliary 6831E401 6833F501 6835G604 6837H701 6831E402 6833F503 6835G605 6837H702 6831E403 6833F504 6835G606 6837H704 6831E405 6833F506 6835G607 6837H705 6831E406 6833F509 6835G608 6837H706 6831E407 6833F510 6835G611 6837H707 6831E409 6833F511 6835G612 6837H708 6831E410 6833F512 6835G614 6837H709 6831E411 6833F514 6835G615 6837H710 6831E412 6833F515 6835G616 6837H711 6831E413 6833F517 6835G618 6837H713 6831E414 6833F518 6835G619 6837H715 6831E415 6833F521 6835G620 6837H716 6831E416 6833F522 6835G622 6837H717 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-24
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 6831E417 6833F524 6835G623 6837H718 6831E418 6833F527 6835G624 6837H719 6831E419 6833F528 6835G625 6837H720 6831E420 6833F529 6835G626 6837H721 6831E421 6833F530 6835G627 6837H722 6831E422 6833F531 6835G629 6837H723 6831E423 6833F532 6835G631 6837H725 6831E424 6833F533 6835G632 6837H726 6831E425 6833F535 6835G633 6837H727 6831E426 6833F537 6835G634 6837H728 6831E427 6833F538 6835G635 6837H729 6831E428 6833F539 6835G636 6837H730 6831E429 6833F540 6835G637 6837H731 6831E430 6833F541 6835G639 6837H732 6831E431 6833F542 6835G640 6837H733 6831E432 6833F545 6835G641 6837H734 6831E433 6833F546 6835G642 6837H735 6831E434 6833F548 6835G643 6837H736 6831E436 6833F549 6835G644 6837H737 6831E437 6833F550 6835G645 6837H738 6831E438 6835G646 6837H739 6831E440 6835G647 6837H740 6831E441 6835G650 6837H741 6831E442 6837H742 6831E443 6837H743 6831E444 6837H744 6831E445 6837H745 6831E446 6837H746 6831E447 6837H747 6831E448 6837H748 6831E449 6837H749 6837H750 Hyperplasia, hepatocellular, regenerative 6831E423 6833F513 6835G606 6837H723 6833F541 6835G645 6837H724 6833F544 6835G649 B-Adenoma, hepatocellular 6831E415 6835G631 6837H747 M-Carcinoma, hepatocellular 6831E442 M-Sarcoma, histiocytic 6833F543 6837H712 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-25
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 M-Sarcoma, undifferentiated 6835G607 M-Leukemia, mononuclear 6831E401 6833F501 6835G604 6837H703 6831E402 6833F503 6835G605 6837H705 6831E403 6833F504 6835G606 6837H707 6831E405 6833F506 6835G608 6837H708 6831E409 6833F507 6835G611 6837H709 6831E410 6833F512 6835G612 6837H712 6831E411 6833F513 6835G615 6837H713 6831E415 6833F514 6835G616 6837H715 6831E416 6833F515 6835G618 6837H717 6831E419 6833F517 6835G619 6837H719 6831E420 6833F518 6835G620 6837H720 6831E421 6833F520 6835G622 6837H722 6831E423 6833F521 6835G624 6837H723 6831E424 6833F522 6835G625 6837H724 6831E426 6833F527 6835G626 6837H725 6831E427 6833F528 6835G627 6837H726 6831E429 6833F532 6835G629 6837H727 6831E432 6833F533 6835G631 6837H729 6831E438 6833F534 6835G632 6837H731 6831E441 6833F535 6835G633 6837H733 6831E442 6833F537 6835G634 6837H734 6831E444 6833F538 6835G636 6837H737 6831E445 6833F540 6835G637 6837H738 6831E446 6833F541 6835G640 6837H740 6831E447 6833F544 6835G641 6837H741 6831E448 6833F545 6835G642 6837H742 6831E450 6833F546 6835G644 6837H743 6833F548 6835G646 6837H744 6833F549 6835G649 6837H746 6837H748 6837H750 Spleen .........................................Number examined: 50 39 38 50 M-Fibrosarcoma 6837H736 M-Leukemia, mononuclear 6831E401 6833F501 6835G604 6837H703 6831E402 6833F503 6835G605 6837H705 6831E403 6833F504 6835G606 6837H707 6831E405 6833F506 6835G608 6837H708 6831E409 6833F507 6835G611 6837H709 6831E410 6833F512 6835G612 6837H712 6831E411 6833F513 6835G615 6837H713 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-26
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spleen .........................................Number examined: 50 39 38 50 6831E415 6833F514 6835G616 6837H715 6831E416 6833F515 6835G618 6837H717 6831E419 6833F516 6835G619 6837H719 6831E420 6833F517 6835G620 6837H720 6831E421 6833F518 6835G622 6837H722 6831E423 6833F520 6835G624 6837H723 6831E424 6833F521 6835G625 6837H724 6831E426 6833F522 6835G626 6837H725 6831E427 6833F526 6835G627 6837H726 6831E429 6833F527 6835G629 6837H727 6831E432 6833F528 6835G631 6837H729 6831E438 6833F532 6835G632 6837H731 6831E441 6833F533 6835G633 6837H733 6831E442 6833F534 6835G636 6837H734 6831E444 6833F535 6835G637 6837H737 6831E445 6833F537 6835G638 6837H738 6831E446 6833F538 6835G639 6837H740 6831E447 6833F540 6835G640 6837H741 6831E448 6833F541 6835G641 6837H742 6831E450 6833F544 6835G642 6837H743 6833F545 6835G644 6837H744 6833F546 6835G646 6837H746 6833F548 6835G648 6837H748 6833F549 6835G649 6837H750 N-Sarcoma, histiocytic 6837H712 Kidneys ........................................Number examined: 50 50 50 50 B-Adenoma, renal tubule 6835G604 6837H727 6835G605 6837H747 6835G608 6835G609 6835G633 6835G648 M-Carcinoma, renal tubule 6833F546 6837H724 M-Leukemia, mononuclear 6831E411 6833F532 6835G604 6837H725 6831E420 6833F533 6831E427 6833F534 6831E429 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-27
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Heart ..........................................Number examined: 50 34 30 50 M-Leukemia, mononuclear 6831E405 6833F504 6835G604 6837H708 6831E411 6833F507 6835G618 6837H722 6831E420 6833F517 6835G631 6837H724 6831E427 6833F532 6837H725 6833F534 6837H742 Stomach ........................................Number examined: 50 34 30 49 Hyperplasia, squamous epithelial 6831E417 6831E434 Cecum ..........................................Number examined: 50 34 30 48 N-Leukemia, mononuclear 6831E411 6831E427 Urinary bladder ................................Number examined: 50 33 29 50 B-Papilloma, transitional cell 6831E409 M-Leukemia, mononuclear 6831E427 6833F518 6837H708 Duodenum .......................................Number examined: 50 34 30 49 Jejunum ........................................Number examined: 50 34 30 48 M-Adenocarcinoma 6831E412 6831E428 Ileum ..........................................Number examined: 50 34 30 49 Hyperplasia, lymphoid 6831E425 6831E439 B-Fibroma 6831E428 N-Leukemia, mononuclear 6833F515 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-28
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Colon ..........................................Number examined: 50 34 30 49 B-Leiomyoma 6837H706 Pancreas .......................................Number examined: 50 34 30 49 M-Carcinoma, ductal cell 6837H712 M-Leukemia, mononuclear 6831E427 Rectum .........................................Number examined: 50 34 30 50 Adrenal glands .................................Number examined: 49 35 30 50 Hyperplasia, cortical, diffuse 6835G625 Hyperplasia, medullary, focal 6831E403 6833F517 6835G608 6837H703 6831E407 6833F520 6835G616 6837H705 6831E413 6835G620 6837H708 6831E419 6835G631 6837H713 6831E429 6835G633 6837H714 6831E432 6837H715 6831E446 6837H717 6831E449 6837H718 6837H720 6837H724 6837H727 6837H729 6837H734 6837H738 6837H739 6837H744 6837H745 B-Pheochromocytoma, benign 6831E401 6833F504 6835G619 6837H708 6831E416 6833F520 6835G622 6837H714 6831E426 6833F544 6835G627 6837H717 6831E429 6833F546 6835G642 6837H734 6831E442 6835G646 6837H737 6831E443 6837H741 6831E444 6837H747 B-Pheochromocytoma, complex, benign 6831E424 6833F525 M-Pheochromocytoma, malignant 6831E416 6837H746 6831E440 6831E442 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-29
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Adrenal glands .................................Number examined: 49 35 30 50 M-Leukemia, mononuclear 6831E405 6833F538 6835G611 6837H722 6831E411 6835G618 6837H725 6831E447 6835G632 6835G636 Prostate .......................................Number examined: 50 33 29 50 Hyperplasia 6835G624 Epididymis .....................................Number examined: 50 36 31 50 M-Mesothelioma, malignant 6833F509 6837H703 6837H736 Seminal vesicle ................................Number examined: 50 35 37 50 Hyperplasia 6833F536 M-Leukemia, mononuclear 6831E427 6835G604 Mesenteric LN ..................................Number examined: 50 34 30 50 N-Sarcoma, histiocytic 6833F543 N-Leukemia, mononuclear 6831E410 6833F506 6835G604 6837H720 6831E411 6833F515 6835G606 6837H722 6831E420 6833F533 6835G631 6837H723 6831E424 6835G636 6837H725 6831E446 6835G644 6837H740 6831E447 6837H742 Testes .........................................Number examined: 50 50 50 50 Hyperplasia, interstitial cell 6831E417 6833F512 6835G611 6837H718 6831E427 6833F514 6835G644 6837H744 6831E431 6833F530 6835G650 6831E439 6833F532 6831E444 6833F538 6833F540 B-Adenoma, interstitial cell 6831E401 6833F501 6835G601 6837H701 6831E402 6833F502 6835G602 6837H702 6831E403 6833F503 6835G603 6837H703 6831E404 6833F504 6835G604 6837H704 6831E405 6833F505 6835G605 6837H705 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-30
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Testes .........................................Number examined: 50 50 50 50 6831E406 6833F506 6835G606 6837H706 6831E407 6833F507 6835G607 6837H707 6831E410 6833F508 6835G608 6837H708 6831E411 6833F509 6835G609 6837H709 6831E412 6833F510 6835G610 6837H710 6831E413 6833F511 6835G612 6837H711 6831E414 6833F513 6835G613 6837H712 6831E415 6833F514 6835G614 6837H713 6831E416 6833F515 6835G615 6837H714 6831E418 6833F516 6835G616 6837H715 6831E419 6833F517 6835G617 6837H716 6831E420 6833F518 6835G618 6837H717 6831E421 6833F519 6835G619 6837H718 6831E422 6833F520 6835G620 6837H719 6831E423 6833F521 6835G621 6837H720 6831E424 6833F522 6835G622 6837H721 6831E425 6833F523 6835G623 6837H722 6831E426 6833F524 6835G624 6837H723 6831E428 6833F525 6835G625 6837H724 6831E429 6833F526 6835G626 6837H725 6831E430 6833F527 6835G627 6837H726 6831E432 6833F528 6835G628 6837H727 6831E433 6833F529 6835G629 6837H728 6831E435 6833F531 6835G630 6837H729 6831E436 6833F532 6835G631 6837H730 6831E437 6833F533 6835G632 6837H731 6831E438 6833F534 6835G633 6837H732 6831E440 6833F535 6835G634 6837H733 6831E441 6833F536 6835G635 6837H734 6831E442 6833F537 6835G636 6837H735 6831E443 6833F538 6835G637 6837H736 6831E444 6833F539 6835G638 6837H737 6831E445 6833F541 6835G639 6837H738 6831E446 6833F542 6835G640 6837H739 6831E447 6833F543 6835G641 6837H740 6831E448 6833F544 6835G642 6837H741 6831E449 6833F545 6835G643 6837H742 6831E450 6833F546 6835G644 6837H743 6833F547 6835G645 6837H744 6833F548 6835G646 6837H745 6833F549 6835G647 6837H746 6833F550 6835G648 6837H747 6835G649 6837H748 6837H749 6837H750 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-31
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Testes .........................................Number examined: 50 50 50 50 M-Mesothelioma, malignant 6833F509 6835G614 6837H703 6837H736 Sciatic nerve ..................................Number examined: 50 34 30 50 N-Leukemia, mononuclear 6831E429 Muscle, skeletal ...............................Number examined: 50 34 30 50 N-Sarcoma, histiocytic 6833F518 6833F543 M-Leukemia, mononuclear 6835G604 Mammary gland ..................................Number examined: 36 31 29 47 Hyperplasia, lobular 6833F520 6837H706 6837H714 6837H718 6837H735 6837H749 B-Fibroadenoma 6837H718 B-Fibroma 6831E404 6833F529 6835G633 6837H704 6831E435 6833F548 6835G643 6835G649 N-Sarcoma, histiocytic 6833F518 6833F543 Skin ...........................................Number examined: 49 37 35 50 B-Fibroma 6831E439 6835G617 6831E440 B-Keratoacanthoma 6837H714 B-Tumor, basal cell, benign 6837H710 B-Tumor, hair follicle, benign 6835G607 M-Carcinoma, sebaceous cell 6833F502 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-32
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 13 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Skin ...........................................Number examined: 49 37 35 50 M-Sarcoma, undifferentiated 6833F511 6835G614 6835G623 N-Sarcoma, histiocytic 6833F518 6833F543 Brain ..........................................Number examined: 50 34 31 50 M-Astrocytoma, malignant 6833F518 6837H711 Eyes/optic nerve ...............................Number examined: 50 34 33 50 M-Leukemia, mononuclear 6831E420 6833F515 Bone, femur ....................................Number examined: 50 50 50 50 Spinal cord ....................................Number examined: 50 34 30 50 Nose/Turbinate 1 ...............................Number examined: 50 50 50 50 Hyperplasia - respiratory epithelium 6831E408 6835G614 6837H701 6831E414 6835G638 6837H719 6831E433 6835G644 6837H721 6837H737 M-Leukemia, mononuclear 6831E420 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Hyperplasia - respiratory epithelium 6833F517 6835G622 6837H719 6833F533 6835G638 6837H721 6837H746 M-Carcinoma, squamous cell 6831E406 M-Leukemia, mononuclear 6831E420 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 M-Carcinoma, squamous cell 6833F539 6837H730 M-Leukemia, mononuclear 6831E420 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-33
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 14 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 N-Carcinoma, squamous cell 6833F510 6837H730 6833F539 6837H745 M-Leukemia, mononuclear 6831E420 Preputial gland ................................Number examined: 4 1 3 2 Pancreatic LN ..................................Number examined: 5 2 2 4 N-Leukemia, mononuclear 6831E411 6833F501 6835G604 6837H709 6831E416 6833F533 6835G631 6837H722 6831E424 6837H742 6831E442 6837H750 6831E447 Iliac LN .......................................Number examined: 3 1 4 2 N-Leukemia, mononuclear 6831E411 6833F501 6835G629 6837H709 6831E420 6835G636 6837H733 6831E442 6835G644 Lymph node other ...............................Number examined: 6 4 9 7 N-Leukemia, mononuclear 6831E416 6833F501 6835G604 6837H705 6831E420 6833F515 6835G619 6837H707 6831E427 6835G620 6837H709 6831E429 6835G625 6837H723 6831E442 6835G629 6837H727 6835G636 6837H733 6835G644 Mediastinal LN .................................Number examined: 49 30 30 50 N-Sarcoma, histiocytic 6833F543 N-Leukemia, mononuclear 6831E410 6833F501 6835G604 6837H705 6831E411 6833F515 6835G616 6837H707 6831E420 6833F518 6835G631 6837H708 6831E427 6833F532 6835G636 6837H709 6831E429 6833F533 6835G644 6837H722 6831E442 6833F534 6837H723 6831E444 6833F545 6837H725 6831E446 6837H750 6831E447 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-34
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 15 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pituitary gland ................................Number examined: 49 37 34 50 Hyperplasia, pars distalis, focal 6831E401 6833F509 6835G637 6837H705 6831E405 6833F514 6835G641 6837H712 6831E410 6833F516 6835G646 6837H714 6831E417 6833F539 6837H716 6831E427 6837H718 6837H719 6837H745 6837H746 B-Adenoma, pars distalis 6831E407 6833F504 6835G625 6837H704 6831E409 6833F511 6835G634 6837H711 6831E414 6833F516 6835G636 6837H713 6831E417 6833F520 6835G644 6837H716 6831E425 6833F530 6835G647 6837H735 6831E430 6833F531 6835G650 6831E434 6833F546 6831E435 6833F547 6831E441 6833F549 M-Leukemia, mononuclear 6831E427 6833F503 6835G604 6837H725 Tiss.not specifi ...............................Number examined: 1 2 3 5 B-Fibroma 6835G602 B-Lipoma 6831E406 6837H728 M-Mesothelioma, malignant 6837H703 6837H736 N-Sarcoma, histiocytic 6833F543 Harderian gland ................................Number examined: 1 0 0 0 N-Carcinoma, squamous cell 6831E406 Thymus .........................................Number examined: 1 0 0 2 M-Leukemia, mononuclear 6831E427 6837H723 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-35
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 16 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mediastinum ....................................Number examined: 1 0 0 0 N-Leukemia, mononuclear 6831E427 Tail ...........................................Number examined: 1 2 1 0 Hyperplasia/hyperkeratosis 6833F505 6835G602 6833F521 Popliteal LN ...................................Number examined: 2 0 2 2 N-Leukemia, mononuclear 6831E420 6835G604 6837H707 6831E442 6835G636 6837H733 Bone, other ....................................Number examined: 0 1 0 1 M-Sarcoma, NOS 6837H721 Zymbal’s gland .................................Number examined: 0 0 0 1 M-Carcinoma, squamous cell 6837H716 Mesentery ......................................Number examined: 0 1 1 0 M-Mesothelioma, malignant 6835G614 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-36
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Non-neoplastic Lesions 

M-37
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Alveolar histiocytosis 6831E415 6833F504 6835G602 6837H701 6831E417 6833F509 6835G603 6837H706 6831E420 6833F513 6835G609 6837H709 6831E428 6833F525 6835G616 6837H717 6831E433 6833F531 6835G622 6837H722 6831E440 6833F539 6835G629 6837H728 6831E449 6833F540 6835G632 6837H730 6833F547 6835G633 6837H737 6833F548 6835G646 6837H740 6833F550 6835G649 6837H741 6837H747 Autolysis, marked 6837H732 Congestion 6833F524 6833F541 Fibrosis, focal 6831E429 6837H724 Hemorrhage 6831E402 6833F515 6835G607 6837H740 6831E403 6833F521 6835G610 6831E440 6833F523 6835G611 6833F535 6835G616 6833F544 6835G624 6833F545 6835G644 6833F550 6835G646 Metaplasia, squamous - alveolar epithelium 6833F525 6833F536 Mineralization, uremic 6837H701 Cyst, squamous cell, keratinizing 6837H732 Inflammation, acute 6831E414 6835G636 6837H745 Inflammation, mixed 6831E430 6833F520 6835G602 6837H710 6835G607 6837H711 6835G609 6835G633 6835G637 Inflammation, granulomatous 6833F507 6835G634 6837H749 6833F525 6835G635 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-38
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Trachea ........................................Number examined: 50 49 50 50 Metaplasia, squamous 6831E414 Inflammation, acute 6833F508 Inflammation, mixed 6831E430 6833F520 6837H701 6837H703 6837H710 6837H740 Inflammation, chronic 6831E439 6833F539 6835G617 6837H717 6833F541 Bronchial (TBLN) ...............................Number examined: 49 33 28 47 Hemorrhage 6833F536 6837H714 6833F548 6837H728 6833F549 Thyroid glands .................................Number examined: 50 35 31 50 Cyst, follicular 6831E407 6833F528 6835G608 6837H721 6835G633 6837H725 6835G637 6837H741 Parathyroid ....................................Number examined: 45 33 30 46 Aorta ..........................................Number examined: 50 34 30 50 Dilatation 6837H701 Esophagus ......................................Number examined: 50 33 30 50 Larynx .........................................Number examined: 50 49 50 50 Ulceration 6831E432 Inflammation, mixed 6831E401 6833F501 6835G601 6837H701 6831E402 6833F502 6835G602 6837H702 6831E403 6833F503 6835G603 6837H703 6831E404 6833F504 6835G604 6837H704 6831E405 6833F505 6835G605 6837H705 6831E407 6833F507 6835G606 6837H706 6831E408 6833F508 6835G607 6837H707 6831E409 6833F510 6835G608 6837H708 6831E410 6833F511 6835G609 6837H709 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-39
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Larynx .........................................Number examined: 50 49 50 50 6831E411 6833F513 6835G610 6837H710 6831E413 6833F514 6835G612 6837H711 6831E414 6833F515 6835G613 6837H712 6831E415 6833F516 6835G614 6837H713 6831E416 6833F517 6835G615 6837H714 6831E417 6833F518 6835G616 6837H715 6831E418 6833F520 6835G618 6837H716 6831E419 6833F521 6835G619 6837H717 6831E420 6833F522 6835G620 6837H719 6831E421 6833F523 6835G621 6837H720 6831E423 6833F524 6835G622 6837H721 6831E424 6833F525 6835G623 6837H722 6831E426 6833F527 6835G624 6837H723 6831E427 6833F528 6835G625 6837H724 6831E430 6833F533 6835G626 6837H725 6831E431 6833F534 6835G627 6837H726 6831E432 6833F535 6835G628 6837H727 6831E433 6833F538 6835G629 6837H728 6831E435 6833F539 6835G630 6837H729 6831E436 6833F541 6835G631 6837H730 6831E437 6833F543 6835G632 6837H732 6831E438 6833F544 6835G634 6837H733 6831E440 6833F546 6835G635 6837H734 6831E442 6833F547 6835G636 6837H736 6831E443 6833F548 6835G637 6837H737 6831E444 6833F550 6835G638 6837H738 6831E445 6835G639 6837H739 6831E446 6835G640 6837H740 6831E447 6835G645 6837H741 6831E448 6835G647 6837H742 6831E449 6835G648 6837H743 6835G649 6837H745 6837H746 6837H747 6837H749 Inflammation, chronic 6831E412 6833F506 6835G641 6837H718 6831E422 6833F531 6835G642 6837H731 6831E429 6835G646 6837H748 6831E434 6835G650 Metaplasia, squamous 6831E407 6833F523 6835G602 6837H704 6831E414 6833F533 6835G625 6837H710 6831E419 6833F535 6835G628 6837H717 6831E427 6835G631 6837H721 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-40
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Larynx .........................................Number examined: 50 49 50 50 6831E428 6835G645 6837H726 6831E430 6835G648 6837H739 6831E432 6831E442 Salivary gland .................................Number examined: 50 34 30 50 Degeneration 6837H715 Inflamation, acute 6837H701 Mandibular LN ..................................Number examined: 40 32 30 48 Hemorrhage 6831E422 Sinus plasmacytosis 6831E407 Liver ..........................................Number examined: 50 40 38 50 Angiectasis 6831E402 6833F509 6835G605 6837H701 6831E409 6833F535 6835G608 6837H704 6831E411 6833F548 6835G620 6837H706 6831E416 6833F550 6835G622 6837H710 6831E419 6835G625 6837H713 6831E424 6835G626 6837H717 6831E426 6835G627 6837H722 6831E432 6835G631 6837H723 6831E436 6837H724 6831E438 6837H725 6831E442 6837H726 6831E445 6837H728 6831E446 6837H733 6831E447 6837H734 6831E449 6837H740 6837H741 6837H742 6837H748 Congestion 6837H732 Cyst 6835G618 Fatty Change 6831E434 6833F511 6835G634 6831E435 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-41
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 Foci of cellular alteration, basophilic 6831E437 6833F529 Hepatodiaphragmatic nodule 6831E418 6833F520 6835G614 6837H703 6837H745 Necrosis 6831E403 6833F512 6835G608 6837H723 6831E414 6833F530 6835G619 6837H727 6831E415 6833F538 6837H740 6833F546 6837H743 Thrombus 6837H750 Vaculolization, cytoplasmic 6831E427 6833F514 6835G649 6837H704 6833F530 6837H726 6833F540 6837H730 Inflammation, chronic 6831E404 6833F548 6837H717 6831E407 6837H726 6831E417 6837H728 6831E428 6837H730 6831E430 6837H736 6831E433 6837H749 6831E440 Spleen .........................................Number examined: 50 39 38 50 Congestion 6833F514 6835G617 Fibrosis 6831E410 6833F517 6835G605 6831E425 6833F546 6835G615 6831E432 6835G630 6835G638 6835G640 Hemorrhage 6833F538 Necrosis 6831E403 6833F521 6835G615 6837H720 6831E426 6833F528 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-42
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 50 50 50 Cyst 6833F528 6835G605 6835G634 Degeneration, hyaline droplet 6833F543 Infarct 6835G611 6835G627 Nephropathy, chronic 6831E401 6833F501 6835G601 6837H701 6831E402 6833F502 6835G602 6837H702 6831E403 6833F503 6835G603 6837H703 6831E404 6833F504 6835G604 6837H704 6831E405 6833F505 6835G605 6837H705 6831E406 6833F506 6835G606 6837H706 6831E407 6833F507 6835G607 6837H707 6831E409 6833F508 6835G608 6837H708 6831E410 6833F509 6835G609 6837H709 6831E411 6833F510 6835G610 6837H710 6831E412 6833F511 6835G611 6837H711 6831E413 6833F512 6835G612 6837H712 6831E415 6833F513 6835G613 6837H713 6831E416 6833F514 6835G614 6837H714 6831E417 6833F515 6835G615 6837H716 6831E418 6833F516 6835G616 6837H718 6831E419 6833F517 6835G617 6837H719 6831E420 6833F518 6835G618 6837H720 6831E421 6833F519 6835G619 6837H721 6831E422 6833F520 6835G620 6837H722 6831E424 6833F521 6835G621 6837H723 6831E425 6833F522 6835G622 6837H724 6831E426 6833F523 6835G623 6837H725 6831E428 6833F525 6835G624 6837H726 6831E429 6833F526 6835G625 6837H727 6831E432 6833F527 6835G626 6837H728 6831E433 6833F528 6835G627 6837H729 6831E434 6833F530 6835G628 6837H731 6831E435 6833F531 6835G629 6837H732 6831E436 6833F532 6835G630 6837H733 6831E437 6833F533 6835G631 6837H734 6831E438 6833F534 6835G632 6837H735 6831E439 6833F535 6835G633 6837H736 6831E440 6833F536 6835G634 6837H738 6831E441 6833F537 6835G635 6837H739 6831E442 6833F538 6835G636 6837H740 6831E443 6833F539 6835G637 6837H741 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-43
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 50 50 50 6831E444 6833F541 6835G638 6837H742 6831E445 6833F542 6835G639 6837H743 6831E446 6833F543 6835G640 6837H744 6831E447 6833F544 6835G641 6837H745 6831E448 6833F545 6835G642 6837H746 6831E449 6833F546 6835G643 6837H747 6831E450 6833F547 6835G644 6837H748 6833F548 6835G645 6837H749 6833F549 6835G646 6837H750 6833F550 6835G647 6835G648 6835G649 6835G650 Pigment accumulation, tubular epithelium 6831E403 6833F506 6835G646 6837H703 6831E426 6833F509 6837H719 6831E438 6833F540 6837H746 Inflamation, acute 6833F539 6835G625 6835G636 Heart ..........................................Number examined: 50 34 30 50 Degeneration, myocyte 6831E420 6833F546 6835G608 6837H701 6831E432 6835G616 6837H706 6835G624 6837H733 Fibrosis 6831E407 6833F517 6835G625 6837H701 6831E414 6833F518 6835G642 6837H709 6831E421 6833F522 6837H717 6831E437 6833F538 6837H742 6831E442 6833F541 Thrombus 6833F530 6835G608 6837H731 6835G625 6837H746 Inflamation, acute 6835G636 Inflammation, focal, chronic 6831E401 6833F509 6835G606 6837H701 6831E404 6833F520 6835G622 6837H702 6831E408 6833F522 6835G626 6837H704 6831E410 6833F527 6835G627 6837H705 6831E413 6833F529 6835G632 6837H714 6831E416 6833F530 6835G633 6837H715 6831E418 6833F531 6835G641 6837H716 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-44
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Heart ..........................................Number examined: 50 34 30 50 6831E421 6833F544 6835G643 6837H719 6831E423 6833F545 6835G644 6837H721 6831E424 6835G645 6837H726 6831E425 6837H728 6831E428 6837H729 6831E431 6837H730 6831E438 6837H731 6831E439 6837H741 6831E441 6837H747 6831E444 6837H748 6831E448 6837H749 6831E450 6837H750 Stomach ........................................Number examined: 50 34 30 49 Inflammation, mixed 6831E417 6833F539 6831E434 Cecum ..........................................Number examined: 50 34 30 48 Urinary bladder ................................Number examined: 50 33 29 50 Hemorrhage 6837H718 Inflammation, mixed 6837H725 Inflammation, chronic 6831E404 6837H704 6831E447 6837H739 6831E449 6837H741 Duodenum .......................................Number examined: 50 34 30 49 Jejunum ........................................Number examined: 50 34 30 48 Ileum ..........................................Number examined: 50 34 30 49 Colon ..........................................Number examined: 50 34 30 49 Inflammation, mixed 6831E450 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-45
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pancreas .......................................Number examined: 50 34 30 49 Rectum .........................................Number examined: 50 34 30 50 Adrenal glands .................................Number examined: 49 35 30 50 Cyst 6837H718 Degeneration, cytoplasmic vacuolization 6831E409 6833F507 6835G619 6837H704 6831E415 6833F534 6835G625 6837H724 6831E418 6837H726 6831E435 6837H737 6831E436 Necrosis 6835G611 6837H725 Thrombus 6831E426 6833F537 6835G612 6837H707 6831E445 6833F544 6835G629 6837H718 6835G636 6837H734 6837H741 6837H743 Prostate .......................................Number examined: 50 33 29 50 Atrophy 6831E419 6837H705 6831E436 6837H708 6831E440 6837H722 6837H726 6837H729 Hemorrhage 6837H718 Mineralization 6831E445 Inflamation, acute 6831E402 6833F540 6831E406 Inflammation, mixed 6831E407 6833F504 6835G608 6837H701 6831E410 6833F512 6835G611 6837H702 6831E415 6833F520 6835G616 6837H703 6831E417 6833F522 6835G618 6837H704 6831E421 6833F530 6835G619 6837H705 6831E427 6833F531 6835G625 6837H711 6831E430 6833F533 6835G626 6837H713 6831E431 6833F538 6835G627 6837H718 6831E434 6833F539 6835G632 6837H719 6831E435 6833F545 6835G636 6837H725 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-46
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Prostate .......................................Number examined: 50 33 29 50 6831E437 6833F546 6835G640 6837H727 6831E442 6833F549 6835G641 6837H735 6831E443 6835G642 6837H738 6831E444 6835G643 6831E447 6835G645 6835G650 Epididymis .....................................Number examined: 50 36 31 50 Atrophy 6831E413 6833F506 6835G630 6837H705 6831E419 6833F525 6837H722 6831E436 6833F531 6837H726 6831E440 6833F539 6837H728 6833F550 6837H729 6837H735 6837H740 Granuloma, sperm 6833F537 Inflammation, chronic 6831E433 6835G642 6831E442 Seminal vesicle ................................Number examined: 50 35 37 50 Atrophy 6831E413 6833F516 6835G603 6837H705 6831E414 6833F527 6835G605 6837H708 6831E415 6835G607 6837H710 6831E418 6835G610 6837H717 6831E419 6835G615 6837H722 6831E420 6835G617 6837H724 6831E422 6835G621 6837H725 6831E426 6835G643 6837H726 6831E427 6837H728 6831E436 6837H729 6831E439 6837H733 6831E440 6837H734 6831E442 6837H735 6831E443 6837H736 6831E446 6837H741 6837H743 6837H747 6837H748 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-47
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Seminal vesicle ................................Number examined: 50 35 37 50 Dilatation 6833F536 6835G648 6837H718 Mesenteric LN ..................................Number examined: 50 34 30 50 Hemorrhage 6831E437 Histiocytosis, sinus 6831E428 Testes .........................................Number examined: 50 50 50 50 Atrophy 6831E446 6833F513 6835G604 6837H718 6833F519 6835G616 6837H723 6833F531 6835G642 6837H727 6833F538 6837H737 6837H742 Hemorrhage 6833F508 6837H716 Sciatic nerve ..................................Number examined: 50 34 30 50 Muscle, skeletal ...............................Number examined: 50 34 30 50 Inflammation, chronic 6835G623 Mammary gland ..................................Number examined: 36 31 29 47 Cyst 6835G631 Ectasia 6831E414 6837H711 Skin ...........................................Number examined: 49 37 35 50 Cyst, epithelial inclusion 6837H740 Fibrosis 6831E435 6833F510 6833F519 Hyperkeratosis 6831E438 6833F519 6835G615 6835G631 Necrosis 6833F518 Inflammation, mixed 6833F510 6835G605 6833F519 6835G635 6833F546 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-48
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Skin ...........................................Number examined: 49 37 35 50 Inflammation, chronic 6831E437 Brain ..........................................Number examined: 50 34 31 50 Compression 6831E409 6833F531 6835G647 6837H704 6831E414 6833F546 6835G650 6837H711 6831E417 6837H713 6831E427 6837H735 6831E434 6831E435 Ectasia, ventricular system 6831E427 6831E434 Edema 6837H720 Gliosis 6831E431 Hemorrhage 6831E403 6835G611 6835G625 Mineralization 6837H724 Necrosis 6837H733 Inflamation, acute 6835G625 6835G636 Inflammation, chronic 6831E431 Eyes/optic nerve ...............................Number examined: 50 34 33 50 Atrophy 6831E430 Atrophy, retinal, unilateral 6831E445 6835G601 6837H725 6835G645 6835G648 Cataract 6831E445 6835G601 6837H725 6835G645 6835G648 Degeneration 6831E430 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-49
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 13 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Eyes/optic nerve ...............................Number examined: 50 34 33 50 Metaplasia, osseous, scleral 6831E403 6831E412 6831E436 Mineralization, corneal stromal 6831E402 6835G636 6837H747 6831E422 6835G648 6831E448 Mineralization, scleral 6831E405 6833F522 6835G618 6837H725 6831E424 6835G620 6837H730 6831E429 6835G622 6837H738 6835G641 6837H750 6835G646 6835G650 Neovascularization, corneal 6831E415 6835G645 6831E422 6835G648 6831E448 Inflamation, acute 6835G636 6837H718 Inflammation, mixed 6831E422 6833F510 6833F539 Inflammation, chronic 6835G635 Bone, femur ....................................Number examined: 50 50 50 50 New bone formation, endosteal 6831E402 6833F534 6837H743 Inflamation, acute 6837H743 Spinal cord ....................................Number examined: 50 34 30 50 Degeneration, white matter 6831E427 Hemorrhage 6831E403 6835G611 Inflamation, acute 6835G636 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-50
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 14 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 1 ...............................Number examined: 50 50 50 50 Degeneration - respiratory epithelium 6831E433 Degeneration, hyaline - respiratory epithelium 6833F532 6835G615 6837H707 6833F534 6835G617 6837H710 6833F549 6835G622 6837H748 6835G625 6835G641 Metaplasia, squamous - respiratory epithelium 6831E427 6833F521 6835G638 6831E444 6833F531 6831E446 Metaplasia, squamous - transitional epithelium 6831E418 Inflammation, mixed 6831E406 6833F504 6835G610 6837H707 6831E412 6833F521 6835G622 6837H718 6831E414 6833F531 6835G629 6837H719 6831E427 6833F539 6835G635 6837H721 6831E430 6833F541 6835G636 6837H737 6831E432 6835G638 6837H741 6831E446 6835G647 6835G649 Inflammation - nasolacrimal duct 6831E407 6833F502 6835G602 6837H707 6831E410 6833F504 6835G609 6837H718 6831E416 6833F510 6835G610 6837H721 6831E422 6833F514 6835G611 6837H723 6831E424 6833F521 6835G612 6837H728 6831E431 6833F527 6835G615 6837H729 6831E433 6833F531 6835G622 6837H731 6831E440 6833F539 6835G625 6837H741 6831E443 6833F542 6835G629 6837H744 6831E444 6833F546 6835G631 6837H746 6831E449 6833F547 6835G635 6837H748 6835G637 6837H749 6835G641 6835G643 6835G644 Inflammation - respiratory epithelium 6831E444 6837H701 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-51
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 15 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 6831E433 Degeneration, hyaline - olfactory epithelium 6833F512 6835G606 6837H712 6833F517 6835G615 6837H730 6833F531 6835G617 6837H736 6833F532 6835G622 6837H741 6833F534 6835G625 6837H748 6835G629 6837H750 6835G630 Degeneration - respiratory epithelium 6835G610 Degeneration, hyaline - respiratory epithelium 6833F549 6835G617 6837H710 6835G625 6837H741 6837H745 Metaplasia, secretory - olfactory epithelium 6833F531 Metaplasia, squamous - olfactory epithelium 6833F542 Metaplasia, squamous - respiratory epithelium 6835G638 Inflammation, mixed 6831E414 6833F517 6835G610 6837H701 6831E430 6833F518 6835G622 6837H719 6831E442 6833F531 6835G638 6837H721 6831E446 6833F540 6837H736 6833F542 6837H746 6833F546 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 6831E402 6833F534 6835G610 6837H710 6831E405 6835G617 6837H714 6835G621 6837H721 6835G625 6837H726 6835G629 6837H741 6835G641 6837H745 6835G642 6837H748 Inflammation, mixed 6831E414 6833F539 6835G638 6837H701 6831E430 6837H736 6831E435 6837H747 6831E446 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-52
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 16 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 6835G638 Degeneration, hyaline - olfactory epithelium 6835G617 6837H741 Inflammation, mixed 6831E414 6835G638 6837H701 6831E430 6837H747 Preputial gland ................................Number examined: 4 1 3 2 Cyst, epithelial inclusion 6835G608 Ectasia 6831E410 6833F513 6835G605 6837H736 6831E443 6835G621 6837H747 Inflammation, chronic 6831E422 6837H747 Inflammation, mixed 6831E410 6837H736 6831E418 6831E443 Pancreatic LN ..................................Number examined: 5 2 2 4 Iliac LN .......................................Number examined: 3 1 4 2 Dilatation, sinusoidal 6835G641 Lymph node other ...............................Number examined: 6 4 9 7 Dilatation, sinusoidal 6833F531 Infiltration, histiocytic 6833F525 6835G602 Sinus plasmacytosis 6831E435 6837H713 Mediastinal LN .................................Number examined: 49 30 30 50 Hemorrhage 6831E412 6833F548 6835G602 6837H726 6831E438 6835G620 6837H728 Pigmentation 6833F509 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-53
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 17 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pituitary gland ................................Number examined: 49 37 34 50 Angiectasis 6831E404 6837H711 6831E406 6837H740 6837H746 Cyst 6831E419 6833F512 6835G616 6837H707 6831E426 6833F515 6835G620 6837H709 6831E437 6833F517 6835G622 6837H724 6831E447 6833F534 6835G627 6837H738 6833F537 6835G638 6837H739 6833F538 6835G641 6837H742 6833F544 6835G645 Hemorrhage 6831E403 6837H714 6831E419 6837H742 6831E438 Inflammation, chronic 6837H750 Tiss.not specifi ...............................Number examined: 1 2 3 5 Cyst 6837H718 Mammary tissue 6835G625 Myodegeneration 6833F546 Inflammation, mixed 6835G636 Splenic tissue, "accessory" 6837H742 Harderian gland ................................Number examined: 1 0 0 0 Thymus .........................................Number examined: 1 0 0 2 Hemorrhage 6837H712 Mediastinum ....................................Number examined: 1 0 0 0 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-54
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 18 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Tail ...........................................Number examined: 1 2 1 0 Cyst, epithelial inclusion 6833F505 Inflammation, acute 6831E436 Inflammation, mixed 6833F505 6835G602 6833F521 Popliteal LN ...................................Number examined: 2 0 2 2 Bone, other ....................................Number examined: 0 1 0 1 Hyperostosis 6833F543 Zymbal’s gland .................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 0 1 1 0 Inflammation, mixed 6833F505 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-55
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-3 Incidence Summary (with percentages) of Microscopic Observations 

M-56
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Proliferative (including Neoplastic) Lesions 

M-57
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Hyperplasia, alveolar epithelial, focal 8 7 2 4 16% 14% 4% 8% Hyperplasia, alveolar epithelial, widespread 1 1 0 0 2% 2% 0% 0% B-Adenoma, bronchiolo-alveolar 1 0 1 0 2% 0% 2% 0% N-Sarcoma, histiocytic 0 2 0 0 0% 4% 0% 0% N-Leukemia, mononuclear - capillary involvement 24 31 32 25 48% 62% 64% 50% N-Leukemia, mononuclear - invasive involvement 1 1 1 1 2% 2% 2% 2% Trachea ........................................Number examined: 50 49 50 50 Hyperplasia, epithelial 1 1 0 0 2% 2% 0% 0% N-Leukemia, mononuclear 2 0 1 0 4% 0% 2% 0% Bronchial (TBLN) ...............................Number examined: 49 33 28 47 N-Sarcoma, histiocytic 0 1 0 0 0% 3% 0% 0% N-Leukemia, mononuclear 10 9 7 7 20% 27% 25% 15% Thyroid glands .................................Number examined: 50 35 31 50 Hyperplasia, C-cell, focal 4 2 0 7 8% 6% 0% 14% Hyperplasia, follicular cell 0 0 1 0 0% 0% 3% 0% B-Adenoma, C-cell 3 4 4 3 6% 11% 13% 6% B-Adenoma, follicular cell 2 0 0 3 4% 0% 0% 6% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-58
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thyroid glands .................................Number examined: 50 35 31 50 M-Carcinoma, C-cell 0 2 0 0 0% 6% 0% 0% M-Carcinoma, follicular cell 1 0 1 3 2% 0% 3% 6% Parathyroid ....................................Number examined: 45 33 30 46 Hyperplasia, diffuse 0 0 0 1 0% 0% 0% 2% Hyperplasia, focal 0 0 0 2 0% 0% 0% 4% Aorta ..........................................Number examined: 50 34 30 50 N-Leukemia, mononuclear - invasive involvement 1 0 0 0 2% 0% 0% 0% Esophagus ......................................Number examined: 50 33 30 50 Larynx .........................................Number examined: 50 49 50 50 Hyperplasia, epithelial 24 15 15 24 48% 31% 30% 48% Salivary gland .................................Number examined: 50 34 30 50 M-Leukemia, mononuclear 0 0 2 1 0% 0% 7% 2% Mandibular LN ..................................Number examined: 40 32 30 48 Hyperplasia, lymphoid 1 0 1 0 3% 0% 3% 0% N-Leukemia, mononuclear 13 10 9 9 33% 31% 30% 19% Liver ..........................................Number examined: 50 40 38 50 Hyperplasia, biliary 45 34 37 46 90% 85% 97% 92% Hyperplasia, hepatocellular, regenerative 1 3 3 2 2% 8% 8% 4% B-Adenoma, hepatocellular 1 0 1 1 2% 0% 3% 2% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-59
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 M-Carcinoma, hepatocellular 1 0 0 0 2% 0% 0% 0% M-Sarcoma, histiocytic 0 1 0 1 0% 3% 0% 2% M-Sarcoma, undifferentiated 0 0 1 0 0% 0% 3% 0% M-Leukemia, mononuclear 27 29 29 31 54% 73% 76% 62% Spleen .........................................Number examined: 50 39 38 50 M-Fibrosarcoma 0 0 0 1 0% 0% 0% 2% M-Leukemia, mononuclear 27 31 31 31 54% 79% 82% 62% N-Sarcoma, histiocytic 0 0 0 1 0% 0% 0% 2% Kidneys ........................................Number examined: 50 50 50 50 B-Adenoma, renal tubule 0 0 6 2 0% 0% 12% 4% M-Carcinoma, renal tubule 0 1 0 1 0% 2% 0% 2% M-Leukemia, mononuclear 4 3 1 1 8% 6% 2% 2% Heart ..........................................Number examined: 50 34 30 50 M-Leukemia, mononuclear 4 5 3 5 8% 15% 10% 10% Stomach ........................................Number examined: 50 34 30 49 Hyperplasia, squamous epithelial 2 0 0 0 4% 0% 0% 0% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-60
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Cecum ..........................................Number examined: 50 34 30 48 N-Leukemia, mononuclear 2 0 0 0 4% 0% 0% 0% Urinary bladder ................................Number examined: 50 33 29 50 B-Papilloma, transitional cell 1 0 0 0 2% 0% 0% 0% M-Leukemia, mononuclear 1 1 0 1 2% 3% 0% 2% Duodenum .......................................Number examined: 50 34 30 49 Jejunum ........................................Number examined: 50 34 30 48 M-Adenocarcinoma 2 0 0 0 4% 0% 0% 0% Ileum ..........................................Number examined: 50 34 30 49 Hyperplasia, lymphoid 2 0 0 0 4% 0% 0% 0% B-Fibroma 1 0 0 0 2% 0% 0% 0% N-Leukemia, mononuclear 0 1 0 0 0% 3% 0% 0% Colon ..........................................Number examined: 50 34 30 49 B-Leiomyoma 0 0 0 1 0% 0% 0% 2% Pancreas .......................................Number examined: 50 34 30 49 M-Carcinoma, ductal cell 0 0 0 1 0% 0% 0% 2% M-Leukemia, mononuclear 1 0 0 0 2% 0% 0% 0% Rectum .........................................Number examined: 50 34 30 50 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-61
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Adrenal glands .................................Number examined: 49 35 30 50 Hyperplasia, cortical, diffuse 0 0 1 0 0% 0% 3% 0% Hyperplasia, medullary, focal 8 2 5 17 16% 6% 17% 34% B-Pheochromocytoma, benign 7 4 5 7 14% 11% 17% 14% B-Pheochromocytoma, complex, benign 1 1 0 0 2% 3% 0% 0% M-Pheochromocytoma, malignant 3 0 0 1 6% 0% 0% 2% M-Leukemia, mononuclear 3 1 4 2 6% 3% 13% 4% Prostate .......................................Number examined: 50 33 29 50 Hyperplasia 0 0 1 0 0% 0% 3% 0% Epididymis .....................................Number examined: 50 36 31 50 M-Mesothelioma, malignant 0 1 0 2 0% 3% 0% 4% Seminal vesicle ................................Number examined: 50 35 37 50 Hyperplasia 0 1 0 0 0% 3% 0% 0% M-Leukemia, mononuclear 1 0 1 0 2% 0% 3% 0% Mesenteric LN ..................................Number examined: 50 34 30 50 N-Sarcoma, histiocytic 0 1 0 0 0% 3% 0% 0% N-Leukemia, mononuclear 6 3 5 6 12% 9% 17% 12% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-62
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Testes .........................................Number examined: 50 50 50 50 Hyperplasia, interstitial cell 5 6 3 2 10% 12% 6% 4% B-Adenoma, interstitial cell 43 47 48 50 86% 94% 96% 100% M-Mesothelioma, malignant 0 1 1 2 0% 2% 2% 4% Sciatic nerve ..................................Number examined: 50 34 30 50 N-Leukemia, mononuclear 1 0 0 0 2% 0% 0% 0% Muscle, skeletal ...............................Number examined: 50 34 30 50 N-Sarcoma, histiocytic 0 2 0 0 0% 6% 0% 0% M-Leukemia, mononuclear 0 0 1 0 0% 0% 3% 0% Mammary gland ..................................Number examined: 36 31 29 47 Hyperplasia, lobular 0 1 0 5 0% 3% 0% 11% B-Fibroadenoma 0 0 0 1 0% 0% 0% 2% B-Fibroma 2 2 3 1 6% 6% 10% 2% N-Sarcoma, histiocytic 0 2 0 0 0% 6% 0% 0% Skin ...........................................Number examined: 49 37 35 50 B-Fibroma 2 0 1 0 4% 0% 3% 0% B-Keratoacanthoma 0 0 0 1 0% 0% 0% 2% B-Tumor, basal cell, benign 0 0 0 1 0% 0% 0% 2% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-63
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Skin ...........................................Number examined: 49 37 35 50 B-Tumor, hair follicle, benign 0 0 1 0 0% 0% 3% 0% M-Carcinoma, sebaceous cell 0 1 0 0 0% 3% 0% 0% M-Sarcoma, undifferentiated 0 1 2 0 0% 3% 6% 0% N-Sarcoma, histiocytic 0 2 0 0 0% 5% 0% 0% Brain ..........................................Number examined: 50 34 31 50 M-Astrocytoma, malignant 0 1 0 1 0% 3% 0% 2% Eyes/optic nerve ...............................Number examined: 50 34 33 50 M-Leukemia, mononuclear 1 1 0 0 2% 3% 0% 0% Bone, femur ....................................Number examined: 50 50 50 50 Spinal cord ....................................Number examined: 50 34 30 50 Nose/Turbinate 1 ...............................Number examined: 50 50 50 50 Hyperplasia - respiratory epithelium 3 0 3 4 6% 0% 6% 8% M-Leukemia, mononuclear 1 0 0 0 2% 0% 0% 0% Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Hyperplasia - respiratory epithelium 0 2 2 3 0% 4% 4% 6% M-Carcinoma, squamous cell 1 0 0 0 2% 0% 0% 0% M-Leukemia, mononuclear 1 0 0 0 2% 0% 0% 0% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-64
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 M-Carcinoma, squamous cell 0 1 0 1 0% 2% 0% 2% M-Leukemia, mononuclear 1 0 0 0 2% 0% 0% 0% Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 N-Carcinoma, squamous cell 0 2 0 2 0% 4% 0% 4% M-Leukemia, mononuclear 1 0 0 0 2% 0% 0% 0% Preputial gland ................................Number examined: 4 1 3 2 Pancreatic LN ..................................Number examined: 5 2 2 4 N-Leukemia, mononuclear 5 2 2 4 100% 100% 100% 100% Iliac LN .......................................Number examined: 3 1 4 2 N-Leukemia, mononuclear 3 1 3 2 100% 100% 75% 100% Lymph node other ...............................Number examined: 6 4 9 7 N-Leukemia, mononuclear 5 2 7 6 83% 50% 78% 86% Mediastinal LN .................................Number examined: 49 30 30 50 N-Sarcoma, histiocytic 0 1 0 0 0% 3% 0% 0% N-Leukemia, mononuclear 9 7 5 8 18% 23% 17% 16% Pituitary gland ................................Number examined: 49 37 34 50 Hyperplasia, pars distalis, focal 5 4 3 8 10% 11% 9% 16% B-Adenoma, pars distalis 9 9 6 5 18% 24% 18% 10% M-Leukemia, mononuclear 1 1 1 1 2% 3% 3% 2% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-65
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Tiss.not specifi ...............................Number examined: 1 2 3 5 B-Fibroma 0 0 1 0 0% 0% 33% 0% B-Lipoma 1 0 0 1 100% 0% 0% 20% M-Mesothelioma, malignant 0 0 0 2 0% 0% 0% 40% N-Sarcoma, histiocytic 0 1 0 0 0% 50% 0% 0% Harderian gland ................................Number examined: 1 0 0 0 N-Carcinoma, squamous cell 1 0 0 0 100% 0% 0% 0% Thymus .........................................Number examined: 1 0 0 2 M-Leukemia, mononuclear 1 0 0 1 100% 0% 0% 50% Mediastinum ....................................Number examined: 1 0 0 0 N-Leukemia, mononuclear 1 0 0 0 100% 0% 0% 0% Tail ...........................................Number examined: 1 2 1 0 Hyperplasia/hyperkeratosis 0 2 1 0 0% 100% 100% 0% Popliteal LN ...................................Number examined: 2 0 2 2 N-Leukemia, mononuclear 2 0 2 2 100% 0% 100% 100% Bone, other ....................................Number examined: 0 1 0 1 M-Sarcoma, NOS 0 0 0 1 0% 0% 0% 100% Zymbal’s gland .................................Number examined: 0 0 0 1 M-Carcinoma, squamous cell 0 0 0 1 0% 0% 0% 100% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-66
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mesentery ......................................Number examined: 0 1 1 0 M-Mesothelioma, malignant 0 0 1 0 0% 0% 100% 0% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-67
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Non-neoplastic Lesions 

M-68
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Alveolar histiocytosis 7 10 10 11 14% 20% 20% 22% Autolysis, marked 0 0 0 1 0% 0% 0% 2% Congestion 0 2 0 0 0% 4% 0% 0% Fibrosis, focal 1 0 0 1 2% 0% 0% 2% Hemorrhage 3 7 7 1 6% 14% 14% 2% Metaplasia, squamous - alveolar epithelium 0 2 0 0 0% 4% 0% 0% Mineralization, uremic 0 0 0 1 0% 0% 0% 2% Cyst, squamous cell, keratinizing 0 0 0 1 0% 0% 0% 2% Inflammation, acute 1 0 1 1 2% 0% 2% 2% Inflammation, mixed 1 1 5 2 2% 2% 10% 4% Inflammation, granulomatous 0 2 2 1 0% 4% 4% 2% Trachea ........................................Number examined: 50 49 50 50 Metaplasia, squamous 1 0 0 0 2% 0% 0% 0% Inflammation, acute 0 1 0 0 0% 2% 0% 0% Inflammation, mixed 1 1 0 4 2% 2% 0% 8% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-69
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Trachea ........................................Number examined: 50 49 50 50 Inflammation, chronic 1 2 1 1 2% 4% 2% 2% Bronchial (TBLN) ...............................Number examined: 49 33 28 47 Hemorrhage 0 3 0 2 0% 9% 0% 4% Thyroid glands .................................Number examined: 50 35 31 50 Cyst, follicular 1 1 3 3 2% 3% 10% 6% Parathyroid ....................................Number examined: 45 33 30 46 Aorta ..........................................Number examined: 50 34 30 50 Dilatation 0 0 0 1 0% 0% 0% 2% Esophagus ......................................Number examined: 50 33 30 50 Larynx .........................................Number examined: 50 49 50 50 Ulceration 1 0 0 0 2% 0% 0% 0% Inflammation, mixed 40 35 41 44 80% 71% 82% 88% Inflammation, chronic 4 2 4 3 8% 4% 8% 6% Metaplasia, squamous 8 3 6 6 16% 6% 12% 12% Salivary gland .................................Number examined: 50 34 30 50 Degeneration 0 0 0 1 0% 0% 0% 2% Inflamation, acute 0 0 0 1 0% 0% 0% 2% Mandibular LN ..................................Number examined: 40 32 30 48 Hemorrhage 1 0 0 0 3% 0% 0% 0% Sinus plasmacytosis 1 0 0 0 3% 0% 0% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-70
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 Angiectasis 15 4 8 18 30% 10% 21% 36% Congestion 0 0 0 1 0% 0% 0% 2% Cyst 0 0 1 0 0% 0% 3% 0% Fatty Change 2 1 1 0 4% 3% 3% 0% Foci of cellular alteration, basophilic 1 1 0 0 2% 3% 0% 0% Hepatodiaphragmatic nodule 1 1 1 2 2% 3% 3% 4% Necrosis 3 4 2 4 6% 10% 5% 8% Thrombus 0 0 0 1 0% 0% 0% 2% Vaculolization, cytoplasmic 1 3 1 3 2% 8% 3% 6% Inflammation, chronic 7 1 0 6 14% 3% 0% 12% Spleen .........................................Number examined: 50 39 38 50 Congestion 0 1 1 0 0% 3% 3% 0% Fibrosis 3 2 5 0 6% 5% 13% 0% Hemorrhage 0 1 0 0 0% 3% 0% 0% Necrosis 2 2 1 1 4% 5% 3% 2% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-71
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 50 50 50 Cyst 0 1 2 0 0% 2% 4% 0% Degeneration, hyaline droplet 0 1 0 0 0% 2% 0% 0% Infarct 0 0 2 0 0% 0% 4% 0% Nephropathy, chronic 44 47 50 46 88% 94% 100% 92% Pigment accumulation, tubular epithelium 3 3 1 3 6% 6% 2% 6% Inflamation, acute 0 1 2 0 0% 2% 4% 0% Heart ..........................................Number examined: 50 34 30 50 Degeneration, myocyte 2 1 3 3 4% 3% 10% 6% Fibrosis 5 5 2 4 10% 15% 7% 8% Thrombus 0 1 2 2 0% 3% 7% 4% Inflamation, acute 0 0 1 0 0% 0% 3% 0% Inflammation, focal, chronic 19 9 10 19 38% 26% 33% 38% Stomach ........................................Number examined: 50 34 30 49 Inflammation, mixed 2 1 0 0 4% 3% 0% 0% Cecum ..........................................Number examined: 50 34 30 48 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-72
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Urinary bladder ................................Number examined: 50 33 29 50 Hemorrhage 0 0 0 1 0% 0% 0% 2% Inflammation, mixed 0 0 0 1 0% 0% 0% 2% Inflammation, chronic 3 0 0 3 6% 0% 0% 6% Duodenum .......................................Number examined: 50 34 30 49 Jejunum ........................................Number examined: 50 34 30 48 Ileum ..........................................Number examined: 50 34 30 49 Colon ..........................................Number examined: 50 34 30 49 Inflammation, mixed 1 0 0 0 2% 0% 0% 0% Pancreas .......................................Number examined: 50 34 30 49 Rectum .........................................Number examined: 50 34 30 50 Adrenal glands .................................Number examined: 49 35 30 50 Cyst 0 0 0 1 0% 0% 0% 2% Degeneration, cytoplasmic vacuolization 5 2 2 4 10% 6% 7% 8% Necrosis 0 0 1 1 0% 0% 3% 2% Thrombus 2 2 3 5 4% 6% 10% 10% Prostate .......................................Number examined: 50 33 29 50 Atrophy 3 0 0 5 6% 0% 0% 10% Hemorrhage 0 0 0 1 0% 0% 0% 2% Mineralization 1 0 0 0 2% 0% 0% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-73
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Prostate .......................................Number examined: 50 33 29 50 Inflamation, acute 2 1 0 0 4% 3% 0% 0% Inflammation, mixed 15 12 16 13 30% 36% 55% 26% Epididymis .....................................Number examined: 50 36 31 50 Atrophy 4 5 1 7 8% 14% 3% 14% Granuloma, sperm 0 1 0 0 0% 3% 0% 0% Inflammation, chronic 2 0 1 0 4% 0% 3% 0% Seminal vesicle ................................Number examined: 50 35 37 50 Atrophy 15 2 8 18 30% 6% 22% 36% Dilatation 0 1 1 1 0% 3% 3% 2% Mesenteric LN ..................................Number examined: 50 34 30 50 Hemorrhage 1 0 0 0 2% 0% 0% 0% Histiocytosis, sinus 1 0 0 0 2% 0% 0% 0% Testes .........................................Number examined: 50 50 50 50 Atrophy 1 4 3 5 2% 8% 6% 10% Hemorrhage 0 1 0 1 0% 2% 0% 2% Sciatic nerve ..................................Number examined: 50 34 30 50 Muscle, skeletal ...............................Number examined: 50 34 30 50 Inflammation, chronic 0 0 1 0 0% 0% 3% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-74
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mammary gland ..................................Number examined: 36 31 29 47 Cyst 0 0 1 0 0% 0% 3% 0% Ectasia 1 0 0 1 3% 0% 0% 2% Skin ...........................................Number examined: 49 37 35 50 Cyst, epithelial inclusion 0 0 0 1 0% 0% 0% 2% Fibrosis 1 2 0 0 2% 5% 0% 0% Hyperkeratosis 1 1 2 0 2% 3% 6% 0% Necrosis 0 1 0 0 0% 3% 0% 0% Inflammation, mixed 0 3 2 0 0% 8% 6% 0% Inflammation, chronic 1 0 0 0 2% 0% 0% 0% Brain ..........................................Number examined: 50 34 31 50 Compression 6 2 2 4 12% 6% 6% 8% Ectasia, ventricular system 2 0 0 0 4% 0% 0% 0% Edema 0 0 0 1 0% 0% 0% 2% Gliosis 1 0 0 0 2% 0% 0% 0% Hemorrhage 1 0 2 0 2% 0% 6% 0% Mineralization 0 0 0 1 0% 0% 0% 2% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-75
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Brain ..........................................Number examined: 50 34 31 50 Necrosis 0 0 0 1 0% 0% 0% 2% Inflamation, acute 0 0 2 0 0% 0% 6% 0% Inflammation, chronic 1 0 0 0 2% 0% 0% 0% Eyes/optic nerve ...............................Number examined: 50 34 33 50 Atrophy 1 0 0 0 2% 0% 0% 0% Atrophy, retinal, unilateral 1 0 3 1 2% 0% 9% 2% Cataract 1 0 3 1 2% 0% 9% 2% Degeneration 1 0 0 0 2% 0% 0% 0% Metaplasia, osseous, scleral 3 0 0 0 6% 0% 0% 0% Mineralization, corneal stromal 3 0 2 1 6% 0% 6% 2% Mineralization, scleral 3 1 6 4 6% 3% 18% 8% Neovascularization, corneal 3 0 2 0 6% 0% 6% 0% Inflamation, acute 0 0 1 1 0% 0% 3% 2% Inflammation, mixed 1 2 0 0 2% 6% 0% 0% Inflammation, chronic 0 0 1 0 0% 0% 3% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-76
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Bone, femur ....................................Number examined: 50 50 50 50 New bone formation, endosteal 1 1 0 1 2% 2% 0% 2% Inflamation, acute 0 0 0 1 0% 0% 0% 2% Spinal cord ....................................Number examined: 50 34 30 50 Degeneration, white matter 1 0 0 0 2% 0% 0% 0% Hemorrhage 1 0 1 0 2% 0% 3% 0% Inflamation, acute 0 0 1 0 0% 0% 3% 0% Nose/Turbinate 1 ...............................Number examined: 50 50 50 50 Degeneration - respiratory epithelium 1 0 0 0 2% 0% 0% 0% Degeneration, hyaline - respiratory epithelium 0 3 5 3 0% 6% 10% 6% Metaplasia, squamous - respiratory epithelium 3 2 1 0 6% 4% 2% 0% Metaplasia, squamous - transitional epithelium 1 0 0 0 2% 0% 0% 0% Inflammation, mixed 7 5 8 6 14% 10% 16% 12% Inflammation - nasolacrimal duct 11 11 15 12 22% 22% 30% 24% Inflammation - respiratory epithelium 1 0 0 1 2% 0% 0% 2% Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 1 0 0 0 2% 0% 0% 0% Degeneration, hyaline - olfactory epithelium 0 5 7 6 0% 10% 14% 12% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-77
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration - respiratory epithelium 0 0 1 0 0% 0% 2% 0% Degeneration, hyaline - respiratory epithelium 0 1 2 3 0% 2% 4% 6% Metaplasia, secretory - olfactory epithelium 0 1 0 0 0% 2% 0% 0% Metaplasia, squamous - olfactory epithelium 0 1 0 0 0% 2% 0% 0% Metaplasia, squamous - respiratory epithelium 0 0 1 0 0% 0% 2% 0% Inflammation, mixed 4 6 3 5 8% 12% 6% 10% Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 2 1 7 7 4% 2% 14% 14% Inflammation, mixed 4 1 1 3 8% 2% 2% 6% Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 0 0 1 0 0% 0% 2% 0% Degeneration, hyaline - olfactory epithelium 0 0 1 1 0% 0% 2% 2% Inflammation, mixed 2 0 1 2 4% 0% 2% 4% Preputial gland ................................Number examined: 4 1 3 2 Cyst, epithelial inclusion 0 0 1 0 0% 0% 33% 0% Ectasia 2 1 2 2 50% 100% 67% 100% Inflammation, chronic 1 0 0 1 25% 0% 0% 50% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-78
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Preputial gland ................................Number examined: 4 1 3 2 Inflammation, mixed 3 0 0 1 75% 0% 0% 50% Pancreatic LN ..................................Number examined: 5 2 2 4 Iliac LN .......................................Number examined: 3 1 4 2 Dilatation, sinusoidal 0 0 1 0 0% 0% 25% 0% Lymph node other ...............................Number examined: 6 4 9 7 Dilatation, sinusoidal 0 1 0 0 0% 25% 0% 0% Infiltration, histiocytic 0 1 1 0 0% 25% 11% 0% Sinus plasmacytosis 1 0 0 1 17% 0% 0% 14% Mediastinal LN .................................Number examined: 49 30 30 50 Hemorrhage 2 1 2 2 4% 3% 7% 4% Pigmentation 0 1 0 0 0% 3% 0% 0% Pituitary gland ................................Number examined: 49 37 34 50 Angiectasis 2 0 0 3 4% 0% 0% 6% Cyst 4 7 7 6 8% 19% 21% 12% Hemorrhage 3 0 0 2 6% 0% 0% 4% Inflammation, chronic 0 0 0 1 0% 0% 0% 2% Tiss.not specifi ...............................Number examined: 1 2 3 5 Cyst 0 0 0 1 0% 0% 0% 20% Mammary tissue 0 0 1 0 0% 0% 33% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-79
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013M Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Tiss.not specifi ...............................Number examined: 1 2 3 5 Myodegeneration 0 1 0 0 0% 50% 0% 0% Inflammation, mixed 0 0 1 0 0% 0% 33% 0% Splenic tissue, "accessory" 0 0 0 1 0% 0% 0% 20% Harderian gland ................................Number examined: 1 0 0 0 Thymus .........................................Number examined: 1 0 0 2 Hemorrhage 0 0 0 1 0% 0% 0% 50% Mediastinum ....................................Number examined: 1 0 0 0 Tail ...........................................Number examined: 1 2 1 0 Cyst, epithelial inclusion 0 1 0 0 0% 50% 0% 0% Inflammation, acute 1 0 0 0 100% 0% 0% 0% Inflammation, mixed 0 2 1 0 0% 100% 100% 0% Popliteal LN ...................................Number examined: 2 0 2 2 Bone, other ....................................Number examined: 0 1 0 1 Hyperostosis 0 1 0 0 0% 100% 0% 0% Zymbal’s gland .................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 0 1 1 0 Inflammation, mixed 0 1 0 0 0% 100% 0% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-80
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-4 Tabulated Incidence Summary of Non-neoplastic Lesions 

M-81
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Hyperplasia, alveolar epithelial, focal, Minimal. 6 4 1 2 Hyperplasia, alveolar epithelial, focal, Mild. 2 3 1 2 Congestion, Mild. 0 1 0 0 Congestion, Moderate. 0 1 0 0 Alveolar histiocytosis, Minimal. 7 10 10 11 Hyperplasia, alveolar epithelial, widespread, Mild. 1 1 0 0 Fibrosis, focal, Mild. 1 0 0 1 Inflammation, mixed, Minimal. 0 0 3 2 Inflammation, mixed, Mild. 0 1 2 0 Inflammation, mixed, Moderate. 1 0 0 0 Hemorrhage, Minimal. 3 4 5 1 Hemorrhage, Mild. 0 2 2 0 Hemorrhage, Moderate. 0 1 0 0 Inflammation, acute, Minimal. 0 0 1 0 Inflammation, acute, Moderate. 0 0 0 1 Inflammation, acute, Marked. 1 0 0 0 Inflammation, granulomatous, Minimal. 0 2 2 0 Inflammation, granulomatous, Moderate. 0 0 0 1 Mineralization, uremic, Moderate. 0 0 0 1 Cyst, squamous cell, keratinizing, Present. 0 0 0 1 Autolysis, marked, Present. 0 0 0 1 Metaplasia, squamous - alveolar epithelium, Minimal. 0 1 0 0 Metaplasia, squamous - alveolar epithelium, Moderate. 0 1 0 0 Trachea ........................................Number examined: 50 49 50 50 Inflammation, acute, Minimal. 0 1 0 0 Inflammation, mixed, Minimal. 0 0 0 1 Inflammation, mixed, Mild. 1 1 0 3 Hyperplasia, epithelial, Mild. 1 0 0 0 Hyperplasia, epithelial, Moderate. 0 1 0 0 Inflammation, chronic, Minimal. 1 1 0 1 Inflammation, chronic, Mild. 0 1 1 0 Metaplasia, squamous, Moderate. 1 0 0 0 Bronchial (TBLN) ...............................Number examined: 49 33 28 47 Hemorrhage, Minimal. 0 0 0 1 Hemorrhage, Mild. 0 3 0 1 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-82
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thyroid glands .................................Number examined: 50 35 31 50 Hyperplasia, C-cell, focal, Minimal. 1 1 0 5 Hyperplasia, C-cell, focal, Mild. 2 1 0 2 Hyperplasia, C-cell, focal, Moderate. 1 0 0 0 Cyst, follicular, Present. 1 1 3 3 Hyperplasia, follicular cell, Moderate. 0 0 1 0 Parathyroid ....................................Number examined: 45 33 30 46 Hyperplasia, focal, Minimal. 0 0 0 1 Hyperplasia, focal, Moderate. 0 0 0 1 Hyperplasia, diffuse, Moderate. 0 0 0 1 Aorta ..........................................Number examined: 50 34 30 50 Dilatation, Present. 0 0 0 1 Esophagus ......................................Number examined: 50 33 30 50 Larynx .........................................Number examined: 50 49 50 50 Hyperplasia, epithelial, Minimal. 15 5 8 10 Hyperplasia, epithelial, Mild. 9 10 7 14 Metaplasia, squamous, Minimal. 4 1 6 2 Metaplasia, squamous, Mild. 3 2 0 4 Metaplasia, squamous, Moderate. 1 0 0 0 Inflammation, mixed, Minimal. 14 10 11 5 Inflammation, mixed, Mild. 25 23 30 36 Inflammation, mixed, Moderate. 1 2 0 3 Inflammation, chronic, Minimal. 3 2 2 2 Inflammation, chronic, Mild. 1 0 2 1 Ulceration, Mild. 1 0 0 0 Salivary gland .................................Number examined: 50 34 30 50 Degeneration, Minimal. 0 0 0 1 Inflamation, acute, Minimal. 0 0 0 1 Mandibular LN ..................................Number examined: 40 32 30 48 Hyperplasia, lymphoid, Mild. 1 0 1 0 Sinus plasmacytosis, Moderate. 1 0 0 0 Hemorrhage, Mild. 1 0 0 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-83
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 Necrosis, Minimal. 2 3 2 1 Necrosis, Mild. 1 1 0 3 Vaculolization, cytoplasmic, Minimal. 1 1 0 2 Vaculolization, cytoplasmic, Mild. 0 1 1 1 Vaculolization, cytoplasmic, Moderate. 0 1 0 0 Angiectasis, Minimal. 9 3 6 12 Angiectasis, Mild. 6 0 2 6 Angiectasis, Marked. 0 1 0 0 Hyperplasia, biliary, Minimal. 6 1 1 3 Hyperplasia, biliary, Mild. 23 19 16 25 Hyperplasia, biliary, Moderate. 14 13 19 16 Hyperplasia, biliary, Marked. 2 1 1 2 Hyperplasia, hepatocellular, regenerative, Minimal. 0 0 1 1 Hyperplasia, hepatocellular, regenerative, Mild. 1 3 2 1 Inflammation, chronic, Minimal. 7 1 0 5 Inflammation, chronic, Mild. 0 0 0 1 Fatty Change, Minimal. 0 1 1 0 Fatty Change, Mild. 1 0 0 0 Fatty Change, Moderate. 1 0 0 0 Hepatodiaphragmatic nodule, Present. 1 1 1 2 Foci of cellular alteration, basophilic, Minimal. 1 0 0 0 Foci of cellular alteration, basophilic, Mild. 0 1 0 0 Congestion, Moderate. 0 0 0 1 Thrombus, Mild. 0 0 0 1 Cyst, Moderate. 0 0 1 0 Spleen .........................................Number examined: 50 39 38 50 Fibrosis, Minimal. 0 0 1 0 Fibrosis, Mild. 2 1 4 0 Fibrosis, Moderate. 1 0 0 0 Fibrosis, Marked. 0 1 0 0 Necrosis, Mild. 0 1 1 0 Necrosis, Moderate. 0 1 0 1 Necrosis, Marked. 2 0 0 0 Hemorrhage, Moderate. 0 1 0 0 Congestion, Mild. 0 0 1 0 Congestion, Moderate. 0 1 0 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-84
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 50 50 50 Nephropathy, chronic, Minimal. 7 8 2 0 Nephropathy, chronic, Mild. 23 23 17 8 Nephropathy, chronic, Moderate. 13 14 29 34 Nephropathy, chronic, Marked. 1 2 2 4 Pigment accumulation, tubular epithelium, Moderate. 2 3 1 2 Pigment accumulation, tubular epithelium, Marked. 1 0 0 1 Cyst, Minimal. 0 1 1 0 Cyst, Mild. 0 0 1 0 Degeneration, hyaline droplet, Marked. 0 1 0 0 Infarct, Mild. 0 0 2 0 Inflamation, acute, Minimal. 0 1 0 0 Inflamation, acute, Moderate. 0 0 2 0 Heart ..........................................Number examined: 50 34 30 50 Inflammation, focal, chronic, Minimal. 17 9 10 18 Inflammation, focal, chronic, Mild. 2 0 0 1 Degeneration, myocyte, Minimal. 2 1 3 2 Degeneration, myocyte, Mild. 0 0 0 1 Fibrosis, Minimal. 2 3 2 2 Fibrosis, Mild. 3 1 0 2 Fibrosis, Moderate. 0 1 0 0 Thrombus, Minimal. 0 0 1 0 Thrombus, Mild. 0 0 1 1 Thrombus, Moderate. 0 1 0 1 Inflamation, acute, Moderate. 0 0 1 0 Stomach ........................................Number examined: 50 34 30 49 Hyperplasia, squamous epithelial, Marked. 2 0 0 0 Inflammation, mixed, Mild. 1 1 0 0 Inflammation, mixed, Moderate. 1 0 0 0 Cecum ..........................................Number examined: 50 34 30 48 Urinary bladder ................................Number examined: 50 33 29 50 Inflammation, chronic, Minimal. 3 0 0 3 Hemorrhage, Marked. 0 0 0 1 Inflammation, mixed, Marked. 0 0 0 1 Duodenum .......................................Number examined: 50 34 30 49 Jejunum ........................................Number examined: 50 34 30 48 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-85
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Ileum ..........................................Number examined: 50 34 30 49 Hyperplasia, lymphoid, Mild. 1 0 0 0 Hyperplasia, lymphoid, Moderate. 1 0 0 0 Colon ..........................................Number examined: 50 34 30 49 Inflammation, mixed, Marked. 1 0 0 0 Pancreas .......................................Number examined: 50 34 30 49 Rectum .........................................Number examined: 50 34 30 50 Adrenal glands .................................Number examined: 49 35 30 50 Hyperplasia, medullary, focal, Present. 8 2 5 17 Degeneration, cytoplasmic vacuolization, Minimal. 4 1 1 4 Degeneration, cytoplasmic vacuolization, Mild. 1 0 1 0 Degeneration, cytoplasmic vacuolization, Moderate. 0 1 0 0 Thrombus, Minimal. 1 0 0 3 Thrombus, Mild. 1 1 1 1 Thrombus, Moderate. 0 1 2 0 Thrombus, Marked. 0 0 0 1 Cyst, Moderate. 0 0 0 1 Necrosis, Mild. 0 0 1 0 Necrosis, Moderate. 0 0 0 1 Hyperplasia, cortical, diffuse, Moderate. 0 0 1 0 Prostate .......................................Number examined: 50 33 29 50 Inflammation, mixed, Minimal. 5 1 4 3 Inflammation, mixed, Mild. 8 6 8 4 Inflammation, mixed, Moderate. 2 4 4 4 Inflammation, mixed, Marked. 0 1 0 2 Inflamation, acute, Minimal. 2 0 0 0 Inflamation, acute, Moderate. 0 1 0 0 Mineralization, Minimal. 1 0 0 0 Atrophy, Minimal. 0 0 0 4 Atrophy, Mild. 3 0 0 0 Atrophy, Moderate. 0 0 0 1 Hemorrhage, Mild. 0 0 0 1 Hyperplasia, Minimal. 0 0 1 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-86
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Epididymis .....................................Number examined: 50 36 31 50 Inflammation, chronic, Mild. 2 0 0 0 Inflammation, chronic, Moderate. 0 0 1 0 Atrophy, Minimal. 0 1 0 2 Atrophy, Mild. 2 3 1 5 Atrophy, Moderate. 2 1 0 0 Granuloma, sperm, Mild. 0 1 0 0 Seminal vesicle ................................Number examined: 50 35 37 50 Atrophy, Minimal. 1 0 0 3 Atrophy, Mild. 10 1 5 13 Atrophy, Moderate. 4 1 3 2 Dilatation, Mild. 0 1 0 0 Dilatation, Moderate. 0 0 0 1 Dilatation, Marked. 0 0 1 0 Hyperplasia, Moderate. 0 1 0 0 Mesenteric LN ..................................Number examined: 50 34 30 50 Histiocytosis, sinus, Moderate. 1 0 0 0 Hemorrhage, Mild. 1 0 0 0 Testes .........................................Number examined: 50 50 50 50 Hyperplasia, interstitial cell, Present. 5 6 3 2 Atrophy, Mild. 0 0 2 1 Atrophy, Moderate. 0 1 1 1 Atrophy, Marked. 1 3 0 3 Hemorrhage, Moderate. 0 1 0 1 Sciatic nerve ..................................Number examined: 50 34 30 50 Muscle, skeletal ...............................Number examined: 50 34 30 50 Inflammation, chronic, Mild. 0 0 1 0 Mammary gland ..................................Number examined: 36 31 29 47 Hyperplasia, lobular, Minimal. 0 0 0 1 Hyperplasia, lobular, Mild. 0 1 0 1 Hyperplasia, lobular, Moderate. 0 0 0 1 Hyperplasia, lobular, Marked. 0 0 0 2 Ectasia, Moderate. 1 0 0 0 Ectasia, Marked. 0 0 0 1 Cyst, Present. 0 0 1 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-87
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Skin ...........................................Number examined: 49 37 35 50 Fibrosis, Mild. 1 0 0 0 Fibrosis, Moderate. 0 2 0 0 Inflammation, chronic, Minimal. 1 0 0 0 Hyperkeratosis, Moderate. 0 1 1 0 Hyperkeratosis, Marked. 1 0 1 0 Cyst, epithelial inclusion, Present. 0 0 0 1 Inflammation, mixed, Moderate. 0 2 1 0 Inflammation, mixed, Marked. 0 1 1 0 Necrosis, Marked. 0 1 0 0 Brain ..........................................Number examined: 50 34 31 50 Compression, Minimal. 0 0 1 0 Compression, Mild. 1 2 0 2 Compression, Moderate. 5 0 0 2 Compression, Marked. 0 0 1 0 Necrosis, Mild. 0 0 0 1 Ectasia, ventricular system, Mild. 1 0 0 0 Ectasia, ventricular system, Moderate. 1 0 0 0 Hemorrhage, Mild. 1 0 1 0 Hemorrhage, Moderate. 0 0 1 0 Gliosis, Marked. 1 0 0 0 Inflammation, chronic, Marked. 1 0 0 0 Mineralization, Minimal. 0 0 0 1 Edema, Moderate. 0 0 0 1 Inflamation, acute, Minimal. 0 0 1 0 Inflamation, acute, Mild. 0 0 1 0 Eyes/optic nerve ...............................Number examined: 50 34 33 50 Mineralization, corneal stromal, Minimal. 2 0 2 1 Mineralization, corneal stromal, Mild. 1 0 0 0 Mineralization, scleral, Minimal. 3 1 5 4 Mineralization, scleral, Mild. 0 0 1 0 Atrophy, Marked. 1 0 0 0 Degeneration, Marked. 1 0 0 0 Atrophy, retinal, unilateral, Moderate. 1 0 2 0 Atrophy, retinal, unilateral, Marked. 0 0 1 1 Cataract, Present. 1 0 3 1 Neovascularization, corneal, Minimal. 2 0 0 0 Neovascularization, corneal, Mild. 1 0 1 0 Neovascularization, corneal, Moderate. 0 0 1 0 Inflammation, mixed, Minimal. 1 0 0 0 Inflammation, mixed, Moderate. 0 1 0 0 Inflammation, mixed, Marked. 0 1 0 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-88
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Eyes/optic nerve ...............................Number examined: 50 34 33 50 Metaplasia, osseous, scleral, Minimal. 3 0 0 0 Inflamation, acute, Minimal. 0 0 1 0 Inflamation, acute, Mild. 0 0 0 1 Inflammation, chronic, Moderate. 0 0 1 0 Bone, femur ....................................Number examined: 50 50 50 50 New bone formation, endosteal, Minimal. 1 0 0 0 New bone formation, endosteal, Mild. 0 0 0 1 New bone formation, endosteal, Marked. 0 1 0 0 Inflamation, acute, Mild. 0 0 0 1 Spinal cord ....................................Number examined: 50 34 30 50 Degeneration, white matter, Minimal. 1 0 0 0 Hemorrhage, Mild. 1 0 1 0 Inflamation, acute, Minimal. 0 0 1 0 Nose/Turbinate 1 ...............................Number examined: 50 50 50 50 Inflammation - nasolacrimal duct, Minimal. 0 0 4 0 Inflammation - nasolacrimal duct, Mild. 6 5 5 4 Inflammation - nasolacrimal duct, Moderate. 5 6 6 6 Inflammation - nasolacrimal duct, Marked. 0 0 0 2 Inflammation, mixed, Minimal. 1 2 6 2 Inflammation, mixed, Mild. 3 1 1 2 Inflammation, mixed, Moderate. 2 1 1 2 Inflammation, mixed, Marked. 1 1 0 0 Metaplasia, squamous - respiratory epithelium, Minimal. 1 0 1 0 Metaplasia, squamous - respiratory epithelium, Mild. 1 1 0 0 Metaplasia, squamous - respiratory epithelium, Moderate. 1 1 0 0 Inflammation - respiratory epithelium, Minimal. 1 0 0 0 Inflammation - respiratory epithelium, Mild. 0 0 0 1 Metaplasia, squamous - transitional epithelium, Minimal. 1 0 0 0 Hyperplasia - respiratory epithelium, Minimal. 0 0 2 0 Hyperplasia - respiratory epithelium, Mild. 1 0 0 1 Hyperplasia - respiratory epithelium, Moderate. 2 0 1 3 Degeneration, hyaline - respiratory epithelium, Minimal. 0 2 2 1 Degeneration, hyaline - respiratory epithelium, Mild. 0 0 3 2 Degeneration, hyaline - respiratory epithelium, Moderate. 0 1 0 0 Degeneration - respiratory epithelium, Minimal. 1 0 0 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-89
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium, Minimal. 0 3 3 3 Degeneration, hyaline - olfactory epithelium, Mild. 0 1 4 1 Degeneration, hyaline - olfactory epithelium, Moderate. 0 1 0 2 Inflammation, mixed, Minimal. 0 2 1 0 Inflammation, mixed, Mild. 1 3 2 4 Inflammation, mixed, Moderate. 2 1 0 1 Inflammation, mixed, Marked. 1 0 0 0 Degeneration - olfactory epithelium, Minimal. 1 0 0 0 Degeneration, hyaline - respiratory epithelium, Minimal. 0 1 0 0 Degeneration, hyaline - respiratory epithelium, Mild. 0 0 2 2 Degeneration, hyaline - respiratory epithelium, Moderate. 0 0 0 1 Metaplasia, secretory - olfactory epithelium, Moderate. 0 1 0 0 Hyperplasia - respiratory epithelium, Minimal. 0 1 1 0 Hyperplasia - respiratory epithelium, Mild. 0 1 1 1 Hyperplasia - respiratory epithelium, Moderate. 0 0 0 2 Degeneration - respiratory epithelium, Minimal. 0 0 1 0 Metaplasia, squamous - olfactory epithelium, Minimal. 0 1 0 0 Metaplasia, squamous - respiratory epithelium, Minimal. 0 0 1 0 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium, Minimal. 2 0 3 2 Degeneration, hyaline - olfactory epithelium, Mild. 0 1 4 3 Degeneration, hyaline - olfactory epithelium, Moderate. 0 0 0 2 Inflammation, mixed, Minimal. 0 1 1 2 Inflammation, mixed, Minimal, Focal. 1 0 0 0 Inflammation, mixed, Mild. 1 0 0 1 Inflammation, mixed, Moderate. 1 0 0 0 Inflammation, mixed, Marked. 1 0 0 0 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Inflammation, mixed, Minimal. 0 0 0 2 Inflammation, mixed, Mild. 0 0 1 0 Inflammation, mixed, Moderate. 2 0 0 0 Degeneration, hyaline - olfactory epithelium, Minimal. 0 0 1 1 Degeneration - olfactory epithelium, Mild. 0 0 1 0 Preputial gland ................................Number examined: 4 1 3 2 Ectasia, Moderate. 1 0 2 2 Ectasia, Marked. 1 1 0 0 Inflammation, mixed, Mild. 0 0 0 1 Inflammation, mixed, Moderate. 2 0 0 0 Inflammation, mixed, Marked. 1 0 0 0 Inflammation, chronic, Minimal. 0 0 0 1 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-90
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Preputial gland ................................Number examined: 4 1 3 2 Inflammation, chronic, Mild. 1 0 0 0 Cyst, epithelial inclusion, Present. 0 0 1 0 Pancreatic LN ..................................Number examined: 5 2 2 4 Iliac LN .......................................Number examined: 3 1 4 2 Dilatation, sinusoidal, Mild. 0 0 1 0 Lymph node other ...............................Number examined: 6 4 9 7 Sinus plasmacytosis, Marked. 1 0 0 1 Infiltration, histiocytic, Moderate. 0 0 1 0 Infiltration, histiocytic, Marked. 0 1 0 0 Dilatation, sinusoidal, Marked. 0 1 0 0 Mediastinal LN .................................Number examined: 49 30 30 50 Hemorrhage, Minimal. 1 0 0 0 Hemorrhage, Mild. 1 1 2 2 Pigmentation, Marked. 0 1 0 0 Pituitary gland ................................Number examined: 49 37 34 50 Cyst, Minimal. 1 5 4 3 Cyst, Mild. 2 2 3 2 Cyst, Moderate. 1 0 0 0 Cyst, Marked. 0 0 0 1 Hyperplasia, pars distalis, focal, Minimal. 3 3 3 5 Hyperplasia, pars distalis, focal, Mild. 2 1 0 0 Hyperplasia, pars distalis, focal, Moderate. 0 0 0 3 Hemorrhage, Minimal. 1 0 0 0 Hemorrhage, Mild. 2 0 0 0 Hemorrhage, Moderate. 0 0 0 1 Hemorrhage, Marked. 0 0 0 1 Angiectasis, Minimal. 2 0 0 1 Angiectasis, Mild. 0 0 0 1 Angiectasis, Moderate. 0 0 0 1 Inflammation, chronic, Minimal. 0 0 0 1 Tiss.not specifi ...............................Number examined: 1 2 3 5 Cyst, Moderate. 0 0 0 1 Mammary tissue, Present. 0 0 1 0 Inflammation, mixed, Marked. 0 0 1 0 Myodegeneration, Mild. 0 1 0 0 Splenic tissue, "accessory", Present. 0 0 0 1 Harderian gland ................................Number examined: 1 0 0 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-91
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04

 Research Institute Study Number:FY01013M Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thymus .........................................Number examined: 1 0 0 2 Hemorrhage, Mild. 0 0 0 1 Mediastinum ....................................Number examined: 1 0 0 0 Tail ...........................................Number examined: 1 2 1 0 Inflammation, acute, Marked. 1 0 0 0 Inflammation, mixed, Moderate. 0 2 0 0 Inflammation, mixed, Marked. 0 0 1 0 Hyperplasia/hyperkeratosis, Moderate. 0 1 1 0 Hyperplasia/hyperkeratosis, Marked. 0 1 0 0 Cyst, epithelial inclusion, Present. 0 1 0 0 Popliteal LN ...................................Number examined: 2 0 2 2 Bone, other ....................................Number examined: 0 1 0 1 Hyperostosis, Mild. 0 1 0 0 Zymbal’s gland .................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 0 1 1 0 Inflammation, mixed, Marked. 0 1 0 0 Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

M-92
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-5 Lesion Incidence Summary with Average Severity Grades 

M-93
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Alveolar histiocytosis 7 10 10 11 Average severity: 0.1 0.2 0.2 0.2 Autolysis, marked 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Congestion 0 2 0 0 Average severity: 0.0 0.1 0.0 0.0 Fibrosis, focal 1 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Hemorrhage 3 7 7 1 Average severity: 0.1 0.2 0.2 0.0 Metaplasia, squamous - alveolar epithelium 0 2 0 0 Average severity: 0.0 0.1 0.0 0.0 Mineralization, uremic 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Cyst, squamous cell, keratinizing 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Inflammation, acute 1 0 1 1 Average severity: 0.1 0.0 0.0 0.1 Inflammation, mixed 1 1 5 2 Average severity: 0.1 0.0 0.1 0.0 Inflammation, granulomatous 0 2 2 1 Average severity: 0.0 0.0 0.0 0.1 Hyperplasia, alveolar epithelial, focal 8 7 2 4 Average severity: 0.2 0.2 0.1 0.1 Hyperplasia, alveolar epithelial, widespread 1 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-94
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Trachea ........................................Number examined: 50 49 50 50 Metaplasia, squamous 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Inflammation, acute 0 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 1 1 0 4 Average severity: 0.0 0.0 0.0 0.1 Inflammation, chronic 1 2 1 1 Average severity: 0.0 0.1 0.0 0.0 Hyperplasia, epithelial 1 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Bronchial (TBLN) ...............................Number examined: 49 33 28 47 Hemorrhage 0 3 0 2 Average severity: 0.0 0.2 0.0 0.1 Thyroid glands .................................Number examined: 50 35 31 50 Cyst, follicular 1 1 3 3 Average severity: 0.0 0.0 0.1 0.1 Hyperplasia, C-cell, focal 4 2 0 7 Average severity: 0.2 0.1 0.0 0.2 Hyperplasia, follicular cell 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Parathyroid ....................................Number examined: 45 33 30 46 Hyperplasia, diffuse 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Hyperplasia, focal 0 0 0 2 Average severity: 0.0 0.0 0.0 0.1 Aorta ..........................................Number examined: 50 34 30 50 Dilatation 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Esophagus ......................................Number examined: 50 33 30 50 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-95
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Larynx .........................................Number examined: 50 49 50 50 Ulceration 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 40 35 41 44 Average severity: 1.3 1.3 1.4 1.7 Inflammation, chronic 4 2 4 3 Average severity: 0.1 0.0 0.1 0.1 Metaplasia, squamous 8 3 6 6 Average severity: 0.3 0.1 0.1 0.2 Hyperplasia, epithelial 24 15 15 24 Average severity: 0.7 0.5 0.4 0.8 Salivary gland .................................Number examined: 50 34 30 50 Degeneration 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Inflamation, acute 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Mandibular LN ..................................Number examined: 40 32 30 48 Hemorrhage 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Sinus plasmacytosis 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Hyperplasia, lymphoid 1 0 1 0 Average severity: 0.1 0.0 0.1 0.0 Liver ..........................................Number examined: 50 40 38 50 Angiectasis 15 4 8 18 Average severity: 0.4 0.2 0.3 0.5 Congestion 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Cyst 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-96
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 40 38 50 Fatty Change 2 1 1 0 Average severity: 0.1 0.0 0.0 0.0 Foci of cellular alteration, basophilic 1 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Hepatodiaphragmatic nodule 1 1 1 2 Average severity: 0.0 0.0 0.0 0.0 Necrosis 3 4 2 4 Average severity: 0.1 0.1 0.1 0.1 Thrombus 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Vaculolization, cytoplasmic 1 3 1 3 Average severity: 0.0 0.2 0.1 0.1 Inflammation, chronic 7 1 0 6 Average severity: 0.1 0.0 0.0 0.1 Hyperplasia, biliary 45 34 37 46 Average severity: 2.0 2.1 2.5 2.2 Hyperplasia, hepatocellular, regenerative 1 3 3 2 Average severity: 0.0 0.2 0.1 0.1 Spleen .........................................Number examined: 50 39 38 50 Congestion 0 1 1 0 Average severity: 0.0 0.1 0.1 0.0 Fibrosis 3 2 5 0 Average severity: 0.1 0.2 0.2 0.0 Hemorrhage 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Necrosis 2 2 1 1 Average severity: 0.2 0.1 0.1 0.1 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-97
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 50 50 50 Cyst 0 1 2 0 Average severity: 0.0 0.0 0.1 0.0 Degeneration, hyaline droplet 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Infarct 0 0 2 0 Average severity: 0.0 0.0 0.1 0.0 Nephropathy, chronic 44 47 50 46 Average severity: 1.9 2.1 2.6 2.7 Pigment accumulation, tubular epithelium 3 3 1 3 Average severity: 0.2 0.2 0.1 0.2 Inflamation, acute 0 1 2 0 Average severity: 0.0 0.0 0.1 0.0 Heart ..........................................Number examined: 50 34 30 50 Degeneration, myocyte 2 1 3 3 Average severity: 0.0 0.0 0.1 0.1 Fibrosis 5 5 2 4 Average severity: 0.2 0.2 0.1 0.1 Thrombus 0 1 2 2 Average severity: 0.0 0.1 0.1 0.1 Inflamation, acute 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Inflammation, focal, chronic 19 9 10 19 Average severity: 0.4 0.3 0.3 0.4 Stomach ........................................Number examined: 50 34 30 49 Inflammation, mixed 2 1 0 0 Average severity: 0.1 0.1 0.0 0.0 Hyperplasia, squamous epithelial 2 0 0 0 Average severity: 0.2 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-98
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Cecum ..........................................Number examined: 50 34 30 48 Urinary bladder ................................Number examined: 50 33 29 50 Hemorrhage 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Inflammation, mixed 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Inflammation, chronic 3 0 0 3 Average severity: 0.1 0.0 0.0 0.1 Duodenum .......................................Number examined: 50 34 30 49 Jejunum ........................................Number examined: 50 34 30 48 Ileum ..........................................Number examined: 50 34 30 49 Hyperplasia, lymphoid 2 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Colon ..........................................Number examined: 50 34 30 49 Inflammation, mixed 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Pancreas .......................................Number examined: 50 34 30 49 Rectum .........................................Number examined: 50 34 30 50 Adrenal glands .................................Number examined: 49 35 30 50 Cyst 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Degeneration, cytoplasmic vacuolization 5 2 2 4 Average severity: 0.1 0.1 0.1 0.1 Necrosis 0 0 1 1 Average severity: 0.0 0.0 0.1 0.1 Thrombus 2 2 3 5 Average severity: 0.1 0.1 0.3 0.2 Hyperplasia, cortical, diffuse 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-99
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Adrenal glands .................................Number examined: 49 35 30 50 Hyperplasia, medullary, focal 8 2 5 17 Average severity: 0.2 0.1 0.2 0.3 Prostate .......................................Number examined: 50 33 29 50 Atrophy 3 0 0 5 Average severity: 0.1 0.0 0.0 0.1 Hemorrhage 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Mineralization 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Inflamation, acute 2 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Inflammation, mixed 15 12 16 13 Average severity: 0.5 0.9 1.1 0.6 Epididymis .....................................Number examined: 50 36 31 50 Atrophy 4 5 1 7 Average severity: 0.2 0.3 0.1 0.2 Granuloma, sperm 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Inflammation, chronic 2 0 1 0 Average severity: 0.1 0.0 0.1 0.0 Seminal vesicle ................................Number examined: 50 35 37 50 Atrophy 15 2 8 18 Average severity: 0.7 0.1 0.5 0.7 Dilatation 0 1 1 1 Average severity: 0.0 0.1 0.1 0.1 Hyperplasia 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-100
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mesenteric LN ..................................Number examined: 50 34 30 50 Hemorrhage 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Histiocytosis, sinus 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Testes .........................................Number examined: 50 50 50 50 Atrophy 1 4 3 5 Average severity: 0.1 0.3 0.1 0.3 Hemorrhage 0 1 0 1 Average severity: 0.0 0.1 0.0 0.1 Hyperplasia, interstitial cell 5 6 3 2 Average severity: 0.1 0.1 0.1 0.0 Sciatic nerve ..................................Number examined: 50 34 30 50 Muscle, skeletal ...............................Number examined: 50 34 30 50 Inflammation, chronic 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Mammary gland ..................................Number examined: 36 31 29 47 Cyst 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Ectasia 1 0 0 1 Average severity: 0.1 0.0 0.0 0.1 Hyperplasia, lobular 0 1 0 5 Average severity: 0.0 0.1 0.0 0.3 Skin ...........................................Number examined: 49 37 35 50 Cyst, epithelial inclusion 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Fibrosis 1 2 0 0 Average severity: 0.0 0.2 0.0 0.0 Hyperkeratosis 1 1 2 0 Average severity: 0.1 0.1 0.2 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-101
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Skin ...........................................Number examined: 49 37 35 50 Necrosis 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Inflammation, mixed 0 3 2 0 Average severity: 0.0 0.3 0.2 0.0 Inflammation, chronic 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Brain ..........................................Number examined: 50 34 31 50 Compression 6 2 2 4 Average severity: 0.3 0.1 0.2 0.2 Ectasia, ventricular system 2 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Edema 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Gliosis 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Hemorrhage 1 0 2 0 Average severity: 0.0 0.0 0.2 0.0 Mineralization 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Necrosis 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Inflamation, acute 0 0 2 0 Average severity: 0.0 0.0 0.1 0.0 Inflammation, chronic 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Eyes/optic nerve ...............................Number examined: 50 34 33 50 Atrophy 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Atrophy, retinal, unilateral 1 0 3 1 Average severity: 0.1 0.0 0.3 0.1 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-102
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Eyes/optic nerve ...............................Number examined: 50 34 33 50 Cataract 1 0 3 1 Average severity: 0.0 0.0 0.1 0.0 Degeneration 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Metaplasia, osseous, scleral 3 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Mineralization, corneal stromal 3 0 2 1 Average severity: 0.1 0.0 0.1 0.0 Mineralization, scleral 3 1 6 4 Average severity: 0.1 0.0 0.2 0.1 Neovascularization, corneal 3 0 2 0 Average severity: 0.1 0.0 0.2 0.0 Inflamation, acute 0 0 1 1 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 1 2 0 0 Average severity: 0.0 0.2 0.0 0.0 Inflammation, chronic 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Bone, femur ....................................Number examined: 50 50 50 50 New bone formation, endosteal 1 1 0 1 Average severity: 0.0 0.1 0.0 0.0 Inflamation, acute 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Spinal cord ....................................Number examined: 50 34 30 50 Degeneration, white matter 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Hemorrhage 1 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Inflamation, acute 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-103
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 1 ...............................Number examined: 50 50 50 50 Degeneration - respiratory epithelium 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Degeneration, hyaline - respiratory epithelium 0 3 5 3 Average severity: 0.0 0.1 0.2 0.1 Metaplasia, squamous - respiratory epithelium 3 2 1 0 Average severity: 0.1 0.1 0.0 0.0 Metaplasia, squamous - transitional epithelium 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 7 5 8 6 Average severity: 0.3 0.2 0.2 0.2 Inflammation - nasolacrimal duct 11 11 15 12 Average severity: 0.5 0.6 0.6 0.7 Inflammation - respiratory epithelium 1 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia - respiratory epithelium 3 0 3 4 Average severity: 0.2 0.0 0.1 0.2 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Degeneration, hyaline - olfactory epithelium 0 5 7 6 Average severity: 0.0 0.2 0.2 0.2 Degeneration - respiratory epithelium 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Degeneration, hyaline - respiratory epithelium 0 1 2 3 Average severity: 0.0 0.0 0.1 0.1 Metaplasia, secretory - olfactory epithelium 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Metaplasia, squamous - olfactory epithelium 0 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-104
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Metaplasia, squamous - respiratory epithelium 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 4 6 3 5 Average severity: 0.2 0.2 0.1 0.2 Hyperplasia - respiratory epithelium 0 2 2 3 Average severity: 0.0 0.1 0.1 0.2 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 2 1 7 7 Average severity: 0.0 0.0 0.2 0.3 Inflammation, mixed 4 1 1 3 Average severity: 0.2 0.0 0.0 0.1 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Degeneration, hyaline - olfactory epithelium 0 0 1 1 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 2 0 1 2 Average severity: 0.1 0.0 0.0 0.0 Preputial gland ................................Number examined: 4 1 3 2 Cyst, epithelial inclusion 0 0 1 0 Average severity: 0.0 0.0 0.3 0.0 Ectasia 2 1 2 2 Average severity: 1.8 4.0 2.0 3.0 Inflammation, chronic 1 0 0 1 Average severity: 0.5 0.0 0.0 0.5 Inflammation, mixed 3 0 0 1 Average severity: 2.5 0.0 0.0 1.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-105
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 13 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pancreatic LN ..................................Number examined: 5 2 2 4 Iliac LN .......................................Number examined: 3 1 4 2 Dilatation, sinusoidal 0 0 1 0 Average severity: 0.0 0.0 0.5 0.0 Lymph node other ...............................Number examined: 6 4 9 7 Dilatation, sinusoidal 0 1 0 0 Average severity: 0.0 1.0 0.0 0.0 Infiltration, histiocytic 0 1 1 0 Average severity: 0.0 1.0 0.3 0.0 Sinus plasmacytosis 1 0 0 1 Average severity: 0.7 0.0 0.0 0.6 Mediastinal LN .................................Number examined: 49 30 30 50 Hemorrhage 2 1 2 2 Average severity: 0.1 0.1 0.1 0.1 Pigmentation 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Pituitary gland ................................Number examined: 49 37 34 50 Angiectasis 2 0 0 3 Average severity: 0.0 0.0 0.0 0.1 Cyst 4 7 7 6 Average severity: 0.2 0.2 0.3 0.2 Hemorrhage 3 0 0 2 Average severity: 0.1 0.0 0.0 0.1 Inflammation, chronic 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia, pars distalis, focal 5 4 3 8 Average severity: 0.1 0.1 0.1 0.3 Tiss.not specifi ...............................Number examined: 1 2 3 5 Cyst 0 0 0 1 Average severity: 0.0 0.0 0.0 0.6 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-106
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 14 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Tiss.not specifi ...............................Number examined: 1 2 3 5 Mammary tissue 0 0 1 0 Average severity: 0.0 0.0 0.3 0.0 Myodegeneration 0 1 0 0 Average severity: 0.0 1.0 0.0 0.0 Inflammation, mixed 0 0 1 0 Average severity: 0.0 0.0 1.3 0.0 Splenic tissue, "accessory" 0 0 0 1 Average severity: 0.0 0.0 0.0 0.2 Harderian gland ................................Number examined: 1 0 0 0 Thymus .........................................Number examined: 1 0 0 2 Hemorrhage 0 0 0 1 Average severity: 0.0 0.0 0.0 1.0 Mediastinum ....................................Number examined: 1 0 0 0 Tail ...........................................Number examined: 1 2 1 0 Cyst, epithelial inclusion 0 1 0 0 Average severity: 0.0 0.5 0.0 0.0 Inflammation, acute 1 0 0 0 Average severity: 4.0 0.0 0.0 0.0 Inflammation, mixed 0 2 1 0 Average severity: 0.0 3.0 4.0 0.0 Hyperplasia/hyperkeratosis 0 2 1 0 Average severity: 0.0 3.5 3.0 0.0 Popliteal LN ...................................Number examined: 2 0 2 2 Bone, other ....................................Number examined: 0 1 0 1 Hyperostosis 0 1 0 0 Average severity: 0.0 2.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-107
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 15 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Zymbal’s gland .................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 0 1 1 0 Inflammation, mixed 0 1 0 0 Average severity: 0.0 4.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-108
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-6 Raw Data 

M-109
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Lungs (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - - - - - - - - - - - - - - 1 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - 1= 1 - - - - - - - - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - 4= - 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - 2= - - - - - - - 1 - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol 1= 2 2= - 2 - - - 2 2= 2= - - - 2 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - 3 - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 9-N-Leukemia, monuc - - - - 1= - - - - - 1= - - - - Thyroid glands (7) Status > m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - P - - - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 10-B-Adenoma, C-cell - - 1 - - - - - - - - - - - - 87-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -

Study Number FY01-013

M-110
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Parathyroid (2) Status > m mH mH mH m m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 2 2 2 2 1 - 1 1 2 2 2 - 2 2 1 19-Inflammation, chronic s - - - - - - - - - - - 1 - - - 16-Metaplasia, squamous s - - - - - - 1 - - - - - - 2 - 15-Hyperplasia, epithelial s 1 1 2 1 - - - - 1 1 1 - 1 - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (4) Status > *H *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - 3= - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - 2= - - - - - - 21-N-Leukemia, monuc - - - - - - - 1 1 - - - 1 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - 2 - - - - - - 1 - 1 - - - - 160-Congestion s - - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - - - - - 22-Necrosis s - - 2 - - - - - - - - - - 1 1 231-Thrombus s - - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - - - - - - 29-Inflammation, chronic s - - - 1 - - 1 - - - - - - - - 27-Hyperplasia, biliary s 3 3 3 - 3 2 2 - 2 3 3 1 2 1 3 28-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - 1=

Study Number FY01-013

M-111
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 24-M-Leukemia, monuc 2= 2 2 - 2= - - - 2 2= 1 - - - 2 Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - 2= - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - - 129-Necrosis s - - 4= - - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - - - 30-M-Leukemia, monuc 2= 2= 2= - 2= - - - 2 2= 2= - - - 2= 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 2 1 2 2 2 2 3 - 3 3 3 1 3 - 2 130-Pigment, tubular epithelium s - - 3 - - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - 1 - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - - - - - - - - - - - - 116-Fibrosis s - - - - - - 1 - - - - - - 1 - 206-Thrombus s - - - - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - - - - 34-Inflammation, focal, chronic s 1 - - 1 - - - 1 - 1 - - 1 - - 35-M-Leukemia, monuc - - - - 1 - - - - - 1 - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - 1 - - - -

Study Number FY01-013

M-112
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - - - - 37-Inflammation, chronic s - - - 1 - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - 1= - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - 2= - - - Ileum (3) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - - - - - 1 - - - - - 1 194-Necrosis s - - - - - - - - - - - - - - - 108-Thrombus s - - - - - - - - - - - - - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - - P - - - P - - - - - P - - 77-B-Pheochrom, bgn 1 - - - - - - - - - - - - - - 305-B-Pheochro, complex, benign - - - - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - - 57-M-Leukemia, monuc - - - - 1 - - - - - 1 - - - -

Study Number FY01-013

M-113
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - - - - 88-Inflammation, acute s - 1 - - - 1 - - - - - - - - - 64-Inflammation, mixed s - - - - - - 3 - - 1 - - - - 2 Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - - - - - - - - - 3= - - 242-Granuloma, sperm s - - - - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - - - - 198-M-Mesothelio, mal - - - - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - - - - - - - - - - - 3 2 3= 182-Dilatation s - - - - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 43-N-Leukemia, monuc - - - - - - - - - 1 1 - - - - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= - - 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-114
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 6 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Mammary gland (6) Status > * * * *H * * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - 166-Ectasia s - - - - - - 3 - 155-Hyperplasia, lobular s - - - - - - - - 165-B-Fibroadenoma - - - - - - - - 55-B-Fibroma - 1= - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - Skin (13) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - - - - - - 3= - - - - 2= - 103-Ectasia, ventricular sys s - - - - - - - - - - - - - - - 226-Edema s - - - - - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - - - - 183-Hemorrhage s - - 2 - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 111-Cataract p - - - - - - - - - - - - - - - 90-Degen s - - - - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - 1 - - - - - - - - 1 - - - 46-Mineralization, corneal str s - 2 - - - - - - - - - - - - - 59-Mineralization, scleral s - - - - 1 - - - - - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - - - - - 2 180-Inflammation, acute s - - - - - - - - - - - - - - -

Study Number FY01-013

M-115
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 7 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - 1 - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - - - - 184-Hemorrhage s - - 2 - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - 2 - - - - - 1 - 3 - 49-Inflammation-nasolac duct s - - - - - - 3 - - 2 - - - - - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - 3 - - - - - 3 - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - - - - - - - - - 3 - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - 2= - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > H H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - 1 - - 1 - - - - - - - - - - 93-Inflammation, mixed s - - - - - - - - - - - - - 3 - 195-M-Carcinoma, squamous cell - - - - - 2 - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-116
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 8 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Nose/Turbinate 4 (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - 3 - 196-N-Carcinoma, squamous cell - - - - - 2= - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 142 283-Cyst, epithelial inclusion p - 66-Ectasia s 3= 128-Inflammation, chronic s - 67-Inflammation, mixed s 3 Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 270-Dilatation, sinusoidal s 169-Infiltration, histiocytic s 142-Sinus plasmacytosis s 75-N-Leukemia, monuc Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - - 2 - - - 171-Pigmentation s - - - - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-N-Leukemia, monuc - - - - - - - - - 1= 1= - - - - Pituitary gland (7) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - 1 - 1 - - - - - - - - - 40-Cyst s - - - - - - - - - - - - - - - 172-Hemorrhage s - - 2= - - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s 2 - - - 1 - - - - 1 - - - - - 39-B-Adenoma, pars distalis - - - - - - 1= - 1= - - - - 1= - 138-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-117
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 9 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p - 286-Myodegeneration s - 281-Inflammation, mixed s - 308-B-Fibroma - 113-B-Lipoma 1= 200-M-Mesothelio, mal - 328-N-Sarcoma, histiocytic - 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 142 114-N-Carcinoma, squamous cell 2NT. Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-118
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 10 Rat/F344/N Group Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E414 1 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415 Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FS Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-119
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 11 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Lungs (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - 1 - - 1 - - - - - - - 1 - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - 2 - 154-Hemorrhage s - - - - - - - - - - - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - - - - - - 3= 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - 1 - 5-Hyperplasia, alv epi, wdsprd s 2 - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol 2= - - 2 2= 2 - 2 2= - 2 - - 2= - 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - 2= - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - 2 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - 2 215-N-Leukemia, mononuclear - - - - 1 - - - - - - - - - - Bronchial (TBLN) (3) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 9-N-Leukemia, monuc 1 - - - 1= 1= - - - - - 2= - 1= - Thyroid glands (7) Status > m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - - - - - - - 73-Hyperplasia, C-cell, focal s 2 3 - - - - - - - - - 1 - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 10-B-Adenoma, C-cell - - - - - - - - - - - - - - - 87-B-Adenoma, follicular cell - - - - - - - - - - - - - - 2= 204-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - 1= - - - - - - - -

Study Number FY01-013

M-120
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 12 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Parathyroid (2) Status > *H H mH mH *H m m *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - 2 - - - 325-Dilatation p - - - - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 1 2 2 1 2 2 - 2 2 - 1 1 - - 3= 19-Inflammation, chronic s - - - - - - 2 - - - - - - 1 - 16-Metaplasia, squamous s - - - 1 - - - - - - - 1 1 - 3 15-Hyperplasia, epithelial s - 1 2 - 2 1 - 2 - - 2 - - - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (4) Status > * * * *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - 2= - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - 21-N-Leukemia, monuc 1 - - 1= - - 1 - 1= 1= - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s 2 - - 1 - - - - 1 - 2 - - - - 160-Congestion s - - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 123-Hdn p - - P= - - - - - - - - - - - - 22-Necrosis s - - - - - - - - - - - - - - - 231-Thrombus s - - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - - 1 - - - 29-Inflammation, chronic s - 1 - - - - - - - - - - 1 - 1 27-Hyperplasia, biliary s 3 2 2 4 3 3 2 3 4 2 2 1 2 2 1 28-Hyperplasia, hepato, regen s - - - - - - - 2= - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -

Study Number FY01-013

M-121
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 13 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 24-M-Leukemia, monuc 2= - - 2 2 2= - 2 2 - 2 2= - 2 - Spleen (7) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - 2= - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - 4= - - - - 201-M-Fibrosarc - - - - - - - - - - - - - - - 30-M-Leukemia, monuc 2= - - 2= 2= 2= - 2= 2= - 2= 2= - 2= - 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 3 3= 2 2 2 2 2 - 3= 2 1 - 1 2 - 130-Pigment, tubular epithelium s - - - - - - - - - - 4 - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - 1 - - - - - - 1 - 1 - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - 1 - - - - - - - - - - 116-Fibrosis s - - - - - 2 - - - - - - - - - 206-Thrombus s - - - - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - - - - 34-Inflammation, focal, chronic s 1 - 1 - - 1 - 1 2 1 - - 1 - - 35-M-Leukemia, monuc - - - - 1 - - - - - - 1 - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - 2 - - - - - - - - - - - - - 100-Hyperplasia, sq epi s - 4 - - - - - - - - - - - - - Cecum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - 1 - - -

Study Number FY01-013

M-122
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 14 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - 1 - - - Duodenum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - 2= - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - 3 - - - - - 81-B-Fibroma - - - - - - - - - - - - 1= - - 207-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon (2) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - 1 - - - Rectum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - 1 - - - - - - - - - - - 194-Necrosis s - - - - - - - - - - - - - - 108-Thrombus s - - - - - - - - - - 2 - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - - - P - - - - - - - - P - 77-B-Pheochrom, bgn 1 - - - - - - - - - 1 - 1 - 305-B-Pheochro, complex, benign - - - - - - - - 1= - - - - - 74-M-Pheochromocytoma, malig 1 - - - - - - - - - - - - - 57-M-Leukemia, monuc - - - - - - - - - - - - - -

Study Number FY01-013

M-123
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 15 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - 2 - - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - - - - - - 64-Inflammation, mixed s - 1 - - - 1 - - - - - 2 - - 2= Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - 2 - - - - - - - - - - - 242-Granuloma, sperm s - - - - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - - - - 198-M-Mesothelio, mal - - - - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - 3= 2 2 - 2 - - - 2 2 - - - 182-Dilatation s - - - - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - 1= - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - 3 - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 43-N-Leukemia, monuc - - - - 1= - - - 1 - - - - - - Testes (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - P - - - - - - - - - P - - - 54-B-Adenoma, interstitial 1= - 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - - 1 - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-124
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 16 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Mammary gland (6) Status > * * * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - - 155-Hyperplasia, lobular s - - - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - - - 55-B-Fibroma - - - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - 3= - - - - - - - - - 3= - - - 103-Ectasia, ventricular sys s - - - - - - - - - - - 3 - - - 226-Edema s - - - - - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - - - 4= 110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 111-Cataract p - - - - - - - - - - - - - - - 90-Degen s - - - - - - - - - - - - - - 4 144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - 1 - - - - - - - - 59-Mineralization, scleral s - - - - - - - - 1 - - - - 1 - 121-Neovascularization, corneal s - - - - - - 1 - - - - - - - - 180-Inflammation, acute s - - - - - - - - - - - - - - -

Study Number FY01-013

M-125
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 17 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - 1 - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - 1= - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - 1 - - - 184-Hemorrhage s - - - - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - 3 - - - 124-Metaplasia, squ-trans epith s - - 1 - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - - - - - - - 2 - - 4 49-Inflammation-nasolac duct s 2 - - - - - 2 - 3 - - - - - - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - 1 - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - - - - - - - - - - 4 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - 1 - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 93-Inflammation, mixed s - - - - - - - - - - - - - - 4 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - 1 - - - - - - - - - -

Study Number FY01-013

M-126
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 18 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - 3 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - 1 - - - - - - - - - - Preputial gland (4) Status > M M MH M M M M M M M M M M M M Operator > 142 142 283-Cyst, epithelial inclusion p - - 66-Ectasia s - - 128-Inflammation, chronic s - 2= 67-Inflammation, mixed s 4= - Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 142 71-N-Leukemia, monuc 1= 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 142 270-Dilatation, sinusoidal s - - - - 169-Infiltration, histiocytic s - - - - 142-Sinus plasmacytosis s - - - - 75-N-Leukemia, monuc 1= 1= 1= 1= Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - - - - - - 171-Pigmentation s - - - - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-N-Leukemia, monuc - - - - 1= - - - - - - 1= - 1= - Pituitary gland (7) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - - - - - 40-Cyst s - - - 2= - - - - - - 1 - - - - 172-Hemorrhage s - - - 2 - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - 1 - - - - - - - - - 2 - - - 39-B-Adenoma, pars distalis - 1= - - - - - - - 1 - - - - 1= 138-M-Leukemia, monuc - - - - - - - - - - - 2= - - -

Study Number FY01-013

M-127
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 19 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 142 324-Hemorrhage s - 137-M-Leukemia, monuc 1= Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 142 139-N-Leukemia, monuc 1= Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 151-N-Leukemia, monuc 1= Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-128
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 20 Rat/F344/N Group Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E429 1 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430 Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-129
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 21 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Lungs (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - - 1 - - - - - - 1 - - - - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - - - - - 1= - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - 2 - - - 1= - - 1 - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - 1= - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol - - - - - - - 2 - - 2 2 - 2 2 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - - 1 - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - 1 - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 9-N-Leukemia, monuc - - - - - - - - - - - 1= - - - Thyroid glands (7) Status > m m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 10-B-Adenoma, C-cell - 1 - - - - - - - - - 1 - - - 87-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -

Study Number FY01-013

M-130
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 22 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Parathyroid (2) Status > m m mH m m mH * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - 2 - - - - - - - - - - - - - 18-Inflammation, mixed s 1 2 2 - 2 1 1 2 - 2 - 2 1 2 1 19-Inflammation, chronic s - - - 1 - - - - - - - - - - - 16-Metaplasia, squamous s - 2 - - - - - - - - - 2 - - - 15-Hyperplasia, epithelial s 1 2 - 1 2 - 1 1 - - - - - 2 - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (4) Status > *H * * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - 21-N-Leukemia, monuc - - - - - 1 - - 1 - 1 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - 1 - - - 1 - 2 - - - 1 - - 2 160-Congestion s - - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - - 99-Fatty Change s - - - 3= 2= - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - 1 - - - - - - - - 123-Hdn p - - - - - - - - - - - - - - - 22-Necrosis s - - - - - - - - - - - - - - - 231-Thrombus s - - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - - - - - - 29-Inflammation, chronic s - - 1 - - - - - - 1 - - - - - 27-Hyperplasia, biliary s 2 3 1 1 - 2 2 3 - 2 2 2 2 3 2 28-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -

Study Number FY01-013

M-131
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 23 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - 2= - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 24-M-Leukemia, monuc - 2= - - - - - 2= - - 2 2= - 2= 2= Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - - 63-Fibrosis s - 3= - - - - - - - - - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - - - 30-M-Leukemia, monuc - 2= - - - - - 2= - - 2= 2= - 2= 2= 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s - 2 2 3= 3= 2 1 2 1 2 1 4= 2 3= 2 130-Pigment, tubular epithelium s - - - - - - - 3 - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - 1 - - - - - - - - - - - - - 116-Fibrosis s - - - - - - 2 - - - - 2 - - - 206-Thrombus s - - - - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - - - - 34-Inflammation, focal, chronic s 1 - - - - - - 2 1 - 1 - - 1 - 35-M-Leukemia, monuc - - - - - - - - - - - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - 3= - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - 4 - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-132
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 24 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - 2 - - - - - - 81-B-Fibroma - - - - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon (2) Status > a H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - 2 1 - - - - - - - - - 194-Necrosis s - - - - - - - - - - - - - - - 108-Thrombus s - - - - - - - - - - - - - - 1 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - P - - - - - - - - - - - - - 77-B-Pheochrom, bgn - - - - - - - - - - - 1 1 1= - 305-B-Pheochro, complex, benign - - - - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - 1= - 1= - - - 57-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-133
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 25 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - 2 - - - 2 - - - - - 179-Hemorrhage s - - - - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - - - 1 273-Hyperplasia s - - - - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - - - - - - 64-Inflammation, mixed s 2 - - 2 3 - 2 - - - - 2 1 2 - Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - - 3 - - - 2 - - - - - 242-Granuloma, sperm s - - - - - - - - - - - - - - - 97-Inflammation, chronic s - - 2 - - - - - - - - 2 - - - 198-M-Mesothelio, mal - - - - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - - - - 3= - - 2= 2= - 2 2 - - 182-Dilatation s - - - - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - 2 - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 43-N-Leukemia, monuc - - - - - - - - - - - - - - - Testes (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p P - - - - - - - P - - - - P - 54-B-Adenoma, interstitial - 1= 1= - 1= 1= 1= 1= - 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-134
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 26 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Mammary gland (6) Status > * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - - - - 155-Hyperplasia, lobular s - - - - - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - - - - - 55-B-Fibroma - - - 1= - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - - - - 140-Fibrosis s - - - - 2 - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - 4= - - - - - - - 241-Necrosis s - - - - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - 1 - - - - - - - - 149-B-Fibroma - - - - - - - - 1= 1= - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Brain (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - 3= 3= - - - - - - - - - - 103-Ectasia, ventricular sys s - - - 2 - - - - - - - - - - - 226-Edema s - - - - - - - - - - - - - - - 189-Gliosis s 4 - - - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - - - - 190-Inflammation, chronic s 4 - - - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - 3 111-Cataract p - - - - - - - - - - - - - - P 90-Degen s - - - - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - 1 - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - - - - - - 59-Mineralization, scleral s - - - - - - - - - - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - - - - - - 180-Inflammation, acute s - - - - - - - - - - - - - - -

Study Number FY01-013

M-135
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 27 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - 1 - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - 1 - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - 2 - - - - - - - - - - - - - 49-Inflammation-nasolac duct s 2 - 2 - - - - - - 3 - - 2 3 - 107-Inflammation-resp epith s - - - - - - - - - - - - - 1 - 186-Hyperplasia-resp epith s - - 2 - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - 1 - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - - - - - - - 2 - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 93-Inflammation, mixed s - - - - 1F - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-136
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 28 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 142 283-Cyst, epithelial inclusion p - 66-Ectasia s 4= 128-Inflammation, chronic s - 67-Inflammation, mixed s 3 Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 270-Dilatation, sinusoidal s - - 169-Infiltration, histiocytic s - - 142-Sinus plasmacytosis s 4= - 75-N-Leukemia, monuc - 1= Mediastinal LN (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - 1= - - - - - - 171-Pigmentation s - - - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - 14-N-Leukemia, monuc - - - - - - - - - - 1= - 2= - Pituitary gland (7) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - - - - - 40-Cyst s - - - - - - 2 - - - - - - - - 172-Hemorrhage s - - - - - - - 1 - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - - - - - - - - - - - 39-B-Adenoma, pars distalis - - - 1= 1= - - - - - 1= - - - - 138-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-137
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 29 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 142 302-Cyst, epi inclusion p - 145-Inflammation, acute s 4= 174-Inflammation, mixed s - 175-Hyperplasia/hyperkeratosis s - Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 151-N-Leukemia, monuc 1= Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-138
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 30 Rat/F344/N Group Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E444 1 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-139
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 31 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Lungs (17) Status > Operator > 142 142 142 142 142 4-Alveolar histiocytosis s - - - 1 - 299-Autolysis, marked p - - - - - 3-Congestion s - - - - - 82-Fibrosis, focal s - - - - - 154-Hemorrhage s - - - - - 306-Metaplasia, squam - alv epi s - - - - - 233-Mineralization, uremic s - - - - - 298-Cyst, squamous, keratiniz p - - - - - 187-Inflammation, acute s - - - - - 84-Inflammation, mixed s - - - - - 214-Inflammation, granulomatous s - - - - - 1-Hyperplasia, alv epi, focal s 1 - 1 - - 5-Hyperplasia, alv epi, wdsprd s - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - 240-N-Sarcoma, histiocytic - - - - - 2-N-Leukemia,monuc - cap invol 2 2 - - 1 131-N-Leukemia,monuc - inv invol - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 188-Metaplasia, squamous s - - - - - 7-Inflammation, acute s - - - - - 85-Inflammation, mixed s - - - - - 177-Inflammation, chronic s - - - - - 86-Hyperplasia, epithelial s - - - - - 215-N-Leukemia, mononuclear - - - - - Bronchial (TBLN) (3) Status > * Operator > 142 142 142 142 142 8-Hemorrhage s - - - - 243-N-Sarcoma, histiocytic - - - - 9-N-Leukemia, monuc 1 1 - - Thyroid glands (7) Status > Operator > 142 142 142 142 142 115-Cyst, follicular p - - - - - 73-Hyperplasia, C-cell, focal s 2 - - - - 153-Hyperplasia, follicular cell s - - - - - 10-B-Adenoma, C-cell - - - - - 87-B-Adenoma, follicular cell - - 1 - - 204-M-Carcinoma, C-cell - - - - - 125-M-Carcinoma, follicular cell - - - - -

Study Number FY01-013

M-140
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 32 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Parathyroid (2) Status > mH * mH Operator > 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - 203-Hyperplasia, focal s - - - - Aorta (2) Status > Operator > 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - 325-Dilatation p - - - - - Esophagus Status > U U U U U Operator > 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 95-Ulceration s - - - - - 18-Inflammation, mixed s 2 2 2 1 - 19-Inflammation, chronic s - - - - - 16-Metaplasia, squamous s - - - - - 15-Hyperplasia, epithelial s 2 1 1 - - Salivary gland (3) Status > Operator > 142 142 142 142 142 225-Degen s - - - - - 236-Inflammation, acute s - - - - - 20-M-Leukemia, monuc - - - - - Mandibular LN (4) Status > Operator > 142 142 142 142 142 126-Hemorrhage s - - - - - 118-Sinus plasmacytosis s - - - - - 60-Hyperplasia, lymphoid s - - - - - 21-N-Leukemia, monuc 1 1 - - - Liver (17) Status > Operator > 142 142 142 142 142 26-Angiectasis s 2 1 - 1 - 160-Congestion s - - - - - 272-Cyst s - - - - - 99-Fatty Change s - - - - - 158-Foci cell alter, basophilic s - - - - - 123-Hdn p - - - - - 22-Necrosis s - - - - - 231-Thrombus s - - - - - 23-Vaculoliz, cyto s - - - - - 29-Inflammation, chronic s - - - - - 27-Hyperplasia, biliary s 2 2 2 2 - 28-Hyperplasia, hepato, regen s - - - - - 122-B-Adenoma, hepatocellular - - - - -

Study Number FY01-013

M-141
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 33 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Liver (17) Status > Operator > 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - 246-M-Sarcoma, histiocytic - - - - - 310-M-Sarcoma, undifferentiated - - - - - 24-M-Leukemia, monuc 2 2= 1 - 2= Spleen (7) Status > Operator > 142 142 142 142 142 285-Congestion s - - - - - 63-Fibrosis s - - - - - 247-Hemorrhage s - - - - - 129-Necrosis s - - - - - 201-M-Fibrosarc - - - - - 30-M-Leukemia, monuc 2= 2= 1 - 1 326-N-Sarcoma, histiocytic - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 161-Cyst s - - - - - 248-Degen, hyaline droplet s - - - - - 251-Infarct s - - - - - 33-Nephropathy, chronic s 3 2 2 3 2 130-Pigment, tubular epithelium s - - - - - 274-Inflammation, acute s - - - - - 213-B-Adenoma, renal tubule - - - - - 191-M-Carcinoma, renal tubule - - - - - 68-M-Leukemia, monuc - - - - - Heart (6) Status > Operator > 142 142 142 142 142 96-Degen, myocyte s - - - - - 116-Fibrosis s - - - - - 206-Thrombus s - - - - - 279-Inflammation, acute s - - - - - 34-Inflammation, focal, chronic s - - 1 - 1 35-M-Leukemia, monuc - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 101-Inflammation, mixed s - - - - - 100-Hyperplasia, sq epi s - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 69-N-Leukemia, monuc - - - - -

Study Number FY01-013

M-142
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 34 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 178-Hemorrhage s - - - - - 193-Inflammation, mixed s - - - - - 37-Inflammation, chronic s - 1 - 1 - 61-B-Papilloma, transitional - - - - - 134-M-Leukemia, monuc - - - - - Duodenum Status > U U U U U Operator > 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 80-M-Adenocarcinoma - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - 81-B-Fibroma - - - - - 207-N-Leukemia, monuc - - - - - Colon (2) Status > Operator > 142 142 142 142 142 197-Inflammation, mixed s - - - - 4 156-B-Leiomyoma - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - 135-M-Leukemia, monuc - - - - - Rectum Status > U U U U U Operator > 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 164-Cyst s - - - - - 62-Degen, cytopl vacuol s - - - - - 194-Necrosis s - - - - - 108-Thrombus s - - - - - 277-Hyperplasia, cort, diffuse s - - - - - 38-Hyperplasia, medulla, focal p P - - P= - 77-B-Pheochrom, bgn - - - - - 305-B-Pheochro, complex, benign - - - - - 74-M-Pheochromocytoma, malig - - - - - 57-M-Leukemia, monuc - 1 - - -

Study Number FY01-013

M-143
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 35 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Prostate (6) Status > Operator > 142 142 142 142 142 143-Atrophy s - - - - - 179-Hemorrhage s - - - - - 109-Mineralization s - - - - - 273-Hyperplasia s - - - - - 88-Inflammation, acute s - - - - - 64-Inflammation, mixed s - 1 - - - Epididymis (4) Status > Operator > 142 142 142 142 142 119-Atrophy s - - - - - 242-Granuloma, sperm s - - - - - 97-Inflammation, chronic s - - - - - 198-M-Mesothelio, mal - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 120-Atrophy s 1 - - - - 182-Dilatation s - - - - - 307-Hyperplasia s - - - - - 136-M-Leukemia, monuc - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 147-Hemorrhage s - - - - - 79-Histiocytosis, sinus s - - - - - 257-N-Sarcoma, histiocytic - - - - - 43-N-Leukemia, monuc 2 2 - - - Testes (5) Status > Operator > 142 142 142 142 142 152-Atrophy s 4 - - - - 287-Hemorrhage s - - - - - 105-Hyperplasia, interst cell p - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 83-N-Leukemia, monuc - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 304-Inflammation, chronic s - - - - - 258-N-Sarcoma, histiocytic - - - - - 271-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-144
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 36 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Mammary gland (6) Status > * Operator > 142 142 142 142 142 284-Cyst p - - - - 166-Ectasia s - - - - 155-Hyperplasia, lobular s - - - - 165-B-Fibroadenoma - - - - 55-B-Fibroma - - - - 266-N-Sarcoma, histiocytic - - - - Skin (13) Status > Operator > 142 142 142 142 142 229-Cyst, epith inc p - - - - - 140-Fibrosis s - - - - - 221-Hyperkeratosis s - - - - - 241-Necrosis s - - - - - 237-Inflammation, mixed s - - - - - 148-Inflammation, chronic s - - - - - 149-B-Fibroma - - - - - 176-B-Keratoacanthoma - - - - - 223-B-Tumor, basal cell, benign - - - - - 309-B-Tumor, hair follicle, ben - - - - - 300-M-Carcinoma, sebaceous cell - - - - - 303-M-Sarcoma, undifferentiated - - - - - 327-N-Sarcoma, histiocytic - - - - - Brain (10) Status > Operator > 142 142 142 142 142 44-Compression s - - - - - 103-Ectasia, ventricular sys s - - - - - 226-Edema s - - - - - 189-Gliosis s - - - - - 183-Hemorrhage s - - - - - 192-Mineralization s - - - - - 45-Necrosis s - - - - - 275-Inflammation, acute s - - - - - 190-Inflammation, chronic s - - - - - 224-M-Astrocytoma, malignant - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 89-Atrophy s - - - - - 110-Atrophy, retinal, unilat s - - - - - 111-Cataract p - - - - - 90-Degen s - - - - - 144-Metaplasia, osseous, sclera s - - - - - 46-Mineralization, corneal str s - - 1 - - 59-Mineralization, scleral s - - - - - 121-Neovascularization, corneal s - - 1 - - 180-Inflammation, acute s - - - - -

Study Number FY01-013

M-145
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 37 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 127-Inflammation, mixed s - - - - - 278-Inflammation, chronic s - - - - - 216-M-Leukemia, monuc - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 209-New bone, endosteal s - - - - - 212-Inflammation, acute s - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 48-Degen, white matter s - - - - - 184-Hemorrhage s - - - - - 280-Inflammation, acute s - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 261-Degeneration-resp epith s - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - 106-Metaplasia, squ-resp epith s 2 - - - - 124-Metaplasia, squ-trans epith s - - - - - 91-Inflammation, mixed s 3 - - - - 49-Inflammation-nasolac duct s - - - 3 - 107-Inflammation-resp epith s - - - - - 186-Hyperplasia-resp epith s - - - - - 217-M-Leukemia, monuc - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - 51-Degeneration,hyaline-olf epi s - - - - - 262-Degeneration-resp epith s - - - - - 202-Degeneration, hyal-resp epit s - - - - - 210-Metaplasia, sec-olfact epith s - - - - - 292-Metaplasia, squ-olfact epith s - - - - - 312-Metaplasia, squ-resp epith s - - - - - 92-Inflammation, mixed s 3 - - - - 227-Hyperplasia-resp epith s - - - - - 112-M-Carcinoma, squamous cell - - - - - 218-M-Leukemia, monuc - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - 93-Inflammation, mixed s 2 - - - - 195-M-Carcinoma, squamous cell - - - - - 219-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-146
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 38 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - 168-Degeneration, hyal-olf epi s - - - - - 94-Inflammation, mixed s - - - - - 196-N-Carcinoma, squamous cell - - - - - 220-M-Leukemia, monuc - - - - - Preputial gland (4) Status > M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M Operator > 270-Dilatation, sinusoidal s 169-Infiltration, histiocytic s 142-Sinus plasmacytosis s 75-N-Leukemia, monuc Mediastinal LN (4) Status > Operator > 142 142 142 142 142 13-Hemorrhage s - - - - - 171-Pigmentation s - - - - - 267-N-Sarcoma, histiocytic - - - - - 14-N-Leukemia, monuc 1= 2 - - - Pituitary gland (7) Status > H *H Operator > 142 142 142 142 142 173-Angiectasis s - - - - 40-Cyst s - 3= - - 172-Hemorrhage s - - - - 232-Inflammation, chronic s - - - - 42-Hyperplasia, pars dist, fcl s - - - - 39-B-Adenoma, pars distalis - - - - 138-M-Leukemia, monuc - - - -

Study Number FY01-013

M-147
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 39 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Tiss.not specifi (9) Status > M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-148
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 40 Rat/F344/N Group Sex Dosage Animal > 6831E447 6831E449 1 M 0 g/m3 Animal > 6831E446 6831E448 6831E450 Tissue/diagnosis Death code > FS U2 FS FS U2 Mesentery (2) Status > M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-149
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 41 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Lungs (17) Status > a a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - - - 1 - - - - 1 - - - 1 - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - - - - - - - - - - 1= 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - 1 - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - 2= - - - - - - 2= - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol 2 - 2= 2 - 2= 2= - - - - 2 2 - 2 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - 1 - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - 9-N-Leukemia, monuc 1= - - 1= - - - - 1= Thyroid glands (7) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - 10-B-Adenoma, C-cell - - - - - - - - - 87-B-Adenoma, follicular cell - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - - - -

Study Number FY01-013

M-150
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 42 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Parathyroid (2) Status > mH mH *H mH m m m Operator > 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - 325-Dilatation p - - - - - - - - - - Esophagus Status > U U U U U *H U U U U Operator > 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - 18-Inflammation, mixed s 2 2 1 2 1 - 2 3 2 2 - 2 2 2 19-Inflammation, chronic s - - - - - 1 - - - - - - - - 16-Metaplasia, squamous s - - - - - - - - - - - - - - 15-Hyperplasia, epithelial s 1 - - 2 - - - 2 - 1 - 2 - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - Mandibular LN (4) Status > m Operator > 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - 21-N-Leukemia, monuc 1 - - 1= - - - - - 1= Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - - - - - 1 - - - - - - 160-Congestion s - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - 99-Fatty Change s - - - - - - - 1= - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - - 22-Necrosis s - - - - - - - - 1 - - - 231-Thrombus s - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - 1 - 29-Inflammation, chronic s - - - - - - - - - - - - 27-Hyperplasia, biliary s 3 3 3 3 - 2 2 2 2 - 2 2 28-Hyperplasia, hepato, regen s - - - - - - - - - 2= - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - -

Study Number FY01-013

M-151
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 43 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - 24-M-Leukemia, monuc 2= 2= 2 2= 2 - - - 2 2 2 2 Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - 3= - 63-Fibrosis s - - - - - - - - - - - 247-Hemorrhage s - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - 30-M-Leukemia, monuc 2= 2= 2= 2= 2= - - 2= 2= 1 2= 326-N-Sarcoma, histiocytic - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 2 2 2 3 3 2 2 3 1 1 3 1 3 2 1 130-Pigment, tubular epithelium s - - - - - 3 - - 3 - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - - - - - - - 116-Fibrosis s - - - - - - - - - - 206-Thrombus s - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - 34-Inflammation, focal, chronic s - - - - - 1 - - - - 35-M-Leukemia, monuc - - 1 - 1 - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - -

Study Number FY01-013

M-152
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 44 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - Duodenum Status > U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - 1 Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - Rectum Status > U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - 1 - - - - - 194-Necrosis s - - - - - - - - - - 108-Thrombus s - - - - - - - - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - 38-Hyperplasia, medulla, focal p - - - - - - - - - - 77-B-Pheochrom, bgn - - 1= - - - - - - - 305-B-Pheochro, complex, benign - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - 57-M-Leukemia, monuc - - - - - - - - - -

Study Number FY01-013

M-153
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 45 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - 109-Mineralization s - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - 64-Inflammation, mixed s - - 2 - - - - 4 - - Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - 2= - - - - - - 242-Granuloma, sperm s - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - 198-M-Mesothelio, mal - - - - - 2= - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - - - - - - - - - 182-Dilatation s - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - 43-N-Leukemia, monuc - - - 1 - - - - - 1= Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - - - - - - - 3= - - 287-Hemorrhage s - - - - - - - 3 - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - P - P - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - 2 - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - -

Study Number FY01-013

M-154
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 46 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Mammary gland (6) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - 166-Ectasia s - - - - - - - - - 155-Hyperplasia, lobular s - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - 55-B-Fibroma - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - 140-Fibrosis s - - - - - - - 3 - - - - 221-Hyperkeratosis s - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - 4= - - - - 148-Inflammation, chronic s - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - 1= - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - 2= - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - - 226-Edema s - - - - - - - - - - 189-Gliosis s - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - 192-Mineralization s - - - - - - - - - - 45-Necrosis s - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - Eyes/optic nerve (12) Status > mH Operator > 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - 111-Cataract p - - - - - - - - - - 90-Degen s - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - 59-Mineralization, scleral s - - - - - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - 180-Inflammation, acute s - - - - - - - - - -

Study Number FY01-013

M-155
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 47 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Eyes/optic nerve (12) Status > mH Operator > 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - 3 - - - 278-Inflammation, chronic s - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - 1 Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - 3 - - - - - - - - - - - 49-Inflammation-nasolac duct s - 3 - 3 - - - - - 3 - - - 2 - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - 1 - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 93-Inflammation, mixed s - - - - - - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-156
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 48 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Nose/Turbinate 4 (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - 2 - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 142 283-Cyst, epithelial inclusion p - 66-Ectasia s 4= 128-Inflammation, chronic s - 67-Inflammation, mixed s - Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M *MH Operator > 142 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 270-Dilatation, sinusoidal s - - 169-Infiltration, histiocytic s - - 142-Sinus plasmacytosis s - - 75-N-Leukemia, monuc 1= 1= Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - 171-Pigmentation s - - - - - 4= - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - 14-N-Leukemia, monuc 1= - - - - - - - - 1= Pituitary gland (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - 40-Cyst s - - - - - - - - 1 - 1 172-Hemorrhage s - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - 2 - - - 1 - 39-B-Adenoma, pars distalis - - 1 - - - - 1= - - - 138-M-Leukemia, monuc - 1 - - - - - - - - -

Study Number FY01-013

M-157
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 49 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 142 302-Cyst, epi inclusion p P= 145-Inflammation, acute s - 174-Inflammation, mixed s 3 175-Hyperplasia/hyperkeratosis s 3= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-158
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 50 Rat/F344/N Group Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F514 2 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515 Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 142 301-Inflammation, mixed s 4= 311-M-Mesothelio, mal -

Study Number FY01-013

M-159
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 51 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Lungs (17) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - - - - - - - - - 1 - - - - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - 3= - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - 1= - 1= - - - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - 1 - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - 2 - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - 1 - - - - - 1-Hyperplasia, alv epi, focal s - - 1= - 1 - - - - - - 1= - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - 2 - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol 2 2 2= - 1 2 2 2 - 2 2 - 2 - 2= 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - 2 - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - 3 - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > *H Operator > 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - 9-N-Leukemia, monuc - - - - - - - - Thyroid glands (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - P - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - 10-B-Adenoma, C-cell - - - - - 1= - - 1 - 87-B-Adenoma, follicular cell - - - - - - - - - - 204-M-Carcinoma, C-cell - - 2= - - - - - - 1= 125-M-Carcinoma, follicular cell - - - - - - - - - -

Study Number FY01-013

M-160
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 52 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Parathyroid (2) Status > m m Operator > 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - 325-Dilatation p - - - - - - - - - Esophagus Status > U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 1 3 2 - 2 2 1 2 1 2 - 2 2 - - 19-Inflammation, chronic s - - - - - - - - - - - - - - - 16-Metaplasia, squamous s - - - - - - - 2 - - - - - - - 15-Hyperplasia, epithelial s - 2 2 - 2 - - - - 2 - 2 - - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - Mandibular LN (4) Status > * Operator > 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - 21-N-Leukemia, monuc 1 - - - - - - - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - - - - - - - - - - 160-Congestion s - - - - - - - - - - 272-Cyst s - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - 2 - 123-Hdn p - - P= - - - - - - - 22-Necrosis s - - - - - - - - - 2= 231-Thrombus s - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - 3= 29-Inflammation, chronic s - - - - - - - - - - 27-Hyperplasia, biliary s 3 2 - 2 3 2 2 2 1 3 28-Hyperplasia, hepato, regen s - - - - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - -

Study Number FY01-013

M-161
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 53 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - 24-M-Leukemia, monuc 2= 1= 1 2= 2 - 1= 2 - - Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - 63-Fibrosis s - 2 - - - - - - - - - - 247-Hemorrhage s - - - - - - - - - - - - 129-Necrosis s - - - - 3= - - - - 2 - - 201-M-Fibrosarc - - - - - - - - - - - - 30-M-Leukemia, monuc 2= 2= 1 1= 2= 2= - 1= 1= 2= - - 326-N-Sarcoma, histiocytic - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - 1 - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 3 2 1 3 3= 3 2 2 - 4 4 2 1 - 2= 130-Pigment, tubular epithelium s - - - - - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - - - - - - 116-Fibrosis s 1 1 - 1 - - - - - 206-Thrombus s - - - - - - - - 3= 279-Inflammation, acute s - - - - - - - - - 34-Inflammation, focal, chronic s - - 1 1 - 1 - 1 1 35-M-Leukemia, monuc 1 - - - - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - -

Study Number FY01-013

M-162
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 54 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Urinary bladder (5) Status > *H Operator > 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - 193-Inflammation, mixed s - - - - - - - - 37-Inflammation, chronic s - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - 134-M-Leukemia, monuc 1 - - - - - - - Duodenum Status > U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - 81-B-Fibroma - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - Rectum Status > U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - - - - - - - 194-Necrosis s - - - - - - - - - - 108-Thrombus s - - - - - - - - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - 38-Hyperplasia, medulla, focal p P - P - - - - - - - 77-B-Pheochrom, bgn - - 1= - - - - - - - 305-B-Pheochro, complex, benign - - - - - 1= - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - 57-M-Leukemia, monuc - - - - - - - - - -

Study Number FY01-013

M-163
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 55 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Prostate (6) Status > *H Operator > 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - 179-Hemorrhage s - - - - - - - - 109-Mineralization s - - - - - - - - 273-Hyperplasia s - - - - - - - - 88-Inflammation, acute s - - - - - - - - 64-Inflammation, mixed s - 3 2 - - - - 3 Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - - 2= - - - - 242-Granuloma, sperm s - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - 198-M-Mesothelio, mal - - - - - - - - - - Seminal vesicle (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 120-Atrophy s 3= - - - - 2= - - - 182-Dilatation s - - - - - - - - - 307-Hyperplasia s - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - 43-N-Leukemia, monuc - - - - - - - - - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - 4= - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - - - - P 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= - 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - 258-N-Sarcoma, histiocytic - 1= - - - - - - - 271-M-Leukemia, monuc - - - - - - - - -

Study Number FY01-013

M-164
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 56 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Mammary gland (6) Status > *H Operator > 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - 166-Ectasia s - - - - - - - - 155-Hyperplasia, lobular s - - 2 - - - - - 165-B-Fibroadenoma - - - - - - - - 55-B-Fibroma - - - - - - 1= - 266-N-Sarcoma, histiocytic - 1 - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - 140-Fibrosis s - - 3= - - - - - - - 221-Hyperkeratosis s - - 3 - - - - - - - 241-Necrosis s - 4= - - - - - - - - 237-Inflammation, mixed s - - 3 - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - 327-N-Sarcoma, histiocytic - 1= - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 44-Compression s - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - 226-Edema s - - - - - - - - - 189-Gliosis s - - - - - - - - - 183-Hemorrhage s - - - - - - - - - 192-Mineralization s - - - - - - - - - 45-Necrosis s - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - 224-M-Astrocytoma, malignant - 2= - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - 111-Cataract p - - - - - - - - - 90-Degen s - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - 59-Mineralization, scleral s - - - 1 - - - - - 121-Neovascularization, corneal s - - - - - - - - - 180-Inflammation, acute s - - - - - - - - -

Study Number FY01-013

M-165
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 57 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - 184-Hemorrhage s - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - 3 - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - 4 - - - - - - - - - 49-Inflammation-nasolac duct s - - - - - 3 - - - - - 3 - - - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - 2 - - - - - - - - - - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - 2 2 - - - - - - - - - - - - 227-Hyperplasia-resp epith s - 2 - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 93-Inflammation, mixed s - - - - - - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-166
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 58 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 71-N-Leukemia, monuc Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 270-Dilatation, sinusoidal s - 169-Infiltration, histiocytic s 4= 142-Sinus plasmacytosis s - 75-N-Leukemia, monuc - Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - 171-Pigmentation s - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - 14-N-Leukemia, monuc - 1 - - - - - - - Pituitary gland (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - 40-Cyst s - 1 - - - - - - - - 172-Hemorrhage s - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s 1 - - - - - - - - - 39-B-Adenoma, pars distalis 1= - - 1= - - - - - 1= 138-M-Leukemia, monuc - - - - - - - - - -

Study Number FY01-013

M-167
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 59 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 142 302-Cyst, epi inclusion p - 145-Inflammation, acute s - 174-Inflammation, mixed s 3= 175-Hyperplasia/hyperkeratosis s 4= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-168
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 60 Rat/F344/N Group Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F529 2 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-169
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 61 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Lungs (17) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s 1 - - - - - - - 1 1 - - - - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - 2= - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - 2= - - - - - - - - 3= 2= 306-Metaplasia, squam - alv epi s - - - - - 3= - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - 1 2 - - - - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - 2= - - 2-N-Leukemia,monuc - cap invol - - 2 2 1 - 2 2 - 2 - - - 2 2= 131-N-Leukemia,monuc - inv invol - 2 - - - - - - - - - - - - - Trachea (6) Status > * H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - 1 - 2 - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - 2= - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - 1 - - 9-N-Leukemia, monuc - 1= 1 1 - 1 - - - - - - 1 Thyroid glands (7) Status > m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - 1 - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - 10-B-Adenoma, C-cell - - - - - - - - - - 1= - 87-B-Adenoma, follicular cell - - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - - - - - - -

Study Number FY01-013

M-170
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 62 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Parathyroid (2) Status > mH m m m m m mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s - - 2 1 2 - - 2 1 - 1 - 2 1 - 19-Inflammation, chronic s 1 - - - - - - - - - - - - - - 16-Metaplasia, squamous s - - 2 - 1 - - - - - - - - - - 15-Hyperplasia, epithelial s 1 - - - - - - 1 - - - - - - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - Mandibular LN (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - 21-N-Leukemia, monuc - 1 - 1 1 - - 1 - - 1 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - - - - 1 - - - - - - - - - 160-Congestion s - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - - - - 22-Necrosis s - - - - - - 1 - - - - - - - 231-Thrombus s - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - 2 - - - - - 29-Inflammation, chronic s - - - - - - - - - - - - - - 27-Hyperplasia, biliary s 2 2 3 - 2 4 3 2 3 2 3 - - 2 28-Hyperplasia, hepato, regen s - - - - - - - - - 2 - - 2= - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - -

Study Number FY01-013

M-171
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 63 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - 1= - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - 24-M-Leukemia, monuc - 2 2= 2= 1= 2= 2= - 2 1= - - 2= 2= Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - - - - - 247-Hemorrhage s - - - - - - 3= - - - - - - 129-Necrosis s - - - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - 30-M-Leukemia, monuc - 2= 2= 1 1= 2= 2= - 2= 1 - 2= 2= 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - 4= - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 2 1 2 2 3 3 2 2 3 - 2 2 1 2 2 130-Pigment, tubular epithelium s - - - - - - - - - 3= - - - - - 274-Inflammation, acute s - - - - - - - - 1 - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - 1 1 1 - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - - - - - - - - - 116-Fibrosis s - - - - - 2 - - 3= - - - 206-Thrombus s - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - 34-Inflammation, focal, chronic s 1 - - - - - - - - - 1 1 35-M-Leukemia, monuc - 1 - 2 - - - - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - 2 - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - -

Study Number FY01-013

M-172
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 64 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - - Duodenum Status > U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - - Rectum Status > U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - 3 - - - - - - - - 194-Necrosis s - - - - - - - - - - - - 108-Thrombus s - - - - 2 - - - - - 3 - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - - - - - - - - - - - - 77-B-Pheochrom, bgn - - - - - - - - - - 1 - 305-B-Pheochro, complex, benign - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - - 57-M-Leukemia, monuc - - - - - 1 - - - - - -

Study Number FY01-013

M-173
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 65 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - 3 - - - - 64-Inflammation, mixed s 3 - 1 - - 2 2 - - - - 2 Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s 1= - - - - - 2= - - - - - 242-Granuloma, sperm s - - - - 2 - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - 198-M-Mesothelio, mal - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - - - - - - - - - - - - 182-Dilatation s - - - - 2= - - - - - - - - 307-Hyperplasia s - - - - 3 - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - 1= - - 43-N-Leukemia, monuc - - 1 - - - - - - - - - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s 4= - - - - - - 4= - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - P - - - - - P - P - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - 1= - - 271-M-Leukemia, monuc - - - - - - - - - - - -

Study Number FY01-013

M-174
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 66 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Mammary gland (6) Status > mH *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - - 155-Hyperplasia, lobular s - - - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - - - 55-B-Fibroma - - - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - 1= - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - 1= - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s 2= - - - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - - - - 226-Edema s - - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - - 111-Cataract p - - - - - - - - - - - - 90-Degen s - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - - - 59-Mineralization, scleral s - - - - - - - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - - - 180-Inflammation, acute s - - - - - - - - - - - -

Study Number FY01-013

M-175
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 67 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - 4= - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - 4 - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - 1 - 3 - - - - - - - - - - - 106-Metaplasia, squ-resp epith s 2 - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s 2 - - - - - - - 1 - 1 - - - - 49-Inflammation-nasolac duct s 3 - - - - - - - 2 - - 2 - - - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s 1 1 - 3 - - - - - - - - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s 3 - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - 1 - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s 3 - - - - - - - - 2 - 1 - - - 227-Hyperplasia-resp epith s - - 1 - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > a H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - 2 - - - - - - - - - - - 93-Inflammation, mixed s - - - - - - - - 1 - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - 2 - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-176
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 68 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Nose/Turbinate 4 (5) Status > a H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - 2 - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 270-Dilatation, sinusoidal s 4= 169-Infiltration, histiocytic s - 142-Sinus plasmacytosis s - 75-N-Leukemia, monuc - Mediastinal LN (4) Status > *H *H *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - 171-Pigmentation s - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - 1= - - 14-N-Leukemia, monuc - 1 1 1 - - - - 1 Pituitary gland (7) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - - 40-Cyst s - - - 2 2= 1 - - - - 1 - 172-Hemorrhage s - - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - - 1 - - - - - 39-B-Adenoma, pars distalis 1= - - - - - - - - - - - 138-M-Leukemia, monuc - - - - - - - - - - - -

Study Number FY01-013

M-177
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 69 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p - 286-Myodegeneration s - 281-Inflammation, mixed s - 308-B-Fibroma - 113-B-Lipoma - 200-M-Mesothelio, mal - 328-N-Sarcoma, histiocytic 1= 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 142 269-Hyperostosis s 2= 228-M-Sarcoma, NOS - Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-178
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 70 Rat/F344/N Group Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F544 2 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545 Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-179
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 71 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Lungs (17) Status > a Operator > 142 142 142 142 142 4-Alveolar histiocytosis s - 1 1 - 1 299-Autolysis, marked p - - - - - 3-Congestion s - - - - - 82-Fibrosis, focal s - - - - - 154-Hemorrhage s - - - - 1= 306-Metaplasia, squam - alv epi s - - - - - 233-Mineralization, uremic s - - - - - 298-Cyst, squamous, keratiniz p - - - - - 187-Inflammation, acute s - - - - - 84-Inflammation, mixed s - - - - - 214-Inflammation, granulomatous s - - - - - 1-Hyperplasia, alv epi, focal s - - - - - 5-Hyperplasia, alv epi, wdsprd s 2 - - - - 104-B-Adenoma, bronchiolo-alv - - - - - 240-N-Sarcoma, histiocytic - - - - - 2-N-Leukemia,monuc - cap invol 2= - 2= 2= 1 131-N-Leukemia,monuc - inv invol - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 188-Metaplasia, squamous s - - - - - 7-Inflammation, acute s - - - - - 85-Inflammation, mixed s - - - - - 177-Inflammation, chronic s - - - - - 86-Hyperplasia, epithelial s - - - - - 215-N-Leukemia, mononuclear - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 8-Hemorrhage s - 2 2 243-N-Sarcoma, histiocytic - - - 9-N-Leukemia, monuc 1 - - Thyroid glands (7) Status > Operator > 142 142 142 142 115-Cyst, follicular p - - - - 73-Hyperplasia, C-cell, focal s 2 - - - 153-Hyperplasia, follicular cell s - - - - 10-B-Adenoma, C-cell - - - 1= 87-B-Adenoma, follicular cell - - - - 204-M-Carcinoma, C-cell - - - - 125-M-Carcinoma, follicular cell - - - -

Study Number FY01-013

M-180
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 72 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Parathyroid (2) Status > *H Operator > 142 142 142 142 235-Hyperplasia, diffuse s - - - 203-Hyperplasia, focal s - - - Aorta (2) Status > Operator > 142 142 142 132-N-Leukemia,monuc - inv invol - - - 325-Dilatation p - - - Esophagus Status > U U U Operator > 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 95-Ulceration s - - - - - 18-Inflammation, mixed s 2 2 2 - 1 19-Inflammation, chronic s - - - - - 16-Metaplasia, squamous s - - - - - 15-Hyperplasia, epithelial s 2 1 2 - - Salivary gland (3) Status > Operator > 142 142 142 225-Degen s - - - 236-Inflammation, acute s - - - 20-M-Leukemia, monuc - - - Mandibular LN (4) Status > Operator > 142 142 142 126-Hemorrhage s - - - 118-Sinus plasmacytosis s - - - 60-Hyperplasia, lymphoid s - - - 21-N-Leukemia, monuc 1 - - Liver (17) Status > Operator > 142 142 142 142 26-Angiectasis s - 1 - 4= 160-Congestion s - - - - 272-Cyst s - - - - 99-Fatty Change s - - - - 158-Foci cell alter, basophilic s - - - - 123-Hdn p - - - - 22-Necrosis s 1 - - - 231-Thrombus s - - - - 23-Vaculoliz, cyto s - - - - 29-Inflammation, chronic s - 1 - - 27-Hyperplasia, biliary s 3 2 2 3 28-Hyperplasia, hepato, regen s - - - - 122-B-Adenoma, hepatocellular - - - -

Study Number FY01-013

M-181
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 73 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Liver (17) Status > Operator > 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - 246-M-Sarcoma, histiocytic - - - - 310-M-Sarcoma, undifferentiated - - - - 24-M-Leukemia, monuc 2 2= 2= - Spleen (7) Status > Operator > 142 142 142 285-Congestion s - - - 63-Fibrosis s 4= - - 247-Hemorrhage s - - - 129-Necrosis s - - - 201-M-Fibrosarc - - - 30-M-Leukemia, monuc 2= 2= 2= 326-N-Sarcoma, histiocytic - - - Kidneys (9) Status > Operator > 142 142 142 142 142 161-Cyst s - - - - - 248-Degen, hyaline droplet s - - - - - 251-Infarct s - - - - - 33-Nephropathy, chronic s 2 2 3 2 3= 130-Pigment, tubular epithelium s - - - - - 274-Inflammation, acute s - - - - - 213-B-Adenoma, renal tubule - - - - - 191-M-Carcinoma, renal tubule 1= - - - - 68-M-Leukemia, monuc - - - - - Heart (6) Status > Operator > 142 142 142 96-Degen, myocyte s 1 - - 116-Fibrosis s - - - 206-Thrombus s - - - 279-Inflammation, acute s - - - 34-Inflammation, focal, chronic s - - - 35-M-Leukemia, monuc - - - Stomach (2) Status > Operator > 142 142 142 101-Inflammation, mixed s - - - 100-Hyperplasia, sq epi s - - - Cecum (1) Status > Operator > 142 142 142 69-N-Leukemia, monuc - - -

Study Number FY01-013

M-182
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 74 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Urinary bladder (5) Status > Operator > 142 142 142 178-Hemorrhage s - - - 193-Inflammation, mixed s - - - 37-Inflammation, chronic s - - - 61-B-Papilloma, transitional - - - 134-M-Leukemia, monuc - - - Duodenum Status > U U U Operator > 142 142 142 Jejunum (1) Status > Operator > 142 142 142 80-M-Adenocarcinoma - - - Ileum (3) Status > Operator > 142 142 142 78-Hyperplasia, lymphoid s - - - 81-B-Fibroma - - - 207-N-Leukemia, monuc - - - Colon (2) Status > Operator > 142 142 142 197-Inflammation, mixed s - - - 156-B-Leiomyoma - - - Pancreas (2) Status > Operator > 142 142 142 323-M-Carcinoma, ductal cell - - - 135-M-Leukemia, monuc - - - Rectum Status > U U U Operator > 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 164-Cyst s - - - 62-Degen, cytopl vacuol s - - - 194-Necrosis s - - - 108-Thrombus s - - - 277-Hyperplasia, cort, diffuse s - - - 38-Hyperplasia, medulla, focal p - - - 77-B-Pheochrom, bgn 1 - - 305-B-Pheochro, complex, benign - - - 74-M-Pheochromocytoma, malig - - - 57-M-Leukemia, monuc - - -

Study Number FY01-013

M-183
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 75 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Prostate (6) Status > Operator > 142 142 142 143-Atrophy s - - - 179-Hemorrhage s - - - 109-Mineralization s - - - 273-Hyperplasia s - - - 88-Inflammation, acute s - - - 64-Inflammation, mixed s 3= - 2 Epididymis (4) Status > Operator > 142 142 142 142 119-Atrophy s - - - 3= 242-Granuloma, sperm s - - - - 97-Inflammation, chronic s - - - - 198-M-Mesothelio, mal - - - - Seminal vesicle (4) Status > Operator > 142 142 142 120-Atrophy s - - - 182-Dilatation s - - - 307-Hyperplasia s - - - 136-M-Leukemia, monuc - - - Mesenteric LN (4) Status > Operator > 142 142 142 147-Hemorrhage s - - - 79-Histiocytosis, sinus s - - - 257-N-Sarcoma, histiocytic - - - 43-N-Leukemia, monuc - - - Testes (5) Status > Operator > 142 142 142 142 142 152-Atrophy s - - - - - 287-Hemorrhage s - - - - - 105-Hyperplasia, interst cell p - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 83-N-Leukemia, monuc - - - Muscle, skeletal (3) Status > Operator > 142 142 142 304-Inflammation, chronic s - - - 258-N-Sarcoma, histiocytic - - - 271-M-Leukemia, monuc - - -

Study Number FY01-013

M-184
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 76 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Mammary gland (6) Status > Operator > 142 142 142 284-Cyst p - - - 166-Ectasia s - - - 155-Hyperplasia, lobular s - - - 165-B-Fibroadenoma - - - 55-B-Fibroma - 1= - 266-N-Sarcoma, histiocytic - - - Skin (13) Status > Operator > 142 142 142 229-Cyst, epith inc p - - - 140-Fibrosis s - - - 221-Hyperkeratosis s - - - 241-Necrosis s - - - 237-Inflammation, mixed s 3= - - 148-Inflammation, chronic s - - - 149-B-Fibroma - - - 176-B-Keratoacanthoma - - - 223-B-Tumor, basal cell, benign - - - 309-B-Tumor, hair follicle, ben - - - 300-M-Carcinoma, sebaceous cell - - - 303-M-Sarcoma, undifferentiated - - - 327-N-Sarcoma, histiocytic - - - Brain (10) Status > Operator > 142 142 142 44-Compression s 2 - - 103-Ectasia, ventricular sys s - - - 226-Edema s - - - 189-Gliosis s - - - 183-Hemorrhage s - - - 192-Mineralization s - - - 45-Necrosis s - - - 275-Inflammation, acute s - - - 190-Inflammation, chronic s - - - 224-M-Astrocytoma, malignant - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 89-Atrophy s - - - 110-Atrophy, retinal, unilat s - - - 111-Cataract p - - - 90-Degen s - - - 144-Metaplasia, osseous, sclera s - - - 46-Mineralization, corneal str s - - - 59-Mineralization, scleral s - - - 121-Neovascularization, corneal s - - - 180-Inflammation, acute s - - -

Study Number FY01-013

M-185
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 77 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Eyes/optic nerve (12) Status > Operator > 142 142 142 127-Inflammation, mixed s - - - 278-Inflammation, chronic s - - - 216-M-Leukemia, monuc - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 209-New bone, endosteal s - - - - - 212-Inflammation, acute s - - - - - Spinal cord (3) Status > Operator > 142 142 142 48-Degen, white matter s - - - 184-Hemorrhage s - - - 280-Inflammation, acute s - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 261-Degeneration-resp epith s - - - - - 222-Degeneration,hyal-Resp Epith s - - - 1 - 106-Metaplasia, squ-resp epith s - - - - - 124-Metaplasia, squ-trans epith s - - - - - 91-Inflammation, mixed s - - - - - 49-Inflammation-nasolac duct s 2 2 - - - 107-Inflammation-resp epith s - - - - - 186-Hyperplasia-resp epith s - - - - - 217-M-Leukemia, monuc - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - 51-Degeneration,hyaline-olf epi s - - - - - 262-Degeneration-resp epith s - - - - - 202-Degeneration, hyal-resp epit s - - - 1 - 210-Metaplasia, sec-olfact epith s - - - - - 292-Metaplasia, squ-olfact epith s - - - - - 312-Metaplasia, squ-resp epith s - - - - - 92-Inflammation, mixed s 1 - - - - 227-Hyperplasia-resp epith s - - - - - 112-M-Carcinoma, squamous cell - - - - - 218-M-Leukemia, monuc - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - 93-Inflammation, mixed s - - - - - 195-M-Carcinoma, squamous cell - - - - - 219-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-186
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 78 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - 168-Degeneration, hyal-olf epi s - - - - - 94-Inflammation, mixed s - - - - - 196-N-Carcinoma, squamous cell - - - - - 220-M-Leukemia, monuc - - - - - Preputial gland (4) Status > M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M Operator > 71-N-Leukemia, monuc Iliac LN (2) Status > M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M Operator > 270-Dilatation, sinusoidal s 169-Infiltration, histiocytic s 142-Sinus plasmacytosis s 75-N-Leukemia, monuc Mediastinal LN (4) Status > * Operator > 142 142 142 13-Hemorrhage s 2 - 171-Pigmentation s - - 267-N-Sarcoma, histiocytic - - 14-N-Leukemia, monuc - - Pituitary gland (7) Status > Operator > 142 142 142 142 173-Angiectasis s - - - - 40-Cyst s - - - - 172-Hemorrhage s - - - - 232-Inflammation, chronic s - - - - 42-Hyperplasia, pars dist, fcl s - - - - 39-B-Adenoma, pars distalis 1= 1= - 1= 138-M-Leukemia, monuc - - - -

Study Number FY01-013

M-187
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 79 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Tiss.not specifi (9) Status > M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p - 286-Myodegeneration s 2 281-Inflammation, mixed s - 308-B-Fibroma - 113-B-Lipoma - 200-M-Mesothelio, mal - 328-N-Sarcoma, histiocytic - 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-188
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 80 Rat/F344/N Group Sex Dosage Animal > 6833F547 6833F549 2 M 2 g/m3 Animal > 6833F546 6833F548 6833F550 Tissue/diagnosis Death code > U2 FS U2 U1 FS Mesentery (2) Status > M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-189
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 81 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Lungs (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - 1 1 - - - - - 1 - - - - - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - - 1 - - 1= 1= - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - 1 - - - - 1 - 2 - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - 1= 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol - - - - 1 1= - 2 - 1 2 2 - - 1 131-N-Leukemia,monuc - inv invol - - - 2= - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - 2 - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 8-Hemorrhage s - - - - - 243-N-Sarcoma, histiocytic - - - - - 9-N-Leukemia, monuc 2 - - - - Thyroid glands (7) Status > Operator > 142 142 142 142 142 142 115-Cyst, follicular p - - P - - - 73-Hyperplasia, C-cell, focal s - - - - - - 153-Hyperplasia, follicular cell s - - - - - 3= 10-B-Adenoma, C-cell - - - - - - 87-B-Adenoma, follicular cell - - - - - - 204-M-Carcinoma, C-cell - - - - - - 125-M-Carcinoma, follicular cell - - - - - -

Study Number FY01-013

M-190
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 82 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Parathyroid (2) Status > m mH Operator > 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - 203-Hyperplasia, focal s - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - 325-Dilatation p - - - - - Esophagus Status > U U U U U Operator > 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 2 2 1 2 2 1 2 2 1 2 - 1 2 2 1 19-Inflammation, chronic s - - - - - - - - - - - - - - - 16-Metaplasia, squamous s - 1 - - - - - - - - - - - - - 15-Hyperplasia, epithelial s - - - 2 - - - 2 - - - - 1 1 - Salivary gland (3) Status > Operator > 142 142 142 142 142 225-Degen s - - - - - 236-Inflammation, acute s - - - - - 20-M-Leukemia, monuc 1= - - - - Mandibular LN (4) Status > Operator > 142 142 142 142 142 126-Hemorrhage s - - - - - 118-Sinus plasmacytosis s - - - - - 60-Hyperplasia, lymphoid s - - - - - 21-N-Leukemia, monuc 2= - 1 - - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 26-Angiectasis s - 2 - - 1 - - - - 160-Congestion s - - - - - - - - - 272-Cyst s - - - - - - - - - 99-Fatty Change s - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - 123-Hdn p - - - - - - - P= - 22-Necrosis s - - - - 1 - - - - 231-Thrombus s - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - 29-Inflammation, chronic s - - - - - - - - - 27-Hyperplasia, biliary s 2 3 3 1 3 2 2 2 3 28-Hyperplasia, hepato, regen s - - 1= - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - -

Study Number FY01-013

M-191
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 83 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - 1= - - - - - 24-M-Leukemia, monuc 2 1= 2= - 2 2 2 - 1= Spleen (7) Status > Operator > 142 142 142 142 142 142 142 285-Congestion s - - - - - - - 63-Fibrosis s - 2= - - - - 2= 247-Hemorrhage s - - - - - - - 129-Necrosis s - - - - - - 2= 201-M-Fibrosarc - - - - - - - 30-M-Leukemia, monuc 2= 1= 2= 2= 2= 2= 1= 326-N-Sarcoma, histiocytic - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - 1 - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - 2 - - - - 33-Nephropathy, chronic s 3 4= 2 2 3 3 3 3 3 2 3 3 2 3 3 130-Pigment, tubular epithelium s - - - - - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - 1 1= - - 1= 1= - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - 2= - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 96-Degen, myocyte s - - 1 - - 116-Fibrosis s - - - - - 206-Thrombus s - - 2 - - 279-Inflammation, acute s - - - - - 34-Inflammation, focal, chronic s - 1 - - - 35-M-Leukemia, monuc 1 - - - - Stomach (2) Status > Operator > 142 142 142 142 142 101-Inflammation, mixed s - - - - - 100-Hyperplasia, sq epi s - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 69-N-Leukemia, monuc - - - - -

Study Number FY01-013

M-192
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 84 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Urinary bladder (5) Status > Operator > 142 142 142 142 142 178-Hemorrhage s - - - - - 193-Inflammation, mixed s - - - - - 37-Inflammation, chronic s - - - - - 61-B-Papilloma, transitional - - - - - 134-M-Leukemia, monuc - - - - - Duodenum Status > U U U U U Operator > 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 80-M-Adenocarcinoma - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - 81-B-Fibroma - - - - - 207-N-Leukemia, monuc - - - - - Colon (2) Status > Operator > 142 142 142 142 142 197-Inflammation, mixed s - - - - - 156-B-Leiomyoma - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - 135-M-Leukemia, monuc - - - - - Rectum Status > U U U U U Operator > 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 164-Cyst s - - - - - 62-Degen, cytopl vacuol s - - - - - 194-Necrosis s - - - 2 - 108-Thrombus s - - - - 3 277-Hyperplasia, cort, diffuse s - - - - - 38-Hyperplasia, medulla, focal p - - P - - 77-B-Pheochrom, bgn - - - - - 305-B-Pheochro, complex, benign - - - - - 74-M-Pheochromocytoma, malig - - - - - 57-M-Leukemia, monuc - - - 2 -

Study Number FY01-013

M-193
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 85 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Prostate (6) Status > Operator > 142 142 142 142 142 143-Atrophy s - - - - - 179-Hemorrhage s - - - - - 109-Mineralization s - - - - - 273-Hyperplasia s - - - - - 88-Inflammation, acute s - - - - - 64-Inflammation, mixed s - - 2 3 - Epididymis (4) Status > Operator > 142 142 142 142 142 119-Atrophy s - - - - - 242-Granuloma, sperm s - - - - - 97-Inflammation, chronic s - - - - - 198-M-Mesothelio, mal - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 120-Atrophy s 3= - 2= - 2= - 3= - - 2= 182-Dilatation s - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - 136-M-Leukemia, monuc - 1= - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 147-Hemorrhage s - - - - - 79-Histiocytosis, sinus s - - - - - 257-N-Sarcoma, histiocytic - - - - - 43-N-Leukemia, monuc 1= 1 - - - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - 2= - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - P - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - 1 - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 83-N-Leukemia, monuc - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 304-Inflammation, chronic s - - - - - 258-N-Sarcoma, histiocytic - - - - - 271-M-Leukemia, monuc 1= - - - -

Study Number FY01-013

M-194
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 86 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Mammary gland (6) Status > Operator > 142 142 142 142 142 284-Cyst p - - - - - 166-Ectasia s - - - - - 155-Hyperplasia, lobular s - - - - - 165-B-Fibroadenoma - - - - - 55-B-Fibroma - - - - - 266-N-Sarcoma, histiocytic - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - 140-Fibrosis s - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - 3= 241-Necrosis s - - - - - - - - - 237-Inflammation, mixed s - 4= - - - - - - - 148-Inflammation, chronic s - - - - - - - - - 149-B-Fibroma - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - 1= - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - 1= - 327-N-Sarcoma, histiocytic - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 44-Compression s - - - - - 103-Ectasia, ventricular sys s - - - - - 226-Edema s - - - - - 189-Gliosis s - - - - - 183-Hemorrhage s - - - 3= - 192-Mineralization s - - - - - 45-Necrosis s - - - - - 275-Inflammation, acute s - - - - - 190-Inflammation, chronic s - - - - - 224-M-Astrocytoma, malignant - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - 110-Atrophy, retinal, unilat s 3 - - - - - - 111-Cataract p P= - - - - - - 90-Degen s - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - 46-Mineralization, corneal str s - - - - - - - 59-Mineralization, scleral s - - - - - - - 121-Neovascularization, corneal s - - - - - - - 180-Inflammation, acute s - - - - - - -

Study Number FY01-013

M-195
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 87 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - 278-Inflammation, chronic s - - - - - - - 216-M-Leukemia, monuc - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 48-Degen, white matter s - - - - - 184-Hemorrhage s - - - 2 - 280-Inflammation, acute s - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - 2 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - - - - - 2 - - - - - 49-Inflammation-nasolac duct s - 1 - - - - - - 3 2 2 3 - - 3 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - - - - - - - 1 - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - 1 - - - - - - - - 1 262-Degeneration-resp epith s - - - - - - - - - 1 - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - - - - - 2 - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - 1 - - - - - 93-Inflammation, mixed s - - - - - - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-196
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 88 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 283-Cyst, epithelial inclusion p - P= 66-Ectasia s 3= - 128-Inflammation, chronic s - - 67-Inflammation, mixed s - - Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 270-Dilatation, sinusoidal s - - 169-Infiltration, histiocytic s 3= - 142-Sinus plasmacytosis s - - 75-N-Leukemia, monuc - 1= Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 13-Hemorrhage s 2= - - - - - 171-Pigmentation s - - - - - - 267-N-Sarcoma, histiocytic - - - - - - 14-N-Leukemia, monuc - 1= - - - - Pituitary gland (7) Status > Operator > 142 142 142 142 142 173-Angiectasis s - - - - - 40-Cyst s - - - - - 172-Hemorrhage s - - - - - 232-Inflammation, chronic s - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - 39-B-Adenoma, pars distalis - - - - - 138-M-Leukemia, monuc 1 - - - -

Study Number FY01-013

M-197
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 89 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p - 286-Myodegeneration s - 281-Inflammation, mixed s - 308-B-Fibroma 1= 113-B-Lipoma - 200-M-Mesothelio, mal - 328-N-Sarcoma, histiocytic - 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 142 302-Cyst, epi inclusion p - 145-Inflammation, acute s - 174-Inflammation, mixed s 4= 175-Hyperplasia/hyperkeratosis s 3= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 151-N-Leukemia, monuc 1= Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-198
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 90 Rat/F344/N Group Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G614 3 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615 Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FS Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 142 301-Inflammation, mixed s - 311-M-Mesothelio, mal 2=

Study Number FY01-013

M-199
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 91 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Lungs (17) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s 1 - - - - - 1 - - - - - - 1 - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s 1= - - - - - - - 2= - - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - - - 2 - - - - 1 - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol 2 - 2 2 2= - 2 - 2 2= 2 2 - 2 1 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - 2 - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - - 9-N-Leukemia, monuc 1= - - - - - - - 1 - - Thyroid glands (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - 10-B-Adenoma, C-cell 1 - - - - - - - - - - 87-B-Adenoma, follicular cell - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - - - - - -

Study Number FY01-013

M-200
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 92 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Parathyroid (2) Status > mH mH m m m Operator > 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 2 - 2 2 2 2 1 2 2 1 2 2 2 1 1 19-Inflammation, chronic s - - - - - - - - - - - - - - - 16-Metaplasia, squamous s - - - - - - - - - 1 - - 1 - - 15-Hyperplasia, epithelial s - - 1 2 2 - 1 - - - 2 1 - - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - 2 - Mandibular LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - 21-N-Leukemia, monuc 1= - - - 1 - - - - 1 - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - - - 1 1 - - 1 1 2 - 160-Congestion s - - - - - - - - - - - 272-Cyst s - 3= - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - 22-Necrosis s - - 1 - - - - - - - - 231-Thrombus s - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - - 29-Inflammation, chronic s - - - - - - - - - - - 27-Hyperplasia, biliary s 2 3 3 2 3 2 3 3 3 3 3 28-Hyperplasia, hepato, regen s - - - - - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - -

Study Number FY01-013

M-201
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 93 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - 24-M-Leukemia, monuc 2= 2 2 2= 2= - 2 2= 2 2= 2= Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - 2= - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - - - - 2= 247-Hemorrhage s - - - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - 30-M-Leukemia, monuc 2= - 2= 2= 2= 2= - 2= 2= 2= 2 2= - 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - 2 - - - 33-Nephropathy, chronic s 3 3 2 2 2 3 3 1 2 2 3 2 3 2 3 130-Pigment, tubular epithelium s - - - - - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - 3= - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s 1 - - - - - 1 - - - - 116-Fibrosis s - - - - - - - 1 - - - 206-Thrombus s - - - - - - - 1 - - - 279-Inflammation, acute s - - - - - - - - - - - 34-Inflammation, focal, chronic s - - - - 1 - - - 1 1 - 35-M-Leukemia, monuc - 1 - - - - - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - -

Study Number FY01-013

M-202
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 94 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Urinary bladder (5) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - Duodenum Status > U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - Rectum Status > U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - 62-Degen, cytopl vacuol s - - 2 - - - - 1 - - - 194-Necrosis s - - - - - - - - - - - 108-Thrombus s - - - - - - - - - - 2 277-Hyperplasia, cort, diffuse s - - - - - - - 3= - - - 38-Hyperplasia, medulla, focal p P - - P - - - - - - - 77-B-Pheochrom, bgn - - 1= - 1 - - - - 1= - 305-B-Pheochro, complex, benign - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - 57-M-Leukemia, monuc - 1 - - - - - - - - -

Study Number FY01-013

M-203
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 95 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Prostate (6) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - 109-Mineralization s - - - - - - - - - - 273-Hyperplasia s - - - - - 1 - - - - 88-Inflammation, acute s - - - - - - - - - - 64-Inflammation, mixed s 1 3 2 - - - 2 1 2 - Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - - - - - - - - 2= 242-Granuloma, sperm s - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - 198-M-Mesothelio, mal - - - - - - - - - - - - Seminal vesicle (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - 2= - - - 3= - - - - - - 182-Dilatation s - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - 43-N-Leukemia, monuc - - - - - - - - - - - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s 3= - - - - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - 2 - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - -

Study Number FY01-013

M-204
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 96 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Mammary gland (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - - 155-Hyperplasia, lobular s - - - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - - - 55-B-Fibroma - - - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - 149-B-Fibroma - 1= - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - 2= - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - - - 226-Edema s - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - 183-Hemorrhage s - - - - - - - 2 - - - 192-Mineralization s - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - 2= - - - 190-Inflammation, chronic s - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - 111-Cataract p - - - - - - - - - - - 90-Degen s - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - - 59-Mineralization, scleral s - 1 - 1 2 - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - - 180-Inflammation, acute s - - - - - - - - - - -

Study Number FY01-013

M-205
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 97 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - 1 - - - - 2 - - 2 - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - - 1 - - - - - - 3 - 49-Inflammation-nasolac duct s - - - - - - 3 - - 1 - - - 2 - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - 2 - - - - 2 - - 2 - - - 2 1 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - 2 - - - - - - - 2 - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - - 2 - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - 2 - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - 2 - - - 1 - - - 2 - - - 2 - 93-Inflammation, mixed s - - - - - - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-206
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 98 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - 1 - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 142 283-Cyst, epithelial inclusion p - 66-Ectasia s 3= 128-Inflammation, chronic s - 67-Inflammation, mixed s - Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 71-N-Leukemia, monuc Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 142 270-Dilatation, sinusoidal s - - - - 169-Infiltration, histiocytic s - - - - 142-Sinus plasmacytosis s - - - - 75-N-Leukemia, monuc 1= 1= 1= 1= Mediastinal LN (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - 2= - - - - - - 171-Pigmentation s - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - 14-N-Leukemia, monuc 1= - - - - - - - - - Pituitary gland (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - - 40-Cyst s 2 - - 2= 1 - - - - 1= - - 172-Hemorrhage s - - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - - - - - - - - 39-B-Adenoma, pars distalis - - - - - - - 1= - - - - 138-M-Leukemia, monuc - - - - - - - - - - - -

Study Number FY01-013

M-207
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 99 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p P= 286-Myodegeneration s - 281-Inflammation, mixed s - 308-B-Fibroma - 113-B-Lipoma - 200-M-Mesothelio, mal - 328-N-Sarcoma, histiocytic - 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-208
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:100 Rat/F344/N Group Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G629 3 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630 Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FS Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-209
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:101 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Lungs (17) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - 1 1 - - - - - - - - - - - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - - - - - - - - - 2= - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - 1= - - - - - - - - - 84-Inflammation, mixed s - - 1 - - - 2 - - - - - - - - 214-Inflammation, granulomatous s - - - 1 1 - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol 2 2 1 - - 2 1= 1 1= 2= 1 2 - 2 - 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > *H *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - 9-N-Leukemia, monuc 1= - - 1= - - - - 1 - Thyroid glands (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - P - - P - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - 10-B-Adenoma, C-cell - 1= - - - - - 1= - - - - 87-B-Adenoma, follicular cell - - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - 1= - - - - - -

Study Number FY01-013

M-210
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:102 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Parathyroid (2) Status > m m mH m m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 2 2 - 2 2 1 2 2 2 1 - - - - 2 19-Inflammation, chronic s - - - - - - - - - - 2 1 - - - 16-Metaplasia, squamous s 1 - - - - - - - - - - - - - 1 15-Hyperplasia, epithelial s - 1 - - 1 1 - - - - - - - - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - Mandibular LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - 2= - - - - - - - - 21-N-Leukemia, monuc 1= - - - 1 - - 1 - - 1 - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s 1 - - - - - - - - - - - - - 160-Congestion s - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - 99-Fatty Change s - - - 1 - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - - - - 22-Necrosis s - - - - - - - - - - - - - - 231-Thrombus s - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - - - - - 29-Inflammation, chronic s - - - - - - - - - - - - - - 27-Hyperplasia, biliary s 3 3 2 2 2 4 3 2= 2 2 3 2 3 2 28-Hyperplasia, hepato, regen s - - - - - - - - - - - - - 2 122-B-Adenoma, hepatocellular 1= - - - - - - - - - - - - -

Study Number FY01-013

M-211
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:103 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - 24-M-Leukemia, monuc 1 2= 1 1= - 2 2= - 2= 2 2= - 2 - Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - 63-Fibrosis s - - - - - - 2 - 1= - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - - 30-M-Leukemia, monuc 2= 2= 1= - 2= 2= 1= 1= 2= 2= 2= - 2= - 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - 2 - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 3 2 3 3= 2 2 3 3 3= 2 2 3 2 1 3 130-Pigment, tubular epithelium s - - - - - - - - - - - - - - - 274-Inflammation, acute s - - - - - 3= - - - - - - - - - 213-B-Adenoma, renal tubule - - 1 - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - - - - - - - - - 116-Fibrosis s - - - - - - - - 1 - - - 206-Thrombus s - - - - - - - - - - - - 279-Inflammation, acute s - - - - 3 - - - - - - - 34-Inflammation, focal, chronic s - 1 1 - - - - 1 - 1 1 1 35-M-Leukemia, monuc 1 - - - - - - - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - -

Study Number FY01-013

M-212
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:104 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - - Duodenum Status > U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - - Rectum Status > U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - - - - - - - - - 194-Necrosis s - - - - - - - - - - - - 108-Thrombus s - - - - 3 - - - - - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p P - P - - - - - - - - - 77-B-Pheochrom, bgn - - - - - - - - 1 - - - 305-B-Pheochro, complex, benign - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - - 57-M-Leukemia, monuc - 1 - - 2= - - - - - - -

Study Number FY01-013

M-213
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:105 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - - - 64-Inflammation, mixed s - 2 - - 2 - 2 1 2 1 - 3 Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - - - - - - - - - 242-Granuloma, sperm s - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - 3 - - - 198-M-Mesothelio, mal - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - - - - - - - - 2= - - 182-Dilatation s - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - 43-N-Leukemia, monuc 1 - - - 1 - - - - - 1= - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - - - - - - 2= - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - - - P - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - -

Study Number FY01-013

M-214
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:106 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Mammary gland (6) Status > *H *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p P= - - - - - - - - - 166-Ectasia s - - - - - - - - - - 155-Hyperplasia, lobular s - - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - - 55-B-Fibroma - - 1= - - - - 1= - - 266-N-Sarcoma, histiocytic - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - 221-Hyperkeratosis s 4= - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - 237-Inflammation, mixed s - - - 3= - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - - - - 226-Edema s - - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - - 275-Inflammation, acute s - - - - 1 - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - 4 111-Cataract p - - - - - - - - - - - P 90-Degen s - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - - - 46-Mineralization, corneal str s - - - - 1= - - - - - - - 59-Mineralization, scleral s - - - - - - - 1 - - - - 121-Neovascularization, corneal s - - - - - - - - - - - 3 180-Inflammation, acute s - - - - 1 - - - - - - -

Study Number FY01-013

M-215
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:107 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - - 278-Inflammation, chronic s - - - 3 - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - - 280-Inflammation, acute s - - - - 1 - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - 1 - - - - 106-Metaplasia, squ-resp epith s - - - - - - - 1 - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - 1 1 - 1 - - - - - - - 49-Inflammation-nasolac duct s 1 - - - 2 - 2 - - - 1 - 3 3 - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - - 1 - - - - - 3 - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - 1 - - - - - - - 92-Inflammation, mixed s - - - - - - - 1 - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - 1 - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - - 2 1 - - - 93-Inflammation, mixed s - - - - - - - 1 - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-216
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:108 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - 2 - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - 2 - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 282-Dilatation, sinusoidal s - 2= - 72-N-Leukemia, monuc 2= - 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 270-Dilatation, sinusoidal s - - - 169-Infiltration, histiocytic s - - - 142-Sinus plasmacytosis s - - - 75-N-Leukemia, monuc 2= - 1= Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - - - 171-Pigmentation s - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - 14-N-Leukemia, monuc 1 - - - 1= - - - - - 1= - Pituitary gland (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - - - - 40-Cyst s - - - - - - - 2= - 1= - - - 1 172-Hemorrhage s - - - - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - - 1 - - 1 - - - - 39-B-Adenoma, pars distalis - - - 1= - 1= - - - - - - 1= - 138-M-Leukemia, monuc - - - - - - - - - - - - - -

Study Number FY01-013

M-217
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:109 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p - 286-Myodegeneration s - 281-Inflammation, mixed s 4= 308-B-Fibroma - 113-B-Lipoma - 200-M-Mesothelio, mal - 328-N-Sarcoma, histiocytic - 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 151-N-Leukemia, monuc 1= Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-218
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:110 Rat/F344/N Group Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G644 3 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645 Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-219
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:111 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Lungs (17) Status > Operator > 142 142 142 142 142 4-Alveolar histiocytosis s 1 - - 1 - 299-Autolysis, marked p - - - - - 3-Congestion s - - - - - 82-Fibrosis, focal s - - - - - 154-Hemorrhage s 1 - - - - 306-Metaplasia, squam - alv epi s - - - - - 233-Mineralization, uremic s - - - - - 298-Cyst, squamous, keratiniz p - - - - - 187-Inflammation, acute s - - - - - 84-Inflammation, mixed s - - - - - 214-Inflammation, granulomatous s - - - - - 1-Hyperplasia, alv epi, focal s - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - 240-N-Sarcoma, histiocytic - - - - - 2-N-Leukemia,monuc - cap invol 2 - 1 1 - 131-N-Leukemia,monuc - inv invol - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 188-Metaplasia, squamous s - - - - - 7-Inflammation, acute s - - - - - 85-Inflammation, mixed s - - - - - 177-Inflammation, chronic s - - - - - 86-Hyperplasia, epithelial s - - - - - 215-N-Leukemia, mononuclear - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 8-Hemorrhage s - - 243-N-Sarcoma, histiocytic - - 9-N-Leukemia, monuc 1= - Thyroid glands (7) Status > Operator > 142 142 115-Cyst, follicular p - - 73-Hyperplasia, C-cell, focal s - - 153-Hyperplasia, follicular cell s - - 10-B-Adenoma, C-cell 1= - 87-B-Adenoma, follicular cell - - 204-M-Carcinoma, C-cell - - 125-M-Carcinoma, follicular cell - -

Study Number FY01-013

M-220
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:112 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Parathyroid (2) Status > Operator > 142 142 235-Hyperplasia, diffuse s - - 203-Hyperplasia, focal s - - Aorta (2) Status > Operator > 142 142 132-N-Leukemia,monuc - inv invol - - 325-Dilatation p - - Esophagus Status > U U Operator > 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 95-Ulceration s - - - - - 18-Inflammation, mixed s - 2 2 2 - 19-Inflammation, chronic s 1 - - - 2 16-Metaplasia, squamous s - - 1 - - 15-Hyperplasia, epithelial s - - - 2 2 Salivary gland (3) Status > Operator > 142 142 225-Degen s - - 236-Inflammation, acute s - - 20-M-Leukemia, monuc - - Mandibular LN (4) Status > Operator > 142 142 126-Hemorrhage s - - 118-Sinus plasmacytosis s - - 60-Hyperplasia, lymphoid s - - 21-N-Leukemia, monuc - - Liver (17) Status > Operator > 142 142 142 142 26-Angiectasis s - - - - 160-Congestion s - - - - 272-Cyst s - - - - 99-Fatty Change s - - - - 158-Foci cell alter, basophilic s - - - - 123-Hdn p - - - - 22-Necrosis s - - - - 231-Thrombus s - - - - 23-Vaculoliz, cyto s - - 2 - 29-Inflammation, chronic s - - - - 27-Hyperplasia, biliary s 3 2 - 3 28-Hyperplasia, hepato, regen s - - 2= - 122-B-Adenoma, hepatocellular - - - -

Study Number FY01-013

M-221
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:113 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Liver (17) Status > Operator > 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - 246-M-Sarcoma, histiocytic - - - - 310-M-Sarcoma, undifferentiated - - - - 24-M-Leukemia, monuc 2= - 1= - Spleen (7) Status > Operator > 142 142 142 142 285-Congestion s - - - - 63-Fibrosis s - - - - 247-Hemorrhage s - - - - 129-Necrosis s - - - - 201-M-Fibrosarc - - - - 30-M-Leukemia, monuc 2= 1= 1= - 326-N-Sarcoma, histiocytic - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 161-Cyst s - - - - - 248-Degen, hyaline droplet s - - - - - 251-Infarct s - - - - - 33-Nephropathy, chronic s 3 3= 4= 3 3 130-Pigment, tubular epithelium s 3 - - - - 274-Inflammation, acute s - - - - - 213-B-Adenoma, renal tubule - - 1 - - 191-M-Carcinoma, renal tubule - - - - - 68-M-Leukemia, monuc - - - - - Heart (6) Status > Operator > 142 142 96-Degen, myocyte s - - 116-Fibrosis s - - 206-Thrombus s - - 279-Inflammation, acute s - - 34-Inflammation, focal, chronic s - - 35-M-Leukemia, monuc - - Stomach (2) Status > Operator > 142 142 101-Inflammation, mixed s - - 100-Hyperplasia, sq epi s - - Cecum (1) Status > Operator > 142 142 69-N-Leukemia, monuc - -

Study Number FY01-013

M-222
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:114 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Urinary bladder (5) Status > Operator > 142 142 178-Hemorrhage s - - 193-Inflammation, mixed s - - 37-Inflammation, chronic s - - 61-B-Papilloma, transitional - - 134-M-Leukemia, monuc - - Duodenum Status > U U Operator > 142 142 Jejunum (1) Status > Operator > 142 142 80-M-Adenocarcinoma - - Ileum (3) Status > Operator > 142 142 78-Hyperplasia, lymphoid s - - 81-B-Fibroma - - 207-N-Leukemia, monuc - - Colon (2) Status > Operator > 142 142 197-Inflammation, mixed s - - 156-B-Leiomyoma - - Pancreas (2) Status > Operator > 142 142 323-M-Carcinoma, ductal cell - - 135-M-Leukemia, monuc - - Rectum Status > U U Operator > 142 142 Adrenal glands (10) Status > Operator > 142 142 164-Cyst s - - 62-Degen, cytopl vacuol s - - 194-Necrosis s - - 108-Thrombus s - - 277-Hyperplasia, cort, diffuse s - - 38-Hyperplasia, medulla, focal p - - 77-B-Pheochrom, bgn 1= - 305-B-Pheochro, complex, benign - - 74-M-Pheochromocytoma, malig - - 57-M-Leukemia, monuc - -

Study Number FY01-013

M-223
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:115 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Prostate (6) Status > Operator > 142 142 143-Atrophy s - - 179-Hemorrhage s - - 109-Mineralization s - - 273-Hyperplasia s - - 88-Inflammation, acute s - - 64-Inflammation, mixed s - 3 Epididymis (4) Status > Operator > 142 142 119-Atrophy s - - 242-Granuloma, sperm s - - 97-Inflammation, chronic s - - 198-M-Mesothelio, mal - - Seminal vesicle (4) Status > Operator > 142 142 142 120-Atrophy s - - - 182-Dilatation s - 4= - 307-Hyperplasia s - - - 136-M-Leukemia, monuc - - - Mesenteric LN (4) Status > Operator > 142 142 147-Hemorrhage s - - 79-Histiocytosis, sinus s - - 257-N-Sarcoma, histiocytic - - 43-N-Leukemia, monuc - - Testes (5) Status > Operator > 142 142 142 142 142 152-Atrophy s - - - - - 287-Hemorrhage s - - - - - 105-Hyperplasia, interst cell p - - - - P= 54-B-Adenoma, interstitial 1= 1= 1= 1= - 199-M-Mesothelioma, malig - - - - - Sciatic nerve (1) Status > Operator > 142 142 83-N-Leukemia, monuc - - Muscle, skeletal (3) Status > Operator > 142 142 304-Inflammation, chronic s - - 258-N-Sarcoma, histiocytic - - 271-M-Leukemia, monuc - -

Study Number FY01-013

M-224
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:116 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Mammary gland (6) Status > Operator > 142 142 142 284-Cyst p - - - 166-Ectasia s - - - 155-Hyperplasia, lobular s - - - 165-B-Fibroadenoma - - - 55-B-Fibroma - 1= - 266-N-Sarcoma, histiocytic - - - Skin (13) Status > Operator > 142 142 229-Cyst, epith inc p - - 140-Fibrosis s - - 221-Hyperkeratosis s - - 241-Necrosis s - - 237-Inflammation, mixed s - - 148-Inflammation, chronic s - - 149-B-Fibroma - - 176-B-Keratoacanthoma - - 223-B-Tumor, basal cell, benign - - 309-B-Tumor, hair follicle, ben - - 300-M-Carcinoma, sebaceous cell - - 303-M-Sarcoma, undifferentiated - - 327-N-Sarcoma, histiocytic - - Brain (10) Status > Operator > 142 142 142 44-Compression s - 1= 4= 103-Ectasia, ventricular sys s - - - 226-Edema s - - - 189-Gliosis s - - - 183-Hemorrhage s - - - 192-Mineralization s - - - 45-Necrosis s - - - 275-Inflammation, acute s - - - 190-Inflammation, chronic s - - - 224-M-Astrocytoma, malignant - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 89-Atrophy s - - - 110-Atrophy, retinal, unilat s - 3 - 111-Cataract p - P= - 90-Degen s - - - 144-Metaplasia, osseous, sclera s - - - 46-Mineralization, corneal str s - 1 - 59-Mineralization, scleral s 1 - 1 121-Neovascularization, corneal s - 2 - 180-Inflammation, acute s - - -

Study Number FY01-013

M-225
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:117 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 127-Inflammation, mixed s - - - 278-Inflammation, chronic s - - - 216-M-Leukemia, monuc - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 209-New bone, endosteal s - - - - - 212-Inflammation, acute s - - - - - Spinal cord (3) Status > Operator > 142 142 48-Degen, white matter s - - 184-Hemorrhage s - - 280-Inflammation, acute s - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 261-Degeneration-resp epith s - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - 106-Metaplasia, squ-resp epith s - - - - - 124-Metaplasia, squ-trans epith s - - - - - 91-Inflammation, mixed s - 1 - 1 - 49-Inflammation-nasolac duct s - - - - - 107-Inflammation-resp epith s - - - - - 186-Hyperplasia-resp epith s - - - - - 217-M-Leukemia, monuc - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - 51-Degeneration,hyaline-olf epi s - - - - - 262-Degeneration-resp epith s - - - - - 202-Degeneration, hyal-resp epit s - - - - - 210-Metaplasia, sec-olfact epith s - - - - - 292-Metaplasia, squ-olfact epith s - - - - - 312-Metaplasia, squ-resp epith s - - - - - 92-Inflammation, mixed s - - - - - 227-Hyperplasia-resp epith s - - - - - 112-M-Carcinoma, squamous cell - - - - - 218-M-Leukemia, monuc - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - 93-Inflammation, mixed s - - - - - 195-M-Carcinoma, squamous cell - - - - - 219-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-226
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:118 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - 168-Degeneration, hyal-olf epi s - - - - - 94-Inflammation, mixed s - - - - - 196-N-Carcinoma, squamous cell - - - - - 220-M-Leukemia, monuc - - - - - Preputial gland (4) Status > M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M Operator > 71-N-Leukemia, monuc Iliac LN (2) Status > M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M Operator > 270-Dilatation, sinusoidal s 169-Infiltration, histiocytic s 142-Sinus plasmacytosis s 75-N-Leukemia, monuc Mediastinal LN (4) Status > Operator > 142 142 13-Hemorrhage s - - 171-Pigmentation s - - 267-N-Sarcoma, histiocytic - - 14-N-Leukemia, monuc - - Pituitary gland (7) Status > Operator > 142 142 142 173-Angiectasis s - - - 40-Cyst s - - - 172-Hemorrhage s - - - 232-Inflammation, chronic s - - - 42-Hyperplasia, pars dist, fcl s 1 - - 39-B-Adenoma, pars distalis - 1= 1= 138-M-Leukemia, monuc - - -

Study Number FY01-013

M-227
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:119 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Tiss.not specifi (9) Status > M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-228
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:120 Rat/F344/N Group Sex Dosage Animal > 6835G647 6835G649 3 M 10 g/m3 Animal > 6835G646 6835G648 6835G650 Tissue/diagnosis Death code > U2 FS FS FS U2 Mesentery (2) Status > M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-229
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:121 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Lungs (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s 1 - - - - 1 - - 1 - - - - - - 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - - - - - - - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s 3 - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - 1 1 - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - - - - - 1 - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol - - - - 2 - 2 - 2= - - 1 2 - 2 131-N-Leukemia,monuc - inv invol - - - - - - - 2 - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s 2 - 2 - - - - - - 2 - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - 2= - 243-N-Sarcoma, histiocytic - - - - - - - - - - - - - 9-N-Leukemia, monuc - - 1= - - - 1= - - - - - - Thyroid glands (7) Status > m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - - - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - 1 - - - - - - 1 - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 10-B-Adenoma, C-cell - - - - - - - - - - - - 1 - - 87-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - - - - - - 1= - - - - -

Study Number FY01-013

M-230
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:122 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Parathyroid (2) Status > * mH *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s 3 - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 325-Dilatation p P= - - - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 3 2 2 2 2 2 3 2 3 2 2 2 2 2 2 19-Inflammation, chronic s - - - - - - - - - - - - - - - 16-Metaplasia, squamous s - - - 2 - - - - - 2 - - - - - 15-Hyperplasia, epithelial s 2 1 2 2 1 2 2 2 2 - - - 1 2 - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - - - 1 236-Inflammation, acute s 1 - - - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - - - - - 21-N-Leukemia, monuc - - - - - - - 1 1 - - 1 - - - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s 2 - - 1 - 2 - - - 1 - - 1 - - 160-Congestion s - - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 123-Hdn p - - P= - - - - - - - - - - - - 22-Necrosis s - - - - - - - - - - - - - - - 231-Thrombus s - - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - 2 - - - - - - - - - - - 29-Inflammation, chronic s - - - - - - - - - - - - - - - 27-Hyperplasia, biliary s 3= 2 - 2 3 2 3 3 3 2 2 - 1 - 4 28-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -

Study Number FY01-013

M-231
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:123 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - 2 - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 24-M-Leukemia, monuc - - 2= - 2= - 2 2= 2= - - 1 2= - 2= Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - - - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - - - 30-M-Leukemia, monuc - - 1 - 2= - 2= 2= 2= - - 1 2= - 2= 326-N-Sarcoma, histiocytic - - - - - - - - - - - 2 - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 4= 3 3= 3 3= 3= 2 3= 3 3 3 2= 4= 4= - 130-Pigment, tubular epithelium s - - 3 - - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s 2 - - - - 1 - - - - - - - - - 116-Fibrosis s 2 - - - - - - - 1= - - - - - - 206-Thrombus s - - - - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - - - - 34-Inflammation, focal, chronic s 1 1 - 1 1 - - - - - - - - 1 1 35-M-Leukemia, monuc - - - - - - - 1 - - - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - - - - - Cecum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-232
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:124 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - - - - 37-Inflammation, chronic s - - - 1 - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - 1 - - - - - - - Duodenum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - - - - 156-B-Leiomyoma - - - - - 1= - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - 2= - - - 135-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - 1 - - - - - - - - - - - 194-Necrosis s - - - - - - - - - - - - - - - 108-Thrombus s - - - - - - 4= - - - - - - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - - P= - P - - P - - - - P P P 77-B-Pheochrom, bgn - - - - - - - 1 - - - - - 1 - 305-B-Pheochro, complex, benign - - - - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - - 57-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-233
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:125 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - 1 - - 1 - - - - - - - 179-Hemorrhage s - - - - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - - - - - - 64-Inflammation, mixed s 3 1 2 3 1 - - - - - 2 - 4= - - Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - 1 - - - - - - - - - - 242-Granuloma, sperm s - - - - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - - - - 198-M-Mesothelio, mal - - 2= - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - - - 1 - - 3 - 1 - - - - - 182-Dilatation s - - - - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 43-N-Leukemia, monuc - - - - - - - - - - - - - - - Testes (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - - - - - - - - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - 2 - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-234
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:126 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Mammary gland (6) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - 4= - - - 155-Hyperplasia, lobular s - - - - - 3 - - - - - - 2 - 165-B-Fibroadenoma - - - - - - - - - - - - - - 55-B-Fibroma - - - 1= - - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - - 1= - 223-B-Tumor, basal cell, benign - - - - - - - - - 1= - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - 2 - - - - - - 2= - 3= - - 103-Ectasia, ventricular sys s - - - - - - - - - - - - - - - 226-Edema s - - - - - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - - - - 45-Necrosis s - - - - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - 2 - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 111-Cataract p - - - - - - - - - - - - - - - 90-Degen s - - - - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - - - - - - 59-Mineralization, scleral s - - - - - - - - - - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - - - - - - 180-Inflammation, acute s - - - - - - - - - - - - - - -

Study Number FY01-013

M-235
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:127 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - 1 - - 2 - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - - 1 - - - - - - - - 49-Inflammation-nasolac duct s - - - - - - 3 - - - - - - - - 107-Inflammation-resp epith s 2 - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s 2 - - - - - - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - 1 - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - 2 - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s 2 - - - - - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - 2 - - - 2 - 93-Inflammation, mixed s 1 - - - - - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-236
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:128 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s 1 - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 142 270-Dilatation, sinusoidal s - - - - 169-Infiltration, histiocytic s - - - - 142-Sinus plasmacytosis s - - - 4= 75-N-Leukemia, monuc 1= 1= 1= - Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - - - - - - 171-Pigmentation s - - - - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-N-Leukemia, monuc - - - - 1= - 1 1 1 - - - - - - Pituitary gland (7) Status > H H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - 3 - - - - 40-Cyst s - - - - - - 1 - 1 - - - - - - 172-Hemorrhage s - - - - - - - - - - - - - 3= - 232-Inflammation, chronic s - - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - 1 - - - - - - 1 - 3 - 39-B-Adenoma, pars distalis - - - 1= - - - - - - 1= - 1= - - 138-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-237
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:129 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Tiss.not specifi (9) Status > M M MH M M M M M M M M M M M M Operator > 142 181-Cyst s - 276-Mammary tissue p - 286-Myodegeneration s - 281-Inflammation, mixed s - 308-B-Fibroma - 113-B-Lipoma - 200-M-Mesothelio, mal 2= 328-N-Sarcoma, histiocytic - 331-Splenic tissue, "accessory" p - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 142 324-Hemorrhage s 2= 137-M-Leukemia, monuc - Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 151-N-Leukemia, monuc 1= Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-238
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:130 Rat/F344/N Group Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H714 4 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715 Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-239
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:131 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Lungs (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - 1 - - - - 1 - - - - - 1= - 1 299-Autolysis, marked p - - - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - 2 - - - - - - 154-Hemorrhage s - - - - - - - - - - - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - - 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s 2 - - - - - - - 2= - - - 1 - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol - - - 2= 2= - 2 2= 2 2= - 2= - 1 - 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - - - - - - - 177-Inflammation, chronic s - 1 - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - - 1= - - 243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 9-N-Leukemia, monuc - - - - - - 1= 1= - 1 - - - - - Thyroid glands (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - P - - - P - - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - 2 - - 1 - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 10-B-Adenoma, C-cell - - - - - - - - - - - - 1 - - 87-B-Adenoma, follicular cell - - 1= - - - - - - - - - - - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - 1= - - - - - - - - - -

Study Number FY01-013

M-240
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:132 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Parathyroid (2) Status > mH mH *H mH m mH mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - - - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s 1 2 - 1 2 2 2 2 2 2 2 2 2 2 2 19-Inflammation, chronic s - - 2 - - - - - - - - - - - - 16-Metaplasia, squamous s - 1 - - - 1 - - - - 2 - - - - 15-Hyperplasia, epithelial s - - - - - - 2 1 2 - - - - - 2 Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - - - - 21-N-Leukemia, monuc - - - - - 1= 1 1 1 - - - - - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - 1 - - - - 2 1 2= 1 1 - 1 - - 160-Congestion s - - - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - - - - - 22-Necrosis s - - - - - - - 1 - - - 2 - - - 231-Thrombus s - - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - 1 - - - 1 29-Inflammation, chronic s - 1 - - - - - - - - 2 - 1 - 1 27-Hyperplasia, biliary s 2 1 2 2 3 2 3 2 - 4 2 3 2 2 2 28-Hyperplasia, hepato, regen s - - - - - - - 1 2 - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -

Study Number FY01-013

M-241
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:133 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 24-M-Leukemia, monuc - 1 - 2 2= - 2= 2= 2= 2= 1 2 - 1 - Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - - - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - - 129-Necrosis s - - - - 3= - - - - - - - - - - 201-M-Fibrosarc - - - - - - - - - - - - - - - 30-M-Leukemia, monuc - 1 - 2= 2= - 2= 2= 2 2= 1 2= - 1 - 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 2 - 3 2 2 3 3= 3 3 3= 3 3 3 3 - 130-Pigment, tubular epithelium s - - - 3 - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - 1= - - - 191-M-Carcinoma, renal tubule - - - - - - - - 2= - - - - - - 68-M-Leukemia, monuc - - - - - - - - - 1 - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - - - - - - - - - - - - - - 116-Fibrosis s - 2 - - - - - - - - - - - - - 206-Thrombus s - - - - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - - - - 34-Inflammation, focal, chronic s 1 - - 1 - 1 - - - - 1 - 1 1 1 35-M-Leukemia, monuc - - - - - - 1 - 2 1 - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - - - - - Cecum (1) Status > A a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - - - -

Study Number FY01-013

M-242
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:134 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - 4= - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - 4 - - - - - 37-Inflammation, chronic s - - - - - - - - - - - - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum Status > U U Ua U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - 3 - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - - - - - 1 - 1 - - - - 194-Necrosis s - - - - - - - - - 3 - - - - - 108-Thrombus s - - 1 - - - - - - - - - - - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - P P - P - - - P - - P - P - 77-B-Pheochrom, bgn - 1 - - - - - - - - - - - - - 305-B-Pheochro, complex, benign - - - - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - - 57-M-Leukemia, monuc - - - - - - 1 - - 2 - - - - -

Study Number FY01-013

M-243
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:135 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - 3 - - - 1 - - 1 - 179-Hemorrhage s - - 2 - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - - - - - - 64-Inflammation, mixed s - - 3= 1 - - - - - 4 - 2 - - - Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - - - 2 - - - 2 - 2 1 - 242-Granuloma, sperm s - - - - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - - - - 198-M-Mesothelio, mal - - - - - - - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - 3= - - - - 2 - 2 1 2= - 2 2 - 182-Dilatation s - - 3= - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 43-N-Leukemia, monuc - - - - 1 - 1 1= - 1 - - - - - Testes (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - 3= - - - - 2= - - - 4= - - - 287-Hemorrhage s 3 - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - P - - - - - - - - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - - - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-244
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:136 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Mammary gland (6) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - - - - - 155-Hyperplasia, lobular s - - 4 - - - - - - - - - - - 165-B-Fibroadenoma - - 1= - - - - - - - - - - - 55-B-Fibroma - - - - - - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - - - - - - - 140-Fibrosis s - - - - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - - - - - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - - - - - - - 226-Edema s - - - - 3 - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - - - - 192-Mineralization s - - - - - - - - 1= - - - - - - 45-Necrosis s - - - - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (12) Status > mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - 4 - - - - - 111-Cataract p - - - - - - - - - P= - - - - - 90-Degen s - - - - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - - - - - - 59-Mineralization, scleral s - - - - - - - - - 1 - - - - 1 121-Neovascularization, corneal s - - - - - - - - - - - - - - - 180-Inflammation, acute s - - 2 - - - - - - - - - - - -

Study Number FY01-013

M-245
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:137 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Eyes/optic nerve (12) Status > mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - - - - 212-Inflammation, acute s - - - - - - - - - - - - - - - Spinal cord (3) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - 3 3 - 2 - - - - - - - - - 49-Inflammation-nasolac duct s - - 3 - - 4 - 4 - - - - 2 2 - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - 3 - 3 - - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - 1 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - - 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - 3 - 2 - - - - - - - - - 227-Hyperplasia-resp epith s - - - 2 - 3 - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - 1 - - - - 2 - - - - 93-Inflammation, mixed s - - - - - - - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - 2 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-246
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:138 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Nose/Turbinate 4 (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - 2 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 283-Cyst, epithelial inclusion p 66-Ectasia s 128-Inflammation, chronic s 67-Inflammation, mixed s Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 142 270-Dilatation, sinusoidal s - - 169-Infiltration, histiocytic s - - 142-Sinus plasmacytosis s - - 75-N-Leukemia, monuc 1= 1= Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - 2 - 2 - - 171-Pigmentation s - - - - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-N-Leukemia, monuc - - - - - - 1 1 - 1 - - - - - Pituitary gland (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - - - - - - - 40-Cyst s - - - - - - - - 2 - - - - - - 172-Hemorrhage s - - - - - - - - - - - - - - - 232-Inflammation, chronic s - - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s 1 - 1= 3 - - - - - - - - - - - 39-B-Adenoma, pars distalis 1 - - - - - - - - - - - - - - 138-M-Leukemia, monuc - - - - - - - - - 1= - - - - -

Study Number FY01-013

M-247
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:139 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 181-Cyst s 3= - 276-Mammary tissue p - - 286-Myodegeneration s - - 281-Inflammation, mixed s - - 308-B-Fibroma - - 113-B-Lipoma - 1= 200-M-Mesothelio, mal - - 328-N-Sarcoma, histiocytic - - 331-Splenic tissue, "accessory" p - - Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M M M M M M M M M M M Operator > 142 324-Hemorrhage s - 137-M-Leukemia, monuc 1= Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 142 269-Hyperostosis s - 228-M-Sarcoma, NOS 1= Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 142 297-M-Carcinoma, squamous cell 1=

Study Number FY01-013

M-248
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:140 Rat/F344/N Group Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H729 4 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730 Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-249
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:141 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Lungs (17) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 4-Alveolar histiocytosis s - - - - - - 1 - - 1 1= - - - - 299-Autolysis, marked p - P= - - - - - - - - - - - - - 3-Congestion s - - - - - - - - - - - - - - - 82-Fibrosis, focal s - - - - - - - - - - - - - - - 154-Hemorrhage s - - - - - - - - - 1 - - - - - 306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - - 233-Mineralization, uremic s - - - - - - - - - - - - - - - 298-Cyst, squamous, keratiniz p - P= - - - - - - - - - - - - - 187-Inflammation, acute s - - - - - - - - - - - - - - 3 84-Inflammation, mixed s - - - - - - - - - - - - - - - 214-Inflammation, granulomatous s - - - - - - - - - - - - - - - 1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - - 240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 2-N-Leukemia,monuc - cap invol - - 2 2 - - 2 2 - 2 - 2 2= 2 - 131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 188-Metaplasia, squamous s - - - - - - - - - - - - - - - 7-Inflammation, acute s - - - - - - - - - - - - - - - 85-Inflammation, mixed s - - - - - - - - - 1 - - - - - 177-Inflammation, chronic s - - - - - - - - - - - - - - - 86-Hyperplasia, epithelial s - - - - - - - - - - - - - - - 215-N-Leukemia, mononuclear - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 8-Hemorrhage s - - - - - - - - - - - - - - 243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - 9-N-Leukemia, monuc - - - - - - - - - - - - - - Thyroid glands (7) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 115-Cyst, follicular p - - - - - - - - - - P - - - - 73-Hyperplasia, C-cell, focal s - - - - - - - - - - 1 - - - - 153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 10-B-Adenoma, C-cell - - - 1 - - - - - - - - - - - 87-B-Adenoma, follicular cell - - - - 1= - - - - - - - 1 - - 204-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 125-M-Carcinoma, follicular cell - - - - 1 - - - - - - - - - -

Study Number FY01-013

M-250
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:142 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Parathyroid (2) Status > m *H m m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - - - - - - - - - - 203-Hyperplasia, focal s - - - - - - - - 3 - - 1 - - Aorta (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 325-Dilatation p - - - - - - - - - - - - - - - Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 95-Ulceration s - - - - - - - - - - - - - - - 18-Inflammation, mixed s - 1 2 2 - 2 1 2 2 2 2 2 2 - 1 19-Inflammation, chronic s 1 - - - - - - - - - - - - - - 16-Metaplasia, squamous s - - - - - - - - 2 - - - - - - 15-Hyperplasia, epithelial s - - - 2 - - - 1 - 2 1 1 1 - - Salivary gland (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 225-Degen s - - - - - - - - - - - - - - - 236-Inflammation, acute s - - - - - - - - - - - - - - - 20-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (4) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 126-Hemorrhage s - - - - - - - - - - - - - - 118-Sinus plasmacytosis s - - - - - - - - - - - - - - 60-Hyperplasia, lymphoid s - - - - - - - - - - - - - - 21-N-Leukemia, monuc - 1 - - - - - - 1= - - - - - Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Angiectasis s - - 1 2 - - - - - 2 1 1 - - - 160-Congestion s - 3= - - - - - - - - - - - - - 272-Cyst s - - - - - - - - - - - - - - - 99-Fatty Change s - - - - - - - - - - - - - - - 158-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 123-Hdn p - - - - - - - - - - - - - - P 22-Necrosis s - - - - - - - - - 2 - - 2 - - 231-Thrombus s - - - - - - - - - - - - - - - 23-Vaculoliz, cyto s - - - - - - - - - - - - - - - 29-Inflammation, chronic s - - - - - 1 - - - - - - - - - 27-Hyperplasia, biliary s 3 2 2 3 1 2 2 3 2 2 2 2 3 3 2 28-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -

Study Number FY01-013

M-251
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:143 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Liver (17) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - - 246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 24-M-Leukemia, monuc 2= - 2= 2= - - 2 2 - 2= 1 2= 2= 2 - Spleen (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Congestion s - - - - - - - - - - - - - - - 63-Fibrosis s - - - - - - - - - - - - - - - 247-Hemorrhage s - - - - - - - - - - - - - - - 129-Necrosis s - - - - - - - - - - - - - - - 201-M-Fibrosarc - - - - - 1= - - - - - - - - - 30-M-Leukemia, monuc 2= - 2= 2= - - 2= 2= - 2= 1= 2= 1= 2= - 326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Kidneys (9) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 248-Degen, hyaline droplet s - - - - - - - - - - - - - - - 251-Infarct s - - - - - - - - - - - - - - - 33-Nephropathy, chronic s 2 2 3 3= 3= 4= - 3 3 3= 3 3 3 2 3 130-Pigment, tubular epithelium s - - - - - - - - - - - - - - - 274-Inflammation, acute s - - - - - - - - - - - - - - - 213-B-Adenoma, renal tubule - - - - - - - - - - - - - - - 191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - - 68-M-Leukemia, monuc - - - - - - - - - - - - - - - Heart (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Degen, myocyte s - - 1 - - - - - - - - - - - - 116-Fibrosis s - - - - - - - - - - - 1 - - - 206-Thrombus s 3= - - - - - - - - - - - - - - 279-Inflammation, acute s - - - - - - - - - - - - - - - 34-Inflammation, focal, chronic s 2 - - - - - - - - - 1 - - - - 35-M-Leukemia, monuc - - - - - - - - - - - 1 - - - Stomach (2) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 101-Inflammation, mixed s - - - - - - - - - - - - - - 100-Hyperplasia, sq epi s - - - - - - - - - - - - - - Cecum (1) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 69-N-Leukemia, monuc - - - - - - - - - - - - - -

Study Number FY01-013

M-252
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:144 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 178-Hemorrhage s - - - - - - - - - - - - - - - 193-Inflammation, mixed s - - - - - - - - - - - - - - - 37-Inflammation, chronic s - - - - - - - - 1 - 1 - - - - 61-B-Papilloma, transitional - - - - - - - - - - - - - - - 134-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum Status > U A U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Jejunum (1) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 80-M-Adenocarcinoma - - - - - - - - - - - - - - Ileum (3) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - - - - - - - - - - 81-B-Fibroma - - - - - - - - - - - - - - 207-N-Leukemia, monuc - - - - - - - - - - - - - - Colon (2) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 197-Inflammation, mixed s - - - - - - - - - - - - - - 156-B-Leiomyoma - - - - - - - - - - - - - - Pancreas (2) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - 135-M-Leukemia, monuc - - - - - - - - - - - - - - Rectum Status > U Ua U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 164-Cyst s - - - - - - - - - - - - - - - 62-Degen, cytopl vacuol s - - - - - - 1 - - - - - - - - 194-Necrosis s - - - - - - - - - - - - - - - 108-Thrombus s - - - 1 - - - - - - 1 - 2 - - 277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - - 38-Hyperplasia, medulla, focal p - - - P - - - P P - - - - P P 77-B-Pheochrom, bgn - - - 1= - - 1 - - - 1 - - - - 305-B-Pheochro, complex, benign - - - - - - - - - - - - - - - 74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - - 57-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-253
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:145 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Prostate (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143-Atrophy s - - - - - - - - - - - - - - - 179-Hemorrhage s - - - - - - - - - - - - - - - 109-Mineralization s - - - - - - - - - - - - - - - 273-Hyperplasia s - - - - - - - - - - - - - - - 88-Inflammation, acute s - - - - - - - - - - - - - - - 64-Inflammation, mixed s - - - - 2 - - 3 - - - - - - - Epididymis (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 119-Atrophy s - - - - 2= - - - - 2= - - - - - 242-Granuloma, sperm s - - - - - - - - - - - - - - - 97-Inflammation, chronic s - - - - - - - - - - - - - - - 198-M-Mesothelio, mal - - - - - 1 - - - - - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Atrophy s - - 2= 2 2 2 - - - - 2 - 2 - - 182-Dilatation s - - - - - - - - - - - - - - - 307-Hyperplasia s - - - - - - - - - - - - - - - 136-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 147-Hemorrhage s - - - - - - - - - - - - - - - 79-Histiocytosis, sinus s - - - - - - - - - - - - - - - 257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 43-N-Leukemia, monuc - - - - - - - - - 1 - 1 - - - Testes (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 152-Atrophy s - - - - - - 4= - - - - 4= - - - 287-Hemorrhage s - - - - - - - - - - - - - - - 105-Hyperplasia, interst cell p - - - - - - - - - - - - - P - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - 1 - - - - - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia, monuc - - - - - - - - - - - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 304-Inflammation, chronic s - - - - - - - - - - - - - - - 258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 271-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-254
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:146 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Mammary gland (6) Status > H *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Cyst p - - - - - - - - - - - - - - 166-Ectasia s - - - - - - - - - - - - - - 155-Hyperplasia, lobular s - - - - 1 - - - - - - - - - 165-B-Fibroadenoma - - - - - - - - - - - - - - 55-B-Fibroma - - - - - - - - - - - - - - 266-N-Sarcoma, histiocytic - - - - - - - - - - - - - - Skin (13) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 229-Cyst, epith inc p - - - - - - - - - P= - - - - - 140-Fibrosis s - - - - - - - - - - - - - - - 221-Hyperkeratosis s - - - - - - - - - - - - - - - 241-Necrosis s - - - - - - - - - - - - - - - 237-Inflammation, mixed s - - - - - - - - - - - - - - - 148-Inflammation, chronic s - - - - - - - - - - - - - - - 149-B-Fibroma - - - - - - - - - - - - - - - 176-B-Keratoacanthoma - - - - - - - - - - - - - - - 223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - - 309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - - 300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - - 303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - - 327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Brain (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 44-Compression s - - - - 3= - - - - - - - - - - 103-Ectasia, ventricular sys s - - - - - - - - - - - - - - - 226-Edema s - - - - - - - - - - - - - - - 189-Gliosis s - - - - - - - - - - - - - - - 183-Hemorrhage s - - - - - - - - - - - - - - - 192-Mineralization s - - - - - - - - - - - - - - - 45-Necrosis s - - 2= - - - - - - - - - - - - 275-Inflammation, acute s - - - - - - - - - - - - - - - 190-Inflammation, chronic s - - - - - - - - - - - - - - - 224-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Atrophy s - - - - - - - - - - - - - - - 110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 111-Cataract p - - - - - - - - - - - - - - - 90-Degen s - - - - - - - - - - - - - - - 144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - - 46-Mineralization, corneal str s - - - - - - - - - - - - - - - 59-Mineralization, scleral s - - - - - - - 1 - - - - - - - 121-Neovascularization, corneal s - - - - - - - - - - - - - - - 180-Inflammation, acute s - - - - - - - - - - - - - - -

Study Number FY01-013

M-255
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:147 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Inflammation, mixed s - - - - - - - - - - - - - - - 278-Inflammation, chronic s - - - - - - - - - - - - - - - 216-M-Leukemia, monuc - - - - - - - - - - - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 209-New bone, endosteal s - - - - - - - - - - - - 2 - - 212-Inflammation, acute s - - - - - - - - - - - - 2 - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 48-Degen, white matter s - - - - - - - - - - - - - - - 184-Hemorrhage s - - - - - - - - - - - - - - - 280-Inflammation, acute s - - - - - - - - - - - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 261-Degeneration-resp epith s - - - - - - - - - - - - - - - 222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - - 106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - - 91-Inflammation, mixed s - - - - - - 2 - - - 1 - - - - 49-Inflammation-nasolac duct s 3 - - - - - - - - - 3 - - 3 - 107-Inflammation-resp epith s - - - - - - - - - - - - - - - 186-Hyperplasia-resp epith s - - - - - - 3 - - - - - - - - 217-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - - - - - - - - - - - 51-Degeneration,hyaline-olf epi s - - - - - 1 - - - - 3 - - - - 262-Degeneration-resp epith s - - - - - - - - - - - - - - - 202-Degeneration, hyal-resp epit s - - - - - - - - - - 3 - - - 2 210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - - 92-Inflammation, mixed s - - - - - 2 - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - 112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 218-M-Leukemia, monuc - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - - - - - - - - - 3 - - - 1 93-Inflammation, mixed s - - - - - 2 - - - - - - - - - 195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - - 219-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-256
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:148 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Nose/Turbinate 4 (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - - - - - - - - - - - 168-Degeneration, hyal-olf epi s - - - - - - - - - - 1 - - - - 94-Inflammation, mixed s - - - - - - - - - - - - - - - 196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - 1 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Preputial gland (4) Status > M M M M M M M M M M M M M M M Operator > 142 283-Cyst, epithelial inclusion p - 66-Ectasia s 3= 128-Inflammation, chronic s - 67-Inflammation, mixed s 2 Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M M M M M M M M M M M Operator > 142 282-Dilatation, sinusoidal s - 72-N-Leukemia, monuc 1= Lymph node other (4) Status > M M M M M M M M M M M M M M M Operator > 142 270-Dilatation, sinusoidal s - 169-Infiltration, histiocytic s - 142-Sinus plasmacytosis s - 75-N-Leukemia, monuc 1= Mediastinal LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 13-Hemorrhage s - - - - - - - - - - - - - - - 171-Pigmentation s - - - - - - - - - - - - - - - 267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-N-Leukemia, monuc - - - - - - - - - - - - - - - Pituitary gland (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 173-Angiectasis s - - - - - - - - - 1 - - - - - 40-Cyst s - - - - - - - 2 1 - - 4= - - - 172-Hemorrhage s - - - - - - - - - - - 4 - - - 232-Inflammation, chronic s - - - - - - - - - - - - - - - 42-Hyperplasia, pars dist, fcl s - - - - - - - - - - - - - - 1 39-B-Adenoma, pars distalis - - - - 1= - - - - - - - - - - 138-M-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

M-257
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:149 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Tiss.not specifi (9) Status > M M M M M M M M M M M M M M M Operator > 142 142 181-Cyst s - - 276-Mammary tissue p - - 286-Myodegeneration s - - 281-Inflammation, mixed s - - 308-B-Fibroma - - 113-B-Lipoma - - 200-M-Mesothelio, mal 1= - 328-N-Sarcoma, histiocytic - - 331-Splenic tissue, "accessory" p - P= Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M MH M M M M M M M M M M M M M Operator > 142 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M M M M M M M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 151-N-Leukemia, monuc 1= Bone, other (2) Status > M M M M M M M M M M M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-258
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:150 Rat/F344/N Group Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H744 4 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745 Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2 Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 142 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-259
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:151 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Lungs (17) Status > H Operator > 142 142 142 142 142 4-Alveolar histiocytosis s - 1= - - - 299-Autolysis, marked p - - - - - 3-Congestion s - - - - - 82-Fibrosis, focal s - - - - - 154-Hemorrhage s - - - - - 306-Metaplasia, squam - alv epi s - - - - - 233-Mineralization, uremic s - - - - - 298-Cyst, squamous, keratiniz p - - - - - 187-Inflammation, acute s - - - - - 84-Inflammation, mixed s - - - - - 214-Inflammation, granulomatous s - - - 3 - 1-Hyperplasia, alv epi, focal s - - - - - 5-Hyperplasia, alv epi, wdsprd s - - - - - 104-B-Adenoma, bronchiolo-alv - - - - - 240-N-Sarcoma, histiocytic - - - - - 2-N-Leukemia,monuc - cap invol 2 - 2= - 2= 131-N-Leukemia,monuc - inv invol - - - - - Trachea (6) Status > Operator > 142 142 142 142 142 188-Metaplasia, squamous s - - - - - 7-Inflammation, acute s - - - - - 85-Inflammation, mixed s - - - - - 177-Inflammation, chronic s - - - - - 86-Hyperplasia, epithelial s - - - - - 215-N-Leukemia, mononuclear - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 8-Hemorrhage s - - - - - 243-N-Sarcoma, histiocytic - - - - - 9-N-Leukemia, monuc 1= - - - 1= Thyroid glands (7) Status > Operator > 142 142 142 142 142 115-Cyst, follicular p - - - - - 73-Hyperplasia, C-cell, focal s 2 - - - 1 153-Hyperplasia, follicular cell s - - - - - 10-B-Adenoma, C-cell - - - - - 87-B-Adenoma, follicular cell - - - - - 204-M-Carcinoma, C-cell - - - - - 125-M-Carcinoma, follicular cell - - - - -

Study Number FY01-013

M-260
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:152 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Parathyroid (2) Status > mH Operator > 142 142 142 142 142 235-Hyperplasia, diffuse s - - - - - 203-Hyperplasia, focal s - - - - - Aorta (2) Status > Operator > 142 142 142 142 142 132-N-Leukemia,monuc - inv invol - - - - - 325-Dilatation p - - - - - Esophagus Status > U U U U U Operator > 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 95-Ulceration s - - - - - 18-Inflammation, mixed s 2 2 - 2 - 19-Inflammation, chronic s - - 1 - - 16-Metaplasia, squamous s - - - - - 15-Hyperplasia, epithelial s 1 2 - 1 - Salivary gland (3) Status > Operator > 142 142 142 142 142 225-Degen s - - - - - 236-Inflammation, acute s - - - - - 20-M-Leukemia, monuc - - - - 1 Mandibular LN (4) Status > Operator > 142 142 142 142 142 126-Hemorrhage s - - - - - 118-Sinus plasmacytosis s - - - - - 60-Hyperplasia, lymphoid s - - - - - 21-N-Leukemia, monuc - - - - - Liver (17) Status > Operator > 142 142 142 142 142 26-Angiectasis s - - 1 - - 160-Congestion s - - - - - 272-Cyst s - - - - - 99-Fatty Change s - - - - - 158-Foci cell alter, basophilic s - - - - - 123-Hdn p - - - - - 22-Necrosis s - - - - - 231-Thrombus s - - - - 2 23-Vaculoliz, cyto s - - - - - 29-Inflammation, chronic s - - - 1 - 27-Hyperplasia, biliary s 3 2 3 2 3 28-Hyperplasia, hepato, regen s - - - - - 122-B-Adenoma, hepatocellular - 1= - - -

Study Number FY01-013

M-261
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:153 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Liver (17) Status > Operator > 142 142 142 142 142 150-M-Carcinoma, hepatocellular - - - - - 246-M-Sarcoma, histiocytic - - - - - 310-M-Sarcoma, undifferentiated - - - - - 24-M-Leukemia, monuc 2= - 2= - 2 Spleen (7) Status > Operator > 142 142 142 142 142 285-Congestion s - - - - - 63-Fibrosis s - - - - - 247-Hemorrhage s - - - - - 129-Necrosis s - - - - - 201-M-Fibrosarc - - - - - 30-M-Leukemia, monuc 2= - 2= - 2= 326-N-Sarcoma, histiocytic - - - - - Kidneys (9) Status > Operator > 142 142 142 142 142 161-Cyst s - - - - - 248-Degen, hyaline droplet s - - - - - 251-Infarct s - - - - - 33-Nephropathy, chronic s 3 3 3 3 3 130-Pigment, tubular epithelium s 4 - - - - 274-Inflammation, acute s - - - - - 213-B-Adenoma, renal tubule - 1= - - - 191-M-Carcinoma, renal tubule - - - - - 68-M-Leukemia, monuc - - - - - Heart (6) Status > Operator > 142 142 142 142 142 96-Degen, myocyte s - - - - - 116-Fibrosis s - - - - - 206-Thrombus s 2= - - - - 279-Inflammation, acute s - - - - - 34-Inflammation, focal, chronic s - 1 1 1 1 35-M-Leukemia, monuc - - - - - Stomach (2) Status > Operator > 142 142 142 142 142 101-Inflammation, mixed s - - - - - 100-Hyperplasia, sq epi s - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 69-N-Leukemia, monuc - - - - -

Study Number FY01-013

M-262
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:154 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Urinary bladder (5) Status > Operator > 142 142 142 142 142 178-Hemorrhage s - - - - - 193-Inflammation, mixed s - - - - - 37-Inflammation, chronic s - - - - - 61-B-Papilloma, transitional - - - - - 134-M-Leukemia, monuc - - - - - Duodenum Status > U U U U U Operator > 142 142 142 142 142 Jejunum (1) Status > Operator > 142 142 142 142 142 80-M-Adenocarcinoma - - - - - Ileum (3) Status > Operator > 142 142 142 142 142 78-Hyperplasia, lymphoid s - - - - - 81-B-Fibroma - - - - - 207-N-Leukemia, monuc - - - - - Colon (2) Status > Operator > 142 142 142 142 142 197-Inflammation, mixed s - - - - - 156-B-Leiomyoma - - - - - Pancreas (2) Status > Operator > 142 142 142 142 142 323-M-Carcinoma, ductal cell - - - - - 135-M-Leukemia, monuc - - - - - Rectum Status > U U U U U Operator > 142 142 142 142 142 Adrenal glands (10) Status > Operator > 142 142 142 142 142 164-Cyst s - - - - - 62-Degen, cytopl vacuol s - - - - - 194-Necrosis s - - - - - 108-Thrombus s - - - - - 277-Hyperplasia, cort, diffuse s - - - - - 38-Hyperplasia, medulla, focal p - - - - - 77-B-Pheochrom, bgn - 1 - - - 305-B-Pheochro, complex, benign - - - - - 74-M-Pheochromocytoma, malig 1= - - - - 57-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-263
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:155 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Prostate (6) Status > Operator > 142 142 142 142 142 143-Atrophy s - - - - - 179-Hemorrhage s - - - - - 109-Mineralization s - - - - - 273-Hyperplasia s - - - - - 88-Inflammation, acute s - - - - - 64-Inflammation, mixed s - - - - - Epididymis (4) Status > Operator > 142 142 142 142 142 119-Atrophy s - - - - - 242-Granuloma, sperm s - - - - - 97-Inflammation, chronic s - - - - - 198-M-Mesothelio, mal - - - - - Seminal vesicle (4) Status > Operator > 142 142 142 142 142 120-Atrophy s - 2= 2= - - 182-Dilatation s - - - - - 307-Hyperplasia s - - - - - 136-M-Leukemia, monuc - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 147-Hemorrhage s - - - - - 79-Histiocytosis, sinus s - - - - - 257-N-Sarcoma, histiocytic - - - - - 43-N-Leukemia, monuc - - - - - Testes (5) Status > Operator > 142 142 142 142 142 152-Atrophy s - - - - - 287-Hemorrhage s - - - - - 105-Hyperplasia, interst cell p - - - - - 54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 199-M-Mesothelioma, malig - - - - - Sciatic nerve (1) Status > Operator > 142 142 142 142 142 83-N-Leukemia, monuc - - - - - Muscle, skeletal (3) Status > Operator > 142 142 142 142 142 304-Inflammation, chronic s - - - - - 258-N-Sarcoma, histiocytic - - - - - 271-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-264
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:156 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Mammary gland (6) Status > Operator > 142 142 142 142 142 284-Cyst p - - - - - 166-Ectasia s - - - - - 155-Hyperplasia, lobular s - - - 4 - 165-B-Fibroadenoma - - - - - 55-B-Fibroma - - - - - 266-N-Sarcoma, histiocytic - - - - - Skin (13) Status > Operator > 142 142 142 142 142 229-Cyst, epith inc p - - - - - 140-Fibrosis s - - - - - 221-Hyperkeratosis s - - - - - 241-Necrosis s - - - - - 237-Inflammation, mixed s - - - - - 148-Inflammation, chronic s - - - - - 149-B-Fibroma - - - - - 176-B-Keratoacanthoma - - - - - 223-B-Tumor, basal cell, benign - - - - - 309-B-Tumor, hair follicle, ben - - - - - 300-M-Carcinoma, sebaceous cell - - - - - 303-M-Sarcoma, undifferentiated - - - - - 327-N-Sarcoma, histiocytic - - - - - Brain (10) Status > Operator > 142 142 142 142 142 44-Compression s - - - - - 103-Ectasia, ventricular sys s - - - - - 226-Edema s - - - - - 189-Gliosis s - - - - - 183-Hemorrhage s - - - - - 192-Mineralization s - - - - - 45-Necrosis s - - - - - 275-Inflammation, acute s - - - - - 190-Inflammation, chronic s - - - - - 224-M-Astrocytoma, malignant - - - - - Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 89-Atrophy s - - - - - 110-Atrophy, retinal, unilat s - - - - - 111-Cataract p - - - - - 90-Degen s - - - - - 144-Metaplasia, osseous, sclera s - - - - - 46-Mineralization, corneal str s - 1 - - - 59-Mineralization, scleral s - - - - 1 121-Neovascularization, corneal s - - - - - 180-Inflammation, acute s - - - - -

Study Number FY01-013

M-265
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:157 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Eyes/optic nerve (12) Status > Operator > 142 142 142 142 142 127-Inflammation, mixed s - - - - - 278-Inflammation, chronic s - - - - - 216-M-Leukemia, monuc - - - - - Bone, femur (2) Status > Operator > 142 142 142 142 142 209-New bone, endosteal s - - - - - 212-Inflammation, acute s - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 48-Degen, white matter s - - - - - 184-Hemorrhage s - - - - - 280-Inflammation, acute s - - - - - Nose/Turbinate 1 (9) Status > Operator > 142 142 142 142 142 261-Degeneration-resp epith s - - - - - 222-Degeneration,hyal-Resp Epith s - - 2 - - 106-Metaplasia, squ-resp epith s - - - - - 124-Metaplasia, squ-trans epith s - - - - - 91-Inflammation, mixed s - - - - - 49-Inflammation-nasolac duct s 2 - 2 3 - 107-Inflammation-resp epith s - - - - - 186-Hyperplasia-resp epith s - - - - - 217-M-Leukemia, monuc - - - - - Nose/Turbinate 2 (11) Status > Operator > 142 142 142 142 142 98-Degeneration-olfact epith s - - - - - 51-Degeneration,hyaline-olf epi s - - 3 - 2 262-Degeneration-resp epith s - - - - - 202-Degeneration, hyal-resp epit s - - - - - 210-Metaplasia, sec-olfact epith s - - - - - 292-Metaplasia, squ-olfact epith s - - - - - 312-Metaplasia, squ-resp epith s - - - - - 92-Inflammation, mixed s 2 - - - - 227-Hyperplasia-resp epith s 3 - - - - 112-M-Carcinoma, squamous cell - - - - - 218-M-Leukemia, monuc - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 52-Degeneration, hyal-olf epi s - - 3 - - 93-Inflammation, mixed s - 1 - - - 195-M-Carcinoma, squamous cell - - - - - 219-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-266
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:158 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Nose/Turbinate 4 (5) Status > Operator > 142 142 142 142 142 313-Degeneration-olfact epith s - - - - - 168-Degeneration, hyal-olf epi s - - - - - 94-Inflammation, mixed s - 1 - - - 196-N-Carcinoma, squamous cell - - - - - 220-M-Leukemia, monuc - - - - - Preputial gland (4) Status > M M M M M Operator > 142 283-Cyst, epithelial inclusion p - 66-Ectasia s 3= 128-Inflammation, chronic s 1 67-Inflammation, mixed s - Pancreatic LN (1) Status > M M M M M Operator > 142 71-N-Leukemia, monuc 1= Iliac LN (2) Status > M M M M M Operator > 282-Dilatation, sinusoidal s 72-N-Leukemia, monuc Lymph node other (4) Status > M M M M M Operator > 270-Dilatation, sinusoidal s 169-Infiltration, histiocytic s 142-Sinus plasmacytosis s 75-N-Leukemia, monuc Mediastinal LN (4) Status > Operator > 142 142 142 142 142 13-Hemorrhage s - - - - - 171-Pigmentation s - - - - - 267-N-Sarcoma, histiocytic - - - - - 14-N-Leukemia, monuc - - - - 1= Pituitary gland (7) Status > Operator > 142 142 142 142 142 173-Angiectasis s 2= - - - - 40-Cyst s - - - - - 172-Hemorrhage s - - - - - 232-Inflammation, chronic s - - - - 1 42-Hyperplasia, pars dist, fcl s 3= - - - - 39-B-Adenoma, pars distalis - - - - - 138-M-Leukemia, monuc - - - - -

Study Number FY01-013

M-267
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:159 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Tiss.not specifi (9) Status > M M M M M Operator > 181-Cyst s 276-Mammary tissue p 286-Myodegeneration s 281-Inflammation, mixed s 308-B-Fibroma 113-B-Lipoma 200-M-Mesothelio, mal 328-N-Sarcoma, histiocytic 331-Splenic tissue, "accessory" p Harderian gland (1) Status > M M M M M Operator > 114-N-Carcinoma, squamous cell Thymus (2) Status > M M M M M Operator > 324-Hemorrhage s 137-M-Leukemia, monuc Mediastinum (1) Status > M M M M M Operator > 139-N-Leukemia, monuc Tail (4) Status > M M M M M Operator > 302-Cyst, epi inclusion p 145-Inflammation, acute s 174-Inflammation, mixed s 175-Hyperplasia/hyperkeratosis s Popliteal LN (1) Status > M M M M M Operator > 151-N-Leukemia, monuc Bone, other (2) Status > M M M M M Operator > 269-Hyperostosis s 228-M-Sarcoma, NOS Zymbal’s gland (1) Status > M M M M M Operator > 297-M-Carcinoma, squamous cell

Study Number FY01-013

M-268
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:160 Rat/F344/N Group Sex Dosage Animal > 6837H747 6837H749 4 M 20 g/m3 Animal > 6837H746 6837H748 6837H750 Tissue/diagnosis Death code > U2 FS U2 FS U2 Mesentery (2) Status > M M M M M Operator > 301-Inflammation, mixed s 311-M-Mesothelio, mal

Study Number FY01-013

M-269
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page:161 Rat/F344/N SYMBOLS, ABBREVIATIONS, AND CODES USED IN THE "MICROSCOPIC EVALUATION OF TISSUES" *** DISTRIBUTION OF FINDINGS *** *** NEOPLASTIC FINDINGS *** " " NO PARENTHESIS = NOT SPECIFIED " B- " = PRIMARY, BENIGN NEOPLASM IN ORGAN/TISSUE " M " M = FINDING MULTI-FOCAL " M- " = PRIMARY, MALIGNANT NEOPLASM IN ORGAN/TISSUE " F " F = FINDING FOCAL " X- " = MALIGNANT NEOPLASM - TISSUE OR ORIGIN UNKNOW

N

 " D " D = FINDING DIFFUSE " N- " = METASTATIC NEOPLASM WITHIN ORGAN/TISSUE *** GRADES FOR DEFINING SEVERITY (DEGREE) OR AMOUNT OF CHANGE *** " I- " = LOCALLY INVASIVE NEOPLASM FROM NEARBY ORGAN " NON-NEOPLASMS " " NEOPLASMS " " + " = PRESENCE OF A NEOPLASTIC FINDING IN ORGAN/TISSUE " 1 " = MINIMUM " 1 " = INCIDENTAL " +AA" = SECONDARY NEOPLASM FROM ORGAN/TISSUE INDICATED BY TWO LETTER ABBREVIATION (FOR EXAMPLE, LI=LIVER) " 2 " = MILD " 2 " = CONTRIBUTORY " +N " = MORE THAN ONE NEOPLASM OF THE SAME TYPE IN THE " 3 " = MODERATE " 3 " = FATAL SAME ORGAN, N EQUALS THE NUMBER OBSERVED " 4 " = MARKED " / " = NEOPLASM PRESENT AND RELATED TO ANIMAL DEATH *** OTHER SYMBOLS *** *** ANIMAL DEATH CODES *** " U " = ORGAN/TISSUE HISTOLOGICALLY NOT REMARKABLE " Un " = USER DEFINDED UNSCHEDULED DEATH CODES " M " = MISCELLANEOUS TISSUE " I1 " = INTERIM SACRIFICE #1 " - " = FINDING NOT PRESENT OR OBSERVED " I2 " = INTERIM SACRIFICE #2 " P " = FINDINGS PRESENT OR CONFIRMED (GRADING INAPPROPRIATE) " I3 " = INTERIM SACRIFICE #3 " * " = TISSUE NOT AVAILABLE FOR MICROSCOPIC EXAMINATION " I4 " = INTERIM SACRIFICE #4 " H " = SPECIAL HISTOLOGICAL COMMENTS ON TISSUE " I5 " = INTERIM SACRIFICE #5 " A " = TISSUE NOT READABLE - AUTOLYTIC " FS " = FINAL SACRIFICE " a " = TISSUE READABLE - AUTOLYTIC " R " = RE-CUT OF TISSUE REQUESTED " m " = ONE OF PAIRED ORGANS MISSING " I " = TISSUE INADEQUATE AND UNREADABLE

Study Number FY01-013

M-270
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-7 Individual Animal Report of Correlated Gross and Microscopic Diagnoses 

M-271
Study Number FY01-013

M-272
Study Number FY01-013

M-273
Study Number FY01-013

M-274
Study Number FY01-013

M-275
Study Number FY01-013

M-276
Study Number FY01-013

M-277
Study Number FY01-013

M-278
Study Number FY01-013

M-279
Study Number FY01-013

M-280
Study Number FY01-013

M-281
Study Number FY01-013

M-282
Study Number FY01-013

M-283
Study Number FY01-013

M-284
Study Number FY01-013

M-285
Study Number FY01-013

M-286
Study Number FY01-013

M-287
Study Number FY01-013

M-288
Study Number FY01-013

M-289
Study Number FY01-013

M-290
Study Number FY01-013

M-291
Study Number FY01-013

M-292
Study Number FY01-013

M-293
Study Number FY01-013

M-294
Study Number FY01-013

M-295
Study Number FY01-013

M-296
Study Number FY01-013

M-297
Study Number FY01-013

M-298
Study Number FY01-013

M-299
Study Number FY01-013

M-300
Study Number FY01-013

M-301
Study Number FY01-013

M-302
Study Number FY01-013

M-303
Study Number FY01-013

M-304
Study Number FY01-013

M-305
Study Number FY01-013

M-306
Study Number FY01-013

M-307
Study Number FY01-013

M-308
Study Number FY01-013

M-309
Study Number FY01-013

M-310
Study Number FY01-013

M-311
Study Number FY01-013

M-312
Study Number FY01-013

M-313
Study Number FY01-013

M-314
Study Number FY01-013

M-315
Study Number FY01-013

M-316
Study Number FY01-013

M-317
Study Number FY01-013

M-318
Study Number FY01-013

M-319
Study Number FY01-013

M-320
Study Number FY01-013

M-321
Study Number FY01-013

M-322
Study Number FY01-013

M-323
Study Number FY01-013

M-324
Study Number FY01-013

M-325
Study Number FY01-013

M-326
Study Number FY01-013

M-327
Study Number FY01-013

M-328
Study Number FY01-013

M-329
Study Number FY01-013

M-330
Study Number FY01-013

M-331
Study Number FY01-013

M-332
Study Number FY01-013

M-333
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-8 Histological Comments on Tissue 

M-334
 Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6831E404 M 1/1 12-Jan-04 09:08 142 Mandibular LN Tissue not represented on recut 6831E406 M 1/1 24-Oct-03 14:54 142 Parathyroid One of pair not represented on slide. 05-Mar-09 09:57 142 Nose/Turbinate 2 SCC is of oral origin. 05-Mar-09 09:57 142 Nose/Turbinate 3 SCC is of oral origin. 05-Mar-09 09:58 142 Nose/Turbinate 4 SCC is of oral origin. 6831E408 M 1/1 30-Oct-03 10:24 142 Bronchial (TBLN) On slide 4. 12-Jan-04 09:39 142 Parathyroid One of pair not represented on slide. 03-Feb-04 14:34 142 Mandibular LN Not on recut 1 (R/C 1) 6831E409 M 1/1 12-Jan-04 09:47 142 Parathyroid One of pair not represented on slide. 23-Oct-03 11:25 142 Mammary gland Tissue not represented on slide, missing at trim. 05-Feb-04 09:24 142 Skin Tissue not represented on slide, missing at trim. 6831E410 M 1/1 03-Feb-04 14:37 142 Pituitary gland Grossly noted enlargement, nothing on recut 1, minimal hyperplasia on R/C 2. 6831E414 M 1/1 30-Oct-03 12:36 142 Nose/Turbinate 3 Fragmented specimen. 6831E415 M 1/1 24-Oct-03 16:23 142 Trachea Very poor tinctorial properties in section. Staining fine in slide 04. 6831E417 M 1/1 24-Oct-03 16:57 142 Spleen Focal region without congestion. 6831E418 M 1/1 03-Feb-04 14:38 142 Parathyroid Tissue not represented on R/C 1 or 2. 27-Oct-03 11:04 142 Preputial gland Slide consists of necrotic debris mixed with bacteria. 6831E419 M 1/1 13-Nov-03 10:03 142 Parathyroid One of pair not represented on slide. 18-Feb-04 14:19 142 Testes Both testes largely effaced by adenomas, even small one. 6831E420 M 1/1 17-Nov-03 12:47 142 Colon Submucosal/lamina propria rarefaction interpreted as artifact of formalin injection at necropsy. 6831E423 M 1/1 30-Oct-03 14:02 142 Parathyroid One of pair not represented on slide. 6831E424 M 1/1 23-Oct-03 12:48 142 Parathyroid One of pair not represented on slide. 6831E425 M 1/1 03-Feb-04 14:44 142 Larynx Incomplete specimen on original and R/C 1 and 2.

Study Number FY01-013

M-335
 Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 2 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6831E425 M 1/1 10-Feb-04 09:27 142 Pituitary gland Fragmented lesion judged adenoma based primarily on compression in original, less so in R/C 1 and 2. 6831E426 M 1/1 03-Feb-04 14:48 142 Parathyroid Tissue not represented on slide, R/C 1 or 2. 6831E427 M 1/1 27-Oct-03 11:56 142 Bronchial (TBLN) Leukemia/lymphoma effacing tissues. 05-Feb-04 12:31 142 Adrenal glands Lost in processing. 6831E428 M 1/1 03-Feb-04 14:50 142 Mandibular LN Tissue not represented on slide or recut 6831E430 M 1/1 03-Feb-04 14:53 142 Parathyroid Tissue distortion due to thyroid mass, no parathyroids on slide or on recuts. 6831E431 M 1/1 12-Jan-04 11:31 142 Mandibular LN Tissue not represented on slide or recut 1. 30-Oct-03 14:40 142 Brain Focally extensive gliosis and granulomatous enephalitis with thrombosis, presumed infarct. 6831E434 M 1/1 23-Oct-03 17:05 142 Sciatic nerve Scattered histiocyte like cells distributed through otherwise unremarkable nerve. 6831E435 M 1/1 27-Oct-03 14:02 142 Parathyroid One of pair not represented on slide. 6831E439 M 1/1 30-Oct-03 15:37 142 Testes Unilateral 03-Feb-04 14:55 142 Spinal cord Only 1 section available for evaluation. 6831E440 M 1/1 03-Feb-04 14:57 142 Pituitary gland Pars distalis only on original and recut. 6831E441 M 1/1 24-Oct-03 09:24 142 Mediastinal LN No tissue found at embedding. 6831E442 M 1/1 27-Oct-03 17:00 142 Parathyroid One of pair not represented on slide. 6831E443 M 1/1 27-Oct-03 17:24 142 Colon Rarefaction of l.p. and submucosa interpreted as artifact of formalin injection. 6831E447 M 1/1 24-Oct-03 10:53 142 Parathyroid One of pair not represented on slide. 6831E448 M 1/1 28-Oct-03 09:00 142 Pituitary gland Focal hemorrhage interpreted as artifact. 6831E449 M 1/1 28-Oct-03 09:02 142 Parathyroid One of pair not represented on slide. 6831E450 M 1/1 10-Feb-04 10:21 142 Pituitary gland Tissue not represented on slide, lymphoid tissue only present. 6833F506 M 2/1 05-Feb-04 12:36 142 Parathyroid One of pair not represented on slide. 6833F507 M 2/1 31-Dec-03 10:56 142 Parathyroid One of pair not represented on slide. 6833F509 M 2/1 13-Jan-04 07:49 142 Thyroid glands Missing at trim

Study Number FY01-013

M-336
 Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 3 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6833F509 M 2/1 05-Feb-04 12:38 142 Parathyroid Missing at trim 05-Feb-04 12:38 142 Esophagus Missing at trim 13-Jan-04 07:49 142 Larynx Missing at trim 03-Feb-04 15:01 142 Mammary gland Tissue not represented on slide or recut. 6833F510 M 2/1 31-Dec-03 11:07 142 Parathyroid One of pair not represented on slide. 05-Mar-09 09:59 142 Nose/Turbinate 4 SCC of oral origin 6833F512 M 2/1 13-Jan-04 09:02 142 Eyes/optic nerve One eye presumed missing at trim 6833F515 M 2/1 13-Jan-04 09:57 142 Iliac LN Not recorded as trimmed. Gross enlargement presumed due to leukemia/lymphoma. 6833F517 M 2/1 05-Jan-04 09:40 142 Urinary bladder Bladder missing at trim. 05-Jan-04 09:43 142 Prostate Missing at trim. 05-Jan-04 09:44 142 Seminal vesicle Missing at trim. 6833F524 M 2/1 03-Feb-04 15:06 142 Bronchial (TBLN) Tissue not represented on slide or recut 6833F528 M 2/1 04-Feb-04 12:16 142 Mammary gland Tissue not represented on slide or recut 6833F531 M 2/1 08-Jan-04 08:58 142 Parathyroid One of pair not represented on slide. 6833F537 M 2/1 03-Feb-04 15:14 142 Mammary gland Tissue not represented on slide or recut 6833F539 M 2/1 05-Mar-09 10:01 142 Nose/Turbinate 3 SCC of oral origin. 05-Mar-09 10:00 142 Nose/Turbinate 4 SCC oral origin. 04-Feb-04 11:06 142 Mediastinal LN Tissue not represented on slide or recut 6833F540 M 2/1 05-Feb-04 12:31 142 Mammary gland Missing at trim. 13-Jan-04 12:15 142 Mediastinal LN Tissue trimmed as mediastinal node is pancreas. 6833F541 M 2/1 06-Jan-04 13:09 142 Lungs Prominent deposition of birefringent pigment interpreted as acid hematin, often within macrophages. 04-Feb-04 11:08 142 Mandibular LN Tissue not represented on slide or recut 04-Feb-04 11:07 142 Mediastinal LN Tissue not represented on slide or recut 6833F542 M 2/1 19-Jan-04 13:11 142 Trachea Extensive artifactual epithelial loss.

Study Number FY01-013

M-337
 Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 4 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6833F543 M 2/1 06-Jan-04 15:36 142 Parathyroid One of pair not represented on slide. 6833F545 M 2/1 13-Jan-04 12:38 142 Pituitary gland Fragmented 6833F550 M 2/1 19-Jan-04 13:33 142 Parathyroid Distortion due to bilateral thyroid C-cell adenomas. 6835G612 M 3/1 08-Jan-04 11:01 142 Parathyroid Tissue not represented on slide. 6835G619 M 3/1 08-Jan-04 11:29 142 Parathyroid One of pair missing 6835G620 M 3/1 08-Jan-04 11:45 142 Parathyroid One of pair not represented on slide. 6835G622 M 3/1 14-Jan-04 08:18 142 Urinary bladder Missing at trim 14-Jan-04 08:21 142 Prostate Missing at trim 13-Feb-04 08:43 142 Seminal vesicle Missing at trim, small size described grossly presumed due to atrophy. 6835G623 M 3/1 04-Feb-04 11:20 142 Trachea Lost in processing, evaluated on slide 4. 6835G629 M 3/1 04-Feb-04 11:21 142 Mediastinal LN Tissue not represented on slide or recut 6835G635 M 3/1 04-Feb-04 11:24 142 Bronchial (TBLN) Tissue not represented on slide or recut 04-Feb-04 11:26 142 Mammary gland Tissue not represented on slide or recut 6835G637 M 3/1 04-Feb-04 11:29 142 Mammary gland Tissue not represented on slide or recut 6835G641 M 3/1 04-Feb-04 11:31 142 Lungs Grossly described nodule not present on slide or recut 6835G642 M 3/1 09-Jan-04 10:39 142 Parathyroid One of pair not represented on slide. 6835G643 M 3/1 04-Feb-04 11:34 142 Bronchial (TBLN) Tissue not represented on slide or recut 6837H703 M 4/1 07-Jan-04 12:18 142 Tiss.not specifi Malignant mesothelioma widespread on mesothelial surfaces 6837H705 M 4/1 29-Oct-03 10:55 142 Spinal cord Focus of hematopoietic cells interpreted as artifact (from bone marrow). 6837H708 M 4/1 29-Oct-03 11:29 142 Parathyroid One of pair not represented on slide. 6837H710 M 4/1 20-Nov-03 10:18 142 Parathyroid Thyroid mass interferes, no recut. 6837H713 M 4/1 29-Oct-03 12:00 142 Testes Unilateral 6837H714 M 4/1 29-Oct-03 16:03 142 Pituitary gland Hemorrhage within cystic spaces in proliferative area. 6837H715 M 4/1 20-Nov-03 15:13 142 Pituitary gland Slide 22 fragment of pituitary, slide 23 good section.

Study Number FY01-013

M-338
 Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09

 Research Institute Study Number:FY01013M Page: 5 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6837H716 M 4/1 04-Feb-04 11:40 142 Mandibular LN Tissue not represented on slide or recut 6837H717 M 4/1 29-Oct-03 16:32 142 Parathyroid One of pair not represented on slide. 6837H718 M 4/1 29-Oct-03 17:12 142 Parathyroid One of pair not represented on slide. 29-Oct-03 17:24 142 Jejunum No recut based on autolysis in other GI sections. 29-Oct-03 17:31 142 Testes Unilateral 6837H719 M 4/1 04-Feb-04 11:42 142 Mammary gland Tissue not represented on slide or recut 6837H720 M 4/1 04-Feb-04 11:44 142 Parathyroid Tissue not represented on slide recut. Distorted by thyroid mass. 21-Nov-03 09:59 142 Eyes/optic nerve One eye missing at trim 6837H722 M 4/1 30-Oct-03 16:12 142 Parathyroid One of pair not represented on slide. 6837H724 M 4/1 30-Oct-03 16:33 142 Parathyroid One of pair not represented on slide. 6837H729 M 4/1 04-Feb-04 12:00 142 Parathyroid Tissue not represented on slide or recut 1, small amount on recut 2. 12-Jan-04 12:56 142 Spinal cord Scattered spheroid-like bodies. 6837H730 M 4/1 05-Mar-09 10:02 142 Nose/Turbinate 3 Carcinoma is likely of oral origin. 05-Mar-09 10:02 142 Nose/Turbinate 4 Carcinoma likely of oral origin. 6837H732 M 4/1 04-Feb-04 12:03 142 Mandibular LN Tissue not represented on slide or recut 20-Feb-04 10:02 142 Thymus Gross findings correlated to autolysis (widespread autolysis noted in lungs only due to software constraints). 6837H735 M 4/1 07-Nov-03 12:16 142 Thyroid glands Follicular carcinoma arising within follicular adenoma. 12-Jan-04 12:58 142 Parathyroid Parathyroids not present on slide, distortion due to thyroid lesion. 07-Nov-03 14:25 142 Mammary gland Mammary tissue on slide 6 6837H745 M 4/1 04-Feb-04 12:15 142 Mammary gland Tissue not represented on slide or recut 05-Mar-09 10:03 142 Nose/Turbinate 4 SCC likely of oral origin. 6837H748 M 4/1 07-Jan-04 14:08 142 Parathyroid One of pair not represented on slide. 6837H749 M 4/1 11-Nov-03 15:10 142 Lungs Multifocal granulomatous inflammation often associated with foreign material (interpreted as plant material).

Study Number FY01-013

M-339
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-9 Summary of Missing Tissues 

M-340
 Lovelace Respiratory Summary Table of Missing Tissues Printed:14-Jun-04

 Research Institute Study number:FY01013M Page: 1 Rat/F344/N Tissue Animals Trachea 6833F536 Bronchial (TBLN) 6831E450 6833F504 6833F524 6835G635 6835G643 6837H703 6837H704 6837H736 Thyroid glands 6831E412* 6831E428* 6831E432* 6831E437* 6833F509 6833F537* 6837H709* Parathyroid 6831E404* 6831E406* 6831E408* 6831E409* 6831E412* 6831E413* 6831E418 6831E423* 6831E424* 6831E426 6831E427* Parathyroid 6831E428* 6831E430 6831E432* 6831E433* 6831E435* 6831E437* 6831E441* 6831E442* 6831E443 6831E447* 6831E448 Parathyroid 6831E449* 6833F506* 6833F507* 6833F509 6833F510* 6833F512* 6833F514* 6833F515* 6833F518* 6833F528* 6833F531* Parathyroid 6833F533* 6833F534* 6833F537* 6833F538* 6833F541* 6833F543* 6833F550 6835G608* 6835G612* 6835G619* 6835G620* Parathyroid 6835G622* 6835G623* 6835G626* 6835G632* 6835G640* 6835G642* 6835G643* 6835G644* 6837H706 6837H708* 6837H710 Parathyroid 6837H717* 6837H718* 6837H720 6837H722* 6837H723* 6837H724* 6837H729* 6837H731* 6837H735 6837H736* 6837H742* Parathyroid 6837H748* Esophagus 6833F509 Larynx 6833F509 Mandibular LN 6831E404 6831E408 6831E417 6831E421 6831E425 6831E428 6831E431 6831E432 6831E439 6831E445 6833F507* Mandibular LN 6833F520 6833F541 6837H716 6837H732 Urinary bladder 6833F517 6835G622 Jejunum 6837H718 Adrenal glands 6831E427 Prostate 6833F517 6835G622 Seminal vesicle 6833F517 6835G622 Mammary gland 6831E401 6831E402 6831E407 6831E409 6831E410 6831E412 6831E413 6831E421 6831E424 6831E429 6831E430 Mammary gland 6831E432 6831E437 6831E449 6833F509 6833F528 6833F537* 6833F540 6835G635 6835G637 6837H713 6837H719 Mammary gland 6837H745 Skin 6831E409 Eyes/optic nerve 6833F512* 6837H720* Iliac LN 6833F515 Mediastinal LN 6831E441 6833F539 6833F540 6833F541 6833F546 6835G629 Pituitary gland 6831E450 * Only one of the pair is missing

Study Number FY01-013

M-341
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

M-10 Lesion Incidence Summary with K-S (comparison > control) 

M-342
 Lovelace Respiratory Lesion incidence summary with K-S (comparison > control) Printed:30-Jun-04

 Research Institute Study Number:FY01013M Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- M a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 50 50 50 Cyst 0 1 2 0 Degeneration, hyaline droplet 0 1 0 0 Infarct 0 0 2 0 Nephropathy, chronic 44 47 -50 -46 Pigment accumulation, tubular epithelium 3 3 1 3 Inflamation, acute 0 1 2 0 Note: Entries flagged with a - (minus) are significantly higher than control at the 0.05 level using the Kolmogorov-Smirnov one-tailed test. All Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

Study Number FY01-013

M-343
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

N-1 

APPENDIX N 

NEOPLASTIC AND NON-NEOPLASTIC LESIONS AND 

GROSS NECROPSY OBSERVATIONS IN FEMALE RATS 

N-1 Gross Necropsy Observations 

N-2 Lesion Incidence by Animal Number for Microscopic Observations 

N-3 Incidence Summary (with percentages) of Microscopic Observations 

N-4 Tabulated Incidence Summary of Non-neoplastic Lesions 

N-5 Lesion Incidence Summary with Average Severity Grades 

N-6 Raw Data 

N-7 Individual Animal Report of Correlated Gross and Microscopic Diagnoses 

N-8 Histological Comments on Tissue 

N-9 Summary of Missing Tissues 

N-10 Lesion Incidence Summary with K-S (comparison > control) 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-1 Gross Necropsy Observations 

N-2
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013F Page: 1  All Sacrifices  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Females --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Adrenal glands  Discolored ..................... 1 2 0 1  Enlarged ....................... 0 1 1 0  Mass ........................... 0 0 1 0  Brain  Deformity ...................... 2 8 9 8  Discolored ..................... 1 2 1 0  Duodenum  Discolored ..................... 0 0 1 0  Esophagus  Discolored ..................... 0 0 1 0  Eyes/optic nerve  Crust .......................... 3 0 3 3  Small .......................... 0 0 1 1  Discolored ..................... 1 3 1 5  Ileum  Discolored ..................... 0 0 1 1  Jejunum  Discolored ..................... 0 0 1 0  Kidneys  Cyst ........................... 2 0 0 3  Discolored ..................... 1 1 1 1  Liver  Deformity ...................... 1 0 0 0  Enlarged ....................... 0 0 0 1  Hernia ......................... 0 5 0 3  Mass ........................... 2 1 0 1  Nodule ......................... 1 0 2 0  Small .......................... 1 0 0 0  Thick .......................... 0 2 1 2  Discolored ..................... 18 14 8 9  Pancreas  Small .......................... 0 0 0 1 

Study Number FY01-013

N-3
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013F Page: 2  All Sacrifices  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Females --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Pituitary gland  Cyst ........................... 1 1 0 1  Enlarged ....................... 4 3 6 4  Focus .......................... 0 0 0 1  Mass ........................... 1 5 4 4  Nodule ......................... 1 2 0 1  Discolored ..................... 18 7 15 4  Salivary gland  Discolored ..................... 0 1 0 0  Skin  Crust .......................... 0 0 1 0  Mass ........................... 0 2 0 0  Spleen  Adhesion ....................... 1 0 0 0  Discolored ..................... 3 2 1 2  Enlarged ....................... 23 11 11 19  Mass ........................... 1 1 0 0  Nodule ......................... 1 1 0 0  Small .......................... 1 1 1 0  Stomach  Mass ........................... 0 0 0 1  Thyroid glands  Cyst ........................... 1 0 0 0  Enlarged ....................... 2 1 2 3  Mass ........................... 0 0 1 0  Nodule ......................... 0 1 0 0  Discolored ..................... 0 0 0 1  Urinary bladder  Fluid .......................... 1 0 0 0  Discolored ..................... 1 0 0 0  Lungs  Discolored ..................... 15 5 8 14  Mass ........................... 0 0 0 1  Nodule ......................... 2 1 2 1  Tail  Amputation ..................... 0 1 0 0 

Study Number FY01-013

N-4
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013F Page: 3  All Sacrifices  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Females --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Tail  Crust .......................... 0 0 1 1  Bronchial (TBLN)  Enlarged ....................... 6 1 3 1  Discolored ..................... 1 1 0 0  Mandibular LN  Enlarged ....................... 4 3 3 2  Mediastinal LN  Enlarged ....................... 8 3 4 4  Discolored ..................... 1 0 0 1  Mesenteric LN  Enlarged ....................... 7 1 1 1  Discolored ..................... 1 0 0 0  Uterus  Cyst ........................... 1 0 1 0  Dilatation ..................... 0 1 1 1  Enlarged ....................... 2 3 2 2  Focus .......................... 0 0 0 1  Intussusception ................ 0 0 0 1  Mass ........................... 2 8 9 8  Nodule ......................... 1 1 1 0  Prolapse ....................... 2 1 0 0  Thick .......................... 0 0 1 0  Discolored ..................... 1 3 3 2  Ovaries  Cyst ........................... 1 0 2 1  Enlarged ....................... 0 2 0 1  Mass ........................... 0 1 0 0  Small .......................... 0 0 0 2  Discolored ..................... 1 0 2 1  Mammary gland  Mass ........................... 2 5 3 5  Discolored ..................... 0 0 1 0  Cervix  Enlarged ....................... 1 5 3 2 

Study Number FY01-013

N-5
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013F Page: 4  All Sacrifices  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Females --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Cervix  Mass ........................... 1 0 0 1  Thick .......................... 1 1 0 0  Mesentery  Nodule ......................... 1 0 0 0  Mediastinum  Mass ........................... 1 0 0 0  Lymph node other  Enlarged ....................... 5 2 4 2  Bone, vertebrae  Mass ........................... 1 0 0 0  Pancreatic LN  Enlarged ....................... 2 2 2 1  Iliac LN  Enlarged ....................... 2 2 2 0  Discolored ..................... 0 0 1 0  Zymbal's gland  Mass ........................... 1 0 0 0  Clitoral gland  Mass ........................... 1 1 3 0  Popliteal LN  Enlarged ....................... 1 1 0 0  Vagina  Mass ........................... 0 1 0 0  Harderian gland  Discolored ..................... 0 0 1 0  Tiss.not specifi  Mass ........................... 0 0 1 0  Malocclusion ................... 0 0 1 0  Bone, other  Deformity ...................... 0 0 1 0 

Study Number FY01-013

N-6
 Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08

 Research Institute Study number: FY01013F Page: 5  All Sacrifices  Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________ -- Females --  Group: 1 2 3 4  Number in group: 50 50 50 50  ----------------------------------------------------------------------------------------------------------------------------------- Cavities  Fluid .......................... 0 0 1 1  Bone, rib  Mass ........................... 0 0 0 1 

Study Number FY01-013

N-7
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Adrenal glands 

 Discolored 6832E487 6834F552 6838H7

 - 6834F599 

 Enlarged 6834F576 6836G668 

 Mass 6836G693 

 

 Brain 

 Deformity 6832E473 6834F563 6836G654 6838H7

 - 6832E488 6834F564 6836G655 6838H7

 - 6834F565 6836G665 6838H7

 - 6834F569 6836G666 6838H7

 - 6834F576 6836G669 6838H7

 - 6834F579 6836G679 6838H7

 - 6834F584 6836G687 6838H7

 - 6834F593 6836G692 6838H8

 - 6836G695 

 Discolored 6832E474 6834F564 6836G695 

 - 6834F584 

 

 Duodenum 

 Discolored 6836G671 

 Esophagus 

 Discolored 6836G653 

 Eyes/optic nerve 

 Crust 6832E468 6836G654 6838H7

 - 6832E478 6836G655 6838H7

 - 6832E489 6836G689 6838H7

 Small 6836G666 6838H7

 Discolored 6832E476 6834F555 6836G699 6838H7

 - 6834F572 6838H7

 - 6834F585 6838H7

 - 6838H7

 - 6838H7

 

 Ileum 

 Discolored 6836G671 6838H7

 Jejunum 

 Discolored 6836G671 

N-8
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Kidneys 

 Cyst 6832E472 6838H7

 - 6832E472 6838H7

 - 6838H7

 Discolored 6832E474 6834F599 6836G660 6838H7

 

 Liver 

 Deformity 6832E468 

 Enlarged 6838H7

 Hernia 6834F566 6838H7

 - 6834F575 6838H7

 - 6834F577 6838H7

 - 6834F578 

 - 6834F596 

 Mass 6832E484 6834F584 6838H7

 - 6832E497 

 Nodule 6832E453 6836G653 

 - 6836G660 

 Small 6832E464 

 Thick 6834F576 6836G682 6838H7

 - 6834F584 6838H8

 Discolored 6832E452 6834F551 6836G655 6838H7

 - 6832E454 6834F552 6836G659 6838H7

 - 6832E457 6834F553 6836G660 6838H7

 - 6832E462 6834F556 6836G676 6838H7

 - 6832E464 6834F558 6836G680 6838H7

 - 6832E469 6834F562 6836G682 6838H7

 - 6832E470 6834F566 6836G685 6838H7

 - 6832E474 6834F571 6836G687 6838H7

 - 6832E476 6834F579 6838H7

 - 6832E477 6834F581 

 - 6832E480 6834F589 

 - 6832E485 6834F589 

 - 6832E490 6834F591 

 - 6832E491 6834F599 

 - 6832E493 

 - 6832E496 

 - 6832E499 

 - 6832E500 

 

 Pancreas 

 Small 6838H7

N-9
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Pituitary gland 

 Cyst 6832E496 6834F563 6838H7

 Enlarged 6832E452 6834F577 6836G654 6838H7

 - 6832E474 6834F579 6836G655 6838H7

 - 6832E488 6834F593 6836G669 6838H7

 - 6832E493 6836G678 6838H7

 - 6836G692 

 - 6836G695 

 Focus 6838H7

 Mass 6832E473 6834F564 6836G665 6838H7

 - 6834F565 6836G666 6838H7

 - 6834F569 6836G679 6838H7

 - 6834F576 6836G687 6838H8

 - 6834F584 

 Nodule 6832E482 6834F561 6838H7

 - 6834F594 

 Discolored 6832E451 6834F558 6836G652 6838H7

 - 6832E454 6834F573 6836G653 6838H7

 - 6832E455 6834F580 6836G657 6838H7

 - 6832E456 6834F582 6836G663 6838H7

 - 6832E457 6834F585 6836G664 

 - 6832E458 6834F596 6836G672 

 - 6832E460 6834F600 6836G675 

 - 6832E461 6836G676 

 - 6832E462 6836G680 

 - 6832E463 6836G681 

 - 6832E471 6836G683 

 - 6832E475 6836G684 

 - 6832E479 6836G685 

 - 6832E483 6836G689 

 - 6832E484 6836G694 

 - 6832E489 

 - 6832E496 

 - 6832E497 

 

 Salivary gland 

 Discolored 6834F562 

 Skin 

 Crust 6836G666 

 Mass 6834F551 

 - 6834F576 

N-10
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Spleen 

 Adhesion 6832E466 

 Discolored 6832E456 6834F572 6836G660 6838H7

 - 6832E479 6834F576 6838H7

 - 6832E490 

 Enlarged 6832E453 6834F552 6836G659 6838H7

 - 6832E454 6834F556 6836G660 6838H7

 - 6832E456 6834F567 6836G675 6838H7

 - 6832E457 6834F568 6836G676 6838H7

 - 6832E459 6834F571 6836G680 6838H7

 - 6832E463 6834F572 6836G682 6838H7

 - 6832E464 6834F576 6836G685 6838H7

 - 6832E466 6834F579 6836G686 6838H7

 - 6832E469 6834F581 6836G687 6838H7

 - 6832E470 6834F589 6836G688 6838H7

 - 6832E471 6834F599 6836G698 6838H7

 - 6832E474 6838H7

 - 6832E476 6838H7

 - 6832E477 6838H7

 - 6832E479 6838H7

 - 6832E482 6838H7

 - 6832E484 6838H7

 - 6832E485 6838H7

 - 6832E487 6838H8

 - 6832E491 

 - 6832E493 

 - 6832E496 

 - 6832E499 

 Mass 6832E470 6834F568 

 Nodule 6832E453 6834F577 

 Small 6832E483 6834F575 6836G700 

 

 Stomach 

 Mass 6838H7

 Thyroid glands 

 Cyst 6832E479 

 Enlarged 6832E462 6834F570 6836G686 6838H7

 - 6832E482 6836G694 6838H7

 - 6838H7

 Mass 6836G653 

N-11
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Thyroid glands 

 Nodule 6834F557 

 Discolored 6838H7

 

 Urinary bladder 

 Fluid 6832E468 

 Discolored 6832E491 

 Lungs 

 Discolored 6832E459 6834F566 6836G660 6838H7

 - 6832E466 6834F568 6836G665 6838H7

 - 6832E469 6834F576 6836G667 6838H7

 - 6832E470 6834F586 6836G673 6838H7

 - 6832E470 6834F599 6836G676 6838H7

 - 6832E471 6836G677 6838H7

 - 6832E473 6836G682 6838H7

 - 6832E474 6836G693 6838H7

 - 6832E476 6838H7

 - 6832E477 6838H7

 - 6832E480 6838H7

 - 6832E482 6838H7

 - 6832E485 6838H7

 - 6832E491 6838H7

 - 6832E494 

 Mass 6838H7

 Nodule 6832E453 6834F592 6836G686 6838H7

 - 6832E490 6836G692 

 

 Tail 

 Amputation 6834F559 

 Crust 6836G689 6838H7

 Bronchial (TBLN) 

 Enlarged 6832E453 6834F568 6836G682 6838H7

 - 6832E459 6836G686 

 - 6832E470 6836G698 

 - 6832E485 

 - 6832E493 

 - 6832E496 

 Discolored 6832E473 6834F562 

 

 Mandibular LN 

 Enlarged 6832E459 6834F568 6836G666 6838H7

 - 6832E487 6834F569 6836G672 6838H7

N-12
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Mandibular LN 

 Enlarged 6832E491 6834F596 6836G682 

 - 6832E496 

 

 Mediastinal LN 

 Enlarged 6832E453 6834F568 6836G660 6838H7

 - 6832E459 6834F572 6836G682 6838H7

 - 6832E466 6834F577 6836G688 6838H7

 - 6832E487 6836G698 6838H7

 - 6832E490 

 - 6832E491 

 - 6832E493 

 - 6832E496 

 Discolored 6832E473 6838H7

 

 Mesenteric LN 

 Enlarged 6832E453 6834F568 6836G682 6838H7

 - 6832E459 

 - 6832E485 

 - 6832E487 

 - 6832E491 

 - 6832E493 

 - 6832E496 

 Discolored 6832E485 

 

 Uterus 

 Cyst 6832E495 6836G674 

 Dilatation 6834F595 6836G683 6838H7

 Enlarged 6832E456 6834F557 6836G673 6838H7

 - 6832E485 6834F562 6836G676 6838H7

 - 6834F589 

 Focus 6838H7

 Intussusception 6838H7

 Mass 6832E453 6834F556 6836G651 6838H7

 - 6832E460 6834F561 6836G661 6838H7

 - 6834F562 6836G666 6838H7

 - 6834F563 6836G667 6838H7

 - 6834F566 6836G670 6838H7

 - 6834F573 6836G671 6838H7

 - 6834F576 6836G683 6838H7

 - 6834F582 6836G690 6838H7

 - 6836G700 

N-13
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Uterus 

 Nodule 6832E489 6834F594 6836G659 

 Prolapse 6832E455 6834F590 

 - 6832E481 

 Thick 6836G669 

 Discolored 6832E480 6834F552 6836G660 6838H7

 - 6834F562 6836G665 6838H7

 - 6834F565 6836G669 

 

 Ovaries 

 Cyst 6832E495 6836G661 6838H7

 - 6836G675 

 Enlarged 6834F562 6838H7

 - 6834F568 

 Mass 6834F596 

 Small 6838H7

 - 6838H7

 Discolored 6832E473 6836G657 6838H7

 - 6836G665 

 

 Mammary gland 

 Mass 6832E459 6834F563 6836G672 6838H7

 - 6832E499 6834F565 6836G687 6838H7

 - 6834F565 6836G697 6838H7

 - 6834F567 6838H7

 - 6834F571 6838H7

 Discolored 6836G679 

 

 Cervix 

 Enlarged 6832E489 6834F569 6836G657 6838H7

 - 6834F570 6836G668 6838H7

 - 6834F574 6836G673 

 - 6834F575 

 - 6834F576 

 Mass 6832E454 6838H7

 Thick 6832E473 6834F595 

 

 Lymph node other 

 Enlarged 6832E491 6834F568 6836G653 6838H7

 - 6832E491 6834F568 6836G680 6838H7

 - 6832E491 6836G682 

 - 6832E494 6836G682 

 - 6832E496 

N-14
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Mesentery 

 Nodule 6832E477 

 

 Mediastinum 

 Mass 6832E490 

 Bone, vertebrae 

 Mass 6832E491 

 Pancreatic LN 

 Enlarged 6832E491 6834F572 6836G682 6838H7

 - 6832E496 6834F577 6836G688 

 Iliac LN 

 Enlarged 6832E491 6834F568 6836G682 

 - 6832E496 6834F577 6836G688 

 Discolored 6836G682 

 Zymbal's gland 

 Mass 6832E492 

 Clitoral gland 

 Mass 6832E494 6834F594 6836G669 

 - 6836G678 

 - 6836G687 

 Popliteal LN 

 Enlarged 6832E496 6834F568 

 Vagina 

 Mass 6834F561 

 Harderian gland 

 Discolored 6836G683 

 Tiss.not specifi 

 Mass 6836G684 

 Malocclusion 6836G699 

 Bone, other 

 Deformity 6836G688 

N-15
 Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printe

 Research Institute Study number: FY01013F Page

 All Sacrifices 

 Rat/F344/N Study start date: 30-May-01 Inhalation/whole

+_______________________________________________________________________________________________________________________

 Controls from group(s): 1 -- F e m a l e s -- 

 Group: Ctls 2 3 4 

 Number in group: 50 50 50 50 

 -----------------------------------------------------------------------------------------------------------------------

 Cavities 

 Fluid 6836G693 6838H7

 

 Bone, rib 

 Mass 6838H7

N-16
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-2 Lesion Incidence by Animal Number for Microscopic Observations 

N-17
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Proliferative (including Neoplastic) Lesions 

N-18
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Hyperplasia, alveolar epithelial, focal 6832E459 6834F592 6836G700 6838H772 6832E460 6832E462 6832E469 6832E476 6832E487 6832E494 N-Carcinoma, metastatic 6838H753 N-Leukemia, mononuclear - capillary involvement 6832E454 6834F551 6836G652 6838H757 6832E456 6834F552 6836G655 6838H761 6832E459 6834F556 6836G659 6838H764 6832E462 6834F568 6836G675 6838H766 6832E463 6834F571 6836G676 6838H767 6832E464 6834F572 6836G678 6838H768 6832E466 6834F574 6836G680 6838H770 6832E469 6834F576 6836G685 6838H772 6832E471 6834F579 6836G687 6838H774 6832E474 6834F581 6836G688 6838H775 6832E476 6834F584 6836G694 6838H778 6832E477 6834F585 6836G698 6838H780 6832E479 6834F589 6838H785 6832E480 6834F591 6838H787 6832E482 6834F599 6838H791 6832E484 6834F600 6838H792 6832E485 6838H793 6832E487 6838H797 6832E491 6838H800 6832E493 6832E496 6832E499 N-Leukemia, mononuclear - invasive involvement 6832E453 6834F577 6836G682 6838H752 6832E470 6836G686 6832E490 N-Sarcoma, histiocytic 6836G660 6838H751 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-19
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Trachea ........................................Number examined: 50 50 50 50 Hyperplasia 6836G653 N-Leukemia, mononuclear 6834F577 6836G682 Bronchial (TBLN) ...............................Number examined: 48 19 20 48 N-Leukemia, mononuclear 6832E453 6834F568 6836G676 6838H752 6832E459 6834F571 6836G678 6838H785 6832E470 6834F599 6836G682 6832E476 6836G686 6832E485 6836G687 6832E490 6836G688 6832E491 6836G698 6832E493 6832E496 Thyroid glands .................................Number examined: 50 22 22 50 Hyperplasia, C-cell, focal 6832E455 6834F570 6836G685 6838H761 6832E460 6834F572 6838H767 6832E461 6834F589 6838H773 6834F594 6838H776 6838H781 6838H788 Hyperplasia, follicular cell 6832E479 B-Adenoma, C-cell 6832E482 6834F557 6836G659 6838H759 6834F570 6836G686 6838H791 6836G694 B-Adenoma, follicular cell 6838H770 6838H791 M-Carcinoma, C-cell 6832E462 M-Carcinoma, follicular cell 6832E454 6836G653 M-Leukemia, mononuclear 6838H770 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-20
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Parathyroid ....................................Number examined: 47 20 20 50 Hyperplasia, focal 6832E497 B-Adenoma 6832E494 Aorta ..........................................Number examined: 49 20 20 50 N-Leukemia, mononuclear - invasive involvement 6832E490 Esophagus ......................................Number examined: 50 20 20 50 Larynx .........................................Number examined: 50 50 50 50 Hyperplasia 6832E451 6834F553 6836G655 6838H752 6832E452 6834F560 6836G656 6838H754 6832E453 6834F563 6836G670 6838H763 6832E455 6834F567 6836G672 6838H765 6832E457 6834F571 6836G676 6838H768 6832E462 6834F572 6838H770 6832E464 6834F582 6838H771 6832E470 6834F585 6838H772 6832E471 6834F593 6838H775 6832E473 6834F595 6838H776 6832E476 6838H791 6832E479 6838H792 6832E480 6838H796 6832E482 6838H797 6832E488 6838H800 6832E489 6832E500 Salivary gland .................................Number examined: 50 20 20 50 M-Leukemia, mononuclear 6832E484 6838H764 6832E485 Mandibular LN ..................................Number examined: 44 19 21 47 N-Leukemia, mononuclear 6832E459 6834F552 6836G659 6838H752 6832E464 6834F568 6836G678 6838H761 6832E470 6834F571 6836G682 6838H770 6832E471 6834F572 6836G685 6838H772 6832E476 6834F589 6836G688 6838H785 6832E477 6834F596 6832E484 6832E487 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-21
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mandibular LN ..................................Number examined: 44 19 21 47 6832E490 6832E491 6832E493 6832E496 Liver ..........................................Number examined: 50 28 22 50 Hyperplasia, biliary 6832E451 6834F551 6836G653 6838H754 6832E453 6834F553 6836G655 6838H755 6832E454 6834F556 6836G659 6838H756 6832E455 6834F565 6836G664 6838H757 6832E456 6834F566 6836G665 6838H759 6832E458 6834F571 6836G676 6838H760 6832E460 6834F576 6836G678 6838H762 6832E463 6834F578 6836G679 6838H765 6832E466 6834F579 6836G680 6838H768 6832E467 6834F581 6836G682 6838H770 6832E468 6834F582 6836G683 6838H771 6832E470 6834F589 6836G685 6838H774 6832E471 6834F593 6836G687 6838H775 6832E472 6834F594 6836G688 6838H776 6832E475 6834F595 6836G693 6838H779 6832E476 6834F599 6836G695 6838H782 6832E478 6836G698 6838H783 6832E479 6838H787 6832E480 6838H788 6832E483 6838H790 6832E484 6838H792 6832E485 6838H793 6832E486 6838H796 6832E487 6838H800 6832E488 6832E489 6832E490 6832E491 6832E492 6832E493 6832E494 6832E496 6832E498 6832E499 6832E500 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-22
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 28 22 50 Hyperplasia, hepatocellular, regenerative 6832E484 6834F584 6836G659 6838H772 B-Adenoma, hepatocellular 6832E497 M-Sarcoma. histiocytic 6836G660 6838H751 M-Leukemia, mononuclear 6832E452 6834F551 6836G655 6838H752 6832E453 6834F552 6836G659 6838H753 6832E454 6834F553 6836G676 6838H757 6832E456 6834F556 6836G678 6838H759 6832E457 6834F567 6836G680 6838H760 6832E459 6834F568 6836G682 6838H761 6832E462 6834F571 6836G685 6838H764 6832E463 6834F572 6836G687 6838H766 6832E464 6834F576 6836G688 6838H767 6832E466 6834F577 6836G698 6838H768 6832E468 6834F579 6838H770 6832E469 6834F581 6838H772 6832E470 6834F584 6838H774 6832E471 6834F589 6838H775 6832E474 6834F591 6838H778 6832E476 6834F596 6838H780 6832E477 6834F599 6838H785 6832E479 6838H787 6832E482 6838H791 6832E485 6838H792 6832E487 6838H793 6832E490 6838H797 6832E491 6838H800 6832E493 6832E496 6832E497 6832E499 Spleen .........................................Number examined: 50 22 24 50 M-Leukemia, mononuclear 6832E453 6834F552 6836G659 6838H752 6832E454 6834F556 6836G675 6838H753 6832E456 6834F567 6836G676 6838H757 6832E457 6834F568 6836G678 6838H759 6832E459 6834F571 6836G680 6838H760 6832E462 6834F572 6836G682 6838H761 6832E463 6834F576 6836G685 6838H764 6832E464 6834F577 6836G686 6838H766 6832E466 6834F579 6836G687 6838H767 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-23
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spleen .........................................Number examined: 50 22 24 50 6832E468 6834F581 6836G688 6838H768 6832E469 6834F589 6836G698 6838H770 6832E470 6834F599 6838H772 6832E471 6838H774 6832E474 6838H775 6832E476 6838H778 6832E477 6838H780 6832E479 6838H785 6832E482 6838H787 6832E484 6838H791 6832E485 6838H792 6832E487 6838H793 6832E490 6838H797 6832E491 6838H800 6832E493 6832E496 6832E497 6832E499 N-Sarcoma, histiocytic 6836G660 Kidneys ........................................Number examined: 50 20 21 50 M-Leukemia, mononuclear 6832E491 6834F568 6836G682 6838H752 6838H766 N-Sarcoma, histiocytic 6836G660 Heart ..........................................Number examined: 50 20 20 50 M-Leukemia, mononuclear 6832E453 6834F568 6838H752 6832E459 6834F577 6838H764 6832E484 6832E490 6832E496 Stomach ........................................Number examined: 50 20 20 50 M-Carcinoma, metastatic 6838H753 M-Leukemia, mononuclear 6832E491 6834F577 6836G682 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-24
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Cecum ..........................................Number examined: 49 20 20 49 N-Leukemia, mononuclear 6832E485 6834F568 6832E491 Urinary bladder ................................Number examined: 50 20 19 50 Hyperplasia, papillary 6832E456 M-Leukemia, mononuclear 6832E453 6836G676 Duodenum .......................................Number examined: 50 20 20 50 Jejunum ........................................Number examined: 50 20 20 50 Ileum ..........................................Number examined: 50 20 19 50 N-Leukemia, mononuclear 6832E485 6838H772 Colon ..........................................Number examined: 50 20 20 50 Pancreas .......................................Number examined: 50 18 20 50 M-Leukemia, mononuclear 6834F568 Rectum .........................................Number examined: 50 20 20 50 Adrenal glands .................................Number examined: 49 20 21 50 Hyperplasia, cortical, focal 6832E454 6838H791 6832E476 Hyperplasia, focal 6832E496 6836G653 6838H782 6836G698 6838H792 B-Pheochromocytoma, benign 6832E487 6834F576 6836G668 6838H757 6836G693 M-Carcinoma, metastatic 6838H753 M-Leukemia, mononuclear 6832E453 6834F599 6838H752 6832E457 6838H774 6832E491 6838H793 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-25
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Uterus .........................................Number examined: 50 24 31 50 Hyperplasia, cystic endometrial 6832E456 6834F552 6836G670 6838H759 6832E458 6834F556 6836G674 6838H760 6832E459 6834F572 6836G679 6838H767 6832E468 6834F582 6836G690 6838H778 6832E469 6838H779 6832E472 6838H781 6832E478 6838H787 6832E483 6838H789 6832E489 6838H791 6832E491 6838H792 6832E497 6838H794 B-Adenoma, endometrial 6834F561 B-Polyp, endometrial stromal 6832E455 6834F552 6836G651 6838H757 6832E460 6834F556 6836G660 6838H763 6832E485 6834F562 6836G661 6838H767 6832E492 6834F563 6836G665 6838H769 6832E495 6834F565 6836G666 6838H770 6834F566 6836G667 6838H772 6834F573 6836G669 6838H780 6834F582 6836G676 6838H781 6834F589 6836G683 6838H790 6834F594 6836G698 6838H791 6834F595 6836G700 6838H798 M-Adenocarcinoma, endometrial 6834F576 6836G667 6838H753 6836G670 M-Leiomyosarcoma 6834F562 6836G671 M-Leukemia, mononuclear 6832E453 6834F568 6838H752 6832E470 6834F576 6834F577 Mesenteric LN ..................................Number examined: 50 19 20 50 N-Sarcoma, histiocytic 6838H751 N-Leukemia, mononuclear 6832E453 6834F552 6836G659 6838H752 6832E459 6834F568 6836G676 6838H764 6832E462 6834F581 6836G680 6838H770 6832E470 6836G682 6838H774 6832E474 6836G685 6832E476 6836G687 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-26
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mesenteric LN ..................................Number examined: 50 19 20 50 6832E477 6836G688 6832E484 6832E485 6832E487 6832E491 6832E493 6832E496 Ovaries ........................................Number examined: 49 21 23 50 N-Sarcoma, histiocytic 6838H751 M-Leukemia, mononuclear 6832E453 6834F568 6836G682 6838H752 Sciatic nerve ..................................Number examined: 50 20 19 50 Muscle, skeletal ...............................Number examined: 50 20 20 50 N-Sarcoma, histiocytic 6838H751 Mammary gland ..................................Number examined: 49 20 22 47 Hyperplasia, lobular 6832E500 6836G695 6838H772 6838H787 B-Fibroadenoma 6834F563 6836G672 6838H756 6834F567 6836G684 6838H761 6834F594 6838H773 6838H782 6838H798 B-Fibroma 6832E459 6834F551 6836G697 6834F571 M-Adenocarcinoma 6834F565 6836G687 M-Adenocarcinoma arising in fibroadenoma 6832E499 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-27
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Skin ...........................................Number examined: 50 19 20 49 Brain ..........................................Number examined: 50 25 25 50 M-Astrocytoma, malignant 6834F578 Eyes/optic nerve ...............................Number examined: 50 22 24 50 Bone, femur ....................................Number examined: 50 20 19 50 Spinal cord ....................................Number examined: 50 20 19 50 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 Hyperplasia - respiratory epithelium 6834F585 6836G664 6838H776 6836G700 6838H788 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Hyperplasia - respiratory epithelium 6834F568 6838H783 6834F569 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Cervix .........................................Number examined: 2 5 3 2 B-Polyp, endometrial stromal 6838H769 M-Leiomyosarcoma 6834F570 N-Adenocarcinoma, endometrial 6834F576 Clitoral gland .................................Number examined: 1 0 3 0 B-Adenoma 6836G669 M-Carcinoma, squamous cell 6832E494 N-Adenocarcinoma 6836G678 6836G687 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-28
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lymph node other ...............................Number examined: 3 1 3 1 N-Leukemia, mononuclear 6832E491 6834F568 6836G680 6838H752 6832E496 6836G682 Popliteal LN ...................................Number examined: 1 1 0 0 N-Leukemia, mononuclear 6832E496 6834F568 Iliac LN .......................................Number examined: 2 2 2 0 N-Leukemia, mononuclear 6832E491 6834F568 6836G682 6832E496 6834F577 6836G688 Pancreatic LN ..................................Number examined: 2 1 2 1 N-Leukemia, mononuclear 6832E491 6834F572 6836G682 6838H752 6832E496 6836G688 Mediastinal LN .................................Number examined: 50 20 20 47 B-Thymoma 6836G688 M-Carcinoma, metastatic 6838H753 N-Sarcoma, histiocytic 6836G660 N-Leukemia, mononuclear 6832E453 6834F552 6836G676 6838H752 6832E459 6834F567 6836G678 6838H766 6832E470 6834F568 6836G682 6838H770 6832E476 6834F572 6836G685 6838H772 6832E477 6834F577 6836G698 6838H778 6832E484 6832E485 6832E487 6832E490 6832E491 6832E493 6832E496 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-29
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pituitary gland ................................Number examined: 50 32 34 50 Hyperplasia, focal 6832E455 6834F567 6836G653 6838H762 6832E460 6834F585 6836G663 6838H768 6832E461 6834F596 6836G664 6838H770 6832E471 6836G675 6838H777 6832E479 6836G676 6832E489 6836G684 6832E494 6836G689 6832E496 6836G693 B-Adenoma, pars distalis 6832E458 6834F558 6836G654 6838H754 6832E463 6834F561 6836G655 6838H769 6832E473 6834F565 6836G657 6838H770 6832E474 6834F569 6836G663 6838H779 6832E484 6834F573 6836G665 6838H783 6832E488 6834F576 6836G666 6838H787 6832E493 6834F577 6836G669 6838H788 6834F579 6836G672 6838H790 6834F580 6836G678 6838H791 6834F584 6836G679 6838H799 6834F593 6836G687 6838H800 6834F594 6836G692 6834F600 6836G694 6836G695 B-Adenoma, pars intermedia 6836G695 M-Carcinoma 6834F564 M-Leukemia, mononuclear 6834F577 6838H772 Tail ...........................................Number examined: 0 0 1 1 Hyperplasia/hyperkeratosis 6836G689 6838H759 Bone, rib ......................................Number examined: 0 0 0 1 M-Osteosarcoma 6838H761 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-30
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 13 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mesentery ......................................Number examined: 1 0 0 1 M-Carcinoma, metastatic 6838H753 Bone, vertebrae ................................Number examined: 1 0 0 0 N-Leukemia, mononuclear 6832E491 Zymbal’s gland .................................Number examined: 1 0 0 0 M-Carcinoma, squamous cell 6832E492 Mediastinum ....................................Number examined: 1 0 0 0 N-Leukemia, mononuclear 6832E490 Bone, other ....................................Number examined: 0 0 1 0 Harderian gland ................................Number examined: 0 0 1 0 Vagina .........................................Number examined: 0 1 0 0 M-Leiomoysarcoma 6834F561 Tiss.not specifi ...............................Number examined: 0 0 0 0 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-31
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Non-neoplastic Lesions 

N-32
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Alveolar histiocytosis 6832E456 6834F566 6836G651 6838H760 6832E460 6834F568 6836G657 6838H762 6832E461 6834F575 6836G692 6838H771 6832E463 6838H772 6832E479 6838H776 6832E484 6838H777 6832E485 6838H779 6832E488 6838H782 6832E492 6838H789 Congestion 6832E473 6836G660 6838H795 6836G665 Fibrosis, focal 6834F592 Hemorrhage 6832E466 6834F576 6836G660 6838H766 6832E479 6838H774 6832E485 6838H791 6832E487 6832E491 Inflammation, acute 6832E467 6834F578 Inflammation, mixed 6836G653 Inflammation, granulomatous 6836G654 Trachea ........................................Number examined: 50 50 50 50 Inflammation, acute 6832E467 6832E473 Inflammation, mixed 6832E495 6838H764 Bronchial (TBLN) ...............................Number examined: 48 19 20 48 Hemorrhage 6832E473 6834F552 6838H760 6834F562 6838H776 6834F576 6838H781 6838H798 Inflammation, mixed 6836G686 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-33
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thyroid glands .................................Number examined: 50 22 22 50 Cyst, follicular 6836G693 Parathyroid ....................................Number examined: 47 20 20 50 Aorta ..........................................Number examined: 49 20 20 50 Esophagus ......................................Number examined: 50 20 20 50 Larynx .........................................Number examined: 50 50 50 50 Metaplasia, squamous 6832E458 6834F554 6836G651 6838H755 6832E472 6834F561 6836G654 6838H759 6832E484 6834F564 6836G655 6838H760 6832E495 6834F574 6836G657 6838H762 6832E496 6834F580 6836G665 6838H766 6834F583 6836G666 6838H768 6834F588 6836G669 6838H778 6834F591 6836G677 6838H784 6834F592 6836G684 6838H787 6834F600 6836G700 Inflammation, acute 6832E459 6836G696 6832E460 Inflammation, mixed 6832E451 6834F551 6836G654 6838H752 6832E452 6834F553 6836G655 6838H754 6832E453 6834F554 6836G656 6838H757 6832E455 6834F555 6836G658 6838H759 6832E457 6834F556 6836G659 6838H760 6832E458 6834F559 6836G660 6838H761 6832E461 6834F561 6836G662 6838H762 6832E462 6834F563 6836G665 6838H764 6832E464 6834F564 6836G667 6838H766 6832E467 6834F565 6836G668 6838H768 6832E470 6834F567 6836G670 6838H769 6832E471 6834F568 6836G672 6838H770 6832E473 6834F570 6836G674 6838H771 6832E476 6834F571 6836G675 6838H772 6832E477 6834F572 6836G678 6838H773 6832E478 6834F574 6836G679 6838H775 6832E479 6834F575 6836G680 6838H777 6832E480 6834F577 6836G684 6838H778 6832E483 6834F578 6836G685 6838H779 6832E484 6834F580 6836G688 6838H783 6832E487 6834F581 6836G689 6838H784 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-34
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Larynx .........................................Number examined: 50 50 50 50 6832E488 6834F582 6836G693 6838H786 6832E489 6834F583 6836G695 6838H787 6832E493 6834F584 6838H788 6832E495 6834F585 6838H791 6832E496 6834F586 6838H792 6832E499 6834F588 6838H793 6832E500 6834F589 6838H794 6834F591 6838H795 6834F592 6838H796 6834F593 6838H797 6834F596 6838H799 6834F598 6838H800 6834F599 6834F600 Inflammation, chronic 6832E456 6834F594 6836G657 6838H755 6832E465 6836G669 6838H776 6832E472 6836G676 6838H780 6832E475 6836G677 6838H781 6832E490 6836G682 6838H782 6832E491 6836G687 6838H789 6832E492 6838H790 6832E494 Salivary gland .................................Number examined: 50 20 20 50 Mandibular LN ..................................Number examined: 44 19 21 47 Hemorrhage 6834F576 Liver ..........................................Number examined: 50 28 22 50 Angiectasis 6832E482 6838H791 Congestion 6832E452 6836G665 Fatty Change 6834F571 6836G655 6838H758 6836G660 6838H783 6838H787 Foci of cellular alteration, basophilic 6832E478 6838H758 Hepatodiaphragmatic nodule 6834F566 6838H756 6834F575 6838H771 6834F577 6838H786 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-35
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 28 22 50 6834F578 6834F596 Necrosis 6832E452 6834F566 6836G660 6838H763 6832E474 6834F582 6838H768 6832E480 6834F589 6838H778 6838H781 6838H785 Thrombus 6838H793 Vaculolization cytoplasmic 6832E452 6834F581 6836G687 6838H800 6832E457 6832E464 6832E469 6832E477 Inflammation, acute 6832E473 Inflammation, chronic 6832E458 6834F558 6836G671 6838H754 6832E461 6834F565 6836G679 6838H755 6832E467 6834F567 6836G695 6838H756 6832E468 6834F578 6838H760 6832E472 6834F582 6838H765 6832E475 6838H773 6832E481 6838H776 6832E483 6838H779 6832E486 6838H781 6832E489 6838H782 6832E494 6838H783 6832E495 6838H788 6832E498 6838H789 6838H790 6838H794 6838H798 6838H800 Spleen .........................................Number examined: 50 22 24 50 Fibrosis 6832E466 6836G685 6832E479 6832E490 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-36
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spleen .........................................Number examined: 50 22 24 50 Hemorrhage 6838H778 Necrosis 6832E491 6834F572 6838H772 6838H778 Kidneys ........................................Number examined: 50 20 21 50 Atrophy 6838H753 Cyst 6832E472 6838H755 6838H757 6838H762 Degeneration, hyaline droplet 6838H751 Dilatation 6838H753 Infarct 6838H784 Nephropathy, chronic 6832E451 6834F552 6836G653 6838H751 6832E452 6834F556 6836G659 6838H752 6832E453 6834F562 6836G660 6838H753 6832E456 6834F565 6836G664 6838H754 6832E457 6834F567 6836G665 6838H755 6832E458 6834F568 6836G676 6838H757 6832E460 6834F571 6836G678 6838H758 6832E461 6834F572 6836G679 6838H759 6832E462 6834F576 6836G680 6838H760 6832E463 6834F577 6836G682 6838H761 6832E465 6834F578 6836G683 6838H762 6832E466 6834F581 6836G685 6838H764 6832E467 6834F582 6836G687 6838H767 6832E468 6834F589 6836G693 6838H768 6832E469 6834F593 6836G695 6838H770 6832E470 6834F594 6838H771 6832E471 6834F599 6838H772 6832E472 6838H773 6832E473 6838H774 6832E474 6838H776 6832E475 6838H777 6832E476 6838H778 6832E478 6838H779 6832E480 6838H780 6832E481 6838H781 6832E482 6838H782 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-37
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 20 21 50 6832E483 6838H783 6832E484 6838H784 6832E485 6838H785 6832E486 6838H787 6832E487 6838H788 6832E488 6838H789 6832E489 6838H790 6832E490 6838H791 6832E491 6838H792 6832E493 6838H793 6832E494 6838H794 6832E495 6838H795 6832E496 6838H796 6832E497 6838H797 6832E499 6838H798 6832E500 6838H799 6838H800 Pigment accumulation, tubular epithelium 6834F581 6838H763 6834F599 6838H792 Heart ..........................................Number examined: 50 20 20 50 Degeneration, myocyte 6832E452 6838H758 6832E472 6838H759 6832E483 6838H790 Fibrosis 6832E500 Thrombus 6832E464 Inflammation, focal, chronic 6832E451 6834F562 6836G664 6838H751 6832E454 6834F565 6836G665 6838H754 6832E455 6834F566 6836G671 6838H755 6832E460 6834F567 6836G678 6838H756 6832E461 6834F576 6836G687 6838H758 6832E462 6834F581 6836G688 6838H760 6832E463 6834F589 6836G695 6838H761 6832E465 6836G696 6838H769 6832E467 6838H770 6832E468 6838H774 6832E470 6838H775 6832E475 6838H776 6832E482 6838H777 6832E484 6838H779 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-38
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Heart ..........................................Number examined: 50 20 20 50 6832E486 6838H780 6832E487 6838H784 6832E488 6838H787 6832E492 6838H788 6832E494 6838H789 6832E495 6838H791 6832E497 6838H792 6832E498 6838H793 6832E499 6838H794 6832E500 6838H796 6838H799 6838H800 Stomach ........................................Number examined: 50 20 20 50 Ulcer 6834F576 Inflammation, mixed 6834F576 Cecum ..........................................Number examined: 49 20 20 49 Urinary bladder ................................Number examined: 50 20 19 50 Hemorrhage 6832E491 Inflammation, chronic 6832E455 6838H751 6832E494 6838H754 6838H773 Duodenum .......................................Number examined: 50 20 20 50 Inflamation, acute 6834F581 Jejunum ........................................Number examined: 50 20 20 50 Ileum ..........................................Number examined: 50 20 19 50 Colon ..........................................Number examined: 50 20 20 50 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-39
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pancreas .......................................Number examined: 50 18 20 50 Fibrosis 6838H753 Rectum .........................................Number examined: 50 20 20 50 Metaplasia, squamous 6834F581 Adrenal glands .................................Number examined: 49 20 21 50 Cyst 6836G653 6838H765 Degeneration, cytoplasmic vacuolization 6832E452 6834F593 6838H754 6832E458 6838H758 6832E462 6838H762 6832E464 6838H766 6832E467 6838H767 6832E477 6838H769 6832E478 6838H772 6832E483 6838H773 6832E487 6838H781 6832E490 6838H784 6832E495 6838H789 6832E500 6838H793 6838H796 6838H800 Necrosis 6832E457 Thrombus 6832E457 Uterus .........................................Number examined: 50 24 31 50 Angiectasis 6836G659 Dilatation 6834F557 6836G669 6838H752 6836G673 6838H753 6836G678 6838H763 6836G683 Intussusception 6832E481 6834F590 6838H769 6838H786 Inflammation, mixed 6832E453 6832E455 6832E460 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-40
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Uterus .........................................Number examined: 50 24 31 50 Inflammation, chronic 6832E466 6832E484 6832E496 Mesenteric LN ..................................Number examined: 50 19 20 50 Hemorrhage 6832E472 6836G693 Inflammation, chronic 6832E481 6836G659 Ovaries ........................................Number examined: 49 21 23 50 Congestion 6836G665 Cyst, bursa 6836G675 6838H759 Cyst, epithelial 6832E495 6834F556 Cyst, follicular 6836G661 Cyst, rete ovarii 6836G657 Hemorrhage 6832E473 Necrosis, mesenteric fat 6834F596 Sciatic nerve ..................................Number examined: 50 20 19 50 Muscle, skeletal ...............................Number examined: 50 20 20 50 Mammary gland ..................................Number examined: 49 20 22 47 Ectasia 6832E452 6838H769 6832E476 6832E490 Skin ...........................................Number examined: 50 19 20 49 Cyst, epithelial inclusion 6834F576 Fibrosis 6836G666 Inflammation, mixed 6836G699 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-41
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Brain ..........................................Number examined: 50 25 25 50 Compression 6832E473 6834F563 6836G654 6838H754 6832E488 6834F564 6836G655 6838H762 6834F565 6836G665 6838H769 6834F569 6836G666 6838H783 6834F576 6836G669 6838H787 6834F579 6836G679 6838H788 6834F584 6836G687 6838H790 6834F593 6836G692 6838H799 6836G695 6838H800 Hemorrhage 6832E473 6834F584 Metaplasia, osseous, meninges 6838H761 Necrosis 6832E474 Inflammation, chronic 6838H755 Eyes/optic nerve ...............................Number examined: 50 22 24 50 Atrophy 6832E476 6834F572 6838H767 6838H777 Atrophy, retinal, unilateral 6834F555 6836G699 6834F585 Cataract 6832E476 6834F555 6836G699 6838H777 6834F572 6838H798 6834F585 Metaplasia, osseous, scleral 6832E463 Mineralization, corneal stromal 6832E453 6838H754 6832E459 6838H759 6832E476 6838H767 6832E494 6838H785 Mineralization, scleral 6832E480 6834F576 6836G682 6838H752 6832E498 6834F589 6836G693 6838H765 6838H780 6838H782 Neovascularization, corneal 6832E453 6838H759 6838H760 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-42
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Bone, femur ....................................Number examined: 50 20 19 50 New bone formation, endosteal 6838H770 Spinal cord ....................................Number examined: 50 20 19 50 Degeneration, white matter 6832E473 6838H792 Hemorrhage 6832E491 6836G682 Necrosis, neuronal 6838H785 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 Degeneration, hyaline - respiratory epithelium 6832E482 6834F552 6836G657 6838H766 6832E487 6834F563 6836G680 6838H782 6832E492 6834F572 6836G690 6834F582 6836G693 6834F585 6836G697 6834F589 6836G698 6834F590 Inflammation, mixed 6832E457 6834F557 6836G664 6838H752 6832E464 6834F561 6836G666 6838H753 6832E472 6834F569 6836G671 6838H757 6832E477 6834F571 6836G691 6838H783 6832E486 6834F593 Inflammation - nasolacrimal duct 6832E451 6834F556 6836G653 6838H751 6832E452 6834F557 6836G654 6838H752 6832E456 6834F559 6836G655 6838H753 6832E457 6834F561 6836G657 6838H754 6832E465 6834F563 6836G659 6838H755 6832E471 6834F571 6836G663 6838H757 6832E472 6834F578 6836G664 6838H758 6832E474 6834F584 6836G665 6838H759 6832E475 6834F585 6836G669 6838H760 6832E476 6834F593 6836G670 6838H762 6832E477 6834F594 6836G671 6838H767 6832E478 6834F596 6836G674 6838H770 6832E480 6834F597 6836G678 6838H772 6832E484 6834F598 6836G679 6838H776 6832E485 6834F599 6836G680 6838H780 6832E489 6836G686 6838H783 6832E490 6836G691 6838H785 6832E494 6836G693 6838H788 6832E495 6836G695 6838H789 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-43
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 6832E496 6836G697 6838H790 6832E497 6838H793 6838H796 Inflammation - respiratory epithelium 6832E486 6838H788 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 6832E453 6834F552 6836G651 6838H751 6832E465 6834F576 6836G657 6838H754 6832E468 6834F581 6836G659 6838H766 6832E469 6834F585 6836G664 6838H768 6834F590 6836G695 6838H769 6836G697 6838H776 6838H777 6838H782 6838H784 6838H789 Degeneration, hyaline - respiratory epithelium 6834F582 6836G654 6838H776 6836G657 6838H779 6836G660 6838H788 6836G662 6838H791 6836G679 6838H792 6836G680 6838H797 6836G697 Metaplasia, secretory - olfactory epithelium 6832E464 Metaplasia, squamous - olfactory epithelium 6836G687 Inflammation, mixed 6832E464 6834F557 6836G655 6838H752 6832E477 6834F568 6836G685 6838H783 6832E486 6834F569 6834F593 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 6834F561 Degeneration, hyaline - olfactory epithelium 6832E453 6834F556 6836G652 6838H752 6832E465 6834F576 6836G655 6838H753 6832E469 6836G657 6838H769 6832E472 6836G659 6838H776 6836G662 6838H782 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-44
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 13 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 6836G664 6838H785 6836G679 6838H791 6836G680 6838H792 6836G695 6836G697 Degeneration - respiratory epithelium 6834F557 6838H797 6834F588 Inflammation, mixed 6832E477 6834F557 6836G666 6834F561 6834F588 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 6834F557 Degeneration, hyaline - olfactory epithelium 6832E453 6838H753 6832E472 6838H768 6832E475 6838H791 Inflammation, mixed 6832E477 6834F557 Cervix .........................................Number examined: 2 5 3 2 Clitoral gland .................................Number examined: 1 0 3 0 Lymph node other ...............................Number examined: 3 1 3 1 Hemorrhage 6832E494 Infiltration, histiocytic 6832E494 Popliteal LN ...................................Number examined: 1 1 0 0 Iliac LN .......................................Number examined: 2 2 2 0 Pancreatic LN ..................................Number examined: 2 1 2 1 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-45
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 14 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mediastinal LN .................................Number examined: 50 20 20 47 Hemorrhage 6832E465 6834F582 6836G653 6838H799 6832E466 6832E473 6832E480 Infiltration, histiocytic 6838H763 Pigmentation 6838H763 Pituitary gland ................................Number examined: 50 32 34 50 Angiectasis 6832E455 6834F596 6836G676 6838H762 6832E457 6836G683 6838H764 6832E460 6836G685 6838H768 6832E471 6838H769 6832E479 6838H779 6832E483 6838H782 6832E488 6832E490 6832E497 Cyst 6832E451 6834F556 6836G652 6838H751 6832E452 6834F558 6836G653 6838H752 6832E453 6834F561 6836G663 6838H757 6832E454 6834F563 6836G664 6838H759 6832E456 6834F567 6836G675 6838H761 6832E457 6834F568 6836G680 6838H775 6832E461 6834F573 6836G681 6838H776 6832E462 6834F590 6836G682 6838H780 6832E464 6834F595 6836G689 6838H781 6832E466 6836G694 6838H791 6832E467 6838H797 6832E470 6838H798 6832E475 6832E476 6832E478 6832E479 6832E482 6832E486 6832E489 6832E490 6832E491 6832E496 6832E498 6832E500 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-46
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 15 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pituitary gland ................................Number examined: 50 32 34 50 Degeneration 6832E482 Hemorrhage 6832E465 6838H754 6832E475 6838H757 6832E489 6838H761 6832E493 6838H783 6832E497 6838H787 6838H788 6838H790 6838H791 6838H799 6838H800 Necrosis 6838H772 Tail ...........................................Number examined: 0 0 1 1 Inflammation, acute 6836G689 Inflammation, mixed 6838H759 Bone, rib ......................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 1 0 0 1 Splenic tissue, "accessory" 6832E477 Bone, vertebrae ................................Number examined: 1 0 0 0 Zymbal’s gland .................................Number examined: 1 0 0 0 Mediastinum ....................................Number examined: 1 0 0 0 Bone, other ....................................Number examined: 0 0 1 0 Fracture 6836G688 Harderian gland ................................Number examined: 0 0 1 0 Pigment 6836G683 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-47
 Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 16 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Vagina .........................................Number examined: 0 1 0 0 Tiss.not specifi ...............................Number examined: 0 0 0 0 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-48
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-3 Incidence Summary (with percentages) of Microscopic Observations 

N-49
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Proliferative (including Neoplastic) Lesions 

N-50
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Hyperplasia, alveolar epithelial, focal 7 1 1 1 14% 2% 2% 2% N-Carcinoma, metastatic 0 0 0 1 0% 0% 0% 2% N-Leukemia, mononuclear - capillary involvement 22 16 12 19 44% 32% 24% 38% N-Leukemia, mononuclear - invasive involvement 3 1 2 1 6% 2% 4% 2% N-Sarcoma, histiocytic 0 0 1 1 0% 0% 2% 2% Trachea ........................................Number examined: 50 50 50 50 Hyperplasia 0 0 1 0 0% 0% 2% 0% N-Leukemia, mononuclear 0 1 1 0 0% 2% 2% 0% Bronchial (TBLN) ...............................Number examined: 48 19 20 48 N-Leukemia, mononuclear 9 3 7 2 19% 16% 35% 4% Thyroid glands .................................Number examined: 50 22 22 50 Hyperplasia, C-cell, focal 3 4 1 6 6% 18% 5% 12% Hyperplasia, follicular cell 1 0 0 0 2% 0% 0% 0% B-Adenoma, C-cell 1 2 3 2 2% 9% 14% 4% B-Adenoma, follicular cell 0 0 0 2 0% 0% 0% 4% M-Carcinoma, C-cell 1 0 0 0 2% 0% 0% 0% M-Carcinoma, follicular cell 1 0 1 0 2% 0% 5% 0% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-51
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thyroid glands .................................Number examined: 50 22 22 50 M-Leukemia, mononuclear 0 0 0 1 0% 0% 0% 2% Parathyroid ....................................Number examined: 47 20 20 50 Hyperplasia, focal 1 0 0 0 2% 0% 0% 0% B-Adenoma 1 0 0 0 2% 0% 0% 0% Aorta ..........................................Number examined: 49 20 20 50 N-Leukemia, mononuclear - invasive involvement 1 0 0 0 2% 0% 0% 0% Esophagus ......................................Number examined: 50 20 20 50 Larynx .........................................Number examined: 50 50 50 50 Hyperplasia 17 10 5 15 34% 20% 10% 30% Salivary gland .................................Number examined: 50 20 20 50 M-Leukemia, mononuclear 2 0 0 1 4% 0% 0% 2% Mandibular LN ..................................Number examined: 44 19 21 47 N-Leukemia, mononuclear 12 6 5 5 27% 32% 24% 11% Liver ..........................................Number examined: 50 28 22 50 Hyperplasia, biliary 35 16 17 24 70% 57% 77% 48% Hyperplasia, hepatocellular, regenerative 1 1 1 1 2% 4% 5% 2% B-Adenoma, hepatocellular 1 0 0 0 2% 0% 0% 0% M-Sarcoma. histiocytic 0 0 1 1 0% 0% 5% 2% M-Leukemia, mononuclear 27 17 10 23 54% 61% 45% 46% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-52
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spleen .........................................Number examined: 50 22 24 50 M-Leukemia, mononuclear 27 12 11 23 54% 55% 46% 46% N-Sarcoma, histiocytic 0 0 1 0 0% 0% 4% 0% Kidneys ........................................Number examined: 50 20 21 50 M-Leukemia, mononuclear 1 1 1 2 2% 5% 5% 4% N-Sarcoma, histiocytic 0 0 1 0 0% 0% 5% 0% Heart ..........................................Number examined: 50 20 20 50 M-Leukemia, mononuclear 5 2 0 2 10% 10% 0% 4% Stomach ........................................Number examined: 50 20 20 50 M-Carcinoma, metastatic 0 0 0 1 0% 0% 0% 2% M-Leukemia, mononuclear 1 1 1 0 2% 5% 5% 0% Cecum ..........................................Number examined: 49 20 20 49 N-Leukemia, mononuclear 2 1 0 0 4% 5% 0% 0% Urinary bladder ................................Number examined: 50 20 19 50 Hyperplasia, papillary 1 0 0 0 2% 0% 0% 0% M-Leukemia, mononuclear 1 0 1 0 2% 0% 5% 0% Duodenum .......................................Number examined: 50 20 20 50 Jejunum ........................................Number examined: 50 20 20 50 Ileum ..........................................Number examined: 50 20 19 50 N-Leukemia, mononuclear 1 0 0 1 2% 0% 0% 2% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-53
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Colon ..........................................Number examined: 50 20 20 50 Pancreas .......................................Number examined: 50 18 20 50 M-Leukemia, mononuclear 0 1 0 0 0% 6% 0% 0% Rectum .........................................Number examined: 50 20 20 50 Adrenal glands .................................Number examined: 49 20 21 50 Hyperplasia, cortical, focal 2 0 0 1 4% 0% 0% 2% Hyperplasia, focal 1 0 2 2 2% 0% 10% 4% B-Pheochromocytoma, benign 1 1 2 1 2% 5% 10% 2% M-Carcinoma, metastatic 0 0 0 1 0% 0% 0% 2% M-Leukemia, mononuclear 3 1 0 3 6% 5% 0% 6% Uterus .........................................Number examined: 50 24 31 50 Hyperplasia, cystic endometrial 11 4 4 11 22% 17% 13% 22% B-Adenoma, endometrial 0 1 0 0 0% 4% 0% 0% B-Polyp, endometrial stromal 5 11 11 11 10% 46% 35% 22% M-Adenocarcinoma, endometrial 0 1 2 1 0% 4% 6% 2% M-Leiomyosarcoma 0 1 1 0 0% 4% 3% 0% M-Leukemia, mononuclear 2 3 0 1 4% 13% 0% 2% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-54
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mesenteric LN ..................................Number examined: 50 19 20 50 N-Sarcoma, histiocytic 0 0 0 1 0% 0% 0% 2% N-Leukemia, mononuclear 13 3 7 4 26% 16% 35% 8% Ovaries ........................................Number examined: 49 21 23 50 N-Sarcoma, histiocytic 0 0 0 1 0% 0% 0% 2% M-Leukemia, mononuclear 1 1 1 1 2% 5% 4% 2% Sciatic nerve ..................................Number examined: 50 20 19 50 Muscle, skeletal ...............................Number examined: 50 20 20 50 N-Sarcoma, histiocytic 0 0 0 1 0% 0% 0% 2% Mammary gland ..................................Number examined: 49 20 22 47 Hyperplasia, lobular 1 0 1 2 2% 0% 5% 4% B-Fibroadenoma 0 3 2 5 0% 15% 9% 11% B-Fibroma 1 2 1 0 2% 10% 5% 0% M-Adenocarcinoma 0 1 1 0 0% 5% 5% 0% M-Adenocarcinoma arising in fibroadenoma 1 0 0 0 2% 0% 0% 0% Skin ...........................................Number examined: 50 19 20 49 Brain ..........................................Number examined: 50 25 25 50 M-Astrocytoma, malignant 0 1 0 0 0% 4% 0% 0% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-55
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Eyes/optic nerve ...............................Number examined: 50 22 24 50 Bone, femur ....................................Number examined: 50 20 19 50 Spinal cord ....................................Number examined: 50 20 19 50 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 Hyperplasia - respiratory epithelium 0 1 2 2 0% 2% 4% 4% Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Hyperplasia - respiratory epithelium 0 2 0 1 0% 4% 0% 2% Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Cervix .........................................Number examined: 2 5 3 2 B-Polyp, endometrial stromal 0 0 0 1 0% 0% 0% 50% M-Leiomyosarcoma 0 1 0 0 0% 20% 0% 0% N-Adenocarcinoma, endometrial 0 1 0 0 0% 20% 0% 0% Clitoral gland .................................Number examined: 1 0 3 0 B-Adenoma 0 0 1 0 0% 0% 33% 0% M-Carcinoma, squamous cell 1 0 0 0 100% 0% 0% 0% N-Adenocarcinoma 0 0 2 0 0% 0% 67% 0% Lymph node other ...............................Number examined: 3 1 3 1 N-Leukemia, mononuclear 2 1 2 1 67% 100% 67% 100% Popliteal LN ...................................Number examined: 1 1 0 0 N-Leukemia, mononuclear 1 1 0 0 100% 100% 0% 0% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-56
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Iliac LN .......................................Number examined: 2 2 2 0 N-Leukemia, mononuclear 2 2 2 0 100% 100% 100% 0% Pancreatic LN ..................................Number examined: 2 1 2 1 N-Leukemia, mononuclear 2 1 2 1 100% 100% 100% 100% Mediastinal LN .................................Number examined: 50 20 20 47 B-Thymoma 0 0 1 0 0% 0% 5% 0% M-Carcinoma, metastatic 0 0 0 1 0% 0% 0% 2% N-Sarcoma, histiocytic 0 0 1 0 0% 0% 5% 0% N-Leukemia, mononuclear 12 5 5 5 24% 25% 25% 11% Pituitary gland ................................Number examined: 50 32 34 50 Hyperplasia, focal 8 3 8 4 16% 9% 24% 8% B-Adenoma, pars distalis 7 13 14 11 14% 41% 41% 22% B-Adenoma, pars intermedia 0 0 1 0 0% 0% 3% 0% M-Carcinoma 0 1 0 0 0% 3% 0% 0% M-Leukemia, mononuclear 0 1 0 1 0% 3% 0% 2% Tail ...........................................Number examined: 0 0 1 1 Hyperplasia/hyperkeratosis 0 0 1 1 0% 0% 100% 100% All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-57
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Bone, rib ......................................Number examined: 0 0 0 1 M-Osteosarcoma 0 0 0 1 0% 0% 0% 100% Mesentery ......................................Number examined: 1 0 0 1 M-Carcinoma, metastatic 0 0 0 1 0% 0% 0% 100% Bone, vertebrae ................................Number examined: 1 0 0 0 N-Leukemia, mononuclear 1 0 0 0 100% 0% 0% 0% Zymbal’s gland .................................Number examined: 1 0 0 0 M-Carcinoma, squamous cell 1 0 0 0 100% 0% 0% 0% Mediastinum ....................................Number examined: 1 0 0 0 N-Leukemia, mononuclear 1 0 0 0 100% 0% 0% 0% Bone, other ....................................Number examined: 0 0 1 0 Harderian gland ................................Number examined: 0 0 1 0 Vagina .........................................Number examined: 0 1 0 0 M-Leiomoysarcoma 0 1 0 0 0% 100% 0% 0% Tiss.not specifi ...............................Number examined: 0 0 0 0 All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-58
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

Non-neoplastic Lesions 

N-59
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Alveolar histiocytosis 9 3 3 9 18% 6% 6% 18% Congestion 1 0 2 1 2% 0% 4% 2% Fibrosis, focal 0 1 0 0 0% 2% 0% 0% Hemorrhage 5 1 1 3 10% 2% 2% 6% Inflammation, acute 1 1 0 0 2% 2% 0% 0% Inflammation, mixed 0 0 1 0 0% 0% 2% 0% Inflammation, granulomatous 0 0 1 0 0% 0% 2% 0% Trachea ........................................Number examined: 50 50 50 50 Inflammation, acute 2 0 0 0 4% 0% 0% 0% Inflammation, mixed 1 0 0 1 2% 0% 0% 2% Bronchial (TBLN) ...............................Number examined: 48 19 20 48 Hemorrhage 1 3 0 4 2% 16% 0% 8% Inflammation, mixed 0 0 1 0 0% 0% 5% 0% Thyroid glands .................................Number examined: 50 22 22 50 Cyst, follicular 0 0 1 0 0% 0% 5% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-60
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Parathyroid ....................................Number examined: 47 20 20 50 Aorta ..........................................Number examined: 49 20 20 50 Esophagus ......................................Number examined: 50 20 20 50 Larynx .........................................Number examined: 50 50 50 50 Metaplasia, squamous 5 10 10 9 10% 20% 20% 18% Inflammation, acute 2 0 1 0 4% 0% 2% 0% Inflammation, mixed 28 35 23 33 56% 70% 46% 66% Inflammation, chronic 8 1 6 7 16% 2% 12% 14% Salivary gland .................................Number examined: 50 20 20 50 Mandibular LN ..................................Number examined: 44 19 21 47 Hemorrhage 0 1 0 0 0% 5% 0% 0% Liver ..........................................Number examined: 50 28 22 50 Angiectasis 1 0 0 1 2% 0% 0% 2% Congestion 1 0 1 0 2% 0% 5% 0% Fatty Change 0 1 2 3 0% 4% 9% 6% Foci of cellular alteration, basophilic 1 0 0 1 2% 0% 0% 2% Hepatodiaphragmatic nodule 0 5 0 3 0% 18% 0% 6% Necrosis 3 3 1 5 6% 11% 5% 10% Thrombus 0 0 0 1 0% 0% 0% 2% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-61
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 28 22 50 Vaculolization cytoplasmic 5 1 1 1 10% 4% 5% 2% Inflammation, acute 1 0 0 0 2% 0% 0% 0% Inflammation, chronic 13 5 3 17 26% 18% 14% 34% Spleen .........................................Number examined: 50 22 24 50 Fibrosis 3 0 1 0 6% 0% 4% 0% Hemorrhage 0 0 0 1 0% 0% 0% 2% Necrosis 1 1 0 2 2% 5% 0% 4% Kidneys ........................................Number examined: 50 20 21 50 Atrophy 0 0 0 1 0% 0% 0% 2% Cyst 1 0 0 3 2% 0% 0% 6% Degeneration, hyaline droplet 0 0 0 1 0% 0% 0% 2% Dilatation 0 0 0 1 0% 0% 0% 2% Infarct 0 0 0 1 0% 0% 0% 2% Nephropathy, chronic 42 17 15 43 84% 85% 71% 86% Pigment accumulation, tubular epithelium 0 2 0 2 0% 10% 0% 4% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-62
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Heart ..........................................Number examined: 50 20 20 50 Degeneration, myocyte 3 0 0 3 6% 0% 0% 6% Fibrosis 1 0 0 0 2% 0% 0% 0% Thrombus 1 0 0 0 2% 0% 0% 0% Inflammation, focal, chronic 24 7 8 26 48% 35% 40% 52% Stomach ........................................Number examined: 50 20 20 50 Ulcer 0 1 0 0 0% 5% 0% 0% Inflammation, mixed 0 1 0 0 0% 5% 0% 0% Cecum ..........................................Number examined: 49 20 20 49 Urinary bladder ................................Number examined: 50 20 19 50 Hemorrhage 1 0 0 0 2% 0% 0% 0% Inflammation, chronic 2 0 0 3 4% 0% 0% 6% Duodenum .......................................Number examined: 50 20 20 50 Inflamation, acute 0 1 0 0 0% 5% 0% 0% Jejunum ........................................Number examined: 50 20 20 50 Ileum ..........................................Number examined: 50 20 19 50 Colon ..........................................Number examined: 50 20 20 50 Pancreas .......................................Number examined: 50 18 20 50 Fibrosis 0 0 0 1 0% 0% 0% 2% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-63
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Rectum .........................................Number examined: 50 20 20 50 Metaplasia, squamous 0 1 0 0 0% 5% 0% 0% Adrenal glands .................................Number examined: 49 20 21 50 Cyst 0 0 1 1 0% 0% 5% 2% Degeneration, cytoplasmic vacuolization 12 1 0 14 24% 5% 0% 28% Necrosis 1 0 0 0 2% 0% 0% 0% Thrombus 1 0 0 0 2% 0% 0% 0% Uterus .........................................Number examined: 50 24 31 50 Angiectasis 0 0 1 0 0% 0% 3% 0% Dilatation 0 1 4 3 0% 4% 13% 6% Intussusception 1 1 0 2 2% 4% 0% 4% Inflammation, mixed 3 0 0 0 6% 0% 0% 0% Inflammation, chronic 3 0 0 0 6% 0% 0% 0% Mesenteric LN ..................................Number examined: 50 19 20 50 Hemorrhage 1 0 1 0 2% 0% 5% 0% Inflammation, chronic 1 0 1 0 2% 0% 5% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-64
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Ovaries ........................................Number examined: 49 21 23 50 Congestion 0 0 1 0 0% 0% 4% 0% Cyst, bursa 0 0 1 1 0% 0% 4% 2% Cyst, epithelial 1 1 0 0 2% 5% 0% 0% Cyst, follicular 0 0 1 0 0% 0% 4% 0% Cyst, rete ovarii 0 0 1 0 0% 0% 4% 0% Hemorrhage 1 0 0 0 2% 0% 0% 0% Necrosis, mesenteric fat 0 1 0 0 0% 5% 0% 0% Sciatic nerve ..................................Number examined: 50 20 19 50 Muscle, skeletal ...............................Number examined: 50 20 20 50 Mammary gland ..................................Number examined: 49 20 22 47 Ectasia 3 0 0 1 6% 0% 0% 2% Skin ...........................................Number examined: 50 19 20 49 Cyst, epithelial inclusion 0 1 0 0 0% 5% 0% 0% Fibrosis 0 0 1 0 0% 0% 5% 0% Inflammation, mixed 0 0 1 0 0% 0% 5% 0% Brain ..........................................Number examined: 50 25 25 50 Compression 2 8 9 9 4% 32% 36% 18% Hemorrhage 1 1 0 0 2% 4% 0% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-65
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Brain ..........................................Number examined: 50 25 25 50 Metaplasia, osseous, meninges 0 0 0 1 0% 0% 0% 2% Necrosis 1 0 0 0 2% 0% 0% 0% Inflammation, chronic 0 0 0 1 0% 0% 0% 2% Eyes/optic nerve ...............................Number examined: 50 22 24 50 Atrophy 1 1 0 2 2% 5% 0% 4% Atrophy, retinal, unilateral 0 2 1 0 0% 9% 4% 0% Cataract 1 3 1 2 2% 14% 4% 4% Metaplasia, osseous, scleral 1 0 0 0 2% 0% 0% 0% Mineralization, corneal stromal 4 0 0 4 8% 0% 0% 8% Mineralization, scleral 2 2 2 4 4% 9% 8% 8% Neovascularization, corneal 1 0 0 2 2% 0% 0% 4% Bone, femur ....................................Number examined: 50 20 19 50 New bone formation, endosteal 0 0 0 1 0% 0% 0% 2% Spinal cord ....................................Number examined: 50 20 19 50 Degeneration, white matter 1 0 0 1 2% 0% 0% 2% Hemorrhage 1 0 1 0 2% 0% 5% 0% Necrosis, neuronal 0 0 0 1 0% 0% 0% 2% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-66
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 Degeneration, hyaline - respiratory epithelium 3 7 6 2 6% 14% 12% 4% Inflammation, mixed 5 5 4 4 10% 10% 8% 8% Inflammation - nasolacrimal duct 21 15 20 22 42% 30% 41% 44% Inflammation - respiratory epithelium 1 0 0 1 2% 0% 0% 2% Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 4 5 6 10 8% 10% 12% 20% Degeneration, hyaline - respiratory epithelium 0 1 7 6 0% 2% 14% 12% Metaplasia, secretory - olfactory epithelium 1 0 0 0 2% 0% 0% 0% Metaplasia, squamous - olfactory epithelium 0 0 1 0 0% 0% 2% 0% Inflammation, mixed 3 4 2 2 6% 8% 4% 4% Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 0 1 0 0 0% 2% 0% 0% Degeneration, hyaline - olfactory epithelium 4 2 10 8 8% 4% 20% 16% Degeneration - respiratory epithelium 0 2 0 1 0% 4% 0% 2% Inflammation, mixed 1 3 1 0 2% 6% 2% 0% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-67
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 0 1 0 0 0% 2% 0% 0% Degeneration, hyaline - olfactory epithelium 3 0 0 3 6% 0% 0% 6% Inflammation, mixed 1 1 0 0 2% 2% 0% 0% Cervix .........................................Number examined: 2 5 3 2 Clitoral gland .................................Number examined: 1 0 3 0 Lymph node other ...............................Number examined: 3 1 3 1 Hemorrhage 1 0 0 0 33% 0% 0% 0% Infiltration, histiocytic 1 0 0 0 33% 0% 0% 0% Popliteal LN ...................................Number examined: 1 1 0 0 Iliac LN .......................................Number examined: 2 2 2 0 Pancreatic LN ..................................Number examined: 2 1 2 1 Mediastinal LN .................................Number examined: 50 20 20 47 Hemorrhage 4 1 1 1 8% 5% 5% 2% Infiltration, histiocytic 0 0 0 1 0% 0% 0% 2% Pigmentation 0 0 0 1 0% 0% 0% 2% Pituitary gland ................................Number examined: 50 32 34 50 Angiectasis 9 1 3 6 18% 3% 9% 12% Cyst 24 9 10 12 48% 28% 29% 24% Degeneration 1 0 0 0 2% 0% 0% 0% Hemorrhage 5 0 0 10 10% 0% 0% 20% All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-68
 Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Pituitary gland ................................Number examined: 50 32 34 50 Necrosis 0 0 0 1 0% 0% 0% 2% Tail ...........................................Number examined: 0 0 1 1 Inflammation, acute 0 0 1 0 0% 0% 100% 0% Inflammation, mixed 0 0 0 1 0% 0% 0% 100% Bone, rib ......................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 1 0 0 1 Splenic tissue, "accessory" 1 0 0 0 100% 0% 0% 0% Bone, vertebrae ................................Number examined: 1 0 0 0 Zymbal’s gland .................................Number examined: 1 0 0 0 Mediastinum ....................................Number examined: 1 0 0 0 Bone, other ....................................Number examined: 0 0 1 0 Fracture 0 0 1 0 0% 0% 100% 0% Harderian gland ................................Number examined: 0 0 1 0 Pigment 0 0 1 0 0% 0% 100% 0% Vagina .........................................Number examined: 0 1 0 0 Tiss.not specifi ...............................Number examined: 0 0 0 0 All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-69
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-4 Tabulated Incidence Summary of Non-neoplastic Lesions 

N-70
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Hyperplasia, alveolar epithelial, focal, Minimal. 4 0 0 0 Hyperplasia, alveolar epithelial, focal, Mild. 2 1 1 1 Hyperplasia, alveolar epithelial, focal, Moderate. 1 0 0 0 Congestion, Minimal. 0 0 1 0 Congestion, Mild. 1 0 1 1 Alveolar histiocytosis, Minimal. 9 3 3 9 Fibrosis, focal, Mild. 0 1 0 0 Inflammation, mixed, Moderate. 0 0 1 0 Inflammation, acute, Minimal. 1 1 0 0 Hemorrhage, Minimal. 3 0 0 2 Hemorrhage, Mild. 2 1 1 1 Inflammation, granulomatous, Minimal. 0 0 1 0 Trachea ........................................Number examined: 50 50 50 50 Inflammation, acute, Mild. 2 0 0 0 Inflammation, mixed, Mild. 1 0 0 1 Hyperplasia, Moderate. 0 0 1 0 Bronchial (TBLN) ...............................Number examined: 48 19 20 48 Hemorrhage, Mild. 1 2 0 4 Hemorrhage, Moderate. 0 1 0 0 Inflammation, mixed, Minimal. 0 0 1 0 Thyroid glands .................................Number examined: 50 22 22 50 Hyperplasia, C-cell, focal, Minimal. 1 1 1 0 Hyperplasia, C-cell, focal, Mild. 1 1 0 4 Hyperplasia, C-cell, focal, Moderate. 1 1 0 2 Hyperplasia, C-cell, focal, Marked. 0 1 0 0 Cyst, follicular, Present. 0 0 1 0 Hyperplasia, follicular cell, Mild. 1 0 0 0 Parathyroid ....................................Number examined: 47 20 20 50 Hyperplasia, focal, Mild. 1 0 0 0 Aorta ..........................................Number examined: 49 20 20 50 Esophagus ......................................Number examined: 50 20 20 50 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-71
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Larynx .........................................Number examined: 50 50 50 50 Hyperplasia, Minimal. 12 8 5 7 Hyperplasia, Mild. 5 2 0 8 Metaplasia, squamous, Minimal. 1 5 7 9 Metaplasia, squamous, Mild. 3 5 3 0 Metaplasia, squamous, Moderate. 1 0 0 0 Inflammation, acute, Minimal. 2 0 1 0 Inflammation, mixed, Minimal. 10 20 14 17 Inflammation, mixed, Mild. 17 15 9 16 Inflammation, mixed, Moderate. 1 0 0 0 Inflammation, chronic, Minimal. 8 1 4 5 Inflammation, chronic, Mild. 0 0 2 2 Salivary gland .................................Number examined: 50 20 20 50 Mandibular LN ..................................Number examined: 44 19 21 47 Hemorrhage, Mild. 0 1 0 0 Liver ..........................................Number examined: 50 28 22 50 Necrosis, Minimal. 2 1 0 3 Necrosis, Mild. 0 1 1 1 Necrosis, Moderate. 1 1 0 1 Vaculolization cytoplasmic, Minimal. 1 0 0 0 Vaculolization cytoplasmic, Mild. 1 1 1 1 Vaculolization cytoplasmic, Moderate. 3 0 0 0 Inflammation, acute, Mild. 1 0 0 0 Angiectasis, Minimal. 1 0 0 1 Hyperplasia, biliary, Minimal. 12 8 9 19 Hyperplasia, biliary, Mild. 22 8 7 5 Hyperplasia, biliary, Moderate. 1 0 1 0 Hyperplasia, hepatocellular, regenerative, Minimal. 0 0 0 1 Hyperplasia, hepatocellular, regenerative, Mild. 0 1 1 0 Hyperplasia, hepatocellular, regenerative, Moderate. 1 0 0 0 Inflammation, chronic, Minimal. 10 4 2 16 Inflammation, chronic, Mild. 3 1 1 1 Fatty Change, Minimal. 0 1 1 1 Fatty Change, Mild. 0 0 1 2 Hepatodiaphragmatic nodule, Present. 0 5 0 3 Foci of cellular alteration, basophilic, Mild. 0 0 0 1 Foci of cellular alteration, basophilic, Moderate. 1 0 0 0 Congestion, Mild. 1 0 1 0 Thrombus, Mild. 0 0 0 1 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-72
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spleen .........................................Number examined: 50 22 24 50 Fibrosis, Minimal. 1 0 1 0 Fibrosis, Mild. 1 0 0 0 Fibrosis, Moderate. 1 0 0 0 Necrosis, Mild. 1 0 0 0 Necrosis, Moderate. 0 0 0 1 Necrosis, Marked. 0 1 0 1 Hemorrhage, Moderate. 0 0 0 1 Kidneys ........................................Number examined: 50 20 21 50 Pigment accumulation, tubular epithelium, Minimal. 0 0 0 1 Pigment accumulation, tubular epithelium, Moderate. 0 2 0 1 Nephropathy, chronic, Minimal. 32 14 11 16 Nephropathy, chronic, Mild. 10 3 3 20 Nephropathy, chronic, Moderate. 0 0 1 7 Cyst, Mild. 0 0 0 1 Cyst, Moderate. 1 0 0 2 Degeneration, hyaline droplet, Marked. 0 0 0 1 Dilatation, Moderate. 0 0 0 1 Atrophy, Marked. 0 0 0 1 Infarct, Moderate. 0 0 0 1 Heart ..........................................Number examined: 50 20 20 50 Inflammation, focal, chronic, Minimal. 23 7 8 25 Inflammation, focal, chronic, Mild. 1 0 0 1 Degeneration, myocyte, Minimal. 2 0 0 3 Degeneration, myocyte, Mild. 1 0 0 0 Fibrosis, Minimal. 1 0 0 0 Thrombus, Minimal. 1 0 0 0 Stomach ........................................Number examined: 50 20 20 50 Inflammation, mixed, Mild. 0 1 0 0 Ulcer, Mild. 0 1 0 0 Cecum ..........................................Number examined: 49 20 20 49 Urinary bladder ................................Number examined: 50 20 19 50 Inflammation, chronic, Minimal. 2 0 0 3 Hyperplasia, papillary, Mild. 1 0 0 0 Hemorrhage, Mild. 1 0 0 0 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-73
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Duodenum .......................................Number examined: 50 20 20 50 Inflamation, acute, Moderate. 0 1 0 0 Jejunum ........................................Number examined: 50 20 20 50 Ileum ..........................................Number examined: 50 20 19 50 Colon ..........................................Number examined: 50 20 20 50 Pancreas .......................................Number examined: 50 18 20 50 Fibrosis, Mild. 0 0 0 1 Rectum .........................................Number examined: 50 20 20 50 Metaplasia, squamous, Mild. 0 1 0 0 Adrenal glands .................................Number examined: 49 20 21 50 Hyperplasia, focal, Present. 1 0 2 2 Degeneration, cytoplasmic vacuolization, Minimal. 10 0 0 12 Degeneration, cytoplasmic vacuolization, Mild. 1 1 0 2 Degeneration, cytoplasmic vacuolization, Moderate. 1 0 0 0 Hyperplasia, cortical, focal, Minimal. 2 0 0 1 Thrombus, Minimal. 1 0 0 0 Cyst, Minimal. 0 0 0 1 Cyst, Mild. 0 0 1 0 Necrosis, Minimal. 1 0 0 0 Uterus .........................................Number examined: 50 24 31 50 Dilatation, Minimal. 0 0 1 0 Dilatation, Mild. 0 1 2 0 Dilatation, Moderate. 0 0 1 1 Dilatation, Marked. 0 0 0 2 Hyperplasia, cystic endometrial, Minimal. 5 0 0 6 Hyperplasia, cystic endometrial, Mild. 4 3 2 3 Hyperplasia, cystic endometrial, Moderate. 1 1 2 2 Hyperplasia, cystic endometrial, Marked. 1 0 0 0 Inflammation, chronic, Minimal. 3 0 0 0 Inflammation, mixed, Minimal. 1 0 0 0 Inflammation, mixed, Mild. 2 0 0 0 Intussusception, Present. 1 1 0 2 Angiectasis, Mild. 0 0 1 0 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-74
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mesenteric LN ..................................Number examined: 50 19 20 50 Hemorrhage, Mild. 1 0 1 0 Inflammation, chronic, Minimal. 0 0 1 0 Inflammation, chronic, Moderate. 1 0 0 0 Ovaries ........................................Number examined: 49 21 23 50 Hemorrhage, Mild. 1 0 0 0 Cyst, bursa, Present. 0 0 1 1 Cyst, epithelial, Present. 1 1 0 0 Congestion, Mild. 0 0 1 0 Necrosis, mesenteric fat, Mild. 0 1 0 0 Cyst, rete ovarii, Mild. 0 0 1 0 Cyst, follicular, Present. 0 0 1 0 Sciatic nerve ..................................Number examined: 50 20 19 50 Muscle, skeletal ...............................Number examined: 50 20 20 50 Mammary gland ..................................Number examined: 49 20 22 47 Ectasia, Minimal. 2 0 0 0 Ectasia, Mild. 0 0 0 1 Ectasia, Moderate. 1 0 0 0 Hyperplasia, lobular, Minimal. 1 0 0 1 Hyperplasia, lobular, Mild. 0 0 1 1 Skin ...........................................Number examined: 50 19 20 49 Fibrosis, Moderate. 0 0 1 0 Cyst, epithelial inclusion, Present. 0 1 0 0 Inflammation, mixed, Minimal. 0 0 1 0 Brain ..........................................Number examined: 50 25 25 50 Compression, Minimal. 0 1 0 1 Compression, Mild. 0 4 3 5 Compression, Moderate. 1 3 4 3 Compression, Marked. 1 0 2 0 Necrosis, Mild. 1 0 0 0 Metaplasia, osseous, meninges, Minimal. 0 0 0 1 Hemorrhage, Mild. 1 1 0 0 Inflammation, chronic, Marked. 0 0 0 1 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-75
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Eyes/optic nerve ...............................Number examined: 50 22 24 50 Mineralization, corneal stromal, Minimal. 3 0 0 3 Mineralization, corneal stromal, Mild. 1 0 0 1 Mineralization, scleral, Minimal. 2 0 2 3 Mineralization, scleral, Mild. 0 2 0 1 Atrophy, Moderate. 1 0 0 0 Atrophy, Marked. 0 1 0 2 Atrophy, retinal, unilateral, Mild. 0 0 1 0 Atrophy, retinal, unilateral, Marked. 0 2 0 0 Cataract, Present. 1 3 1 2 Neovascularization, corneal, Minimal. 1 0 0 2 Metaplasia, osseous, scleral, Minimal. 1 0 0 0 Bone, femur ....................................Number examined: 50 20 19 50 New bone formation, endosteal, Minimal. 0 0 0 1 Spinal cord ....................................Number examined: 50 20 19 50 Degeneration, white matter, Minimal. 0 0 0 1 Degeneration, white matter, Mild. 1 0 0 0 Hemorrhage, Minimal. 0 0 1 0 Hemorrhage, Mild. 1 0 0 0 Necrosis, neuronal, Minimal. 0 0 0 1 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 Inflammation - nasolacrimal duct, Minimal. 4 2 1 1 Inflammation - nasolacrimal duct, Mild. 9 6 5 6 Inflammation - nasolacrimal duct, Moderate. 8 7 14 10 Inflammation - nasolacrimal duct, Marked. 0 0 0 5 Inflammation, mixed, Minimal. 0 2 1 1 Inflammation, mixed, Mild. 1 2 1 3 Inflammation, mixed, Moderate. 3 1 2 0 Inflammation, mixed, Marked. 1 0 0 0 Inflammation - respiratory epithelium, Mild. 0 0 0 1 Inflammation - respiratory epithelium, Moderate. 1 0 0 0 Hyperplasia - respiratory epithelium, Minimal. 0 1 0 0 Hyperplasia - respiratory epithelium, Mild. 0 0 2 2 Degeneration, hyaline - respiratory epithelium, Minimal. 1 5 4 1 Degeneration, hyaline - respiratory epithelium, Mild. 0 2 1 1 Degeneration, hyaline - respiratory epithelium, Moderate. 2 0 1 0 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-76
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium, Minimal. 3 2 3 5 Degeneration, hyaline - olfactory epithelium, Mild. 1 3 2 5 Degeneration, hyaline - olfactory epithelium, Moderate. 0 0 1 0 Inflammation, mixed, Minimal. 0 2 1 1 Inflammation, mixed, Mild. 1 2 1 0 Inflammation, mixed, Moderate. 1 0 0 1 Inflammation, mixed, Marked. 1 0 0 0 Metaplasia, secretory - olfactory epithelium, Marked. 1 0 0 0 Hyperplasia - respiratory epithelium, Mild. 0 2 0 0 Hyperplasia - respiratory epithelium, Moderate. 0 0 0 1 Degeneration, hyaline - respiratory epithelium, Minimal. 0 1 2 2 Degeneration, hyaline - respiratory epithelium, Mild. 0 0 4 4 Degeneration, hyaline - respiratory epithelium, Moderate. 0 0 1 0 Metaplasia, squamous - olfactory epithelium, Minimal. 0 0 1 0 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium, Minimal. 3 1 4 2 Degeneration, hyaline - olfactory epithelium, Mild. 0 1 3 4 Degeneration, hyaline - olfactory epithelium, Moderate. 1 0 3 2 Inflammation, mixed, Minimal. 0 1 0 0 Inflammation, mixed, Mild. 0 2 1 0 Inflammation, mixed, Moderate. 1 0 0 0 Degeneration - respiratory epithelium, Mild. 0 2 0 1 Degeneration - olfactory epithelium, Minimal. 0 1 0 0 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Inflammation, mixed, Mild. 1 1 0 0 Degeneration, hyaline - olfactory epithelium, Minimal. 2 0 0 3 Degeneration, hyaline - olfactory epithelium, Mild. 1 0 0 0 Degeneration - olfactory epithelium, Mild. 0 1 0 0 Cervix .........................................Number examined: 2 5 3 2 Clitoral gland .................................Number examined: 1 0 3 0 Lymph node other ...............................Number examined: 3 1 3 1 Infiltration, histiocytic, Mild. 1 0 0 0 Hemorrhage, Minimal. 1 0 0 0 Popliteal LN ...................................Number examined: 1 1 0 0 Iliac LN .......................................Number examined: 2 2 2 0 Pancreatic LN ..................................Number examined: 2 1 2 1 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-77
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mediastinal LN .................................Number examined: 50 20 20 47 Pigmentation, Moderate. 0 0 0 1 Infiltration, histiocytic, Moderate. 0 0 0 1 Hemorrhage, Mild. 3 1 1 1 Hemorrhage, Moderate. 1 0 0 0 Pituitary gland ................................Number examined: 50 32 34 50 Cyst, Minimal. 8 2 2 6 Cyst, Mild. 11 5 4 6 Cyst, Moderate. 4 1 4 0 Cyst, Marked. 1 1 0 0 Degeneration, Mild. 1 0 0 0 Hyperplasia, focal, Minimal. 1 1 2 1 Hyperplasia, focal, Mild. 3 1 3 1 Hyperplasia, focal, Moderate. 4 1 2 2 Hyperplasia, focal, Marked. 0 0 1 0 Hemorrhage, Minimal. 2 0 0 2 Hemorrhage, Mild. 1 0 0 2 Hemorrhage, Moderate. 2 0 0 6 Angiectasis, Minimal. 2 0 0 2 Angiectasis, Mild. 5 0 1 1 Angiectasis, Moderate. 2 1 2 2 Angiectasis, Marked. 0 0 0 1 Necrosis, Moderate. 0 0 0 1 Tail ...........................................Number examined: 0 0 1 1 Inflammation, mixed, Moderate. 0 0 0 1 Hyperplasia/hyperkeratosis, Moderate. 0 0 1 0 Hyperplasia/hyperkeratosis, Marked. 0 0 0 1 Inflammation, acute, Mild. 0 0 1 0 Bone, rib ......................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 1 0 0 1 Splenic tissue, "accessory", Present. 1 0 0 0 Bone, vertebrae ................................Number examined: 1 0 0 0 Zymbal’s gland .................................Number examined: 1 0 0 0 Mediastinum ....................................Number examined: 1 0 0 0 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-78
 Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Bone, other ....................................Number examined: 0 0 1 0 Fracture, Present. 0 0 1 0 Harderian gland ................................Number examined: 0 0 1 0 Pigment, Mild. 0 0 1 0 Vagina .........................................Number examined: 0 1 0 0 Tiss.not specifi ...............................Number examined: 0 0 0 0 Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03 Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

Study Number FY01-013

N-79
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-5 Lesion Incidence Summary with Average Severity Grades 

N-80
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Lungs ..........................................Number examined: 50 50 50 50 Alveolar histiocytosis 9 3 3 9 Average severity: 0.2 0.1 0.1 0.2 Congestion 1 0 2 1 Average severity: 0.0 0.0 0.1 0.0 Fibrosis, focal 0 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Hemorrhage 5 1 1 3 Average severity: 0.1 0.0 0.0 0.1 Inflammation, acute 1 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Inflammation, granulomatous 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia, alveolar epithelial, focal 7 1 1 1 Average severity: 0.2 0.0 0.0 0.0 Trachea ........................................Number examined: 50 50 50 50 Inflammation, acute 2 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Inflammation, mixed 1 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Bronchial (TBLN) ...............................Number examined: 48 19 20 48 Hemorrhage 1 3 0 4 Average severity: 0.0 0.4 0.0 0.2 Inflammation, mixed 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-81
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Thyroid glands .................................Number examined: 50 22 22 50 Cyst, follicular 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia, C-cell, focal 3 4 1 6 Average severity: 0.1 0.5 0.0 0.3 Hyperplasia, follicular cell 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Parathyroid ....................................Number examined: 47 20 20 50 Hyperplasia, focal 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Aorta ..........................................Number examined: 49 20 20 50 Esophagus ......................................Number examined: 50 20 20 50 Larynx .........................................Number examined: 50 50 50 50 Metaplasia, squamous 5 10 10 9 Average severity: 0.2 0.3 0.3 0.2 Hyperplasia 17 10 5 15 Average severity: 0.4 0.2 0.1 0.5 Inflammation, acute 2 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 28 35 23 33 Average severity: 0.9 1.0 0.6 1.0 Inflammation, chronic 8 1 6 7 Average severity: 0.2 0.0 0.2 0.2 Salivary gland .................................Number examined: 50 20 20 50 Mandibular LN ..................................Number examined: 44 19 21 47 Hemorrhage 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-82
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Liver ..........................................Number examined: 50 28 22 50 Angiectasis 1 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Congestion 1 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Fatty Change 0 1 2 3 Average severity: 0.0 0.0 0.1 0.1 Foci of cellular alteration, basophilic 1 0 0 1 Average severity: 0.1 0.0 0.0 0.0 Hepatodiaphragmatic nodule 0 5 0 3 Average severity: 0.0 0.2 0.0 0.1 Necrosis 3 3 1 5 Average severity: 0.1 0.2 0.1 0.2 Thrombus 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Vaculolization cytoplasmic 5 1 1 1 Average severity: 0.2 0.1 0.1 0.0 Inflammation, acute 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, chronic 13 5 3 17 Average severity: 0.3 0.2 0.2 0.4 Hyperplasia, biliary 35 16 17 24 Average severity: 1.2 0.9 1.2 0.6 Hyperplasia, hepatocellular, regenerative 1 1 1 1 Average severity: 0.1 0.1 0.1 0.0 Spleen .........................................Number examined: 50 22 24 50 Fibrosis 3 0 1 0 Average severity: 0.1 0.0 0.0 0.0 Hemorrhage 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-83
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spleen .........................................Number examined: 50 22 24 50 Necrosis 1 1 0 2 Average severity: 0.0 0.2 0.0 0.1 Kidneys ........................................Number examined: 50 20 21 50 Atrophy 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Cyst 1 0 0 3 Average severity: 0.1 0.0 0.0 0.2 Degeneration, hyaline droplet 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Dilatation 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Infarct 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Nephropathy, chronic 42 17 15 43 Average severity: 1.0 1.0 1.0 1.5 Pigment accumulation, tubular epithelium 0 2 0 2 Average severity: 0.0 0.3 0.0 0.1 Heart ..........................................Number examined: 50 20 20 50 Degeneration, myocyte 3 0 0 3 Average severity: 0.1 0.0 0.0 0.1 Fibrosis 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Thrombus 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, focal, chronic 24 7 8 26 Average severity: 0.5 0.4 0.4 0.5 Stomach ........................................Number examined: 50 20 20 50 Ulcer 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-84
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Stomach ........................................Number examined: 50 20 20 50 Inflammation, mixed 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Cecum ..........................................Number examined: 49 20 20 49 Urinary bladder ................................Number examined: 50 20 19 50 Hemorrhage 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, chronic 2 0 0 3 Average severity: 0.0 0.0 0.0 0.1 Hyperplasia, papillary 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Duodenum .......................................Number examined: 50 20 20 50 Inflamation, acute 0 1 0 0 Average severity: 0.0 0.2 0.0 0.0 Jejunum ........................................Number examined: 50 20 20 50 Ileum ..........................................Number examined: 50 20 19 50 Colon ..........................................Number examined: 50 20 20 50 Pancreas .......................................Number examined: 50 18 20 50 Fibrosis 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Rectum .........................................Number examined: 50 20 20 50 Metaplasia, squamous 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Adrenal glands .................................Number examined: 49 20 21 50 Cyst 0 0 1 1 Average severity: 0.0 0.0 0.1 0.0 Degeneration, cytoplasmic vacuolization 12 1 0 14 Average severity: 0.3 0.1 0.0 0.3 Necrosis 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-85
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Adrenal glands .................................Number examined: 49 20 21 50 Thrombus 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia, cortical, focal 2 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Hyperplasia, focal 1 0 2 2 Average severity: 0.0 0.0 0.1 0.0 Uterus .........................................Number examined: 50 24 31 50 Angiectasis 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Dilatation 0 1 4 3 Average severity: 0.0 0.1 0.3 0.2 Intussusception 1 1 0 2 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 3 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Inflammation, chronic 3 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Hyperplasia, cystic endometrial 11 4 4 11 Average severity: 0.4 0.4 0.3 0.4 Mesenteric LN ..................................Number examined: 50 19 20 50 Hemorrhage 1 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Inflammation, chronic 1 0 1 0 Average severity: 0.1 0.0 0.1 0.0 Ovaries ........................................Number examined: 49 21 23 50 Congestion 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Cyst, bursa 0 0 1 1 Average severity: 0.0 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-86
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Ovaries ........................................Number examined: 49 21 23 50 Cyst, epithelial 1 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Cyst, follicular 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Cyst, rete ovarii 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Hemorrhage 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Necrosis, mesenteric fat 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Sciatic nerve ..................................Number examined: 50 20 19 50 Muscle, skeletal ...............................Number examined: 50 20 20 50 Mammary gland ..................................Number examined: 49 20 22 47 Ectasia 3 0 0 1 Average severity: 0.1 0.0 0.0 0.0 Hyperplasia, lobular 1 0 1 2 Average severity: 0.0 0.0 0.1 0.1 Skin ...........................................Number examined: 50 19 20 49 Cyst, epithelial inclusion 0 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Fibrosis 0 0 1 0 Average severity: 0.0 0.0 0.2 0.0 Inflammation, mixed 0 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Brain ..........................................Number examined: 50 25 25 50 Compression 2 8 9 9 Average severity: 0.1 0.7 1.0 0.4 Hemorrhage 1 1 0 0 Average severity: 0.0 0.1 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-87
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Brain ..........................................Number examined: 50 25 25 50 Metaplasia, osseous, meninges 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Necrosis 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, chronic 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Eyes/optic nerve ...............................Number examined: 50 22 24 50 Atrophy 1 1 0 2 Average severity: 0.1 0.2 0.0 0.2 Atrophy, retinal, unilateral 0 2 1 0 Average severity: 0.0 0.4 0.1 0.0 Cataract 1 3 1 2 Average severity: 0.0 0.1 0.0 0.0 Metaplasia, osseous, scleral 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Mineralization, corneal stromal 4 0 0 4 Average severity: 0.1 0.0 0.0 0.1 Mineralization, scleral 2 2 2 4 Average severity: 0.0 0.2 0.1 0.1 Neovascularization, corneal 1 0 0 2 Average severity: 0.0 0.0 0.0 0.0 Bone, femur ....................................Number examined: 50 20 19 50 New bone formation, endosteal 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Spinal cord ....................................Number examined: 50 20 19 50 Degeneration, white matter 1 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Hemorrhage 1 0 1 0 Average severity: 0.0 0.0 0.1 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-88
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 9 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Spinal cord ....................................Number examined: 50 20 19 50 Necrosis, neuronal 0 0 0 1 Average severity: 0.0 0.0 0.0 0.0 Nose/Turbinate 1 ...............................Number examined: 50 50 49 50 Degeneration, hyaline - respiratory epithelium 3 7 6 2 Average severity: 0.1 0.2 0.2 0.1 Inflammation, mixed 5 5 4 4 Average severity: 0.3 0.2 0.2 0.1 Inflammation - nasolacrimal duct 21 15 20 22 Average severity: 0.9 0.7 1.1 1.3 Inflammation - respiratory epithelium 1 0 0 1 Average severity: 0.1 0.0 0.0 0.0 Hyperplasia - respiratory epithelium 0 1 2 2 Average severity: 0.0 0.0 0.1 0.1 Nose/Turbinate 2 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 4 5 6 10 Average severity: 0.1 0.2 0.2 0.3 Degeneration, hyaline - respiratory epithelium 0 1 7 6 Average severity: 0.0 0.0 0.3 0.2 Metaplasia, secretory - olfactory epithelium 1 0 0 0 Average severity: 0.1 0.0 0.0 0.0 Metaplasia, squamous - olfactory epithelium 0 0 1 0 Average severity: 0.0 0.0 0.0 0.0 Inflammation, mixed 3 4 2 2 Average severity: 0.2 0.1 0.1 0.1 Hyperplasia - respiratory epithelium 0 2 0 1 Average severity: 0.0 0.1 0.0 0.1 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 0 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-89
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 10 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Nose/Turbinate 3 ...............................Number examined: 50 50 50 50 Degeneration, hyaline - olfactory epithelium 4 2 10 8 Average severity: 0.1 0.1 0.4 0.3 Degeneration - respiratory epithelium 0 2 0 1 Average severity: 0.0 0.1 0.0 0.0 Inflammation, mixed 1 3 1 0 Average severity: 0.1 0.1 0.0 0.0 Nose/Turbinate 4 ...............................Number examined: 50 50 50 50 Degeneration - olfactory epithelium 0 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Degeneration, hyaline - olfactory epithelium 3 0 0 3 Average severity: 0.1 0.0 0.0 0.1 Inflammation, mixed 1 1 0 0 Average severity: 0.0 0.0 0.0 0.0 Cervix .........................................Number examined: 2 5 3 2 Clitoral gland .................................Number examined: 1 0 3 0 Lymph node other ...............................Number examined: 3 1 3 1 Hemorrhage 1 0 0 0 Average severity: 0.3 0.0 0.0 0.0 Infiltration, histiocytic 1 0 0 0 Average severity: 0.7 0.0 0.0 0.0 Popliteal LN ...................................Number examined: 1 1 0 0 Iliac LN .......................................Number examined: 2 2 2 0 Pancreatic LN ..................................Number examined: 2 1 2 1 Mediastinal LN .................................Number examined: 50 20 20 47 Hemorrhage 4 1 1 1 Average severity: 0.2 0.1 0.1 0.0 Infiltration, histiocytic 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-90
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 11 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Mediastinal LN .................................Number examined: 50 20 20 47 Pigmentation 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Pituitary gland ................................Number examined: 50 32 34 50 Angiectasis 9 1 3 6 Average severity: 0.4 0.1 0.2 0.3 Cyst 24 9 10 12 Average severity: 0.9 0.6 0.6 0.4 Degeneration 1 0 0 0 Average severity: 0.0 0.0 0.0 0.0 Hemorrhage 5 0 0 10 Average severity: 0.2 0.0 0.0 0.5 Necrosis 0 0 0 1 Average severity: 0.0 0.0 0.0 0.1 Hyperplasia, focal 8 3 8 4 Average severity: 0.4 0.2 0.5 0.2 Tail ...........................................Number examined: 0 0 1 1 Inflammation, acute 0 0 1 0 Average severity: 0.0 0.0 2.0 0.0 Inflammation, mixed 0 0 0 1 Average severity: 0.0 0.0 0.0 3.0 Hyperplasia/hyperkeratosis 0 0 1 1 Average severity: 0.0 0.0 3.0 4.0 Bone, rib ......................................Number examined: 0 0 0 1 Mesentery ......................................Number examined: 1 0 0 1 Splenic tissue, "accessory" 1 0 0 0 Average severity: 1.0 0.0 0.0 0.0 Bone, vertebrae ................................Number examined: 1 0 0 0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-91
 Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 12 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Zymbal’s gland .................................Number examined: 1 0 0 0 Mediastinum ....................................Number examined: 1 0 0 0 Bone, other ....................................Number examined: 0 0 1 0 Fracture 0 0 1 0 Average severity: 0.0 0.0 1.0 0.0 Harderian gland ................................Number examined: 0 0 1 0 Pigment 0 0 1 0 Average severity: 0.0 0.0 2.0 0.0 Vagina .........................................Number examined: 0 1 0 0 Tiss.not specifi ...............................Number examined: 0 0 0 0 Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-92
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-6 Raw Data 

N-93
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Lungs (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - 1 - - - 1 1 - 1 - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - 2 1 - 1 - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - - - 2 - 1 - - 2= - - 2 2 2 - 74-N-Leukemia,monuc - inv invol - - 2= - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - - - - - - - - 297-Inflammation, mixed s - - - - - - - - - - - - - - 62-N-Leukemia, monuc - - 1= - - - - 1= - - - - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - - - - - - - 77-Hyperplasia, C-cell, focal s - - - - 1 - - - - 3 2 - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 35-B-Adenoma, C-cell - - - - - - - - - - - - - - - 78-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - - 1= - - - 80-M-Carcinoma, follicular cell - - - 1= - - - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - - - - - - - Parathyroid (2) Status > mH mH mH mH m m mH mH mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - - - - - - - - 296-B-Adenoma - - - - - - - - - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -

Study Number FY01-013

N-94
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - - - - - 2 - - - - - - - 1-Hyperplasia s 1 2 1 - 1 - 1 - - - - 1 - 2 - 23-Inflammation, acute s - - - - - - - - 1 1 - - - - - 42-Inflammation, mixed s 2 2 1 - 1 - 2 2 - - 2 2 - 2 - 53-Inflammation, chronic s - - - - - 1 - - - - - - - - 1 Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (2) Status > * * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - - - - - 44-N-Leukemia, monuc - - - - - - - 1= - - - 1 Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - - - - - - - 158-Congestion s - 2= - - - - - - - - - - - - - 90-Fatty Change s - - - - - - - - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 92-Hdn p - - - - - - - - - - - - - - - 4-Necrosis s - 1 - - - - - - - - - - - - - 230-Thrombus s - - - - - - - - - - - - - - - 13-Vaculoliz cyto s - 1 - - - - 3 - - - - - - 3 - 24-Inflammation, acute s - - - - - - - - - - - - - - - 54-Inflammation, chronic s - - - - - - - 1 - - 1 - - - - 46-Hyperplasia, biliary s 1 - 2 1 2 2 - 1 - 2 - - 2 - - 47-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-M-Leukemia, monuc - 1 1= 2= - 1 2= - 2 - - 2= 2 2= - Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - - - - - - - - - 226-Hemorrhage s - - - - - - - - - - - - - - - 97-Necrosis s - - - - - - - - - - - - - - - 15-M-Leukemia, monuc - - 2= 2= - 1= 2= - 2= - - 1 2= 2= - 298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -

Study Number FY01-013

N-95
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Kidneys (9) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - - - - - - - - 149-Cyst s - - - - - - - - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - - - - - - - - 210-Dilatation s - - - - - - - - - - - - - - - 228-Infarct s - - - - - - - - - - - - - - - 16-Nephropathy, chronic s 1 1 1 - - 1 1 1 - 1 2 2 1 - 1 6-Pigment accum, tub epi s - - - - - - - - - - - - - - - 98-M-Leukemia, monuc - - - - - - - - - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 100-Degen, myocyte s - 2 - - - - - - - - - - - - - 101-Fibrosis s - - - - - - - - - - - - - - - 175-Thrombus s - - - - - - - - - - - - - 1= - 36-Inflammation, focal, chronic s 1 - - 1 2 - - - - 1 1 1 1 - 1 48-M-Leukemia, monuc - - 1 - - - - - 1 - - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - - - - - - - - 103-Inflammation, mixed s - - - - - - - - - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - - - - - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - - - - - - - - 56-Inflammation, chronic s - - - - 1 - - - - - - - - - - 166-Hyperplasia, papillary s - - - - - 2 - - - - - - - - - 106-M-Leukemia, monuc - - 1 - - - - - - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - - - - - - - - Jejunum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142

Study Number FY01-013

N-96
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Ileum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - - - - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 113-Degen, cytopl vacuol s - 1 - - - - - 1 - - - 1 - 1 - 170-Necrosis s - - - - - - 1 - - - - - - - - 118-Thrombus s - - - - - - 1 - - - - - - - - 117-Hyperplasia, cortical, focal s - - - 1 - - - - - - - - - - - 64-Hyperplasia, focal p - - - - - - - - - - - - - - - 116-B-Pheochrom, bgn - - - - - - - - - - - - - - - 216-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 112-M-Leukemia, monuc - - 1 - - - 1 - - - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - - - - - 7-Dilatation s - - - - - - - - - - - - - - - 167-Intussusception p - - - - - - - - - - - - - - - 162-Inflammation, mixed s - - 2 - 1 - - - - 2 - - - - - 49-Inflammation, chronic s - - - - - - - - - - - - - - - 20-Hyperplasia, cystic endom s - - - - - 4= - 1 1 - - - - - - 286-B-Adenoma, endometrial - - - - - - - - - - - - - - - 9-B-Polyp, endometrial stromal - - - - 1= - - - - 1= - - - - - 213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - - - - - - - 165-M-Leukemia, monuc - - 2= - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - - - - - - - - - 173-Inflammation, chronic s - - - - - - - - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 32-N-Leukemia, monuc - - 1= - - - - - 1= - - 1 - - -

Study Number FY01-013

N-97
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Ovaries (9) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - - - - - - - 154-Cyst, bursa p - - - - - - - - - - - - - - 234-Cyst, epithelial p - - - - - - - - - - - - - - 293-Cyst, follicular p - - - - - - - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - - - - - - - 25-Hemorrhage s - - - - - - - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - 163-M-Leukemia, monuc - - 1 - - - - - - - - - - - Sciatic nerve Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Mammary gland (6) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 159-Ectasia s - 3 - - - - - - - - - - - - 190-Hyperplasia, lobular s - - - - - - - - - - - - - - 156-B-Fibroadenoma - - - - - - - - - - - - - - 70-B-Fibroma - - - - - - - - 1= - - - - - 235-M-Adenocarcinoma - - - - - - - - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - - - - - - - - - 122-Fibrosis s - - - - - - - - - - - - - - - 253-Inflammation, mixed s - - - - - - - - - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Compression s - - - - - - - - - - - - - - - 192-Hemorrhage s - - - - - - - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - - 33-Necrosis s - - - - - - - - - - - - - - - 194-Inflammation, chronic s - - - - - - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - - - - - - - - 129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 130-Cataract p - - - - - - - - - - - - - - - 133-Metaplasia, osseous, sclera s - - - - - - - - - - - - 1 - -

Study Number FY01-013

N-98
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 6 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - 1 - - - - - 1 - - - - - - 126-Mineralization, scleral s - - - - - - - - - - - - - - - 131-Neovascularization, corneal s - - 1 - - - - - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - - - - - - - - 197-Hemorrhage s - - - - - - - - - - - - - - - 231-Necrosis, neuronal s - - - - - - - - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 134-Inflammation, mixed s - - - - - - 2 - - - - - - 3 - 34-Inflammation-nasolac duct s 3 2 - - - 3 2 - - - - - - - 2 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - 2 - - - - - - - - - - - 1 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - 4= - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - - - - - - - - - 3 - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - 3 - - - - - - - - - - - 1 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - 2 - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-99
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 7 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 142 168-B-Polyp, endometrial stromal - 289-M-Leiomyosarcoma - 269-N-Adenocarcinoma, endometr - Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - - - - - - - - 2 3-Infiltration, histiocytic s - - - - - - - - - - - - - - - 2-Pigmentation s - - - - - - - - - - - - - - - 273-B-Thymoma - - - - - - - - - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 41-N-Leukemia, monuc - - 1= - - - - - 2= - - - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - 2= - 1 - - 2 - - - - - 37-Cyst s 2= 4= 1 2= - 1= 1 - - - 3= 3= - 2 - 38-Degen s - - - - - - - - - - - - - - - 148-Hemorrhage s - - - - - - - - - - - - - - 1 203-Necrosis s - - - - - - - - - - - - - - - 57-Hyperplasia, focal s - - - - 2 - - - - 3= 3 - - - - 31-B-Adenoma, pars distalis - - - - - - - 1= - - - - 1= - -

Study Number FY01-013

N-100
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 8 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-101
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 9 Rat/F344/N Group Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E464 1 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465 Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-102
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 10 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Lungs (12) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - - - - - - - - - 1 - 30-Congestion s - - - - - - - 2= - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s 2= - - - - - - - - - - - - 1 - 177-Inflammation, acute s - 1 - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - 1 - - - - - - 3 - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol 2 - - 2= - 2= - - 2= - 2= 2= - 1 1= 74-N-Leukemia,monuc - inv invol - - - - 2= - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - 2 - - - - - 2 - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - 2= - - - - - - - 297-Inflammation, mixed s - - - - - - - - - - - - - - - 62-N-Leukemia, monuc - - - - 1= - - - - - 1 - - - - Thyroid glands (8) Status > a a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - - - - - - - 77-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - - - - 2= - 35-B-Adenoma, C-cell - - - - - - - - - - - - - - - 78-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - - - - - - - Parathyroid (2) Status > m mH mH mH *H mH *H mH m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - - - - - - 296-B-Adenoma - - - - - - - - - - - - - Aorta (1) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - -

Study Number FY01-013

N-103
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 11 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - - - - 1 - - - - - - - - 1-Hyperplasia s - - - - 1 1 - 1 - - 2 - - 2 1 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - 1 - - 1 2 - 2 - - 2 1 1 2 2 53-Inflammation, chronic s - - - - - - 1 - - 1 - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (2) Status > *H * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - - - - - - 44-N-Leukemia, monuc - - - - 1 1 - - - 1 1 - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - - - - - - - 158-Congestion s - - - - - - - - - - - - - - - 90-Fatty Change s - - - - - - - - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - - - - 3 - - 92-Hdn p - - - - - - - - - - - - - - - 4-Necrosis s - - - - - - - - 1 - - - - - 3= 230-Thrombus s - - - - - - - - - - - - - - - 13-Vaculoliz cyto s - - - 2 - - - - - - - 3 - - - 24-Inflammation, acute s - - - - - - - 2 - - - - - - - 54-Inflammation, chronic s - 1 2 - - - 1 - - 1 - - - - - 46-Hyperplasia, biliary s 1 2 2 - 2 2 2 - - 2 2 - 1 1 1 47-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-M-Leukemia, monuc 2 - 1 2= 2= 2 - - 2= - 2= 2= - 2 - Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s 2= - - - - - - - - - - - - 1= - 226-Hemorrhage s - - - - - - - - - - - - - - - 97-Necrosis s - - - - - - - - - - - - - - - 15-M-Leukemia, monuc 2= - 1 2= 2= 2= - - 2= - 2= 2= - 2= - 298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -

Study Number FY01-013

N-104
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 12 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Kidneys (9) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - - - - - - - - 149-Cyst s - - - - - - 3= - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - - - - - - - - 210-Dilatation s - - - - - - - - - - - - - - - 228-Infarct s - - - - - - - - - - - - - - - 16-Nephropathy, chronic s 1 1 1 2 2 1 2 1 1= 1 1 - 1 - 1 6-Pigment accum, tub epi s - - - - - - - - - - - - - - - 98-M-Leukemia, monuc - - - - - - - - - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - 1 - - - - - - - - 101-Fibrosis s - - - - - - - - - - - - - - - 175-Thrombus s - - - - - - - - - - - - - - - 36-Inflammation, focal, chronic s - 1 1 - 1 - - - - 1 - - - - - 48-M-Leukemia, monuc - - - - - - - - - - - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - - - - - - - - 103-Inflammation, mixed s - - - - - - - - - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Cecum (1) Status > a A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - - - - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - - - - - - - - 56-Inflammation, chronic s - - - - - - - - - - - - - - - 166-Hyperplasia, papillary s - - - - - - - - - - - - - - - 106-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - - - - - - - - Jejunum Status > U U U U U U U U U U U U U U Ua Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142

Study Number FY01-013

N-105
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 13 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Ileum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum (1) Status > H a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - - - - - - - - Adrenal glands (9) Status > A Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - 113-Degen, cytopl vacuol s - 1 - - - - - - - - - 1 1 - 170-Necrosis s - - - - - - - - - - - - - - 118-Thrombus s - - - - - - - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - - - 1 - - - 64-Hyperplasia, focal p - - - - - - - - - - - - - - 116-B-Pheochrom, bgn - - - - - - - - - - - - - - 216-M-Carcinoma, metastatic - - - - - - - - - - - - - - 112-M-Leukemia, monuc - - - - - - - - - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - - - - - 7-Dilatation s - - - - - - - - - - - - - - - 167-Intussusception p - - - - - - - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - - - - - - - 49-Inflammation, chronic s 1 - - - - - - - - - - - - - - 20-Hyperplasia, cystic endom s - - 2= 2 - - 2 - - - - - 1 - - 286-B-Adenoma, endometrial - - - - - - - - - - - - - - - 9-B-Polyp, endometrial stromal - - - - - - - - - - - - - - - 213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - - - - - - - 165-M-Leukemia, monuc - - - - 1 - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - 2 - - - - - - - - 173-Inflammation, chronic s - - - - - - - - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 32-N-Leukemia, monuc - - - - 1 - - - 2 - 1 1 - - -

Study Number FY01-013

N-106
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 14 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Ovaries (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - - - - - - - - 154-Cyst, bursa p - - - - - - - - - - - - - - - 234-Cyst, epithelial p - - - - - - - - - - - - - - - 293-Cyst, follicular p - - - - - - - - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - - - - - - - - 25-Hemorrhage s - - - - - - - 2= - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 163-M-Leukemia, monuc - - - - - - - - - - - - - - - Sciatic nerve Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - - - - 1 - - - - 190-Hyperplasia, lobular s - - - - - - - - - - - - - - - 156-B-Fibroadenoma - - - - - - - - - - - - - - - 70-B-Fibroma - - - - - - - - - - - - - - - 235-M-Adenocarcinoma - - - - - - - - - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - - - - - - - - - 122-Fibrosis s - - - - - - - - - - - - - - - 253-Inflammation, mixed s - - - - - - - - - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Compression s - - - - - - - 3= - - - - - - - 192-Hemorrhage s - - - - - - - 2 - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - - 33-Necrosis s - - - - - - - - 2= - - - - - - 194-Inflammation, chronic s - - - - - - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (7) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - - - 3 - - - - 129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 130-Cataract p - - - - - - - - - - P= - - - - 133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -

Study Number FY01-013

N-107
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 15 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Eyes/optic nerve (7) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - - - - - 2 - - - - 126-Mineralization, scleral s - - - - - - - - - - - - - - 1 131-Neovascularization, corneal s - - - - - - - - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - - - - - - - - Spinal cord (3) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - 2 - - - - - - - 197-Hemorrhage s - - - - - - - - - - - - - - - 231-Necrosis, neuronal s - - - - - - - - - - - - - - - Nose/Turbinate 1 (5) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 134-Inflammation, mixed s - - - - - - 3 - - - - 4 - - - 34-Inflammation-nasolac duct s - - - - - 3 3 - 3 2 2 2 2 - 2 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - 1 1 - - - - - - - - - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - - - - - - - 4 - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - 1 - - 1 - - - - - - - - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - 3 - - - Nose/Turbinate 4 (3) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - 1 - - 1 - - - - - 144-Inflammation, mixed s - - - - - - - - - - - 2 - - -

Study Number FY01-013

N-108
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 16 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 142 168-B-Polyp, endometrial stromal - 289-M-Leiomyosarcoma - 269-N-Adenocarcinoma, endometr - Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 29-Hemorrhage s 2= - - - - - - 3= - - - - - - 2 3-Infiltration, histiocytic s - - - - - - - - - - - - - - - 2-Pigmentation s - - - - - - - - - - - - - - - 273-B-Thymoma - - - - - - - - - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 41-N-Leukemia, monuc - - - - 1 - - - - - 1 1 - - - Pituitary gland (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - 3= - - - - - - - 2= - 37-Cyst s 2 1 - - 1 - - - - 2 1 - 1 2 - 38-Degen s - - - - - - - - - - - - - - - 148-Hemorrhage s - - - - - - - - - 1= - - - - - 203-Necrosis s - - - - - - - - - - - - - - - 57-Hyperplasia, focal s - - - - - 3 - - - - - - - 2 - 31-B-Adenoma, pars distalis - - - - - - - 1= 1= - - - - - -

Study Number FY01-013

N-109
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 17 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Pituitary gland (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 142 171-Splenic tissue, "accessory" p P= 218-M-Carcinoma, metastatic - Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-110
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 18 Rat/F344/N Group Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E479 1 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480 Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-111
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 19 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Lungs (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - 1 1 - - 1 - - - 1 - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - 1 - 1 - - - 2= - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - 1 - - - - - - 2= - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - 2= - 2 2= - 2 - - - 2 - 2 - - 74-N-Leukemia,monuc - inv invol - - - - - - - - - 2= - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - 2 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - - - - - - - - - 297-Inflammation, mixed s - - - - - - - - - - - - - - - 62-N-Leukemia, monuc - - - - 1= - - - - 1 1 - 1= - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - - - - - - - 77-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 35-B-Adenoma, C-cell - 1= - - - - - - - - - - - - - 78-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - - - - - - - Parathyroid (2) Status > *H m m mH mH mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - - - - - - - 296-B-Adenoma - - - - - - - - - - - - 1= - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - - - 1 - - - - -

Study Number FY01-013

N-112
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 20 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - 3 - - - - - - - - - - 2 1-Hyperplasia s - 1 - - - - - 1 2 - - - - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - - 1 2 - - 2 2 2 - - - 1 - 2 53-Inflammation, chronic s - - - - - - - - - 1 1 1 - 1 - Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - 1 1 - - - - - - - - - - Mandibular LN (2) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - - - - - - - 44-N-Leukemia, monuc - - 1 - - 1= - - 1 1= - 1 - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - 1 - - - - - - - - - - - - - 158-Congestion s - - - - - - - - - - - - - - - 90-Fatty Change s - - - - - - - - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 92-Hdn p - - - - - - - - - - - - - - - 4-Necrosis s - - - - - - - - - - - - - - - 230-Thrombus s - - - - - - - - - - - - - - - 13-Vaculoliz cyto s - - - - - - - - - - - - - - - 24-Inflammation, acute s - - - - - - - - - - - - - - - 54-Inflammation, chronic s 1 - 2 - - 1 - - 1 - - - - 1 2 46-Hyperplasia, biliary s - - 1 2 1 2 1 2 2 2 3 2 2 1 - 47-Hyperplasia, hepato, regen s - - - 3= - - - - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-M-Leukemia, monuc - 2 - - 2= - 2 - - 2= 2= - 2= - - Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - - - 3= - - - - - 226-Hemorrhage s - - - - - - - - - - - - - - - 97-Necrosis s - - - - - - - - - - 2 - - - - 15-M-Leukemia, monuc - 1= - 2= 2= - 2= - - 2 2= - 2= - - 298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -

Study Number FY01-013

N-113
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 21 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - - - - - - - - 149-Cyst s - - - - - - - - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - - - - - - - - 210-Dilatation s - - - - - - - - - - - - - - - 228-Infarct s - - - - - - - - - - - - - - - 16-Nephropathy, chronic s 1 2 1 1 1 1 1 2 1 2 1 - 2 1 2 6-Pigment accum, tub epi s - - - - - - - - - - - - - - - 98-M-Leukemia, monuc - - - - - - - - - - 1 - - - - 299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - 1 - - - - - - - - - - - - 101-Fibrosis s - - - - - - - - - - - - - - - 175-Thrombus s - - - - - - - - - - - - - - - 36-Inflammation, focal, chronic s - 1 - 1 - 1 1 1 - - - 1 - 1 1 48-M-Leukemia, monuc - - - 1 - - - - - 1 - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - - - - - - - - 103-Inflammation, mixed s - - - - - - - - - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - 1 - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - 1 - - - - - 1 - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - - - 2= - - - - 56-Inflammation, chronic s - - - - - - - - - - - - - 1 - 166-Hyperplasia, papillary s - - - - - - - - - - - - - - - 106-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - - - - - - - - Jejunum Status > U U U Ua U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142

Study Number FY01-013

N-114
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 22 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Ileum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - 1 - - - - - - - - - - Colon Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - - - - - - - - Adrenal glands (9) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 113-Degen, cytopl vacuol s - - 1 - - - 3 - - 2 - - - - 1 170-Necrosis s - - - - - - - - - - - - - - - 118-Thrombus s - - - - - - - - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - - - - - - - - 64-Hyperplasia, focal p - - - - - - - - - - - - - - - 116-B-Pheochrom, bgn - - - - - - 1= - - - - - - - - 216-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 112-M-Leukemia, monuc - - - - - - - - - - 1 - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - - - - - 7-Dilatation s - - - - - - - - - - - - - - - 167-Intussusception p P= - - - - - - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - - - - - - - 49-Inflammation, chronic s - - - 1 - - - - - - - - - - - 20-Hyperplasia, cystic endom s - - 1 - - - - - 3= - 2 - - - - 286-B-Adenoma, endometrial - - - - - - - - - - - - - - - 9-B-Polyp, endometrial stromal - - - - 1= - - - - - - 1 - - 1= 213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - - - - - - - 165-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - - - - - - - - - 173-Inflammation, chronic s 3 - - - - - - - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 32-N-Leukemia, monuc - - - 1 1= - 1= - - - 1= - 1= - -

Study Number FY01-013

N-115
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 23 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Ovaries (9) Status > mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - - - - - - - - 154-Cyst, bursa p - - - - - - - - - - - - - - - 234-Cyst, epithelial p - - - - - - - - - - - - - - P= 293-Cyst, follicular p - - - - - - - - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - - - - - - - - 25-Hemorrhage s - - - - - - - - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 163-M-Leukemia, monuc - - - - - - - - - - - - - - - Sciatic nerve Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - - - 1 - - - - - 190-Hyperplasia, lobular s - - - - - - - - - - - - - - - 156-B-Fibroadenoma - - - - - - - - - - - - - - - 70-B-Fibroma - - - - - - - - - - - - - - - 235-M-Adenocarcinoma - - - - - - - - - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - - - - - - - - - 122-Fibrosis s - - - - - - - - - - - - - - - 253-Inflammation, mixed s - - - - - - - - - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Compression s - - - - - - - 4= - - - - - - - 192-Hemorrhage s - - - - - - - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - - 33-Necrosis s - - - - - - - - - - - - - - - 194-Inflammation, chronic s - - - - - - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - - - - - - - - 129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 130-Cataract p - - - - - - - - - - - - - - - 133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -

Study Number FY01-013

N-116
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 24 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - - - - - - - - 1 - 126-Mineralization, scleral s - - - - - - - - - - - - - - - 131-Neovascularization, corneal s - - - - - - - - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - - - - - - - - 197-Hemorrhage s - - - - - - - - - - 2 - - - - 231-Necrosis, neuronal s - - - - - - - - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - 3 - - - - 3 - - - - 1 - - - 134-Inflammation, mixed s - - - - - 3 - - - - - - - - - 34-Inflammation-nasolac duct s - - - 1 3 - - - 3 2 - - - 1 3 136-Inflammation-resp epith s - - - - - 3 - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - 2 - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-117
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 25 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M M M M M M M M M aM M Operator > 142 294-B-Adenoma - 61-M-Carcinoma, squamous cell 2= 271-N-Adenocarcinoma - Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 142 142 60-Hemorrhage s - 1= 59-Infiltration, histiocytic s - 2 65-N-Leukemia, monuc 1= - Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 67-N-Leukemia, monuc 1= Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 68-N-Leukemia, monuc 1= Mediastinal LN (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - - - - - - - - - 3-Infiltration, histiocytic s - - - - - - - - - - - - - - - 2-Pigmentation s - - - - - - - - - - - - - - - 273-B-Thymoma - - - - - - - - - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 41-N-Leukemia, monuc - - - 1 1 - 1= - - 1= 1= - 1= - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - 2= - - - - 3= - 1 - - - - - 37-Cyst s - 2= - - - 2 - - 3 2 2 - - - - 38-Degen s - 2 - - - - - - - - - - - - - 148-Hemorrhage s - - - - - - - - 3= - - - 2 - - 203-Necrosis s - - - - - - - - - - - - - - - 57-Hyperplasia, focal s - - - - - - - - 2 - - - - 1 - 31-B-Adenoma, pars distalis - - - 1= - - - 1 - - - - 1= - -

Study Number FY01-013

N-118
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 26 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 142 221-N-Leukemia, monuc 1= Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 142 223-M-Carcinoma, squamous cell 1= Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 142 233-N-Leukemia, monuc 2= Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-119
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 27 Rat/F344/N Group Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E494 1 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495 Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FS Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-120
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 28 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Lungs (12) Status > Operator > 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - 30-Congestion s - - - - - 71-Fibrosis, focal s - - - - - 182-Hemorrhage s - - - - - 177-Inflammation, acute s - - - - - 72-Inflammation, mixed s - - - - - 236-Inflammation, granulomatous s - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - 214-N-Carcinoma, metastatic - - - - - 11-N-Leukemia,monuc - cap invol 2 - - 2 - 74-N-Leukemia,monuc - inv invol - - - - - 204-N-Sarcoma, histiocytic - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 22-Inflammation, acute s - - - - - 75-Inflammation, mixed s - - - - - 76-Hyperplasia s - - - - - 238-N-Leukemia, monuc - - - - - Bronchial (TBLN) (3) Status > *H Operator > 142 142 142 142 142 21-Hemorrhage s - - - - 297-Inflammation, mixed s - - - - 62-N-Leukemia, monuc 1= - - - Thyroid glands (8) Status > m Operator > 142 142 142 142 142 79-Cyst, follicular p - - - - - 77-Hyperplasia, C-cell, focal s - - - - - 81-Hyperplasia, follicular cell s - - - - - 35-B-Adenoma, C-cell - - - - - 78-B-Adenoma, follicular cell - - - - - 174-M-Carcinoma, C-cell - - - - - 80-M-Carcinoma, follicular cell - - - - - 178-M-Leukemia, monuc - - - - - Parathyroid (2) Status > mH m Operator > 142 142 142 142 142 241-Hyperplasia, focal s - 2 - - - 296-B-Adenoma - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - -

Study Number FY01-013

N-121
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 29 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Esophagus Status > U U U U U Operator > 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 12-Metaplasia, squamous s 2 - - - - 1-Hyperplasia s - - - - 1 23-Inflammation, acute s - - - - - 42-Inflammation, mixed s 3 - - 1 1 53-Inflammation, chronic s - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 43-M-Leukemia, monuc - - - - - Mandibular LN (2) Status > Operator > 142 142 142 142 142 89-Hemorrhage s - - - - - 44-N-Leukemia, monuc 1= - - - - Liver (15) Status > Operator > 142 142 142 142 142 45-Angiectasis s - - - - - 158-Congestion s - - - - - 90-Fatty Change s - - - - - 150-Foci cell alter, basophilic s - - - - - 92-Hdn p - - - - - 4-Necrosis s - - - - - 230-Thrombus s - - - - - 13-Vaculoliz cyto s - - - - - 24-Inflammation, acute s - - - - - 54-Inflammation, chronic s - - 1 - - 46-Hyperplasia, biliary s 1 - 2 2 2 47-Hyperplasia, hepato, regen s - - - - - 91-B-Adenoma, hepatocellular - 1= - - - 205-M-Sarcoma, histiocytic - - - - - 14-M-Leukemia, monuc 2= 1 - 2= - Spleen (5) Status > Operator > 142 142 142 142 142 96-Fibrosis s - - - - - 226-Hemorrhage s - - - - - 97-Necrosis s - - - - - 15-M-Leukemia, monuc 1= 1 - 2= - 298-N-Sarcoma, histiocytic - - - - -

Study Number FY01-013

N-122
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 30 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Kidneys (9) Status > Operator > 142 142 142 142 142 211-Atrophy s - - - - - 149-Cyst s - - - - - 209-Degen, hyaline droplet s - - - - - 210-Dilatation s - - - - - 228-Infarct s - - - - - 16-Nephropathy, chronic s 1 1 - 1 1 6-Pigment accum, tub epi s - - - - - 98-M-Leukemia, monuc - - - - - 299-N-Sarcoma, histiocytic - - - - - Heart (5) Status > Operator > 142 142 142 142 142 100-Degen, myocyte s - - - - - 101-Fibrosis s - - - - 1 175-Thrombus s - - - - - 36-Inflammation, focal, chronic s - 1 1 1 1 48-M-Leukemia, monuc 1 - - - - Stomach (4) Status > Operator > 142 142 142 142 142 268-Ulcer s - - - - - 103-Inflammation, mixed s - - - - - 217-M-Carcinoma, metastatic - - - - - 220-M-Leukemia, monuc - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 104-N-Leukemia, monuc - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 186-Hemorrhage s - - - - - 56-Inflammation, chronic s - - - - - 166-Hyperplasia, papillary s - - - - - 106-M-Leukemia, monuc - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 275-Inflammation, acute s - - - - - Jejunum Status > U U U U U Operator > 142 142 142 142 142

Study Number FY01-013

N-123
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 31 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Ileum (1) Status > Operator > 142 142 142 142 142 181-N-Leukemia, monuc - - - - - Colon Status > U U U U U Operator > 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 212-Fibrosis s - - - - - 110-M-Leukemia, monuc - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 276-Metaplasia, squamous s - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 161-Cyst s - - - - - 113-Degen, cytopl vacuol s - - - - 1 170-Necrosis s - - - - - 118-Thrombus s - - - - - 117-Hyperplasia, cortical, focal s - - - - - 64-Hyperplasia, focal p P - - - - 116-B-Pheochrom, bgn - - - - - 216-M-Carcinoma, metastatic - - - - - 112-M-Leukemia, monuc - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 277-Angiectasis s - - - - - 7-Dilatation s - - - - - 167-Intussusception p - - - - - 162-Inflammation, mixed s - - - - - 49-Inflammation, chronic s 1 - - - - 20-Hyperplasia, cystic endom s - 1 - - - 286-B-Adenoma, endometrial - - - - - 9-B-Polyp, endometrial stromal - - - - - 213-M-Adenocarcinoma, endometr - - - - - 279-M-Leiomyosar - - - - - 165-M-Leukemia, monuc - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 120-Hemorrhage s - - - - - 173-Inflammation, chronic s - - - - - 206-N-Sarcoma, histiocytic - - - - - 32-N-Leukemia, monuc 1= - - - -

Study Number FY01-013

N-124
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 32 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Ovaries (9) Status > Operator > 142 142 142 142 142 284-Congestion s - - - - - 154-Cyst, bursa p - - - - - 234-Cyst, epithelial p - - - - - 293-Cyst, follicular p - - - - - 291-Cyst, rete ovarii s - - - - - 25-Hemorrhage s - - - - - 290-Necrosis, mesenteric fat s - - - - - 207-N-Sarcoma, histiocytic - - - - - 163-M-Leukemia, monuc - - - - - Sciatic nerve Status > U U U U U Operator > 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 159-Ectasia s - - - - - 190-Hyperplasia, lobular s - - - - 1= 156-B-Fibroadenoma - - - - - 70-B-Fibroma - - - - - 235-M-Adenocarcinoma - - - - - 224-M-AdenoCA arising in fibroAD - - - 2= - Skin (3) Status > Operator > 142 142 142 142 142 252-Cyst, epith inc p - - - - - 122-Fibrosis s - - - - - 253-Inflammation, mixed s - - - - - Brain (6) Status > Operator > 142 142 142 142 142 26-Compression s - - - - - 192-Hemorrhage s - - - - - 155-Metaplasia, osseous, meninge s - - - - - 33-Necrosis s - - - - - 194-Inflammation, chronic s - - - - - 256-M-Astrocytoma, malignant - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 127-Atrophy s - - - - - 129-Atrophy, retinal, unilat s - - - - - 130-Cataract p - - - - - 133-Metaplasia, osseous, sclera s - - - - -

Study Number FY01-013

N-125
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 33 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 58-Mineralization, corneal str s - - - - - 126-Mineralization, scleral s - - 1 - - 131-Neovascularization, corneal s - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 179-New bone, endosteal s - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 27-Degen, white matter s - - - - - 197-Hemorrhage s - - - - - 231-Necrosis, neuronal s - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - 134-Inflammation, mixed s - - - - - 34-Inflammation-nasolac duct s 1 1 - - - 136-Inflammation-resp epith s - - - - - 199-Hyperplasia-resp epith s - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - 261-Degeneration,hyal-resp epith s - - - - - 176-Metaplasia, sec-olfact epith s - - - - - 270-Metaplasia, squ-olfact epith s - - - - - 138-Inflammation, mixed s - - - - - 227-Hyperplasia-resp epith s - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - 19-Degeneration,hyaline-olf epi s - - - - - 232-Degeneration-resp epith s - - - - - 142-Inflammation, mixed s - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - 164-Degeneration,hyaline-olf epi s - - - - - 144-Inflammation, mixed s - - - - -

Study Number FY01-013

N-126
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 34 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Cervix (3) Status > M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M Operator > 142 60-Hemorrhage s - 59-Infiltration, histiocytic s - 65-N-Leukemia, monuc 1= Popliteal LN (1) Status > M M M M M Operator > 142 66-N-Leukemia, monuc 1= Iliac LN (1) Status > M M M M M Operator > 142 67-N-Leukemia, monuc 1= Pancreatic LN (1) Status > M M M M M Operator > 142 68-N-Leukemia, monuc 1= Mediastinal LN (7) Status > Operator > 142 142 142 142 142 29-Hemorrhage s - - - - - 3-Infiltration, histiocytic s - - - - - 2-Pigmentation s - - - - - 273-B-Thymoma - - - - - 219-M-Carcinoma, metastatic - - - - - 265-N-Sarcoma, histiocytic - - - - - 41-N-Leukemia, monuc 1= - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 160-Angiectasis s - 2 - - - 37-Cyst s 2= - 3 - 1 38-Degen s - - - - - 148-Hemorrhage s - 3= - - - 203-Necrosis s - - - - - 57-Hyperplasia, focal s 3 - - - - 31-B-Adenoma, pars distalis - - - - -

Study Number FY01-013

N-127
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 35 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Pituitary gland (10) Status > Operator > 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - 288-M-Carcinoma - - - - - 146-M-Leukemia, monuc - - - - - Tail (3) Status > M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-128
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 36 Rat/F344/N Group Sex Dosage Animal > 6832E497 6832E499 1 F 0 g/m3 Animal > 6832E496 6832E498 6832E500 Tissue/diagnosis Death code > U2 FS FS U2 FS Tiss.not specifi Status > M M M M M Operator >

Study Number FY01-013

N-129
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 37 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Lungs (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - - - - - - - - - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol 1 2 - - - 1 - - - - - - - - - 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 21-Hemorrhage s 2 - 3= - 297-Inflammation, mixed s - - - - 62-N-Leukemia, monuc - - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 79-Cyst, follicular p - - - - - 77-Hyperplasia, C-cell, focal s - - - - - 81-Hyperplasia, follicular cell s - - - - - 35-B-Adenoma, C-cell - - 1= - - 78-B-Adenoma, follicular cell - - - - - 174-M-Carcinoma, C-cell - - - - - 80-M-Carcinoma, follicular cell - - - - - 178-M-Leukemia, monuc - - - - - Parathyroid (2) Status > mH Operator > 142 142 142 142 241-Hyperplasia, focal s - - - - 296-B-Adenoma - - - - Aorta (1) Status > Operator > 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - -

Study Number FY01-013

N-130
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 38 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Esophagus Status > U U U U Operator > 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - 2 - - - - - - 1 - - 1 - 1-Hyperplasia s - - 1 - - - - - - 1 - - 1 - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s 1 - 1 2 1 1 - - 1 - 2 - 2 2 1 53-Inflammation, chronic s - - - - - - - - - - - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 43-M-Leukemia, monuc - - - - Mandibular LN (2) Status > *H Operator > 142 142 142 142 89-Hemorrhage s - - - 44-N-Leukemia, monuc 1 - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - 158-Congestion s - - - - - - - 90-Fatty Change s - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - 92-Hdn p - - - - - - - 4-Necrosis s - - - - - - - 230-Thrombus s - - - - - - - 13-Vaculoliz cyto s - - - - - - - 24-Inflammation, acute s - - - - - - - 54-Inflammation, chronic s - - - - 1 - 2 46-Hyperplasia, biliary s 2 - 2 1 - - 1 47-Hyperplasia, hepato, regen s - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - 14-M-Leukemia, monuc 1= 2= 1= 1= - - - Spleen (5) Status > Operator > 142 142 142 142 96-Fibrosis s - - - - 226-Hemorrhage s - - - - 97-Necrosis s - - - - 15-M-Leukemia, monuc 2= 1= - - 298-N-Sarcoma, histiocytic - - - -

Study Number FY01-013

N-131
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 39 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Kidneys (9) Status > Operator > 142 142 142 142 211-Atrophy s - - - - 149-Cyst s - - - - 209-Degen, hyaline droplet s - - - - 210-Dilatation s - - - - 228-Infarct s - - - - 16-Nephropathy, chronic s 1 1 1 1 6-Pigment accum, tub epi s - - - - 98-M-Leukemia, monuc - - - - 299-N-Sarcoma, histiocytic - - - - Heart (5) Status > Operator > 142 142 142 142 100-Degen, myocyte s - - - - 101-Fibrosis s - - - - 175-Thrombus s - - - - 36-Inflammation, focal, chronic s - - 1 1 48-M-Leukemia, monuc - - - - Stomach (4) Status > Operator > 142 142 142 142 268-Ulcer s - - - - 103-Inflammation, mixed s - - - - 217-M-Carcinoma, metastatic - - - - 220-M-Leukemia, monuc - - - - Cecum (1) Status > Operator > 142 142 142 142 104-N-Leukemia, monuc - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 186-Hemorrhage s - - - - 56-Inflammation, chronic s - - - - 166-Hyperplasia, papillary s - - - - 106-M-Leukemia, monuc - - - - Duodenum (1) Status > Operator > 142 142 142 142 275-Inflammation, acute s - - - - Jejunum Status > U U U U Operator > 142 142 142 142

Study Number FY01-013

N-132
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 40 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Ileum (1) Status > Operator > 142 142 142 142 181-N-Leukemia, monuc - - - - Colon Status > U U U U Operator > 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 212-Fibrosis s - - - - 110-M-Leukemia, monuc - - - - Rectum (1) Status > Operator > 142 142 142 142 276-Metaplasia, squamous s - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 161-Cyst s - - - - 113-Degen, cytopl vacuol s - - - - 170-Necrosis s - - - - 118-Thrombus s - - - - 117-Hyperplasia, cortical, focal s - - - - 64-Hyperplasia, focal p - - - - 116-B-Pheochrom, bgn - - - - 216-M-Carcinoma, metastatic - - - - 112-M-Leukemia, monuc - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - 7-Dilatation s - - 2= - - - - 167-Intussusception p - - - - - - - 162-Inflammation, mixed s - - - - - - - 49-Inflammation, chronic s - - - - - - - 20-Hyperplasia, cystic endom s 2 2 - - - - - 286-B-Adenoma, endometrial - - - 1= - - - 9-B-Polyp, endometrial stromal 1= 2= - - 1 1= 1= 213-M-Adenocarcinoma, endometr - - - - - - - 279-M-Leiomyosar - - - - 2= - - 165-M-Leukemia, monuc - - - - - - - Mesenteric LN (4) Status > *H Operator > 142 142 142 142 120-Hemorrhage s - - - 173-Inflammation, chronic s - - - 206-N-Sarcoma, histiocytic - - - 32-N-Leukemia, monuc 1 - -

Study Number FY01-013

N-133
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 41 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Ovaries (9) Status > Operator > 142 142 142 142 284-Congestion s - - - - 154-Cyst, bursa p - - - - 234-Cyst, epithelial p - P - - 293-Cyst, follicular p - - - - 291-Cyst, rete ovarii s - - - - 25-Hemorrhage s - - - - 290-Necrosis, mesenteric fat s - - - - 207-N-Sarcoma, histiocytic - - - - 163-M-Leukemia, monuc - - - - Sciatic nerve Status > U U U U Operator > 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 208-N-Sarcoma, histiocytic - - - - Mammary gland (6) Status > *H Operator > 142 142 142 142 142 142 159-Ectasia s - - - - - 190-Hyperplasia, lobular s - - - - - 156-B-Fibroadenoma - - - 1= - 70-B-Fibroma 1= - - - - 235-M-Adenocarcinoma - - - - 1= 224-M-AdenoCA arising in fibroAD - - - - - Skin (3) Status > *H Operator > 142 142 142 142 252-Cyst, epith inc p - - - 122-Fibrosis s - - - 253-Inflammation, mixed s - - - Brain (6) Status > Operator > 142 142 142 142 142 142 26-Compression s - - - 2= 2= 3= 192-Hemorrhage s - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - 33-Necrosis s - - - - - - 194-Inflammation, chronic s - - - - - - 256-M-Astrocytoma, malignant - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 127-Atrophy s - - - - - 129-Atrophy, retinal, unilat s - 4 - - - 130-Cataract p - P= - - - 133-Metaplasia, osseous, sclera s - - - - -

Study Number FY01-013

N-134
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 42 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 58-Mineralization, corneal str s - - - - - 126-Mineralization, scleral s - - - - - 131-Neovascularization, corneal s - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 179-New bone, endosteal s - - - - Spinal cord (3) Status > Operator > 142 142 142 142 27-Degen, white matter s - - - - 197-Hemorrhage s - - - - 231-Necrosis, neuronal s - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - 1 - - - - - - - - - - 1 - - 134-Inflammation, mixed s - - - - - - 1 - - - 2 - - - - 34-Inflammation-nasolac duct s - - - - - 1 2 - 2 - 3 - 3 - - 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - 1 - - - - - - - - - - - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - - 1 - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - 1 - - - - 19-Degeneration,hyaline-olf epi s - - - - - 1 - - - - - - - - - 232-Degeneration-resp epith s - - - - - - 2 - - - - - - - - 142-Inflammation, mixed s - - - - - - 2 - - - 1 - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - 2 - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - 2 - - - - - - - -

Study Number FY01-013

N-135
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 43 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 29-Hemorrhage s - - - - 3-Infiltration, histiocytic s - - - - 2-Pigmentation s - - - - 273-B-Thymoma - - - - 219-M-Carcinoma, metastatic - - - - 265-N-Sarcoma, histiocytic - - - - 41-N-Leukemia, monuc 1 - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - - - - 37-Cyst s - 2 2 2 - 4= - - 38-Degen s - - - - - - - - 148-Hemorrhage s - - - - - - - - 203-Necrosis s - - - - - - - - 57-Hyperplasia, focal s - - - - - - - - 31-B-Adenoma, pars distalis - - 1= 1= - - - 1=

Study Number FY01-013

N-136
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 44 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - 288-M-Carcinoma - - - - - - 1= - 146-M-Leukemia, monuc - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 142 287-M-Leiomyosarcoma 1=

Study Number FY01-013

N-137
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 45 Rat/F344/N Group Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F564 2 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565 Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-138
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 46 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Lungs (12) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s 1 - 1 - - - - - - 1 - - - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - 2= - - - - 177-Inflammation, acute s - - - - - - - - - - - - 1 - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - - 1= - - 2 1 - 1 - 2 - - 1 - 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - 2 - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - 1 - - - Bronchial (TBLN) (3) Status > *H Operator > 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - 2 - 297-Inflammation, mixed s - - - - - - - 62-N-Leukemia, monuc - - 1= 1 - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - 77-Hyperplasia, C-cell, focal s - - - 1 - 4 - - - 81-Hyperplasia, follicular cell s - - - - - - - - - 35-B-Adenoma, C-cell - - - 1= - - - - - 78-B-Adenoma, follicular cell - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - Parathyroid (2) Status > m mH mH Operator > 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - 296-B-Adenoma - - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - -

Study Number FY01-013

N-139
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 47 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Esophagus Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - - - - - - 2 - - - - - 2 1-Hyperplasia s - 1 - - - 2 2 - - - - - - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - 2 2 - 1 2 2 - 2 1 - 1 1 - 2 53-Inflammation, chronic s - - - - - - - - - - - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - Mandibular LN (2) Status > *H Operator > 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - 2 - 44-N-Leukemia, monuc - - 1= - 1 1 - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - - 158-Congestion s - - - - - - - - - - 90-Fatty Change s - - - 1 - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - - 92-Hdn p P= - - - - P= - P= P= - 4-Necrosis s 3= - - - - - - - - - 230-Thrombus s - - - - - - - - - - 13-Vaculoliz cyto s - - - - - - - - - - 24-Inflammation, acute s - - - - - - - - - - 54-Inflammation, chronic s - 1 - - - - - - 1 - 46-Hyperplasia, biliary s 2 - - 2 - - 2 - 1 1 47-Hyperplasia, hepato, regen s - - - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - - 14-M-Leukemia, monuc - 1 2 2= 2 - 2= 2 - 1= Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - - - - 226-Hemorrhage s - - - - - - - - - - 97-Necrosis s - - - - 4= - - - - - 15-M-Leukemia, monuc - 1= 2= 2= 2= - 2= 2= - 1= 298-N-Sarcoma, histiocytic - - - - - - - - - -

Study Number FY01-013

N-140
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 48 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - 149-Cyst s - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - 210-Dilatation s - - - - - - - - 228-Infarct s - - - - - - - - 16-Nephropathy, chronic s - 1 1 2 1 1 2 1 6-Pigment accum, tub epi s - - - - - - - - 98-M-Leukemia, monuc - - 1 - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - - - 101-Fibrosis s - - - - - - - - 175-Thrombus s - - - - - - - - 36-Inflammation, focal, chronic s 1 1 - - - 1 - - 48-M-Leukemia, monuc - - 1 - - - 1 - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - 2 - - 103-Inflammation, mixed s - - - - - 2 - - 217-M-Carcinoma, metastatic - - - - - - - - 220-M-Leukemia, monuc - - - - - - 2 - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - 2 - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - 56-Inflammation, chronic s - - - - - - - - 166-Hyperplasia, papillary s - - - - - - - - 106-M-Leukemia, monuc - - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - Jejunum Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142

Study Number FY01-013

N-141
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 49 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Ileum (1) Status > Operator > 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - - Colon Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142 Pancreas (2) Status > H *H Operator > 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - 110-M-Leukemia, monuc - - 2 - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - Adrenal glands (9) Status > m Operator > 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - 113-Degen, cytopl vacuol s - - - - - - - - 170-Necrosis s - - - - - - - - 118-Thrombus s - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - 64-Hyperplasia, focal p - - - - - - - - 116-B-Pheochrom, bgn - - - - - 1= - - 216-M-Carcinoma, metastatic - - - - - - - - 112-M-Leukemia, monuc - - - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - 7-Dilatation s - - - - - - - - - 167-Intussusception p - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - 49-Inflammation, chronic s - - - - - - - - - 20-Hyperplasia, cystic endom s - - - - 2 - - - - 286-B-Adenoma, endometrial - - - - - - - - - 9-B-Polyp, endometrial stromal 1= - - - - 1= - - - 213-M-Adenocarcinoma, endometr - - - - - - 2= - - 279-M-Leiomyosar - - - - - - - - - 165-M-Leukemia, monuc - - 1 - - - 1 1 - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - - 173-Inflammation, chronic s - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - 32-N-Leukemia, monuc - - 1= - - - - -

Study Number FY01-013

N-142
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 50 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Ovaries (9) Status > Operator > 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - 154-Cyst, bursa p - - - - - - - - 234-Cyst, epithelial p - - - - - - - - 293-Cyst, follicular p - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - 25-Hemorrhage s - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - 163-M-Leukemia, monuc - - 2= - - - - - Sciatic nerve Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - Mammary gland (6) Status > *H Operator > 142 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - 190-Hyperplasia, lobular s - - - - - - - 156-B-Fibroadenoma - 1= - - - - - 70-B-Fibroma - - 1= - - - - 235-M-Adenocarcinoma - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - P= - - 122-Fibrosis s - - - - - - - - 253-Inflammation, mixed s - - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 26-Compression s - - - 2= - - 3= - - 1= 192-Hemorrhage s - - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - 33-Necrosis s - - - - - - - - - - 194-Inflammation, chronic s - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - 2 - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 127-Atrophy s - - - - 4= - - - 129-Atrophy, retinal, unilat s - - - - - - - - 130-Cataract p - - - - P= - - - 133-Metaplasia, osseous, sclera s - - - - - - - -

Study Number FY01-013

N-143
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 51 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - - - 126-Mineralization, scleral s - - - - - 2 - - 131-Neovascularization, corneal s - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - 197-Hemorrhage s - - - - - - - - 231-Necrosis, neuronal s - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - 1 - - - - - - - - 134-Inflammation, mixed s - - - 1 - 2 - - - - - - - - - 34-Inflammation-nasolac duct s - - - - - 1 - - - - - - 3 - - 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - - - - - - 2 - - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - 2 2 - - - - - - - - - - - 227-Hyperplasia-resp epith s - - 2 2 - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - - - - - - - - 2 - - - - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-144
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 52 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 142 142 142 142 142 168-B-Polyp, endometrial stromal - - - - - 289-M-Leiomyosarcoma - 1= - - - 269-N-Adenocarcinoma, endometr - - - - 1= Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 142 60-Hemorrhage s - 59-Infiltration, histiocytic s - 65-N-Leukemia, monuc 1= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 66-N-Leukemia, monuc 1= Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 142 67-N-Leukemia, monuc 1= 1= Pancreatic LN (1) Status > M M M M M M M M M M M *MH M M M Operator > 142 142 68-N-Leukemia, monuc 1= Mediastinal LN (7) Status > Operator > 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - - 3-Infiltration, histiocytic s - - - - - - - - 2-Pigmentation s - - - - - - - - 273-B-Thymoma - - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - 41-N-Leukemia, monuc - 1 1= - 1= - 1= - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - - - - - - - - 37-Cyst s - 2 1 - - - 3 - - - - - 38-Degen s - - - - - - - - - - - - 148-Hemorrhage s - - - - - - - - - - - - 203-Necrosis s - - - - - - - - - - - - 57-Hyperplasia, focal s - 1 - - - - - - - - - - 31-B-Adenoma, pars distalis - - - 1= - - 1= 1= 1= - 1= 1=

Study Number FY01-013

N-145
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 53 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - 1= - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-146
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 54 Rat/F344/N Group Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F579 2 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580 Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FS Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-147
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 55 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Lungs (12) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - - - - - - - - - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - 2= - - - 182-Hemorrhage s - - - - - - - - - - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - 2= - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol 2 - - 1 1 - - - 2 - 1 - - - - 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - 297-Inflammation, mixed s - - - - - - - 62-N-Leukemia, monuc - - - - - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - 77-Hyperplasia, C-cell, focal s - - 2 - - 3 - 81-Hyperplasia, follicular cell s - - - - - - - 35-B-Adenoma, C-cell - - - - - - - 78-B-Adenoma, follicular cell - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - 178-M-Leukemia, monuc - - - - - - - Parathyroid (2) Status > m m Operator > 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - 296-B-Adenoma - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - -

Study Number FY01-013

N-148
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 56 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Esophagus Status > U U U U U U U Operator > 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - 1 - - - - 2 - - 1 1 - - - 1-Hyperplasia s - 1 - - 1 - - - - - - - 1 - 1 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s 1 2 2 1 1 1 - 2 1 - 1 1 1 - - 53-Inflammation, chronic s - - - - - - - - - - - - - 1 - Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - Mandibular LN (2) Status > * Operator > 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - 44-N-Leukemia, monuc - 1 - - - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - 158-Congestion s - - - - - - - - - 90-Fatty Change s - - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - 92-Hdn p - - - - - - - - - 4-Necrosis s - 1 - 2= - - - - - 230-Thrombus s - - - - - - - - - 13-Vaculoliz cyto s 2 - - - - - - - - 24-Inflammation, acute s - - - - - - - - - 54-Inflammation, chronic s - 1 - - - - - - - 46-Hyperplasia, biliary s 2 1 - 2 - - 1 1 1 47-Hyperplasia, hepato, regen s - - 2= - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - 14-M-Leukemia, monuc 2= - 1= 2= - 1= - - - Spleen (5) Status > Operator > 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - 226-Hemorrhage s - - - - - - - 97-Necrosis s - - - - - - - 15-M-Leukemia, monuc 2= - 2= - - - - 298-N-Sarcoma, histiocytic - - - - - - -

Study Number FY01-013

N-149
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 57 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - 149-Cyst s - - - - - - - 209-Degen, hyaline droplet s - - - - - - - 210-Dilatation s - - - - - - - 228-Infarct s - - - - - - - 16-Nephropathy, chronic s 2 1 1 - 1 1 - 6-Pigment accum, tub epi s 3 - - - - - - 98-M-Leukemia, monuc - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - - 101-Fibrosis s - - - - - - - 175-Thrombus s - - - - - - - 36-Inflammation, focal, chronic s 1 - 1 - - - - 48-M-Leukemia, monuc - - - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - 103-Inflammation, mixed s - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - 220-M-Leukemia, monuc - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - 56-Inflammation, chronic s - - - - - - - 166-Hyperplasia, papillary s - - - - - - - 106-M-Leukemia, monuc - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 275-Inflammation, acute s 3 - - - - - - Jejunum Status > U U U U U U U Operator > 142 142 142 142 142 142 142

Study Number FY01-013

N-150
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 58 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Ileum (1) Status > Operator > 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - Colon Status > U U U U U U U Operator > 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - 110-M-Leukemia, monuc - - - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 276-Metaplasia, squamous s 2 - - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 142 161-Cyst s - - - - - - - 113-Degen, cytopl vacuol s - - - - 2 - - 170-Necrosis s - - - - - - - 118-Thrombus s - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - 64-Hyperplasia, focal p - - - - - - - 116-B-Pheochrom, bgn - - - - - - - 216-M-Carcinoma, metastatic - - - - - - - 112-M-Leukemia, monuc - - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - 7-Dilatation s - - - - - - - 167-Intussusception p - - - P= - - - 162-Inflammation, mixed s - - - - - - - 49-Inflammation, chronic s - - - - - - - 20-Hyperplasia, cystic endom s - 3 - - - - - 286-B-Adenoma, endometrial - - - - - - - 9-B-Polyp, endometrial stromal - 2= 1= - - 1= 1= 213-M-Adenocarcinoma, endometr - - - - - - - 279-M-Leiomyosar - - - - - - - 165-M-Leukemia, monuc - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - 173-Inflammation, chronic s - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - 32-N-Leukemia, monuc 1 - - - - - -

Study Number FY01-013

N-151
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 59 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Ovaries (9) Status > Operator > 142 142 142 142 142 142 142 284-Congestion s - - - - - - - 154-Cyst, bursa p - - - - - - - 234-Cyst, epithelial p - - - - - - - 293-Cyst, follicular p - - - - - - - 291-Cyst, rete ovarii s - - - - - - - 25-Hemorrhage s - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - 163-M-Leukemia, monuc - - - - - - - Sciatic nerve Status > U U U U U U U Operator > 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - Mammary gland (6) Status > H Operator > 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - 190-Hyperplasia, lobular s - - - - - - - 156-B-Fibroadenoma - - - - - 2= - 70-B-Fibroma - - - - - - - 235-M-Adenocarcinoma - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - 122-Fibrosis s - - - - - - - 253-Inflammation, mixed s - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 26-Compression s - - 3= - - 2= - - 192-Hemorrhage s - - 2= - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - 33-Necrosis s - - - - - - - - 194-Inflammation, chronic s - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - 129-Atrophy, retinal, unilat s - - 4 - - - - - 130-Cataract p - - P= - - - - - 133-Metaplasia, osseous, sclera s - - - - - - - -

Study Number FY01-013

N-152
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 60 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - - - 126-Mineralization, scleral s - - - 2 - - - - 131-Neovascularization, corneal s - - - - - - - - Bone, femur (1) Status > H Operator > 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - 197-Hemorrhage s - - - - - - - 231-Necrosis, neuronal s - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - 1 - - 2 - - - 1 2 - - - - - 134-Inflammation, mixed s - - - - - - - - - - - - 3 - - 34-Inflammation-nasolac duct s - - - 3 2 - - - - - - - 3 2 - 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - 1 - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s 1 - - - 2 - - - - 2 - - - - - 261-Degeneration,hyal-resp epith s - 1 - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - - - - - - - - 1 - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 232-Degeneration-resp epith s - - - - - - - 2 - - - - - - - 142-Inflammation, mixed s - - - - - - - 2 - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-153
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 61 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 142 142 142 29-Hemorrhage s - 2 - - - - - 3-Infiltration, histiocytic s - - - - - - - 2-Pigmentation s - - - - - - - 273-B-Thymoma - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - 41-N-Leukemia, monuc - - - - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - - - - - 37-Cyst s - - - - - 1 - - 2 38-Degen s - - - - - - - - - 148-Hemorrhage s - - - - - - - - - 203-Necrosis s - - - - - - - - - 57-Hyperplasia, focal s - - - 3= - - - - - 31-B-Adenoma, pars distalis - - 1= - - - 1= 1= -

Study Number FY01-013

N-154
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 62 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - 288-M-Carcinoma - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-155
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 63 Rat/F344/N Group Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F594 2 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595 Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-156
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 64 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Lungs (12) Status > Operator > 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - 30-Congestion s - - - - - 71-Fibrosis, focal s - - - - - 182-Hemorrhage s - - - - - 177-Inflammation, acute s - - - - - 72-Inflammation, mixed s - - - - - 236-Inflammation, granulomatous s - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - 214-N-Carcinoma, metastatic - - - - - 11-N-Leukemia,monuc - cap invol - - - 2= 1 74-N-Leukemia,monuc - inv invol - - - - - 204-N-Sarcoma, histiocytic - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 22-Inflammation, acute s - - - - - 75-Inflammation, mixed s - - - - - 76-Hyperplasia s - - - - - 238-N-Leukemia, monuc - - - - - Bronchial (TBLN) (3) Status > Operator > 142 21-Hemorrhage s - 297-Inflammation, mixed s - 62-N-Leukemia, monuc 1 Thyroid glands (8) Status > Operator > 142 79-Cyst, follicular p - 77-Hyperplasia, C-cell, focal s - 81-Hyperplasia, follicular cell s - 35-B-Adenoma, C-cell - 78-B-Adenoma, follicular cell - 174-M-Carcinoma, C-cell - 80-M-Carcinoma, follicular cell - 178-M-Leukemia, monuc - Parathyroid (2) Status > m Operator > 142 241-Hyperplasia, focal s - 296-B-Adenoma - Aorta (1) Status > Operator > 142 83-N-Leukemia,monuc - inv invol -

Study Number FY01-013

N-157
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 65 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Esophagus Status > U Operator > 142 Larynx (5) Status > Operator > 142 142 142 142 142 12-Metaplasia, squamous s - - - - 2 1-Hyperplasia s - - - - - 23-Inflammation, acute s - - - - - 42-Inflammation, mixed s 2 - 1 1 2 53-Inflammation, chronic s - - - - - Salivary gland (1) Status > Operator > 142 43-M-Leukemia, monuc - Mandibular LN (2) Status > Operator > 142 142 89-Hemorrhage s - - 44-N-Leukemia, monuc 1= - Liver (15) Status > Operator > 142 142 45-Angiectasis s - - 158-Congestion s - - 90-Fatty Change s - - 150-Foci cell alter, basophilic s - - 92-Hdn p P= - 4-Necrosis s - - 230-Thrombus s - - 13-Vaculoliz cyto s - - 24-Inflammation, acute s - - 54-Inflammation, chronic s - - 46-Hyperplasia, biliary s - 2 47-Hyperplasia, hepato, regen s - - 91-B-Adenoma, hepatocellular - - 205-M-Sarcoma, histiocytic - - 14-M-Leukemia, monuc 1 2= Spleen (5) Status > Operator > 142 96-Fibrosis s - 226-Hemorrhage s - 97-Necrosis s - 15-M-Leukemia, monuc 2= 298-N-Sarcoma, histiocytic -

Study Number FY01-013

N-158
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 66 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Kidneys (9) Status > Operator > 142 211-Atrophy s - 149-Cyst s - 209-Degen, hyaline droplet s - 210-Dilatation s - 228-Infarct s - 16-Nephropathy, chronic s 1 6-Pigment accum, tub epi s 3= 98-M-Leukemia, monuc - 299-N-Sarcoma, histiocytic - Heart (5) Status > Operator > 142 100-Degen, myocyte s - 101-Fibrosis s - 175-Thrombus s - 36-Inflammation, focal, chronic s - 48-M-Leukemia, monuc - Stomach (4) Status > Operator > 142 268-Ulcer s - 103-Inflammation, mixed s - 217-M-Carcinoma, metastatic - 220-M-Leukemia, monuc - Cecum (1) Status > Operator > 142 104-N-Leukemia, monuc - Urinary bladder (4) Status > Operator > 142 186-Hemorrhage s - 56-Inflammation, chronic s - 166-Hyperplasia, papillary s - 106-M-Leukemia, monuc - Duodenum (1) Status > Operator > 142 275-Inflammation, acute s - Jejunum Status > U Operator > 142

Study Number FY01-013

N-159
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 67 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Ileum (1) Status > Operator > 142 181-N-Leukemia, monuc - Colon Status > U Operator > 142 Pancreas (2) Status > *H Operator > 142 212-Fibrosis s 110-M-Leukemia, monuc Rectum (1) Status > Operator > 142 276-Metaplasia, squamous s - Adrenal glands (9) Status > Operator > 142 161-Cyst s - 113-Degen, cytopl vacuol s - 170-Necrosis s - 118-Thrombus s - 117-Hyperplasia, cortical, focal s - 64-Hyperplasia, focal p - 116-B-Pheochrom, bgn - 216-M-Carcinoma, metastatic - 112-M-Leukemia, monuc 1= Uterus (11) Status > Operator > 142 277-Angiectasis s - 7-Dilatation s - 167-Intussusception p - 162-Inflammation, mixed s - 49-Inflammation, chronic s - 20-Hyperplasia, cystic endom s - 286-B-Adenoma, endometrial - 9-B-Polyp, endometrial stromal - 213-M-Adenocarcinoma, endometr - 279-M-Leiomyosar - 165-M-Leukemia, monuc - Mesenteric LN (4) Status > Operator > 142 120-Hemorrhage s - 173-Inflammation, chronic s - 206-N-Sarcoma, histiocytic - 32-N-Leukemia, monuc -

Study Number FY01-013

N-160
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 68 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Ovaries (9) Status > Operator > 142 142 284-Congestion s - - 154-Cyst, bursa p - - 234-Cyst, epithelial p - - 293-Cyst, follicular p - - 291-Cyst, rete ovarii s - - 25-Hemorrhage s - - 290-Necrosis, mesenteric fat s 2= - 207-N-Sarcoma, histiocytic - - 163-M-Leukemia, monuc - - Sciatic nerve Status > U Operator > 142 Muscle, skeletal (1) Status > Operator > 142 208-N-Sarcoma, histiocytic - Mammary gland (6) Status > Operator > 142 159-Ectasia s - 190-Hyperplasia, lobular s - 156-B-Fibroadenoma - 70-B-Fibroma - 235-M-Adenocarcinoma - 224-M-AdenoCA arising in fibroAD - Skin (3) Status > Operator > 142 252-Cyst, epith inc p - 122-Fibrosis s - 253-Inflammation, mixed s - Brain (6) Status > Operator > 142 26-Compression s - 192-Hemorrhage s - 155-Metaplasia, osseous, meninge s - 33-Necrosis s - 194-Inflammation, chronic s - 256-M-Astrocytoma, malignant - Eyes/optic nerve (7) Status > Operator > 142 127-Atrophy s - 129-Atrophy, retinal, unilat s - 130-Cataract p - 133-Metaplasia, osseous, sclera s -

Study Number FY01-013

N-161
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 69 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Eyes/optic nerve (7) Status > Operator > 142 58-Mineralization, corneal str s - 126-Mineralization, scleral s - 131-Neovascularization, corneal s - Bone, femur (1) Status > Operator > 142 179-New bone, endosteal s - Spinal cord (3) Status > Operator > 142 27-Degen, white matter s - 197-Hemorrhage s - 231-Necrosis, neuronal s - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - 134-Inflammation, mixed s - - - - - 34-Inflammation-nasolac duct s 3 2 3 2 - 136-Inflammation-resp epith s - - - - - 199-Hyperplasia-resp epith s - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - 261-Degeneration,hyal-resp epith s - - - - - 176-Metaplasia, sec-olfact epith s - - - - - 270-Metaplasia, squ-olfact epith s - - - - - 138-Inflammation, mixed s - - - - - 227-Hyperplasia-resp epith s - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - 19-Degeneration,hyaline-olf epi s - - - - - 232-Degeneration-resp epith s - - - - - 142-Inflammation, mixed s - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - 164-Degeneration,hyaline-olf epi s - - - - - 144-Inflammation, mixed s - - - - -

Study Number FY01-013

N-162
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 70 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Cervix (3) Status > M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 29-Hemorrhage s - 3-Infiltration, histiocytic s - 2-Pigmentation s - 273-B-Thymoma - 219-M-Carcinoma, metastatic - 265-N-Sarcoma, histiocytic - 41-N-Leukemia, monuc - Pituitary gland (10) Status > Operator > 142 142 142 160-Angiectasis s 3= - - 37-Cyst s - - - 38-Degen s - - - 148-Hemorrhage s - - - 203-Necrosis s - - - 57-Hyperplasia, focal s 2 - - 31-B-Adenoma, pars distalis - - 1=

Study Number FY01-013

N-163
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 71 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Pituitary gland (10) Status > Operator > 142 142 142 274-B-Adenoma, pars intermedia - - - 288-M-Carcinoma - - - 146-M-Leukemia, monuc - - - Tail (3) Status > M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-164
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 72 Rat/F344/N Group Sex Dosage Animal > 6834F597 6834F599 2 F 2 g/m3 Animal > 6834F596 6834F598 6834F600 Tissue/diagnosis Death code > FS FS FS U2 FS Tiss.not specifi Status > M M M M M Operator >

Study Number FY01-013

N-165
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 73 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Lungs (12) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s 1 - - - - - 1 - - - - - - - - 30-Congestion s - - - - - - - - - 1 - - - - 2= 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - 2 - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - 3 - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - 1 - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - 1 - - 1 - - - 2 - - - - - - 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - 1= - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - 3 - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > *H Operator > 142 142 142 142 21-Hemorrhage s - - - 297-Inflammation, mixed s - - - 62-N-Leukemia, monuc - - - Thyroid glands (8) Status > Operator > 142 142 142 142 79-Cyst, follicular p - - - - 77-Hyperplasia, C-cell, focal s - - - - 81-Hyperplasia, follicular cell s - - - - 35-B-Adenoma, C-cell - 1 - - 78-B-Adenoma, follicular cell - - - - 174-M-Carcinoma, C-cell - - - - 80-M-Carcinoma, follicular cell 2= - - - 178-M-Leukemia, monuc - - - - Parathyroid (2) Status > m m m Operator > 142 142 142 142 241-Hyperplasia, focal s - - - - 296-B-Adenoma - - - - Aorta (1) Status > Operator > 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - -

Study Number FY01-013

N-166
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 74 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Esophagus Status > UH U U U Operator > 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s 1 - - 1 1 - 1 - - - - - - - 2 1-Hyperplasia s - - - - 1 1 - - - - - - - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - - - 2 2 2 - 1 2 2 - 1 - - 2 53-Inflammation, chronic s - - - - - - 1 - - - - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 43-M-Leukemia, monuc - - - - Mandibular LN (2) Status > Operator > 142 142 142 142 89-Hemorrhage s - - - - 44-N-Leukemia, monuc - 1 - - Liver (15) Status > H Operator > 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - 158-Congestion s - - - - - 2 90-Fatty Change s - 1 - 2 - - 150-Foci cell alter, basophilic s - - - - - - 92-Hdn p - - - - - - 4-Necrosis s - - - 2 - - 230-Thrombus s - - - - - - 13-Vaculoliz cyto s - - - - - - 24-Inflammation, acute s - - - - - - 54-Inflammation, chronic s - - - - - - 46-Hyperplasia, biliary s 1 3 2 - 2 1 47-Hyperplasia, hepato, regen s - - 2 - - - 91-B-Adenoma, hepatocellular - - - - - - 205-M-Sarcoma, histiocytic - - - 1= - - 14-M-Leukemia, monuc - 1= 2= - - - Spleen (5) Status > Operator > 142 142 142 142 142 96-Fibrosis s - - - - - 226-Hemorrhage s - - - - - 97-Necrosis s - - - - - 15-M-Leukemia, monuc - 2= - - - 298-N-Sarcoma, histiocytic - - 1= - -

Study Number FY01-013

N-167
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 75 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Kidneys (9) Status > Operator > 142 142 142 142 142 211-Atrophy s - - - - - 149-Cyst s - - - - - 209-Degen, hyaline droplet s - - - - - 210-Dilatation s - - - - - 228-Infarct s - - - - - 16-Nephropathy, chronic s 1 1 3= 1 1 6-Pigment accum, tub epi s - - - - - 98-M-Leukemia, monuc - - - - - 299-N-Sarcoma, histiocytic - - 1= - - Heart (5) Status > Operator > 142 142 142 142 100-Degen, myocyte s - - - - 101-Fibrosis s - - - - 175-Thrombus s - - - - 36-Inflammation, focal, chronic s - - 1 1 48-M-Leukemia, monuc - - - - Stomach (4) Status > Operator > 142 142 142 142 268-Ulcer s - - - - 103-Inflammation, mixed s - - - - 217-M-Carcinoma, metastatic - - - - 220-M-Leukemia, monuc - - - - Cecum (1) Status > Operator > 142 142 142 142 104-N-Leukemia, monuc - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 186-Hemorrhage s - - - - 56-Inflammation, chronic s - - - - 166-Hyperplasia, papillary s - - - - 106-M-Leukemia, monuc - - - - Duodenum (1) Status > Operator > 142 142 142 142 275-Inflammation, acute s - - - - Jejunum Status > U U U U Operator > 142 142 142 142

Study Number FY01-013

N-168
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 76 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Ileum (1) Status > * Operator > 142 142 142 142 181-N-Leukemia, monuc - - - Colon Status > U U U U Operator > 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 212-Fibrosis s - - - - 110-M-Leukemia, monuc - - - - Rectum (1) Status > Operator > 142 142 142 142 276-Metaplasia, squamous s - - - - Adrenal glands (9) Status > mH Operator > 142 142 142 142 161-Cyst s 2 - - - 113-Degen, cytopl vacuol s - - - - 170-Necrosis s - - - - 118-Thrombus s - - - - 117-Hyperplasia, cortical, focal s - - - - 64-Hyperplasia, focal p P - - - 116-B-Pheochrom, bgn - - - - 216-M-Carcinoma, metastatic - - - - 112-M-Leukemia, monuc - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 277-Angiectasis s - - 2= - - - - 7-Dilatation s - - - - - - - 167-Intussusception p - - - - - - - 162-Inflammation, mixed s - - - - - - - 49-Inflammation, chronic s - - - - - - - 20-Hyperplasia, cystic endom s - - - - - - - 286-B-Adenoma, endometrial - - - - - - - 9-B-Polyp, endometrial stromal 1= - - 1= 1= - 1= 213-M-Adenocarcinoma, endometr - - - - - - - 279-M-Leiomyosar - - - - - - - 165-M-Leukemia, monuc - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 120-Hemorrhage s - - - - 173-Inflammation, chronic s - 1 - - 206-N-Sarcoma, histiocytic - - - - 32-N-Leukemia, monuc - 1 - -

Study Number FY01-013

N-169
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 77 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Ovaries (9) Status > Operator > 142 142 142 142 142 142 142 284-Congestion s - - - - - 2= 154-Cyst, bursa p - - - - - - 234-Cyst, epithelial p - - - - - - 293-Cyst, follicular p - - - P= - - 291-Cyst, rete ovarii s - 2= - - - - 25-Hemorrhage s - - - - - - 290-Necrosis, mesenteric fat s - - - - - - 207-N-Sarcoma, histiocytic - - - - - - 163-M-Leukemia, monuc - - - - - - Sciatic nerve Status > U U U U Operator > 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 208-N-Sarcoma, histiocytic - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 159-Ectasia s - - - - 190-Hyperplasia, lobular s - - - - 156-B-Fibroadenoma - - - - 70-B-Fibroma - - - - 235-M-Adenocarcinoma - - - - 224-M-AdenoCA arising in fibroAD - - - - Skin (3) Status > Operator > 142 142 142 142 252-Cyst, epith inc p - - - - 122-Fibrosis s - - - - 253-Inflammation, mixed s - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 26-Compression s - 4= 2= - - 3= 192-Hemorrhage s - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - 33-Necrosis s - - - - - - 194-Inflammation, chronic s - - - - - - 256-M-Astrocytoma, malignant - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 127-Atrophy s - - - - - - 129-Atrophy, retinal, unilat s - - - - - - 130-Cataract p - - - - - - 133-Metaplasia, osseous, sclera s - - - - - -

Study Number FY01-013

N-170
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 78 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - 126-Mineralization, scleral s - - - - - - 131-Neovascularization, corneal s - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 179-New bone, endosteal s - - - - Spinal cord (3) Status > Operator > 142 142 142 142 27-Degen, white matter s - - - - 197-Hemorrhage s - - - - 231-Necrosis, neuronal s - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - 2 - - - - - - - - 134-Inflammation, mixed s - - - - - - - - - - - - - 2 - 34-Inflammation-nasolac duct s - - 3 3 3 - 2 - 2 - - - 3 3 2 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - 2 - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s 1 - - - - - 2 - 1 - - - - 3 - 261-Degeneration,hyal-resp epith s - - - 2 - - 2 - - 1 - 2 - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - 1 - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - 2 - - 1 - 2 - 3 - - 1 - 3 - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-171
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 79 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 142 168-B-Polyp, endometrial stromal - 289-M-Leiomyosarcoma - 269-N-Adenocarcinoma, endometr - Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M MH M M M M M M M M M M M M Operator > 142 60-Hemorrhage s - 59-Infiltration, histiocytic s - 65-N-Leukemia, monuc - Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 142 29-Hemorrhage s 2 - - - - 3-Infiltration, histiocytic s - - - - - 2-Pigmentation s - - - - - 273-B-Thymoma - - - - - 219-M-Carcinoma, metastatic - - - - - 265-N-Sarcoma, histiocytic - - 1 - - 41-N-Leukemia, monuc - - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - - - - - 37-Cyst s 3= 2= - - - - 1 2= - 38-Degen s - - - - - - - - - 148-Hemorrhage s - - - - - - - - - 203-Necrosis s - - - - - - - - - 57-Hyperplasia, focal s - 3 - - - - 2 1 - 31-B-Adenoma, pars distalis - - 1= 1= 1= - 1= - 1=

Study Number FY01-013

N-172
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 80 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - 288-M-Carcinoma - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-173
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 81 Rat/F344/N Group Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G664 3 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665 Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-174
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 82 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Lungs (12) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - - - - - - - - - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - - - - - - - - - 1 2= - 2 - 2 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 21-Hemorrhage s - - - - - 297-Inflammation, mixed s - - - - - 62-N-Leukemia, monuc - 1 1 - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 79-Cyst, follicular p - - - - - 77-Hyperplasia, C-cell, focal s - - - - - 81-Hyperplasia, follicular cell s - - - - - 35-B-Adenoma, C-cell - - - - - 78-B-Adenoma, follicular cell - - - - - 174-M-Carcinoma, C-cell - - - - - 80-M-Carcinoma, follicular cell - - - - - 178-M-Leukemia, monuc - - - - - Parathyroid (2) Status > m mH Operator > 142 142 142 142 142 241-Hyperplasia, focal s - - - - - 296-B-Adenoma - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - -

Study Number FY01-013

N-175
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 83 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Esophagus Status > U U U U U Operator > 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s 1 - - 1 - - - - - - - 2 - - - 1-Hyperplasia s - - - - 1 - 1 - - - 1 - - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - 1 1 - 2 - 2 - 1 1 - - 1 1 1 53-Inflammation, chronic s - - - 1 - - - - - - 2 1 - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 43-M-Leukemia, monuc - - - - - Mandibular LN (2) Status > Operator > 142 142 142 142 142 142 89-Hemorrhage s - - - - - - 44-N-Leukemia, monuc - - - 1 - - Liver (15) Status > Operator > 142 142 142 142 142 45-Angiectasis s - - - - - 158-Congestion s - - - - - 90-Fatty Change s - - - - - 150-Foci cell alter, basophilic s - - - - - 92-Hdn p - - - - - 4-Necrosis s - - - - - 230-Thrombus s - - - - - 13-Vaculoliz cyto s - - - - - 24-Inflammation, acute s - - - - - 54-Inflammation, chronic s 1 - - 1 - 46-Hyperplasia, biliary s - 1 1 2 2 47-Hyperplasia, hepato, regen s - - - - - 91-B-Adenoma, hepatocellular - - - - - 205-M-Sarcoma, histiocytic - - - - - 14-M-Leukemia, monuc - 2= 2 - 2= Spleen (5) Status > Operator > 142 142 142 142 142 142 96-Fibrosis s - - - - - - 226-Hemorrhage s - - - - - - 97-Necrosis s - - - - - - 15-M-Leukemia, monuc - 1= 2= 2 - 2= 298-N-Sarcoma, histiocytic - - - - - -

Study Number FY01-013

N-176
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 84 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Kidneys (9) Status > Operator > 142 142 142 142 142 211-Atrophy s - - - - - 149-Cyst s - - - - - 209-Degen, hyaline droplet s - - - - - 210-Dilatation s - - - - - 228-Infarct s - - - - - 16-Nephropathy, chronic s - 1 1 2 1 6-Pigment accum, tub epi s - - - - - 98-M-Leukemia, monuc - - - - - 299-N-Sarcoma, histiocytic - - - - - Heart (5) Status > Operator > 142 142 142 142 142 100-Degen, myocyte s - - - - - 101-Fibrosis s - - - - - 175-Thrombus s - - - - - 36-Inflammation, focal, chronic s 1 - 1 - - 48-M-Leukemia, monuc - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 268-Ulcer s - - - - - 103-Inflammation, mixed s - - - - - 217-M-Carcinoma, metastatic - - - - - 220-M-Leukemia, monuc - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 104-N-Leukemia, monuc - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 186-Hemorrhage s - - - - - 56-Inflammation, chronic s - - - - - 166-Hyperplasia, papillary s - - - - - 106-M-Leukemia, monuc - 1 - - - Duodenum (1) Status > Operator > 142 142 142 142 142 275-Inflammation, acute s - - - - - Jejunum Status > U U U U U Operator > 142 142 142 142 142

Study Number FY01-013

N-177
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 85 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Ileum (1) Status > Operator > 142 142 142 142 142 181-N-Leukemia, monuc - - - - - Colon Status > U U U U U Operator > 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 212-Fibrosis s - - - - - 110-M-Leukemia, monuc - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 276-Metaplasia, squamous s - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 161-Cyst s - - - - - - 113-Degen, cytopl vacuol s - - - - - - 170-Necrosis s - - - - - - 118-Thrombus s - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - 64-Hyperplasia, focal p - - - - - - 116-B-Pheochrom, bgn 1= - - - - - 216-M-Carcinoma, metastatic - - - - - - 112-M-Leukemia, monuc - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - 7-Dilatation s - - 2 - - 1= - - 3 - - 167-Intussusception p - - - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - - - 49-Inflammation, chronic s - - - - - - - - - - - 20-Hyperplasia, cystic endom s - - - 3= - - 3= - - 2 - 286-B-Adenoma, endometrial - - - - - - - - - - - 9-B-Polyp, endometrial stromal 1= 1= 1= - - - - 1= - - - 213-M-Adenocarcinoma, endometr - 1= - 1 - - - - - - - 279-M-Leiomyosar - - - - 2= - - - - - - 165-M-Leukemia, monuc - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 120-Hemorrhage s - - - - - 173-Inflammation, chronic s - - - - - 206-N-Sarcoma, histiocytic - - - - - 32-N-Leukemia, monuc - 1 - - 1

Study Number FY01-013

N-178
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 86 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Ovaries (9) Status > Operator > 142 142 142 142 142 142 284-Congestion s - - - - - - 154-Cyst, bursa p - P= - - - - 234-Cyst, epithelial p - - - - - - 293-Cyst, follicular p - - - - - - 291-Cyst, rete ovarii s - - - - - - 25-Hemorrhage s - - - - - - 290-Necrosis, mesenteric fat s - - - - - - 207-N-Sarcoma, histiocytic - - - - - - 163-M-Leukemia, monuc - - - - - - Sciatic nerve Status > U U U U U Operator > 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 142 159-Ectasia s - - - - - - 190-Hyperplasia, lobular s - - - - - - 156-B-Fibroadenoma - 1= - - - - 70-B-Fibroma - - - - - - 235-M-Adenocarcinoma - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - 122-Fibrosis s 3= - - - - - 253-Inflammation, mixed s - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 26-Compression s 3= 2= - - - 3= - 192-Hemorrhage s - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - 33-Necrosis s - - - - - - - 194-Inflammation, chronic s - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 127-Atrophy s - - - - - - 129-Atrophy, retinal, unilat s - - - - - - 130-Cataract p - - - - - - 133-Metaplasia, osseous, sclera s - - - - - -

Study Number FY01-013

N-179
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 87 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - 126-Mineralization, scleral s - - - - - - 131-Neovascularization, corneal s - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 179-New bone, endosteal s - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 27-Degen, white matter s - - - - - 197-Hemorrhage s - - - - - 231-Necrosis, neuronal s - - - - - Nose/Turbinate 1 (5) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - 1 134-Inflammation, mixed s 1 - - - - 3 - - - - - - - - 34-Inflammation-nasolac duct s - - - 3 2 3 - 3 - - - 3 3 1 136-Inflammation-resp epith s - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - 1 3 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - 1 2 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s 2 - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-180
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 88 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 142 142 168-B-Polyp, endometrial stromal - - 289-M-Leiomyosarcoma - - 269-N-Adenocarcinoma, endometr - - Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 142 142 294-B-Adenoma 1= - 61-M-Carcinoma, squamous cell - - 271-N-Adenocarcinoma - 1= Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 142 60-Hemorrhage s - 59-Infiltration, histiocytic s - 65-N-Leukemia, monuc 1= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 142 29-Hemorrhage s - - - - - 3-Infiltration, histiocytic s - - - - - 2-Pigmentation s - - - - - 273-B-Thymoma - - - - - 219-M-Carcinoma, metastatic - - - - - 265-N-Sarcoma, histiocytic - - - - - 41-N-Leukemia, monuc - 1 1 - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - 3= - - - 37-Cyst s - - - - 3= - - - 2= 38-Degen s - - - - - - - - - 148-Hemorrhage s - - - - - - - - - 203-Necrosis s - - - - - - - - - 57-Hyperplasia, focal s - - - - 1 3 - - - 31-B-Adenoma, pars distalis 1= 1= - 1= - - 1= 1= -

Study Number FY01-013

N-181
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 89 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - 288-M-Carcinoma - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-182
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 90 Rat/F344/N Group Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G679 3 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680 Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-183
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 91 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Lungs (12) Status > H a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - - - - - - - 1 - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - - - - 2 - 2 2 - - - - - 1 - 74-N-Leukemia,monuc - inv invol - 2= - - - 1= - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - 1 - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - - - 297-Inflammation, mixed s - - - 1= - - - - - 62-N-Leukemia, monuc 1= - - 1 1 1 - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - P - - 77-Hyperplasia, C-cell, focal s - - 1 - - - - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - 35-B-Adenoma, C-cell - - - 1= - - - - 1= - 78-B-Adenoma, follicular cell - - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - - Parathyroid (2) Status > mH m m mH Operator > 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - 296-B-Adenoma - - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - -

Study Number FY01-013

N-184
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 92 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Esophagus Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142 Larynx (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - 2 - - - - - - - - - - - 1-Hyperplasia s - - - - - - - - - - - - - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - - - 1 1 - - 1 1 - - - 2 - 1 53-Inflammation, chronic s - 1 - - - - 2 - - - - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - Mandibular LN (2) Status > Operator > 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - 44-N-Leukemia, monuc 1= - 1 - 1 - - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - 158-Congestion s - - - - - - - - 90-Fatty Change s - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - 92-Hdn p - - - - - - - - 4-Necrosis s - - - - - - - - 230-Thrombus s - - - - - - - - 13-Vaculoliz cyto s - - - 2 - - - - 24-Inflammation, acute s - - - - - - - - 54-Inflammation, chronic s - - - - - - - 2 46-Hyperplasia, biliary s 1 1 2 2 1 - 1 2 47-Hyperplasia, hepato, regen s - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - 14-M-Leukemia, monuc 2= - 2= 2= 2 - - - Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - 1 - - - - - - 226-Hemorrhage s - - - - - - - - - 97-Necrosis s - - - - - - - - - 15-M-Leukemia, monuc 2= - 2= 1= 2= 2= - - - 298-N-Sarcoma, histiocytic - - - - - - - - -

Study Number FY01-013

N-185
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 93 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - 149-Cyst s - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - 210-Dilatation s - - - - - - - - 228-Infarct s - - - - - - - - 16-Nephropathy, chronic s 1 1 1 2 - - 1 2 6-Pigment accum, tub epi s - - - - - - - - 98-M-Leukemia, monuc 1 - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - - - 101-Fibrosis s - - - - - - - - 175-Thrombus s - - - - - - - - 36-Inflammation, focal, chronic s - - - 1 1 - - 1 48-M-Leukemia, monuc - - - - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - 103-Inflammation, mixed s - - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - - 220-M-Leukemia, monuc 1 - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - - Urinary bladder (4) Status > *H Operator > 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - 56-Inflammation, chronic s - - - - - - - 166-Hyperplasia, papillary s - - - - - - - 106-M-Leukemia, monuc - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - Jejunum Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142

Study Number FY01-013

N-186
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 94 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Ileum (1) Status > Operator > 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - - Colon Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - 113-Degen, cytopl vacuol s - - - - - - - - 170-Necrosis s - - - - - - - - 118-Thrombus s - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - 64-Hyperplasia, focal p - - - - - - - - 116-B-Pheochrom, bgn - - - - - - 2= - 216-M-Carcinoma, metastatic - - - - - - - - 112-M-Leukemia, monuc - - - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - 7-Dilatation s - 2= - - - - - - - 167-Intussusception p - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - 49-Inflammation, chronic s - - - - - - - - - 20-Hyperplasia, cystic endom s - - - - - 2= - - - 286-B-Adenoma, endometrial - - - - - - - - - 9-B-Polyp, endometrial stromal - 1= - - - - - - - 213-M-Adenocarcinoma, endometr - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - 165-M-Leukemia, monuc - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - 2 - 173-Inflammation, chronic s - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - 32-N-Leukemia, monuc 1= - 1 1 1 - - -

Study Number FY01-013

N-187
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 95 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Ovaries (9) Status > Operator > 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - 154-Cyst, bursa p - - - - - - - - 234-Cyst, epithelial p - - - - - - - - 293-Cyst, follicular p - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - 25-Hemorrhage s - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - 163-M-Leukemia, monuc 1 - - - - - - - Sciatic nerve Status > U U U U U U U U Operator > 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - Mammary gland (6) Status > *H Operator > 142 142 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - - 190-Hyperplasia, lobular s - - - - - - - 2 156-B-Fibroadenoma - 1= - - - - - - 70-B-Fibroma - - - - - - - - 235-M-Adenocarcinoma - - - 1= - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - Skin (3) Status > *H Operator > 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - 122-Fibrosis s - - - - - - - 253-Inflammation, mixed s - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 26-Compression s - - - 3= - - 2= - 4= 192-Hemorrhage s - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - 33-Necrosis s - - - - - - - - - 194-Inflammation, chronic s - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - - 129-Atrophy, retinal, unilat s - - - - - - - - - 130-Cataract p - - - - - - - - - 133-Metaplasia, osseous, sclera s - - - - - - - - -

Study Number FY01-013

N-188
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 96 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - - - - - - 126-Mineralization, scleral s 1 - - - - - - 1 - 131-Neovascularization, corneal s - - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - 197-Hemorrhage s 1 - - - - - - - 231-Necrosis, neuronal s - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - - - - 1 - - 1 - - 134-Inflammation, mixed s - - - - - - - - - - 3 - - - - 34-Inflammation-nasolac duct s - - - - - 3 - - - - 3 - 3 - 2 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - 1 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - 1 - - - - - - - - 138-Inflammation, mixed s - - - - 2 - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - 1 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-189
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 97 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 142 294-B-Adenoma - 61-M-Carcinoma, squamous cell - 271-N-Adenocarcinoma 1= Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 142 60-Hemorrhage s - 59-Infiltration, histiocytic s - 65-N-Leukemia, monuc 1= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 142 67-N-Leukemia, monuc 1= 1= Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 142 68-N-Leukemia, monuc 1= 1= Mediastinal LN (7) Status > H *H Operator > 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - 3-Infiltration, histiocytic s - - - - - - - 2-Pigmentation s - - - - - - - 273-B-Thymoma - - - - 1= - - 219-M-Carcinoma, metastatic - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - 41-N-Leukemia, monuc 1= - 1 - - - - Pituitary gland (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - 2= - 3= - - - - - - - - 37-Cyst s 1 2 - - - - - 3= - - - 3 - 38-Degen s - - - - - - - - - - - - - 148-Hemorrhage s - - - - - - - - - - - - - 203-Necrosis s - - - - - - - - - - - - - 57-Hyperplasia, focal s - - - 2= - - - 4 - - 2 - - 31-B-Adenoma, pars distalis - - - - - 1= - - - 1= - 1= 1=

Study Number FY01-013

N-190
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 98 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Pituitary gland (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - 2= 288-M-Carcinoma - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 142 202-Inflammation, acute s 2 152-Inflammation, mixed s - 153-Hyperplasia/hyperkeratosis s 3= Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 142 272-Fracture p P= Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 142 278-Pigment s 2= Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-191
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page: 99 Rat/F344/N Group Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G694 3 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695 Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2 Tiss.not specifi Status > M M M MH M M M M M M M M M M M Operator > 142

Study Number FY01-013

N-192
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:100 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Lungs (12) Status > Operator > 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - 30-Congestion s - - - - - 71-Fibrosis, focal s - - - - - 182-Hemorrhage s - - - - - 177-Inflammation, acute s - - - - - 72-Inflammation, mixed s - - - - - 236-Inflammation, granulomatous s - - - - - 10-Hyperplasia, alv. epi. focal s - - - - 2 214-N-Carcinoma, metastatic - - - - - 11-N-Leukemia,monuc - cap invol - - 2 - - 74-N-Leukemia,monuc - inv invol - - - - - 204-N-Sarcoma, histiocytic - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 22-Inflammation, acute s - - - - - 75-Inflammation, mixed s - - - - - 76-Hyperplasia s - - - - - 238-N-Leukemia, monuc - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 21-Hemorrhage s - - - 297-Inflammation, mixed s - - - 62-N-Leukemia, monuc - 1= - Thyroid glands (8) Status > Operator > 142 142 142 79-Cyst, follicular p - - - 77-Hyperplasia, C-cell, focal s - - - 81-Hyperplasia, follicular cell s - - - 35-B-Adenoma, C-cell - - - 78-B-Adenoma, follicular cell - - - 174-M-Carcinoma, C-cell - - - 80-M-Carcinoma, follicular cell - - - 178-M-Leukemia, monuc - - - Parathyroid (2) Status > mH Operator > 142 142 142 241-Hyperplasia, focal s - - - 296-B-Adenoma - - - Aorta (1) Status > Operator > 142 142 142 83-N-Leukemia,monuc - inv invol - - -

Study Number FY01-013

N-193
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:101 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Esophagus Status > U U U Operator > 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 12-Metaplasia, squamous s - - - - 1 1-Hyperplasia s - - - - - 23-Inflammation, acute s 1 - - - - 42-Inflammation, mixed s - - - - - 53-Inflammation, chronic s - - - - - Salivary gland (1) Status > Operator > 142 142 142 43-M-Leukemia, monuc - - - Mandibular LN (2) Status > Operator > 142 142 142 89-Hemorrhage s - - - 44-N-Leukemia, monuc - - - Liver (15) Status > Operator > 142 142 142 45-Angiectasis s - - - 158-Congestion s - - - 90-Fatty Change s - - - 150-Foci cell alter, basophilic s - - - 92-Hdn p - - - 4-Necrosis s - - - 230-Thrombus s - - - 13-Vaculoliz cyto s - - - 24-Inflammation, acute s - - - 54-Inflammation, chronic s - - - 46-Hyperplasia, biliary s - 1 - 47-Hyperplasia, hepato, regen s - - - 91-B-Adenoma, hepatocellular - - - 205-M-Sarcoma, histiocytic - - - 14-M-Leukemia, monuc - 2 - Spleen (5) Status > Operator > 142 142 142 142 96-Fibrosis s - - - - 226-Hemorrhage s - - - - 97-Necrosis s - - - - 15-M-Leukemia, monuc - 2= - - 298-N-Sarcoma, histiocytic - - - -

Study Number FY01-013

N-194
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:102 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Kidneys (9) Status > Operator > 142 142 142 211-Atrophy s - - - 149-Cyst s - - - 209-Degen, hyaline droplet s - - - 210-Dilatation s - - - 228-Infarct s - - - 16-Nephropathy, chronic s - - - 6-Pigment accum, tub epi s - - - 98-M-Leukemia, monuc - - - 299-N-Sarcoma, histiocytic - - - Heart (5) Status > Operator > 142 142 142 100-Degen, myocyte s - - - 101-Fibrosis s - - - 175-Thrombus s - - - 36-Inflammation, focal, chronic s 1 - - 48-M-Leukemia, monuc - - - Stomach (4) Status > Operator > 142 142 142 268-Ulcer s - - - 103-Inflammation, mixed s - - - 217-M-Carcinoma, metastatic - - - 220-M-Leukemia, monuc - - - Cecum (1) Status > Operator > 142 142 142 104-N-Leukemia, monuc - - - Urinary bladder (4) Status > Operator > 142 142 142 186-Hemorrhage s - - - 56-Inflammation, chronic s - - - 166-Hyperplasia, papillary s - - - 106-M-Leukemia, monuc - - - Duodenum (1) Status > Operator > 142 142 142 275-Inflammation, acute s - - - Jejunum Status > U U U Operator > 142 142 142

Study Number FY01-013

N-195
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:103 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Ileum (1) Status > Operator > 142 142 142 181-N-Leukemia, monuc - - - Colon Status > U U U Operator > 142 142 142 Pancreas (2) Status > Operator > 142 142 142 212-Fibrosis s - - - 110-M-Leukemia, monuc - - - Rectum (1) Status > Operator > 142 142 142 276-Metaplasia, squamous s - - - Adrenal glands (9) Status > Operator > 142 142 142 161-Cyst s - - - 113-Degen, cytopl vacuol s - - - 170-Necrosis s - - - 118-Thrombus s - - - 117-Hyperplasia, cortical, focal s - - - 64-Hyperplasia, focal p - P - 116-B-Pheochrom, bgn - - - 216-M-Carcinoma, metastatic - - - 112-M-Leukemia, monuc - - - Uterus (11) Status > Operator > 142 142 142 142 277-Angiectasis s - - - - 7-Dilatation s - - - - 167-Intussusception p - - - - 162-Inflammation, mixed s - - - - 49-Inflammation, chronic s - - - - 20-Hyperplasia, cystic endom s - - - - 286-B-Adenoma, endometrial - - - - 9-B-Polyp, endometrial stromal - 1 - 1= 213-M-Adenocarcinoma, endometr - - - - 279-M-Leiomyosar - - - - 165-M-Leukemia, monuc - - - - Mesenteric LN (4) Status > Operator > 142 142 142 120-Hemorrhage s - - - 173-Inflammation, chronic s - - - 206-N-Sarcoma, histiocytic - - - 32-N-Leukemia, monuc - - -

Study Number FY01-013

N-196
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:104 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Ovaries (9) Status > Operator > 142 142 142 284-Congestion s - - - 154-Cyst, bursa p - - - 234-Cyst, epithelial p - - - 293-Cyst, follicular p - - - 291-Cyst, rete ovarii s - - - 25-Hemorrhage s - - - 290-Necrosis, mesenteric fat s - - - 207-N-Sarcoma, histiocytic - - - 163-M-Leukemia, monuc - - - Sciatic nerve Status > U *H U Operator > 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 208-N-Sarcoma, histiocytic - - - Mammary gland (6) Status > Operator > 142 142 142 142 159-Ectasia s - - - - 190-Hyperplasia, lobular s - - - - 156-B-Fibroadenoma - - - - 70-B-Fibroma - 1= - - 235-M-Adenocarcinoma - - - - 224-M-AdenoCA arising in fibroAD - - - - Skin (3) Status > Operator > 142 142 142 252-Cyst, epith inc p - - - 122-Fibrosis s - - - 253-Inflammation, mixed s - - 1 Brain (6) Status > Operator > 142 142 142 26-Compression s - - - 192-Hemorrhage s - - - 155-Metaplasia, osseous, meninge s - - - 33-Necrosis s - - - 194-Inflammation, chronic s - - - 256-M-Astrocytoma, malignant - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 127-Atrophy s - - - 129-Atrophy, retinal, unilat s - - 2 130-Cataract p - - P= 133-Metaplasia, osseous, sclera s - - -

Study Number FY01-013

N-197
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:105 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Eyes/optic nerve (7) Status > Operator > 142 142 142 58-Mineralization, corneal str s - - - 126-Mineralization, scleral s - - - 131-Neovascularization, corneal s - - - Bone, femur (1) Status > *H Operator > 142 142 142 179-New bone, endosteal s - - Spinal cord (3) Status > *H Operator > 142 142 142 27-Degen, white matter s - - 197-Hemorrhage s - - 231-Necrosis, neuronal s - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 260-Degeneration,hyal-resp epith s - 3 1 - - 134-Inflammation, mixed s - - - - - 34-Inflammation-nasolac duct s - 3 - - - 136-Inflammation-resp epith s - - - - - 199-Hyperplasia-resp epith s - - - - 2 Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - 2 - - - 261-Degeneration,hyal-resp epith s - 2 - - - 176-Metaplasia, sec-olfact epith s - - - - - 270-Metaplasia, squ-olfact epith s - - - - - 138-Inflammation, mixed s - - - - - 227-Hyperplasia-resp epith s - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - 19-Degeneration,hyaline-olf epi s - 3 - - - 232-Degeneration-resp epith s - - - - - 142-Inflammation, mixed s - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - 164-Degeneration,hyaline-olf epi s - - - - - 144-Inflammation, mixed s - - - - -

Study Number FY01-013

N-198
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:106 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Cervix (3) Status > M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 29-Hemorrhage s - - - 3-Infiltration, histiocytic s - - - 2-Pigmentation s - - - 273-B-Thymoma - - - 219-M-Carcinoma, metastatic - - - 265-N-Sarcoma, histiocytic - - - 41-N-Leukemia, monuc - 1= - Pituitary gland (10) Status > Operator > 142 142 142 160-Angiectasis s - - - 37-Cyst s - - - 38-Degen s - - - 148-Hemorrhage s - - - 203-Necrosis s - - - 57-Hyperplasia, focal s - - - 31-B-Adenoma, pars distalis - - -

Study Number FY01-013

N-199
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:107 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Pituitary gland (10) Status > Operator > 142 142 142 274-B-Adenoma, pars intermedia - - - 288-M-Carcinoma - - - 146-M-Leukemia, monuc - - - Tail (3) Status > M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-200
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:108 Rat/F344/N Group Sex Dosage Animal > 6836G697 6836G699 3 F 10 g/m3 Animal > 6836G696 6836G698 6836G700 Tissue/diagnosis Death code > U2 FS U2 U2 FS Tiss.not specifi Status > M M M M M Operator >

Study Number FY01-013

N-201
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:109 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Lungs (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - - - - - 1 - 1 - - - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - 2= - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - - - - - - 2 - - - 1 - - 2 - 74-N-Leukemia,monuc - inv invol - 2 - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic 2= - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - 2 - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - - - 2 - - - - 297-Inflammation, mixed s - - - - - - - - - - - - - - 62-N-Leukemia, monuc - 1= - - - - - - - - - - - - Thyroid glands (8) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - - - - - - - 77-Hyperplasia, C-cell, focal s - - - - - - - - - - 2 - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 35-B-Adenoma, C-cell - - - - - - - - 1 - - - - - - 78-B-Adenoma, follicular cell - - - - - - - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - - - - - - - Parathyroid (2) Status > mH mH m m m mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - - - - - - - - 296-B-Adenoma - - - - - - - - - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -

Study Number FY01-013

N-202
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:110 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - - 1 - - - 1 1 - 1 - - - 1-Hyperplasia s - 2 - 2 - - - - - - - - 1 - 2 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - 2 - 2 - - 1 - 2 1 2 2 - 1 - 53-Inflammation, chronic s - - - - 1 - - - - - - - - - - Salivary gland (1) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - - - - - - 1 - Mandibular LN (2) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - - - - - - - 44-N-Leukemia, monuc 1= - - - - - - - - 1= - - - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - - - - - - - 158-Congestion s - - - - - - - - - - - - - - - 90-Fatty Change s - - - - - - - 1 - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - 2 - - - - - - - 92-Hdn p - - - - - P= - - - - - - - - - 4-Necrosis s - - - - - - - - - - - - 3= - - 230-Thrombus s - - - - - - - - - - - - - - - 13-Vaculoliz cyto s - - - - - - - - - - - - - - - 24-Inflammation, acute s - - - - - - - - - - - - - - - 54-Inflammation, chronic s - - - 1 1 1 - - - 1 - - - - 1 46-Hyperplasia, biliary s - - - 1 1 1 1 - 1 1 - 1 - - 1 47-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - - 205-M-Sarcoma, histiocytic 2= - - - - - - - - - - - - - - 14-M-Leukemia, monuc - 2 1 - - - 2 - 1 1 1 - - 2 - Spleen (5) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - - - - - - - - - 226-Hemorrhage s - - - - - - - - - - - - - - - 97-Necrosis s - - - - - - - - - - - - - - - 15-M-Leukemia, monuc - 2= 1 - - - 2= - 1 1 1= - - 2= - 298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -

Study Number FY01-013

N-203
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:111 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 211-Atrophy s - - 4= - - - - - - - - - - - - 149-Cyst s - - - - 3= - 3= - - - - 2= - - - 209-Degen, hyaline droplet s 4 - - - - - - - - - - - - - - 210-Dilatation s - - 3= - - - - - - - - - - - - 228-Infarct s - - - - - - - - - - - - - - - 16-Nephropathy, chronic s 1 1 1 2 2 - 2 1 2 2 2 2 - 1 - 6-Pigment accum, tub epi s - - - - - - - - - - - - 1 - - 98-M-Leukemia, monuc - 1 - - - - - - - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - - 1 1 - - - - - - 101-Fibrosis s - - - - - - - - - - - - - - - 175-Thrombus s - - - - - - - - - - - - - - - 36-Inflammation, focal, chronic s 1 - - 1 1 2 - 1 - 1 1 - - - - 48-M-Leukemia, monuc - 1 - - - - - - - - - - - 1 - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - - - - - - - - 103-Inflammation, mixed s - - - - - - - - - - - - - - - 217-M-Carcinoma, metastatic - - 1= - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Cecum (1) Status > A a a a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - - - - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - - - - - - - - 56-Inflammation, chronic s 1 - - 1 - - - - - - - - - - - 166-Hyperplasia, papillary s - - - - - - - - - - - - - - - 106-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - - - - - - - - Jejunum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142

Study Number FY01-013

N-204
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:112 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Ileum (1) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 212-Fibrosis s - - 2 - - - - - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - - - - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - 1 113-Degen, cytopl vacuol s - - - 1 - - - 1 - - - 1 - - - 170-Necrosis s - - - - - - - - - - - - - - - 118-Thrombus s - - - - - - - - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - - - - - - - - 64-Hyperplasia, focal p - - - - - - - - - - - - - - - 116-B-Pheochrom, bgn - - - - - - 1 - - - - - - - - 216-M-Carcinoma, metastatic - - 1 - - - - - - - - - - - - 112-M-Leukemia, monuc - 1 - - - - - - - - - - - - - Uterus (11) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - - - - - 7-Dilatation s - 4= 4= - - - - - - - - - 3 - - 167-Intussusception p - - - - - - - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - - - - - - - 49-Inflammation, chronic s - - - - - - - - - - - - - - - 20-Hyperplasia, cystic endom s - - - - - - - - 3 1 - - - - - 286-B-Adenoma, endometrial - - - - - - - - - - - - - - - 9-B-Polyp, endometrial stromal - - - - - - 1= - - - - - 2= - - 213-M-Adenocarcinoma, endometr - - 2= - - - - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - - - - - - - 165-M-Leukemia, monuc - 1 - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - - - - - - - - - 173-Inflammation, chronic s - - - - - - - - - - - - - - - 206-N-Sarcoma, histiocytic 1 - - - - - - - - - - - - - - 32-N-Leukemia, monuc - 1= - - - - - - - - - - - 1 -

Study Number FY01-013

N-205
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:113 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Ovaries (9) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - - - - - - - - 154-Cyst, bursa p - - - - - - - - P= - - - - - - 234-Cyst, epithelial p - - - - - - - - - - - - - - - 293-Cyst, follicular p - - - - - - - - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - - - - - - - - 25-Hemorrhage s - - - - - - - - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - - 207-N-Sarcoma, histiocytic 1 - - - - - - - - - - - - - - 163-M-Leukemia, monuc - 1= - - - - - - - - - - - - - Sciatic nerve Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic 1 - - - - - - - - - - - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - - - - - - - - - 190-Hyperplasia, lobular s - - - - - - - - - - - - - - - 156-B-Fibroadenoma - - - - - 1= - - - - 1= - - - - 70-B-Fibroma - - - - - - - - - - - - - - - 235-M-Adenocarcinoma - - - - - - - - - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - - - - - - - - - 122-Fibrosis s - - - - - - - - - - - - - - - 253-Inflammation, mixed s - - - - - - - - - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Compression s - - - 2= - - - - - - - 2= - - - 192-Hemorrhage s - - - - - - - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - 1 - - - - 33-Necrosis s - - - - - - - - - - - - - - - 194-Inflammation, chronic s - - - - 4= - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - - - - - - - - 129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 130-Cataract p - - - - - - - - - - - - - - - 133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -

Study Number FY01-013

N-206
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:114 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - 1 - - - - 1 - - - - - - 126-Mineralization, scleral s - 2 - - - - - - - - - - - - 1 131-Neovascularization, corneal s - - - - - - - - 1 1 - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - - - - - - - - 197-Hemorrhage s - - - - - - - - - - - - - - - 231-Necrosis, neuronal s - - - - - - - - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 134-Inflammation, mixed s - 2 2 - - - 2 - - - - - - - - 34-Inflammation-nasolac duct s 3 2 2 1 3 - 4 3 3 3 - 4 - - - 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s 2 - - 2 - - - - - - - - - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - 1 - - - - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - 2 2 - - - - - - - - - - - - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - 1 - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-207
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:115 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 142 60-Hemorrhage s - 59-Infiltration, histiocytic s - 65-N-Leukemia, monuc 1= Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 142 68-N-Leukemia, monuc 1= Mediastinal LN (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - - - - - - - - - 3-Infiltration, histiocytic s - - - - - - - - - - - - 3 - - 2-Pigmentation s - - - - - - - - - - - - 3 - - 273-B-Thymoma - - - - - - - - - - - - - - - 219-M-Carcinoma, metastatic - - 1= - - - - - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 41-N-Leukemia, monuc - 1= - - - - - - - - - - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - - - - - - - - - - 4= - 1 - 37-Cyst s 2 1 - - - - 2 - 2= - 1 - - - - 38-Degen s - - - - - - - - - - - - - - - 148-Hemorrhage s - - - 3 - - 1= - - - 1 - - - - 203-Necrosis s - - - - - - - - - - - - - - - 57-Hyperplasia, focal s - - - - - - - - - - - 3 - - - 31-B-Adenoma, pars distalis - - - 1= - - - - - - - - - - -

Study Number FY01-013

N-208
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:116 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 142 202-Inflammation, acute s - 152-Inflammation, mixed s 3 153-Hyperplasia/hyperkeratosis s 4= Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 142 157-M-Osteosarcoma 1= Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 142 171-Splenic tissue, "accessory" p - 218-M-Carcinoma, metastatic 1 Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-209
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:117 Rat/F344/N Group Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H764 4 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765 Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FS Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-210
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:118 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Lungs (12) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - 1= 1 - - - 1 1 - 1 - 30-Congestion s - - - - - - - - - - - - - - - 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s 2= - - - - - - - 1= - - - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - 2= - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol 2 1 1 - 2 - 2 - 2= 2 - - 2 - 1 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 21-Hemorrhage s - - - - - - - - - - 2 - - - 297-Inflammation, mixed s - - - - - - - - - - - - - - 62-N-Leukemia, monuc - - - - - - - - - - - - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - - - - - - - 77-Hyperplasia, C-cell, focal s - 2 - - - - - 2 - - 3= - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 35-B-Adenoma, C-cell - - - - - - - - - - - - - - - 78-B-Adenoma, follicular cell - - - - 1 - - - - - - - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - - 178-M-Leukemia, monuc - - - - 1 - - - - - - - - - - Parathyroid (2) Status > m mH mH mH mH mH Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - - - - - - - - 296-B-Adenoma - - - - - - - - - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -

Study Number FY01-013

N-211
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:119 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s 1 - 1 - - - - - - - - - 1 - - 1-Hyperplasia s - - 1 - 1 2 1 - - 2 2 - - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s 1 - 2 2 2 2 2 1 - 2 - 1 1 1 - 53-Inflammation, chronic s - - - - - - - - - - 2 - - - 2 Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (2) Status > * * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - - - - - - 44-N-Leukemia, monuc - - - 1 - 1 - - - - - - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - - - - - - - 158-Congestion s - - - - - - - - - - - - - - - 90-Fatty Change s - - - - - - - - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 92-Hdn p - - - - - P= - - - - - - - - - 4-Necrosis s - - 1 - - - - - - - - - 1 - - 230-Thrombus s - - - - - - - - - - - - - - - 13-Vaculoliz cyto s - - - - - - - - - - - - - - - 24-Inflammation, acute s - - - - - - - - - - - - - - - 54-Inflammation, chronic s - - - - - - - 1 - - 1 - - 1 - 46-Hyperplasia, biliary s - - 1 - 2 2 - - 1 1 1 - - 1 - 47-Hyperplasia, hepato, regen s - - - - - - 1 - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-M-Leukemia, monuc 2 1 1= - 2 - 2= - 2 2= - - 2 - 2 Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - - - - - - - - - 226-Hemorrhage s - - - - - - - - - - - - 3 - - 97-Necrosis s - - - - - - 4= - - - - - 3= - - 15-M-Leukemia, monuc 2= 1= 1 - 2= - 2= - 2= 2= - - 2= - 2= 298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -

Study Number FY01-013

N-212
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:120 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Kidneys (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - - - - - - - - 149-Cyst s - - - - - - - - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - - - - - - - - 210-Dilatation s - - - - - - - - - - - - - - - 228-Infarct s - - - - - - - - - - - - - - - 16-Nephropathy, chronic s - 1 2 - 1 1 2 1 1 - 2 2 2 2 2 6-Pigment accum, tub epi s - - - - - - - - - - - - - - - 98-M-Leukemia, monuc 1 - - - - - - - - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - - - - - - - - - - 101-Fibrosis s - - - - - - - - - - - - - - - 175-Thrombus s - - - - - - - - - - - - - - - 36-Inflammation, focal, chronic s - - - 1 1 - - - 1 1 1 1 - 1 1 48-M-Leukemia, monuc - - - - - - - - - - - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - - - - - - - - 103-Inflammation, mixed s - - - - - - - - - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Cecum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - - - - - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - - - - - - - - 56-Inflammation, chronic s - - - - - - - 1 - - - - - - - 166-Hyperplasia, papillary s - - - - - - - - - - - - - - - 106-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - - - - - - - - Jejunum Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142

Study Number FY01-013

N-213
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:121 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Ileum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - 1= - - - - - - - - Colon Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - - - - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 113-Degen, cytopl vacuol s 1 1 - 2 - - 1 1 - - - - - - - 170-Necrosis s - - - - - - - - - - - - - - - 118-Thrombus s - - - - - - - - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - - - - - - - - 64-Hyperplasia, focal p - - - - - - - - - - - - - - - 116-B-Pheochrom, bgn - - - - - - - - - - - - - - - 216-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 112-M-Leukemia, monuc - - - - - - - - 1 - - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - - - - - 7-Dilatation s - - - - - - - - - - - - - - - 167-Intussusception p - - - P= - - - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - - - - - - - 49-Inflammation, chronic s - - - - - - - - - - - - - - - 20-Hyperplasia, cystic endom s - 2 - - - - - - - - - - 1 1 - 286-B-Adenoma, endometrial - - - - - - - - - - - - - - - 9-B-Polyp, endometrial stromal - 1= - 1 1= - 1= - - - - - - - 1= 213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - - - - - - - 165-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - - - - - - - - - 173-Inflammation, chronic s - - - - - - - - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 32-N-Leukemia, monuc - - - - 1 - - - 1 - - - - - -

Study Number FY01-013

N-214
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:122 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Ovaries (9) Status > H H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - - - - - - - - 154-Cyst, bursa p - - - - - - - - - - - - - - - 234-Cyst, epithelial p - - - - - - - - - - - - - - - 293-Cyst, follicular p - - - - - - - - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - - - - - - - - 25-Hemorrhage s - - - - - - - - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 163-M-Leukemia, monuc - - - - - - - - - - - - - - - Sciatic nerve Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Mammary gland (6) Status > *H *H *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 159-Ectasia s - - 2 - - - - - - - - - 190-Hyperplasia, lobular s - - - - 2 - - - - - - - 156-B-Fibroadenoma - - - - - 1= - - - - - - 70-B-Fibroma - - - - - - - - - - - - 235-M-Adenocarcinoma - - - - - - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - Skin (3) Status > *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - - - - - - - - 122-Fibrosis s - - - - - - - - - - - - - - 253-Inflammation, mixed s - - - - - - - - - - - - - - Brain (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Compression s - - - 2= - - - - - - - - - - - 192-Hemorrhage s - - - - - - - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - - 33-Necrosis s - - - - - - - - - - - - - - - 194-Inflammation, chronic s - - - - - - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Atrophy s - 4= - - - - - - - - - 4 - - - 129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 130-Cataract p - - - - - - - - - - - P= - - - 133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -

Study Number FY01-013

N-215
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:123 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - 1 - - - - - - - - - - - - - 126-Mineralization, scleral s - - - - - - - - - - - - - - 1 131-Neovascularization, corneal s - - - - - - - - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - 1 - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - - - - - - - - 197-Hemorrhage s - - - - - - - - - - - - - - - 231-Necrosis, neuronal s - - - - - - - - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s 2 - - - - - - - - - - - - - - 134-Inflammation, mixed s - - - - - - - - - - - - - - - 34-Inflammation-nasolac duct s - 4 - - 2 - 3 - - - 4 - - - 2 136-Inflammation-resp epith s - - - - - - - - - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - - - - 2 - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s 1 - 2 1 - - - - - - 2 1 - - - 261-Degeneration,hyal-resp epith s - - - - - - - - - - 1 - - 1 - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - - - - - - - - - - - - - - 227-Hyperplasia-resp epith s - - - - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - - - 3 - - - - - - 2 - - - - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - 1 - - - - - - - - - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-216
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:124 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 142 142 168-B-Polyp, endometrial stromal 1= - 289-M-Leiomyosarcoma - - 269-N-Adenocarcinoma, endometr - - Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > * *H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - - - - - - - 3-Infiltration, histiocytic s - - - - - - - - - - - - - 2-Pigmentation s - - - - - - - - - - - - - 273-B-Thymoma - - - - - - - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - - - - - - 41-N-Leukemia, monuc 1 - - - 1= 1 - - - - - 1= - Pituitary gland (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - - 3= 2 - - - - - - - - - 3 - 37-Cyst s - - - - - - - - - 1 1 - - - 2 38-Degen s - - - - - - - - - - - - - - - 148-Hemorrhage s - - - - - - - - - - - - - - - 203-Necrosis s - - - - - - 3 - - - - - - - - 57-Hyperplasia, focal s - - 2 - 3 - - - - - - 1 - - - 31-B-Adenoma, pars distalis - - - 1= 1= - - - - - - - - 1= -

Study Number FY01-013

N-217
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:125 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Pituitary gland (10) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - 1 - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-218
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:126 Rat/F344/N Group Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H779 4 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780 Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FS Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-219
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:127 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Lungs (12) Status > H a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 40-Alveolar histiocytosis s - 1 - - - - - - 1 - - - - - - 30-Congestion s - - - - - - - - - - - - - - 2= 71-Fibrosis, focal s - - - - - - - - - - - - - - - 182-Hemorrhage s - - - - - - - - - - 1 - - - - 177-Inflammation, acute s - - - - - - - - - - - - - - - 72-Inflammation, mixed s - - - - - - - - - - - - - - - 236-Inflammation, granulomatous s - - - - - - - - - - - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - - 214-N-Carcinoma, metastatic - - - - - - - - - - - - - - - 11-N-Leukemia,monuc - cap invol - - - - 2= - 1 - - - 2= 2 1 - - 74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - - 204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Trachea (4) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 22-Inflammation, acute s - - - - - - - - - - - - - - - 75-Inflammation, mixed s - - - - - - - - - - - - - - - 76-Hyperplasia s - - - - - - - - - - - - - - - 238-N-Leukemia, monuc - - - - - - - - - - - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 21-Hemorrhage s 2 - - - - - - - - - - - - - - 297-Inflammation, mixed s - - - - - - - - - - - - - - - 62-N-Leukemia, monuc - - - - 1 - - - - - - - - - - Thyroid glands (8) Status > m m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 79-Cyst, follicular p - - - - - - - - - - - - - - - 77-Hyperplasia, C-cell, focal s 3 - - - - - - 2 - - - - - - - 81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - - 35-B-Adenoma, C-cell - - - - - - - - - - 1= - - - - 78-B-Adenoma, follicular cell - - - - - - - - - - 1 - - - - 174-M-Carcinoma, C-cell - - - - - - - - - - - - - - - 80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - - 178-M-Leukemia, monuc - - - - - - - - - - - - - - - Parathyroid (2) Status > mH mH mH mH mH m m m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 241-Hyperplasia, focal s - - - - - - - - - - - - - - - 296-B-Adenoma - - - - - - - - - - - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -

Study Number FY01-013

N-220
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:128 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Esophagus Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 12-Metaplasia, squamous s - - - 1 - - 1 - - - - - - - - 1-Hyperplasia s - - - - - - - - - - 1 1 - - - 23-Inflammation, acute s - - - - - - - - - - - - - - - 42-Inflammation, mixed s - - 2 2 - 1 1 2= - - 1 2 1 1 1 53-Inflammation, chronic s 1 1 - - - - - - 1 1 - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 43-M-Leukemia, monuc - - - - - - - - - - - - - - - Mandibular LN (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 89-Hemorrhage s - - - - - - - - - - - - - - - 44-N-Leukemia, monuc - - - - 1 - - - - - - - - - - Liver (15) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 45-Angiectasis s - - - - - - - - - - 1 - - - - 158-Congestion s - - - - - - - - - - - - - - - 90-Fatty Change s - - 2= - - - 2 - - - - - - - - 150-Foci cell alter, basophilic s - - - - - - - - - - - - - - - 92-Hdn p - - - - - P= - - - - - - - - - 4-Necrosis s 1 - - - 2 - - - - - - - - - - 230-Thrombus s - - - - - - - - - - - - 2 - - 13-Vaculoliz cyto s - - - - - - - - - - - - - - - 24-Inflammation, acute s - - - - - - - - - - - - - - - 54-Inflammation, chronic s 1 1 1 - - - - 1 1 1 - - - 1 - 46-Hyperplasia, biliary s - 1 1 - - - 1 1 - 1 - 2 2 - - 47-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - - 91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - - 205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - - 14-M-Leukemia, monuc - - - - 2= - 1= - - - 2= 2 2 - - Spleen (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 96-Fibrosis s - - - - - - - - - - - - - - - 226-Hemorrhage s - - - - - - - - - - - - - - - 97-Necrosis s - - - - - - - - - - - - - - - 15-M-Leukemia, monuc - - - - 2= - 1= - - - 2= 2= 2= - - 298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -

Study Number FY01-013

N-221
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:129 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Kidneys (9) Status > a a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 211-Atrophy s - - - - - - - - - - - - - - - 149-Cyst s - - - - - - - - - - - - - - - 209-Degen, hyaline droplet s - - - - - - - - - - - - - - - 210-Dilatation s - - - - - - - - - - - - - - - 228-Infarct s - - - 3 - - - - - - - - - - - 16-Nephropathy, chronic s 3 2 3 3 1 - 3= 3 2 2 3 1 1 2 1 6-Pigment accum, tub epi s - - - - - - - - - - - 3 - - - 98-M-Leukemia, monuc - - - - - - - - - - - - - - - 299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Heart (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 100-Degen, myocyte s - - - - - - - - - 1 - - - - - 101-Fibrosis s - - - - - - - - - - - - - - - 175-Thrombus s - - - - - - - - - - - - - - - 36-Inflammation, focal, chronic s - - - 1 - - 1 1 1 - 1 1 1 1 - 48-M-Leukemia, monuc - - - - - - - - - - - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 268-Ulcer s - - - - - - - - - - - - - - - 103-Inflammation, mixed s - - - - - - - - - - - - - - - 217-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 220-M-Leukemia, monuc - - - - - - - - - - - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 104-N-Leukemia, monuc - - - - - - - - - - - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 186-Hemorrhage s - - - - - - - - - - - - - - - 56-Inflammation, chronic s - - - - - - - - - - - - - - - 166-Hyperplasia, papillary s - - - - - - - - - - - - - - - 106-M-Leukemia, monuc - - - - - - - - - - - - - - - Duodenum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 275-Inflammation, acute s - - - - - - - - - - - - - - - Jejunum Status > U U U U U U U U U U U U U U Ua Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142

Study Number FY01-013

N-222
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:130 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Ileum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 181-N-Leukemia, monuc - - - - - - - - - - - - - - - Colon Status > U U U U U U U U U U U U U U Ua Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 212-Fibrosis s - - - - - - - - - - - - - - - 110-M-Leukemia, monuc - - - - - - - - - - - - - - - Rectum (1) Status > a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 276-Metaplasia, squamous s - - - - - - - - - - - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 161-Cyst s - - - - - - - - - - - - - - - 113-Degen, cytopl vacuol s 1 - - 2 - - - - 1 - - - 1 - - 170-Necrosis s - - - - - - - - - - - - - - - 118-Thrombus s - - - - - - - - - - - - - - - 117-Hyperplasia, cortical, focal s - - - - - - - - - - 1 - - - - 64-Hyperplasia, focal p - P - - - - - - - - - P - - - 116-B-Pheochrom, bgn - - - - - - - - - - - - - - - 216-M-Carcinoma, metastatic - - - - - - - - - - - - - - - 112-M-Leukemia, monuc - - - - - - - - - - - - 1 - - Uterus (11) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 277-Angiectasis s - - - - - - - - - - - - - - - 7-Dilatation s - - - - - - - - - - - - - - - 167-Intussusception p - - - - - P= - - - - - - - - - 162-Inflammation, mixed s - - - - - - - - - - - - - - - 49-Inflammation, chronic s - - - - - - - - - - - - - - - 20-Hyperplasia, cystic endom s 1 - - - - - 3 - 2 - 2 1 - 1 - 286-B-Adenoma, endometrial - - - - - - - - - - - - - - - 9-B-Polyp, endometrial stromal 1= - - - - - - - - 1 1= - - - - 213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - - 279-M-Leiomyosar - - - - - - - - - - - - - - - 165-M-Leukemia, monuc - - - - - - - - - - - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 120-Hemorrhage s - - - - - - - - - - - - - - - 173-Inflammation, chronic s - - - - - - - - - - - - - - - 206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 32-N-Leukemia, monuc - - - - - - - - - - - - - - -

Study Number FY01-013

N-223
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:131 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Ovaries (9) Status > m Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 284-Congestion s - - - - - - - - - - - - - - - 154-Cyst, bursa p - - - - - - - - - - - - - - - 234-Cyst, epithelial p - - - - - - - - - - - - - - - 293-Cyst, follicular p - - - - - - - - - - - - - - - 291-Cyst, rete ovarii s - - - - - - - - - - - - - - - 25-Hemorrhage s - - - - - - - - - - - - - - - 290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - - 207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - 163-M-Leukemia, monuc - - - - - - - - - - - - - - - Sciatic nerve Status > U U U U U U U U U U U U U U U Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - - Mammary gland (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 159-Ectasia s - - - - - - - - - - - - - - - 190-Hyperplasia, lobular s - - - - - - 1 - - - - - - - - 156-B-Fibroadenoma - 1= - - - - - - - - - - - - - 70-B-Fibroma - - - - - - - - - - - - - - - 235-M-Adenocarcinoma - - - - - - - - - - - - - - - 224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - - Skin (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 252-Cyst, epith inc p - - - - - - - - - - - - - - - 122-Fibrosis s - - - - - - - - - - - - - - - 253-Inflammation, mixed s - - - - - - - - - - - - - - - Brain (6) Status > H Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 26-Compression s - - 3= - - - 2= 1 - 3= - - - - - 192-Hemorrhage s - - - - - - - - - - - - - - - 155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - - 33-Necrosis s - - - - - - - - - - - - - - - 194-Inflammation, chronic s - - - - - - - - - - - - - - - 256-M-Astrocytoma, malignant - - - - - - - - - - - - - - - Eyes/optic nerve (7) Status > H a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 127-Atrophy s - - - - - - - - - - - - - - - 129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - - 130-Cataract p - - - - - - - - - - - - - - - 133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -

Study Number FY01-013

N-224
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:132 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Eyes/optic nerve (7) Status > H a Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 58-Mineralization, corneal str s - - - - 2= - - - - - - - - - - 126-Mineralization, scleral s - 1 - - - - - - - - - - - - - 131-Neovascularization, corneal s - - - - - - - - - - - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 179-New bone, endosteal s - - - - - - - - - - - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 27-Degen, white matter s - - - - - - - - - - - 1 - - - 197-Hemorrhage s - - - - - - - - - - - - - - - 231-Necrosis, neuronal s - - - - 1 - - - - - - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 260-Degeneration,hyal-resp epith s - 1 - - - - - - - - - - - - - 134-Inflammation, mixed s - - 1 - - - - - - - - - - - - 34-Inflammation-nasolac duct s - - 4 - 2 - - 2 3 3 - - 3 - - 136-Inflammation-resp epith s - - - - - - - 2 - - - - - - - 199-Hyperplasia-resp epith s - - - - - - - 2 - - - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - 2 - 1 - - - - 1 - - - - - - 261-Degeneration,hyal-resp epith s - - - - - - - 2 - - 2 2 - - - 176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - - 270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - - 138-Inflammation, mixed s - - 3 - - - - - - - - - - - - 227-Hyperplasia-resp epith s - - 3 - - - - - - - - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - - - - - - - - - - - 19-Degeneration,hyaline-olf epi s - 1 - - 1 - - - - - 3 2 - - - 232-Degeneration-resp epith s - - - - - - - - - - - - - - - 142-Inflammation, mixed s - - - - - - - - - - - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - - - - - - - - - - - 164-Degeneration,hyaline-olf epi s - - - - - - - - - - 1 - - - - 144-Inflammation, mixed s - - - - - - - - - - - - - - -

Study Number FY01-013

N-225
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:133 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Cervix (3) Status > M M M M M M M M M M M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M M M M M M M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M M M M M M M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M M M M M M M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M M M M M M M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M M M M M M M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > * Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 29-Hemorrhage s - - - - - - - - - - - - - - 3-Infiltration, histiocytic s - - - - - - - - - - - - - - 2-Pigmentation s - - - - - - - - - - - - - - 273-B-Thymoma - - - - - - - - - - - - - - 219-M-Carcinoma, metastatic - - - - - - - - - - - - - - 265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - 41-N-Leukemia, monuc - - - - - - - - - - - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 160-Angiectasis s - 1 - - - - - - - - - - - - - 37-Cyst s 1 - - - - - - - - - 1 - - - - 38-Degen s - - - - - - - - - - - - - - - 148-Hemorrhage s - - 3 - - - 3 3 - 3 2 - - - - 203-Necrosis s - - - - - - - - - - - - - - - 57-Hyperplasia, focal s - - - - - - - - - - - - - - - 31-B-Adenoma, pars distalis - - 1= - - - 1= 1= - 1= 1= - - - -

Study Number FY01-013

N-226
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:134 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Pituitary gland (10) Status > Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - - 288-M-Carcinoma - - - - - - - - - - - - - - - 146-M-Leukemia, monuc - - - - - - - - - - - - - - - Tail (3) Status > M M M M M M M M M M M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M M M M M M M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M M M M M M M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M M M M M M M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M M M M M M M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M M M M M M M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M M M M M M M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M M M M M M M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M M M M M M M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-227
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:135 Rat/F344/N Group Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H794 4 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795 Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1 Tiss.not specifi Status > M M M M M M M M M M M M M M M Operator >

Study Number FY01-013

N-228
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:136 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Lungs (12) Status > Operator > 142 142 142 142 142 40-Alveolar histiocytosis s - - - - - 30-Congestion s - - - - - 71-Fibrosis, focal s - - - - - 182-Hemorrhage s - - - - - 177-Inflammation, acute s - - - - - 72-Inflammation, mixed s - - - - - 236-Inflammation, granulomatous s - - - - - 10-Hyperplasia, alv. epi. focal s - - - - - 214-N-Carcinoma, metastatic - - - - - 11-N-Leukemia,monuc - cap invol - 2= - - 2 74-N-Leukemia,monuc - inv invol - - - - - 204-N-Sarcoma, histiocytic - - - - - Trachea (4) Status > Operator > 142 142 142 142 142 22-Inflammation, acute s - - - - - 75-Inflammation, mixed s - - - - - 76-Hyperplasia s - - - - - 238-N-Leukemia, monuc - - - - - Bronchial (TBLN) (3) Status > Operator > 142 142 142 142 142 21-Hemorrhage s - - 2 - - 297-Inflammation, mixed s - - - - - 62-N-Leukemia, monuc - - - - - Thyroid glands (8) Status > Operator > 142 142 142 142 142 79-Cyst, follicular p - - - - - 77-Hyperplasia, C-cell, focal s - - - - - 81-Hyperplasia, follicular cell s - - - - - 35-B-Adenoma, C-cell - - - - - 78-B-Adenoma, follicular cell - - - - - 174-M-Carcinoma, C-cell - - - - - 80-M-Carcinoma, follicular cell - - - - - 178-M-Leukemia, monuc - - - - - Parathyroid (2) Status > m m Operator > 142 142 142 142 142 241-Hyperplasia, focal s - - - - - 296-B-Adenoma - - - - - Aorta (1) Status > Operator > 142 142 142 142 142 83-N-Leukemia,monuc - inv invol - - - - -

Study Number FY01-013

N-229
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:137 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Esophagus Status > U U U U U Operator > 142 142 142 142 142 Larynx (5) Status > Operator > 142 142 142 142 142 12-Metaplasia, squamous s - - - - - 1-Hyperplasia s 1 2 - - 2 23-Inflammation, acute s - - - - - 42-Inflammation, mixed s 1 1 - 1 2 53-Inflammation, chronic s - - - - - Salivary gland (1) Status > Operator > 142 142 142 142 142 43-M-Leukemia, monuc - - - - - Mandibular LN (2) Status > Operator > 142 142 142 142 142 89-Hemorrhage s - - - - - 44-N-Leukemia, monuc - - - - - Liver (15) Status > Operator > 142 142 142 142 142 45-Angiectasis s - - - - - 158-Congestion s - - - - - 90-Fatty Change s - - - - - 150-Foci cell alter, basophilic s - - - - - 92-Hdn p - - - - - 4-Necrosis s - - - - - 230-Thrombus s - - - - - 13-Vaculoliz cyto s - - - - 2 24-Inflammation, acute s - - - - - 54-Inflammation, chronic s - - 1 - 2 46-Hyperplasia, biliary s 2 - - - 1 47-Hyperplasia, hepato, regen s - - - - - 91-B-Adenoma, hepatocellular - - - - - 205-M-Sarcoma, histiocytic - - - - - 14-M-Leukemia, monuc - 2= - - 2= Spleen (5) Status > Operator > 142 142 142 142 142 96-Fibrosis s - - - - - 226-Hemorrhage s - - - - - 97-Necrosis s - - - - - 15-M-Leukemia, monuc - 2= - - 2= 298-N-Sarcoma, histiocytic - - - - -

Study Number FY01-013

N-230
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:138 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Kidneys (9) Status > Operator > 142 142 142 142 142 211-Atrophy s - - - - - 149-Cyst s - - - - - 209-Degen, hyaline droplet s - - - - - 210-Dilatation s - - - - - 228-Infarct s - - - - - 16-Nephropathy, chronic s 2 1 1 2 3 6-Pigment accum, tub epi s - - - - - 98-M-Leukemia, monuc - - - - - 299-N-Sarcoma, histiocytic - - - - - Heart (5) Status > Operator > 142 142 142 142 142 100-Degen, myocyte s - - - - - 101-Fibrosis s - - - - - 175-Thrombus s - - - - - 36-Inflammation, focal, chronic s 1 - - 1 1 48-M-Leukemia, monuc - - - - - Stomach (4) Status > Operator > 142 142 142 142 142 268-Ulcer s - - - - - 103-Inflammation, mixed s - - - - - 217-M-Carcinoma, metastatic - - - - - 220-M-Leukemia, monuc - - - - - Cecum (1) Status > Operator > 142 142 142 142 142 104-N-Leukemia, monuc - - - - - Urinary bladder (4) Status > Operator > 142 142 142 142 142 186-Hemorrhage s - - - - - 56-Inflammation, chronic s - - - - - 166-Hyperplasia, papillary s - - - - - 106-M-Leukemia, monuc - - - - - Duodenum (1) Status > Operator > 142 142 142 142 142 275-Inflammation, acute s - - - - - Jejunum Status > U U U U U Operator > 142 142 142 142 142

Study Number FY01-013

N-231
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:139 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Ileum (1) Status > Operator > 142 142 142 142 142 181-N-Leukemia, monuc - - - - - Colon Status > U U U U U Operator > 142 142 142 142 142 Pancreas (2) Status > Operator > 142 142 142 142 142 212-Fibrosis s - - - - - 110-M-Leukemia, monuc - - - - - Rectum (1) Status > Operator > 142 142 142 142 142 276-Metaplasia, squamous s - - - - - Adrenal glands (9) Status > Operator > 142 142 142 142 142 161-Cyst s - - - - - 113-Degen, cytopl vacuol s 1 - - - 1 170-Necrosis s - - - - - 118-Thrombus s - - - - - 117-Hyperplasia, cortical, focal s - - - - - 64-Hyperplasia, focal p - - - - - 116-B-Pheochrom, bgn - - - - - 216-M-Carcinoma, metastatic - - - - - 112-M-Leukemia, monuc - - - - - Uterus (11) Status > Operator > 142 142 142 142 142 277-Angiectasis s - - - - - 7-Dilatation s - - - - - 167-Intussusception p - - - - - 162-Inflammation, mixed s - - - - - 49-Inflammation, chronic s - - - - - 20-Hyperplasia, cystic endom s - - - - - 286-B-Adenoma, endometrial - - - - - 9-B-Polyp, endometrial stromal - - 1= - - 213-M-Adenocarcinoma, endometr - - - - - 279-M-Leiomyosar - - - - - 165-M-Leukemia, monuc - - - - - Mesenteric LN (4) Status > Operator > 142 142 142 142 142 120-Hemorrhage s - - - - - 173-Inflammation, chronic s - - - - - 206-N-Sarcoma, histiocytic - - - - - 32-N-Leukemia, monuc - - - - -

Study Number FY01-013

N-232
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:140 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Ovaries (9) Status > Operator > 142 142 142 142 142 284-Congestion s - - - - - 154-Cyst, bursa p - - - - - 234-Cyst, epithelial p - - - - - 293-Cyst, follicular p - - - - - 291-Cyst, rete ovarii s - - - - - 25-Hemorrhage s - - - - - 290-Necrosis, mesenteric fat s - - - - - 207-N-Sarcoma, histiocytic - - - - - 163-M-Leukemia, monuc - - - - - Sciatic nerve Status > U U U U U Operator > 142 142 142 142 142 Muscle, skeletal (1) Status > Operator > 142 142 142 142 142 208-N-Sarcoma, histiocytic - - - - - Mammary gland (6) Status > H Operator > 142 142 142 142 142 159-Ectasia s - - - - - 190-Hyperplasia, lobular s - - - - - 156-B-Fibroadenoma - - 1= - - 70-B-Fibroma - - - - - 235-M-Adenocarcinoma - - - - - 224-M-AdenoCA arising in fibroAD - - - - - Skin (3) Status > Operator > 142 142 142 142 142 252-Cyst, epith inc p - - - - - 122-Fibrosis s - - - - - 253-Inflammation, mixed s - - - - - Brain (6) Status > Operator > 142 142 142 142 142 26-Compression s - - - 3= 2= 192-Hemorrhage s - - - - - 155-Metaplasia, osseous, meninge s - - - - - 33-Necrosis s - - - - - 194-Inflammation, chronic s - - - - - 256-M-Astrocytoma, malignant - - - - - Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 127-Atrophy s - - - - - 129-Atrophy, retinal, unilat s - - - - - 130-Cataract p - - P= - - 133-Metaplasia, osseous, sclera s - - - - -

Study Number FY01-013

N-233
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:141 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Eyes/optic nerve (7) Status > Operator > 142 142 142 142 142 58-Mineralization, corneal str s - - - - - 126-Mineralization, scleral s - - - - - 131-Neovascularization, corneal s - - - - - Bone, femur (1) Status > Operator > 142 142 142 142 142 179-New bone, endosteal s - - - - - Spinal cord (3) Status > Operator > 142 142 142 142 142 27-Degen, white matter s - - - - - 197-Hemorrhage s - - - - - 231-Necrosis, neuronal s - - - - - Nose/Turbinate 1 (5) Status > Operator > 142 142 142 142 142 260-Degeneration,hyal-resp epith s - - - - - 134-Inflammation, mixed s - - - - - 34-Inflammation-nasolac duct s 3 - - - - 136-Inflammation-resp epith s - - - - - 199-Hyperplasia-resp epith s - - - - - Nose/Turbinate 2 (6) Status > Operator > 142 142 142 142 142 18-Degeneration,hyaline-olf epi s - - - - - 261-Degeneration,hyal-resp epith s - 2 - - - 176-Metaplasia, sec-olfact epith s - - - - - 270-Metaplasia, squ-olfact epith s - - - - - 138-Inflammation, mixed s - - - - - 227-Hyperplasia-resp epith s - - - - - Nose/Turbinate 3 (4) Status > Operator > 142 142 142 142 142 295-Degeneration-olfact epith s - - - - - 19-Degeneration,hyaline-olf epi s - - - - - 232-Degeneration-resp epith s - 2 - - - 142-Inflammation, mixed s - - - - - Nose/Turbinate 4 (3) Status > Operator > 142 142 142 142 142 285-Degeneration-olfact epith s - - - - - 164-Degeneration,hyaline-olf epi s - - - - - 144-Inflammation, mixed s - - - - -

Study Number FY01-013

N-234
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:142 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Cervix (3) Status > M M M M M Operator > 168-B-Polyp, endometrial stromal 289-M-Leiomyosarcoma 269-N-Adenocarcinoma, endometr Clitoral gland (3) Status > M M M M M Operator > 294-B-Adenoma 61-M-Carcinoma, squamous cell 271-N-Adenocarcinoma Lymph node other (3) Status > M M M M M Operator > 60-Hemorrhage s 59-Infiltration, histiocytic s 65-N-Leukemia, monuc Popliteal LN (1) Status > M M M M M Operator > 66-N-Leukemia, monuc Iliac LN (1) Status > M M M M M Operator > 67-N-Leukemia, monuc Pancreatic LN (1) Status > M M M M M Operator > 68-N-Leukemia, monuc Mediastinal LN (7) Status > Operator > 142 142 142 142 142 29-Hemorrhage s - - - 2 - 3-Infiltration, histiocytic s - - - - - 2-Pigmentation s - - - - - 273-B-Thymoma - - - - - 219-M-Carcinoma, metastatic - - - - - 265-N-Sarcoma, histiocytic - - - - - 41-N-Leukemia, monuc - - - - - Pituitary gland (10) Status > Operator > 142 142 142 142 142 160-Angiectasis s - - - - - 37-Cyst s - 2 2 - - 38-Degen s - - - - - 148-Hemorrhage s - - - 3 2 203-Necrosis s - - - - - 57-Hyperplasia, focal s - - - - - 31-B-Adenoma, pars distalis - - - 1= 1=

Study Number FY01-013

N-235
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:143 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Pituitary gland (10) Status > Operator > 142 142 142 142 142 274-B-Adenoma, pars intermedia - - - - - 288-M-Carcinoma - - - - - 146-M-Leukemia, monuc - - - - - Tail (3) Status > M M M M M Operator > 202-Inflammation, acute s 152-Inflammation, mixed s 153-Hyperplasia/hyperkeratosis s Bone, rib (1) Status > M M M M M Operator > 157-M-Osteosarcoma Mesentery (2) Status > M M M M M Operator > 171-Splenic tissue, "accessory" p 218-M-Carcinoma, metastatic Bone, vertebrae (1) Status > M M M M M Operator > 221-N-Leukemia, monuc Zymbal’s gland (1) Status > M M M M M Operator > 223-M-Carcinoma, squamous cell Mediastinum (1) Status > M M M M M Operator > 233-N-Leukemia, monuc Bone, other (1) Status > M M M M M Operator > 272-Fracture p Harderian gland (1) Status > M M M M M Operator > 278-Pigment s Vagina (1) Status > M M M M M Operator > 287-M-Leiomyosarcoma

Study Number FY01-013

N-236
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:144 Rat/F344/N Group Sex Dosage Animal > 6838H797 6838H799 4 F 20 g/m3 Animal > 6838H796 6838H798 6838H800 Tissue/diagnosis Death code > FS U2 FS FS FS Tiss.not specifi Status > M M M M M Operator >

Study Number FY01-013

N-237
 Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:145 Rat/F344/N SYMBOLS, ABBREVIATIONS, AND CODES USED IN THE "MICROSCOPIC EVALUATION OF TISSUES" *** DISTRIBUTION OF FINDINGS *** *** NEOPLASTIC FINDINGS *** " " NO PARENTHESIS = NOT SPECIFIED " B- " = PRIMARY, BENIGN NEOPLASM IN ORGAN/TISSUE " M " M = FINDING MULTI-FOCAL " M- " = PRIMARY, MALIGNANT NEOPLASM IN ORGAN/TISSUE " F " F = FINDING FOCAL " X- " = MALIGNANT NEOPLASM - TISSUE OR ORIGIN UNKNOW

N

 " D " D = FINDING DIFFUSE " N- " = METASTATIC NEOPLASM WITHIN ORGAN/TISSUE *** GRADES FOR DEFINING SEVERITY (DEGREE) OR AMOUNT OF CHANGE *** " I- " = LOCALLY INVASIVE NEOPLASM FROM NEARBY ORGAN " NON-NEOPLASMS " " NEOPLASMS " " + " = PRESENCE OF A NEOPLASTIC FINDING IN ORGAN/TISSUE " 1 " = MINIMUM " 1 " = INCIDENTAL " +AA" = SECONDARY NEOPLASM FROM ORGAN/TISSUE INDICATED BY TWO LETTER ABBREVIATION (FOR EXAMPLE, LI=LIVER) " 2 " = MILD " 2 " = CONTRIBUTORY " +N " = MORE THAN ONE NEOPLASM OF THE SAME TYPE IN THE " 3 " = MODERATE " 3 " = FATAL SAME ORGAN, N EQUALS THE NUMBER OBSERVED " 4 " = MARKED " / " = NEOPLASM PRESENT AND RELATED TO ANIMAL DEATH *** OTHER SYMBOLS *** *** ANIMAL DEATH CODES *** " U " = ORGAN/TISSUE HISTOLOGICALLY NOT REMARKABLE " Un " = USER DEFINDED UNSCHEDULED DEATH CODES " M " = MISCELLANEOUS TISSUE " I1 " = INTERIM SACRIFICE #1 " - " = FINDING NOT PRESENT OR OBSERVED " I2 " = INTERIM SACRIFICE #2 " P " = FINDINGS PRESENT OR CONFIRMED (GRADING INAPPROPRIATE) " I3 " = INTERIM SACRIFICE #3 " * " = TISSUE NOT AVAILABLE FOR MICROSCOPIC EXAMINATION " I4 " = INTERIM SACRIFICE #4 " H " = SPECIAL HISTOLOGICAL COMMENTS ON TISSUE " I5 " = INTERIM SACRIFICE #5 " A " = TISSUE NOT READABLE - AUTOLYTIC " FS " = FINAL SACRIFICE " a " = TISSUE READABLE - AUTOLYTIC " R " = RE-CUT OF TISSUE REQUESTED " m " = ONE OF PAIRED ORGANS MISSING " I " = TISSUE INADEQUATE AND UNREADABLE

Study Number FY01-013

N-238
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-7 Individual Animal Report of Correlated Gross and Microscopic Diagnoses 

N-239
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:1 Rat/F344/N Animal: 6832E451 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 290.9 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Purple, +2/ 2 Round Cyst, Mild. Animal: 6832E452 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.5 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Enlarged, 3-5 mm, Black/ Single Round Cyst, Marked. Liver . . . . . . . Discolored, Diffuse, Mottled, +2 Congestion, Mild. Animal: 6832E453 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 707 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 219.3 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, Multiple, +1/ 2-6 N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory. Nodule, Confluent, +2/ 3-4 Raised M-Leukemia, mononuclear, Contributory. Bronchial (TBLN) . Enlarged, 3-5 mm, +1/ Diffuse N-Leukemia, mononuclear, Incidental. Lungs . . . . . . . Nodule, Right caudal, 3-5 mm, Pale, Firm, +1/ Round N-Leukemia, mononuclear - invasive involvement, Contributory. Uterus . . . . . . Mass, Right, 21-45 mm, Mottled, +2/ Irregular M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Nodule, Confluent, Mottled, +3/ 2-6 Raised M-Leukemia, mononuclear, Incidental. Mesenteric LN . . . Enlarged, Multiple, +4/ Irregular 6-10 N-Leukemia, mononuclear, Incidental. Animal: 6832E454 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 612 Dosing phase Status: Found Dead Terminal body weight (g): 273.6 Tissue Gross observations / Comments Correlated microscopic observations Cervix . . . . . . Mass, 6-10 mm, Firm, +1 Examined; no correlation found Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, 0-2 mm, Grey/ Focus, Round Cyst, Mild. Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.

Study Number FY01-013

N-240
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:2 Rat/F344/N Animal: 6832E455 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 279.2 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark/ 1 Focus Round Angiectasis, Mild. Uterus . . . . . . Prolapse, 21-45 mm, +3 B-Polyp, endometrial stromal, Incidental. Animal: 6832E456 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 272.8 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Incidental. Discolored, 0-2 mm, Pale, Gritty/ Multifocal Round Examined; no correlation found Uterus . . . . . . Enlarged, Right, 11-15 mm, Soft/ Patchy Hyperplasia, cystic endometrial, Marked. Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus, round Cyst, Minimal. Animal: 6832E457 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 588 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 201.2 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, 0-2 mm, Red/ 1 Focus Round No correlation entry made Animal: 6832E458 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 257.4 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark Red, +2/ Focus Irregular B-Adenoma, pars distalis, Incidental. Animal: 6832E459 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 626 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 90-112 mm, Mottled, Friable, +3 M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, 0-2 mm, Dark Red, +2/ Multifocus Round N-Leukemia, mononuclear - capillary involvement, Contributory. Bronchial (TBLN) . Enlarged, 6-10 mm, +2/ Diffuse N-Leukemia, mononuclear, Incidental. Mammary gland . . . Mass, Left Thoracic, 16-20 mm, White, Firm, +3/ Round B-Fibroma, Incidental.

Study Number FY01-013

N-241
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:3 Rat/F344/N Animal: 6832E459 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 626 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0 Tissue Gross observations / Comments Correlated microscopic observations (continued) Mediastinal LN . . Enlarged, 6-10 mm, +1/ Oval Diffuse N-Leukemia, mononuclear, Contributory. Mesenteric LN . . . Enlarged, 6-10 mm, +3/ Multiple Oval N-Leukemia, mononuclear, Incidental. Mandibular LN . . . Enlarged, 6-10 mm, +2/ Oval N-Leukemia, mononuclear, Incidental. Animal: 6832E460 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.6 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Dark, Soft/ Patchy Irregular Hyperplasia, focal, Moderate. Uterus . . . . . . Mass, Right, 21-45 mm, Dark, Firm/ Diffuse B-Polyp, endometrial stromal, Incidental. Animal: 6832E461 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 300.6 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Black, +2/ Foci Round Cyst, Moderate. Animal: 6832E462 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 304.3 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, 3-5 mm, Dark, +2/ Focus Irregular Cyst, Moderate. Thyroid glands . . Enlarged, Left, 6-10 mm, Dark, +1/ Diffuse M-Carcinoma, C-cell, Incidental. Animal: 6832E463 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.1 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Irregular B-Adenoma, pars distalis, Incidental.

Study Number FY01-013

N-242
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:4 Rat/F344/N Animal: 6832E464 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 217.4 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +3 M-Leukemia, mononuclear, Contributory. Small, +3 Examined; no correlation found Spleen . . . . . . Enlarged, 46-67 mm, +2 M-Leukemia, mononuclear, Contributory. Animal: 6832E466 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 682 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 237.0 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 3-5 mm, Red, Firm, +2 Hemorrhage, Mild. Lungs . . . . . . . Discolored, 0-2 mm, Dark Red, Soft, +3/ Multifocal Hemorrhage, Mild. Round Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory. Adhesion, 11-15 mm, Cloudy, +2/ Irregular Fibrosis, Mild. Animal: 6832E468 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 260.6 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Left, Diffuse, Pale/ Irregular No correlation entry made Liver . . . . . . . Deformity, Diffuse, Mottled Examined; no correlation found Urinary bladder . . Fluid, Diffuse, Cloudy, +2 No correlation entry made Animal: 6832E469 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 632 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 201.9 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round N-Leukemia, mononuclear - capillary involvement, Contributory. Spleen . . . . . . Enlarged, 46-67 mm, +2 M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory.

Study Number FY01-013

N-243
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:5 Rat/F344/N Animal: 6832E470 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 540 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 239.4 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Friable, +2/ Mottled Pale M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory. Mass, 16-20 mm, Firm/ Oval M-Leukemia, mononuclear, Contributory. Bronchial (TBLN) . Enlarged, 6-10 mm/ Pale Yellow Oval N-Leukemia, mononuclear, Incidental. Lungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round N-Leukemia, mononuclear - invasive involvement, Contributory. Discolored, Diffuse, +1/ Mottled Brown N-Leukemia, mononuclear - invasive involvement, Contributory. Animal: 6832E471 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 673 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 236.9 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Mottled, +1/ Focus Irregular Angiectasis, Moderate. Spleen . . . . . . Enlarged, 68-89 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, 0-2 mm, Red, +2/ Multifocus Round N-Leukemia, mononuclear - capillary involvement, Contributory. Animal: 6832E472 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 165.8 Tissue Gross observations / Comments Correlated microscopic observations Kidneys . . . . . . Cyst, Left, 16-20 mm, Clear, Watery/ 1 Round Cyst, Moderate. Cyst, Right, 3-5 mm, Pale, +1/ Irregular, 1 Cyst, Moderate. Animal: 6832E473 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 657 Dosing phase Status: Found Dead Terminal body weight (g): 227.3 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Discolored, Dark Red, +4 Hemorrhage, Moderate. Lungs . . . . . . . Discolored, Diffuse, Mottled Red, +3 Congestion, Mild. Ovaries . . . . . . Discolored, Bilateral, Dark Red, +3 Hemorrhage, Mild. Cervix . . . . . . Thick, +3 Examined; no correlation found

Study Number FY01-013

N-244
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:6 Rat/F344/N Animal: 6832E473 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 657 Dosing phase Status: Found Dead Terminal body weight (g): 227.3 Tissue Gross observations / Comments Correlated microscopic observations (continued) Brain . . . . . . . Deformity, 6-10 mm, Soft, +2/ Depressed Compression, Moderate. Pituitary gland . . Mass, 6-10 mm, Dark Red, Soft, +2 B-Adenoma, pars distalis, Incidental. Bronchial (TBLN) . Discolored, Dark Red, +3 Hemorrhage, Mild. Animal: 6832E474 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 632 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 189.3 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Discolored, Left, 0-2 mm, Red, +1/ Focus Round Necrosis, Mild. Kidneys . . . . . . Discolored, Right, Patchy, Mottled, +1 Nephropathy, chronic, Minimal. Liver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory. Pituitary gland . . Enlarged, 3-5 mm, Dark Red, +2/ Oval B-Adenoma, pars distalis, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, Left Lobe, 0-2 mm, Red, +1/ Multifocus N-Leukemia, mononuclear - capillary involvement, Round Contributory. Animal: 6832E475 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 260.0 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Dark, +1/ Focus Irregular Hemorrhage, Minimal. Animal: 6832E476 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 723 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 259.5 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, All Lobes, Diffuse, Mottled Red, +2 N-Leukemia, mononuclear - capillary involvement, Contributory. Spleen . . . . . . Enlarged, 68-89 mm, +4 M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Friable, +2 M-Leukemia, mononuclear, Contributory. Eyes/optic nerve . Discolored, Right, Opaque, +2 Cataract, Present.

Study Number FY01-013

N-245
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:7 Rat/F344/N Animal: 6832E477 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 588 Dosing phase Status: Found Dead Terminal body weight (g): 187.7 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Pale, Friable M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, Firm M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, All Lobes, Diffuse, Mottled, +3 N-Leukemia, mononuclear - capillary involvement, Contributory. Mesentery . . . . . Nodule, 3-5 mm, Dark Red, Rubbery/ Single Round Splenic tissue, "accessory", Present. Animal: 6832E478 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.4 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Left, Diffuse, Red, +1 No correlation entry made Animal: 6832E479 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 709 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 263.3 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Purple, +1/ Foci Round Angiectasis, Mild. Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Discolored, 0-2 mm, White, +1/ Foci Round Fibrosis, Minimal. Thyroid glands . . Cyst, Right, 3-5 mm, Yellow, +3/ Oval Hyperplasia, follicular cell, Mild. Animal: 6832E480 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 669 Dosing phase Status: Found Dead Terminal body weight (g): 225.3 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Pale, Friable, +3 Necrosis, Moderate. Lungs . . . . . . . Discolored, Left Lobe, Diffuse, Mottled Red, +2 N-Leukemia, mononuclear - capillary involvement, Incidental. Uterus . . . . . . Discolored, Bilateral, Diffuse, Dark, +3 Examined; no correlation found Animal: 6832E481 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 316 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 203.4 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Prolapse, Left, 6-10 mm, Dark Red, +4/ Round Intussusception, Present.

Study Number FY01-013

N-246
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:8 Rat/F344/N Animal: 6832E482 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 647 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 250.2 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Nodule, 3-5 mm, Mottled/ Oval Cyst, Mild. Spleen . . . . . . Enlarged, 68-89 mm/ Diffuse M-Leukemia, mononuclear, Incidental. Thyroid glands . . Enlarged, Left, 6-10 mm, Dark/ Oval B-Adenoma, C-cell, Incidental. Lungs . . . . . . . Discolored, Diffuse, Mottled, +1 N-Leukemia, mononuclear - capillary involvement, Contributory. Animal: 6832E483 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 271.8 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark Red, Soft, +1/ Single Angiectasis, Mild. Spleen . . . . . . Small, 21-45 mm, +1 Examined; no correlation found Animal: 6832E484 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 659 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 212.8 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Mass, Left Lobe, 11-15 mm/ Round Hyperplasia, hepatocellular, regenerative, Moderate. Pituitary gland . . Discolored, Single, Dark/ Round, focus B-Adenoma, pars distalis, Incidental. Spleen . . . . . . Enlarged, 21-45 mm/ Diffuse M-Leukemia, mononuclear, Contributory. Animal: 6832E485 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 483 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 211.2 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Mottled, +1 M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, 0-2 mm, Mottled, +1/ Diffuse N-Leukemia, mononuclear - capillary involvement, Contributory. Bronchial (TBLN) . Enlarged, 6-10 mm N-Leukemia, mononuclear, Incidental. Uterus . . . . . . Enlarged, +2 B-Polyp, endometrial stromal, Incidental. Mesenteric LN . . . Discolored, Diffuse, Mottled, +3 N-Leukemia, mononuclear, Incidental. Enlarged, Multiple/ Oval N-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-247
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:9 Rat/F344/N Animal: 6832E487 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 589 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 226.0 Tissue Gross observations / Comments Correlated microscopic observations Adrenal glands . . Discolored, Left, 3-5 mm, Yellow B-Pheochromocytoma, benign, Incidental. Spleen . . . . . . Enlarged, 90-112 mm, Dark Red, +3/ Single M-Leukemia, mononuclear, Contributory. Mandibular LN . . . Enlarged, 6-10 mm, Pink/ Single Oval N-Leukemia, mononuclear, Incidental. Mediastinal LN . . Enlarged, 6-10 mm, Pale/ Multiple Oval N-Leukemia, mononuclear, Incidental. Mesenteric LN . . . Enlarged, 16-20 mm, Pale/ Multiple Oval N-Leukemia, mononuclear, Incidental. Animal: 6832E488 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 681 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 220.2 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 6-10 mm Compression, Marked. Pituitary gland . . Enlarged, 6-10 mm, Mottled Red, Firm, +3/ Diffuse Angiectasis, Moderate. Irregular Animal: 6832E489 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.9 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Right, Diffuse, Red, +1 No correlation entry made Pituitary gland . . Discolored, 0-2 mm, Dark, +2/ Single Round Tan Hemorrhage, Moderate. Uterus . . . . . . Nodule, Right, 3-5 mm, Firm/ Single Round Hyperplasia, cystic endometrial, Moderate. Cervix . . . . . . Enlarged, White, Firm, +2 Examined; no correlation found Animal: 6832E490 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 223.6 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 11-15 mm, Pale, +3/ Multiple Oval N-Leukemia, mononuclear, Incidental. Mediastinum . . . . Mass, 21-45 mm, Pale, +3/ Irregular N-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Nodule, All Lobes, 3-5 mm, Pale, Firm, +3/ Multiple N-Leukemia, mononuclear - invasive involvement, Round Contributory. Spleen . . . . . . Discolored, 6-10 mm, Pale, +1/ Focus Irregular Fibrosis, Moderate. Liver . . . . . . . Discolored, 3-5 mm, Pale, +3/ Mottled Foci Round M-Leukemia, mononuclear, Contributory.

Study Number FY01-013

N-248
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:10 Rat/F344/N Animal: 6832E491 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 678 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 217.6 Tissue Gross observations / Comments Correlated microscopic observations Mandibular LN . . . Enlarged, 16-20 mm, Dark, +3/ 2 Irregular N-Leukemia, mononuclear, Incidental. Mediastinal LN . . Enlarged, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental. Lymph node other . Enlarged, Submandibular, 11-15 mm, +3/ Quant 4 N-Leukemia, mononuclear, Incidental. Enlarged, Renal, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental. Enlarged, Cervical, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental. Lungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round Hemorrhage, Mild. Bone, vertebrae . . Mass, Thoracic, 11-15 mm, Pale, Firm/ Single Irregular N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 68-89 mm, +3 M-Leukemia, mononuclear, Contributory. Urinary bladder . . Discolored, 0-2 mm, Red/ Multifocal Round Hemorrhage, Mild. Pancreatic LN . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental. Mesenteric LN . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental. Liver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory. Iliac LN . . . . . Enlarged, 6-10 mm, +3 N-Leukemia, mononuclear, Incidental. Animal: 6832E492 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 512 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 186.5 Tissue Gross observations / Comments Correlated microscopic observations Zymbal’s gland . . Mass, Right, 16-20 mm, Mottled, Firm/ Round M-Carcinoma, squamous cell, Incidental. Animal: 6832E493 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 230.8 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 68-89 mm, +4 M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Irregular M-Leukemia, mononuclear, Contributory. Pituitary gland . . Enlarged, 3-5 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental. Mediastinal LN . . Enlarged, 6-10 mm, +1/ Multiple, Irregular N-Leukemia, mononuclear, Incidental. Bronchial (TBLN) . Enlarged, 6-10 mm, +2/ Diffuse N-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-249
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:11 Rat/F344/N Animal: 6832E493 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 230.8 Tissue Gross observations / Comments Correlated microscopic observations (continued) Mesenteric LN . . . Enlarged, 3-5 mm, Dark, +2/ Multiple, Irregular N-Leukemia, mononuclear, Incidental. Animal: 6832E494 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 637 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 276.5 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, Right cranial, 0-2 mm, Brown, +1/ Focus Hyperplasia, alveolar epithelial, focal, Mild. Round Clitoral gland . . Mass, Left, 21-45 mm, Firm, +4/ Diffuse Irregular M-Carcinoma, squamous cell, Contributory. Lymph node other . Enlarged, Renal, 3-5 mm, Dark, +1/ Diffuse Oval Hemorrhage, Minimal. Animal: 6832E495 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 301.6 Tissue Gross observations / Comments Correlated microscopic observations Ovaries . . . . . . Cyst, Left, 6-10 mm, Yellow, Watery, +3/ Single Round Cyst, epithelial, Present. Uterus . . . . . . Cyst, Left, 3-5 mm, Clear, Watery, +2/ Single Round B-Polyp, endometrial stromal, Incidental. Left Upper Animal: 6832E496 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 637 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 200.1 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, 3-5 mm, Red, +2/ Patchy Cyst, Mild. Cyst, 3-5 mm, Clear Cyst, Mild. Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Incidental. Bronchial (TBLN) . Enlarged, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental. Mandibular LN . . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental. Mediastinal LN . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental. Mesenteric LN . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental. Popliteal LN . . . Enlarged, 3-5 mm, +1 N-Leukemia, mononuclear, Incidental. Iliac LN . . . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-250
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:12 Rat/F344/N Animal: 6832E496 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 637 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 200.1 Tissue Gross observations / Comments Correlated microscopic observations (continued) Pancreatic LN . . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental. Lymph node other . Enlarged, Renal, 3-5 mm, +1 N-Leukemia, mononuclear, Incidental. Animal: 6832E497 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 269.1 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Mottled, Soft, +2/ Focus Hemorrhage, Moderate. Liver . . . . . . . Mass, Left Lobe, 11-15 mm, Mottled, +2/ Single B-Adenoma, hepatocellular, Incidental. Animal: 6832E499 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 562 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 248.6 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 68-89 mm, +3 M-Leukemia, mononuclear, Contributory. Mammary gland . . . Mass, Right, 46-67 mm, +4/ Mottled Dark Irregular M-Adenocarcinoma arising in fibroadenoma, Contributory. Animal: 6832E500 Sex: Female Group: 1 Dose level: 0 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 303.6 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Patchy, Dark, +2/ Irregular Examined; no correlation found Animal: 6834F551 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 280.6 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Pale, Friable, +2/ Irregular M-Leukemia, mononuclear, Incidental. Skin . . . . . . . Mass, Thoracic, 21-45 mm, Pale, Firm/ Rt Thoracic (Mammary gland) B-Fibroma, Incidental. Animal: 6834F552 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 574 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 229.7 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, Firm, +3/ single M-Leukemia, mononuclear, Contributory.

Study Number FY01-013

N-251
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:13 Rat/F344/N Animal: 6834F552 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 574 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 229.7 Tissue Gross observations / Comments Correlated microscopic observations (continued) Adrenal glands . . Discolored, Bilateral, Diffuse, Dark Red, +4 Examined; no correlation found Uterus . . . . . . Discolored, Right, 6-10 mm, Black, Soft, +3/ focus B-Polyp, endometrial stromal, Incidental. Liver . . . . . . . Discolored, Diffuse, Pale, Oily, +4 M-Leukemia, mononuclear, Contributory. Animal: 6834F553 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 278.5 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2 M-Leukemia, mononuclear, Incidental. Animal: 6834F555 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 297.4 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Right, Diffuse, Opaque, +4/ Mottled Cataract, Present. Animal: 6834F556 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 672 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 225.7 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Pale M-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 21-45 mm/ Diffuse M-Leukemia, mononuclear, Incidental. Uterus . . . . . . Mass, Right, 21-45 mm, Dark Red/ Irregular B-Polyp, endometrial stromal, Contributory. Animal: 6834F557 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 264.6 Tissue Gross observations / Comments Correlated microscopic observations Thyroid glands . . Nodule, Left, 0-2 mm, Firm B-Adenoma, C-cell, Incidental. Uterus . . . . . . Enlarged, Bilateral, +1 Dilatation, Mild. Animal: 6834F558 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.2 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Dark, +1/ Focus Irregular B-Adenoma, pars distalis, Incidental. Liver . . . . . . . Discolored, Diffuse, Mottled, +2 Examined; no correlation found

Study Number FY01-013

N-252
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:14 Rat/F344/N Animal: 6834F559 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 245.3 Tissue Gross observations / Comments Correlated microscopic observations Tail . . . . . . . Amputation, Tip, +2 No correlation entry made Animal: 6834F561 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.0 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Nodule, 3-5 mm, Soft B-Adenoma, pars distalis, Incidental. Uterus . . . . . . Mass, Right, 6-10 mm, Dark, Soft/ 2 Round B-Adenoma, endometrial, Incidental. Vagina . . . . . . Mass, 11-15 mm, Dark, Firm/ Diffuse M-Leiomoysarcoma, Incidental. Animal: 6834F562 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 488 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 238.4 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, All Lobes, Diffuse, Pale, +2 Examined; no correlation found Bronchial (TBLN) . Discolored, Diffuse, +4/ Dark Red Hemorrhage, Moderate. Uterus . . . . . . Enlarged, Right, Diffuse, Dark Red, +3 M-Leiomyosarcoma, Contributory. Discolored, Right, Diffuse, Dark Red, +3 M-Leiomyosarcoma, Contributory. Mass, Right, 46-67 mm, Mottled Red, +4/ single M-Leiomyosarcoma, Contributory. Ovaries . . . . . . Enlarged, Left, 6-10 mm, Red Examined; no correlation found Salivary gland . . Discolored, Bilateral, Diffuse, Brown Examined; no correlation found Animal: 6834F563 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 288.7 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm/ Depressed Compression, Mild. Pituitary gland . . Cyst, 3-5 mm, Clear, Watery Cyst, Marked. Uterus . . . . . . Mass, Right, 6-10 mm, Dark, Firm/ Diffuse B-Polyp, endometrial stromal, Incidental. Mammary gland . . . Mass, Thoracic, 21-45 mm, Firm/ Right Thoracic B-Fibroadenoma, Incidental.

Study Number FY01-013

N-253
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:15 Rat/F344/N Animal: 6834F564 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 221.5 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 6-10 mm/ Depressed Compression, Mild. Discolored, 6-10 mm, Dark/ Patchy Irregular (Pituitary gland) M-Carcinoma, Incidental. Pituitary gland . . Mass, 6-10 mm, Dark, Firm/ Diffuse M-Carcinoma, Incidental. Animal: 6834F565 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 640 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 268.4 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 6-10 mm, +3 Compression, Moderate. Uterus . . . . . . Discolored, Right, 0-2 mm, Dark, Soft, +1/ Focus Oval B-Polyp, endometrial stromal, Incidental. Pituitary gland . . Mass, 6-10 mm, Mottled, Firm, +3/ Diffuse Oval B-Adenoma, pars distalis, Incidental. Mammary gland . . . Mass, Thoracic, 21-45 mm, +3 M-Adenocarcinoma, Incidental. Mass, Lumbar, 21-45 mm, +4 M-Adenocarcinoma, Incidental. Animal: 6834F566 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 508 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 226.8 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Mass, Left, 21-45 mm, Mottled Dark, Firm/ Irregular B-Polyp, endometrial stromal, Incidental. Lungs . . . . . . . Discolored, Diffuse, Pale White, +2 Examined; no correlation found Liver . . . . . . . Hernia, Medial, 6-10 mm Hepatodiaphragmatic nodule, Present. Discolored, Diffuse, +2/ Pale tan Necrosis, Moderate. Animal: 6834F567 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 710 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 282.2 Tissue Gross observations / Comments Correlated microscopic observations Mammary gland . . . Mass, Right, 46-67 mm, Mottled, Firm, +3/ Round B-Fibroadenoma, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-254
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:16 Rat/F344/N Animal: 6834F568 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 589 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 203.6 Tissue Gross observations / Comments Correlated microscopic observations Mandibular LN . . . Enlarged, 6-10 mm/ Diffuse N-Leukemia, mononuclear, Incidental. Mediastinal LN . . Enlarged, 6-10 mm/ Diffuse N-Leukemia, mononuclear, Incidental. Lungs . . . . . . . Discolored, 0-2 mm, Red, +1/ Focus Round N-Leukemia, mononuclear - capillary involvement, Incidental. Bronchial (TBLN) . Enlarged, 3-5 mm/ Diffuse N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, +3 M-Leukemia, mononuclear, Contributory. Mass, 21-45 mm, Mottled, Firm/ Diffuse Irregular M-Leukemia, mononuclear, Contributory. Mesenteric LN . . . Enlarged, 6-10 mm, +3 N-Leukemia, mononuclear, Incidental. Lymph node other . Enlarged, Submandibular, 6-10 mm N-Leukemia, mononuclear, Incidental. Enlarged, Renal, 11-15 mm N-Leukemia, mononuclear, Incidental. Ovaries . . . . . . Enlarged, Bilateral, 11-15 mm, +3 M-Leukemia, mononuclear, Contributory. Popliteal LN . . . Enlarged, 3-5 mm N-Leukemia, mononuclear, Incidental. Iliac LN . . . . . Enlarged, 6-10 mm N-Leukemia, mononuclear, Incidental. Animal: 6834F569 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 312.4 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm, +1/ Irregular Compression, Mild. Pituitary gland . . Mass, 6-10 mm, Dark, Firm, +2/ Diffuse Irregular B-Adenoma, pars distalis, Incidental. Mandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple Examined; no correlation found Cervix . . . . . . Enlarged, 6-10 mm, Firm, +2/ Diffuse Irregular Examined; no correlation found Animal: 6834F570 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 268.6 Tissue Gross observations / Comments Correlated microscopic observations Thyroid glands . . Enlarged, Left, 3-5 mm, +2 B-Adenoma, C-cell, Incidental. Cervix . . . . . . Enlarged, 11-15 mm, +3 M-Leiomyosarcoma, Incidental.

Study Number FY01-013

N-255
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:17 Rat/F344/N Animal: 6834F571 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 723 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 211.9 Tissue Gross observations / Comments Correlated microscopic observations Mammary gland . . . Mass, Right, 11-15 mm, Pale, +2/ Rt Abd Single Oval B-Fibroma, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Pale, +3 M-Leukemia, mononuclear, Contributory. Animal: 6834F572 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 688 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 256.4 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Right, Diffuse, Cloudy, +3 Atrophy, Marked. Cataract, Present. Mediastinal LN . . Enlarged, 6-10 mm, +3 N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 68-89 mm, +3 M-Leukemia, mononuclear, Contributory. Discolored, 16-20 mm, Mottled/ Patchy Irregular Necrosis, Marked. Pancreatic LN . . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental. Animal: 6834F573 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Dark/ Single Oval B-Adenoma, pars distalis, Incidental. Uterus . . . . . . Mass, Left, 6-10 mm, Firm/ Single Oval B-Polyp, endometrial stromal, Incidental. Animal: 6834F574 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.2 Tissue Gross observations / Comments Correlated microscopic observations Cervix . . . . . . Enlarged, 6-10 mm, +2 Examined; no correlation found Animal: 6834F575 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 309.2 Tissue Gross observations / Comments Correlated microscopic observations Cervix . . . . . . Enlarged, 6-10 mm, +2 Examined; no correlation found Spleen . . . . . . Small, 21-45 mm, Mottled Red, +2 Examined; no correlation found

Study Number FY01-013

N-256
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:18 Rat/F344/N Animal: 6834F575 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 309.2 Tissue Gross observations / Comments Correlated microscopic observations (continued) Liver . . . . . . . Hernia, Median Lobe, 3-5 mm, +1 Hepatodiaphragmatic nodule, Present. Animal: 6834F576 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 685 Dosing phase Status: Found Dead Terminal body weight (g): 212.6 Tissue Gross observations / Comments Correlated microscopic observations Skin . . . . . . . Mass, 6-10 mm, Hard, +1/ Right Side Irregular Cyst, epithelial inclusion, Present. Lungs . . . . . . . Discolored, 3-5 mm, Dark Red, +2/ Multifocus Round Hemorrhage, Mild. Spleen . . . . . . Discolored, 11-15 mm, Yellow, +1/ Irregular Mottled M-Leukemia, mononuclear, Contributory. yellow Enlarged, 46-67 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Mass, Right, 16-20 mm, Mottled Red, Firm, +3/ M-Adenocarcinoma, endometrial, Contributory. Irregular Cervix . . . . . . Enlarged, Diffuse, +2 N-Adenocarcinoma, endometrial, Incidental. Liver . . . . . . . Thick, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory. Adrenal glands . . Enlarged, Left, 6-10 mm, Mottled, +2/ Diffuse B-Pheochromocytoma, benign, Incidental. Brain . . . . . . . Deformity, 6-10 mm, +2 Compression, Moderate. Pituitary gland . . Mass, 6-10 mm, +2/ Diffuse B-Adenoma, pars distalis, Incidental. Animal: 6834F577 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 708 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 248.1 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Hernia, Median Lobe, 3-5 mm, Mottled, +3/ Irregular Hepatodiaphragmatic nodule, Present. Pituitary gland . . Enlarged, Diffuse, Mottled, +2 B-Adenoma, pars distalis, Incidental. M-Leukemia, mononuclear, Incidental. Spleen . . . . . . Nodule, 3-5 mm, Mottled, +2/ Confluent M-Leukemia, mononuclear, Contributory. Mediastinal LN . . Enlarged, Multiple, +2/ 2-4 Irregular N-Leukemia, mononuclear, Incidental. Pancreatic LN . . . Enlarged, 6-10 mm, +3/ Multiple Irregular No correlation entry made Iliac LN . . . . . Enlarged, Left, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-257
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:19 Rat/F344/N Animal: 6834F578 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 664 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 218.3 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Hernia, Median Lobe, Firm Hepatodiaphragmatic nodule, Present. Animal: 6834F579 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 299.6 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm/ Depressed Compression, Minimal. Liver . . . . . . . Discolored, Diffuse, Mottled, Friable M-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Incidental. Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Patchy Irregular B-Adenoma, pars distalis, Incidental. Animal: 6834F580 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 296.3 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark/ 1 Focus Round B-Adenoma, pars distalis, Incidental. Animal: 6834F581 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 729 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 207.5 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Brown, +4/ Red M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Animal: 6834F582 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 636 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 248.6 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Round Examined; no correlation found Uterus . . . . . . Mass, Right, 46-67 mm, Mottled, Firm, +4/ Diffuse B-Polyp, endometrial stromal, Contributory. Irregular Animal: 6834F584 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 6-10 mm, +4/ Round Compression, Moderate.

Study Number FY01-013

N-258
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:20 Rat/F344/N Animal: 6834F584 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5 Tissue Gross observations / Comments Correlated microscopic observations (continued) Brain . . . . . . . Discolored, Patchy, Dark Red, +2/ Irregular Hemorrhage, Mild. Liver . . . . . . . Mass, 6-10 mm, Pale, Firm, +4/ Multiple Irregular Hyperplasia, hepatocellular, regenerative, Mild. Thick, Red, +4 M-Leukemia, mononuclear, Incidental. Pituitary gland . . Mass, 6-10 mm, Purple, +4/ Round B-Adenoma, pars distalis, Incidental. Animal: 6834F585 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 234.6 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Left, Diffuse, Opaque, +2 Cataract, Present. Pituitary gland . . Discolored, 3-5 mm, +1/ Multifocus Irregular Hyperplasia, focal, Moderate. Animal: 6834F586 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 286.9 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, Diffuse, Mottled Red, +2 Examined; no correlation found Animal: 6834F589 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 267.9 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, 0-2 mm, White, +2/ Single Focus Necrosis, Mild. Discolored, Diffuse, Pale, Friable, +3 M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, Dark Red, +2 M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Enlarged, Left, 3-5 mm, Purple, +4/ Oval B-Polyp, endometrial stromal, Incidental. Animal: 6834F590 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 350 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 234.0 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Prolapse, Red, +3 Intussusception, Present.

Study Number FY01-013

N-259
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:21 Rat/F344/N Animal: 6834F591 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.1 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled Red, +1/ Irregular M-Leukemia, mononuclear, Incidental. Animal: 6834F592 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 274.7 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Nodule, Left Lobe, 3-5 mm, Pale, Firm/ Single Round Fibrosis, focal, Mild. Hyperplasia, alveolar epithelial, focal, Mild. Animal: 6834F593 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 725 Dosing phase Status: Found Dead Terminal body weight (g): 257.4 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Enlarged, 6-10 mm, Purple, Soft, +4/ Round B-Adenoma, pars distalis, Incidental. Brain . . . . . . . Deformity, 6-10 mm, Pale, Soft, +4 Compression, Mild. Animal: 6834F594 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 589 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 299.0 Tissue Gross observations / Comments Correlated microscopic observations Clitoral gland . . Mass, 46-67 mm, Soft/ Irregular (Mammary gland) B-Fibroadenoma, Contributory. Uterus . . . . . . Nodule, Right, 3-5 mm, Dark, Firm/ Round B-Polyp, endometrial stromal, Incidental. Pituitary gland . . Nodule, 0-2 mm, Dark/ Focus Round B-Adenoma, pars distalis, Incidental. Animal: 6834F595 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 488 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 214.2 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Dilatation, Right, 16-20 mm, Red B-Polyp, endometrial stromal, Incidental. Cervix . . . . . . Thick, 11-15 mm, Pale Examined; no correlation found Animal: 6834F596 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 262.2 Tissue Gross observations / Comments Correlated microscopic observations Mandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple Irregular N-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-260
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:22 Rat/F344/N Animal: 6834F596 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 262.2 Tissue Gross observations / Comments Correlated microscopic observations (continued) Ovaries . . . . . . Mass, Right, 6-10 mm, Mottled, Firm, +2/ Diffuse Necrosis, mesenteric fat, Mild. Irregular Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Angiectasis, Moderate. Liver . . . . . . . Hernia, Median Lobe, 6-10 mm, Firm, +2/ Irregular Hepatodiaphragmatic nodule, Present. Animal: 6834F599 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 561 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 200.0 Tissue Gross observations / Comments Correlated microscopic observations Adrenal glands . . Discolored, Diffuse, Dark Red, +4 M-Leukemia, mononuclear, Incidental. Kidneys . . . . . . Discolored, Diffuse, Black, +4 Pigment accumulation, tubular epithelium, Moderate. Liver . . . . . . . Discolored, All Lobes, Diffuse, Pale, +2 M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, Firm, +3 M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, All Lobes, Diffuse, +2/ Pale Yellow N-Leukemia, mononuclear - capillary involvement, Contributory. Animal: 6834F600 Sex: Female Group: 2 Dose level: 2 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 280.6 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Red, +1/ Irregular B-Adenoma, pars distalis, Incidental. Animal: 6836G651 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 262.8 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Mass, Right, 16-20 mm, Soft/ Single Oval B-Polyp, endometrial stromal, Incidental. Animal: 6836G652 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.7 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark Red, Soft/ Single Round Cyst, Moderate.

Study Number FY01-013

N-261
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:23 Rat/F344/N Animal: 6836G653 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 489 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 207.9 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark Red/ Focus Cyst, Mild. Thyroid glands . . Mass, Right, 11-15 mm, Mottled, Firm/ Oval M-Carcinoma, follicular cell, Contributory. Esophagus . . . . . Discolored, 6-10 mm, Dark Red/ Oval Examined; no correlation found Liver . . . . . . . Nodule, Median Lobe, 3-5 mm, Pale/ Single Round Examined; no correlation found Lymph node other . Enlarged, Cervical, 3-5 mm, Dark Red, Firm Examined; no correlation found Animal: 6836G654 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 238.3 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Right, Diffuse, Red, +1 No correlation entry made Brain . . . . . . . Deformity, 6-10 mm/ Single Depression Compression, Marked. Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental. Animal: 6836G655 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 259.9 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Left, Diffuse, Red, +1 No correlation entry made Brain . . . . . . . Deformity, 3-5 mm/ Single Depressed Compression, Mild. Liver . . . . . . . Discolored, Diffuse, Mottled Red, Friable, +2/ M-Leukemia, mononuclear, Incidental. Irregular Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Round B-Adenoma, pars distalis, Incidental. Animal: 6836G657 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.5 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark/ Focus Round B-Adenoma, pars distalis, Incidental. Ovaries . . . . . . Discolored, Left, 0-2 mm, Dark/ Patchy Irregular Cyst, rete ovarii, Mild. Cervix . . . . . . Enlarged, +1 Examined; no correlation found

Study Number FY01-013

N-262
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:24 Rat/F344/N Animal: 6836G659 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 730 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 232.0 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Pale M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 90-112 mm, +4 M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Nodule, Bilateral, 3-5 mm, Dark, Firm, +1/ 2 Oval Angiectasis, Mild. Animal: 6836G660 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 295.8 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 3-5 mm, Pale/ Diffuse Round Infiltration, histiocytic. Lungs . . . . . . . Discolored, Patchy, Dark, +2/ Irregular N-Sarcoma, histiocytic, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, +1 N-Sarcoma, histiocytic, Incidental. Discolored, 3-5 mm, Pale/ Focus Round N-Sarcoma, histiocytic, Incidental. Uterus . . . . . . Discolored, Left, 6-10 mm, Dark/ Patchy B-Polyp, endometrial stromal, Incidental. Liver . . . . . . . Discolored, Diffuse, Mottled, +4 M-Sarcoma. histiocytic, Incidental. Nodule, 3-5 mm, Pale, Firm/ Multiple Irregular M-Sarcoma. histiocytic, Incidental. Kidneys . . . . . . Discolored, Left, 0-2 mm, Pale/ 2-foci Round Nephropathy, chronic, Moderate. N-Sarcoma, histiocytic, Incidental. Animal: 6836G661 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.0 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Mass, Right, 21-45 mm, Red, Soft, +4/ Single Oval B-Polyp, endometrial stromal, Incidental. Ovaries . . . . . . Cyst, Left, 6-10 mm, Yellow, Watery, +4/ Single Round Cyst, follicular, Present. Animal: 6836G663 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, Patchy, Black, +1/ Irregular B-Adenoma, pars distalis, Incidental.

Study Number FY01-013

N-263
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:25 Rat/F344/N Animal: 6836G664 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 562 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Round Cyst, Mild. Animal: 6836G665 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 511 Dosing phase Status: Found Dead Terminal body weight (g): 191.0 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, All Lobes, Diffuse, Dark Red, +4 Congestion, Mild. Uterus . . . . . . Discolored, Right Horn, Diffuse, Black, +4/ Left Horn B-Polyp, endometrial stromal, Incidental. Brain . . . . . . . Deformity, 6-10 mm/ Depressed Compression, Moderate. Pituitary gland . . Mass, 6-10 mm, Dark Red, Soft/ Round B-Adenoma, pars distalis, Incidental. Ovaries . . . . . . Discolored, Diffuse, Red, +3 Congestion, Mild. Animal: 6836G666 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 226.0 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Small, Left, Diffuse, +1/ Irregular Examined; no correlation found Brain . . . . . . . Deformity, 6-10 mm, +2/ Irregular Compression, Moderate. Pituitary gland . . Mass, 6-10 mm, Dark, Firm, +2/ Diffuse Irregular B-Adenoma, pars distalis, Incidental. Mandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple Irregular Examined; no correlation found Uterus . . . . . . Mass, Right, 11-15 mm, Firm, +2/ Irregular B-Polyp, endometrial stromal, Incidental. Skin . . . . . . . Crust, Irregular, Dark Red, Hard, +1/ Left eye Fibrosis, Moderate. Animal: 6836G667 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 271.4 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, Diffuse, Mottled Red, +2 Examined; no correlation found Uterus . . . . . . Mass, Left, 6-10 mm, Pale, Firm B-Polyp, endometrial stromal, Incidental.

Study Number FY01-013

N-264
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:26 Rat/F344/N Animal: 6836G668 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 212.8 Tissue Gross observations / Comments Correlated microscopic observations Cervix . . . . . . Enlarged, 6-10 mm, +2/ Diffuse Examined; no correlation found Adrenal glands . . Enlarged, Right, 6-10 mm, +1/ Diffuse B-Pheochromocytoma, benign, Incidental. Animal: 6836G669 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.3 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Discolored, Right, 11-15 mm, Mottled, +2/ Focus B-Polyp, endometrial stromal, Incidental. Irregular Thick, Right, Mottled, Soft, +3/ Lower B-Polyp, endometrial stromal, Incidental. Clitoral gland . . Mass, Left, 11-15 mm, Mottled, Firm, +3/ Single Round B-Adenoma, Incidental. Pituitary gland . . Enlarged, 3-5 mm, Purple, Soft, +3/ Round B-Adenoma, pars distalis, Incidental. Brain . . . . . . . Deformity, 3-5 mm, +3/ Round Compression, Mild. Animal: 6836G670 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 267.4 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Mass, Left, 11-15 mm, Soft/ Single Oval Hyperplasia, cystic endometrial, Moderate. Animal: 6836G671 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 548 Dosing phase Status: Found Dead Terminal body weight (g): 240.6 Tissue Gross observations / Comments Correlated microscopic observations Duodenum . . . . . Discolored, Diffuse, Dark Red, +3 Examined; no correlation found Ileum . . . . . . . Discolored, Diffuse, Dark Red, +3 Examined; no correlation found Jejunum . . . . . . Discolored, Diffuse, Dark Red, +3 Examined; no correlation found Uterus . . . . . . Mass, 21-45 mm, Red, Soft, +4/ Single Irregular M-Leiomyosarcoma, Contributory. Animal: 6836G672 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 283.2 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Purple, +3/ Foci Oval B-Adenoma, pars distalis, Incidental. Mandibular LN . . . Enlarged, 11-15 mm, White, Firm, +3/ Single Oval (Mammary gland) B-Fibroadenoma, Incidental.

Study Number FY01-013

N-265
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:27 Rat/F344/N Animal: 6836G672 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 283.2 Tissue Gross observations / Comments Correlated microscopic observations (continued) Mammary gland . . . Mass, Right, 21-45 mm, Mottled, Firm, +3/ Single Oval B-Fibroadenoma, Incidental. Upper Right Animal: 6836G673 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.1 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round Examined; no correlation found Uterus . . . . . . Enlarged, Bilateral, +1 Dilatation, Minimal. Cervix . . . . . . Enlarged, Firm, +1 Examined; no correlation found Animal: 6836G674 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 287.6 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Cyst, Left, 6-10 mm, Opaque, Watery/ Single Oval Hyperplasia, cystic endometrial, Moderate. Animal: 6836G675 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 257.6 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Purple, +2/ Single Irregular Cyst, Moderate. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Incidental. Ovaries . . . . . . Cyst, Right, 6-10 mm, Yellow, Watery, +2/ Single Round Cyst, bursa, Present. Animal: 6836G676 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 654 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 232.8 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, All Lobes, Diffuse, Mottled, +1 N-Leukemia, mononuclear - capillary involvement, Contributory. Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +2 M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Enlarged, Bilateral, 11-15 mm, Pale, +3/ Oval B-Polyp, endometrial stromal, Incidental. Pituitary gland . . Discolored, 11-15 mm, Purple, +1/ Foci Irregular Angiectasis, Moderate.

Study Number FY01-013

N-266
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:28 Rat/F344/N Animal: 6836G677 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 268.4 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, Diffuse, Mottled Red, +2 Examined; no correlation found Animal: 6836G678 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 696 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 235.4 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Enlarged, 3-5 mm, Purple, Firm, +2/ Round B-Adenoma, pars distalis, Incidental. Clitoral gland . . Mass, 11-15 mm, Purple, Firm, +3/ Single Irregular N-Adenocarcinoma, Incidental. Animal: 6836G679 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 654 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 217.4 Tissue Gross observations / Comments Correlated microscopic observations Mammary gland . . . Discolored, Diffuse, Brown, +2 Examined; no correlation found Pituitary gland . . Mass, 6-10 mm, Firm B-Adenoma, pars distalis, Incidental. Brain . . . . . . . Deformity, 6-10 mm Compression, Moderate. Animal: 6836G680 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 645 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 213.1 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 68-89 mm/ Diffuse M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory. Lymph node other . Enlarged, Renal, 6-10 mm, Firm/ Oval Bilateral N-Leukemia, mononuclear, Incidental. Pituitary gland . . Discolored, 0-2 mm, Dark/ 1 Focus Round Cyst, Mild. Animal: 6836G681 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 272.3 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Examined; no correlation found

Study Number FY01-013

N-267
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:29 Rat/F344/N Animal: 6836G682 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 647 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.1 Tissue Gross observations / Comments Correlated microscopic observations Mandibular LN . . . Enlarged, 6-10 mm, Pale, +3/ Oval Multiple N-Leukemia, mononuclear, Incidental. Mediastinal LN . . Enlarged, 6-10 mm, Pale, +4/ Multiple Oval N-Leukemia, mononuclear, Incidental. Bronchial (TBLN) . Enlarged, 6-10 mm, Pale, +4/ Oval N-Leukemia, mononuclear, Incidental. Lungs . . . . . . . Discolored, All Lobes, Round, Brown, +4/ Foci N-Leukemia, mononuclear - invasive involvement, Contributory. Lymph node other . Enlarged, Axillary, 11-15 mm, Pale, +3/ Oval N-Leukemia, mononuclear, Incidental. Enlarged, Renal, 6-10 mm, Pale, +3/ Multiple N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory. Thick, Mottled, +3 M-Leukemia, mononuclear, Contributory. Mesenteric LN . . . Enlarged, 6-10 mm, Pale, +4/ Multiple N-Leukemia, mononuclear, Incidental. Pancreatic LN . . . Enlarged, 6-10 mm, Pale, +3/ Multiple N-Leukemia, mononuclear, Incidental. Iliac LN . . . . . Enlarged, Left, 6-10 mm, +2/ Single N-Leukemia, mononuclear, Incidental. Discolored, Left, Black, +3 Examined; no correlation found Animal: 6836G683 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 702 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 240.7 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Dilatation, Right, 6-10 mm, Mottled, +2/ Lower Right Dilatation, Mild. B-Polyp, endometrial stromal, Incidental. Mass, Right, 46-67 mm, Purple, +4/ Upper Right Oval B-Polyp, endometrial stromal, Incidental. Harderian gland . . Discolored, Right, Diffuse, Mottled, +3 Pigment, Mild. Pituitary gland . . Discolored, 0-2 mm, Purple, +1/ Single Round Angiectasis, Mild.

Study Number FY01-013

N-268
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:30 Rat/F344/N Animal: 6836G684 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 287.6 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Red, +2/ Focus Round Hyperplasia, focal, Mild. Tiss.not specifi . Mass, Neck, 6-10 mm, Mottled, Firm, +1/ Oval (Mammary gland) B-Fibroadenoma, Incidental. Subcutaneous Animal: 6836G685 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 540 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 186.6 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Pale M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, Black, +4/ Focus Angiectasis, Moderate. Spleen . . . . . . Enlarged, 46-67 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory. Animal: 6836G686 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 231.0 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm, +3/ Diffuse M-Leukemia, mononuclear, Incidental. Thyroid glands . . Enlarged, Right, 6-10 mm, Dark, Firm, +2/ Diffuse B-Adenoma, C-cell, Incidental. Irregular Lungs . . . . . . . Nodule, Right caudal, 0-2 mm, Clear, Firm, +2/ Round N-Leukemia, mononuclear - invasive involvement, Incidental. Bronchial (TBLN) . Enlarged, 6-10 mm, +3/ Diffuse Irregular Inflammation, mixed, Minimal. Animal: 6836G687 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0 Tissue Gross observations / Comments Correlated microscopic observations Mammary gland . . . Mass, Left, 21-45 mm, Dark, Firm/ Irregular M-Adenocarcinoma, Incidental. Spleen . . . . . . Enlarged, 46-67 mm/ Diffuse M-Leukemia, mononuclear, Contributory. Clitoral gland . . Mass, Left, 21-45 mm, Mottled, Firm/ Diffuse Irregular N-Adenocarcinoma, Incidental. Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory. Brain . . . . . . . Deformity, 6-10 mm Compression, Moderate. Pituitary gland . . Mass, 6-10 mm, Dark, Firm/ Diffuse Irregular B-Adenoma, pars distalis, Incidental.

Study Number FY01-013

N-269
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:31 Rat/F344/N Animal: 6836G688 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 666 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 246.4 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 6-10 mm, +1 B-Thymoma, Incidental. Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory. Pancreatic LN . . . Enlarged, 3-5 mm, +1 N-Leukemia, mononuclear, Incidental. Iliac LN . . . . . Enlarged, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental. Bone, other . . . . Deformity, Rt Fore Paw, +3 Fracture, Present. Animal: 6836G689 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 241.1 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Right, Diffuse, Red, +1 Examined; no correlation found Pituitary gland . . Discolored, Surface, 3-5 mm, Black/ Single Round Cyst, Moderate. Tail . . . . . . . Crust, Surface, Diffuse, Brown, Hard, +4/ Irregular Hyperplasia/hyperkeratosis, Moderate. Brown/Tan Animal: 6836G690 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 236.8 Tissue Gross observations / Comments Correlated microscopic observations Uterus . . . . . . Mass, Right, 6-10 mm, Mottled, Firm, +2/ Single Hyperplasia, cystic endometrial, Mild. Animal: 6836G692 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 244.1 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm/ Single Depressed Compression, Mild. Pituitary gland . . Enlarged, 3-5 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental. Lungs . . . . . . . Nodule, Left Lobe, 3-5 mm, Tan, Firm/ Single Round Examined; no correlation found Animal: 6836G693 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 658 Dosing phase Status: Found Dead Terminal body weight (g): 260.8 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, Diffuse, Mottled Red, +4 Examined; no correlation found Adrenal glands . . Mass, Right, 21-45 mm, Mottled, Firm, +4/ Irregular B-Pheochromocytoma, benign, Contributory.

Study Number FY01-013

N-270
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:32 Rat/F344/N Animal: 6836G693 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 658 Dosing phase Status: Found Dead Terminal body weight (g): 260.8 Tissue Gross observations / Comments Correlated microscopic observations (continued) Cavities . . . . . Fluid, Abdominal, Dark Red, Gelatinous, +3 No correlation entry made Animal: 6836G694 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 255.8 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Single Round B-Adenoma, pars distalis, Incidental. Thyroid glands . . Enlarged, Left, 3-5 mm, +2/ Single Round B-Adenoma, C-cell, Incidental. Animal: 6836G695 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 661 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 204.4 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Enlarged, 6-10 mm, Purple, +3/ Irregular B-Adenoma, pars distalis, Incidental. Brain . . . . . . . Deformity, 6-10 mm, +3/ Irregular Compression, Marked. Discolored, 3-5 mm, Purple, +2/ Foci Round (Pituitary gland) B-Adenoma, pars intermedia, Contributory. Animal: 6836G697 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 252.0 Tissue Gross observations / Comments Correlated microscopic observations Mammary gland . . . Mass, Thoracic, 11-15 mm, Firm/ Rt Thoracic B-Fibroma, Incidental. Animal: 6836G698 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 625 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 226.0 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 3-5 mm, Pale, +3/ Multiple, oval N-Leukemia, mononuclear, Incidental. Bronchial (TBLN) . Enlarged, 6-10 mm, Pale, +3/ Single, oval N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Animal: 6836G699 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 114 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 153.9 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Left, White, +4 Cataract, Present.

Study Number FY01-013

N-271
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:33 Rat/F344/N Animal: 6836G699 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 114 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 153.9 Tissue Gross observations / Comments Correlated microscopic observations (continued) Tiss.not specifi . Malocclusion, Teeth, +3 No correlation entry made Animal: 6836G700 Sex: Female Group: 3 Dose level: 10 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 209.6 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Small, 21-45 mm, +2 Examined; no correlation found Uterus . . . . . . Mass, Bilateral, 16-20 mm, Mottled, Firm, +3/ Mult B-Polyp, endometrial stromal, Incidental. Oval Animal: 6838H751 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 659 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 197.9 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Mass, 21-45 mm, Mottled, +4/ Multiple Round M-Sarcoma. histiocytic, Contributory. Spleen . . . . . . Enlarged, 21-45 mm, +2 Examined; no correlation found Lungs . . . . . . . Discolored, Patchy, Dark, +3 N-Sarcoma, histiocytic, Contributory. Animal: 6838H752 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 687 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 216.2 Tissue Gross observations / Comments Correlated microscopic observations Mandibular LN . . . Enlarged, 6-10 mm, Firm, +2/ Multiple Irregular N-Leukemia, mononuclear, Incidental. Mediastinal LN . . Enlarged, 6-10 mm, Firm, +2/ Multiple Irregular N-Leukemia, mononuclear, Incidental. Bronchial (TBLN) . Enlarged, 3-5 mm, +2/ Diffuse Irregular N-Leukemia, mononuclear, Incidental. Lymph node other . Enlarged, Submandibular, 16-20 mm, Dark Red, Firm, +3/ N-Leukemia, mononuclear, Incidental. Multiple Irregular Bilateral Enlarged, Renal, 6-10 mm, Firm, +2/ Multiple Bilateral N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 68-89 mm, +3/ Diffuse M-Leukemia, mononuclear, Contributory. Ovaries . . . . . . Enlarged, Bilateral, Diffuse, +1 M-Leukemia, mononuclear, Incidental. Uterus . . . . . . Mass, Right, 16-20 mm, Dark, Soft, +2/ Irregular Dilatation, Marked. Mesenteric LN . . . Enlarged, 21-45 mm, Firm, +2/ Irregular N-Leukemia, mononuclear, Incidental. Pancreatic LN . . . Enlarged, 16-20 mm, Firm, +2 N-Leukemia, mononuclear, Incidental.

Study Number FY01-013

N-272
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:34 Rat/F344/N Animal: 6838H753 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 715 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 188.8 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 6-10 mm, +1/ Diffuse Irregular M-Carcinoma, metastatic, Incidental. Thyroid glands . . Enlarged, Bilateral, 3-5 mm, +2/ Multiple Examined; no correlation found Lungs . . . . . . . Nodule, 3-5 mm, Pale, Firm, +3/ Multiple Irregular N-Carcinoma, metastatic, Contributory. Mass, Right middle, 3-5 mm, Pale, Firm, +3/ Irregular N-Carcinoma, metastatic, Contributory. Discolored, Diffuse, Mottled, +4 N-Carcinoma, metastatic, Contributory. Stomach . . . . . . Mass, 16-20 mm, Pale, Firm/ Irregular M-Carcinoma, metastatic, Incidental. Uterus . . . . . . Mass, Bilateral, 21-45 mm, Pale, Firm M-Adenocarcinoma, endometrial, Contributory. Dilatation, Bilateral, Irregular, Dark, Soft, +4 Dilatation, Marked. Animal: 6838H754 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 267.9 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm/ Depressed Compression, Mild. Pituitary gland . . Mass, 3-5 mm, Dark, Soft/ Single B-Adenoma, pars distalis, Incidental. Animal: 6838H755 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 229.6 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Left, Patchy, Red, +1 Examined; no correlation found Kidneys . . . . . . Cyst, Left, 11-15 mm, Opaque, Watery/ Single Oval Cyst, Moderate. Animal: 6838H756 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 250.7 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Hernia, Median Lobe, 11-15 mm/ Irregular Hepatodiaphragmatic nodule, Present. Lungs . . . . . . . Discolored, 0-2 mm, Pale, Soft/ Multifocal Round Examined; no correlation found Mammary gland . . . Mass, Right, 21-45 mm, Firm/ Right Abdominal B-Fibroadenoma, Incidental.

Study Number FY01-013

N-273
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:35 Rat/F344/N Animal: 6838H757 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 701 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 183.6 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Cavities . . . . . Fluid, Abdominal, 2.1-5.0 ml, Red, +2 No correlation entry made Kidneys . . . . . . Cyst, Right, +3 Cyst, Moderate. Uterus . . . . . . Focus, Right, 0-2 mm, Purple, +1/ round B-Polyp, endometrial stromal, Incidental. Pituitary gland . . Focus, 0-2 mm, Purple, +1/ round Hemorrhage, Minimal. Animal: 6838H758 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 247.8 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Left Lobe, 0-2 mm, Pale/ Focus Round Examined; no correlation found Animal: 6838H759 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 230.5 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Cyst, 0-2 mm, Grey, Watery, +2/ Single Oval Cyst, Mild. Tail . . . . . . . Crust, 6-10 mm, Brown, Hard, +4/ Multiple Irregular Hyperplasia/hyperkeratosis, Marked. Ovaries . . . . . . Cyst, Left, 6-10 mm, Yellow, Watery, +3/ Single Round Cyst, bursa, Present. Animal: 6838H761 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 244.4 Tissue Gross observations / Comments Correlated microscopic observations Mandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple N-Leukemia, mononuclear, Incidental. Mammary gland . . . Mass, Left, 11-15 mm, Firm, +2 B-Fibroadenoma, Incidental. Spleen . . . . . . Enlarged, 21-45 mm, +2/ Diffuse Irregular M-Leukemia, mononuclear, Incidental. Bone, rib . . . . . Mass, Left, 11-15 mm, Mottled, Firm, +3/ Irregular M-Osteosarcoma, Incidental. Animal: 6838H762 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 237.7 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 0-2 mm/ Single Depressed Compression, Mild.

Study Number FY01-013

N-274
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:36 Rat/F344/N Animal: 6838H762 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 237.7 Tissue Gross observations / Comments Correlated microscopic observations (continued) Eyes/optic nerve . Crust, Left, Diffuse, Red, +1 No correlation entry made Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Irregular Examined; no correlation found Kidneys . . . . . . Cyst, Left, 6-10 mm, Opaque, Watery/ Single Oval Cyst, Mild. Pituitary gland . . Enlarged, 3-5 mm, Dark, Soft/ Single Round Angiectasis, Marked. Animal: 6838H763 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 490 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 229.8 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Pale, +3 Necrosis, Moderate. Uterus . . . . . . Enlarged, Left, 46-67 mm, Soft/ Dark Red/Black B-Polyp, endometrial stromal, Contributory. Irregular Animal: 6838H764 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 526 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 186.0 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory. Animal: 6838H766 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 478 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 198.3 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 68-89 mm M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, Multiple, Mottled Red, +2 Hemorrhage, Mild. Animal: 6838H767 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 251.5 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Right, Diffuse, Opaque, +3 Atrophy, Marked. Spleen . . . . . . Enlarged, 46-67 mm, +2 M-Leukemia, mononuclear, Incidental. Uterus . . . . . . Mass, Right, Oval, Red, Firm, +2 B-Polyp, endometrial stromal, Incidental.

Study Number FY01-013

N-275
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:37 Rat/F344/N Animal: 6838H768 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.4 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Dark, +2/ Multifocus Irregular Angiectasis, Moderate. Liver . . . . . . . Thick, Left Lobe, Patchy, +2/ Irregular M-Leukemia, mononuclear, Incidental. Animal: 6838H769 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 232.5 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm/ Single Depressed Compression, Mild. Pituitary gland . . Enlarged, 3-5 mm, Dark/ Single Round B-Adenoma, pars distalis, Incidental. Uterus . . . . . . Intussusception, Right, Single Intussusception, Present. Cervix . . . . . . Mass, 11-15 mm, Dark, Firm/ Single Round B-Polyp, endometrial stromal, Incidental. Animal: 6838H770 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 661 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 198.8 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 6-10 mm, +2/ Oval N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 46-67 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Mass, Bilateral, 3-5 mm, Pale, Firm/ 2 Round B-Polyp, endometrial stromal, Incidental. Discolored, Left, 6-10 mm, Dark, Soft, +3 B-Polyp, endometrial stromal, Incidental. Ovaries . . . . . . Small, Bilateral, +3 Examined; no correlation found Pituitary gland . . Discolored, 3-5 mm, Purple, +1/ Focus Irregular B-Adenoma, pars distalis, Incidental. Animal: 6838H771 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 217.7 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Hernia, Median Lobe, 6-10 mm, +2/ Multiple Irregular Hepatodiaphragmatic nodule, Present. Lungs . . . . . . . Discolored, Left Lobe, 3-5 mm, White, +1/ Focus Alveolar histiocytosis, Minimal. Irregular Cervix . . . . . . Enlarged, 6-10 mm, +1/ Diffuse Examined; no correlation found

Study Number FY01-013

N-276
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:38 Rat/F344/N Animal: 6838H772 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 729 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 185.1 Tissue Gross observations / Comments Correlated microscopic observations Ovaries . . . . . . Small, Right, 0-2 mm, +2 Examined; no correlation found Uterus . . . . . . Mass, Right, 6-10 mm, Pale, Firm/ Single Irregular B-Polyp, endometrial stromal, Incidental. Spleen . . . . . . Discolored, Diffuse, Mottled Red, +2 Necrosis, Marked. M-Leukemia, mononuclear, Contributory. Ileum . . . . . . . Discolored, 3-5 mm, Red, Soft, +2/ Multifoci Oval N-Leukemia, mononuclear, Incidental. Liver . . . . . . . Discolored, Diffuse, Mottled Red, Friable, +2 M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, Left Lobe, 0-2 mm, Pale, Soft/ Single Hyperplasia, alveolar epithelial, focal, Mild. Round Animal: 6838H773 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.8 Tissue Gross observations / Comments Correlated microscopic observations Mammary gland . . . Mass, Left Inguinal, 46-67 mm, Mottled, Firm, +3/ B-Fibroadenoma, Incidental. Irregular Animal: 6838H774 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 489 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 190.1 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, 0-2 mm, Dark, Soft/ Multifoci Hemorrhage, Minimal. N-Leukemia, mononuclear - capillary involvement, Contributory. Animal: 6838H775 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 688 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 191.6 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.

Study Number FY01-013

N-277
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:39 Rat/F344/N Animal: 6838H776 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 261.4 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Crust, Right, Diffuse, Red, +1 No correlation entry made Lungs . . . . . . . Discolored, All Lobes, 0-2 mm, Red, +1/ Diffuse Round Examined; no correlation found Thyroid glands . . Discolored, Left, 0-2 mm, Dark/ Round, 2 quantity Hyperplasia, C-cell, focal, Moderate. Animal: 6838H777 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.5 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Left, Diffuse, Opaque, +3 Cataract, Present. Animal: 6838H778 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 218.1 Tissue Gross observations / Comments Correlated microscopic observations Mediastinal LN . . Enlarged, 3-5 mm, Brown, +3/ Single Oval N-Leukemia, mononuclear, Incidental. Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Discolored, 6-10 mm, Yellow, +2/ Focus Irregular Necrosis, Moderate. Animal: 6838H779 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.1 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Nodule, 0-2 mm, Soft B-Adenoma, pars distalis, Incidental. Animal: 6838H780 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 236.3 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Mass, Right, 16-20 mm, Purple, Rubbery, +3/ Round B-Polyp, endometrial stromal, Incidental. Animal: 6838H782 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 240.3 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Small, Left, Diffuse, +2 No correlation entry made Mammary gland . . . Mass, Right, 21-45 mm, Mottled, Firm, +4/ Irregular B-Fibroadenoma, Incidental.

Study Number FY01-013

N-278
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:40 Rat/F344/N Animal: 6838H783 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 710 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 196.1 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, +2 Fatty Change, Mild. Brain . . . . . . . Deformity, 6-10 mm, +3/ Irregular Compression, Moderate. Pituitary gland . . Mass, 11-15 mm, Mottled Red, +3/ Round, Diffuse B-Adenoma, pars distalis, Incidental. Animal: 6838H785 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 476 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 230.0 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Diffuse, +3/ Pale Yellow Mineralization, corneal stromal, Mild. Liver . . . . . . . Enlarged, Diffuse, Soft, +1/ Mottled pale M-Leukemia, mononuclear, Contributory. Pancreas . . . . . Small, Diffuse, +3/ Pale Yellow Examined; no correlation found Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, Diffuse, +2/ Dull Yellow N-Leukemia, mononuclear - capillary involvement, Contributory. Discolored, Left Lobe, 0-2 mm, Red/ Focus Round N-Leukemia, mononuclear - capillary involvement, Contributory. Animal: 6838H786 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 716 Dosing phase Status: Found Dead Terminal body weight (g): 240.4 Tissue Gross observations / Comments Correlated microscopic observations Thyroid glands . . Enlarged, Bilateral, 3-5 mm, +1/ Diffuse Examined; no correlation found Lungs . . . . . . . Discolored, Diffuse, Mottled, +2 Examined; no correlation found Uterus . . . . . . Mass, Right, 68-89 mm, Dark Red, Firm, +4/ Diffuse Intussusception, Present. Irregular Liver . . . . . . . Hernia, Median Lobe, 6-10 mm, Mottled, Firm, +3/ Hepatodiaphragmatic nodule, Present. Irregular Adrenal glands . . Discolored, Left, Patchy, Dark, +1 Examined; no correlation found Eyes/optic nerve . Discolored, Bilateral, Diffuse, Pale, +2 Examined; no correlation found

Study Number FY01-013

N-279
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:41 Rat/F344/N Animal: 6838H787 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 266.0 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 6-10 mm, +1 Compression, Mild. Liver . . . . . . . Discolored, Diffuse, Mottled Red, +3 M-Leukemia, mononuclear, Incidental. Kidneys . . . . . . Discolored, Bilateral, Diffuse, Mottled Brown, +2/ Nephropathy, chronic, Moderate. Irregular Spleen . . . . . . Enlarged, 46-67 mm, +1 M-Leukemia, mononuclear, Incidental. Pituitary gland . . Mass, 6-10 mm, Mottled, Soft B-Adenoma, pars distalis, Incidental. Animal: 6838H788 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 244.1 Tissue Gross observations / Comments Correlated microscopic observations Pituitary gland . . Discolored, 3-5 mm, Dark Red, +2/ Irregular B-Adenoma, pars distalis, Incidental. Animal: 6838H790 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 238.2 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm, +3/ Round Compression, Moderate. Pituitary gland . . Enlarged, 3-5 mm, Purple, +3/ Round B-Adenoma, pars distalis, Incidental. Animal: 6838H791 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.6 Tissue Gross observations / Comments Correlated microscopic observations Thyroid glands . . Enlarged, Left, 6-10 mm/ Single Oval B-Adenoma, C-cell, Incidental. Lungs . . . . . . . Discolored, All Lobes, 0-2 mm, Red/ Multifocal Round N-Leukemia, mononuclear - capillary involvement, Contributory. Spleen . . . . . . Enlarged, 68-89 mm M-Leukemia, mononuclear, Contributory. Uterus . . . . . . Mass, Right, 3-5 mm, Opaque, Firm/ Single Round B-Polyp, endometrial stromal, Incidental. Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +3/ Irregular M-Leukemia, mononuclear, Contributory. Pituitary gland . . Discolored, 0-2 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental.

Study Number FY01-013

N-280
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:42 Rat/F344/N Animal: 6838H792 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 730 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 199.7 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory. Mediastinal LN . . Discolored, Diffuse, Red, +3 Examined; no correlation found Animal: 6838H793 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 231.8 Tissue Gross observations / Comments Correlated microscopic observations Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory. Animal: 6838H795 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 716 Dosing phase Status: Found Dead Terminal body weight (g): 219.8 Tissue Gross observations / Comments Correlated microscopic observations Lungs . . . . . . . Discolored, All Lobes, Diffuse, Dark Red, +4 Congestion, Mild. Ovaries . . . . . . Discolored, Bilateral, Diffuse, Purple, +4 Examined; no correlation found Uterus . . . . . . Discolored, Bilateral, Diffuse, Purple, +4 Examined; no correlation found Animal: 6838H797 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 605 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.3 Tissue Gross observations / Comments Correlated microscopic observations Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory. Spleen . . . . . . Enlarged, 21-45 mm, Red, +3 M-Leukemia, mononuclear, Contributory. Lungs . . . . . . . Discolored, 0-2 mm, Dark/ Multifocal Round N-Leukemia, mononuclear - capillary involvement, Contributory. Animal: 6838H798 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.0 Tissue Gross observations / Comments Correlated microscopic observations Eyes/optic nerve . Discolored, Left, Diffuse, Opaque, +4 Cataract, Present. Uterus . . . . . . Enlarged, Left, 6-10 mm, Soft/ Patchy B-Polyp, endometrial stromal, Incidental. Mammary gland . . . Mass, Right, 46-67 mm, Mottled, Firm/ Right Abdomen B-Fibroadenoma, Incidental. Diffuse Irregular

Study Number FY01-013

N-281
 Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04

 Research Institute Study Number:FY01013F Page:43 Rat/F344/N Animal: 6838H799 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 215.8 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 3-5 mm/ Single Depression Compression, Moderate. Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental. Cervix . . . . . . Enlarged, 6-10 mm, Firm, +3/ Single Examined; no correlation found Animal: 6838H800 Sex: Female Group: 4 Dose level: 20 g/m3 Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 247.9 Tissue Gross observations / Comments Correlated microscopic observations Brain . . . . . . . Deformity, 6-10 mm, +2 Compression, Mild. Pituitary gland . . Mass, 6-10 mm, Mottled Red, Firm, +2/ Diffuse B-Adenoma, pars distalis, Incidental. Irregular Spleen . . . . . . Enlarged, 46-67 mm, +3/ Diffuse M-Leukemia, mononuclear, Contributory. Liver . . . . . . . Thick, Diffuse, Mottled, +3/ Irregular M-Leukemia, mononuclear, Contributory.

Study Number FY01-013

N-282
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-8 Histological Comments on Tissue 

N-283
 Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6832E452 F 1/1 28-Oct-03 14:55 142 Parathyroid One of pair not represented on slide. 6832E453 F 1/1 28-Oct-03 15:53 142 Parathyroid One of pair not represented on slide. 6832E454 F 1/1 03-Nov-03 11:51 142 Bronchial (TBLN) TBLN noted missing at trim. 04-Feb-04 12:29 142 Ovaries Tissue not represented on slide. Oviducts only on original and recuts 1, 2. 6832E455 F 1/1 18-Nov-03 11:07 142 Parathyroid One of pair not represented on slide. 6832E457 F 1/1 04-Nov-03 07:10 142 Parathyroid One of pair not represented on slide. 6832E461 F 1/1 05-Feb-04 09:00 142 Parathyroid One of pair not represented on slide. 6832E463 F 1/1 05-Nov-03 10:06 142 Parathyroid One of pair not represented on slide. 6832E465 F 1/1 04-Nov-03 08:14 142 Parathyroid One of pair not represented on slide. 6832E466 F 1/1 18-Nov-03 11:38 142 Rectum Formalin injection artifact 6832E467 F 1/1 05-Nov-03 12:26 142 Parathyroid One of pair not represented on slide. 6832E471 F 1/1 18-Nov-03 14:13 142 Parathyroid One of pair not represented on slide. 6832E472 F 1/1 05-Nov-03 15:21 142 Pituitary gland Focus of chromophobe like cells (without cytologic or structural changes sufficient to call hyperplasia) 6832E473 F 1/1 20-Oct-03 15:50 142 Parathyroid One of pair not represented on slide 6832E475 F 1/1 04-Feb-04 12:38 142 Mandibular LN Tissue not represented on slide or recut 6832E476 F 1/1 04-Feb-04 12:40 142 Parathyroid Tissue not represented on slide or recut 6832E477 F 1/1 04-Nov-03 11:55 142 Parathyroid One of pair not represented on slide. 6832E478 F 1/1 04-Feb-04 12:41 142 Parathyroid Tissue not represented on slide or recut 6832E479 F 1/1 26-Dec-03 16:38 142 Parathyroid One of pair not represented on slide. 6832E480 F 1/1 18-Nov-03 16:14 142 Spinal cord Fragmented sample 6832E482 F 1/1 12-Jan-04 12:32 142 Parathyroid No parathyroids, distortion due to thyroid mass 6832E485 F 1/1 18-Nov-03 17:16 142 Parathyroid One of pair not represented on slide. 6832E487 F 1/1 19-Nov-03 09:07 142 Adrenal glands Mass interpreted as pheochromocytoma (3 foci in current plane of section) with adjacent cortical degeneration. 04-Feb-04 12:43 142 Ovaries One of pair not represented on slide or recut

Study Number FY01-013

N-284
 Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 2 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6832E491 F 1/1 18-Nov-03 16:55 142 Parathyroid One of pair not represented on slide. 6832E492 F 1/1 04-Feb-04 12:46 142 Parathyroid One of pair not represented on slide. 6832E496 F 1/1 05-Feb-04 09:01 142 Parathyroid One of pair not represented on slide. 6832E499 F 1/1 04-Feb-04 12:53 142 Bronchial (TBLN) Tissue not represented on slide or recut 6834F556 F 2/1 04-Feb-04 12:57 142 Parathyroid One of pair not represented on slide. 04-Feb-04 12:58 142 Mandibular LN Tissue not represented on slide or recut 6834F562 F 2/1 15-Jan-04 12:08 142 Mesenteric LN Submitted tissue is focus of fat necrosis/steatitis. 23-Jan-04 12:25 142 Mammary gland Missing at trim. 23-Jan-04 12:24 142 Skin Missing at trim. 6834F568 F 2/1 04-Feb-04 13:45 142 Mammary gland Tissue not represented on slide or recut 6834F572 F 2/1 09-Jan-04 17:07 142 Pancreas Small amount of exocrine pancreas present 6834F577 F 2/1 13-Jan-04 14:57 142 Bronchial (TBLN) Extensive lymphoma, no recut requested. 04-Feb-04 13:47 142 Parathyroid One of pair not represented on slide. 13-Jan-04 14:56 142 Mandibular LN Extensive lymphoma, no recut requested. 13-Jan-04 15:01 142 Pancreas Extensive lymphoma, no recut requested 13-Jan-04 15:08 142 Pancreatic LN Tissue submitted as pancreatic lymph node is fat with invasive lymphoma/leukemia. 6834F578 F 2/1 06-Jan-04 17:54 142 Parathyroid One of pair not represented on slide. 6834F593 F 2/1 04-Feb-04 14:08 142 Bone, femur Minimal marrow on original or recut 6834F594 F 2/1 16-Jan-04 11:59 142 Mammary gland In slide 6 6834F599 F 2/1 04-Feb-04 14:11 142 Pancreas Tissue not represented on slide or recut 6836G653 F 3/1 04-Feb-04 14:12 142 Bronchial (TBLN) Tissue not represented on slide or recut 19-Jan-04 10:39 142 Esophagus Hemorrhage in adjacent tissue interpreted as immature fibrous tissue--origin and significance uncertain. 04-Feb-04 14:14 142 Liver Grossly noted nodule not seen on slide or recut

Study Number FY01-013

N-285
 Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 3 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6836G653 F 3/1 19-Jan-04 10:37 142 Lymph node other Bulk of submitted tissue is immature fibrous tissue with mild histiolymphocytic inflammation. Small amount of lymph node is unremarkable. 6836G664 F 3/1 19-Jan-04 10:51 142 Adrenal glands One of pair missing at trim. 6836G672 F 3/1 05-Feb-04 12:28 142 Nose/Turbinate 1 Lost in processing (missing from block). 6836G679 F 3/1 09-Jan-04 12:02 142 Parathyroid One of pair not represented on slide. 6836G682 F 3/1 09-Jan-04 14:17 142 Parathyroid One of pair not represented on slide. 09-Jan-04 14:24 142 Mammary gland Missing at trim 09-Jan-04 14:24 142 Skin Missing at trim 6836G684 F 3/1 20-Feb-04 09:24 142 Tiss.not specifi Gross mass correlated to mammary gland (fibroadenoma) 6836G688 F 3/1 13-Jan-04 07:13 142 Mediastinal LN Submitted tissue is thymus containing a benign thymoma. 6836G691 F 3/1 04-Feb-04 14:22 142 Larynx Original and recut are fragmentary sections not at optimal level 6836G692 F 3/1 04-Feb-04 16:32 142 Lungs Grossly noted nodule not on slide or recuts. 6836G693 F 3/1 07-Jan-04 11:32 142 Parathyroid One of pair not represented on slide. 04-Feb-04 15:00 142 Mediastinal LN Tissue not represented on slide or recut 6836G695 F 3/1 13-Jan-04 07:27 142 Urinary bladder Missing at trim 13-Jan-04 07:42 142 Pituitary gland Mass within brain section (slide 16) interpreted as pars intermedia pituitary adenoma. 6836G696 F 3/1 04-Feb-04 15:01 142 Parathyroid One of pair not represented on slide. 6836G698 F 3/1 04-Feb-04 15:04 142 Sciatic nerve Tissue not represented on slide or recut 07-Jan-04 11:57 142 Bone, femur Missing at trim 07-Jan-04 11:58 142 Spinal cord Missing at trim 6838H751 F 4/1 11-Nov-03 15:33 142 Parathyroid One of pair not represented on slide. 6838H752 F 4/1 11-Nov-03 16:18 142 Parathyroid One of pair not represented on slide. 12-Nov-03 11:13 142 Spleen Leukemic cells widely disseminated; present to some degree in many tissues. 6838H753 F 4/1 04-Feb-04 15:17 142 Thyroid glands Inactive gland (large follicles with flattened epithelium).

Study Number FY01-013

N-286
 Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 4 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6838H755 F 4/1 12-Nov-03 15:53 142 Ileum Lamina propria of villi often fragmented areas with lymphocytes and plasma cells, interpreted as artifact. 6838H762 F 4/1 05-Feb-04 12:30 142 Salivary gland On recut 6838H763 F 4/1 17-Oct-03 16:53 142 Uterus Polyp necrotic 20-Oct-03 11:08 142 Ovaries Abundant corpora lutea 6838H765 F 4/1 28-Oct-03 15:31 142 Parathyroid One of pair not represented on slide. 6838H766 F 4/1 04-Feb-04 15:29 142 Mammary gland Tissue not represented on slide or recut 6838H770 F 4/1 05-Nov-03 16:14 142 Ovaries No corpora lutea--likely reason for gross description as "small". 05-Nov-03 16:04 142 Mammary gland No skin/mammary at trim 05-Nov-03 16:04 142 Skin No skin/mammary at trim. 6838H771 F 4/1 05-Nov-03 16:21 142 Parathyroid One of pair not represented on slide. 6838H772 F 4/1 05-Nov-03 16:43 142 Parathyroid One of pair not represented on slide. 05-Nov-03 16:54 142 Ovaries No corporea lutea on one ovary, likely reason for gross description of "small". 6838H773 F 4/1 05-Nov-03 17:27 142 Pituitary gland Irregularity interpreted to be due to plane of section. 6838H774 F 4/1 04-Feb-04 15:31 142 Mammary gland Tissue not represented on slide or recut 6838H777 F 4/1 25-Nov-03 09:11 142 Parathyroid One of pair not represented on slide. 6838H778 F 4/1 25-Nov-03 09:37 142 Parathyroid One of pair not represented on slide. 6838H779 F 4/1 04-Feb-04 16:18 142 Bronchial (TBLN) Tissue not represented on slide or recut 25-Nov-03 11:34 142 Parathyroid One of pair not represented on slide. 6838H780 F 4/1 04-Feb-04 16:20 142 Mediastinal LN Tissue not represented on slide or recut 6838H782 F 4/1 25-Nov-03 13:48 142 Parathyroid One of pair not represented on slide. 25-Nov-03 13:57 142 Eyes/optic nerve One eye specimen is fragmentary, could not correlate gross observation. 6838H786 F 4/1 25-Nov-03 16:03 142 Lungs Moderate autolysis in all tissues 25-Nov-03 16:02 142 Parathyroid One of pair not represented on slide.

Study Number FY01-013

N-287
 Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04

 Research Institute Study Number:FY01013F Page: 5 Rat/F344/N Animal Group/ Date and Time Oper. Number Sex Subgroup Data was entered # Tissue Special histological comment 6838H786 F 4/1 25-Nov-03 16:12 142 Brain Focal neuronal swelling and degeneration interpreted as autolysis artifact. 6838H787 F 4/1 25-Nov-03 16:31 142 Parathyroid One of pair not represented on slide. 6838H788 F 4/1 06-Feb-04 12:23 142 Parathyroid One of pair not represented on slide. 6838H792 F 4/1 18-Dec-03 15:17 142 Parathyroid One of pair not represented on slide. 6838H797 F 4/1 26-Dec-03 13:40 142 Mammary gland In salivary gland section

Study Number FY01-013

N-288
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-9 Summary of Missing Tissues 

N-289
 Lovelace Respiratory Summary Table of Missing Tissues Printed:15-Jun-04

 Research Institute Study number:FY01013F Page: 1 Rat/F344/N Tissue Animals Bronchial (TBLN) 6832E454 6832E499 6834F577 6836G653 6838H762 6838H779 Thyroid glands 6832E499* 6838H787* 6838H795* Parathyroid 6832E452* 6832E453* 6832E455* 6832E457* 6832E458* 6832E459* 6832E461* 6832E463* 6832E465* 6832E466* 6832E467* Parathyroid 6832E471* 6832E473* 6832E476 6832E477* 6832E478 6832E479* 6832E480* 6832E482 6832E483* 6832E484* 6832E485* Parathyroid 6832E491* 6832E492* 6832E496* 6832E499* 6834F556* 6834F571* 6834F577* 6834F578* 6834F590* 6834F594* 6834F599* Parathyroid 6836G653* 6836G659* 6836G665* 6836G678* 6836G679* 6836G682* 6836G683* 6836G691* 6836G693* 6836G696* 6838H751* Parathyroid 6838H752* 6838H757* 6838H760* 6838H761* 6838H765* 6838H766* 6838H771* 6838H772* 6838H777* 6838H778* 6838H779* Parathyroid 6838H782* 6838H786* 6838H787* 6838H788* 6838H792* 6838H793* 6838H794* 6838H795* 6838H797* 6838H798* Aorta 6832E476 Mandibular LN 6832E453 6832E463 6832E465 6832E475 6832E480 6832E482 6834F556 6834F577 6834F582 6838H751 6838H767 Mandibular LN 6838H775 Urinary bladder 6836G695 Ileum 6836G665 Pancreas 6834F577 6834F599 Adrenal glands 6834F578* 6836G664* Mesenteric LN 6834F562 Ovaries 6832E454 6832E487* 6838H792* Sciatic nerve 6836G698 Mammary gland 6832E465 6834F562 6834F568 6836G682 6838H766 6838H770 6838H774 Skin 6834F562 6836G682 6838H770 Bone, femur 6836G698 Spinal cord 6836G698 Nose/Turbinate 1 6836G672 Pancreatic LN 6834F577 Mediastinal LN 6836G693 6838H771 6838H780 6838H782 * Only one of the pair is missing

Study Number FY01-013

N-290
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

N-10 Lesion Incidence Summary with K-S (comparison > control) 

N-291
 Lovelace Respiratory Lesion incidence summary with K-S (comparison > control) Printed:30-Jun-04

 Research Institute Study Number:FY01013F Page: 1 Rat/F344/N -- A n i m a l s A f f e c t e d -- Controls from group(s): 1 Animal sex: -- F e m a l e s -- Dosage group: Ctls 2 3 4 T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50 Kidneys ........................................Number examined: 50 20 21 50 Atrophy 0 0 0 1 Cyst 1 0 0 3 Degeneration, hyaline droplet 0 0 0 1 Dilatation 0 0 0 1 Infarct 0 0 0 1 Nephropathy, chronic 42 17 15 -43 Pigment accumulation, tubular epithelium 0 2 0 2 Note: Entries flagged with a - (minus) are significantly higher than control at the 0.05 level using the Kolmogorov-Smirnov one-tailed test. All Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

Study Number FY01-013

N-292
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

O-1 

APPENDIX O 

STATISTICIAN’S REPORT 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-2 

Study Number FY01-013 

Study Title: 211(b) Chronic Carcinogenicity Study Gasoline MTBE Vapor Condensate 

(GMVC) 

LRRI Protocol Number: FY01-013 

Appendix O 

STATISTICIAN’S REPORT 

Betty Skipper, PhD Date 

Director, Biostatistics 

University of New Mexico 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-3 

INTRODUCTION

Groups of 50 male/50 female CDF(F344)CrlBR rats were exposed in H2000 whole-body 

inhalation chambers at GMVC vapor concentrations of 2 g/m3

 (low level), 10 g/m3 (mid level), 

and 20 g/m3

 (high level) 6 hours/day, 5 days/week for 104 weeks (520 exposure days). There 

was also a control group (0 g/m3). Blood was collected after approximately 12 and 18 months 

and at terminal sacrifice for evaluation of total and differential white blood cell counts. Animals 

surviving 104 weeks underwent a final sacrifice. Statistical evaluations were performed for the 

following endpoints: 

a. Survival as a function of sex and dose group 

b. White blood cell count (estimate) and differential white blood cell counts 

c. Histopathological lesions 

METHODS 

Survival Analysis

The number of days of survival was calculated for each animal in the study. Two female 

rats who died subsequent to accidental nose injuries early in the study were deleted from the 

analysis. The probability of survival was estimated by the Kaplan-Meier product-limit method 

using PROC LIFETEST in SAS Version 8.2. Mean numbers of survival days and time to 25% 

mortality were estimated for each dose group. Log-rank tests were used to test the hypothesis 

that there are differences among the four groups for each sex. The significance level was set at 

p = 0.05. All reported p-values for the survival analysis are two sided. 

Analysis of White Blood Cell Total and Differential Cell Counts

For the hematology data, medians and ranges are presented because the distributions are 

highly skewed for some variables. Preliminary analyses were done using the generalized 

estimating equation approach for longitudinal data analysis because there were three time points. 

For some variables these analyses showed significant interactions between time and group. 

Therefore, analyses were done to compare dose groups at each time point and to compare time 

points within each dose group. The Krusal-Wallis test was used for these comparisons. 

Analysis of the Incidences of Microscopic Lesions

The incidences of all neoplastic and non-neoplastic lesions are given as the ratio of the 

number of affected animals to the number of animals with the site examined microscopically. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-4 

Three statistical evaluations were performed on the histopathology lesion incidence data: 

1) Cochran-Armitage test, which tests whether the incidence of lesions shows a trend across dose 

groups; 2) logistic regression that takes death date into account when assessing the presence of a 

dose-dependent trend; and 3) the Fisher’s exact test to compare incidences among the four dose 

groups. The two-sided significance level was set at p = 0.05. If a significant difference was 

detected by the Fisher’s test, six possible pairwise comparisons were calculated. Using the 

Bonferroni correction for pairwise comparisons, each pairwise comparison would be considered 

significant if p < 0.008. 

Fisher’s exact test and the Cochran-Armitage test do not use survival information and are 

appropriate in situations where survival is similar among exposure group as is the case for this 

study. The Fisher’s exact tests the null hypothesis of equality of prevalences across dose groups 

against the alternate hypothesis that the prevalences are not equal, while the Cochran-Armitage 

tests the null hypothesis of equality across doses against the alternate hypothesis of a monotonic 

increasing or decreasing trend. The difference in these hypothesis tests can be seen in the test of 

“degeneration, cytoplasmic vacuolization” for female adrenal glands. The incidences are 24%, 

5%, 0%, and 28% for 0 g/m3, 2 g/m3, 10 g/m3, and 20 g/m3, respectively. The p-value for the 

Fisher’s exact test is 0.006, indicating differences among the incidences. However, the p-value 

for the Cochran-Armitage test is 0.73, indicating no detectable upward or downward trend across 

the doses. 

RESULTS 

Survival

All groups had 50 animals except the mid-level group for females. Two animals in that 

group were omitted from the analysis because of nose injuries. Figures O-1 and O-2 show the 

survival curves for male and female animals, respectively. The differences among the groups are 

not statistically significant for male (p = 0.46) or female animals (p = 0.07). Table O-1 shows 

means, standard errors, and day of 25% mortality for male and female animals under each 

experimental condition. For the calculation of mean and standard errors of survival times, the 

last day of the study was used as the value of the survival time for animals that were sacrificed at 

the time that the study was terminated. Therefore, the means and standard errors may be 

underestimated because some of the animals may have lived longer if the protocol had included 

following them for a longer period of time. The results indicate that chronic GMVC inhalation 

did not shorten the lifespan of the exposed rats compared to the controls. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-5 

Figure O-1. Survival of Male Animals 

Figure O-2. Survival of Female Animals 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-6 

Table O-1. Mean Survival Days and Day of 25% Mortality 

for Male and Female Rats 

Exposure 

Group 

Male Female 

Mean Days of 

Survival 

(SE) 

Estimate Day 

of 25% 

Mortality 

 Mean Days of 

Survival 

(SE) 

Estimated Day 

of 25% 

Mortality 

0 g/m3 652.6 (14.4) 626 665.9 (11.5) 632 

2 g/m3 651.6 (12.8) 633 685.5 (11.9) 680 

10 g/m3

 675.3 ( 9.4) 633 680.9 (15.5) 660 

20 g/m3 674.1 ( 9.5) 645 697.3 (10.6) 715 

Analysis of White Blood Cell Total and Differential Cell Counts

Results for female and male rats are provided in Tables O-2 and O-3, respectively. In 

many cases there were differences in cell numbers over time, but the differences in control and 

high-level animals were in the same direction. Significant differences between exposed and 

control groups occurred primarily in males at the 12-month sampling time. 

Analysis of the Incidences of Microscopic Lesions

Results of analyses on microscopic lesions for female and male rats are provided in 

Tables O-4 and O-5, respectively. Significant trends with increasing GMVC exposure 

concentration were detected in some cases. Incidences of lesions did not always increase with 

increasing concentration. In several cases, although a difference was detected by the Fisher’s 

test, the lesion incidences were not concentration dependent, leading to a lack of similarity 

between the results obtained using the Fisher’s test and results using the Cochran-Armitage test 

and logistic regression. Interpretation of the significance of these differences is provided in the 

main report text and in the Pathologist’s Report (Appendix P). 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-7 

Table O-2a. Alterations in Percentages of White Blood Cell Components - Females 

Variable 

12 months 18 months 24 months 

Median (Range) Median (Range) Median (Range) p-value 

Neutrophils (%) 

 0 g/m3 21 (8, 40) 28 (6, 53) 32 (5, 49) 0.002 

 20 g/m3 26 (15, 41) 29 (16, 45) 36 (7, 71) <0.0001

 p-value 0.02 0.63 0.053 

Band Neutrophils (%) 

 0 g/m3

 0 (0, 0) 0 (0, 3) 0 (0, 1) 0.04 

 20 g/m3

 0 (0, 2) 0 (0, 1) 0 (0, 1) 0.64 

 p-value 0.32 0.98 0.34 

Lymphocytes (%) 

 0 g/m3

 73 (55, 90) 69 (45, 84) 59 (41, 82) <0.0001

 20 g/m3 70 (53, 82) 66 (52, 81) 56 (25, 79) <0.0001

 p-value 0.013 0.40 0.23 

Monocytes (%) 

 0 g/m3 4 (0, 7) 2 (0, 5) 2 (0, 5) <0.0001

 20 g/m3 4 (0, 9) 3 (0, 8) 2 (0, 7) <0.0001

 p-value 0.60 0.003 0.83 

Eosinophils (%) 

 0 g/m3 1 (0, 6) 2 (0, 5) 1 (0, 4) 0.06 

 20 g/m3 2 (0, 5) 1 (0, 4) 0 (0, 3) 0.0005 

 p-value 0.04 0.053 0.10 

Basophils (%) 

 0 g/m3

 0 (0, 1) 0 (0, 0) 0 (0, 0) 0.003 

 20 g/m3

 0 (0, 1) 0 (0, 0) 0 (0, 1) 0.55 

 p-value 0.014 1.00 0.41 

Atypical Lymphocytes (%) 

 0 g/m3

 0 (0, 0) 0 (0, 17) 8 (3, 30) <0.0001

 20 g/m3

 0 (0, 0) 0 (0, 2) 4 (0, 21) <0.0001

 p-value 1.00 0.25 0.02 

Blasts (%) 

 0 g/m3

 0 (0, 0) 0 (0, 1) 0 (0, 3) 0.37 

 20 g/m3 0 (0, 0) 0 (0, 0) 0 (0, 3) 0.003 

 p-value 1.00 0.33 0.35 

Nucleated RBC (#/100WBC) 

 0 g/m3

 0 (0, 4) 2 (0, 14) 5 (1, 42) <0.0001

 20 g/m3 0 (0, 2) 2 (0, 9) 3 (0, 16) <0.0001

 p-value 0.91 0.62 0.38 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-8 

Table O-2b. Alterations in White Blood Cell Total and Differential Cell Counts - Females 

Variable 

12 months 18 months 24 months 

p-value 

Median 

(Range) 

Median 

(Range) 

Median 

(Range) 

WBC Estimate 

 0 g/m3 8.6 (4.4, 13.6) 4.4 (2.0, 9.2) 3.7 (1.8, 130.0) <0.0001

 20 g/m3 8.8 (4.8, 12.0) 4.6 (1.8, 8.2) 3.0 (1.4, 40.0) <0.0001

 p-value 0.58 0.77 0.14 

Absolute Neutrophils 

 0 g/m3

 2.0 (0.4, 5.0) 1.2 (0.3, 2.8) 1.1 (0.6, 6.5) <0.0001

 20 g/m3

 2.1 (1.1, 4.3) 1.3 (0.4, 3.3) 1.1 (0.4, 2.9) <0.0001

 p-value 0.27 0.91 0.50 

Absolute Band Neutrophils 

 0 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 1.3) 0.014 

 20 g/m3 0.0 (0.0, 0.2) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.66 

 p-value 0.32 0.58 0.29 

Absolute Lymphocytes 

 0 g/m3

 6.3 (4.0, 10.5) 3.1 (1.3, 6.9) 1.8 (0.8, 97.5) <0.0001

 20 g/m3

 5.8 (3.3, 8.1) 3.1 (1.3, 5.1) 1.3 (0.7, 31.6) <0.0001

 p-value 0.15 0.87 0.07 

Absolute Monocytes 

 0 g/m3 0.3 (0.0, 0.8) 0.1 (0.0, 0.3) 0.1 (0.0, 0.8) <0.0001

 20 g/m3

 0.3 (0.0, 0.9) 0.1 (0.0, 0.5) 0.0 (0.0, 0.6) <0.0001

 p-value 0.93 0.02 0.42 

Absolute Eosinophils 

 0 g/m3

 0.1 (0.0, 0.5) 0.1 (0.0, 0.3) 0.0 (0.0, 0.2) 0.0008 

 20 g/m3 0.1 (0.0, 0.5) 0.0 (0.0, 0.2) 0.0 (0.0, 0.1) <0.0001

 p-value 0.12 0.048 0.09 

Absolute Basophils 

 0 g/m3

 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.004 

 20 g/m3

 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.56 

 p-value 0.015 1.00 0.41 

Absolute Atypical Lymphocytes 

 0 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.3) 0.3 (0.1, 20.8) <0.0001

 20 g/m3 0.0 (0.0, 0.0) 0.0 (0.0, 0.1) 0.1 (0.0, 4.4) <0.0001

 p-value 1.00 0.16 0.007 

Absolute Blasts 

 0 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 3.9) 0.12 

 20 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.2) 0.003 

 p-value 1.00 1.00 0.38 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-9 

Table O-3a. Alterations in Percentages of White Blood Cell Components - Males 

Variable 

12 months 18 months 24 months 

Median (Range) Median (Range) Median (Range) p-value 

Neutrophils (%) 

 0 g/m3 30 (16, 47) 33 (12, 60) 54 (4, 63) 0.004 

 20 g/m3 40 (22, 57) 36 (17, 71) 45 (5, 64) 0.46 

p-value <0.0001 0.02 0.25 

Band Neutrophils (%) 

 0 g/m3

 0 (0, 1) 0 (0, 1) 0 (0, 0) 0.40 

 20 g/m3

 0 (0, 2) 0 (0, 1) 0 (0, 0) 0.01 

 p-value 0.02 0.31 1.00 

Lymphocytes (%) 

 0 g/m3

 65 (45, 82) 61 (30, 80) 40 (2, 75) 0.0001 

 20 g/m3 55 (37, 70) 59 (27, 76) 47 (27, 85) 0.13 

 p-value <0.0001 0.03 0.13 

Monocytes (%) 

 0 g/m3 4 (0, 8) 4 (1, 9) 4 (1, 6) 0.28 

 20 g/m3 3 (1, 9) 4 (0, 9) 1 (0, 4) <0.0001

 p-value 0.78 0.40 0.002 

Eosinophils (%) 

 0 g/m3 1 (0, 5) 2 (0, 6) 1 (0, 5) 0.003 

 20 g/m3 2 (0, 6) 2 (0, 6) 1 (0, 3) 0.001 

 p-value 0.10 0.98 0.97 

Basophils (%) 

 0 g/m3

 0 (0, 1) 0 (0, 1) 0 (0, 0) 0.66 

 20 g/m3

 0 (0, 1) 0 (0, 0) 0 (0, 0) 0.02 

 p-value 0.16 0.32 1.00 

Atypical Lymphocytes (%) 

 0 g/m3

 0 (0, 0) 0 (0, 0) 6 (0, 19) <0.0001

 20 g/m3

 0 (0, 0) 0 (0, 0) 6 (2, 11) <0.0001

 p-value 1.00 1.00 0.87 

Blasts (%) 

 0 g/m3

 0 (0, 0) 0 (0, 0) 0 (0, 0) 1.00 

 20 g/m3 0 (0, 0) 0 (0, 0) 0 (0, 3) 0.0004 

 p-value 1.00 1.00 0.12 

Nucleated RBC (#/100WBC) 

 0 g/m3

 0 (0, 2) 1 (0, 10) 2 (0, 7) <0.0001

 20 g/m3 0 (0, 2) 1 (0, 6) 4 (0, 12) <0.0001

 p-value 0.63 0.94 0.08 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

O-10 

Table O-3b. Alterations in White Blood Cell Total and Differential Cell Counts - Males 

Variable 

12 months 18 months 24 months 

p-value 

Median 

(Range) 

Median 

(Range) 

Median 

(Range) 

WBC Estimate 

 0 g/m3 10.0 (4.0, 20.0) 12.0 (6.8, 29.6) 3.7 (2.0, 68.8) 0.0001 

 20 g/m3 16.8 (8.8, 29.6) 12.4 (4.4, 36.4) 3.6 (1.6, 362.0) <0.0001

 p-value <0.0001 0.50 0.94 

Absolute Neutrophils 

 0 g/m3

 3.3 (1.0, 8.9) 4.1 (1.2, 17.8) 1.9 (1.1, 5.4) 0.0002 

 20 g/m3

 6.5 (2.5, 13.2) 3.8 (1.6, 24.0) 1.8 (0.7, 25.3) <0.0001

 p-value <0.0001 0.60 0.58 

Absolute Band Neutrophils 

 0 g/m3

 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.0 (0.0, 0.0) 0.39 

 20 g/m3 0.0 (0.0, 0.4) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.014 

 p-value 0.02 0.29 1.00 

Absolute Lymphocytes 

 0 g/m3

 6.3 (2.7, 12.2) 7.3 (4.1, 22.7) 1.6 (0.6, 51.6) 0.0005 

 20 g/m3

 9.2 (4.4, 15.3) 6.2 (2.3, 15.4) 1.4 (0.8, 307.7) <0.0001

 p-value <0.0001 0.13 0.48 

Absolute Monocytes 

 0 g/m3 0.3 (0.0, 1.0) 0.5 (0.1, 2.7) 0.2 (0.0, 1.4) 0.002 

 20 g/m3

 0.6 (0.1, 1.8) 0.4 (0.0, 1.9) 0.0 (0.0, 0.4) <0.0001

 p-value <0.0001 0.47 0.005 

Absolute Eosinophils 

 0 g/m3

 0.1 (0.0, 0.7) 0.3 (0.0, 0.9) 0.0 (0.0, 0.2) <0.0001

 20 g/m3 0.3 (0.0, 1.3) 0.3 (0.0, 0.9) 0.0 (0.0, 0.1) <0.0001

 p-value 0.0003 0.84 0.75 

Absolute Basophils 

 0 g/m3

 0.0 (0.0, 0.2) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.66 

 20 g/m3

 0.0 (0.0, 0.2) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.016 

 p-value 0.15 0.32 1.00 

Absolute Atypical Lymphocytes 

 0 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.2 (0.0, 13.1) <0.0001

 20 g/m3 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.2 (0.1, 25.3) <0.0001

 p-value 1.00 1.00 0.55 

Absolute Blasts 

 0 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.00 

 20 g/m3

 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 3.6) 0.0004 

 p-value 1.00 1.00 0.13 
O-11

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Adrenal glands  B-Pheochromocytoma, benign 1/49 ( 2%) 1/20 ( 5%) 2/21 ( 10%) 1/50 ( 2%) 0.88 0.91 0.28  Cyst 0/49 ( 0%) 0/20 ( 0%) 1/21 ( 5%) 1/50 ( 2%) 0.28 0.33 0.50  Degeneration, cytoplasmic vacuolization 12/49 ( 24%) 1/20 ( 5%) 0/21 ( 0%) 14/50 ( 28%) 0.73 0.77 0.0061 

 Hyperplasia, cortical, focal 2/49 ( 4%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.49 0.46 0.87  Hyperplasia, focal 1/49 ( 2%) 0/20 ( 0%) 2/21 ( 10%) 2/50 ( 4%) 0.39 0.39 0.44  M-Carcinoma, metastatic 0/49 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.25 . 1.00  M-Leukemia, mononuclear 3/49 ( 6%) 1/20 ( 5%) 0/21 ( 0%) 3/50 ( 6%) 0.86 0.87 0.85  Necrosis 1/49 ( 2%) 0/20 ( 0%) 0/21 ( 0%) 0/50 ( 0%) 0.24 . 0.64  Thrombus 1/49 ( 2%) 0/20 ( 0%) 0/21 ( 0%) 0/50 ( 0%) 0.24 . 0.64 Aorta  N-Leukemia, mononuclear - invasive involvement 1/49 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.24 . 0.64 Bone, femur  New bone formation, endosteal 0/50 ( 0%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 0.25 . 1.00 Bone, other  Fracture 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0/0 ( .%) . . . Bone, rib  M-Osteosarcoma 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) 1/1 (100%) . . . Bone, vertebrae  N-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . . Brain  Compression 2/50 ( 4%) 8/25 ( 32%) 9/25 ( 36%) 9/50 ( 18%) 0.07 0.16 0.0012  Hemorrhage 1/50 ( 2%) 1/25 ( 4%) 0/25 ( 0%) 0/50 ( 0%) 0.26 0.31 0.78  Inflammation, chronic 0/50 ( 0%) 0/25 ( 0%) 0/25 ( 0%) 1/50 ( 2%) 0.23 . 1.00  M-Astrocytoma, malignant 0/50 ( 0%) 1/25 ( 4%) 0/25 ( 0%) 0/50 ( 0%) 0.69 0.70 0.33  Metaplasia, osseous, meninges 0/50 ( 0%) 0/25 ( 0%) 0/25 ( 0%) 1/50 ( 2%) 0.23 . 1.00  Necrosis 1/50 ( 2%) 0/25 ( 0%) 0/25 ( 0%) 0/50 ( 0%) 0.23 . 1.00 ___________________________________________________________________________________________________________________________________ 1Pairwise Fisher’s exact tests: p=0.09 for 0 g/m3 cf. 2 g/m3; p=0.013 for 0 g/m3 cf. 10 g/m3; p=0.82 for 0 g/m3 cf. 20 g/m3; 

 p=0.49 for 2 g/m3 cf. 10 g/m3; p=0.051 for 2 g/m3 cf. 20 g/m3; p=0.007 for 10 g/m3 cf. 20 g/m3. 

2Pairwise Fisher’s exact tests: p=0.002 for 0 g/m3 cf. 2 g/m3; p=0.0005 for 0 g/m3 cf. 10 g/m3; p=0.051 for 0 g/m3 cf. 20 g/m3; 

 p=1.00 for 2 g/m3 cf. 10 g/m3; p=0.24 for 2 g/m3 cf. 20 g/m3; p=0.10 for 10 g/m3 cf. 20 g/m3. 
O-12

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Bronchial (TBLN)  Hemorrhage 1/48 ( 2%) 3/19 ( 16%) 0/20 ( 0%) 4/48 ( 8%) 0.40 0.42 0.09  Inflammation, mixed 0/48 ( 0%) 0/19 ( 0%) 1/20 ( 5%) 0/48 ( 0%) 0.70 0.87 0.29  N-Leukemia, mononuclear 9/48 ( 19%) 3/19 ( 16%) 7/20 ( 35%) 2/48 ( 4%) 0.12 0.12 0.0083 

Cecum  N-Leukemia, mononuclear 2/49 ( 4%) 1/20 ( 5%) 0/20 ( 0%) 0/49 ( 0%) 0.11 0.18 0.51 Cervix  B-Polyp, endometrial stromal 0/2 ( 0%) 0/5 ( 0%) 0/3 ( 0%) 1/2 ( 50%) 0.08 . 0.33  M-Leiomyosarcoma 0/2 ( 0%) 1/5 ( 20%) 0/3 ( 0%) 0/2 ( 0%) 0.65 . 1.00  N-Adenocarcinoma, endometrial 0/2 ( 0%) 1/5 ( 20%) 0/3 ( 0%) 0/2 ( 0%) 0.65 0.91 1.00 Clitoral gland  B-Adenoma 0/1 ( 0%) 0/0 ( .%) 1/3 ( 33%) 0/0 ( .%) 0.50 . 1.00  M-Carcinoma, squamous cell 1/1 (100%) 0/0 ( .%) 0/3 ( 0%) 0/0 ( .%) 0.046 . 0.25  N-Adenocarcinoma 0/1 ( 0%) 0/0 ( .%) 2/3 ( 67%) 0/0 ( .%) 0.25 . 1.00 Duodenum  Inflammation, acute 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.61 0.29 Eyes/optic nerve  Atrophy 1/50 ( 2%) 1/22 ( 5%) 0/24 ( 0%) 2/50 ( 4%) 0.70 0.91 0.76  Atrophy, retinal, unilateral 0/50 ( 0%) 2/22 ( 9%) 1/24 ( 4%) 0/50 ( 0%) 0.81 0.78 0.0184  Cataract 1/50 ( 2%) 3/22 ( 14%) 1/24 ( 4%) 2/50 ( 4%) 0.89 0.87 0.18  Metaplasia, osseous, scleral 1/50 ( 2%) 0/22 ( 0%) 0/24 ( 0%) 0/50 ( 0%) 0.23 . 1.00  Mineralization, corneal stromal 4/50 ( 8%) 0/22 ( 0%) 0/24 ( 0%) 4/50 ( 8%) 0.99 0.97 0.31  Mineralization, scleral 2/50 ( 4%) 2/22 ( 9%) 2/24 ( 8%) 4/50 ( 8%) 0.45 0.55 0.77  Neovascularization, corneal 1/50 ( 2%) 0/22 ( 0%) 0/24 ( 0%) 2/50 ( 4%) 0.50 0.71 1.00 Harderian gland  Pigment 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0/0 ( .%) . . . Heart  Degeneration, myocyte 3/50 ( 6%) 0/20 ( 0%) 0/20 ( 0%) 3/50 ( 6%) 1.00 0.59 0.65  Fibrosis 1/50 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.25 . 1.00  Inflammation, focal, chronic 24/50 ( 48%) 7/20 ( 35%) 8/20 ( 40%) 26/50 ( 52%) 0.65 0.73 0.57  M-Leukemia, mononuclear 5/50 ( 10%) 2/20 ( 10%) 0/20 ( 0%) 2/50 ( 4%) 0.14 0.16 0.41  Thrombus 1/50 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.25 . 1.00 ___________________________________________________________________________________________________________________________________ 3Pairwise Fisher’s exact tests: p=1.00 for 0 g/m3 cf. 2 g/m3; p=0.21 for 0 g/m3 cf. 10 g/m3; p=0.051 for 0 g/m3 cf. 20 g/m3; 

 p=0.27 for 2 g/m3 cf. 10 g/m3; p=0.13 for 2 g/m3 cf. 20 g/m3; p=0.002 for 10 g/m3 cf. 20 g/m3. 

4Pairwise Fisher’s exact tests: p=0.09 for 0 g/m3 cf. 2 g/m3; p=0.32 for 0 g/m3 cf. 10 g/m3; p=0.60 for 2 g/m3 cf. 10 g/m3; 

 p=0.09 for 2 g/m3 cf. 20 g/m3; p=0.32 for 10 g/m3 cf. 20 g/m3. 
O-13

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Ileum  N-Leukemia, mononuclear 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 1.00 0.98 1.00 Iliac LN  N-Leukemia, mononuclear 2/2 (100%) 2/2 (100%) 2/2 (100%) 0/0 ( .%) . . . Kidneys  Atrophy 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00  Cyst 1/50 ( 2%) 0/20 ( 0%) 0/21 ( 0%) 3/50 ( 6%) 0.24 0.47 0.52  Degeneration, hyaline droplet 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00  Dilatation 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00  Infarct 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00  M-Leukemia, mononuclear 1/50 ( 2%) 1/20 ( 5%) 1/21 ( 5%) 2/50 ( 4%) 0.60 0.57 0.86  N-Sarcoma, histiocytic 0/50 ( 0%) 0/20 ( 0%) 1/21 ( 5%) 0/50 ( 0%) 0.70 0.89 0.29  Nephropathy, chronic 42/50 ( 84%) 17/20 ( 85%) 15/21 ( 71%) 43/50 ( 86%) 0.99 0.84 0.51  Pigment accumulation, tubular epithelium 0/50 ( 0%) 2/20 ( 10%) 0/21 ( 0%) 2/50 ( 4%) 0.44 0.42 0.13 Larynx  Hyperplasia 17/50 ( 34%) 10/50 ( 20%) 5/50 ( 10%) 15/50 ( 30%) 0.41 0.36 0.0185 

 Inflammation, acute 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.19 0.16 0.62  Inflammation, chronic 8/50 ( 16%) 1/50 ( 2%) 6/50 ( 12%) 7/50 ( 14%) 0.84 0.89 0.08  Inflammation, mixed 28/50 ( 56%) 35/50 ( 70%) 23/50 ( 46%) 33/50 ( 66%) 0.85 0.91 0.07  Metaplasia, squamous 5/50 ( 10%) 10/50 ( 20%) 10/50 ( 20%) 9/50 ( 18%) 0.31 0.50 0.49 ___________________________________________________________________________________________________________________________________ 5Pairwise Fisher’s exact tests: p=0.18 for 0 g/m3 cf. 2 g/m3; p=0.007 for 0 g/m3 cf. 10 g/m3; p=0.83 for 0 g/m3 cf. 20 g/m3; 

 p=0.26 for 2 g/m3 cf. 10 g/m3; p=0.36 for 2 g/m3 cf. 20 g/m3; p=0.02 for 10 g/m3 cf. 20 g/m3. 
O-14

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Liver  Angiectasis 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.98 0.98 1.00  B-Adenoma, hepatocellular 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00  Congestion 1/50 ( 2%) 0/28 ( 0%) 1/22 ( 5%) 0/50 ( 0%) 0.59 0.59 0.31  Fatty Change 0/50 ( 0%) 1/28 ( 4%) 2/22 ( 9%) 3/50 ( 6%) 0.09 0.24 0.16  Foci of cellular alteration, basophilic 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.98 . 1.00  Hepatodiaphragmatic nodule 0/50 ( 0%) 5/28 ( 18%) 0/22 ( 0%) 3/50 ( 6%) 0.53 0.60 0.0066 

 Hyperplasia, biliary 35/50 ( 70%) 16/28 ( 57%) 17/22 ( 77%) 24/50 ( 48%) 0.059 0.041 0.0497  Hyperplasia, hepatocellular, regenerative 1/50 ( 2%) 1/28 ( 4%) 1/22 ( 5%) 1/50 ( 2%) 0.97 0.89 0.83  Inflammation, acute 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00  Inflammation, chronic 13/50 ( 26%) 5/28 ( 18%) 3/22 ( 14%) 17/50 ( 34%) 0.39 0.61 0.25  M-Leukemia, mononuclear 27/50 ( 54%) 17/28 ( 61%) 10/22 ( 45%) 23/50 ( 46%) 0.30 0.27 0.57  M-Sarcoma. histiocytic 0/50 ( 0%) 0/28 ( 0%) 1/22 ( 5%) 1/50 ( 2%) 0.25 0.34 0.31  Necrosis 3/50 ( 6%) 3/28 ( 11%) 1/22 ( 5%) 5/50 ( 10%) 0.59 0.58 0.79  Thrombus 0/50 ( 0%) 0/28 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.23 . 1.00  Vacuolization cytoplasmic 5/50 ( 10%) 1/28 ( 4%) 1/22 ( 5%) 1/50 ( 2%) 0.09 0.11 0.36 Lungs  Alveolar histiocytosis 9/50 ( 18%) 3/50 ( 6%) 3/50 ( 6%) 9/50 ( 18%) 1.00 0.96 0.07  Congestion 1/50 ( 2%) 0/50 ( 0%) 2/50 ( 4%) 1/50 ( 2%) 0.65 0.64 0.90  Fibrosis, focal 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.56 1.00  Hemorrhage 5/50 ( 10%) 1/50 ( 2%) 1/50 ( 2%) 3/50 ( 6%) 0.38 0.39 0.29  Hyperplasia, alveolar epithelial, focal 7/50 ( 14%) 1/50 ( 2%) 1/50 ( 2%) 1/50 ( 2%) 0.009 0.017 0.0148  Inflammation, acute 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.25 1.00  Inflammation, granulomatous 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 . 1.00  Inflammation, mixed 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.66 1.00  N-Carcinoma, metastatic 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00  N-Leukemia, mononuclear - capillary involvement 22/50 ( 44%) 16/50 ( 32%) 12/50 ( 24%) 19/50 ( 38%) 0.39 0.41 0.19  N-Leukemia, mononuclear - invasive involvement 3/50 ( 6%) 1/50 ( 2%) 2/50 ( 4%) 1/50 ( 2%) 0.39 0.40 0.84  N-Sarcoma, histiocytic 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0.20 0.27 1.00 Lymph node other  Hemorrhage 1/3 ( 33%) 0/1 ( 0%) 0/3 ( 0%) 0/1 ( 0%) 0.22 . 1.00  Infiltration, histiocytic 1/3 ( 33%) 0/1 ( 0%) 0/3 ( 0%) 0/1 ( 0%) 0.22 . 1.00  N-Leukemia, mononuclear 2/3 ( 67%) 1/1 (100%) 2/3 ( 67%) 1/1 (100%) 0.71 . 1.00 ___________________________________________________________________________________________________________________________________ 6Pairwise Fisher’s exact tests: p=0.005 for 0 g/m3 cf. 2 g/m3; p=0.24 for 0 g/m3 cf. 20 g/m3; p=0.06 for 2 g/m3 cf. 10 g/m3; 

 p=0.13 for 2 g/m3 cf. 20 g/m3; p=0.55 for 10 g/m3 cf. 20 g/m3. 

7Pairwise Fisher’s exact tests: p=0.32 for 0 g/m3 cf. 2 g/m3; p=0.58 for 0 g/m3 cf. 10 g/m3; p=0.04 for 0 g/m3 cf. 20 g/m3; 

 p=0.23 for 2 g/m3 cf. 10 g/m3; p=0.49 for 2 g/m3 cf. 20 g/m3; p=0.04 for 10 g/m3 cf. 20 g/m3. 

8Pairwise Fisher’s exact tests: p=0.06 for 0 g/m3 cf. 2 g/m3; p=0.06 for 0 g/m3 cf. 10 g/m3; p=0.06 for 0 g/m3 cf. 20 g/m3; 

 p=1.00 for 2 g/m3 cf. 10 g/m3; p=1.00 for 2 g/m3 cf. 20 g/m3; p=1.00 for 10 g/m3 cf. 20 g/m3. 
O-15

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Mammary gland  B-Fibroadenoma 0/49 ( 0%) 3/20 ( 15%) 2/22 ( 9%) 5/47 ( 11%) 0.07 0.18 0.0299 

 B-Fibroma 1/49 ( 2%) 2/20 ( 10%) 1/22 ( 5%) 0/47 ( 0%) 0.44 0.38 0.07  Ectasia 3/49 ( 6%) 0/20 ( 0%) 0/22 ( 0%) 1/47 ( 2%) 0.24 0.16 0.53  Hyperplasia, lobular 1/49 ( 2%) 0/20 ( 0%) 1/22 ( 5%) 2/47 ( 4%) 0.41 0.57 0.83  M-Adenocarcinoma 0/49 ( 0%) 1/20 ( 5%) 1/22 ( 5%) 0/47 ( 0%) 0.99 0.98 0.09  M-Adenocarcinoma arising in fibroadenoma 1/49 ( 2%) 0/20 ( 0%) 0/22 ( 0%) 0/47 ( 0%) 0.24 . 1.00 Mandibular LN  Hemorrhage 0/44 ( 0%) 1/19 ( 5%) 0/21 ( 0%) 0/47 ( 0%) 0.67 0.66 0.15  N-Leukemia, mononuclear 12/44 ( 27%) 6/19 ( 32%) 5/21 ( 24%) 5/47 ( 11%) 0.043 0.045 0.12 Mediastinal LN  B-Thymoma 0/50 ( 0%) 0/20 ( 0%) 1/20 ( 5%) 0/47 ( 0%) 0.68 0.69 0.29  Hemorrhage 4/50 ( 8%) 1/20 ( 5%) 1/20 ( 5%) 1/47 ( 2%) 0.20 0.22 0.62  Infiltration, histiocytic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/47 ( 2%) 0.23 . 0.64  M-Carcinoma, metastatic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/47 ( 2%) 0.23 . 0.64  N-Leukemia, mononuclear 12/50 ( 24%) 5/20 ( 25%) 5/20 ( 25%) 5/47 ( 11%) 0.11 0.12 0.24  N-Sarcoma, histiocytic 0/50 ( 0%) 0/20 ( 0%) 1/20 ( 5%) 0/47 ( 0%) 0.68 0.86 0.29  Pigmentation 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/47 ( 2%) 0.23 . 0.64 Mediastinum  N-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . . Mesenteric LN  Hemorrhage 1/50 ( 2%) 0/19 ( 0%) 1/20 ( 5%) 0/50 ( 0%) 0.58 0.55 0.48  Inflammation, chronic 1/50 ( 2%) 0/19 ( 0%) 1/20 ( 5%) 0/50 ( 0%) 0.58 0.53 0.48  N-Leukemia, mononuclear 13/50 ( 26%) 3/19 ( 16%) 7/20 ( 35%) 4/50 ( 8%) 0.056 0.06 0.02410  N-Sarcoma, histiocytic 0/50 ( 0%) 0/19 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00 Mesentery  M-Carcinoma, metastatic 0/1 ( 0%) 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0.16 . 1.00  Splenic tissue, "accessory" 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/1 ( 0%) 0.16 . 1.00 Muscle, skeletal  N-Sarcoma, histiocytic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00 ___________________________________________________________________________________________________________________________________ 9Pairwise Fisher’s exact tests: p=0.02 for 0 g/m3 cf. 2 g/m3; p=0.09 for 0 g/m3 cf. 10 g/m3; p=0.03 for 0 g/m3 cf. 20 g/m3; 

 p=0.66 for 2 g/m3 cf. 10 g/m3; p=0.69 for 2 g/m3 cf. 20 g/m3; p=1.00 for 10 g/m3 cf. 20 g/m3. 

10Pairwise Fisher’s exact tests: p=0.53 for 0 g/m3 cf. 2 g/m3; p=0.56 for 0 g/m3 cf. 10 g/m3; p=0.03 for 0 g/m3 cf. 20 g/m3; 

 p=0.27 for 2 g/m3 cf. 10 g/m3; p=0.38 for 2 g/m3 cf. 20 g/m3; p=0.009 for 10 g/m3 cf. 20 g/m3. 
O-16

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Nose/Turbinate 1  Degeneration, hyaline - respiratory epithelium 3/50 ( 6%) 7/50 ( 14%) 6/49 ( 12%) 2/50 ( 4%) 0.67 0.70 0.26  Hyperplasia - respiratory epithelium 0/50 ( 0%) 1/50 ( 2%) 2/49 ( 4%) 2/50 ( 4%) 0.16 0.19 0.58  Inflammation - nasolacrimal duct 21/50 ( 42%) 15/50 ( 30%) 20/49 ( 41%) 22/50 ( 44%) 0.59 0.60 0.48  Inflammation - respiratory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/49 ( 0%) 1/50 ( 2%) 1.00 0.85 1.00  Inflammation, mixed 5/50 ( 10%) 5/50 ( 10%) 4/49 ( 8%) 4/50 ( 8%) 0.67 0.69 1.00 Nose/Turbinate 2  Degeneration, hyaline - olfactory epithelium 4/50 ( 8%) 5/50 ( 10%) 6/50 ( 12%) 10/50 ( 20%) 0.07 0.07 0.36  Degeneration, hyaline - respiratory epithelium 0/50 ( 0%) 1/50 ( 2%) 7/50 ( 14%) 6/50 ( 12%) 0.003 0.008 0.00611 

 Hyperplasia - respiratory epithelium 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 0.79 0.79 0.62  Inflammation, mixed 3/50 ( 6%) 4/50 ( 8%) 2/50 ( 4%) 2/50 ( 4%) 0.49 0.49 0.90  Metaplasia, secretory - olfactory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  Metaplasia, squamous - olfactory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.66 1.00 Nose/Turbinate 3  Degeneration - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.57 1.00  Degeneration - respiratory epithelium 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 0.79 0.81 0.62  Degeneration, hyaline - olfactory epithelium 4/50 ( 8%) 2/50 ( 4%) 10/50 ( 20%) 8/50 ( 16%) 0.052 0.058 0.06  Inflammation, mixed 1/50 ( 2%) 3/50 ( 6%) 1/50 ( 2%) 0/50 ( 0%) 0.31 0.29 0.40 Nose/Turbinate 4  Degeneration - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 . 1.00  Degeneration, hyaline - olfactory epithelium 3/50 ( 6%) 0/50 ( 0%) 0/50 ( 0%) 3/50 ( 6%) 1.00 0.79 0.09  Inflammation, mixed 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.26 1.00 Ovaries  Congestion 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 0/50 ( 0%) 0.70 0.69 0.31  Cyst, bursa 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 1/50 ( 2%) 0.27 0.51 0.52  Cyst, epithelial 1/49 ( 2%) 1/21 ( 5%) 0/23 ( 0%) 0/50 ( 0%) 0.26 0.30 0.19  Cyst, follicular 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 0/50 ( 0%) 0.70 0.89 0.31  Cyst, rete ovarii 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 0/50 ( 0%) 0.70 . 0.31  Hemorrhage 1/49 ( 2%) 0/21 ( 0%) 0/23 ( 0%) 0/50 ( 0%) 0.23 . 0.65  M-Leukemia, mononuclear 1/49 ( 2%) 1/21 ( 5%) 1/23 ( 4%) 1/50 ( 2%) 0.98 0.98 0.60  N-Sarcoma, histiocytic 0/49 ( 0%) 0/21 ( 0%) 0/23 ( 0%) 1/50 ( 2%) 0.24 . 1.00  Necrosis, mesenteric fat 0/49 ( 0%) 1/21 ( 5%) 0/23 ( 0%) 0/50 ( 0%) 0.68 0.59 0.15 Pancreas  Fibrosis 0/50 ( 0%) 0/18 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00  M-Leukemia, mononuclear 0/50 ( 0%) 1/18 ( 6%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.69 0.13 ___________________________________________________________________________________________________________________________________ 11Pairwise Fisher’s exact tests: p=0.49 for 0 g/m3 cf. 2 g/m3; p=0.012 for 0 g/m3 cf. 10 g/m3; p=0.03 for 0 g/m3 cf. 20 g/m3; 

 p=0.06 for 2 g/m3 cf. 10 g/m3; p=0.11 for 2 g/m3 cf. 20 g/m3; p=1.00 for 10 g/m3 cf. 20 g/m3. 
O-17

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Pancreatic LN  N-Leukemia, mononuclear 2/2 (100%) 1/1 (100%) 2/2 (100%) 1/1 (100%) . . . Parathyroid  B-Adenoma 1/47 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.23 . 0.64  Hyperplasia, focal 1/47 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.23 . 0.64 Pituitary gland  Angiectasis 9/50 ( 18%) 1/32 ( 3%) 3/34 ( 9%) 6/50 ( 12%) 0.47 0.41 0.22  B-Adenoma, pars distalis 7/50 ( 14%) 13/32 ( 41%) 14/34 ( 41%) 11/50 ( 22%) 0.37 0.64 0.01012 

 B-Adenoma, pars intermedia 0/50 ( 0%) 0/32 ( 0%) 1/34 ( 3%) 0/50 ( 0%) 0.68 0.68 0.40  Cyst 24/50 ( 48%) 9/32 ( 28%) 10/34 ( 29%) 12/50 ( 24%) 0.015 0.011 0.07  Degeneration 1/50 ( 2%) 0/32 ( 0%) 0/34 ( 0%) 0/50 ( 0%) 0.21 . 1.00  Hemorrhage 5/50 ( 10%) 0/32 ( 0%) 0/34 ( 0%) 10/50 ( 20%) 0.10 0.23 0.00213  Hyperplasia, focal 8/50 ( 16%) 3/32 ( 9%) 8/34 ( 24%) 4/50 ( 8%) 0.50 0.43 0.21  M-Carcinoma 0/50 ( 0%) 1/32 ( 3%) 0/34 ( 0%) 0/50 ( 0%) 0.67 . 0.19  M-Leukemia, mononuclear 0/50 ( 0%) 1/32 ( 3%) 0/34 ( 0%) 1/50 ( 2%) 0.56 0.66 0.57  Necrosis 0/50 ( 0%) 0/32 ( 0%) 0/34 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Popliteal LN  N-Leukemia, mononuclear 1/1 (100%) 1/1 (100%) 0/0 ( .%) 0/0 ( .%) . . . Rectum  Metaplasia, squamous 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.61 0.29 Salivary gland  M-Leukemia, mononuclear 2/50 ( 4%) 0/20 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.50 0.47 1.00 Skin  Cyst, epithelial inclusion 0/50 ( 0%) 1/19 ( 5%) 0/20 ( 0%) 0/49 ( 0%) 0.70 0.70 0.14  Fibrosis 0/50 ( 0%) 0/19 ( 0%) 1/20 ( 5%) 0/49 ( 0%) 0.69 . 0.28  Inflammation, mixed 0/50 ( 0%) 0/19 ( 0%) 1/20 ( 5%) 0/49 ( 0%) 0.69 0.86 0.28 Spinal cord  Degeneration, white matter 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 1.00 0.95 1.00  Hemorrhage 1/50 ( 2%) 0/20 ( 0%) 1/19 ( 5%) 0/50 ( 0%) 0.59 0.59 0.28  Necrosis, neuronal 0/50 ( 0%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 0.25 . 1.00 ___________________________________________________________________________________________________________________________________ 12Pairwise Fisher’s exact tests: p=0.009 for 0 g/m3 cf. 2 g/m3; p=0.009 for 0 g/m3 cf. 10 g/m3; p=0.44 for 0 g/m3 cf. 20 g/m3; 

 p=1.00 for 2 g/m3 cf. 10 g/m3; p=0.09 for 2 g/m3 cf. 20 g/m3; p=0.09 for 10 g/m3 cf. 20 g/m3. 

13Pairwise Fisher’s exact tests: p=0.15 for 0 g/m3 cf. 2 g/m3; p=0.08 for 0 g/m3 cf. 10 g/m3; p=0.26 for 0 g/m3 cf. 20 g/m3; 

 p=0.005 for 2 g/m3 cf. 20 g/m3; p=0.005 for 10 g/m3 cf. 20 g/m3. 
O-18

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Spleen  Fibrosis 3/50 ( 6%) 0/22 ( 0%) 1/24 ( 4%) 0/50 ( 0%) 0.11 0.16 0.29  Hemorrhage 0/50 ( 0%) 0/22 ( 0%) 0/24 ( 0%) 1/50 ( 2%) 0.24 . 1.00  M-Leukemia, mononuclear 27/50 ( 54%) 12/22 ( 55%) 11/24 ( 46%) 23/50 ( 46%) 0.36 0.33 0.81  N-Sarcoma, histiocytic 0/50 ( 0%) 0/22 ( 0%) 1/24 ( 4%) 0/50 ( 0%) 0.70 0.87 0.32  Necrosis 1/50 ( 2%) 1/22 ( 5%) 0/24 ( 0%) 2/50 ( 4%) 0.70 0.82 0.76 Stomach  Inflammation, mixed 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.69 0.29  M-Carcinoma, metastatic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00  M-Leukemia, mononuclear 1/50 ( 2%) 1/20 ( 5%) 1/20 ( 5%) 0/50 ( 0%) 0.50 0.50 0.28  Ulcer 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.69 0.29 Tail  Hyperplasia/hyperkeratosis 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 1/1 (100%) . . .  Inflammation, acute 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0/1 ( 0%) 0.16 . 1.00  Inflammation, mixed 0/0 ( .%) 0/0 ( .%) 0/1 ( 0%) 1/1 (100%) 0.16 . 1.00 Thyroid glands  B-Adenoma, C-cell 1/50 ( 2%) 2/22 ( 9%) 3/22 ( 14%) 2/50 ( 4%) 0.57 0.91 0.16  B-Adenoma, follicular cell 0/50 ( 0%) 0/22 ( 0%) 0/22 ( 0%) 2/50 ( 4%) 0.10 . 0.76  Cyst, follicular 0/50 ( 0%) 0/22 ( 0%) 1/22 ( 5%) 0/50 ( 0%) 0.70 0.70 0.31  Hyperplasia, C-cell, focal 3/50 ( 6%) 4/22 ( 18%) 1/22 ( 5%) 6/50 ( 12%) 0.51 0.66 0.34  Hyperplasia, follicular cell 1/50 ( 2%) 0/22 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00  M-Carcinoma, C-cell 1/50 ( 2%) 0/22 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00  M-Carcinoma, follicular cell 1/50 ( 2%) 0/22 ( 0%) 1/22 ( 5%) 0/50 ( 0%) 0.58 0.55 0.52  M-Leukemia, mononuclear 0/50 ( 0%) 0/22 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.24 . 1.00 Trachea  Hyperplasia 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.66 1.00  Inflammation, acute 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.057 . 0.25  Inflammation, mixed 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1.00 0.99 1.00  N-Leukemia, mononuclear 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 1.00 1.00 1.00 Urinary bladder  Hemorrhage 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 0/50 ( 0%) 0.25 . 1.00  Hyperplasia, papillary 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 0/50 ( 0%) 0.25 . 1.00  Inflammation, chronic 2/50 ( 4%) 0/20 ( 0%) 0/19 ( 0%) 3/50 ( 6%) 0.59 0.66 0.85  M-Leukemia, mononuclear 1/50 ( 2%) 0/20 ( 0%) 1/19 ( 5%) 0/50 ( 0%) 0.59 0.58 0.28 ___________________________________________________________________________________________________________________________________ 
O-19

Study Number FY01-013 

Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Concluded) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Uterus  Angiectasis 0/50 ( 0%) 0/24 ( 0%) 1/31 ( 3%) 0/50 ( 0%) 0.70 0.85 0.35  B-Adenoma, endometrial 0/50 ( 0%) 1/24 ( 4%) 0/31 ( 0%) 0/50 ( 0%) 0.67 0.57 0.15  B-Polyp, endometrial stromal 5/50 ( 10%) 11/24 ( 46%) 11/31 ( 35%) 11/50 ( 22%) 0.22 0.22 0.00314 

 Dilatation 0/50 ( 0%) 1/24 ( 4%) 4/31 ( 13%) 3/50 ( 6%) 0.09 0.12 0.053  Hyperplasia, cystic endometrial 11/50 ( 22%) 4/24 ( 17%) 4/31 ( 13%) 11/50 ( 22%) 0.91 0.56 0.74  Inflammation, chronic 3/50 ( 6%) 0/24 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.032 . 0.15  Inflammation, mixed 3/50 ( 6%) 0/24 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.032 . 0.15  Intussusception 1/50 ( 2%) 1/24 ( 4%) 0/31 ( 0%) 2/50 ( 4%) 0.71 0.69 0.69  M-Adenocarcinoma, endometrial 0/50 ( 0%) 1/24 ( 4%) 2/31 ( 6%) 1/50 ( 2%) 0.44 0.59 0.22  M-Leiomyosarcoma 0/50 ( 0%) 1/24 ( 4%) 1/31 ( 3%) 0/50 ( 0%) 0.98 0.96 0.12  M-Leukemia, mononuclear 2/50 ( 4%) 3/24 ( 13%) 0/31 ( 0%) 1/50 ( 2%) 0.29 0.31 0.12 Vagina  M-Leiomyosarcoma 0/0 ( .%) 1/1 (100%) 0/0 ( .%) 0/0 ( .%) . . . Zymbal's gland  M-Carcinoma, squamous cell 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . . ___________________________________________________________________________________________________________________________________ 14Pairwise Fisher’s exact tests: p=0.002 for 0 g/m3 cf. 2 g/m3; p=0.009 for 0 g/m3 cf. 10 g/m3; p=0.17 for 0 g/m3 cf. 20 g/m3; 

 p=0.58 for 2 g/m3 cf. 10 g/m3; p=0.06 for 2 g/m3 cf. 20 g/m3; p=0.21 for 10 g/m3 cf. 20 g/m3. 
O-20

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Adrenal glands  B-Pheochromocytoma, benign 7/49 ( 14%) 4/35 ( 11%) 5/30 ( 17%) 7/50 ( 14%) 0.91 0.79 0.95  B-Pheochromocytoma, complex, benign 1/49 ( 2%) 1/35 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.24 0.30 0.69  Cyst 0/49 ( 0%) 0/35 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Degeneration, cytoplasmic vacuolization 5/49 ( 10%) 2/35 ( 6%) 2/30 ( 7%) 4/50 ( 8%) 0.73 0.55 0.94  Hyperplasia, cortical, diffuse 0/49 ( 0%) 0/35 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.68 0.18  Hyperplasia, medullary, focal 8/49 ( 16%) 2/35 ( 6%) 5/30 ( 17%) 17/50 ( 34%) 0.013 0.039 0.0111 

 M-Leukemia, mononuclear 3/49 ( 6%) 1/35 ( 3%) 4/30 ( 13%) 2/50 ( 4%) 0.99 0.99 0.35  M-Pheochromocytoma, malignant 3/49 ( 6%) 0/35 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 0.21 0.39  Necrosis 0/49 ( 0%) 0/35 ( 0%) 1/30 ( 3%) 1/50 ( 2%) 0.24 0.19 0.56  Thrombus 2/49 ( 4%) 2/35 ( 6%) 3/30 ( 10%) 5/50 ( 10%) 0.21 0.27 0.61 Aorta  Dilatation 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00  N-Leukemia, mononuclear - invasive involvement 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00 Bone, femur  Inflammation, acute 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00  New bone formation, endosteal 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.79 0.84 1.00 Bone, other  Hyperostosis 0/0 ( .%) 1/1 (100%) 0/0 ( .%) 0/1 ( 0%) 0.16 . 1.00  M-Sarcoma, NOS 0/0 ( .%) 0/1 ( 0%) 0/0 ( .%) 1/1 (100%) 0.16 . 1.00 Brain  Compression 6/50 ( 12%) 2/34 ( 6%) 2/31 ( 6%) 4/50 ( 8%) 0.51 0.36 0.85  Ectasia, ventricular system 2/50 ( 4%) 0/34 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.08 . 0.33  Edema 0/50 ( 0%) 0/34 ( 0%) 0/31 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Gliosis 1/50 ( 2%) 0/34 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.22 . 1.00  Hemorrhage 1/50 ( 2%) 0/34 ( 0%) 2/31 ( 6%) 0/50 ( 0%) 0.82 0.95 0.18  Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 2/31 ( 6%) 0/50 ( 0%) 0.55 0.53 0.0342  Inflammation, chronic 1/50 ( 2%) 0/34 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.22 . 1.00  M-Astrocytoma, malignant 0/50 ( 0%) 1/34 ( 3%) 0/31 ( 0%) 1/50 ( 2%) 0.55 0.60 0.82  Mineralization 0/50 ( 0%) 0/34 ( 0%) 0/31 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Necrosis 0/50 ( 0%) 0/34 ( 0%) 0/31 ( 0%) 1/50 ( 2%) 0.21 . 1.00 ___________________________________________________________________________________________________________________________________ 1Pairwise Fisher’s exact tests: p=0.18 for 0 g/m3 cf. 2 g/m3; p=1.00 for 0 g/m3 cf. 10 g/m3; p=0.06 for 0 g/m3 cf. 20 g/m3; 

 p=0.23 for 2 g/m3 cf. 10 g/m3; p=0.003 for 2 g/m3 cf. 20 g/m3; p=0.12 for 10 g/m3 cf. 20 g/m3. 

2Pairwise Fisher’s exact tests: p=0.14 for 0 g/m3 cf. 10 g/m3; p=0.22 for 2 g/m3 cf. 10 g/m3; p=0.14 for 10 g/m3 cf. 20 g/m3. 
O-21

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Bronchial (TBLN)  Hemorrhage 0/49 ( 0%) 3/33 ( 9%) 0/28 ( 0%) 2/47 ( 4%) 0.53 0.66 0.07  N-Leukemia, mononuclear 10/49 ( 20%) 9/33 ( 27%) 7/28 ( 25%) 7/47 ( 15%) 0.48 0.48 0.55  N-Sarcoma, histiocytic 0/49 ( 0%) 1/33 ( 3%) 0/28 ( 0%) 0/47 ( 0%) 0.70 0.71 0.39 Cecum  N-Leukemia, mononuclear 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.08 . 0.34 Colon  B-Leiomyoma 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/49 ( 2%) 0.21 . 0.69  Inflammation, mixed 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.22 . 1.00 Epididymis  Atrophy 4/50 ( 8%) 5/36 ( 14%) 1/31 ( 3%) 7/50 ( 14%) 0.56 0.89 0.36  Granuloma, sperm 0/50 ( 0%) 1/36 ( 3%) 0/31 ( 0%) 0/50 ( 0%) 0.69 0.71 0.40  Inflammation, chronic 2/50 ( 4%) 0/36 ( 0%) 1/31 ( 3%) 0/50 ( 0%) 0.23 0.26 0.36  M-Mesothelioma, malignant 0/50 ( 0%) 1/36 ( 3%) 0/31 ( 0%) 2/50 ( 4%) 0.22 0.26 0.47 Eyes/optic nerve  Atrophy 1/50 ( 2%) 0/34 ( 0%) 0/33 ( 0%) 0/50 ( 0%) 0.21 . 1.00  Atrophy, retinal, unilateral 1/50 ( 2%) 0/34 ( 0%) 3/33 ( 9%) 1/50 ( 2%) 0.57 0.76 0.20  Cataract 1/50 ( 2%) 0/34 ( 0%) 3/33 ( 9%) 1/50 ( 2%) 0.57 0.76 0.20  Degeneration 1/50 ( 2%) 0/34 ( 0%) 0/33 ( 0%) 0/50 ( 0%) 0.21 . 1.00  Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 1/33 ( 3%) 1/50 ( 2%) 0.24 0.32 0.57  Inflammation, chronic 0/50 ( 0%) 0/34 ( 0%) 1/33 ( 3%) 0/50 ( 0%) 0.67 0.64 0.20  Inflammation, mixed 1/50 ( 2%) 2/34 ( 6%) 0/33 ( 0%) 0/50 ( 0%) 0.23 0.25 0.26  M-Leukemia, mononuclear 1/50 ( 2%) 1/34 ( 3%) 0/33 ( 0%) 0/50 ( 0%) 0.24 0.31 0.82  Metaplasia, osseous, scleral 3/50 ( 6%) 0/34 ( 0%) 0/33 ( 0%) 0/50 ( 0%) 0.030 . 0.11  Mineralization, corneal stromal 3/50 ( 6%) 0/34 ( 0%) 2/33 ( 6%) 1/50 ( 2%) 0.49 0.42 0.45  Mineralization, scleral 3/50 ( 6%) 1/34 ( 3%) 6/33 ( 18%) 4/50 ( 8%) 0.35 0.41 0.17  Neovascularization, corneal 3/50 ( 6%) 0/34 ( 0%) 2/33 ( 6%) 0/50 ( 0%) 0.19 0.15 0.14 Harderian gland  N-Carcinoma, squamous cell 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . . Heart  Degeneration, myocyte 2/50 ( 4%) 1/34 ( 3%) 3/30 ( 10%) 3/50 ( 6%) 0.46 0.57 0.65  Fibrosis 5/50 ( 10%) 5/34 ( 15%) 2/30 ( 7%) 4/50 ( 8%) 0.54 0.47 0.74  Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.63 0.18  Inflammation, focal, chronic 19/50 ( 38%) 9/34 ( 26%) 10/30 ( 33%) 19/50 ( 38%) 0.87 0.78 0.70  M-Leukemia, mononuclear 4/50 ( 8%) 5/34 ( 15%) 3/30 ( 10%) 5/50 ( 10%) 0.88 0.98 0.80  Thrombus 0/50 ( 0%) 1/34 ( 3%) 2/30 ( 7%) 2/50 ( 4%) 0.18 0.23 0.27 ___________________________________________________________________________________________________________________________________ 
O-22

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Ileum  B-Fibroma 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.22 . 1.00  Hyperplasia, lymphoid 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.08 . 0.33  N-Leukemia, mononuclear 0/50 ( 0%) 1/34 ( 3%) 0/30 ( 0%) 0/49 ( 0%) 0.69 0.83 0.39 Iliac LN  Dilatation, sinusoidal 0/3 ( 0%) 0/1 ( 0%) 1/4 ( 25%) 0/2 ( 0%) 0.64 0.42 1.00  N-Leukemia, mononuclear 3/3 (100%) 1/1 (100%) 3/4 ( 75%) 2/2 (100%) 0.64 0.42 1.00 Jejunum  M-Adenocarcinoma 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.08 . 0.34 Kidneys  B-Adenoma, renal tubule 0/50 ( 0%) 0/50 ( 0%) 6/50 ( 12%) 2/50 ( 4%) 0.053 0.09 0.0053 

 Cyst 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 0/50 ( 0%) 0.79 0.76 0.62  Degeneration, hyaline droplet 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.67 1.00  Infarct 0/50 ( 0%) 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0.53 0.33 0.25  Inflammation, acute 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 0/50 ( 0%) 0.79 0.75 0.62  M-Carcinoma, renal tubule 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.53 0.61 1.00  M-Leukemia, mononuclear 4/50 ( 8%) 3/50 ( 6%) 1/50 ( 2%) 1/50 ( 2%) 0.09 0.12 0.46  Nephropathy, chronic 44/50 ( 88%) 47/50 ( 94%) 50/50 (100%) 46/50 ( 92%) 0.25 0.63 0.07  Pigment accumulation, tubular epithelium 3/50 ( 6%) 3/50 ( 6%) 1/50 ( 2%) 3/50 ( 6%) 0.77 0.99 0.77 Larynx  Hyperplasia, epithelial 24/50 ( 48%) 15/49 ( 31%) 15/50 ( 30%) 24/50 ( 48%) 0.98 0.79 0.09  Inflammation, chronic 4/50 ( 8%) 2/49 ( 4%) 4/50 ( 8%) 3/50 ( 6%) 0.89 0.95 0.92  Inflammation, mixed 40/50 ( 80%) 35/49 ( 71%) 41/50 ( 82%) 44/50 ( 88%) 0.17 0.34 0.24  Metaplasia, squamous 8/50 ( 16%) 3/49 ( 6%) 6/50 ( 12%) 6/50 ( 12%) 0.76 0.57 0.51  Ulceration 1/50 ( 2%) 0/49 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 ___________________________________________________________________________________________________________________________________ 3Pairwise Fisher’s exact tests: p=0.03 for 0 g/m3 cf. 10 g/m3; p=0.49 for 0 g/m3 cf. 20 g/m3; p=0.03 for 2 g/m3 cf. 10 g/m3; 

 p=0.49 for 2 g/m3 cf. 20 g/m3; p=0.27 for 10 g/m3 cf. 20 g/m3. 
O-23

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Liver  Angiectasis 15/50 ( 30%) 4/40 ( 10%) 8/38 ( 21%) 18/50 ( 36%) 0.32 0.49 0.0264 

 B-Adenoma, hepatocellular 1/50 ( 2%) 0/40 ( 0%) 1/38 ( 3%) 1/50 ( 2%) 0.80 0.95 0.89  Congestion 0/50 ( 0%) 0/40 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00  Cyst 0/50 ( 0%) 0/40 ( 0%) 1/38 ( 3%) 0/50 ( 0%) 0.67 0.63 0.21  Fatty Change 2/50 ( 4%) 1/40 ( 3%) 1/38 ( 3%) 0/50 ( 0%) 0.20 0.19 0.62  Foci of cellular alteration, basophilic 1/50 ( 2%) 1/40 ( 3%) 0/38 ( 0%) 0/50 ( 0%) 0.23 0.31 0.84  Hepatodiaphragmatic nodule 1/50 ( 2%) 1/40 ( 3%) 1/38 ( 3%) 2/50 ( 4%) 0.55 0.69 1.00  Hyperplasia, biliary 45/50 ( 90%) 34/40 ( 85%) 37/38 ( 97%) 46/50 ( 92%) 0.38 0.47 0.28  Hyperplasia, hepatocellular, regenerative 1/50 ( 2%) 3/40 ( 8%) 3/38 ( 8%) 2/50 ( 4%) 0.65 0.69 0.52  Inflammation, chronic 7/50 ( 14%) 1/40 ( 3%) 0/38 ( 0%) 6/50 ( 12%) 0.65 0.46 0.0235  M-Carcinoma, hepatocellular 1/50 ( 2%) 0/40 ( 0%) 0/38 ( 0%) 0/50 ( 0%) 0.20 . 1.00  M-Leukemia, mononuclear 27/50 ( 54%) 29/40 ( 73%) 29/38 ( 76%) 31/50 ( 62%) 0.37 0.31 0.12  M-Sarcoma, histiocytic 0/50 ( 0%) 1/40 ( 3%) 0/38 ( 0%) 1/50 ( 2%) 0.54 0.50 0.84  M-Sarcoma, undifferentiated 0/50 ( 0%) 0/40 ( 0%) 1/38 ( 3%) 0/50 ( 0%) 0.67 0.79 0.21  Necrosis 3/50 ( 6%) 4/40 ( 10%) 2/38 ( 5%) 4/50 ( 8%) 0.89 0.86 0.90  Thrombus 0/50 ( 0%) 0/40 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00  Vacuolization, cytoplasmic 1/50 ( 2%) 3/40 ( 8%) 1/38 ( 3%) 3/50 ( 6%) 0.53 0.57 0.59 Lungs  Alveolar histiocytosis 7/50 ( 14%) 10/50 ( 20%) 10/50 ( 20%) 11/50 ( 22%) 0.33 0.50 0.77  Autolysis, marked 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00  B-Adenoma, bronchiolo-alveolar 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.53 0.51 1.00  Congestion 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0.53 0.82 0.25  Cyst, squamous cell, keratinizing 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00  Fibrosis, focal 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1.00 0.95 1.00  Hemorrhage 3/50 ( 6%) 7/50 ( 14%) 7/50 ( 14%) 1/50 ( 2%) 0.51 0.58 0.07  Hyperplasia, alveolar epithelial, focal 8/50 ( 16%) 7/50 ( 14%) 2/50 ( 4%) 4/50 ( 8%) 0.08 0.08 0.18  Hyperplasia, alveolar epithelial, widespread 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.25 1.00  Inflammation, acute 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0.79 0.72 1.00  Inflammation, granulomatous 0/50 ( 0%) 2/50 ( 4%) 2/50 ( 4%) 1/50 ( 2%) 0.54 0.62 0.76  Inflammation, mixed 1/50 ( 2%) 1/50 ( 2%) 5/50 ( 10%) 2/50 ( 4%) 0.29 0.36 0.32  Metaplasia, squamous - alveolar epithelium 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0.53 0.44 0.25  Mineralization, uremic 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00  N-Leukemia, mononuclear - capillary involvement 24/50 ( 48%) 31/50 ( 62%) 32/50 ( 64%) 25/50 ( 50%) 0.80 0.66 0.27  N-Leukemia, mononuclear - invasive involvement 1/50 ( 2%) 1/50 ( 2%) 1/50 ( 2%) 1/50 ( 2%) 1.00 0.95 1.00  N-Sarcoma, histiocytic 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0.53 0.55 0.25 ___________________________________________________________________________________________________________________________________ 4Pairwise Fisher’s exact tests: p=0.04 for 0 g/m3 cf. 2 g/m3; p=0.46 for 0 g/m3 cf. 10 g/m3; p=0.67 for 0 g/m3 cf. 20 g/m3; 

 p=0.22 for 2 g/m3 cf. 10 g/m3; p=0.006 for 2 g/m3 cf. 20 g/m3; p=0.16 for 10 g/m3 cf. 20 g/m3. 

5Pairwise Fisher’s exact tests: p=0.07 for 0 g/m3 cf. 2 g/m3; p=0.018 for 0 g/m3 cf. 10 g/m3; p=1.00 for 0 g/m3 cf. 20 g/m3; 

 p=1.00 for 2 g/m3 cf. 10 g/m3; p=0.13 for 2 g/m3 cf. 20 g/m3; p=0.03 for 10 g/m3 cf. 20 g/m3. 
O-24

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Lymph node other  Dilatation, sinusoidal 0/6 ( 0%) 1/4 ( 25%) 0/9 ( 0%) 0/7 ( 0%) 0.55 0.71 0.15  Infiltration, histiocytic 0/6 ( 0%) 1/4 ( 25%) 1/9 ( 11%) 0/7 ( 0%) 0.84 0.66 0.51  N-Leukemia, mononuclear 5/6 ( 83%) 2/4 ( 50%) 7/9 ( 78%) 6/7 ( 86%) 0.70 0.49 0.65  Sinus plasmacytosis 1/6 ( 17%) 0/4 ( 0%) 0/9 ( 0%) 1/7 ( 14%) 0.84 0.67 0.64 Mammary gland  B-Fibroadenoma 0/36 ( 0%) 0/31 ( 0%) 0/29 ( 0%) 1/47 ( 2%) 0.24 . 1.00  B-Fibroma 2/36 ( 6%) 2/31 ( 6%) 3/29 ( 10%) 1/47 ( 2%) 0.57 0.53 0.49  Cyst 0/36 ( 0%) 0/31 ( 0%) 1/29 ( 3%) 0/47 ( 0%) 0.74 0.80 0.20  Ectasia 1/36 ( 3%) 0/31 ( 0%) 0/29 ( 0%) 1/47 ( 2%) 0.90 0.88 1.00  Hyperplasia, lobular 0/36 ( 0%) 1/31 ( 3%) 0/29 ( 0%) 5/47 ( 11%) 0.025 0.16 0.056  N-Sarcoma, histiocytic 0/36 ( 0%) 2/31 ( 6%) 0/29 ( 0%) 0/47 ( 0%) 0.46 0.48 0.09 Mandibular LN  Hemorrhage 1/40 ( 3%) 0/32 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.18 . 0.68  Hyperplasia, lymphoid 1/40 ( 3%) 0/32 ( 0%) 1/30 ( 3%) 0/48 ( 0%) 0.49 0.51 0.45  N-Leukemia, mononuclear 13/40 ( 33%) 10/32 ( 31%) 9/30 ( 30%) 9/48 ( 19%) 0.14 0.15 0.42  Sinus plasmacytosis 1/40 ( 3%) 0/32 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.18 . 0.68 Mediastinal LN  Hemorrhage 2/49 ( 4%) 1/30 ( 3%) 2/30 ( 7%) 2/50 ( 4%) 0.89 0.98 0.91  N-Leukemia, mononuclear 9/49 ( 18%) 7/30 ( 23%) 5/30 ( 17%) 8/50 ( 16%) 0.64 0.62 0.86  N-Sarcoma, histiocytic 0/49 ( 0%) 1/30 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.68 0.68 0.38  Pigmentation 0/49 ( 0%) 1/30 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.68 0.75 0.38 Mediastinum  N-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . . Mesenteric LN  Hemorrhage 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00  Histiocytosis, sinus 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00  N-Leukemia, mononuclear 6/50 ( 12%) 3/34 ( 9%) 5/30 ( 17%) 6/50 ( 12%) 0.81 0.74 0.84  N-Sarcoma, histiocytic 0/50 ( 0%) 1/34 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.69 0.69 0.39 Mesentery  Inflammation, mixed 0/0 ( .%) 1/1 (100%) 0/1 ( 0%) 0/0 ( .%) 0.16 . 1.00  M-Mesothelioma, malignant 0/0 ( .%) 0/1 ( 0%) 1/1 (100%) 0/0 ( .%) 0.16 . 1.00 ___________________________________________________________________________________________________________________________________ 
O-25

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Muscle, skeletal  Inflammation, chronic 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.46 0.18  M-Leukemia, mononuclear 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.69 0.18  N-Sarcoma, histiocytic 0/50 ( 0%) 2/34 ( 6%) 0/30 ( 0%) 0/50 ( 0%) 0.57 0.57 0.07 Nose/Turbinate 1  Degeneration - respiratory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  Degeneration, hyaline - respiratory epithelium 0/50 ( 0%) 3/50 ( 6%) 5/50 ( 10%) 3/50 ( 6%) 0.13 0.12 0.15  Hyperplasia - respiratory epithelium 3/50 ( 6%) 0/50 ( 0%) 3/50 ( 6%) 4/50 ( 8%) 0.38 0.21 0.23  Inflammation - nasolacrimal duct 11/50 ( 22%) 11/50 ( 22%) 15/50 ( 30%) 12/50 ( 24%) 0.61 0.60 0.78  Inflammation - respiratory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1.00 0.98 1.00  Inflammation, mixed 7/50 ( 14%) 5/50 ( 10%) 8/50 ( 16%) 6/50 ( 12%) 1.00 0.91 0.89  M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  Metaplasia, squamous - respiratory epithelium 3/50 ( 6%) 2/50 ( 4%) 1/50 ( 2%) 0/50 ( 0%) 0.06 0.060 0.52  Metaplasia, squamous - transitional epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 Nose/Turbinate 2  Degeneration - olfactory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  Degeneration - respiratory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 . 1.00  Degeneration, hyaline - olfactory epithelium 0/50 ( 0%) 5/50 ( 10%) 7/50 ( 14%) 6/50 ( 12%) 0.027 0.026 0.0326 

 Degeneration, hyaline - respiratory epithelium 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 3/50 ( 6%) 0.06 0.10 0.52  Hyperplasia - respiratory epithelium 0/50 ( 0%) 2/50 ( 4%) 2/50 ( 4%) 3/50 ( 6%) 0.12 0.12 0.52  Inflammation, mixed 4/50 ( 8%) 6/50 ( 12%) 3/50 ( 6%) 5/50 ( 10%) 1.00 0.97 0.84  M-Carcinoma, squamous cell 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  Metaplasia, secretory - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.63 1.00  Metaplasia, squamous - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.59 1.00  Metaplasia, squamous - respiratory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.72 1.00 Nose/Turbinate 3  Degeneration, hyaline - olfactory epithelium 2/50 ( 4%) 1/50 ( 2%) 7/50 ( 14%) 7/50 ( 14%) 0.017 0.026 0.054  Inflammation, mixed 4/50 ( 8%) 1/50 ( 2%) 1/50 ( 2%) 3/50 ( 6%) 0.65 0.53 0.46  M-Carcinoma, squamous cell 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.53 0.56 1.00  M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 __________________________________________________________________________________________________________________________________ 6Pairwise Fisher’s exact tests: p=0.06 for 0 g/m3 cf. 2 g/m3; p=0.012 for 0 g/m3 cf. 10 g/m3; p=0.03 for 0 g/m3 cf. 20 g/m3; 

 p=0.76 for 2 g/m3 cf. 10 g/m3; p=1.00 for 2 g/m3 cf. 20 g/m3; p=1.00 for 10 g/m3 cf. 20 g/m3. 
O-26

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Nose/Turbinate 4  Degeneration - olfactory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.72 1.00  Degeneration, hyaline - olfactory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0.20 0.29 1.00  Inflammation, mixed 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 0.84 0.89 0.76  M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  N-Carcinoma, squamous cell 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 2/50 ( 4%) 0.37 0.39 0.34 Pancreas  M-Carcinoma, ductal cell 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/49 ( 2%) 0.21 . 0.69  M-Leukemia, mononuclear 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.22 . 1.00 Pancreatic LN  N-Leukemia, mononuclear 5/5 (100%) 2/2 (100%) 2/2 (100%) 4/4 (100%) . . . Parathyroid  Hyperplasia, diffuse 0/45 ( 0%) 0/33 ( 0%) 0/30 ( 0%) 1/46 ( 2%) 0.21 . 1.00  Hyperplasia, focal 0/45 ( 0%) 0/33 ( 0%) 0/30 ( 0%) 2/46 ( 4%) 0.07 . 0.34 Pituitary gland  Angiectasis 2/49 ( 4%) 0/37 ( 0%) 0/34 ( 0%) 3/50 ( 6%) 0.57 0.61 0.29  B-Adenoma, pars distalis 9/49 ( 18%) 9/37 ( 24%) 6/34 ( 18%) 5/50 ( 10%) 0.20 0.15 0.34  Cyst 4/49 ( 8%) 7/37 ( 19%) 7/34 ( 21%) 6/50 ( 12%) 0.58 0.65 0.31  Hemorrhage 3/49 ( 6%) 0/37 ( 0%) 0/34 ( 0%) 2/50 ( 4%) 0.57 0.55 0.27  Hyperplasia, pars distalis, focal 5/49 ( 10%) 4/37 ( 11%) 3/34 ( 9%) 8/50 ( 16%) 0.42 0.42 0.78  Inflammation, chronic 0/49 ( 0%) 0/37 ( 0%) 0/34 ( 0%) 1/50 ( 2%) 0.21 . 1.00  M-Leukemia, mononuclear 1/49 ( 2%) 1/37 ( 3%) 1/34 ( 3%) 1/50 ( 2%) 1.00 0.86 1.00 Popliteal LN  N-Leukemia, mononuclear 2/2 (100%) 0/0 ( .%) 2/2 (100%) 2/2 (100%) . . . Preputial gland  Cyst, epithelial inclusion 0/4 ( 0%) 0/1 ( 0%) 1/3 ( 33%) 0/2 ( 0%) 0.53 . 0.60  Ectasia 2/4 ( 50%) 1/1 (100%) 2/3 ( 67%) 2/2 (100%) 0.27 0.28 0.80  Inflammation, chronic 1/4 ( 25%) 0/1 ( 0%) 0/3 ( 0%) 1/2 ( 50%) 0.79 . 0.73  Inflammation, mixed 3/4 ( 75%) 0/1 ( 0%) 0/3 ( 0%) 1/2 ( 50%) 0.23 0.31 0.20 Prostate  Atrophy 3/50 ( 6%) 0/33 ( 0%) 0/29 ( 0%) 5/50 ( 10%) 0.36 0.63 0.13  Hemorrhage 0/50 ( 0%) 0/33 ( 0%) 0/29 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Hyperplasia 0/50 ( 0%) 0/33 ( 0%) 1/29 ( 3%) 0/50 ( 0%) 0.67 0.70 0.18  Inflammation, acute 2/50 ( 4%) 1/33 ( 3%) 0/29 ( 0%) 0/50 ( 0%) 0.10 0.19 0.46  Inflammation, mixed 15/50 ( 30%) 12/33 ( 36%) 16/29 ( 55%) 13/50 ( 26%) 0.97 0.80 0.06  Mineralization 1/50 ( 2%) 0/33 ( 0%) 0/29 ( 0%) 0/50 ( 0%) 0.22 . 1.00 __________________________________________________________________________________________________________________________________ 
O-27

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Salivary gland  Degeneration 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00  M-Leukemia, mononuclear 0/50 ( 0%) 0/34 ( 0%) 2/30 ( 7%) 1/50 ( 2%) 0.22 0.29 0.17 Sciatic nerve  N-Leukemia, mononuclear 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00 Seminal vesicle  Atrophy 15/50 ( 30%) 2/35 ( 6%) 8/37 ( 22%) 18/50 ( 36%) 0.28 0.67 0.0067 

 Dilatation 0/50 ( 0%) 1/35 ( 3%) 1/37 ( 3%) 1/50 ( 2%) 0.47 0.67 0.78  Hyperplasia 0/50 ( 0%) 1/35 ( 3%) 0/37 ( 0%) 0/50 ( 0%) 0.67 . 0.20  M-Leukemia, mononuclear 1/50 ( 2%) 0/35 ( 0%) 1/37 ( 3%) 0/50 ( 0%) 0.54 0.51 0.83 Skin  B-Fibroma 2/49 ( 4%) 0/37 ( 0%) 1/35 ( 3%) 0/50 ( 0%) 0.22 0.28 0.32  B-Keratoacanthoma 0/49 ( 0%) 0/37 ( 0%) 0/35 ( 0%) 1/50 ( 2%) 0.21 . 1.00  B-Tumor, basal cell, benign 0/49 ( 0%) 0/37 ( 0%) 0/35 ( 0%) 1/50 ( 2%) 0.21 . 1.00  B-Tumor, hair follicle, benign 0/49 ( 0%) 0/37 ( 0%) 1/35 ( 3%) 0/50 ( 0%) 0.67 0.80 0.20  Cyst, epithelial inclusion 0/49 ( 0%) 0/37 ( 0%) 0/35 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Fibrosis 1/49 ( 2%) 2/37 ( 5%) 0/35 ( 0%) 0/50 ( 0%) 0.22 0.23 0.23  Hyperkeratosis 1/49 ( 2%) 1/37 ( 3%) 2/35 ( 6%) 0/50 ( 0%) 0.67 0.56 0.34  Inflammation, chronic 1/49 ( 2%) 0/37 ( 0%) 0/35 ( 0%) 0/50 ( 0%) 0.20 . 0.71  Inflammation, mixed 0/49 ( 0%) 3/37 ( 8%) 2/35 ( 6%) 0/50 ( 0%) 0.84 0.76 0.0268  M-Carcinoma, sebaceous cell 0/49 ( 0%) 1/37 ( 3%) 0/35 ( 0%) 0/50 ( 0%) 0.67 . 0.42  M-Sarcoma, undifferentiated 0/49 ( 0%) 1/37 ( 3%) 2/35 ( 6%) 0/50 ( 0%) 0.81 0.84 0.09  N-Sarcoma, histiocytic 0/49 ( 0%) 2/37 ( 5%) 0/35 ( 0%) 0/50 ( 0%) 0.55 0.56 0.09  Necrosis 0/49 ( 0%) 1/37 ( 3%) 0/35 ( 0%) 0/50 ( 0%) 0.67 0.68 0.42 Spinal cord  Degeneration, white matter 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00  Hemorrhage 1/50 ( 2%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.57 0.82 0.56  Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.63 0.18 ___________________________________________________________________________________________________________________________________ 7Pairwise Fisher’s exact tests: p=0.006 for 0 g/m3 cf. 2 g/m3; p=0.46 for 0 g/m3 cf. 10 g/m3; p=0.67 for 0 g/m3 cf. 20 g/m3; 

 p=0.09 for 2 g/m3 cf. 10 g/m3; p=0.001 for 2 g/m3 cf. 20 g/m3; p=0.16 for 10 g/m3 cf. 20 g/m3. 

8Pairwise Fisher’s exact tests: p=0.08 for 0 g/m3 cf. 2 g/m3; p=0.17 for 0 g/m3 cf. 10 g/m3; p=1.00 for 2 g/m3 cf. 10 g/m3; 

 p=0.07 for 2 g/m3 cf. 20 g/m3; p=0.17 for 10 g/m3 cf. 20 g/m3. 
O-28

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Continued) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Spleen  Congestion 0/50 ( 0%) 1/39 ( 3%) 1/38 ( 3%) 0/50 ( 0%) 1.00 1.00 0.35  Fibrosis 3/50 ( 6%) 2/39 ( 5%) 5/38 ( 13%) 0/50 ( 0%) 0.41 0.36 0.052  Hemorrhage 0/50 ( 0%) 1/39 ( 3%) 0/38 ( 0%) 0/50 ( 0%) 0.67 0.65 0.44  M-Fibrosarcoma 0/50 ( 0%) 0/39 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00  M-Leukemia, mononuclear 27/50 ( 54%) 31/39 ( 79%) 31/38 ( 82%) 31/50 ( 62%) 0.39 0.36 0.0129 

 N-Sarcoma, histiocytic 0/50 ( 0%) 0/39 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00  Necrosis 2/50 ( 4%) 2/39 ( 5%) 1/38 ( 3%) 1/50 ( 2%) 0.48 0.50 0.94 Stomach  Hyperplasia, squamous epithelial 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.08 . 0.33  Inflammation, mixed 2/50 ( 4%) 1/34 ( 3%) 0/30 ( 0%) 0/49 ( 0%) 0.10 0.18 0.47 Tail  Cyst, epithelial inclusion 0/1 ( 0%) 1/2 ( 50%) 0/1 ( 0%) 0/0 ( .%) 1.00 . 1.00  Hyperplasia/hyperkeratosis 0/1 ( 0%) 2/2 (100%) 1/1 (100%) 0/0 ( .%) 0.10 . 0.50  Inflammation, acute 1/1 (100%) 0/2 ( 0%) 0/1 ( 0%) 0/0 ( .%) 0.10 . 0.50  Inflammation, mixed 0/1 ( 0%) 2/2 (100%) 1/1 (100%) 0/0 ( .%) 0.10 . 0.50 Testes  Atrophy 1/50 ( 2%) 4/50 ( 8%) 3/50 ( 6%) 5/50 ( 10%) 0.16 0.19 0.49  B-Adenoma, interstitial cell 43/50 ( 86%) 47/50 ( 94%) 48/50 ( 96%) 50/50 (100%) 0.003 0.026 0.02910  Hemorrhage 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.53 0.42 1.00  Hyperplasia, interstitial cell 5/50 ( 10%) 6/50 ( 12%) 3/50 ( 6%) 2/50 ( 4%) 0.16 0.45 0.50  M-Mesothelioma, malignant 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 2/50 ( 4%) 0.18 0.21 0.90 Thymus  Hemorrhage 0/1 ( 0%) 0/0 ( .%) 0/0 ( .%) 1/2 ( 50%) 0.39 . 1.00  M-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 1/2 ( 50%) 0.39 . 1.00 Thyroid glands  B-Adenoma, C-cell 3/50 ( 6%) 4/35 ( 11%) 4/31 ( 13%) 3/50 ( 6%) 0.97 0.93 0.59  B-Adenoma, follicular cell 2/50 ( 4%) 0/35 ( 0%) 0/31 ( 0%) 3/50 ( 6%) 0.56 0.73 0.42  Cyst, follicular 1/50 ( 2%) 1/35 ( 3%) 3/31 ( 10%) 3/50 ( 6%) 0.22 0.27 0.38  Hyperplasia, C-cell, focal 4/50 ( 8%) 2/35 ( 6%) 0/31 ( 0%) 7/50 ( 14%) 0.38 0.59 0.14  Hyperplasia, follicular cell 0/50 ( 0%) 0/35 ( 0%) 1/31 ( 3%) 0/50 ( 0%) 0.67 0.80 0.19  M-Carcinoma, C-cell 0/50 ( 0%) 2/35 ( 6%) 0/31 ( 0%) 0/50 ( 0%) 0.56 0.52 0.08  M-Carcinoma, follicular cell 1/50 ( 2%) 0/35 ( 0%) 1/31 ( 3%) 3/50 ( 6%) 0.18 0.26 0.53 ___________________________________________________________________________________________________________________________________ 9Pairwise Fisher’s exact tests: p=0.014 for 0 g/m3 cf. 2 g/m3; p=0.012 for 0 g/m3 cf. 10 g/m3; p=0.54 for 0 g/m3 cf. 20 g/m3; 

 p=1.00 for 2 g/m3 cf. 10 g/m3; p=0.10 for 2 g/m3 cf. 20 g/m3; p=0.06 for 10 g/m3 cf. 20 g/m3. 

10Pairwise Fisher’s exact tests: p=0.32 for 0 g/m3 cf. 2 g/m3; p=0.16 for 0 g/m3 cf. 10 g/m3; p=0.012 for 0 g/m3 cf. 20g/m3; 

 p=1.00 for 2 g/m3 cf. 10 g/m3; p=0.24 for 2 g/m3 cf. 20 g/m3; p=0.49 for 10 g/m3 cf. 20 g/m3. 
O-29

Study Number FY01-013 

Table O-5. Statistical Evaluation of Microscopic Lesions in Males (Concluded) ___________________________________________________________________________________________________________________________________  Cochran Fisher's  Exposure Concentration (g/m3) Armitage Logistic Exact 

Tissue and Diagnosis 0 2 10 20 p-value p-value p-value ___________________________________________________________________________________________________________________________________ Tiss.not specified  B-Fibroma 0/1 ( 0%) 0/2 ( 0%) 1/3 ( 33%) 0/5 ( 0%) 0.92 . 0.55  B-Lipoma 1/1 (100%) 0/2 ( 0%) 0/3 ( 0%) 1/5 ( 20%) 0.35 0.29 0.25  Cyst 0/1 ( 0%) 0/2 ( 0%) 0/3 ( 0%) 1/5 ( 20%) 0.34 . 1.00  Inflammation, mixed 0/1 ( 0%) 0/2 ( 0%) 1/3 ( 33%) 0/5 ( 0%) 0.92 . 0.55  M-Mesothelioma, malignant 0/1 ( 0%) 0/2 ( 0%) 0/3 ( 0%) 2/5 ( 40%) 0.15 . 0.73  Mammary tissue 0/1 ( 0%) 0/2 ( 0%) 1/3 ( 33%) 0/5 ( 0%) 0.92 0.80 0.55  Myodegeneration 0/1 ( 0%) 1/2 ( 50%) 0/3 ( 0%) 0/5 ( 0%) 0.25 0.33 0.27  N-Sarcoma, histiocytic 0/1 ( 0%) 1/2 ( 50%) 0/3 ( 0%) 0/5 ( 0%) 0.25 . 0.27  Splenic tissue, "accessory" 0/1 ( 0%) 0/2 ( 0%) 0/3 ( 0%) 1/5 ( 20%) 0.34 . 1.00 Trachea  Hyperplasia, epithelial 1/50 ( 2%) 1/49 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.25 0.62  Inflammation, acute 0/50 ( 0%) 1/49 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.59 0.25  Inflammation, chronic 1/50 ( 2%) 2/49 ( 4%) 1/50 ( 2%) 1/50 ( 2%) 0.84 0.93 0.82  Inflammation, mixed 1/50 ( 2%) 1/49 ( 2%) 0/50 ( 0%) 4/50 ( 8%) 0.14 0.17 0.15  Metaplasia, squamous 1/50 ( 2%) 0/49 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00  N-Leukemia, mononuclear 2/50 ( 4%) 0/49 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.19 0.21 0.62 Urinary bladder  B-Papilloma, transitional cell 1/50 ( 2%) 0/33 ( 0%) 0/29 ( 0%) 0/50 ( 0%) 0.22 . 1.00  Hemorrhage 0/50 ( 0%) 0/33 ( 0%) 0/29 ( 0%) 1/50 ( 2%) 0.21 . 1.00  Inflammation, chronic 3/50 ( 6%) 0/33 ( 0%) 0/29 ( 0%) 3/50 ( 6%) 0.98 0.86 0.39  Inflammation, mixed 0/50 ( 0%) 0/33 ( 0%) 0/29 ( 0%) 1/50 ( 2%) 0.21 . 1.00  M-Leukemia, mononuclear 1/50 ( 2%) 1/33 ( 3%) 0/29 ( 0%) 1/50 ( 2%) 0.82 0.73 1.00 Zymbal's gland  M-Carcinoma, squamous cell 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) 1/1 (100%) . . . ___________________________________________________________________________________________________________________________________ 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

September 2009 

P-1 

APPENDIX P 

PATHOLOGIST’S REPORT 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-2 

Study Number FY01-013 

Study Title: 211(b) Chronic Carcinogenicity Study Gasoline MTBE Vapor Condensate 

(GMVC) 

LRRI Protocol Number: FY01-013 

Appendix P 

PATHOLOGIST’S REPORT 

Andrew P. Gigliotti DVM, PhD, Diplomate ACVP Date 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-3 

INTRODUCTION 

Four hundred (400) F344 rats exposed to gasoline MTBE vapor condensate (GMVC) in 

whole body inhalation exposure chambers were examined. Males and females were divided 

equally into 4 groups (50 males and 50 females per group) and exposed to 0 g/m3, 2 g/m3, 

10 g/m3 or 20 g/m3 GMVC for 6 hours/day, 5 days/week for 104 weeks (520 exposure days). 

The sole scheduled sacrifice occurred after 104 weeks (520 days) of exposure. Gross necropsy 

and tissue collection was performed as specified in the main report text. 

METHODS 

Hematology

Blood was collected on control and high-level GMVC rats by tail nick at 12 and 18 

months of exposure and was collected from all final sacrifice rats by cardiac puncture for 

assessment of total and differential white blood cell counts. Duplicate blood smears were 

prepared and read manually for the control and high-level groups at all three time points. 

Percentages of each nucleated cell type were counted. An estimate of the number of white blood 

cells in each sample was made according to LRRI SOP. Absolute numbers of each cell type 

were calculated by multiplying the fraction of each cell type by the estimated white blood cell 

count. 

Gross Pathology

As expected in a chronic study, a wide spectrum of gross lesions was documented at 

necropsy. Complete gross lesion incidences as well as correlation of gross and histologic lesions 

are located in Appendix M (males) and N (females). Gross lesions were examined histologically 

in all groups. 

Histopathology

All study animals received a complete necropsy. Animals were euthanized with an 

overdose of intraperitoneally injected barbiturate anesthetic (Euthasol®, Virbac AH Inc., Fort 

Worth, TX). Body weights and fresh organ weights were collected on lungs, liver, kidneys, 

adrenals, testes, epididymides, ovaries, uterus, spleen, brain and heart of final sacrifice and 

moribund sacrifice animals. Animals found dead received a complete necropsy with tissue 

collection, but blood and organ weight data were not routinely collected. Cardiac blood was 

collected from animals at final sacrifice for determination of total and differential white blood 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-4 

cell counts. Gross lesions, body weights, and organ weights were entered on pre-prepared forms 

and then the information was recorded on the Path-Tox database (Version 4.2.2, Module P, 

Xybion Medical Systems, Cedar Knolls, NJ). 

Lungs were gently instilled via the trachea with 10% neutral buffered formalin (NBF) to 

approximate normal volume. Organs/tissues were immersion fixed in 10% NBF for subsequent 

histopathologic examination. Tissues were trimmed, processed routinely, paraffin embedded, 

sectioned at 5 μm and stained with hematoxylin and eosin for histopathologic examination. 

All collected tissues and lesions were examined histologically in control (0 g/m3

) 

animals, high- (20 g/m3

) level animals, and dead or moribund animals of all groups. Respiratory 

tissues (lungs, larynx, trachea and nasal turbinate sections), potential target tissues (testes, 

kidneys of males) and gross lesions were examined histologically from final sacrifice low- (2 

g/m3

) and mid- (10 g/m3) level animals. Nomenclature of proliferative lesions was based on the 

international harmonized nomenclature recommended by the Rat Nomenclature Reconciliation 

Subcommittee of the Society of Toxicologic Pathologists (see http://www.toxpath.org; 

Standardized Rat Nomenclature). Nomenclature of other lesions was routine, widely understood 

usage (see Boorman et al., 1990a; Gopinath et al., 1987). 

Standard, subjective severity scoring of most nonproliferative lesions was based on the 

extent of tissue affected by the change and the severity of the change within affected areas. 

Typically, a score of 0 (none) = essentially no tissue affected; 1 (minimal) = ~1 to 10% affected, 

2 (mild) = ~11 to 25% affected, 3 (moderate) = ~26 to 50% affected, 4 (marked) = ~51 to 100% 

affected. Severity scores may have been adjusted up or down (usually by 1 point) based on the 

intensity of the change within the affected areas. 

Because the diagnosis of chronic progressive nephropathy encompasses a large 

constellation of changes, severity scoring for this diagnosis was somewhat more complex and is 

described in Table P-1. 

Statistical Analyses

Statistical analyses of both hematology and histopathology data were conducted as 

detailed in the statistician’s report (Appendix O). In the case of renal tubule nephropathy and 

nasal epithelial degeneration, statistical evaluation of group differences in severity scores was 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-5 

performed using the Kolmogorov-Smirnov test within the Path-Tox software (significance level 

p = 0.05; c.f. Algorithms used in Path/Tox System 4.2.2; Vol. I, Chap. 7, pp. 24-25). 

Table P-1. Severity Scoring of Chronic Progressive Nephropathy 

Score Histologic Findings 

0 Essentially no changes of CPN. May have rare scattered protein casts in tubules, 

mineral concretions. 

1 Increased number and size of tubular protein casts; primarily within tubules at the 

corticomedullary junction, some within collecting ducts. Minor/scattered foci of 

basophilic, regenerative tubules. Changes affect less than ~5% of tissue component. 

2 Homogeneous protein casts relatively abundant within tubules and collecting ducts 

(especially at corticomedullary junction). Increased size and frequency of tubular 

basophilia. Accompanying changes present, may include small foci of tubular basement 

membrane thickening and/or mineralization, interstitial fibrosis, tubular atrophy and 

dilatation, minor associated mononuclear inflammatory infiltrates, glomerular changes 

(including mesangial proliferation, synechiae, proliferation of parietal epithelium). 

Changes may affect up to ~25% of component. 

3 As 2 with increased tubular atrophy/dilatation/regeneration, interstitial fibrosis, 

increased inflammatory infiltrates, increased thickening of basement membranes of 

tubules and glomeruli. 

4 As 3 with increased severity and extent of changes. Senescent glomeruli relatively 

common. Typically combined changes affect well over 50% of kidney. 

RESULTS 

Hematology

The high incidence of leukemia in aged F344 rats, other physiologic changes with aging, 

sampling differences between time points and the limitations of manual hematology (e.g., the 

small numbers of leukocytes other than neutrophils and lymphocytes counted) dictate that the 

hematology results be interpreted with caution. Trend tests within a group across all sampling 

periods frequently show a statistical difference, but are not expected to be biologically significant 

for the reasons noted above (some specific examples follow). A statistically significant increase 

relative to controls in WBC estimate, “absolute” neutrophils, and “absolute” lymphocytes was 

noted in high-level group males at 12 months. This change is not present in females and does 

not persist in males at 18 or 24 months. It is interpreted as an excitement response probably 

resulting from initial blood sampling difficulties. The increase in atypical lymphocytes in both 

the control and the high-level group at 24 months is consistent with the high incidence of 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-6 

leukemia in these aged F344 rats. Other statistically significant changes are unlikely to be 

biologically significant based on the small numbers of leukocytes of that type (such as band 

neutrophils, monocytes or eosinophils) counted in blood smears. 

Histopathology

Condensed tables including only microscopic lesions judged to be more relevant as 

potential effects of GMVC exposure or those for which reviewers indicated an interest are 

presented below. Note that all microscopic findings are not included here; refer to the summary 

tables in Appendices M and N for a complete listing. Though some comparisons are included 

here, see GMVC main report for more complete comparison between findings from this study 

and the Baseline Gasoline Vapor Condensate (BGVC) study run concurrently. 

Proliferative Lesions. Proliferative lesions include hyperplasias and neoplasias (both benign and 

malignant). As is evident in the complete lesion incidence summary tables (Appendices M and 

N), scattered hyperplasias and neoplasias occur relatively commonly in aged F344 male and 

female rats. 

Male rats in the mid-level GMVC group demonstrated a significant increase in the 

incidence of renal tubule cell adenomas in mid-dose animals, with 0/50 (0%), 0/50 (0%), 6/50 

(12%) and 2/50 (4%) in the control, low, mid and high groups, respectively (Table P-2). 

Although not statistically significant alone, there was also an increase in renal tubule carcinomas 

in the males (1/50; 2% in low- and 1/50; 2% in high-level males). Combining adenomas and 

carcinomas for analysis maintained the statistically significant increase in tumors in mid-dose 

animals, and additionally showed a significant trend toward increased incidence with increased 

exposure concentration (Table P-2). 

Squamous cell carcinoma occurred in nasal sections of males with an animal incidence 

(incidence of tumor occurring in any of turbinates 2–4) of 1/50 (2%), 2/50 (4%), 0/50 (0%) and 

2/50 (4%) for control, low-, mid- and high-dose animals, respectively, with no statistically 

significant differences or trends. In all instances, the tumors were judged to have arisen in the 

oral cavity (Appendix M-6). Animal incidence is relevant because the same tumor may occur in 

more than one nasal section. This is true for the low- and high-level groups for male nasal 

turbinates 3 and 4 (Table P-2), where one animal in each group has a tumor spanning levels 3 

and 4. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-7 

No significant changes in incidence were seen for thyroid follicular cell adenoma or 

carcinoma. Combining thyroid follicular cell adenoma and carcinoma in male rats gave a 

combined incidence of 3/50 (6%), 0/35 (0%), 1/31 (3%) and 5/50 (10%) for control, low-, midand high-level groups, respectively. No statistical signficance was found upon combining the 

incidinces of adenomas and carcinomas. Note that one high-dose male had both an adenoma and 

a carcinoma, yielding a combined incidence of 5/50 (10%). However, even when counting 

adenoma and carcinoma in this animal individually, yielding an incidence 6/50 (12%) for this 

group (arguably the most conservative combined incidence from a risk assessment perspective) 

the difference is not significant using Fisher’s exact test; p = 0.130. See e-mail correspondence 

from statistician including statistical test in study file). A statistically significant increase in 

thyroid follicular cell carcinomas (but not combined adenomas and carcinomas) was observed 

among males in the Baseline Gasoline Vapor Condensate study run concurrently (FY01-027). 

As expected, there was a high background incidence of testicular interstitial adenomas in 

control male rats (43/50; 86%). There was a significant trend toward increased incidence with 

increased dose (with 47/50; 94% in lows and 48/50; 96% in mids), and the incidence among 

high-level males (50/50; 100%) was significantly greater than the control incidence (Table P-2). 

Essentially all testes with adenomas had foci of hyperplasia when the testis was not entirely 

effaced by tumors. However, the frequent effacement of testicular parenchyma by tumors in this 

chronic study renders the diagnosis of hyperplasia in testes with tumors of little or no value. 

Thus interstitial cell hyperplasia was recorded primarily in testes without tumors (see Appendix 

M). 

Mesothelioma was present at a relatively low incidence of 0/50 (0%), 1/50 (2%), 1/50 

(2%) and 2/50 (4%) for control, low-, mid- and high-level groups, respectively, and no statistical 

differences were noted for this neoplasm. Incidences in this study were comparable to the 

historical incidences for NTP studies (0–10% with a mean of ~3% [Haseman et al., 1998]). 

Results are somewhat different from those obtained in the Baseline Gasoline Vapor Condensate 

study, were a significant trend toward increased mesothelioma was noted (Fisher’s Exact test). It 

should be noted that no testicular mesotheliomas were present in control animals in this or in the 

Baseline Gasoline Vapor Condensate study. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-8 

Table P-2. Incidence of Selected Proliferative (Neoplastic and Hyperplastic) Lesions 

 

Control 

(0 g/m3) 

Low 

(2 g/m3) 

Mid 

(10 g/m3) 

High 

(20 g/m3) 

MALES

Kidney No. examined 50 50 50 50 

Adenoma, renal tubule 0 (0%) 0 (0%) 6 (12%)a 2 (4%) 

Carcinoma, renal tubule 0 (0%) 1 (2%) 0 (0%) 1 (2%) 

Renal tubule adenoma and 

carcinoma, combined 

0 (0%) 1 (2%) 6 (12%)b 3 (6%) 

Nasal 

Sections 

(Note that 

the same 

tumor 

may 

appear in 

more than 

one 

level.) 

Turbinate Level 1

 No. examined 50 50 50 50 

 Hyperplasia 

 Avg. severity 

3 (6%) 

0.2 

0 (0%) 

0.0 

3 (6%) 

0.1 

4 (8%) 

0.2 

Turbinate Level 2

 No. examined 50 50 50 50

 Hyperplasia 

 Avg. severity 

0 (0%) 

0.0 

2 (4%) 

0.1 

2 (4%) 

0.1 

3 (6%) 

0.2 

 Carcinoma, squamous cell 1 (2%) 0 (0%) 0 (0%) 0 (0%)

Turbinate Level 3

 No. examined 50 50 50 50 

 Carcinoma, squamous cell 0 (0%) 1 (2%) 0 (0%) 1 (2%)

Turbinate Level 4

 No. examined 50 50 50 50 

 Carcinoma, squamous cell 0 (0%) 2 (4%) 0 (0%) 2 (4%)

Thyroid No. examined 50 35 31 50 

 Hyperplasia, follicular cell 

Avg. severity 

0 (0%) 

0.0

0 (0%) 

0.0

1 (3%) 

0.1

0 (0%) 

0.0

 Adenoma, follicular cell 2 (4%) 0 (0%) 0 (0%) 3 (6%)

 Carcinoma, follicular cell 1 (2%) 0 (0%) 1 (3%) 3 (6%)

 Follicular cell adenoma 

and carcinoma, combined 

3 (6%) 0 (0%) 1 (3%) 5 (10%)

Testes No. examined 50 50 50 50 

 Adenoma, interstitial cellc 43 (86%) 47 (94%) 48 (96%) 50 (100%)d

Mesothelioma 0 (0%) 1 (2%) 1 (2%) 2 (4%)

Spleen No. examined 50 39 38 50 

 Leukemia, mononuclear e 27 (54%) 31 (79%)d 31 (82%)d 31 (62%) 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-9 

Table P-2. Incidence of Selected Proliferative (Neoplastic and Hyperplastic) Lesions 

(Concluded) 

 

Control 

(0 g/m3

) 

Low 

(2 g/m3) 

Mid 

(10 g/m3) 

High 

(20 g/m3) 

FEMALES

Spleen No. examined 50 22 24 50 

 Leukemia, mononuclear 27 (54%) 12 (55%) 11 (46%) 23 (46%) 

Mammary 

Gland 

No. examined 49 20 22 47 

Fibroadenomae 0 (0%) 3 (15%)d 2 (9%) 5 (11%)d

a

Incidence is significantly different from controls and from the 2 g/m3 group (Fisher’s test). 

b

Incidence is significantly different from controls (Fisher’s test). A positive trend toward 

increased incidence with increasing dose was found with the Cochran-Armitage test. c

A positive trend with increasing dose was found with the Cochran-Armitage and Logistic 

tests. A trend was also detected with Fisher’s test with the incidence among the 20 g/m3

group being significantly increased compared to the control incidence. 

d

Incidence significantly different from controls (Fisher’s test). e

Trend detected with Fisher’s Exact test. 

In males, mononuclear leukemia in the spleen demonstrated statistically significant 

increases in low and mid versus control group, these are judged unlikely to be a result of GMVC 

exposure (see Table P-5 and Discussion). 

Female rats had relatively similar incidences of mononuclear leukemia and across groups. 

Mammary fibroadenomas were significantly increased in low and high animals, but a 

surprisingly low incidence in controls complicates the interpretation (see Table P-6, Discussion, 

Appendices M and N). 

Nonproliferative Lesions. Nonproliferative lesions include degenerative and inflammatory 

changes. Such changes are common in many tissues in aged F344 male and female rats, and 

their significance in older animals must be interpreted with caution. 

Kidneys of male rats exposed to GMVC had significant increases in severity, but not 

incidence of chronic progressive nephropathy and both mid- and high-level males (Table P-3). 

Mid- and high-level males also demonstrated a significant increase in incidence (but not 

severity) of hyaline degeneration of olfactory epithelium in nasal section 2 (located at the level 

of the incisive papilla). There was a positive concentration-dependent trend toward degeneration 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-10 

in the olfactory epithelium of turbinate 3 (located midway between the incisive papilla and molar 

teeth). 

Table P-3. Nonproliferative Lesion Incidences and Severity Scores - Males 

 

Control 

(0 g/m3

) 

Low 

(2 g/m3) 

Mid 

(10 g/m3) 

High 

(20 g/m3) 

Kidney No. examined 50 50 50 50 

Nephropathy, chronic 44 (88%)a 47 (94%) 50 (100%) 46 (92%) 

Avg. severity 1.9 2.1 2.6b 2.7b

Nose/Turbinate 2 No. examined 50 50 50 50 

Degeneration, hyaline - 

olfactory epithelium 

0 (0%) 5 (10%) 7c

 (14%) 6c (12%) 

Average severity 0.0 0.2 0.2 0.2

Nose/Turbinate 3 No. examined 50 50 50 50 

Degeneration, hyaline - 

olfactory epithelium 

2 (4%) 1 (2%) 7 (14%) 7 (14%)d

 Average severity 0 0 0.2 0.3 

Nose/Turbinate 4 No. examined 50 50 50 50 

 Degeneration, hyaline - 

olfactory epithelium 

0 0 1 (2%) 1 (2%) 

 Average severity 0 0 0 0 

a

Percentage affected is in parentheses adjacent to incidence. 

b

Significantly higher than controls at 0.05 level using Kolmogorov-Smirnov one-tailed test. c

Significantly different from controls at 0.05 level using Fisher’s exact two-tailed test. 

d

Positive concentration-dependent trend by Cochran-Armitage and logistic tests. p = 0.054 by 

Fisher’s exact (no group comparisons made). 

As in males, high-level GMVC-exposed female rats demonstrated a significant increase 

in severity (but not incidence) of chronic progressive nephropathy (Table P-4). Mid- and highlevel females had a significantly increased incidence (but not severity) of hyaline degeneration of 

respiratory epithelium in nasal turbinate section 2. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-11 

Table P-4. Nonproliferative Lesion Incidences and Severity Scores - Females 

 

Control 

(0 g/m3

) 

Low 

(2 g/m3) 

Mid 

(10 g/m3) 

High 

(20 g/m3) 

Kidney No. examined 50 20 21 50 

Nephropathy, chronic 42 (84%)a

 17 (85%) 15 (71%) 43 (86%) 

Average severity 1.0 1.0 1.0 1.5b

Nose/Turbinate 2 No. examined 50 50 50 50 

Degeneration, hyaline - 

respiratory epithelium 

0 (0%) 1 (2%) 7c (14%) 6c (12%)d

Average severity 0.0 0.0 0.3 0.2 

a

Percentage affected is in parentheses adjacent to incidence. 

b

Significantly higher than controls at 0.05 level using Kolmogorov-Smirnov one-tailed test. c

Significantly different from controls at 0.05 level using Fisher’s exact two-tailed test. 

d

Positive concentration-dependent trend by Cochran-Armitage and logistic tests. p = 0.054 by 

Fisher’s exact (no group comparisons made). 

Lesions Showing Statistical Significance, but Judged Not Likely Due to GMVC Exposure

Other proliferative and nonproliferative lesions occurred which were not clearly 

significant or were judged to have confounding factors which must be considered in 

interpretation. For completeness, these lesions are listed for males (Table P-5) and females 

(Table P-6). Some findings were decreased in exposed animals compared to controls, these are 

not generally discussed. 

Some general notes are warranted: 

1) A number of diagnoses which appear as statistically significant are confounded by 

the fact that the tissues were only examined if grossly abnormal. This is 

particularly true in low- and mid-level animals. For example, liver and uterus were 

examined histologically in low- and mid-level animals only if a gross lesion was 

detected. Thus, the incidence of “leukemia, monocytic” and “polyp, endometrial 

stromal” was skewed upward by a protocol driven sampling bias. For the purpose 

of comments in the tables below, this will be termed “gross lesion sampling bias.” 

2) The incidence data for the diagnosis of “leukemia, mononuclear” should be 

considered only for the spleen. This is typically accepted as the tissue of origin of 

this hematopoietic neoplasm (also termed large granular lymphocytic leukemia, 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-12 

Fischer rat leukemia, monocytic leukemia, etc.) in F344 rats, and the lesion was 

called in the spleen any time it occurred in other tissues. Incidence data for this 

diagnosis in other organs are often spurious because some tissues were examined 

only if abnormal. This is particularly true in low- and mid-level group animals 

which had a more limited routine tissue set (“gross lesion sampling bias”). 

Table P-5. Lesions Judged Not Attributable to GMVC Exposure - Males 

Tissue Diagnosis 

Statistical 

Finding 

(Group) 

Statistical 

Testa Comments 

Adrenal 

Gland 

Hyperplasia, medullary, 

focal 

Trend to 

increase 

C-A, 

Logistic 

Increase was not significant versus 

controls (Fisher’s) and there is no 

evidence of an increase in benign or 

malignant tumors in exposed animals. 

Mammary 

Gland 

Hyperplasia, lobular Trend to 

increase 

C-A Increase was not significant versus 

controls (Fisher’s) and there is no 

evidence of an increase in benign or 

malignant tumors in exposed animals. 

Nose/ 

Turbinate 3 

Degen., hyalineolfactory epithelium Trend to 

increase 

C-A, 

Logistic 

Increase was not significant versus 

controls (Fisher’s), but is complementary to the significant increase seen in 

nasal section 2. 

Spleen Leukemia, 

mononuclear 

Increase 

(low, mid) 

Fisher’s High and variable incidence is 

expected, increase was not significant 

in highs. A corresponding increase 

among females was not present. 

a

C-A = Cochran-Armitage
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-13 

Table P-6. Lesions Judged Not Attributable to GMVC Exposure - Females 

Tissue Diagnosis 

Statistical 

Finding 

(Group) 

Statistical 

Testa Comments 

Brain Compression Increase 

(low, mid) 

Fisher’s Relatively low incidence among 

control females renders interpretation 

problematic (Note: this lesion 

typically results from pituitary gland 

tumors and correlates with those 

findings, see comments for that 

lesion below). 

Liver Hepatodiaphragmatic 

nodule 

Increase 

(low) 

Fisher’s Relatively common congenital 

malformation (control incidences 

reported from 1–11%b

), can be 

affected by gross lesion sampling 

bias. 

Liver Hyperplasia, biliary Trend to 

decrease 

Logistic Significance only achieved with 

Logistic test. Biological significance 

uncertain, deemed unlikely. 

Lung Hyperplasia, alveolar 

epithelial, focal 

Trend to 

decrease 

C-A, 

Logistic 

Biological significance uncertain, 

deemed unlikely. 

Mammary 

Gland 

Fibroadenoma Increase 

(low, high); 

Trend to 

increase 

Fisher’s, 

C-A 

Control incidence of 0% in this study 

remarkably low (reports from ~27–

40%b

), rendering interpretation of 

significance problematic. 

Pituitary 

Gland 

Adenoma, pars distalis Increase 

(low, mid) 

Fisher’s Relatively low incidence among 

control females renders interpretation 

problematic. Common neoplasm 

with historical control incidence high 

(~30%, ranges from 14-60%b

), high 

males show a minor decrease in 

incidence. Biological significance 

uncertain, deemed unlikely. 

Uterus Polyp, endometrial 

stromal 

Increase 

(low, mid) 

Fisher’s Gross lesion sampling bias, no 

evidence of increase in other uterine 

hyperplasia, benign or malignant 

tumors, control incidence rather low 

(reports from 11–37%c

). These 

factors render interpretation of 

significance problematic. 

a

C-A = Cochran-Armitage 

b

Boorman et al., 1990b; Haseman et al., 1998 

c

Haseman et al., 1998; Leininger and Jokinen, 1990 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-14 

DISCUSSION 

Proliferative Lesions

Benign tumors of the kidney and testes in males are the proliferative lesions documented 

most clearly in rats exposed via inhalation to GMVC in this study. 

Adenomas of renal tubule epithelial cells are relatively uncommon background lesions in 

F344 rats, with an average incidence in males of 1.0% (range 0–4%) in NTP study controls 

(Haseman et al., 1998). The lack of a typical exposure concentration response in this study is 

difficult to resolve, but the significantly increased incidence in mid- (12%) and increased 

incidence in high- (4%) level males is presumed to have resulted from GMVC exposure. 

Additionally there was a low incidence of renal tubule carcinoma in low- (2%) and high- (2%) 

level males which was not statistically different from controls. Combining adenomas and 

carcinomas for analysis (controls 0%, low 2%, mid 10% and high 6%) maintained the significant 

increase in tumors in the mid-dose group and yielded a significant positive exposure-related 

trend. These results are consistent with findings of an increased incidence of combined renal 

adenomas and carcinomas in the Baseline Gasoline Vapor Condensate Study (FY01-027). 

Given the increased severity of chronic progressive nephropathy in mid- and high-level 

males, a plausible explanation for the increase in renal tubule tumors may be a sustained increase 

in cell turnover/proliferation and subsequent tumor induction via epigenetic mechanisms of 

carcinogenesis in male rats, including damage related to alpha-2u globulin overload (Hard, 1998; 

Baetcke et al., 1991). Previous studies with wholly vaporized gasoline, MTBE, and related 

compounds have also documented increased nephropathy in male rats, and increases in renal 

tubular adenomas and carcinomas (MacFarland et al., 1984; Medinsky et al., 1999; Bird et al., 

1997). Further consideration of the nonproliferative, but potentially relevant lesion of chronic 

progressive nephropathy is presented below and under the “Nonproliferative Lesions” 

discussion. 

The increase in renal tubule adenomas and carcinomas in males may be related to the 

increased severity of chronic progressive nephropathy through a sustained increase in tubule 

epithelial cell turnover, a recognized occurrence in male rats (Hard, 1998). For compounds 

inducing renal tumors in male rats through increased alpha-2u globulin accumulation and 

subsequent increased renal tubule cell turnover, the human health relevance of the mechanism 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-15 

and thus the tumors is often regarded as suspect (Baetcke et al., 1991; Hard, 1998; Hard and 

Khan, 2004). Alpha-2u globulin nephropathy is a plausible mechanism for GMVC related renal 

adenomas and carcinomas based on other MTBE and similar compound study reports (and 

including the results of a 13-week unpublished study on gasoline vapor condensate without 

MTBE conducted at LRRI). In F344 male rats after approximately 1 year of age, alpha-2u 

globulin overload nephropathy may be masked by age-related chronic progressive nephropathy 

(CPN), since both forms of nephropathy share similar if not identical diagnostic hallmarks. The 

effect of alpha-2u globulin overload nephropathy typically manifests itself in increased severity, 

rather than incidence, since essentially all males surviving past 1 year of age will develop CPN. 

Note that GMVC also induced increased severity of nephropathy in females at the highest dose, 

although via a different mechanism since alpha-2u globulin overload is male rat specific. 

Squamous cell carcinomas (SCC) present in nasal sections of males [animal incidences of 

1/50 (2%), 2/50 (4%), 0/50 (0%) and 2/50 (4%)] were judged to be of oral origin in all cases. 

The low incidences and presence of this neoplasm in a control male render any relationship to 

exposure difficult to discern in this study. Historical control incidences of this tumor in NTP 

inhalation studies are low (~0.6%). However, a large study with cigarette smoke conducted at 

this facility in the early 1990’s had an incidence of 0/118 (0%) squamous cell carcinomas of oral 

origin in males and 3/119 (2.5%) in females. No tumors were of nasal origin. While comparison 

between this study and the concurrent BGVC study is largely done in the GMVC main report, 

note that the BGVC study had none of these tumors (0/50) in control males but one (1/50) in 

control females. In the BGVC, there was a trend for significant increase in squamous cell 

carcinomas in males, but no group differences by the Fisher’s Exact Test. Nonetheless, a minor 

but relatively consistent increase in incidence in exposed animals is present in both studies. 

Clearly the whole body method of inhalation exposure has the potential to result in some degree 

of exposure directly to the oral cavity in addition to the systemic exposure from inhalation (from 

grooming, etc.). 

Interstitial (Leydig) cell adenomas of the testes are very common lesions in male F344 

rats, with average reported incidences up to 89% or even 100% in 2-year studies (Haseman et al., 

1998; Boorman et al., 1990c). Incidence of this benign tumor was similarly high in all groups in 

this study as well, but the incidence in high-level males was significantly increased, and an 

exposure concentration response was present. While within this study with GMVC the data 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-16 

suggest a causal relationship between exposure and testicular interstitial adenomas, the 

relationship between treatment with MTBE and induction of testicular interstitial adenomas is on 

the whole more equivocal, since background incidence of this tumor is quite variable and usually 

extremely high [(NTP control incidence for air inhalation controls: for NIH-07 diet avg. = 

70.1% with range of 46% to 90%; for NTP-2000 diet avg. = 92.1% with range of 82% to 98%), 

and control incidence in the concurrently run Baseline Gasoline Vapor Condensate chronic study 

(LRRI study number FY01-027) was 48/50 (96%)]. Other MTBE toxicity studies have 

documented increases in testicular interstitial cell adenomas (Bird et al., 1997; Belpoggi et al., 

1995). However, in a recent review of the mechanisms of MTBE induced carcinogenicity, the 

overall evidence for MTBE induction of testicular interstitial cell adenoma was considered to be 

equivocal (Cruzan et al., 2007). Note that the human health relevance of interstitial cell tumors 

in rats has been called into question suggesting little predictive value for humans (Prentice and 

Meikle, 1995; Cook et al., 1999). 

Leukemia, a well-documented feature of old age in F344 rats, did not appear to be 

enhanced by GMVC exposure. Results for spleen, the defining organ for this disease, are shown 

for males and females in Table P-2. In males, the incidences of leukemia in the low- and midGMVC levels are greater than controls (Fisher’s test). However, there was no overall significant 

trend with exposure concentration as determined by the Cochran-Armitage and logistic tests, and 

the incidence of leukemia in high-level males was not different from controls (Fisher’s test). The 

incidences of leukemia in GMVC-exposed females were similar to or lower than control but not 

significantly different (Table P-2). 

Mammary gland fibroadenoma was significantly increased in low- and high-level females 

(Tables P-2 and P-6). Interpretation of this finding is problematic due to the atypically low 

control incidence of 0% in control females. Control incidences for this lesion have been reported 

to range from 27–40% (Boorman et al., 1990b). The control incidence in the parallel BGVC 

study (LRRI study number FY01-027) was 4/49 (8%). Additionally, increases in this lesion have 

not been observed in previous studies with neat MTBE or wholly vaporized gasoline (Cruzan et 

al., 2007; MacFarland et al., 1984). Therefore, it is judged unlikely that the increased incidence 

in female mammary gland fibroadenoma was treatment-related.
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-17 

Nonproliferative Lesions

Males. Chronic progressive nephropathy (CPN) is the diagnostic terminology for an entity in 

rats comprised of a constellation of changes commonly affecting the kidneys of F344 rats. 

Lesions in male rats appear earlier and are routinely more severe than those in females 

(Montgomery and Seely, 1990). Renal lesions typically consist of tubular degeneration and 

regeneration, proteinaceous casts, tubular atrophy and dilatation, interstitial fibrosis, basement 

membrane thickening and glomerulosclerosis depending on the severity. The severity scoring 

for this lesion in described in a previous section. 

The increased average severity score for CPN in mid- and high-level males is judged to 

be a consequence of GMVC exposure. It may reflect damage resulting from increased alpha-2u 

globulin associated with hydrocarbon nephropathy (HN). Some classic hallmarks of 

hydrocarbon exposure—including the presence of brightly eosinophilic cytoplasmic droplets 

within tubular epithelium and granular casts/linear mineralization in the outer stripe of the 

medulla—were not apparent even in high-level males (while regions of cytoplasmic eosinophilic 

droplets occurred, they were similar between controls and exposed and not judged representative 

of HN). As discussed below however, the absence of these hallmarks is not unexpected in 

kidneys from aged rats. 

Hyaline droplet or protein accumulation in shorter term MTBE studies is reported 

(Medinsky, 1999; Lington et al., 1997; Bird et al., 1997), but the change is not necessarily noted 

in kidneys from chronic exposures (Bird et al., 1997; Rudo, 1995). It is noteworthy that a 

chronic t-butyl alcohol exposure study conducted by the NTP also lacks a specific diagnosis of 

“hyaline droplet nephropathy,” although such a diagnosis is made during a shorter term (13 

week) exposure study (NTP, 1995). Hyaline droplet accumulation is commonly seen with 

hydrocarbon exposure, and might be expected with GMVC inhalation (Gopinath et al., 1987). 

Such a “hydrocarbon nephropathy” may have occurred as an earlier lesion which was 

masked/obscured in these chronically exposed animals by the progression of CPN. There is also 

some evidence that aged male rats are much less sensitive to hydrocarbon nephropathy and that 

production of the major protein constituent of hyaline droplets, alpha-2u globulin, is greatly 

decreased in old rats (Murty et al., 1988). In addition to renal lesions of hyaline droplet 

formation, increased tubular regeneration/proliferation and CPN have been previously reported 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-18 

in male rats as a result of MTBE and similar compound exposure (Medinsky et al., 1999; 

Lington et al., 1997; Bird et al., 1997; Clary, 1997; Borghoff et al., 2001). 

The human health significance of the chronic progressive nephropathy of male rats 

associated with accumulation of hyaline droplets containing alpha-2u globulin is suspect. It and 

the subsequent development of renal tubule adenomas are often considered male rat specific and 

thus not significant for humans (Greaves, 2000; Baetcke et al., 1991; Hard, 1998) though 

opinions differ (Melnick, 1992). As previously noted, the typical lesions of hyaline droplet 

nephropathy were not documented in this study at the chronic timepoints examined, but this is 

not unexpected since diagnostic hallmarks (primarily linear mineralization) to suggest HN at 

chronic timepoints and with severe overlying CPN are limited. It should be noted that the 

severity of chronic progressive nephropathy was increased in high-level females which are not 

susceptible to typical alpha-2u globulin related nephropathy. This suggests the possibility that 

more than one mechanism may be important in the development of chronic progressive 

nephropathy in response to GMVC. 

Increased hyaline degeneration of nasal epithelium (typically olfactory and respiratory) 

characterized by the accumulation of hyaline droplets/globules is a common, nonspecific finding 

in aged rats and is increased in response to a number of toxicants (Boorman et al., 1990d; 

Gopinath et al., 1987). Mid- and high-level males had significant increases in incidence relative 

to that seen in control animals in nasal section 2, and there was an exposure concentration 

response in turbinate 3 for males. The overall incidence was relatively low, and the severity of 

the lesion ranged from minimal to moderate in most exposure groups. While the lesion is likely 

exposure related, the significance of this common, minor change by itself is uncertain. 

Females. Kidneys of high-level female rats cumulatively demonstrated a slight increase in 

overall severity score of chronic progressive nephropathy. Though the minor severity difference 

renders interpretation less clear than that in males, the increased severity of CPN in high-level 

females is judged to be an effect of GMVC exposure. A lesser severity of CPN is typical in 

female F344 rats compared to males (Montgomery and Seely, 1990). Reports of MTBE effects 

on kidneys in female rats vary. Some do not report significant differences in female renal lesions 

(Lington et al., 1997), others report increased bromodeoxyuridine labeling of tubular epithelium 

or increased CPN incidence and severity (Medinsky et al., 1999; Bird et al., 1997; Clary, 1997). 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-19 

As noted for the males, hyaline droplet accumulation in olfactory and respiratory nasal 

epithelia is a common, nonspecific response to toxicants in rodents. While the lesion is likely 

exposure related, the significance of this common, minor change by itself is uncertain. 

HISTOPATHOLOGY SUMMARY 

Statistically significant increases in GMVC exposure related lesions were seen in both 

male (kidney, testes, nasal epithelia) and female (kidney, nasal epithelia) F344 rats. Exposure 

related proliferative lesions occurred only in males and consisted of renal tubule adenomas (and 

combined adenomas and carcinomas) and testicular interstitial (Leydig) cell adenomas. The 

increase in renal tubule adenomas was significant only in mid-level group males relative to 

controls (Fisher’s exact test, p ≤ 0.05) and lacked significance using trend tests (CochranArmitage and Logistic tests, p ≤ 0.05). Combining renal tubule adenomas and carcinomas 

maintained the significant increase in mid-level males and also resulted in a significant positive 

trend with increased exposure. Renal tubule neoplasms in rats are influenced by epigenetic 

mechanisms related to CPN and this must be taken into account in this study. Increases in 

testicular interstitial cell adenomas were statistically significant relative to controls in high-level 

animals (Fisher’s exact test, p ≤ 0.05) and as an exposure related trend (both Cochran-Armitage 

and Logistic tests, p ≤ 0.05). As noted in the discussion section, the variable and typically very 

high background incidence of this tumor in aged rats must be considered on the whole in risk 

assessment.

Nonproliferative lesions related to GMVC exposure were present in kidneys (as an 

increase in severity of chronic progressive nephropathy) and nasal epithelia (as hyaline 

degeneration) of both genders. Both mid- and high-level males had significant increases in the 

severity, but not incidence of chronic progressive nephropathy relative to controls (KolmogorovSmirnov test, p ≤ 0.05). The incidence of hyaline degeneration of olfactory epithelium (nasal 

turbinate section 2) was significantly increased in male animals of mid- and high-level groups 

(Fisher’s exact test, p ≤ 0.05), and increased as an exposure related trend (Cochran-Armitage and 

Logistic tests, p ≤ 0.05). An exposure-related trend for olfactory epithelial degeneration was also 

present in turbinate 3 for males. Kidneys of females exposed to GMVC did not have an 

increased incidence (Fisher’s exact test, p ≤ 0.05) or exposure related trend to increased 

incidence (Cochran-Armitage and Logistic tests, p ≤ 0.05) of chronic progressive nephropathy, 

but did demonstrate a significant increase in severity of this lesion in high-level females 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-20 

(Kolmogorov-Smirnov test, p ≤ 0.05). Nasal cavities of mid- and high-group females had an 

increased incidence of hyaline degeneration of respiratory epithelium (nasal section 2) relative to 

controls (Fisher’s exact test, p ≤ 0.05), and the exposure-related trend for this change was also 

significant (Cochran-Armitage and Logistic tests, p ≤ 0.05). 

Hyaline degeneration of olfactory and respiratory epithelium is characterized by the 

accumulation of homogeneous, hyaline eosinophilic globules. Small numbers of cells with these 

globules are common in aging rodents and in response to toxicants. The significance of the 

minor nasal epithelial changes noted in this study is uncertain. 

REFERENCES 

Baetcke, K. P., Hard, G. C., Rodgers, I. S., McGaughy, R. E., and Tahan, L. M. (1991). Alpha2υGlobulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the 

Male Rat. (EPA/625/3-91/019F) Risk Assessment Forum, U.S. Environmental 

Protection Agency (U.S. EPA), Washington, D.C. 

Belpoggi, F., Soffritti, M., and Maltoni, C. (1995). Methyl-Tertiary-Butyl Ether (MTBE)—A 

Gasoline Additive—Causes Testicular and Lymphohaematopoietic Cancers in Rats. 

Toxicol. Ind. Health 11(2): 119-149. 

Bird, M. G., Burleigh-Flayer, H. D., Chun, J. S., Douglas, J. F., Kneiss, J. J., and Andrews, L. S. 

(1997). Oncogenicity Studies of Inhaled Methyl-Tertiary-Butyl Ether (MTBE) in CD-1 

Mice and F-344 Rats. J. Appl. Toxicol. 17(Suppl. 1): S45-S55. 

Boorman, G. A., Eustis, S. L., Elwell, M. R., and Leininger, J. R., eds. (1990a). Pathology of the 

Fischer Rat, 1st Ed., Academic Press, San Diego, CA. 

Boorman, G. A., Wilson, J.T., van Zwieten, M.J., and Eutis, S. L. (1990b). Mammary Gland. In 

Pathology of the Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and 

Leininger, J. R., eds.), 1st Ed., pp. 295-314, Academic Press, San Diego, CA. 

Boorman, G. A., Chapin, R. E., and Mitsumori, K. (1990c). Testis and Epididymis. In 

Pathology of the Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and 

Leininger, J. R., eds.), 1st Ed., pp. 405-418, Academic Press, San Diego, CA. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-21 

Boorman, G. A., Morgan, K. T., and Uriah, L. C. (1990d). Nose, Larynx, and Trachea. In 

Pathology of the Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and 

Leininger, J. R., eds.), 1st Ed., pp. 315-338, Academic Press, San Diego, CA. 

Borghoff, S. J., Prescott, J. S., Janszen, D. B., Wong, B. A., and Everitt, J. I. (2001). Alpha 2uGlobulin Nephropathy, Renal Cell Proliferation, and Dosimetry of Inhaled Tert-butyl 

Alcohol in Male and Female F-344 Rats. Toxicol. Sci. 61(1) :176-186. 

Clary, J. J. (1997). Methyl Tert Butyl Ether Systemic Toxicity. Risk Anal. 17(6): 661-672. 

Cook, J. C., Klinefelter, G. R., Hardisty, J. F., Sharpe, R. M., and Foster, P. M. (1999). Rodent 

Leydig Cell Tumorigenesis: A Review of the Physiology, Pathology, Mechanisms, and 

Relevance to Humans. Crit. Rev. Toxicol. 29(2): 169-261. 

Cruzan, G., Borghoff, S. J., dePeyster, A., Hard, G. C., McClain, M., McGregor, D. G., and 

Thomas, M. G. (2007). Methyl Tertiary-Butyl Ether Mode of Action for Cancer 

Endpoints in Rodents. Reg. Toxicol. Pharmacol. 47: 156-165. 

Gopinath, C., Prentice, D. E., and Lewis, D. J. (1987). Atlas of Experimental Toxicological 

Pathology (Gresham, G. A., ed.), MTP Press Limited, Norwell, MA. 

Greaves, P. (2000). Histopathology of Preclinical Toxicity Studies, Elsevier, Amsterdam, 

Netherlands. 

Hard, G. C. (1998). Mechanisms of Chemically Induced Renal Carcinogenesis in the Laboratory 

Rodent. Toxicol. Pathol. 26(1): 104-112. 

Hard, G. C., and Khan, K. N. (2004). A Contemporary Overview of Chronic Progressive 

Nephropathy in the Laboratory Rat, and its Significance for Human Risk Assessment. 

Toxicol. Pathol. 32(2): 171-180. 

Haseman, J. K., Hailey, J. R., and Morris, R. W. (1998). Spontaneous Neoplasm Incidences in 

Fischer 344 Rats and B6C3F1 Mice in Two-Year Carcinogenicity Studies: A National 

Toxicology Program Update. Toxicol. Pathol. 26(3): 428-441. 

Leininger, F. R., and Jokinen, M. P. (1990). Oviduct, Uterus, and Vagina. In Pathology of the 

Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and Leininger, J. R., eds.), 1st

Ed., pp. 443-460, Academic Press, San Diego, CA. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-22 

Lington, A. W., Dodd, D. E., Ridlon, S. A., Douglas, J. F., Kneiss, J. J., and Andrews, L. S. 

(1997). Evaluation of 13-Week Inhalation Toxicity Study on Methyl T-Butyl Ether 

(MTBE) in Fischer 344 Rats. J. Appl. Toxicol. 17(Suppl. 1): S37-S44. 

MacFarland, H. N., Ulrich, C. E., Holdsworth, C. E., Ketchen, D. N., Halliwell, W. H., and 

Blum, S. C. (1984). A Chronic Inhalation Study wth Unleaded Gasoline Vapor. J. Am. 

Coll. Toxicol. 3(4): 231-48. 

Medinsky, M. A., Wolf, D. C., Cattley, R. C., Wong, B., Janszen, D. B., Farris, G. M., Wright, 

G. A., and Bond, J. A. (1999). Effects of a Thirteen-Week Inhalation Exposure to Methyl 

Tertiary Butyl Ether on Fischer-344 Rats and CD-1 Mice. Toxicol. Sci. 51(1): 108-118. 

Melnick, R. L. (1992). An Alternative Hypothesis on the Role of Chemically Induced Protein 

Droplet (Alpha 2u-Globulin) Nephropathy in Renal Carcinogenesis. Regul. Toxicol. 

Pharmacol. 16(2): 111-125. 

Montgomery, C. A., and Seely, J. C. (1990). Kidney. In Pathology of the Fischer Rat

(Boorman, G. A., Eustis, S. L., Elwell, M. R., and Leininger, J. R., eds.), 1st Ed., pp. 127-

153, Academic Press, San Diego, CA. 

Murty, C. V., Olson, M. J., Garg, B. D., and Roy, A. K. (1988). Hydrocarbon-Induced Hyaline 

Droplet Nephropathy in Male Rats During Senescence. Toxicol. Appl. Pharmacol. 96(2): 

380-392. 

National Toxicology Program (1995). Toxicology and Carcinogenesis Studies of T-Butyl 

Alcohol (CAS No. 75-65-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies). 

Technical Report 436, NIH Publ. No. 95-3167, National Toxicology Program, National 

Institutes of Health. 

National Toxicology Program website (as of Sept. 2008). Historical Controls. 

http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid=92E61F1B-F1F6-975E7D3BED551F07DC0A 

Prentice, D. E., and Meikle, A. W. (1995). A Review of Drug-Induced Leydig Cell Hyperplasia 

and Neoplasia in the Rat and Some Comparisons with Man. Hum. Exp. Toxicol. 14(7): 

562-572. 
Study Number FY01-013 

211(b) Chronic Carcinogenicity Study 

Gasoline MTBE Vapor Condensate (GMVC) 

P-23 

Rudo, K. M. (1995). Methyl Tertiary Butyl Ether (MTBE)—Evaluation of MTBE 

Carcinogenicity Studies. Toxicol. Ind. Health 11(2): 167-173.